<SEC-DOCUMENT>0001641489-22-000008.txt : 20220815
<SEC-HEADER>0001641489-22-000008.hdr.sgml : 20220815
<ACCEPTANCE-DATETIME>20220815181556
ACCESSION NUMBER:		0001641489-22-000008
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220815
DATE AS OF CHANGE:		20220815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			vTv Therapeutics Inc.
		CENTRAL INDEX KEY:			0001641489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473916571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37524
		FILM NUMBER:		221167547

	BUSINESS ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265
		BUSINESS PHONE:		336-841-0300

	MAIL ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VTV Therapeutics Inc.
		DATE OF NAME CHANGE:	20150506
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtvt-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:cc23dfa8-b7f1-4dd2-bc21-5440216f3885,g:7d227720-4a1d-461e-9922-f5c0b011aa4f,d:7213a6cb68bb48ed8c21afe0782e56bd--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:vtvt="http://vtvtherapeutics.com/20220630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtvt-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV8yLTEtMS0xLTI5_18b5bc33-84a0-48f8-92c7-090f493f70d3">0001641489</ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV8zLTEtMS0xLTI5_1dad7a44-2371-4a91-a86f-23d3af22b1fc">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV80LTEtMS0xLTI5_be02b0fd-5779-4161-8ab0-e487d03d2ecb">2022</ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV81LTEtMS0xLTI5_724674a4-5e24-4a39-bb79-2c857769421e">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV82LTEtMS0xLTI5_4a38fd44-ac1c-4e99-8b15-e94a6908272d">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="if1e0f604437b48cdbcd972041892c65b_D20170801-20170831" decimals="2" name="vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNy9mcmFnOjQzYWE3NDYzYWNiZTQ2OTZhMzUzMTkwZjFhOWFhNGQyL3RhYmxlOjU2NWFkMmRmZWM1YTQxN2FhYzUwMzhhOGRiNjdlMTk0L3RhYmxlcmFuZ2U6NTY1YWQyZGZlYzVhNDE3YWFjNTAzOGE4ZGI2N2UxOTRfMS0xLTEtMS0yOQ_4b42c586-0592-41a6-ba1d-8343aed2e91a">0.5</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtvt-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb646bb66f5041ab8b597cc264142087_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i69b2ce3d438f47a6bb0e8a99436f206d_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i778989260b33429389e1a9ca9b4b1a6d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id3f1ff84e5e8468880c40caf7f418a85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c05dd51a814c37836f3f0e37c99f3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2632fc86076247a6b51786bef024e90d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bfde1dac36844ceae1f4d006ceddf50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8f41c561ac468dbc33b32b7235be53_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d658467661472da49eea25c17f94b0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e22736f72b44c9afae821088c0ab77_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009bfc074c5a4c0e9142f9616b19f90c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb85c14dc2c74e2996fe107888561e93_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id905d604d9a943f6b7cb9f24d0dd0b48_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29266001f249497b93b47c8e3466fd61_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ef5bed40ce94a93a2cd11d663f62d4f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae4134a6e3344ae8ad4af1f2240f9dd5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib755a24e8a104d1d8d2b3d1f74c11d40_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ef80539aee48d48e6f1bb3a8119477_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b8aa8d7eba49128b8f62637d391235_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18238700dcf14e91a75ec3b06d1825b1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22caf6e5b694a3bbc1d3ce68d75a410_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d9dc5b78d04d55a239f0af2896ed29_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8450413dbc4dd08d8c7650588aa198_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i126a3208a6f742618c2561e7779f1845_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id982b9b09f424a87922b57be194129cb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff9c4e329b59464eb907f13b780450d1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a489bb6b0fe43528a20c591702e09b0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6da094d9ac4affabf82ba8cee1e10f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb0cff36c95e4303a0941bafd6699028_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b13159810f0458a9344038beefe7235_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c3c142ca894d3192a385912e6b2355_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76098cfb60b247ba8a2e8ee82578378e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2452a27b59f747529be02258b1569777_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9521269fab34466aa92f8122d2b5d869_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c32876481864865b9c009d36cd4047c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d35c53128c418ebe084dae0ea68bc8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f41641fa7594bc5b38df0be185b457b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ea0ea093f946ddbe1ea6abb5d7c0ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50c8002790784ec0b6ad74669f5918cf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d8796c4850440b83f57f0567a7ca07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5abc9ec8fa4a5eb2faeea6cc161c75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6abbeb4fa947868b13efda9bde3af0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20f8626d64245639e72db76234f04ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc5c6b914922483ab2156d1e3c1fd332_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6587de2ee5f8460daad2b87becd8ceea_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2ad5a54d8145b688887e50ede3f142_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a34cc4ae17f472882c70dc69f0341b7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac25b8b6e8545729210187897d7d519_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d8922a188e43c18738058811905e2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb96586842464c818639a9b0f427cca5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a93b41b9e8482d8c8a5e90eb6fc5f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548922a8ebe2493e96679d156ae2662c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c78efac0aa24b009a92ea9b1b7ce7c6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882913d768b944228f47edf27a64d407_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e056239209f42eb89288f0b10c1d786_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70938c26b4624098aef25d030f5a7a61_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id13a79cf23134033b57b9a418c172263_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G2InvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510f76f9961e4195a66c407fea3e33b3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic87a37201a68429d87e70c2c68af37bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vtvt:LicenseAgreementObligationsAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec7d98d909f742f7b497b0166dc0cd42_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59fc879b99594e4fa12d9fd8e5ab7977_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3050c6fe4714d81b1d708a35d3bfc8d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89b7ff0156f46f6af23549fe63c886b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c93b4c2e340487692d87888bde8fd1d_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia52cbec3f3c34ef984af52054ced737b_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i391171de436948d1ab5c2af5c2a6b7c3_D20220531-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660eadb2cefb42f6af2828654b2ecaad_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b185c6a31e4b0f875dbc148b1a9690_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7645c4e435b9406cb66205c7447a3bb4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia159a094d3c149ae894a344e958ae6b8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib691d10b9e9048d2ad20c45cc4d7b82a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ef634eb2724783ab3b95d2e1eb87b0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a4c00943074f559aa9f5295140d5d3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida207b1c94f040c49e5bac98b31bd511_I20210114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9402a4a07ef14ae1bd27ed58ddf7c7a7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28ca3ec68a2f405c9d88aea860a19d43_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedcd02d9e7ed46a9be450435bae20a14_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1d4d900a634784a41180096d9af11c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie807e06b03a449358e53f1fe6a28f0c2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7dabf56fb04aae8e954ea2799cbebb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee005b698f440db91b1b86a6598a170_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9644a2a90dd449c3a42d337db0986546_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61786a784a654e5eae26bb310979ad74_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c61470a62b4ea8ad0f4884c7064bd7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c150d5a782c4fc0b12b5a8bf5b8dac1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717440fba9ae463ba4b738d6cc36588b_D20201211-20201211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-11</xbrli:startDate><xbrli:endDate>2020-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4678547c424543bbb17a9eec17b01812_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-11</xbrli:startDate><xbrli:endDate>2020-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if487c4d0351a4b53ad7e192011f347f0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e359c73dd344730844f51f46e651559_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2afc370e61141bdbcb9d5cde256c0e5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i194bd737c73c45978ed3a128fb4083aa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10084af716e84ec69a70340b4c5bd31b_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0bc234ab6f74714aa833022af967b77_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e0f604437b48cdbcd972041892c65b_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d10b9f39fd4c93bfa1d918b158b70d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb1b9c3a3531408ab3529984f8566bc3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fc8150340948bc898873b35fb8418e_D20220329-20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba62023a07f44291bd3078c3cb8c0331_I20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtvt:StrategicAdvisorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtvt:StrategicAdvisorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f49c4740cff40429fb52e44fa210e13_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7317531dde4b48dab33ee85599082a64_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id29697fdb6af49c7bc034a9837816d6d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dda6d8be2724280ae62e19e4a293904_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152676a2e89f49c1b9dc28a02261abd0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1cd4fe75eb46dcab4af04b0635b52a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i762b94f808004bfcb8c828bf3cf727d2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da4992df5e044318a2a0905c425112f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf108c845b044d5b9647b9f0d2f6517e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i783e762f741545f3a0fe0c1d38e6b115_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0147ce52f24edbb65de2e822c1593e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264317da98da4654b1fb27e432d93843_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3367eb43e184818b02b49d5ae5d81a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77b143ad9f4d4ba1ace4e171385ea567_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd78af64b3f948b895cdd7ac3bc5ef42_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa40b257a304d62948a32a686a7716a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic27aa30a7f394af79e2bdf369843816f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ebac4e45e34b82929898cde894745e_I20070228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65905beb758b4791a02bb8d0cb2515a0_I20070228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ead0675511b48ebb66183281497ebc5_I20070228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ddaf589ad6495baf1c05cf44f3896e_I20070228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c0384308fd425590c78419693d5fc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SatisfactionOfMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910db6d0fa4e476cbe83b47a7fea5ee1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92612f3dee2a4b16a5b8ceea2175dc30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6511cf535eb14b879d2b9abaf9fd770f_I20210504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedc1e3243a7443dfb3c90db73fedab5c_D20210504-20210504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f18b37002444e71902e4b504204e08e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7c397af1aa46eea7d046dd11d5461b_I20210504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3de8bb3d5c4970bc7c8e651b6af215_I20210504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54bdcd3ea0d44d0987f04e7b4c3ad6d_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida448d3c156e41c6907f442bbdbdcfd3_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c6864ca64f40938eda9aad11bf61c1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5db27bb04d4dd79864de1cb1a6f970_D20210114-20210114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-14</xbrli:startDate><xbrli:endDate>2021-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf065935ede4806964843da64a9618e_D20210625-20210625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-25</xbrli:startDate><xbrli:endDate>2021-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia312c12a8760465dbb649e1f030f2bd7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c543d697817434690f23877af7b8d92_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de9e3cb791344979fa4282d8da7fd57_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320fb888e6cd44998dc594856dc9724d_D20201124-20201124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-24</xbrli:startDate><xbrli:endDate>2020-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1be42149da4a86877d9aa6d3153d8f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b77eabd9884287918e1f07afb3fdc4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17c637109e34b5bac99defc70fe5b69_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa89db2b5b5402c94ff86a30340034c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69778fbafa14054a1949c92a76c3381_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib893ea7404d94823b4489736f31d8e0a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee68f1d1f0245e088ff9dcad3a1d1ce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbeae5448a4743c4972130e10f6a61e0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12e25238c51408a9b5aabb915d68f4f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3883a4eeb01a4804bfe931960df3630c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aaf9605ec3d4df997dcb31cc1d69aae_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e056d11279c4dd88b534da383cad3ab_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd0c418f4a147dd908cb4bed116af1c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323cbf05f2cd4b229244d58c16833346_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d01a641a694957af47ad5592770a6c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89aaa594ea04677ac3c150ebeb2e739_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b89c4b600ca440bb9a9a90ea5e62a11_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1043be2df62a449880a9ce6cbfb89d1f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cadb9b02403417192c10ca22f8e9080_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91174829dd374e538fa07971c396f3f0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118c349b7b7547779cf5d02c7d07c16b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51365f9948548649ad42309ddd6a7b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e6746b22b7f41f39b2aa3e66ad235be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7f59ded7334cc8a27ff3af075f6369_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d33804ed69446a581a68a89a6ced16b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0291753a44b74ba594c6c841017b8991_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39fd9325e67d49ba929177308a09de11_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4ad6c963f84d1983f4152763b6d5e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82047fa01dff4061ac50b8ba5c19afee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eefc32c333242c2ba2cc3475c9a1886_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cffc7e1fd3a45358f79cce28478fcf9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i549b94495164498ea6721b08e7ae6b51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf1b6a13e34941f6b03007d4d7d9ce76_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4459419f08db4ba1875ab5f3a7f77bd9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0bac167c154e428feb6ddfa2051544_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie909d9404b144715bd0bec2b55db2950_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia333a79c07f744389589fbe58f3bf987_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i281f26cf97534b859fc01285494a83f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534e6c90542a42f48822824cfd33db65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc889929911946cc9f3bc54d6854ca47_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ec27b58aee4985a776ed1774c95950_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106c03246dd94c1291ebcee81f596ece_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie552923b1f3f42379e848afe08b6c2e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f477876785490a8f842fc97272c335_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8bcca13e6e4588aa129bdeb6bb7ec4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic36d6026ee894b0496ae13eeb6079046_I20220725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0826cd3429194c58828df365b21d13d7_D20220725-20220725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301fa4d644bd48b0a42d7d3c43ad4466_D20220725-20220725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_1"></div><div style="min-height:18pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA2_d147a47d-d9a0-4a61-bc76-63bd424248b3">10-Q</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________________</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Mark One)</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6ZDI3MWZkZTNmNjA2NDUzYzhmNGUzMGRjMjRkZmJhNzUvdGFibGVyYW5nZTpkMjcxZmRlM2Y2MDY0NTNjOGY0ZTMwZGMyNGRmYmE3NV8wLTAtMS0xLTI5_289d6f7a-db91-4b0d-8b79-d592e5799ee5">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA3_e0cd2f2c-99cb-4f7d-a571-17b348c4d8ac">June 30, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzM4MTYwZGU0ZDU4NGRkZjhiM2MwMDEwZTAyYjdlNTgvdGFibGVyYW5nZTpjMzgxNjBkZTRkNTg0ZGRmOGIzYzAwMTBlMDJiN2U1OF8wLTAtMS0xLTI5_baf2ddbc-2b95-4aa2-85dd-ca18dc49f7ca">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA4_109bbaa3-ad50-4000-9f0d-5fa0f0e6a1b6">001-37524</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTAx_60027565-b2f1-4b34-beae-c68c46a8b8a1">vTv Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8wLTAtMS0xLTI5_ec4b6ade-4e01-4865-b627-5abe7804ddba">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8wLTEtMS0xLTI5_de113c85-5e87-4399-bf50-889df3d0399e">47-3916571</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfNA_0856a6a7-480d-4f04-8d64-74150917a06c">3980 Premier Dr</ix:nonNumeric>, <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfOA_75f46729-81d1-4b7e-b0b0-04232c87e976">Suite 310</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfMTE_1b7f4212-e954-4c94-8f8b-fa972f936174">High Point</ix:nonNumeric>, <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfMTU_6550016f-0e42-4601-9248-b16e632e3974">NC</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTEtMS0xLTI5_9f5d7c25-458b-4540-961e-c2494dbcda74">27265</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTAy_2b724775-5883-4861-82ac-56ecacd1cde9">336</ix:nonNumeric>) <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTAz_a34d3961-005c-416a-afb9-9e7f982aeb0d">841-0300</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:41.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzBlY2RlNGU3NzY0NGI1N2E2NGZkMTRhZmU3ZWIzYWEvdGFibGVyYW5nZTpjMGVjZGU0ZTc3NjQ0YjU3YTY0ZmQxNGFmZTdlYjNhYV8xLTAtMS0xLTI5_2bab2a1e-b803-4b5c-ae2f-330f04bf7dbc">Class A common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzBlY2RlNGU3NzY0NGI1N2E2NGZkMTRhZmU3ZWIzYWEvdGFibGVyYW5nZTpjMGVjZGU0ZTc3NjQ0YjU3YTY0ZmQxNGFmZTdlYjNhYV8xLTEtMS0xLTI5_69cb015f-2e72-4c89-a5e8-ef129b9d40b2">VTVT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzBlY2RlNGU3NzY0NGI1N2E2NGZkMTRhZmU3ZWIzYWEvdGFibGVyYW5nZTpjMGVjZGU0ZTc3NjQ0YjU3YTY0ZmQxNGFmZTdlYjNhYV8xLTItMS0xLTI5L3RleHRyZWdpb246MzUyZDg0NDQ4MWZkNDU2OGJhMjA5MThmYzdhYTRkZmJfNA_f07917d8-9be8-4db3-9918-0a2bec3d10f9">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA5_2e534f99-f89a-4ba4-a2c1-18e42e4b1567">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA0_ca822708-d9b4-4c4a-b086-dea7f82cabd5">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:30.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6NTI5ODBjYmMwMjM3NDY3NmI2NDJmZTE0ZjUyMmM3ZmQvdGFibGVyYW5nZTo1Mjk4MGNiYzAyMzc0Njc2YjY0MmZlMTRmNTIyYzdmZF8xLTAtMS0xLTI5_a83ff6e2-ffe9-4cc1-ad8c-a535eeec0cef">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6NTI5ODBjYmMwMjM3NDY3NmI2NDJmZTE0ZjUyMmM3ZmQvdGFibGVyYW5nZTo1Mjk4MGNiYzAyMzc0Njc2YjY0MmZlMTRmNTIyYzdmZF8xLTQtMS0xLTI5_0124973d-e843-45e4-b8f9-172282e134e7">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6NTI5ODBjYmMwMjM3NDY3NmI2NDJmZTE0ZjUyMmM3ZmQvdGFibGVyYW5nZTo1Mjk4MGNiYzAyMzc0Njc2YjY0MmZlMTRmNTIyYzdmZF8yLTEtMS0xLTI5_60c0d469-48cf-4f7f-9f41-d9682f270484">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA1_7d2824f9-2e04-4b2c-a57b-95b5a524af86">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Class of Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Outstanding as of August&#160;15, 2022</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class A common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ibb646bb66f5041ab8b597cc264142087_I20220815" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YWQ2MjU2YWM3NmJlNDg0MGIyMDk5YWM3ZDNkOTM0Y2IvdGFibGVyYW5nZTphZDYyNTZhYzc2YmU0ODQwYjIwOTlhYzdkM2Q5MzRjYl8xLTItMS0xLTI5_ea319233-83c3-4a67-b047-2f6bae259037">81,483,600</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class B common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i69b2ce3d438f47a6bb0e8a99436f206d_I20220815" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YWQ2MjU2YWM3NmJlNDg0MGIyMDk5YWM3ZDNkOTM0Y2IvdGFibGVyYW5nZTphZDYyNTZhYzc2YmU0ODQwYjIwOTlhYzdkM2Q5MzRjYl8yLTItMS0xLTI5_5747e7da-d477-44ff-86b5-392d18a8f614">23,093,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.265%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv THERAPEUTICS INC. AND SUBSIDIARIES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED JUNE&#160;30, 2022</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE<br/>NUMBER</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_13">Condensed Consolidated Balance Sheets as of June 30, 2022, (Unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_13">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_16">Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_16">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_19">Unaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and six months ended June 30, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_19">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_22">Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_22">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_25">Notes to Unaudited Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_25">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_73">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_73">25</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_109">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_112">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_115">PART II &#8211; OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_118">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_118">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_121">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_124">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_124">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_127">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_127">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_130">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_130">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_133">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_133">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_136">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_136">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i7213a6cb68bb48ed8c21afe0782e56bd_139">37</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (&#8220;we&#8221;, the &#8220;Company&#8221; or the &#8220;Registrant&#8221;), which is the registrant, and those of vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to vTv Therapeutics Inc. and its consolidated subsidiaries.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNC0xLTEtMS0yOQ_61e2fea8-cf43-4d75-b995-d960911aa073">17,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNC0zLTEtMS0yOQ_d946309e-1fd2-46ad-9cfa-ea4ce3dfd182">13,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNS0xLTEtMS0yOQ_7101e365-70a5-4fb5-a885-38c9b0997090">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNS0zLTEtMS0yOQ_cb43490c-4020-4c7f-a9a3-be7d3b202f87">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory note receivable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="vtvt:NotesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0xLTEtMS04NTI3_5a5327f2-ae2b-4a86-aadd-d8f24f8fd6ce">11,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="vtvt:NotesReceivableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0zLTEtMS04NTI3_a23c190b-02f0-408a-9470-b746305306ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0xLTEtMS0yOQ_2f07e035-b72c-41d3-8840-48cc974d71fd">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0zLTEtMS0yOQ_32d18b12-019d-4102-8f0a-967fc5c3bb13">2,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deposits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNy0xLTEtMS0yOQ_4d7b2b23-add4-4767-9fc1-fd02cc0b7010">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNy0zLTEtMS0yOQ_18d0e955-058e-425a-b90a-ed00efd88783">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOC0xLTEtMS0yOQ_f25f20d3-9af2-4bdd-a9d6-9f862ab62501">30,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOC0zLTEtMS0yOQ_d48b7c1a-fa4d-4697-9417-a8e51a7a94f9">15,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOS0xLTEtMS0yOQ_c778a958-8d3b-4446-9801-fc514b4f961b">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOS0zLTEtMS0yOQ_9d89f1fd-a4e0-4707-b9aa-cc0121b130ab">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTAtMS0xLTEtMjk_955a416a-baee-4ff1-94c4-a846d6c8d192">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTAtMy0xLTEtMjk_538d22d1-1f79-4347-8204-e0fea1e7ab64">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTEtMS0xLTEtMjk_79f90e6b-3ccd-475b-ad91-a68345c3d10a">5,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTEtMy0xLTEtMjk_72af8ff3-0827-4aa1-a141-a28e0af5aa78">9,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTItMS0xLTEtMjk_c1d418fb-fb4d-4165-91ec-d715dce61aa9">36,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTItMy0xLTEtMjk_c0861220-8158-40b0-9015-33fdaa08b360">25,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTUtMS0xLTEtMjk_3598ce41-5a7a-48d3-b21e-44f8034d376e">9,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTUtMy0xLTEtMjk_4d299e20-c4ce-4b32-aafb-78ac5fe27cbe">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTYtMS0xLTEtMjk_aaa4e5f2-422e-42ef-a593-53f15a7b94a8">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTYtMy0xLTEtMjk_0a4a3eca-598e-4658-8a47-97d75f25184a">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTctMS0xLTEtMjk_e4bbeb0a-8e94-44ab-b364-68724dbfa68d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTctMy0xLTEtMjk_8a6b476f-d380-4112-b264-b0306d7c44a7">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTgtMS0xLTEtMjk_eb2163d9-ff5d-4656-a61f-e1bb412f0ad5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTgtMy0xLTEtMjk_51567ae4-a74b-477b-9542-5202608df0ed">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTktMS0xLTEtMjk_634f90aa-f4b0-49af-a510-c3ab8f3c7918">9,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTktMy0xLTEtMjk_79aab99d-9bad-47ba-b88d-21946bbf0c46">8,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMS0xLTEtOTE0NA_de6b02d1-f396-493d-867d-4d8a51e05939">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMy0xLTEtOTE0NA_e0f44d20-6b34-419f-9be0-b02c68a31402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjAtMS0xLTEtMjk_899c17d6-a17b-4be0-8854-0f1da0c9caac">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjAtMy0xLTEtMjk_9ecbf6d8-eef9-450f-a382-02eee4bdfcd5">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMS0xLTEtMjk_9f28f5d4-fbbc-4e68-8af5-06953c60cf71">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMy0xLTEtMjk_3624d149-04ce-4e04-a7af-e78885055d74">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjItMS0xLTEtMjk_97987d1c-9a9f-48c2-829a-a5a10761d64c">29,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjItMy0xLTEtMjk_2ed899ee-3910-41ae-9c05-7602660671fc">10,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjMtMS0xLTEtMjk_26e88a6e-aa3e-4891-adc1-975f55f0d191"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjMtMy0xLTEtMjk_65bee427-a682-405a-a434-719ef84f7af3"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjQtMS0xLTEtMjk_aa8b22cd-d1dd-4510-ae99-69e496507dd9">15,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjQtMy0xLTEtMjk_e9eeaf8a-762b-4c76-855a-781aaef49bca">24,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class A common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM18yNg_8fc138ba-7942-4972-b35f-a68113b2c5ca"><ix:nonFraction unitRef="usdPerShare" contextRef="i2632fc86076247a6b51786bef024e90d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM18yNg_fb8554a4-2c30-4912-bd5c-21898f1b5511">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2632fc86076247a6b51786bef024e90d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM180MA_ad72df9f-d24f-48c7-8089-593a8c0ef9a7"><ix:nonFraction unitRef="shares" contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM180MA_d459afb6-bbc3-41c6-95fe-5da52b359792">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i2632fc86076247a6b51786bef024e90d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM182Mg_2d906bbe-3d00-4e10-8359-473bccfae852">77,329,051</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM18yNzQ4Nzc5MDY5NTQ0_6c24785a-4eff-4fb1-94ca-a676daff6b46">66,942,777</ix:nonFraction> shares outstanding as of June&#160;30, 2022, and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2632fc86076247a6b51786bef024e90d_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMS0xLTEtMjk_9fdb402c-bb99-4796-afd4-62c216a96eb5">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMy0xLTEtMjk_2f990362-4cab-4b4e-a7df-76b9e1edded7">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV8yNg_26acd74d-87d3-4049-8b9f-38f399ccca48"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV8yNg_f2f326ff-2a47-4df3-aa80-dd4948ccc345">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV80MA_25865c3d-4b7e-4591-9195-3943086d23f0"><ix:nonFraction unitRef="shares" contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV80MA_99f3a5f0-04de-48cf-a1f8-e2a32901bf3d">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, and <ix:nonFraction unitRef="shares" contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV82Ng_a71c7014-e503-4e17-88b8-112d09f3edee"><ix:nonFraction unitRef="shares" contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV82Ng_e78d1adf-71fa-45f1-ab12-402f6ad38e27">23,093,860</ix:nonFraction></ix:nonFraction> outstanding as of June&#160;30, 2022, and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMS0xLTEtMjk_0687c60f-dc53-4a56-876f-8262f7f8c234">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMy0xLTEtMjk_360705b9-da21-444c-9143-7afe701b4db7">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjgtMS0xLTEtMjk_36bb4c64-b19b-4b21-b4f8-94fbb1b5ff6b">243,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjgtMy0xLTEtMjk_1291f1b5-698f-4c04-be89-a8ae21f16da6">238,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjktMS0xLTEtMjk_654187a8-3f92-4311-99bf-ed82cbe5f961">253,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjktMy0xLTEtMjk_bde5a6ba-8e05-4f39-8eae-4cb421d86d94">248,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit attributable to vTv Therapeutics Inc.</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzAtMS0xLTEtMjk_2633192a-78d2-41ed-b6de-5330508c4635">8,526</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzAtMy0xLTEtMjk_cc93dbc6-c72f-4c07-aab8-0429db83e808">9,740</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzEtMS0xLTEtMjk_074ab28d-f6b7-4fa9-aeb6-4a42d8c6c40e">36,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzEtMy0xLTEtMjk_3089dd21-f5ae-4d4a-8f60-14b32ef358d9">25,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_16"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi0xLTEtMS0yOQ_92bf9ad0-fe91-4fe4-a006-7b72adeb5e78">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi0zLTEtMS0yOQ_5f56dba4-3e87-4b7d-8570-81fccb0c3280">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi01LTEtMS04MzI_d3e00652-025c-457a-a71a-407d455e0986">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi03LTEtMS0yMTg_d295cf1f-a086-4a29-9df8-d4c215755d47">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC0xLTEtMS0yOQ_4e48a6d2-f4ae-4608-89f1-d24f718938f0">2,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC0zLTEtMS0yOQ_db240b16-9b7f-4d35-b6db-2d7775860cc1">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC01LTEtMS04MzI_b60ce223-79b9-4ac0-a678-eddf007a0cee">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC03LTEtMS0yMTg_4bdff61f-0595-4a63-840b-09031883ebed">5,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS0xLTEtMS0yOQ_c0f208f4-6c80-42c7-88e2-1fe0a99d91b4">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS0zLTEtMS0yOQ_b8c28462-4870-4910-a037-0f4f6267de3c">2,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS01LTEtMS04MzI_120dfcf3-cc3c-4e23-a1bd-9e7b7042b48f">7,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS03LTEtMS0yMTg_fe0cea21-8a58-4426-86cc-bccde2e90b39">4,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi0xLTEtMS0yOQ_d469d60b-35a2-4061-bfb3-2a76cd435aee">4,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi0zLTEtMS0yOQ_3e77c42d-aba0-4334-bacf-01c957f04f2c">4,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi01LTEtMS0yMTg_d5227a2d-c789-4220-bf7c-13080ab197b8">12,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi03LTEtMS0yMTg_26eba022-6686-4f98-bec2-c509a8bacae4">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy0xLTEtMS0yOQ_57599c27-660b-4c6a-973f-6876ec272ad9">4,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy0zLTEtMS0yOQ_2b2b4464-e2ca-4d35-a97e-eb8a01bb8deb">4,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy01LTEtMS0yMTg_6676ba0c-d399-40ca-8cb0-1ad63ee22608">10,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy03LTEtMS0yMTg_9e3053ea-03b5-4284-9db0-b055cc9e6648">8,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC0xLTEtMS0yOQ_b5c71716-da7f-48ea-8db2-892c7f6b472e">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC0zLTEtMS0yOQ_556c9c1a-b96c-4af5-9183-8e311fa24fa4">2,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC01LTEtMS04Mzg_6ba24b5e-947d-4a29-87a2-ac33c98c3072">3,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC03LTEtMS0yMTg_fa234744-d1ab-4306-bf5b-f3e15b889dc7">2,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense) &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="vtvt:OtherIncomeExpensesRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS0xLTEtMS0yOQ_1a04797c-7ba1-4597-bd08-2c2f9d3557f2">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="vtvt:OtherIncomeExpensesRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS0zLTEtMS0yOQ_8c930120-d0bc-42b5-b75f-8f935100be65">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="vtvt:OtherIncomeExpensesRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS01LTEtMS04Mzg_5a647283-c854-4901-9df5-10ea6c4b751b">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="vtvt:OtherIncomeExpensesRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS03LTEtMS0yMTg_98297223-8391-42c1-a2f1-89da46e30783">717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtMS0xLTEtMjk_3acf08b2-4172-4429-addf-00aabefd899b">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtMy0xLTEtMjk_193b3252-af10-4ecf-b34d-617e34ae7fdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtNS0xLTEtODM4_4d947658-03de-4900-bbd4-87d1eaa99838">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtNy0xLTEtMjE4_b6423373-2b09-4ec9-9f63-91e5c23b92f9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtMS0xLTEtMjk_bd30b0ea-9d34-4aa8-98b6-86f33ea8e93a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtMy0xLTEtMjk_4245c21f-6573-4f58-8379-bc3ae20abd8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtNS0xLTEtODM4_36e9db6d-aea6-4a51-bb53-1344d0af7cd4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtNy0xLTEtMjE4_fa31649d-bf4a-4f11-a3e8-f5bd7e1e0454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItMS0xLTEtMjk_0bc16a84-6cf4-4e0c-a82d-a7390e46e59d">4,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItMy0xLTEtMjk_0900f228-0f99-42ee-b8c6-3ff3a4f1e82d">841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItNS0xLTEtMjE4_23f47f7b-3805-4cbd-8412-5111af8b6a14">13,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItNy0xLTEtMjE4_15778a2b-4180-4939-829e-44c52b982f54">6,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtMS0xLTEtMjk_f0849f16-6ec9-4e81-913b-63b1a6dcd4e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtMy0xLTEtMjk_d1cd16e0-253a-4ede-ac82-cf76af224158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtNS0xLTEtODQ1_b3c527e0-ff4a-4b21-81da-9da888b4768b">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtNy0xLTEtMjE4_da63571f-7b57-48b1-8044-6bf56643584b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtMS0xLTEtMjk_17dc62d7-3bf4-497a-8300-c76eb8a1264b">4,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtMy0xLTEtMjk_f31c59d6-3622-443f-8884-a29135b97064">841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtNS0xLTEtMjE4_1f8fddde-81af-46aa-beb4-9a2138d76874">13,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtNy0xLTEtMjE4_05839e48-c0f2-4405-a96d-c500d8fa83ec">6,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtMS0xLTEtMjk_3e0cdee1-e1b3-4e34-8c49-ef77ea808667">940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtMy0xLTEtMjk_6af9eddd-bae6-4563-b5e9-9b85181f9f75">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtNS0xLTEtODUx_7d248093-517a-4488-88e6-d0568ac2f016">3,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtNy0xLTEtMjE4_7f13bf1a-2a2e-49c7-b06e-ca7f371f9d23">1,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtMS0xLTEtMjk_0e2fb8d8-04e7-41b2-a3c9-68fefee75e57">3,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtMy0xLTEtMjk_9d67cb37-3dc3-4800-bebc-6185ba5c4a09">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtNS0xLTEtMjE4_8c3db74f-43a7-4271-8f5f-899d0ba66c4d">10,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtNy0xLTEtMjE4_48bf5ffd-3d8c-4870-82fc-356738c5c7ed">4,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctMS0xLTEtMjk_48a67a14-26c7-410e-a337-a51d20783829">3,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctMy0xLTEtMjk_444c0cae-6d12-4329-b298-f057133d1947">608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctNS0xLTEtMjE4_a860a057-acc5-42c5-9596-27b93bb83479">10,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctNy0xLTEtMjE4_6bc5c83e-a3fc-4000-ac3c-4eb5ef6be6b3">4,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMS0xLTEtMjk_b6d50319-8b88-48af-8663-6ff52c8a9841"><ix:nonFraction unitRef="usdPerShare" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMS0xLTEtMjk_f6721566-cbec-41d3-b653-4da486fe842f">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMy0xLTEtMjk_5c327321-cd7f-4195-ad46-8c41a324e040"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMy0xLTEtMjk_fa2cf0fe-9ed2-4a1c-8a7b-6a8eca3d17ad">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNS0xLTEtODU3_9898b392-ebe3-4e7d-bb93-bcbcaa095b3a"><ix:nonFraction unitRef="usdPerShare" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNS0xLTEtODU3_a605d9d5-9e1d-462e-a4da-1b6c56d0a8d2">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNy0xLTEtMjE4_47d2c0f1-ef6c-46bd-a300-441f19c81d91"><ix:nonFraction unitRef="usdPerShare" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNy0xLTEtMjE4_6669e51e-bb84-4342-80d5-292ce1cdde37">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMS0xLTEtMjk_ab19c233-cd3b-409c-a35d-de98aec65362"><ix:nonFraction unitRef="shares" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMS0xLTEtMjk_e34fa6ea-7a20-48a9-ac72-5e7be50560c4">70,366,823</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMy0xLTEtMjk_5be5ba91-092b-4b98-90ed-5b564d316d0f"><ix:nonFraction unitRef="shares" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMy0xLTEtMjk_8477af44-2f82-4f21-b652-0a8b4c4d2ed6">58,615,137</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNS0xLTEtODU3_207f1f0c-e738-47d0-b9b5-67916e7cd863"><ix:nonFraction unitRef="shares" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNS0xLTEtODU3_4c91b6aa-afeb-43bd-9d43-9867efa8b3fb">68,664,259</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNy0xLTEtMjE4_5990c9b8-df86-4e78-b037-8f71cc5a1129"><ix:nonFraction unitRef="shares" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNy0xLTEtMjE4_c07e6a21-bf27-4215-873f-aabb55a68d2f">57,549,755</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.869%"><tr><td style="width:1.0%"></td><td style="width:22.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the three months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e22736f72b44c9afae821088c0ab77_I20220331" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xLTEtMS05Mg_da6aeb74-f8e6-4bff-948c-1000607aacdd">14,367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i009bfc074c5a4c0e9142f9616b19f90c_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy00LTEtMS05Mg_5385914f-1496-4d4a-8ed7-7c59dc99043b">66,942,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009bfc074c5a4c0e9142f9616b19f90c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy02LTEtMS05Mg_e1b52ece-43df-4d51-83b0-08f42a958ff0">669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb85c14dc2c74e2996fe107888561e93_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy04LTEtMS05Mg_59d89db7-9a62-4989-885d-37482c453344">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb85c14dc2c74e2996fe107888561e93_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xMC0xLTEtOTI_88ef409b-7bf3-4e71-b297-3f24b3f29816">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id905d604d9a943f6b7cb9f24d0dd0b48_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xMi0xLTEtOTI_2f52cee6-b977-41a5-b10e-125097ee67a7">238,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29266001f249497b93b47c8e3466fd61_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xNC0xLTEtOTI_f7cc50b7-d45d-4787-a735-772aba7d25e2">247,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ef5bed40ce94a93a2cd11d663f62d4f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xNi0xLTEtOTI_04a24069-a7f4-4cc4-9b79-74ef3b22b91d">8,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae4134a6e3344ae8ad4af1f2240f9dd5_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNC0xLTEtMS05Mg_e93f4e09-2b3f-4293-9cd5-c44d8f153092">940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib755a24e8a104d1d8d2b3d1f74c11d40_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNC0xNC0xLTEtOTI_036b7346-9a16-4c4d-a0b6-69d06a3c19bf">3,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNC0xNi0xLTEtOTI_500ad076-e554-481d-8712-0e09dce8b6e6">3,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef80539aee48d48e6f1bb3a8119477_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNS0xMi0xLTEtOTI_911349c4-db27-4bf0-81ae-8b1b046406c7">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNS0xNi0xLTEtOTI_2f5d6ed5-3304-410b-9f74-d24be9be3cf6">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock to collaboration partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49b8aa8d7eba49128b8f62637d391235_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi00LTEtMS00MDgy_a2d89fa5-d62b-4604-aa7e-92f19e653cb0">10,386,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b8aa8d7eba49128b8f62637d391235_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi02LTEtMS00MDgy_87b6050b-64e5-480c-ac10-055ab547d5bc">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18238700dcf14e91a75ec3b06d1825b1_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xMi0xLTEtNDA4Mg_a4af8a1f-d13b-4d0e-bdff-a687795770e4">4,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xNi0xLTEtNDA4Mg_e2167b2c-1bec-4ade-9437-4d8ea2858919">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4134a6e3344ae8ad4af1f2240f9dd5_D20220401-20220630" decimals="-3" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xLTEtMS05Mg_23e167ea-29a1-4a97-bb76-8545bb529d3d">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib755a24e8a104d1d8d2b3d1f74c11d40_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xNC0xLTEtOTI_036e75a6-0bfb-49a2-a945-27d9a4e754fb">2,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xNi0xLTEtOTI_4b8797fa-e6c7-469f-a20f-43ad6422ea56">2,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22caf6e5b694a3bbc1d3ce68d75a410_I20220630" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xLTEtMS05Mg_9bcbe05c-2b85-43d9-931f-eb2b7f9672c7">15,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy00LTEtMS05Mg_0c408d46-6005-43c4-be9b-7296eab789f7">77,329,051</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy02LTEtMS05Mg_24cdcd44-f704-4487-8cb9-b3ce93b74c6d">773</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy04LTEtMS05Mg_1648a1d2-4852-4776-a1d1-cc0efef9d2be">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xMC0xLTEtOTI_925c09da-f0b4-49a6-8729-dbca42fdc363">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8450413dbc4dd08d8c7650588aa198_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xMi0xLTEtOTI_5951dbd6-4037-42e5-a956-497ade5a369a">243,772</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i126a3208a6f742618c2561e7779f1845_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xNC0xLTEtOTI_714d09fd-34f8-4ffe-bcf4-963647ae2d30">253,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xNi0xLTEtOTI_5ef63b4c-47ca-4320-b574-a1d3551f634c">8,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.869%"><tr><td style="width:1.0%"></td><td style="width:22.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the three months ended June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balances at March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id982b9b09f424a87922b57be194129cb_I20210331" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xLTEtMS0xOTMz_97417c00-8b9f-45f3-855a-d1c5a990e992">62,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff9c4e329b59464eb907f13b780450d1_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy00LTEtMS0xOTMz_71c8b064-6997-4313-9ce6-59ebf23b80be">57,571,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9c4e329b59464eb907f13b780450d1_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy02LTEtMS0xOTMz_fb43921d-410f-4788-9628-1bdf5f59507d">576</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a489bb6b0fe43528a20c591702e09b0_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy04LTEtMS0xOTMz_745a00d2-10b3-40c0-8862-ba63e59fb3a9">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a489bb6b0fe43528a20c591702e09b0_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xMC0xLTEtMTkzMw_45032156-aff7-4f31-94dd-806f72518e47">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6da094d9ac4affabf82ba8cee1e10f_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xMi0xLTEtMTkzMw_2863bf81-af96-4656-b436-496f25a83bca">217,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb0cff36c95e4303a0941bafd6699028_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xNC0xLTEtMTkzMw_dbe46e24-9293-4956-9435-72b1c8434458">274,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b13159810f0458a9344038beefe7235_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xNi0xLTEtMTkzMw_c21bbb39-170c-436e-9528-79b5c6c369e4">56,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c3c142ca894d3192a385912e6b2355_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNC0xLTEtMS0xOTMz_30234f8c-506c-46d3-9af3-3b3d23718343">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76098cfb60b247ba8a2e8ee82578378e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNC0xNC0xLTEtMTkzMw_c72c5634-4bae-4648-8dbb-b53c30157b9f">608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNC0xNi0xLTEtMTkzMw_074cd4c1-0df8-47a4-bc09-fceb374e27fb">608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNS0xMi0xLTEtMTkzMw_68eadd29-0324-4e5f-821c-a36becad32f2">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNS0xNi0xLTEtMTkzMw_cd9cc7d3-4db6-433d-9b34-3ec8224d8d1b">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock under ATM offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630" decimals="INF" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi00LTEtMS0xOTMz_6df68544-30b0-42f2-8c77-f21369580976">2,180,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi02LTEtMS0xOTMz_276d183d-3f92-4079-b708-9d90fe184394">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi0xMi0xLTEtMTkzMw_4a6e6cca-6db4-48a3-a118-6d7fecccaa94">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi0xNi0xLTEtMTkzMw_dbe6e504-6643-4ff5-a400-39b721936f2c">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock under LPC Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630" decimals="INF" name="vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy00LTEtMS0xOTMz_8e2ae32e-3ed8-4c51-bbdb-774cf361e5bc">441,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy02LTEtMS0xOTMz_2479c7db-1312-4b7f-9be1-9865f5d54b47">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy0xMi0xLTEtMTkzMw_359689fb-4335-40dd-bf90-8e5c9efc9966">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy0xNi0xLTEtMTkzMw_c4ee7718-80ba-45e2-a2d7-bbed61f24ae8">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c3c142ca894d3192a385912e6b2355_D20210401-20210630" decimals="-3" sign="-" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOC0xLTEtMS0xOTMz_9223a671-be86-4d9f-a844-930154432bee">2,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76098cfb60b247ba8a2e8ee82578378e_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOC0xNC0xLTEtMTkzMw_20ac1cb6-f78d-48b7-b385-f85307da914c">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOC0xNi0xLTEtMTkzMw_12067e5d-1bc4-4e82-9fdc-b972993bd557">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9521269fab34466aa92f8122d2b5d869_I20210630" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xLTEtMS0xOTMz_5a77badc-fc71-4105-aa93-26912f59e5d0">60,190</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c32876481864865b9c009d36cd4047c_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS00LTEtMS0xOTMz_6edc541b-dad0-4beb-a4c1-f6479771a9cc">60,193,967</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c32876481864865b9c009d36cd4047c_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS02LTEtMS0xOTMz_9458507f-15e3-4de4-a6aa-6199aa546f66">602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS04LTEtMS0xOTMz_ab47ddbf-a4e0-4080-841c-32f9a1175690">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xMC0xLTEtMTkzMw_037b55d9-df19-49be-af1a-0e158b79838d">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f41641fa7594bc5b38df0be185b457b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xMi0xLTEtMTkzMw_bbe9d984-ef21-4eb8-9edb-f4ffbfcc1660">224,457</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09ea0ea093f946ddbe1ea6abb5d7c0ef_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xNC0xLTEtMTkzMw_bc4f1176-46d0-4ef0-adef-e2043be9d191">273,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xNi0xLTEtMTkzMw_a44597e2-c666-43f2-a317-95b8f2fa3e66">47,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the six months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at December 31, 2021</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xLTEtMS0yOQ_3d93f45e-8cda-4e94-8bf6-740fc2be0d80">24,962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62d8796c4850440b83f57f0567a7ca07_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy00LTEtMS0yOQ_bef20b97-b383-4f60-997a-22b96e859f6e">66,942,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d8796c4850440b83f57f0567a7ca07_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy02LTEtMS0yOQ_19a37ad1-a0d8-45ef-82c8-d7f9e4b7b9af">669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c5abc9ec8fa4a5eb2faeea6cc161c75_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy04LTEtMS0yOQ_d47f7a6f-29f9-41e8-88db-c9135816d2d4">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5abc9ec8fa4a5eb2faeea6cc161c75_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xMC0xLTEtMjk_9d0a5237-3712-4089-9e80-6b08125c0a0c">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6abbeb4fa947868b13efda9bde3af0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xMi0xLTEtMjk_6227a0e9-d789-4034-be50-1b4d5c091ec4">238,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia20f8626d64245639e72db76234f04ba_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xNC0xLTEtMjk_b7db9d48-5938-4008-95f3-262bf1a0fef7">248,834</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xNi0xLTEtMjk_8e0a2dfb-bfb2-48bb-8f2e-43fb1ab5e40f">9,740</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNC0xLTEtMS0yOQ_430c480a-eb77-48b8-8c59-31a0e9d00497">3,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc5c6b914922483ab2156d1e3c1fd332_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNC0xNC0xLTEtMjk_73cec52d-efd1-4dce-b001-5058b19a3dfb">10,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNC0xNi0xLTEtMjk_c735e2f7-f30e-438d-8127-340d92ba1d32">10,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6587de2ee5f8460daad2b87becd8ceea_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNS0xMi0xLTEtMjk_cf6140e0-9251-418f-861d-fd9929bdb6dd">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNS0xNi0xLTEtMjk_cfa18188-c099-473c-8b79-cda673111283">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock to collaboration partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd2ad5a54d8145b688887e50ede3f142_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi00LTEtMS00MDkx_c5fab4dd-3475-49be-9878-b1ae4262d70e">10,386,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2ad5a54d8145b688887e50ede3f142_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi02LTEtMS00MDkx_4401801b-bb82-4c6c-b7a5-20502216ad06">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a34cc4ae17f472882c70dc69f0341b7_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xMi0xLTEtNDA5MQ_7c18dfa7-f53b-44b9-b6d8-e312d199a561">4,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xNi0xLTEtNDA5MQ_73921fd1-fdd2-4b15-ac16-787eeff862da">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xLTEtMS0yOQ_3c000d24-e826-4cb0-8b2a-434244cab697">5,689</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5c6b914922483ab2156d1e3c1fd332_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xNC0xLTEtMjk_59073cf3-d3c1-4403-b66f-e2c01bad2494">5,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xNi0xLTEtMjk_72240d3b-4d32-476c-a2a5-e00b8178d570">5,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xLTEtMS0yOQ_d0053964-cd68-4cb7-aa73-1c1a906e9a80">15,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy00LTEtMS0yOQ_0d848ee2-f879-4660-a3e8-bcbd435536c5">77,329,051</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy02LTEtMS0yOQ_61d23574-2e84-42db-bd76-2bba2f262495">773</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy04LTEtMS0yOQ_e83d1f61-934a-46be-ace0-0ba4dfe4d97f">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xMC0xLTEtMjk_f98214c3-030b-40eb-8f09-d282268e91bb">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8450413dbc4dd08d8c7650588aa198_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xMi0xLTEtMjk_3b9eec52-cd98-445e-92c5-5f3c5eff3255">243,772</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i126a3208a6f742618c2561e7779f1845_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xNC0xLTEtMjk_4d7fe64b-8afd-479b-ae33-11c67c5dcc62">253,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xNi0xLTEtMjk_2c7f58e4-8224-4685-a948-66460685a3df">8,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the six months ended June 30, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balances at December 31, 2020</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xLTEtMS0yOQ_b469fbc6-1db1-4544-bd3b-59d8c2439af5">83,895</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4d8922a188e43c18738058811905e2c_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy00LTEtMS0yOQ_7ff74c91-8425-4f90-96ea-bff59122f752">54,050,710</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d8922a188e43c18738058811905e2c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy02LTEtMS0yOQ_55187918-e1ab-480f-82c3-81f15761652e">541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb96586842464c818639a9b0f427cca5_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy04LTEtMS0yOQ_23d6fcb9-e03f-44b6-a0db-0cc52ec9be70">23,094,221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb96586842464c818639a9b0f427cca5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xMC0xLTEtMjk_9848c94e-ab31-4bbd-9b68-12a30624bd47">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a93b41b9e8482d8c8a5e90eb6fc5f6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xMi0xLTEtMjk_a89e81d9-7c26-4436-b561-2f9c9563b43b">209,161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i548922a8ebe2493e96679d156ae2662c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xNC0xLTEtMjk_16f52b53-01f6-4178-96b2-46114d41ee6d">290,036</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xNi0xLTEtMjk_4682f6bc-70ba-42b0-8589-53c051af575c">80,102</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNC0xLTEtMS0yOQ_2090fba1-b29c-4331-83b8-15e94f87a8cd">1,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c78efac0aa24b009a92ea9b1b7ce7c6_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNC0xNC0xLTEtMjk_431e63fc-21a6-4bbd-8951-e2e3cae25d37">4,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNC0xNi0xLTEtMjk_88aadff9-dc6d-4941-96f8-5b47b8dead5f">4,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNS0xMi0xLTEtMjk_364d5a1b-1f77-4b35-b060-6551152aee0e">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNS0xNi0xLTEtMjk_bfa3b834-4f98-4720-aebf-ad0fd2954c0c">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock under ATM offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi00LTEtMS02MTMx_c866febf-dae3-4afe-b602-ce7a10029598">2,180,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi02LTEtMS02MTMx_0f12fce1-dc75-45d1-98ba-68b6daa9be9f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e056239209f42eb89288f0b10c1d786_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi0xMi0xLTEtNjEzMQ_f5e63ac8-e88d-4526-95d7-436bfc3f26ad">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi0xNi0xLTEtNjEzMQ_86c579d4-025b-42c4-87df-10c3ba7ef30f">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exchange of Class B common stock for Class A common stock</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi00LTEtMS0yOQ_437b83a7-9a89-4311-ab27-4a1eeac89419">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i70938c26b4624098aef25d030f5a7a61_D20210101-20210630" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi04LTEtMS0yOQ_92a37a13-6f44-4a9a-9d2f-e37147303620">361</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNy00LTEtMS0yOQ_f0065d0d-15a1-49c8-8be6-bd3b62830f59">20,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNy0xMi0xLTEtMjk_9eaf4223-2427-4d64-a667-63531daf1070">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNy0xNi0xLTEtMjk_5881b382-b678-4de3-b7fb-b93c276422ef">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock under LPC Agreement</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630" decimals="INF" name="vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC00LTEtMS0yOQ_f7cf99fb-4aa8-42a2-ad38-e9f18b02fd15">3,941,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC02LTEtMS0yOQ_2802b055-f74a-4dab-990b-4bd5043a1ee0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC0xMi0xLTEtMjk_20c67b63-cb43-424c-bcfc-d33f997527cf">9,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC0xNi0xLTEtMjk_b336d761-0db6-4f08-b445-c4672c40815b">9,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOS0xLTEtMS0yOQ_a6e3d6b7-f629-4afe-a73b-1e315480e4a4">21,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c78efac0aa24b009a92ea9b1b7ce7c6_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOS0xNC0xLTEtMjk_0cbec8e0-2797-455b-ab0b-da3685bab538">21,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOS0xNi0xLTEtMjk_b270afd6-a949-4ef7-9fa0-3e2aebbbdb53">21,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMS0xLTEtMjk_b4d70168-6bb2-4909-9069-59dae042bf77">60,190</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c32876481864865b9c009d36cd4047c_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtNC0xLTEtMjk_8590ffc6-c94f-4152-a892-25027ad13276">60,193,967</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c32876481864865b9c009d36cd4047c_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtNi0xLTEtMjk_206281f6-cf46-4d0c-9ee3-ff79cac0c52c">602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtOC0xLTEtMjk_d9822d25-2e68-47c1-ad1d-ca797d554cb4">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTAtMS0xLTI5_584395f4-dfa6-4dbe-aae1-54e0a3daa4e9">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f41641fa7594bc5b38df0be185b457b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTItMS0xLTI5_c9e1d1b1-c3a0-4fb2-9800-1a4346a2da58">224,457</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09ea0ea093f946ddbe1ea6abb5d7c0ef_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTQtMS0xLTI5_c886af3c-6188-471e-93fb-71b8a6b01044">273,114</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTYtMS0xLTI5_0e651b9c-f7d5-4ee4-9691-9e41a23f5874">47,823</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMy0xLTEtMS0yOQ_dbdcb811-b181-4095-a049-ed581e80c13a">13,515</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMy0zLTEtMS0yOQ_c92e3c45-197e-4a99-aebd-554ee2e460aa">6,783</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNS0xLTEtMS0yOQ_1486266f-3776-4219-bb15-eec67ceb520d">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNS0zLTEtMS0yOQ_7cc1054e-556c-47c7-812d-81920be4cf5a">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0xLTEtMS0xMjEzNA_4c79a055-9c68-435e-b67d-5b3b72293a2c">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0zLTEtMS0xMjEzNA_a7f54658-8601-40e6-857a-edbde4521f5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0xLTEtMS0yOQ_26334554-2efa-4ab0-b658-0effac2deb55">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0zLTEtMS0yOQ_18234489-d632-4a0e-80fc-2bb57dd3ff88">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNy0xLTEtMS0yOQ_4443f8fc-c8ce-48c8-8c9b-bf65330dda5e">3,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNy0zLTEtMS0yOQ_c491b75f-e087-4b1a-b7d3-4e117a61f8b7">2,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants, related party</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="vtvt:ChangeInFairValueOfWarrantsRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfOC0xLTEtMS0yOQ_be72e241-a64e-4b84-a659-dca0fcb8552a">545</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="vtvt:ChangeInFairValueOfWarrantsRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfOC0zLTEtMS0yOQ_6d3696e3-7878-49ec-9505-4ae856f6643a">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTAtMS0xLTEtMjk_d00f3655-d331-4666-a90a-047fb1ad500c">20</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTAtMy0xLTEtMjk_530c15a0-049f-498b-9e7c-f541b2533954">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTEtMS0xLTEtMjk_b09c897d-813e-4dc6-ab2e-6e4171e33b00">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTEtMy0xLTEtMjk_f0554c81-6db4-4b9b-b404-ba6417fd9108">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTItMS0xLTEtMjk_239618aa-0f54-4d3d-9d4a-ef3a97881976">1,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTItMy0xLTEtMjk_5c95ba63-9ed2-4d26-9806-af6e0c9cb682">1,302</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTMtMS0xLTEtMjk_61d3576d-93fe-46db-960c-2d0fe6df8bf3">6,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTMtMy0xLTEtMjk_c9b983ba-20a5-4104-9de8-bf64ce4dfa94">996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTQtMS0xLTEtMjk_eb1e1b51-2e42-42b9-9ee5-2fc8075ca164">315</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTQtMy0xLTEtMjk_f05cbd6b-a1d0-4d74-959e-501e77de8052">9,297</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMS0xLTEtMzg3MQ_9ad04297-16f6-4733-8063-e9e35c3a8b16">21</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMy0xLTEtMzg3MQ_5e35c764-9838-4427-bd5e-474cdf0acf4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMS0xLTEtMzg3MQ_bd8742da-a515-449b-8051-4bf21dbb2a8f">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMy0xLTEtMzg3MQ_886c7052-cfc1-41df-9560-bb0c6c25b89d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Class A common stock to collaboration partner, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="vtvt:ProceedsFromSaleOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMS0xLTEtMzg4Mw_8b8be86a-2160-4a33-a5f3-74f635bb93d0">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="vtvt:ProceedsFromSaleOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMy0xLTEtMzg4Mw_7b2b8619-8e0f-4437-80cf-34fb1e906ffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Class A common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMS0xLTEtMjk_ba51868e-f641-40da-9255-063a3e2a6cae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMy0xLTEtMjk_49a052d9-c059-4e9f-aa35-06eaac7a671a">14,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMS0xLTEtMjk_7c37405d-30f0-4c27-a333-b588b15661af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMy0xLTEtMjk_978a903b-2f95-432f-894d-2cd2bd08634b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of notes payable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTgtMS0xLTEtMjk_02dc8f08-cb2a-4774-b088-8eadab2e717c">256</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTgtMy0xLTEtMjk_d114c3c6-895d-4248-904d-786a8e65c001">84</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMS0xLTEtMjk_68565bbd-2046-4b94-8678-d3b43e5dbab9">4,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMy0xLTEtMjk_061c139a-8538-4110-9e32-317b9a3d1ae6">14,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjAtMS0xLTEtMjk_f7d71d7d-add1-4b07-9bcf-1df9945404b2">4,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjAtMy0xLTEtMjk_f5399a87-cd1f-4b43-a23c-0d0717f26eb3">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjEtMS0xLTEtMjk_28305098-2f64-41a8-b6f7-db448be05e12">13,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjEtMy0xLTEtMjk_9216c740-0508-4bac-9f07-c201b2714088">5,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash and cash equivalents, end of period</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjItMS0xLTEtMjk_99334077-f54f-4cd2-a918-7b48498f0dea">17,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjItMy0xLTEtMjk_896f53fb-71b4-4a38-b59a-5cbe6205dc4b">10,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjUtMS0xLTEtMjk_7098f637-3070-4759-8a2b-4ee8448eba4a">5,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjUtMy0xLTEtMjk_08cecb9f-af49-4a34-8a7f-1873e0c50210">21,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable recorded at fair value from collaboration partner</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:NotesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMzEtMS0xLTEtODk3MQ_9636e173-14e2-4af0-82d4-06b418f1571f">11,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:NotesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMzEtMy0xLTEtODk3MQ_79a1dfc8-d1f1-47d4-ae51-2c4dd57a9bb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements &#8211; Unaudited</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollar amounts are in thousands, unless otherwise noted)</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_28"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNjIyOQ_16775de5-cc99-4f2c-98f4-5aea97e21df6" continuedAt="i9e9148b6d2fc4e299471fd8993f3cdf2" escape="true">Description of Business, Basis of Presentation and Going Concern</ix:nonNumeric></span></div><ix:continuation id="i9e9148b6d2fc4e299471fd8993f3cdf2" continuedAt="ifd11cbc5e3d6482f85b15963ad0e00ae"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary, which is a clinical stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Condensed Consolidated Financial Statements. As of June&#160;30, 2022, various holders own non-voting interests in vTv LLC, representing a <ix:nonFraction unitRef="number" contextRef="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfMTU1OA_f82adf74-80b8-409b-9f09-38a10c907d14">23.0</ix:nonFraction>% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#8217;s interest to <ix:nonFraction unitRef="number" contextRef="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterestByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfMTY1MQ_f1e1f955-3f68-473e-875e-67dc66d7e507">77.0</ix:nonFraction>% of vTv LLC&#8217;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (&#8220;vTv Units&#8221;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of Class B common stock) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#8220;Lenders&#8221;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#8220;M&amp;F Group&#8221;), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates &#8220;MacAndrews&#8221;). in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (the &#8220;Letter Agreements&#8221;).  In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor Fitzgerald&#8221;) (the &#8220;ATM Offering&#8221;), the purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) (the &#8220;LPC Purchase Agreement&#8221;), and the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#8220;G42 Investments&#8221;) (the &#8220;G42 Purchase Agreement&#8221;). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern and Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June&#160;30, 2022, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June&#160;30, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNDEyNw_43c6b77d-af5f-49fd-a217-56e217335073">253.3</ix:nonFraction> million and has generated net losses in each year of its existence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company&#8217;s liquidity sources included cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNDI3MQ_8c753637-f2ad-4a79-ac26-425cbef5fec4">17.9</ix:nonFraction> million. To meet our future funding requirements into the third quarter of 2023, including funding the on-going and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also has a promissory note of $<ix:nonFraction unitRef="usd" contextRef="id13a79cf23134033b57b9a418c172263_I20220630" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfMjc0ODc3OTA3OTQ4Mg_18a90141-21cf-496e-88dc-eef7b84828ed">12.5</ix:nonFraction> million under </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="ifd11cbc5e3d6482f85b15963ad0e00ae"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the G42 Purchase Agreement payable to the Company on or before May 31, 2023 (see Note 9) and on July 25, 2022, announced a $<ix:nonFraction unitRef="usd" contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNTQ5NzU1ODIzOTA4_e01793d3-5286-4d6f-b375-3d1963bd5d32">10.0</ix:nonFraction> million investment by CinPax, LLC (see Note 14).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also use its remaining availability of $<ix:nonFraction unitRef="usd" contextRef="i510f76f9961e4195a66c407fea3e33b3_D20220101-20220630" decimals="-5" name="vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNDc4NA_066d9807-e4ad-4352-8e9a-62deab961c6d">37.3</ix:nonFraction> million under our Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company&#8217;s Class A common stock (the &#8220;ATM Offering&#8221;) and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ability to sell an additional <ix:nonFraction unitRef="shares" contextRef="ic87a37201a68429d87e70c2c68af37bb_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNTA4OQ_a05362c3-b724-4cb7-a42d-b0c12d2f750a">9,437,376</ix:nonFraction> shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 9 for further details. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact on our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_31"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA4MQ_17f6d26c-e1dd-4c07-908b-8838c48a2f95" continuedAt="i24ebe8fd32a84f66b83928f4eaaddbab" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i24ebe8fd32a84f66b83928f4eaaddbab" continuedAt="i22b26634ef304f348b14bfce0888dc34"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3OA_12b435dd-0c12-446b-ba6c-adc53c4557ba" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2022, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and six months ended June&#160;30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2021, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of June&#160;30, 2022, the results of operations for the three and six months ended June&#160;30, 2022, and 2021 and cash flows for the six months ended June&#160;30, 2022, and 2021. The December&#160;31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3Nw_2fcfac56-60b5-4d11-a058-4f3a2af2bea5" continuedAt="ic7f48df631534f08baa93cce259b84f1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note receivable, and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i22b26634ef304f348b14bfce0888dc34" continuedAt="ic390b550d61b4c5a9b8e80e13c1afaa4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7f48df631534f08baa93cce259b84f1">experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</ix:continuation></span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3OQ_a49b93fc-cd67-418a-9cf7-c937743cf2d7" continuedAt="i7d4f250fe14b4c58b1c904aa46f46e15" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d4f250fe14b4c58b1c904aa46f46e15">One customer represented <ix:nonFraction unitRef="number" contextRef="iec7d98d909f742f7b497b0166dc0cd42_D20220401-20220630" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_0a0ae344-f568-40f1-8c9a-390556e6bee4"><ix:nonFraction unitRef="number" contextRef="i59fc879b99594e4fa12d9fd8e5ab7977_D20220101-20220630" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_87bce2d4-44c7-4f30-97ab-73e14ddeaaed"><ix:nonFraction unitRef="number" contextRef="ic3050c6fe4714d81b1d708a35d3bfc8d_D20210401-20210630" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_f7a11484-b8bd-452b-a6d8-648628caf300"><ix:nonFraction unitRef="number" contextRef="ia89b7ff0156f46f6af23549fe63c886b_D20210101-20210630" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_f8f7af41-5815-4a1b-9a81-4b7fa7e7610c">100</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the revenue earned during the three and six months ended June&#160;30, 2022, and 2021, respectively.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA4MA_0a853ac2-deff-4134-91ce-47b62b08fcfa" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3Mw_e97707ee-b767-4110-960c-d0cd2b2ad43f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3NA_f36a02a8-0eeb-435e-afa9-17c77ad52602" continuedAt="iaf0b99f6fab04c49b8948d376e365fa5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf0b99f6fab04c49b8948d376e365fa5">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3NQ_b62f26dd-c0e2-4ed7-996f-1e6f8c552289" continuedAt="idb965b1d4c474d4b87b69754adfeb92d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="ic390b550d61b4c5a9b8e80e13c1afaa4"><ix:continuation id="idb965b1d4c474d4b87b69754adfeb92d"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div></ix:continuation><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3Ng_2bb88f23-9410-4ac3-897f-a6e824fbce54" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_34"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA5OTM_38782788-fd44-401c-b00a-1f2fe12ac432" continuedAt="i350a38f5c9d34576867defa927a0f303" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i350a38f5c9d34576867defa927a0f303" continuedAt="i6850b57742784ff583e4afce49139477"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;), pursuant to which the Company sold to G42 Investments <ix:nonFraction unitRef="shares" contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTUxNw_49eff64d-86da-487b-8daa-e14111ae5ebf">10,386,274</ix:nonFraction> shares of the Company&#8217;s Class A common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTUyNQ_1116bf01-1913-46e3-aab3-98c840982fc9">0.01</ix:nonFraction> per share (the &#8220;G42 Common Stock) at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTUzMw_b20464af-71da-479a-bb6c-f878358ecf5f">2.41</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTU0OQ_aa63db3e-bddf-4ac8-88f0-9115953e9ca2">25.0</ix:nonFraction> million, which was paid (i) $<ix:nonFraction unitRef="usd" contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTU5MQ_000e5d3e-36d9-4172-8e9b-52f9aef343e3">12.5</ix:nonFraction> million in cash at the closing and (ii) $<ix:nonFraction unitRef="usd" contextRef="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTU2NQ_4c418cdc-5c56-4883-8fff-65230cc953bb">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments to be paid at the <ix:nonNumeric contextRef="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531" name="vtvt:SaleOfStockConsiderationReceivablePaymentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTE1NDQ4NzIxOTc2MjM_1b8ce159-46a0-4a47-bef0-d61eeecb596a">one-year</ix:nonNumeric> anniversary of the execution of the G42 Purchase Agreement. As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company&#8217;s board of directors approved appointing the new director to the Company&#8217;s board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;FDA Approval&#8221;) of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#8220;Cogna Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#8220;Cogna&#8221;) (&#8220;Collaboration Partner&#8221;), which requires Cogna to work with the Company in performing Phase 3 clinical trials for the Company&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compound (the &#8220;Licensed Product&#8221;) as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Cogna Agreement, Cogna will obtain rights to the Company&#8217;s license of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for purposes of performing Phase 3 clinical trials in the Partner Territory, but will not have access to the various intellectual property (&#8220;IP&#8221;) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. Separately, the Company will conduct its Phase 3 clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. at its own cost that similarly </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i6850b57742784ff583e4afce49139477" continuedAt="i17b9c99185df419380a06c1596b8b7aa"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not be reimbursed. The results of each party&#8217;s Phase 3 clinical trials will be combined by the Company to seek FDA approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Cogna Agreement, Cogna has the right to develop and commercialize the Licensed Product in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of FDA approval of the Licensed Product, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $<ix:nonFraction unitRef="usd" contextRef="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531" decimals="-5" name="vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE2NTMyMQ_80b69025-f3c3-4dff-9bb5-5c6d6f52a905">30.0</ix:nonFraction> million or (b) the payment by the Company of $<ix:nonFraction unitRef="usd" contextRef="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531" decimals="-5" name="vtvt:CollaborateArrangementContingentConsiderationTransferredCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE2NTQ1Ng_26fd75ab-cc72-4cf1-a61a-4ab845db02d1">30.0</ix:nonFraction> million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, are conditioned upon receipt of the FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA Approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territories, the Company will receive royalties of <ix:nonFraction unitRef="rate" contextRef="ia52cbec3f3c34ef984af52054ced737b_I20220531" decimals="2" name="vtvt:CollaborativeArrangementRoyaltiesReceivablePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTE1NDQ4NzIxOTc2MjU_80a7dd85-60b2-41de-a53a-0d58d452881c">8</ix:nonFraction>% from Cogna on the sale of the Licensed Product for <ix:nonNumeric contextRef="i391171de436948d1ab5c2af5c2a6b7c3_D20220531-20220531" name="vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTE1NDQ4NzIxOTc2Mjg_10012510-1373-441c-b246-84f1a12fc04f">ten years</ix:nonNumeric> after the first commercial sale of the Licensed Product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#8220;Recently Issued Accounting Guidance&#8221; in this 10-Q for details of the ASU.  Accordingly, the Company determined that cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i660eadb2cefb42f6af2828654b2ecaad_I20220531" decimals="-5" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjA0NzMxNDA2MjMxMw_d911f193-af39-4cb8-93d7-3a3c63dca3ce">5.7</ix:nonFraction> million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i660eadb2cefb42f6af2828654b2ecaad_I20220531" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTc4MA_330e50ab-8b18-4dfc-aeea-4f4978436b4b">0.55</ix:nonFraction> at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $<ix:nonFraction unitRef="usd" contextRef="i48b185c6a31e4b0f875dbc148b1a9690_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE2MzYyOQ_a292d204-2a25-41d2-83f2-4f0866befb6f">18.7</ix:nonFraction> million, net of a note receivable discount of $<ix:nonFraction unitRef="usd" contextRef="i7645c4e435b9406cb66205c7447a3bb4_D20220101-20220630" decimals="-5" name="vtvt:CollaborativeArrangementNoteReceivableDiscountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjA0NzMxNDA2NDM2OA_d1d0539c-c26a-4b50-be0a-f7396c8e0261">0.6</ix:nonFraction> million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of the Licensed Product, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete R&amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#8220;JDC&#8221;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would have to complete its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the Phase 3 clinical trials. As of June 30, 2022, the Phase 3 clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The material right is predicated upon FDA approval. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after the Licensed Product is approved by the FDA.  As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and six months ended June 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company has recognized the cash and a non-interest bearing promissory note receivable of with a principal balance of $<ix:nonFraction unitRef="usd" contextRef="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE3MDYyNw_4c418cdc-5c56-4883-8fff-65230cc953bb">12.5</ix:nonFraction> million. The promissory note receivable was classified and accounted for under ASC 310 and was measured at its fair value of and will be subsequently remeasured at its amortized cost thru its maturity date. The </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i17b9c99185df419380a06c1596b8b7aa" continuedAt="ia547fb5c40b14f8fb0d2d233831831ae"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company also recorded the $<ix:nonFraction unitRef="usd" contextRef="i48b185c6a31e4b0f875dbc148b1a9690_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE3MDY2Mg_245ceb7d-35a6-478a-9d5f-a2e990e45f93">18.7</ix:nonFraction> million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and six months ended June 30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reneo License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Reneo Pharmaceuticals, Inc. (&#8220;Reneo&#8221;) (the &#8220;Reneo License Agreement&#8221;), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company&#8217;s peroxisome proliferation activated receptor delta (PPAR-&#948;) agonist program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic, prophylactic or diagnostic application in humans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has fully allocated the transaction price to the license and the technology transfer services, which represents a single combined performance obligation because they were not capable of being distinct on their own. The revenue related to this performance obligation was recognized on a straight-line basis over the technology transfer service period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue related to this performance obligation has been fully recognized and <ix:nonFraction unitRef="usd" contextRef="ia159a094d3c149ae894a344e958ae6b8_D20220401-20220630" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_1e98489b-f046-4c1f-8d2b-82eedf069169"><ix:nonFraction unitRef="usd" contextRef="ib691d10b9e9048d2ad20c45cc4d7b82a_D20210101-20210630" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_b8d975b4-39cc-47e3-afc1-c91870bebef0"><ix:nonFraction unitRef="usd" contextRef="i06ef634eb2724783ab3b95d2e1eb87b0_D20220101-20220630" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_c6f7fb3b-48cc-4e37-aa34-d8ccc717dd3f"><ix:nonFraction unitRef="usd" contextRef="ie3a4c00943074f559aa9f5295140d5d3_D20210401-20210630" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_fea1962b-ce3b-4de3-92a6-4485d038f014">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue related to this performance obligation was recognized for the three and six months ended June&#160;30, 2022, and 2021. There have been <ix:nonFraction unitRef="usd" contextRef="ia159a094d3c149ae894a344e958ae6b8_D20220401-20220630" decimals="INF" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_576c7914-b45f-4c4a-84f9-6913f360efa2"><ix:nonFraction unitRef="usd" contextRef="ib691d10b9e9048d2ad20c45cc4d7b82a_D20210101-20210630" decimals="INF" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_8177b582-22f4-46a0-b099-62bf5a300577"><ix:nonFraction unitRef="usd" contextRef="i06ef634eb2724783ab3b95d2e1eb87b0_D20220101-20220630" decimals="INF" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_c57e6958-2f9b-4b6d-b6d5-b6acd9be8c2b"><ix:nonFraction unitRef="usd" contextRef="ie3a4c00943074f559aa9f5295140d5d3_D20210401-20210630" decimals="INF" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_ec7328bc-0adc-4bb6-b006-056169b8dbb7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> adjustments to the transaction price for the performance obligations under the Reneo License Agreement during the three and six months ended June&#160;30, 2022, and 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#8220;Huadong&#8221;) (the &#8220;Huadong License Agreement&#8221;), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s glucagon-like peptide-1 receptor agonist (&#8220;GLP-1r&#8221;) program, including the compound</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic uses in humans or animals, in China and certain other pacific rim countries, including Australia and South Korea (collectively, the &#8220;Huadong License Territory&#8221;). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company&#8217;s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021, the Company entered into the First Huadong Amendment which eliminated the Company&#8217;s obligation to sponsor a multi-region clinical trial (the &#8220;Phase 2 MRCT&#8221;), and corresponding obligation to contribute up to $<ix:nonFraction unitRef="usd" contextRef="ida207b1c94f040c49e5bac98b31bd511_I20210114" decimals="-5" name="vtvt:MaximumSponsoringContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjI2OA_8fa06fd0-cac9-4ab2-9e07-f8aa81cae8e0">3.0</ix:nonFraction> million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $<ix:nonFraction unitRef="usd" contextRef="ida207b1c94f040c49e5bac98b31bd511_I20210114" decimals="-5" name="vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjM5Mw_eca982da-c79a-4f5d-8aaf-261226ef75a1">3.0</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC Topic 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $<ix:nonFraction unitRef="usd" contextRef="i9402a4a07ef14ae1bd27ed58ddf7c7a7_I20210630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjg0OQ_ba9f00ef-bfe2-48dd-beeb-62d04157ada9">1.0</ix:nonFraction> million of revenue on a cumulative catch-up basis during the six months ended June&#160;30, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant performance obligations under this license agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company&#8217;s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company&#8217;s obligation to participate on a joint development committee (the &#8220;JDC&#8221;), and (iv) other obligations considered to be de minimis in nature. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. This combined performance obligation was considered complete as of June&#160;30, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i28ca3ec68a2f405c9d88aea860a19d43_D20210101-20210630" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNDQ4Nw_ed0e1e63-84b6-4516-a181-a98a23e0b4f1">1.0</ix:nonFraction> million of revenue related to this combined performance obligation during the six months ended June&#160;30, 2021. During the six months ended June 30, 2022, the transaction price for this performance obligation was increased by $<ix:nonFraction unitRef="usd" contextRef="iedcd02d9e7ed46a9be450435bae20a14_D20220101-20220630" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNDY3Ng_8737c1b8-d0a2-4fd3-8fa8-2ce0fc475020">2.0</ix:nonFraction> million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the six months ended June&#160;30, 2022, as the related performance obligation was fully satisfied.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="ia547fb5c40b14f8fb0d2d233831831ae" continuedAt="i085562c0efd04ca696e4a5b79a9538ca"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of June&#160;30, 2022, and revenue will be recognized using the proportional performance model over the period of the Company&#8217;s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of June&#160;30, 2022, was de minimis. An immaterial amount of revenue for this performance obligation has been recognized during six months ended June&#160;30, 2022, and 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement-</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#8220;Newsoara&#8221;) (the &#8220;Newsoara License Agreement&#8221;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s phosphodiesterase type 4 inhibitors (&#8220;PDE4&#8221;) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#8220;Newsoara License Territory&#8221;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#8217;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of June&#160;30, 2022. <ix:nonFraction unitRef="usd" contextRef="i7a1d4d900a634784a41180096d9af11c_D20220401-20220630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_0303b78a-3589-44a1-949c-befe84b32428"><ix:nonFraction unitRef="usd" contextRef="ie807e06b03a449358e53f1fe6a28f0c2_D20210101-20210630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_3a97e4c9-751e-4e51-b3bb-5be6dbea4b81"><ix:nonFraction unitRef="usd" contextRef="i7e7dabf56fb04aae8e954ea2799cbebb_D20220101-20220630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_4ca37572-f673-4f79-87f0-be056509d468"><ix:nonFraction unitRef="usd" contextRef="i8ee005b698f440db91b1b86a6598a170_D20210401-20210630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_f184302a-4c6f-4f66-bec8-52e9dbd0ab90">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue related to this performance obligation was recognized and there have been <ix:nonFraction unitRef="usd" contextRef="i9644a2a90dd449c3a42d337db0986546_D20220101-20220630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_07267358-2a15-41f5-8c72-b18622be2307"><ix:nonFraction unitRef="usd" contextRef="i61786a784a654e5eae26bb310979ad74_D20220401-20220630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_52297c3f-472a-48c3-809f-25071a93eb22"><ix:nonFraction unitRef="usd" contextRef="i42c61470a62b4ea8ad0f4884c7064bd7_D20210401-20210630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_8759bc02-0143-4113-b32c-aedfec3fe10f"><ix:nonFraction unitRef="usd" contextRef="i5c150d5a782c4fc0b12b5a8bf5b8dac1_D20210101-20210630" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_875e0fd9-102e-4a48-b835-bb382c866674">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> changes to the transaction price during the three and six months ended June&#160;30, 2022, and 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anteris License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (&#8220;Anteris&#8221;) (the &#8220;Anteris License Agreement&#8221;), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company&#8217;s Nrf2 activator, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of $<ix:nonFraction unitRef="usd" contextRef="i717440fba9ae463ba4b738d6cc36588b_D20201211-20201211" decimals="-5" name="vtvt:LicenseFeeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzUyMw_62131d60-4df0-4643-b90c-62280247bbcd">2.0</ix:nonFraction> million. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i4678547c424543bbb17a9eec17b01812_I20220630" decimals="-5" name="vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzY1OA_a224014c-4a89-4939-8a1e-db55e016c192">151.0</ix:nonFraction> million. Anteris is also obligated to pay the Company royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a <ix:nonNumeric contextRef="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211" name="vtvt:CollaborativeArrangementTechnologyTransferServicesPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE3NTc4NA_6eed24db-9c02-4f5c-9b58-6b6956284edb">30</ix:nonNumeric>-day period after the effective date. In accordance with ASC Topic 606, the Company identified all the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the $<ix:nonFraction unitRef="usd" contextRef="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211" decimals="-5" name="vtvt:LicenseFeeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfODk1Nw_1e4260a4-dd89-48da-8cd2-8ef2d6d96805">2.0</ix:nonFraction> million initial license payment, as well as the fair value of the equity interest received in Anteris of $<ix:nonFraction unitRef="usd" contextRef="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211" decimals="-5" name="us-gaap:ProceedsFromInterestAndDividendsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTA1Nw_aa556f45-d540-4b8c-9876-2b0e07309a52">4.2</ix:nonFraction> million. The revenue related to this performance obligation was fully recognized during the year ended December&#160;31, 2020, as the technology transfer services were considered complete as of that date. <ix:nonFraction unitRef="usd" contextRef="if487c4d0351a4b53ad7e192011f347f0_D20220401-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_08704459-800f-43f2-8eab-3dd61479160f"><ix:nonFraction unitRef="usd" contextRef="i4e359c73dd344730844f51f46e651559_D20210401-20210630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_38697c69-dd0e-4a7f-9ecd-ea37aa73245f"><ix:nonFraction unitRef="usd" contextRef="id2afc370e61141bdbcb9d5cde256c0e5_D20210101-20210630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_a7271ff8-4d54-4f8d-946f-a23e3ab7232d"><ix:nonFraction unitRef="usd" contextRef="i194bd737c73c45978ed3a128fb4083aa_D20220101-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_ed875ea9-89d9-488c-8b0f-848ae33944c0">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue related to this performance obligation was recognized and there have been <ix:nonFraction unitRef="usd" contextRef="id2afc370e61141bdbcb9d5cde256c0e5_D20210101-20210630" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_17bd4f5a-9e1d-49cb-b47a-e145cc9e5b1c"><ix:nonFraction unitRef="usd" contextRef="i4e359c73dd344730844f51f46e651559_D20210401-20210630" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_cdcaad95-7081-418d-8b21-cc2a1fed7bd4"><ix:nonFraction unitRef="usd" contextRef="if487c4d0351a4b53ad7e192011f347f0_D20220401-20220630" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_e55c0b92-7e4a-4bc9-9248-28820ee76f5c"><ix:nonFraction unitRef="usd" contextRef="i194bd737c73c45978ed3a128fb4083aa_D20220101-20220630" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_fa154518-12a9-4d97-a8f2-f054738122c6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> changes to the transaction price during the three and six months ended June&#160;30, 2022, and 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JDRF Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a research and collaboration agreement with JDRF International (the &#8220;JDRF Agreement&#8221;) to support the funding of the Simplici-T1 Study, a Phase 2 study to explore the effects of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with type 1 diabetes. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JDRF Agreement was amended in June 2021 to provide additional funding for the Company&#8217;s mechanistic study exploring the effects of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the terms of the JDRF Agreement, JDRF will provide research funding of up to $<ix:nonFraction unitRef="usd" contextRef="i10084af716e84ec69a70340b4c5bd31b_I20170831" decimals="-5" name="vtvt:MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTk5MA_c087146b-fb9b-4973-ae75-70ce06255232">3.4</ix:nonFraction> million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a treatment for type 1 diabetes.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i085562c0efd04ca696e4a5b79a9538ca"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments that the Company receives from JDRF under this agreement will be recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of June&#160;30, 2022, the Company had received funding under this agreement of $<ix:nonFraction unitRef="usd" contextRef="ic0bc234ab6f74714aa833022af967b77_D20220101-20220630" decimals="-5" name="vtvt:FundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA3NTI_efeac1f7-3196-4317-b1c5-f3f26cb19c28">3.4</ix:nonFraction> million. Research and development costs have been offset by a total of  $<ix:nonFraction unitRef="usd" contextRef="ic0bc234ab6f74714aa833022af967b77_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA4MTk_00d6eea7-f39c-4dae-a270-eeed8046ed37">3.4</ix:nonFraction> million over the course of this agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA5OTQ_86dbab48-55d4-4e8c-835f-278511ff09b6" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company&#8217;s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMS0xLTEtMS0yOQ_3ae20da8-4a5b-4763-acdb-6c99b3deb516">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMS0zLTEtMS0yOQ_51b57d8b-1e86-4222-a7ca-515c5bd839d3">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0xLTEtMS05MTEw_d12af10b-0b81-4468-8739-bbe1541ff892">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0zLTEtMS05MTEw_1e70ada4-413d-4d54-8233-07f6f8ed6f6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0xLTEtMS0yOQ_638c020e-e3ca-4001-86ce-2b4c9b7200c0">18,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0zLTEtMS0yOQ_8d7a440a-4312-46db-a244-15e92bee1993">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="vtvt:ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTY0OTI2NzUzNTgzOA_92faeb85-e9db-471e-9aa1-170b58f1a6c3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in short-term and long-term contract liabilities for the six months ended June&#160;30, 2022, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfMS0xLTEtMS0xMDExNw_8df8d997-902f-4491-8ea3-fc89103577e1">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfMi0xLTEtMS0xMDExNw_a82a5178-a76d-420a-8566-1ad3a0e629d4">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration received in advance and not recognized as revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfMy0xLTEtMS0xMDExNw_6b9b0146-88d9-48ed-88b2-14a1845ee155">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfNC0xLTEtMS0xMDExNw_5decdb9f-59a9-4aa3-a3d3-cb889c6ae24a">18,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_40"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2MA_ea2ee993-ce28-4681-a859-21eb0f718e07" continuedAt="i283c18e6ca9646179dd2a05ba7e67db8" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i283c18e6ca9646179dd2a05ba7e67db8" continuedAt="i757a6c2e1e2a448da48073ce763c0014"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a <ix:nonNumeric contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2MQ_fc25cf67-a564-4192-bb7b-6d4438da5c07">three-year</ix:nonNumeric> period and the option awards expire after a term of <ix:nonNumeric contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjcx_7fcda7fe-7327-4650-ad88-c8db65b8993f">ten years</ix:nonNumeric> from the date of grant. As of June&#160;30, 2022, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $<ix:nonFraction unitRef="usd" contextRef="i82d10b9f39fd4c93bfa1d918b158b70d_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfNDMz_0d768c9c-7847-4586-a8c2-cc12b692d2b1">1.7</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfNTA2_ed2fd8be-ce5f-49d6-b03b-bbb749cc101c">2.3</ix:nonNumeric> years. The weighted average grant date fair value of options granted during the six months ended June&#160;30, 2022, and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfNjA3_6267ead4-81ee-4c4c-b8d5-5554c6c8356a">0.65</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb1b9c3a3531408ab3529984f8566bc3_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjc0ODc3OTA3MTYyOA_3ab5e296-976e-4a8f-bdfb-4636a164ed24">2.21</ix:nonFraction> per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at June&#160;30, 2022, was de minimis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the &#8220;Board&#8221;) of the Company of her decision to resign from her positions as Chief Executive Officer, President, and Board member, effective as of March&#160;29, 2022, and served in these roles through March&#160;29, 2022 (the &#8220;Effective Date&#8221;). Ms. Prasad agreed to serve as a Strategic Advisor to the Company for <ix:nonNumeric contextRef="id5fc8150340948bc898873b35fb8418e_D20220329-20220329" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTE1NDQ4NzIwOTQ0MzI_bdd3f930-e627-42f8-94df-3a3f25f38222">six months</ix:nonNumeric> after the Effective Date. Ms. Prasad will retain <ix:nonFraction unitRef="shares" contextRef="iba62023a07f44291bd3078c3cb8c0331_I20220329" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTMwMQ_4c46aae2-4518-4b02-89eb-5573a4c88d77">624,659</ix:nonFraction> of the outstanding options previously granted to her, which will vest at the end of the <ix:nonNumeric contextRef="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTM5Mg_abb96256-8a28-4b4c-af55-d0af77c9041c">15</ix:nonNumeric>-month period following the Effective Date. As a result of the separation agreement, these options were modified to accelerate vesting at the Effective Date. These options will remain exercisable for the original <ix:nonNumeric contextRef="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTE1NDQ4NzIwOTQ0OTI_024be064-e0d2-4bb4-96e9-583a80d04830">ten-year</ix:nonNumeric> period and the remaining <ix:nonFraction unitRef="shares" contextRef="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329" decimals="INF" name="vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTY0MQ_130bb42c-2809-4342-a854-9b33d77071b0">1,873,976</ix:nonFraction> of her options were cancelled. The additional stock compensation expense for the modification during the six months ended June&#160;30, 2022, was de minimis.</span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2Mg_9e4a5166-88a6-4ad3-900c-32b8ab550a98" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMS0xLTEtMS0yOQ_d30053fd-0b23-4410-a78e-f6d9baaec7ff">7,056,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMS0zLTEtMS0yOQ_ee3eaacb-659d-4986-88ca-8f91aa748460">3.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMi0xLTEtMS0yOQ_681fba0e-9ebe-4a9e-b200-74cef6757c02">1,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMi0zLTEtMS0yOQ_1f241a13-1902-492e-9864-cf374c53ecda">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMy0xLTEtMS0yOQ_7f29b56c-7147-40fa-8f6d-eb8985e1d539">2,871,508</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMy0zLTEtMS0yOQ_2d770e5b-0e27-4761-89cb-91b7d2381831">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNC0xLTEtMS0yOQ_1161ef3d-26de-468b-8e42-69bd9cbc4286">5,384,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNC0zLTEtMS0yOQ_dca40cc5-0945-4dda-a3d9-9bfe4e888738">3.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNS0xLTEtMS0yOQ_a40392f4-62ac-4351-b54e-afd03b3e7ab8">2,496,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNS0zLTEtMS0yOQ_c9c97889-b50a-4b79-bfd3-ebec578462f0">5.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNi0xLTEtMS0yOQ_4ebe738d-d83b-4741-9ec3-7c0cf6073121">6.1</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNy0xLTEtMS0yOQ_2d2dbc2a-54ca-494d-8e9e-70b270c5ff8f">4,858,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNy0zLTEtMS0yOQ_f3f4590a-bdad-4607-b5f2-d32941889e9f">3.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfOC0xLTEtMS0yOQ_f00acf77-54e7-4212-bff7-b62dafa5a0ca">7.6</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i757a6c2e1e2a448da48073ce763c0014"><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2Mw_f7e5a7a4-8fe6-44c8-9d3d-e2434016fdad" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:39.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f49c4740cff40429fb52e44fa210e13_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi0xLTEtMS0yOQ_ca456217-3d5a-43a1-99ef-a28dfb00cbbc">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7317531dde4b48dab33ee85599082a64_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi0zLTEtMS0yOQ_114961bc-ea7f-4bb3-a5cd-86830c177fc8">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29697fdb6af49c7bc034a9837816d6d_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi02LTEtMS0xNDk0_1a45cd54-8e54-406a-b5cb-a2a3498b11d9">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dda6d8be2724280ae62e19e4a293904_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi04LTEtMS0xNDk0_180bfeb1-2c27-4ae5-a458-cf704adf403c">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152676a2e89f49c1b9dc28a02261abd0_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy0xLTEtMS0yOQ_76ca7448-c06a-40f5-b962-136e7de7bf0d">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1cd4fe75eb46dcab4af04b0635b52a_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy0zLTEtMS0yOQ_101a85ba-6e41-4400-bbdb-46f993b7918f">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762b94f808004bfcb8c828bf3cf727d2_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy02LTEtMS0xNDk0_1be9dcde-ae53-4634-b228-e778cbc82a2e">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da4992df5e044318a2a0905c425112f_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy04LTEtMS0xNDk0_50aef29d-a323-4d2a-93b1-9c5d02661d58">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC0xLTEtMS0yOQ_2defc650-91a1-412c-8dc8-2c0cd7f356aa">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC0zLTEtMS0yOQ_a935a825-972b-4066-ae46-77e6570aeb39">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC02LTEtMS0xNDk0_6d572657-1cde-45c0-b358-37cb758a923a">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC04LTEtMS0xNDk0_5a4e5474-85e2-4b32-a17e-7c3ac98c7827">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_43"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTYwNA_6c237700-8fdb-41b6-a47e-13a76b1931e6" continuedAt="i55f6ecaee5cc40bb8221c2fb5c350222" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i55f6ecaee5cc40bb8221c2fb5c350222"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Reneo and Anteris License Agreements, the Company has received equity ownership interests of less than <ix:nonFraction unitRef="number" contextRef="idf108c845b044d5b9647b9f0d2f6517e_I20220630" decimals="INF" name="vtvt:InvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTUx_82820aba-e8dc-4103-ba40-55b3a657f5bf">20</ix:nonFraction>% of the voting equity of the investee. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company&#8217;s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo&#8217;s initial public offering, the Company&#8217;s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.</span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTYwNQ_4775b673-f795-455c-9ad3-4d0dcaf945c0" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:71.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i783e762f741545f3a0fe0c1d38e6b115_I20220630" decimals="-3" name="vtvt:EquityInvestmentsWithReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfMi0xLTEtMS0yOQ_df3eab40-067e-4f16-a6a8-f0954025a655">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0147ce52f24edbb65de2e822c1593e_I20211231" decimals="-3" name="vtvt:EquityInvestmentsWithReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfMi0zLTEtMS0yOQ_633e3a1d-e4c7-442a-9adf-1ceaae6bee27">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264317da98da4654b1fb27e432d93843_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNS0xLTEtMS0yOQ_a9c74ced-ccd1-441c-b6f7-9f2999227ebe">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3367eb43e184818b02b49d5ae5d81a4_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNS0zLTEtMS0yOQ_1c567d31-9ad9-4235-b46a-dfe08f52d774">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNi0xLTEtMS0yOQ_ed120d67-6bde-4a49-af1f-f2c5279276b8">5,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNi0zLTEtMS0yOQ_6dbc01ee-76bb-45a6-9228-8e8388058397">9,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No adjustments have been made to the value of the Company&#8217;s investment in Anteris since its initial measurement either due to impairment or based on observable price changes. The Company recognized an unrealized loss on its investment in Reneo of $<ix:nonFraction unitRef="usd" contextRef="i77b143ad9f4d4ba1ace4e171385ea567_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMjc0ODc3OTA3MTE3NA_1b74c219-0509-4a1e-80b5-aff82a94db99">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icd78af64b3f948b895cdd7ac3bc5ef42_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTQ0Mw_26333ae8-9ebb-4770-8699-f9d7eddaf85e">3.4</ix:nonFraction> million for the three and six months ended June&#160;30, 2022, respectively. During the three and six months ended June 30, 2021, the Company recognized an unrealized gain on its investment in Reneo of $<ix:nonFraction unitRef="usd" contextRef="iffa40b257a304d62948a32a686a7716a_D20210101-20210630" decimals="-5" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfNTQ5NzU1ODE0MDk3Nw_61b90f4e-b2d4-4d73-86e3-d1d00c6728db"><ix:nonFraction unitRef="usd" contextRef="ic27aa30a7f394af79e2bdf369843816f_D20210401-20210630" decimals="-5" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfNTQ5NzU1ODE0MDk3Nw_750543cb-e901-4322-ad3d-9d8479e9e731">2.9</ix:nonFraction></ix:nonFraction> million. These adjustments were recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_46"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTkxMw_a23fb571-4e89-456b-bbd1-b09fcffd70dc" continuedAt="i6633f1a3bd8c4c129d8384748b616acf" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i6633f1a3bd8c4c129d8384748b616acf" continuedAt="if4e05af5c0824a4c9c32e5dbad898e97"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo License Agreement&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This agreement was amended in May 2019 to create </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="if4e05af5c0824a4c9c32e5dbad898e97"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="if4ebac4e45e34b82929898cde894745e_I20070228" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTMzMQ_65499c88-4f2b-4278-abb6-38244c58f9b4">9.0</ix:nonFraction> million for approval of a product for the treatment of type 1 diabetes, $<ix:nonFraction unitRef="usd" contextRef="i65905beb758b4791a02bb8d0cb2515a0_I20070228" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTM5OA_c4d77bd6-d8a9-49b8-b482-e15f0b3579cb">50.5</ix:nonFraction> million for approval of a product for the treatment of type 2 diabetes, or $<ix:nonFraction unitRef="usd" contextRef="i6ead0675511b48ebb66183281497ebc5_I20070228" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTQ2OA_493daaaa-674f-4ebc-9c69-c36d69826001">115.0</ix:nonFraction> million for approval of a product in any other indication. The Company may also be obligated to pay an additional $<ix:nonFraction unitRef="usd" contextRef="i34ddaf589ad6495baf1c05cf44f3896e_I20070228" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTU3Nw_11dcd99c-543a-47ab-8226-a4ee1907e706">75.0</ix:nonFraction> million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $<ix:nonFraction unitRef="usd" contextRef="i56c0384308fd425590c78419693d5fc6_I20211231" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTgwMw_83dd0c57-9e85-414e-97bb-43c7fd04e6c2">2.0</ix:nonFraction> million related to the satisfaction of the milestone to complete the phase 2 trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under this agreement.</span></ix:continuation></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_49"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMTA3MA_c95a0151-116e-4e44-baa9-9fe86e83e329" continuedAt="ie7e6ba6032994d0eb9224e71c25c6e3c" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ie7e6ba6032994d0eb9224e71c25c6e3c"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a <ix:nonNumeric contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMTU5NDI5MTg2MDQ1NjQ_2d30893c-1c5f-44c0-b912-62b0e042e944">five-year</ix:nonNumeric> term as well as an option to terminate after <ix:nonNumeric contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" name="vtvt:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMjc0ODc3OTA3MTE4Nw_20df43c3-f853-44a1-8a91-f2e1f7a78cf7">three years</ix:nonNumeric>, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. The Company has notified the lessor that it intends to exercise the early termination option and is negotiating an amendment to the lease. Further, this lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of June&#160;30, 2022, and December&#160;31, 2021, the weighted average incremental borrowing rate for the operating leases held by the Company was <ix:nonFraction unitRef="number" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfNzA5_937a4f9d-5ccf-4851-bd9b-99c36e18add6"><ix:nonFraction unitRef="number" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfNzA5_c866f834-d87c-49fa-8b82-3cd403b9605d">13.1</ix:nonFraction></ix:nonFraction>%. At June&#160;30, 2022, and December&#160;31, 2021, the weighted average remaining lease terms for the operating leases held by the Company were <ix:nonNumeric contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfODIw_011ec20b-ae78-4c27-bbd6-cff00e6b7432">2.6</ix:nonNumeric> years and <ix:nonNumeric contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfODI3_8bfbb476-a201-4db6-9987-06ab4493bdc6">3.1</ix:nonNumeric> years, respectively.</span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMTA3MQ_e8642fd1-b60b-4bb5-ac88-aff584d5b710" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating leases as of June&#160;30, 2022, were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMC0xLTEtMS0yOQ_780c3078-980b-47d0-bc6f-5f55bbb9693f">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMS0xLTEtMS0yOQ_0dae4cb8-ca95-4ec3-9268-b1466fda7530">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMi0xLTEtMS0yOQ_efad810b-75c8-4043-8137-f1cf1eb14414">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMy0xLTEtMS0yOQ_9af844e6-d580-4f96-92d0-df0428e0797e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNC0xLTEtMS0yOQ_f0586fa1-1b51-4964-9b47-2723e40b7e23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNS0xLTEtMS0yOQ_a5337043-98e0-447c-9316-8379339a8cdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNi0xLTEtMS0yOQ_f286574f-e898-4dd7-a22f-ba82b4e93451">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="vtvt:OperatingLeasesImputedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNy0xLTEtMS0yOQ_0bc1c703-77ae-4bd0-a54c-15bb3dec5dab">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfOC0xLTEtMS0yOQ_dfde90cf-74c1-4f9c-9d09-30192fb75577">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the six months ended June&#160;30, 2022, and 2021 were immaterial amounts.</span></div></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_52"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTY4Mg_08418acf-5ed0-4966-938a-49a7f30d9128" continuedAt="i5457e95f60c3429790600b99664f1511" escape="true">Redeemable Noncontrolling Interest</ix:nonNumeric></span></div><ix:continuation id="i5457e95f60c3429790600b99664f1511" continuedAt="i133cf6464ae04c5b80431654acc1c225"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the <ix:nonFraction unitRef="number" contextRef="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTQ1_df1d4013-30ae-492d-a036-2e17e14f7c3f">23.0</ix:nonFraction>% noncontrolling interest in vTv LLC outstanding as of June&#160;30, 2022 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a <ix:nonFraction unitRef="number" contextRef="i910db6d0fa4e476cbe83b47a7fea5ee1_D20220101-20220630" decimals="INF" name="vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMzY1_643851ec-6d96-42b8-b28b-7a54609ab0b6">one</ix:nonFraction>-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a <ix:nonNumeric contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" name="vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfNzE3_2919ad1c-ae40-40af-875b-50ed83bcfe3b">20</ix:nonNumeric>-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At June&#160;30, 2022, and December&#160;31, 2021, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $<ix:nonFraction unitRef="usd" contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630" decimals="-5" name="vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTI4Ng_43140235-3545-4227-8f1b-37765bf707d3">15.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231" decimals="-5" name="vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTI5Mw_ccae9e8d-dcf3-408c-8d91-2c71e0f12a4a">25.0</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i133cf6464ae04c5b80431654acc1c225"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such changes. <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTY4Mw_bec364ac-07f9-4aff-ae3d-6405fe68190a" continuedAt="i7ccd4a8521aa4e0da78ea1d0b5f003cd" escape="true">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i7ccd4a8521aa4e0da78ea1d0b5f003cd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi0xLTEtMS0yOQ_0c8c4356-c233-4b58-9978-1990a8cc0498">3,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi0zLTEtMS0yOQ_0cfd515c-56da-401c-9e80-512d12d5e6e8">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi01LTEtMS0xNTI5_6c849923-6877-4537-b372-460021f21671">10,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi03LTEtMS0xNTI5_5012e5d2-f653-4874-bf2b-8b6881149502">4,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy0xLTEtMS0yOQ_604fd259-6561-426a-9500-0feef4949842">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy0zLTEtMS0yOQ_35b4ddc2-a656-4049-87a5-3b9c6a3e829b">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy01LTEtMS0xNTI5_f3225006-6e08-4b5a-9e1c-5e2e007f73aa">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy03LTEtMS0xNTI5_fbc10911-2f21-40f4-9c33-253cf30765e1">2,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC0xLTEtMS0yOQ_deb3336c-3651-4c3f-b7b0-d7209c2fe0be">4,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC0zLTEtMS0yOQ_447012aa-0bdd-49ef-b2e8-ea0ee8b5ee1c">723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC01LTEtMS0xNTI5_d1ba36f4-1e4b-429b-b311-55c6d1bd9104">9,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC03LTEtMS0xNTI5_85747235-8697-4cff-a370-5e46741d162a">7,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_55"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjgzMw_5fbb7bb1-175b-410a-922c-34c00bf8928c" continuedAt="i4fee860f51724f9081819d23149b87b6" escape="true">Stockholders&#8217; Deficit</ix:nonNumeric></span></div><ix:continuation id="i4fee860f51724f9081819d23149b87b6" continuedAt="i8174760c241e47ad94c58428a57ad232"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Certificate of Incorporation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to increase the number of shares of Class A common stock that the Company is authorized to issue from <ix:nonFraction unitRef="shares" contextRef="i92612f3dee2a4b16a5b8ceea2175dc30_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjk5_546718a0-d36b-4f01-9f03-47d1436df478">100,000,000</ix:nonFraction> shares of Class A common stock to <ix:nonFraction unitRef="shares" contextRef="i6511cf535eb14b879d2b9abaf9fd770f_I20210504" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMzM2_afb022b2-1b87-45db-980f-379dcd8f4cab">200,000,000</ix:nonFraction> shares of Class A common stock, representing an increase of <ix:nonFraction unitRef="shares" contextRef="iedc1e3243a7443dfb3c90db73fedab5c_D20210504-20210504" decimals="INF" name="vtvt:IncreaseInCommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMzk5_a3aa9c5c-966b-4bdb-9634-3f5fb0807f47">100,000,000</ix:nonFraction> shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from <ix:nonFraction unitRef="shares" contextRef="i0f18b37002444e71902e4b504204e08e_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNTgw_4a256817-3845-41b6-8d09-dd828bf227e1">200,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i3d7c397af1aa46eea7d046dd11d5461b_I20210504" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNTg3_a35e2880-afc2-408a-bd90-e1541d144e01">300,000,000</ix:nonFraction>, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from <ix:nonFraction unitRef="shares" contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231" decimals="INF" name="vtvt:CommonStockAndPreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNzEz_bef62f11-86ae-4a61-9837-1cc5eb47e2e6">250,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="iff3de8bb3d5c4970bc7c8e651b6af215_I20210504" decimals="INF" name="vtvt:CommonStockAndPreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNzI2_bd5ae52b-5e8a-4dac-9ae6-6206cdf501da">350,000,000</ix:nonFraction> shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments <ix:nonFraction unitRef="shares" contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzc3Mg_01b35e09-1b48-4efb-9b89-bfc7eecc80f0">10,386,274</ix:nonFraction> shares of the Company's Class A common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzc4MA_3e778422-fb09-487c-86d1-bfb1b45d3815">0.01</ix:nonFraction> per share at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzc4OQ_a88d881e-78a2-47e9-86de-b93ea8decab3">2.41</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzgwNQ_b42893b7-032a-4813-a776-7e3b529b73f2">25.0</ix:nonFraction> million, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzgyNA_e8244b92-8bf5-42e7-8682-0b9e29d3a2fa">12.5</ix:nonFraction> million in cash at the closing of the transaction and (ii) $<ix:nonFraction unitRef="usd" contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzg0Mw_b1acaa8a-a40f-41a3-a96a-3814d17d1059">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments to be paid at the <ix:nonNumeric contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531" name="vtvt:SaleOfStockConsiderationReceivablesPaymentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTE1NDQ4NzIwOTcxMTE_21ebf9b2-aae1-4ac4-8a0a-cdfaee605977">one-year</ix:nonNumeric> anniversary of the execution of the G42 Purchase Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into the Sales Agreement with Cantor Fitzgerald as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ic54bdcd3ea0d44d0987f04e7b4c3ad6d_I20200430" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfOTY1_cd769398-0093-444f-87a5-d4088ec7bfeb">0.01</ix:nonFraction> per share, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ida448d3c156e41c6907f442bbdbdcfd3_D20200401-20200430" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTAyMw_d773193c-e4f9-4a42-934f-f08ae5197331">13.0</ix:nonFraction> million by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act (the &#8220;ATM Offering&#8221;). The shares are offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3. In no event will we sell Class A common stock under this registration statement with a value exceeding more than one-third of the &#8220;public float&#8221; (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $<ix:nonFraction unitRef="usd" contextRef="i94c6864ca64f40938eda9aad11bf61c1_D20220101-20220630" decimals="-6" name="vtvt:PublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTYxOQ_c24a9937-1c8c-412d-8ccc-82f5d9200101">75</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021, and June&#160;25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company&#8217;s Class A common stock, by an aggregate offering price of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i7b5db27bb04d4dd79864de1cb1a6f970_D20210114-20210114" decimals="-5" name="vtvt:AggregateOfferingPriceOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTk2Nw_8da99cca-9af4-4d6c-8415-b16e7a4ba707">5.5</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="iebf065935ede4806964843da64a9618e_D20210625-20210625" decimals="-5" name="vtvt:AggregateOfferingPriceOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTk3NA_7a1fe813-0106-4477-bcfa-eea73ed8b3cd">50.0</ix:nonFraction> million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="ia312c12a8760465dbb649e1f030f2bd7_D20210101-20210630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYwNA_3696f786-1903-4a92-964b-a960d1e132ba"><ix:nonFraction unitRef="shares" contextRef="i5c543d697817434690f23877af7b8d92_D20210401-20210630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYwNA_ab208109-ac81-4d66-8060-faf01ccf5434">2,180,337</ix:nonFraction></ix:nonFraction> shares of its Class A common stock under the ATM Offering for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5c543d697817434690f23877af7b8d92_D20210401-20210630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYxOQ_ad5900f7-d893-419a-a182-6e0c5c12f1bb"><ix:nonFraction unitRef="usd" contextRef="ia312c12a8760465dbb649e1f030f2bd7_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYxOQ_b28b98fa-ef16-4179-81dd-09b3d9f06d27">5.3</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, the Company did <ix:nonFraction unitRef="shares" contextRef="i7de9e3cb791344979fa4282d8da7fd57_D20220401-20220630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzcxNA_02e2deb1-b39a-40e7-92e5-de519b00f7a9"><ix:nonFraction unitRef="shares" contextRef="i94c6864ca64f40938eda9aad11bf61c1_D20220101-20220630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzcxNA_0af78e4d-15cd-4ce0-aedc-7058abebc12d">not</ix:nonFraction></ix:nonFraction> sell any shares under the ATM Offering. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s Class A common stock having an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="i320fb888e6cd44998dc594856dc9724d_D20201124-20201124" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjQwNQ_d2b2e356-5d12-4c30-a240-2658761add54">47.0</ix:nonFraction> million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i8174760c241e47ad94c58428a57ad232"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Lincoln Park. pursuant to the LPC Purchase Agreement. During the three and six months ended June&#160;30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="icb1be42149da4a86877d9aa6d3153d8f_D20210401-20210630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNDk0NzgwMjMyNzg5OA_a4009195-70ee-41b3-9f69-3590bc85683b">441,726</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i06b77eabd9884287918e1f07afb3fdc4_D20210101-20210630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjY3MQ_64b49abd-a127-4378-a116-44aa3bd8d504">3,941,726</ix:nonFraction> shares under the LPC Purchase Agreement for total proceeds of $<ix:nonFraction unitRef="usd" contextRef="icb1be42149da4a86877d9aa6d3153d8f_D20210401-20210630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNDk0NzgwMjMyNzkwNg_43579ce6-d31c-4bf3-be3f-09bfbea70630">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i06b77eabd9884287918e1f07afb3fdc4_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNDk0NzgwMjMyNzkxOQ_8ad075d1-2ce3-4e96-8c8b-dc30bbb20e9b">9.1</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months June&#160;30, 2022, the Company did <ix:nonFraction unitRef="shares" contextRef="ie17c637109e34b5bac99defc70fe5b69_D20220401-20220630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc4Mg_436eddc0-b2da-4cc1-b33f-4df031f24b41"><ix:nonFraction unitRef="shares" contextRef="ibfa89db2b5b5402c94ff86a30340034c_D20220101-20220630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc4Mg_6ee3526f-df84-494f-8039-c38909adedb5">not</ix:nonFraction></ix:nonFraction> sell any shares under the LPC Purchase Agreement.</span></div></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_58"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfNDI1NA_ef1039c9-24c5-4333-b7a8-8f25204d08f5" continuedAt="i1c3acb068b3e4c5b81067ce4997457e7" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i1c3acb068b3e4c5b81067ce4997457e7" continuedAt="i81d63462642f4e4b80fa72d49947f634"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, subsidiaries and affiliates of MacAndrews &amp; Forbes Incorporated (collectively &#8220;MacAndrews&#8221;) indirectly controlled <ix:nonFraction unitRef="shares" contextRef="id69778fbafa14054a1949c92a76c3381_I20220630" decimals="INF" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMTk4_c08f53e7-d7ab-4f2e-b483-87f8b8a62922">23,084,267</ix:nonFraction> shares of the Company&#8217;s Class B common stock and <ix:nonFraction unitRef="shares" contextRef="ib893ea7404d94823b4489736f31d8e0a_I20220630" decimals="INF" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMjUw_9dce3554-c88e-41e3-8c92-2afe23975a07">36,519,212</ix:nonFraction> shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately <ix:nonFraction unitRef="number" contextRef="i0ee68f1d1f0245e088ff9dcad3a1d1ce_D20220101-20220630" decimals="3" name="vtvt:OwnershipPercentageOfMajorityOwner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMzU3_f89bdb89-2431-4b16-952c-4fc4527df6d0">59.4</ix:nonFraction>% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews has the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#8220;Letter Agreement Warrants&#8221;) to purchase additional shares of the Company&#8217;s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#8217;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to an exchange agreement (the &#8220;Exchange Agreement&#8221;) pursuant to which the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the &#8220;Board of Directors&#8221;). As of June&#160;30, 2022, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="i0ee68f1d1f0245e088ff9dcad3a1d1ce_D20220101-20220630" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMjc5Mw_4e09bb76-7161-48bc-ba11-c658a922b55a">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B commons stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i81d63462642f4e4b80fa72d49947f634">governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.</ix:continuation></span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_61"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMTQzNA_bbda0de9-5f32-495b-9339-09b8c6f992e4" continuedAt="i3cba9a8c54c1448e8ac8b37e63de27b6" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i3cba9a8c54c1448e8ac8b37e63de27b6"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did <ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMjc0ODc3OTA3MTMwMw_6691ea61-e678-4aac-ad97-21380f748ea2">not</ix:nonFraction> record an income tax provision for the three months ended June&#160;30, 2022. The Company&#8217;s income tax provision for the six months ended June&#160;30, 2022, was $<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMTcw_95162708-9ab0-4c28-8310-b2e67db74f27">0.2</ix:nonFraction> million related to foreign withholding taxes. The Company did <ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMjc0ODc3OTA3MTMxMQ_73180f04-f74d-48d0-b09b-aff9948fc021"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMjc0ODc3OTA3MTMxMQ_e3773d8b-d84f-4b0f-ad56-42b533186bac">not</ix:nonFraction></ix:nonFraction> record an income tax provision for the three months ended June 30, 2021. The Company&#8217;s income tax provision for the six months ended June&#160;30, 2021, was a de minimis amount related to foreign withholding taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of  21% on June&#160;30, 2022, is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="ifbeae5448a4743c4972130e10f6a61e0_D20220401-20220630" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMTAzMQ_f4bdaa1f-bb3b-4966-a290-063f0b0f2dad">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June&#160;30, 2022.</span></div></ix:continuation><div id="i7213a6cb68bb48ed8c21afe0782e56bd_64"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RleHRyZWdpb246N2UyYmNmMzE3ZDdkNDUxZmEyY2UxYjg5MjNiM2M3MzZfODEx_dd1b8eab-4163-44b8-8b9a-8ee8c95075e1" continuedAt="id6f4fd8497164c2b8301c8b2bd6be20e" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="id6f4fd8497164c2b8301c8b2bd6be20e" continuedAt="ie2301333a9d54e9f92d67dd1235f6061"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RleHRyZWdpb246N2UyYmNmMzE3ZDdkNDUxZmEyY2UxYjg5MjNiM2M3MzZfODEy_844f0bb7-cf5f-499b-9865-2c247f163b2a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy0xLTEtMS0yOQ_4c7cb393-4020-4286-b869-6696c6ab551a">4,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy0zLTEtMS0yOQ_a8674dda-797c-4a6d-8b37-15e8e7c1f5d8">841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy01LTEtMS0xNTcx_61541c3e-6156-41e4-8837-96dee2046065">13,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy03LTEtMS0xNTcx_16b72604-007c-4242-be24-01b79c910f9d">6,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC0xLTEtMS0yOQ_c54b9a0d-fa79-4775-aa66-e5731b0e8f7a">940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC0zLTEtMS0yOQ_bf551694-1dd5-48bf-9290-9d5dc598eaca">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC01LTEtMS0xNTcx_d80d6c5e-e879-4077-a913-d1eacc4fdd64">3,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC03LTEtMS0xNTcx_c0b8e79a-7e34-407f-ab9b-86b266224c3b">1,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0xLTEtMS0yOQ_145eb8c7-5ee2-4ffd-94d8-f00d12ed8436"><ix:nonFraction unitRef="usd" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0xLTEtMS0yOQ_e17a3abf-d661-49c5-a27a-766f4fcdcbad">3,151</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0zLTEtMS0yOQ_9aee8ea7-4ed8-47df-8714-37578dcd02b7"><ix:nonFraction unitRef="usd" contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0zLTEtMS0yOQ_d89cf0ef-16c2-4dec-9286-7799d5009ce7">608</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS01LTEtMS0xNTcx_b6773204-aa0b-46e8-b1f3-8260ac8d596a"><ix:nonFraction unitRef="usd" contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS01LTEtMS0xNTcx_bbd2e53b-b6eb-4c97-8a67-805baa1aed17">10,158</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS03LTEtMS0xNTcx_40abe82b-6ba2-4367-ba4c-492eb0b27c3c"><ix:nonFraction unitRef="usd" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS03LTEtMS0xNTcx_e7c14d3b-60a1-4fff-9319-bba0c34868a8">4,849</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0xLTEtMS0yOQ_30234d18-cfb2-48a6-955b-467f28791c15"><ix:nonFraction unitRef="shares" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0xLTEtMS0yOQ_8c8e42a8-4b3c-488b-9afe-f4193ddcbc89">70,366,823</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0zLTEtMS0yOQ_0615ed1c-3fba-46b0-a3f5-f74cfee63cb5"><ix:nonFraction unitRef="shares" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0zLTEtMS0yOQ_9f91b997-9509-4b90-a0dc-e575868501b7">58,615,137</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy01LTEtMS0xNTcx_49f5b28b-609d-4761-95fa-43285e37858b"><ix:nonFraction unitRef="shares" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy01LTEtMS0xNTcx_717f52a0-361b-475e-b2bd-a81745ddafd7">68,664,259</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy03LTEtMS0xNTcx_89490be6-6911-4606-804c-3e5629a9b36d"><ix:nonFraction unitRef="shares" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy03LTEtMS0xNTcx_c4688029-bb91-4fe8-a741-208950535f76">57,549,755</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0xLTEtMS0yOQ_1bac57eb-f92f-4ec9-a4d8-8efb5c1832b4"><ix:nonFraction unitRef="usdPerShare" contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0xLTEtMS0yOQ_82ddba05-26f8-4efe-aa3b-33f391400816">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0zLTEtMS0yOQ_6b5ce98e-c5ff-44d7-a51e-f9e7b005a1d9"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0zLTEtMS0yOQ_c483145c-c96a-4a98-ae85-accde792cf8b">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC01LTEtMS0xNTcx_087aa3c2-cf35-482f-9a9a-154a4e2583e9"><ix:nonFraction unitRef="usdPerShare" contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC01LTEtMS0xNTcx_445452ce-158a-4c28-bdf4-a6c5e4154a45">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC03LTEtMS0xNTcx_8cacfa7b-1578-4ba5-b677-5d4e5048278d"><ix:nonFraction unitRef="usdPerShare" contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC03LTEtMS0xNTcx_a7f14686-a853-4a89-bf47-464e11114a41">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RleHRyZWdpb246N2UyYmNmMzE3ZDdkNDUxZmEyY2UxYjg5MjNiM2M3MzZfODEz_3b267752-2e07-4d7c-afd6-9e3b9b6810f8" continuedAt="i073ab46e0b3a4941ba803b9db0356b2b" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia12e25238c51408a9b5aabb915d68f4f_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMS0xLTEtMS0yOQ_590abd08-8971-4f01-a9b5-3cbb6bbea118">23,093,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3883a4eeb01a4804bfe931960df3630c_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMS0zLTEtMS0yOQ_26751bab-bd72-404b-919d-06287b094ce3">23,093,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7aaf9605ec3d4df997dcb31cc1d69aae_D20220401-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMi0xLTEtMS0yOQ_0638b3c0-67a9-4381-a68c-783d20acfffa">5,384,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e056d11279c4dd88b534da383cad3ab_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMi0zLTEtMS0yOQ_24e89566-969d-421e-a5e0-eaff1d998204">4,474,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdd0c418f4a147dd908cb4bed116af1c_D20220401-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMy0xLTEtMS0yOQ_8fd6681a-b184-43e3-8ef8-d566e216ae21">2,014,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i323cbf05f2cd4b229244d58c16833346_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMy0zLTEtMS0yOQ_7b5150fb-b631-4778-ac81-d7e845ff55c1">2,014,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfNC0xLTEtMS0yOQ_24cfe10e-b622-4dcd-9c79-6c56c2d4db50">30,492,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfNC0zLTEtMS0yOQ_40219987-cca2-4f2e-8dce-63211de48654">29,582,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ie2301333a9d54e9f92d67dd1235f6061"><ix:continuation id="i073ab46e0b3a4941ba803b9db0356b2b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></ix:continuation></ix:continuation></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_67"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMjQyNg_1d0f15e9-3923-47c6-bff0-0ed8985c13d3" continuedAt="i9a103e93da0943b3a06b09d954d9b28b" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i9a103e93da0943b3a06b09d954d9b28b" continuedAt="i7fa96ecebdd4422fbf078f1ee2b93d23"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable, and other accrued liabilities, approximate fair value due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the promissory note receivable was level 2 and the fair value measurement was based on the market yield curves. <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMjQyNw_352714f5-dae1-4eba-b4ea-df996d79c68a" continuedAt="i28341627bfe54dc8b8f494ce5ba488b3" escape="true">The following table summarizes the conclusions reached regarding fair value measurements as of June&#160;30, 2022, and December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i28341627bfe54dc8b8f494ce5ba488b3"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d01a641a694957af47ad5592770a6c_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi0xLTEtMS0yOQ_2c74d6fc-1b3b-4f8c-bb1f-efe0b2a31a04">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89aaa594ea04677ac3c150ebeb2e739_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi0zLTEtMS0yOQ_09b9888b-700a-45ba-8072-cd99eb35a6ee">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi01LTEtMS0yOQ_434b563f-47fb-4e45-bf22-167349e36fd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi03LTEtMS0yOQ_b2195e45-1a08-4d45-97f4-1980954238c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d01a641a694957af47ad5592770a6c_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy0xLTEtMS0yOQ_de9bec50-848c-4317-9a8c-b8cf10e16f74">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89aaa594ea04677ac3c150ebeb2e739_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy0zLTEtMS0yOQ_771d4a86-6eaa-4758-b34f-1f08271ec18a">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy01LTEtMS0yOQ_414d0a51-7c37-4914-aa04-376b627c36d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy03LTEtMS0yOQ_49e36711-71c8-440a-b146-0e775e38a76f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b89c4b600ca440bb9a9a90ea5e62a11_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi0xLTEtMS0yOQ_ef75206a-36ea-4fdc-a669-0b4d4b060162">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1043be2df62a449880a9ce6cbfb89d1f_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi0zLTEtMS05NjMw_0af432b6-b4ef-43b7-8d57-225164f276a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cadb9b02403417192c10ca22f8e9080_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi01LTEtMS05NjMw_b7d544c8-bcab-4236-b821-b73b0501908d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91174829dd374e538fa07971c396f3f0_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi03LTEtMS0yOQ_e635f98f-8c73-4e7b-b7c3-e23c4a8e8c95">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d01a641a694957af47ad5592770a6c_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy0xLTEtMS0yOQ_c962ca4f-3bfa-4558-a69b-0aa21b0b7be8">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89aaa594ea04677ac3c150ebeb2e739_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy0zLTEtMS0yOQ_17b2cb88-3820-4f81-8e48-1c1936a80063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy01LTEtMS0yOQ_2209a872-25a7-455e-a444-07f4792c0168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy03LTEtMS0yOQ_88132afa-9d96-4c00-af42-d539796f3650">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi0xLTEtMS0yOQ_eb9632fd-6c5a-4111-8f42-fc84417c13b0">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi0zLTEtMS0yOQ_5d607819-ac9a-493a-aeb3-bf7b0e199420">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118c349b7b7547779cf5d02c7d07c16b_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi01LTEtMS0yOQ_39ea4b1a-d34c-488e-a92d-ee4d1f2e0090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51365f9948548649ad42309ddd6a7b1_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi03LTEtMS0yOQ_e23b64c9-3862-4da9-a0f6-7daaa9d0a48a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy0xLTEtMS0yOQ_866caa01-2b14-49a5-b6fb-d2c189ec3d03">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy0zLTEtMS0yOQ_d71468c0-9819-432f-a2bd-dbc02d4ce0c5">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118c349b7b7547779cf5d02c7d07c16b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy01LTEtMS0yOQ_0e6a0330-48d2-4890-9f0c-2f5b47b3285d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51365f9948548649ad42309ddd6a7b1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy03LTEtMS0yOQ_73c85129-5749-4666-9caf-6857e6bff99e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi0xLTEtMS0yOQ_57e5f775-2374-405f-9529-e68e5566daa6">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6746b22b7f41f39b2aa3e66ad235be_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi0zLTEtMS0yOQ_c2d8f07d-5490-4eff-9196-28e29106897e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7f59ded7334cc8a27ff3af075f6369_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi01LTEtMS0yOQ_1fe0b6e9-a753-4908-aa45-f991c9ab7b01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d33804ed69446a581a68a89a6ced16b_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi03LTEtMS0yOQ_412fc931-171e-411d-80ad-871a4674f90f">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy0xLTEtMS0yOQ_d67bd445-94e5-41e8-89c9-5eb4656ce970">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy0zLTEtMS0yOQ_426a3671-8bf4-42f1-b7fc-bee436ba7d31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118c349b7b7547779cf5d02c7d07c16b_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy01LTEtMS0yOQ_437a0110-ff12-4666-a4c4-d579b01b6a39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51365f9948548649ad42309ddd6a7b1_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy03LTEtMS0yOQ_8c081918-bc9a-4c34-9b95-cc4ad9fe5d1e">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div></ix:continuation></ix:continuation><ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMTY0OTI2NzQ0NzM5MA_2dce6462-1e68-4f39-9dd5-ce6561455976" continuedAt="i58242145b115417dbf06ea4ad3e8a18d" escape="true"></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><ix:continuation id="i7fa96ecebdd4422fbf078f1ee2b93d23" continuedAt="ie215d43492324659becbbbf3b91b4566"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i58242145b115417dbf06ea4ad3e8a18d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:31.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0291753a44b74ba594c6c841017b8991_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy0xLTEtMS0yOQ_b269bbfd-267e-416c-bea0-44a75501f4c5">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy0zLTEtMS0yOQ_86dde42b-650e-4488-8bf1-a10f442354ec">545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy01LTEtMS0yOQ_a30d093f-e137-456c-a059-9ae79e780383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy03LTEtMS0yOQ_b2e462ff-da74-43be-9a76-f1a6ca77f075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39fd9325e67d49ba929177308a09de11_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy05LTEtMS0yOQ_75abb153-2ae9-46c1-83a0-c3b38f74b639">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4ad6c963f84d1983f4152763b6d5e8_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC0xLTEtMS0yOQ_7ef890ba-e286-47cd-b216-4eb9be532761">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC0zLTEtMS0yOQ_6d9c5448-0eef-45d5-bca1-5c0e6468a262">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC01LTEtMS0yOQ_a92a6b8a-37d3-457d-b9c1-ac320da63e26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC03LTEtMS0yOQ_4d985d69-4d8b-4ed1-98a2-ac099276623e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82047fa01dff4061ac50b8ba5c19afee_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC05LTEtMS0yOQ_222ee44b-5a22-4057-852d-2ec296ddf1d0">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eefc32c333242c2ba2cc3475c9a1886_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy0xLTEtMS0yOQ_cca6f221-065e-40d8-a4cc-07ed7a12c964">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy0zLTEtMS0yOQ_b851aa1b-4bb6-4dc3-8e0b-e9fb8aab2e6d">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy01LTEtMS0yOQ_ad7df988-5999-49b5-bb5b-cf15e5cbf097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy03LTEtMS0yOQ_ff6b02fb-fb70-4170-acde-3b24501c5cf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cffc7e1fd3a45358f79cce28478fcf9_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy05LTEtMS0yOQ_67c10141-5b0f-4b83-b889-5945c4bf94f9">3,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549b94495164498ea6721b08e7ae6b51_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC0xLTEtMS0yOQ_48cdd956-bd9f-4756-be82-717d832b4c7a">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC0zLTEtMS0yOQ_500ca8de-66bc-4584-aa11-acf590a05a40">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC01LTEtMS0yOQ_f7eb53d7-ac92-44f2-8928-97b3b5929eee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC03LTEtMS0yOQ_e046a6a1-1fa9-4e67-877c-bb7b1c94f3c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1b6a13e34941f6b03007d4d7d9ce76_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC05LTEtMS0yOQ_f2ad4264-6b34-46ea-84e4-2627301ffc8d">3,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, Reneo completed its initial public offering.  As a result, the fair value of the Company&#8217;s investment in Reneo&#8217;s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.  As such, the Company&#8217;s investment in Reneo is adjusted each reporting period to its fair value based on its most recent closing price, which is considered a Level 1 fair value measurement under the fair value hierarchy.    </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and six months ended June&#160;30, 2022. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#8217;s current capitalization. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMjQyNQ_df2ad41b-1a3f-4de6-a6d6-3b998c56f98b" continuedAt="i4504f93f40e14b9b805d8b35f9c69dfc" escape="true">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June&#160;30, 2022, and December&#160;31, 2021, were:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i4504f93f40e14b9b805d8b35f9c69dfc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4459419f08db4ba1875ab5f3a7f77bd9_I20220630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi0xLTEtMS0yOS90ZXh0cmVnaW9uOmY2ZTM3MjFjZTBmODQzYjNiNjM3MGU2NjMxMjZkMDY2XzQ_af952735-7083-4625-a584-9d6967439a56">83.47</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i2c0bac167c154e428feb6ddfa2051544_I20220630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi0xLTEtMS0yOS90ZXh0cmVnaW9uOmY2ZTM3MjFjZTBmODQzYjNiNjM3MGU2NjMxMjZkMDY2Xzk_58bc928e-c1a1-4862-8f48-b554b645bf9e">138.02</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie909d9404b144715bd0bec2b55db2950_I20220630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi0yLTEtMS0yOQ_a5582348-0757-4dac-910a-8df040ed6528">117.64</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia333a79c07f744389589fbe58f3bf987_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi00LTEtMS0yOS90ZXh0cmVnaW9uOmQyZWUwMTNiYmYwZTQ1YTc5NDc2ZDA5NjA1MDJjY2FlXzQ_ac471d3a-dcb9-4f3d-bcd5-458adf69678f">82.68</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i281f26cf97534b859fc01285494a83f3_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi00LTEtMS0yOS90ZXh0cmVnaW9uOmQyZWUwMTNiYmYwZTQ1YTc5NDc2ZDA5NjA1MDJjY2FlXzk_69e663c2-4b94-4e12-bbbb-864b67f300ad">142.86</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i534e6c90542a42f48822824cfd33db65_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi01LTEtMS0yOQ_51d8e7e9-9502-4350-801c-5f816b7e9641">128.13</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc889929911946cc9f3bc54d6854ca47_I20220630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy0xLTEtMS0yOS90ZXh0cmVnaW9uOmEwNTliMDg2MGUyODRlOGVhODkyNDYwYWNjNDk5YzIwXzQ_998aef53-7e6d-4226-bf84-f93fd9e0f494">2.95</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i12ec27b58aee4985a776ed1774c95950_I20220630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy0xLTEtMS0yOS90ZXh0cmVnaW9uOmEwNTliMDg2MGUyODRlOGVhODkyNDYwYWNjNDk5YzIwXzk_ab91c126-f8ec-4962-9826-40d49d8e7f5b">3.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i106c03246dd94c1291ebcee81f596ece_I20220630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy0yLTEtMS0yOQ_9abf302a-c64a-40bc-9fdb-6009c1ca62b9">3.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie552923b1f3f42379e848afe08b6c2e0_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy00LTEtMS0yOS90ZXh0cmVnaW9uOmJjNTc1ODQzMTVkNjQxN2E4YTJjMzMwY2M1YzQxY2NlXzQ_61976820-dc67-4596-a1f3-5295b3610310">0.95</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic0f477876785490a8f842fc97272c335_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy00LTEtMS0yOS90ZXh0cmVnaW9uOmJjNTc1ODQzMTVkNjQxN2E4YTJjMzMwY2M1YzQxY2NlXzk_52579d50-65ae-4aa3-89df-38fef0da2876">1.26</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e8bcca13e6e4588aa129bdeb6bb7ec4_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy01LTEtMS0yOQ_c09c9205-e837-400a-ba18-e68ca232d2cc">1.15</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie215d43492324659becbbbf3b91b4566">Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants. Increases (decreases) in the estimates of the Company&#8217;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.</ix:continuation> </span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_70"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14:  <ix:nonNumeric contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjY4_18c0d870-0447-457c-a494-355d5bda8274" continuedAt="i196bb3ab25c24190a6d2b3d262a4bded" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i196bb3ab25c24190a6d2b3d262a4bded" continuedAt="i653b71563f5246be949a491199b3df5b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CinPax Partnership</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2022, the Company and CinPax, LLC (&#8220;CinPax&#8221;), a subsidiary of CinRx Pharma, LLC (&#8220;CinRx&#8221;) entered into a Common Stock and Warrant Purchase Agreement (the &#8220;CinRx Purchase Agreement&#8221;). Under the terms of the CinRx Purchase Agreement, CinPax acquired <ix:nonFraction unitRef="shares" contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjM5Mg_ba4a369f-7910-45e8-8a7f-5fa62880087f">4,154,549</ix:nonFraction> shares of Class A common stock at an issue price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQxOQ_6bba18f4-85b7-4625-9053-43389c6d73d0">2.41</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQwOA_e01793d3-5286-4d6f-b375-3d1963bd5d32">10.0</ix:nonFraction> million, consisting of  (i) $<ix:nonFraction unitRef="usd" contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQzNQ_e63640c6-3ab0-4ea0-b679-a72b8a34e245">6.0</ix:nonFraction> million in cash at the closing of the transaction and (ii) $<ix:nonFraction unitRef="usd" contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ1Mw_fb5d6e48-f7ba-4e6c-a00b-278afcf28588">4.0</ix:nonFraction> million in the form of a promissory note of CinPax payable on November 22, 2022. The CinRx Purchase Agreement also provides CinRx a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ2Nw_b15918e2-3676-4266-87c8-52541caba7a3">1,200,000</ix:nonFraction> shares of Class A common stock at an initial exercise price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ3NQ_2e5502bf-bd64-43a6-9420-8db25ee5e7bc">0.72</ix:nonFraction> per share, that become exercisable upon agreed vesting triggers (including FDA Approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In addition to the investment, the CinRx Purchase Agreement sets forth the terms under which the Company will leverage the CinRx team&#8217;s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leadership</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i653b71563f5246be949a491199b3df5b">On July 25, 2022, the Company entered into an employment agreement with Paul Sekhri, who was appointed President and Chief Executive Officer and a member of the Board (the &#8220;Sekhri Employment Agreement&#8221;). In addition to outlining the terms of Mr. Sekhri&#8217;s compensation, it also provides for the grant of stock options (the &#8220;Options&#8221;) to purchase <ix:nonFraction unitRef="shares" contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ4Ng_a5d89fca-9c99-436b-818a-f0d0f1c364a5">2,200,000</ix:nonFraction> shares of Class A common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ5NA_513fcff2-6679-4e97-930d-14e084a5b1cc">0.79</ix:nonFraction> per share pursuant to an inducement award agreement (the &#8220;Inducement Award Agreement&#8221;). Subject to potential acceleration upon the achievement of certain performance metrics as set forth in the Inducement Award Agreement, <ix:nonFraction unitRef="rate" contextRef="i0826cd3429194c58828df365b21d13d7_D20220725-20220725" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjUwMA_203908fd-1695-43e4-b17e-de06bd958bac">25</ix:nonFraction>% of the Options will vest on the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="rate" contextRef="i301fa4d644bd48b0a42d7d3c43ad4466_D20220725-20220725" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjUwNg_c70ad24f-a251-4cc1-a670-c47e8b42fed7">75</ix:nonFraction>% of the Options will vest quarterly over three years thereafter. Upon certain terminations of employment, a portion of the Options will vest on a pro rata basis based on the number of days employed during the <ix:nonNumeric contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMTE1NDQ4NzIxMTE4Mzg_e11b060d-f849-4077-a678-9511df0b9cee">four-year</ix:nonNumeric> term.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, the &#8220;Company&#8221;, the &#8220;Registrant&#8221;, &#8220;we&#8221; or &#8220;us&#8221; refer to vTv Therapeutics Inc. and &#8220;vTv LLC&#8221; refers to vTv Therapeutics LLC. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes that appear elsewhere in this report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, assumptions and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under &#8220;Part II, Other Information&#8212;Item 1A, Risk Factors.&#8221; Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or similar expressions and the negatives of those terms. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and preclinical drug candidates. Our lead program is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an orally administered, small molecule, liver-selective glucokinase activator (&#8220;GKA&#8221;) for the treatment of type 1 diabetes.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022, the Company appointed Paul Sekhri as President, Chief Executive Officer (CEO) effective August 1, 2022, and was confirmed as a member of the board of directors on August 9, 2022. Mr. Sekhri brings nearly 30 years of healthcare experience, including serving as President and CEO of several healthcare companies, experience in several senior business development and strategy roles and he has been a director on more than 30 private, public company and non-profit boards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the positive results of our Simplici-T1 Study, we requested Breakthrough Therapy Designation (&#8220;BTD&#8221;) with the FDA which was granted in April 2021. In October 2021, we began to implement a strategy to focus our efforts on the continued development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a potential treatment for patients with type 1 diabetes (&#8220;T1D&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> After several meetings with the FDA BTD-team, the Company is planning two pivotal, placebo-controlled clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with T1D. The studies will recruit a total of approximately 1,000 patients and at least one of the studies will be one year of treatment. The FDA confirmed that the effect size of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on events of hypoglycemia as demonstrated in the Phase 2 SimpliciT-1 Study is clinically meaningful and has agreed on the primary endpoint for the studies as the difference between placebo and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-treated group in number of hypoglycemia events.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the mechanistic study provided additional evidence to support the idea that treatment with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will not increase the risk of diabetic ketoacidosis (&#8220;DKA&#8221;) in patients with T1D. The data demonstrate that in contrast to agents such as SGLT2 inhibitors and GLP&#8208;1RAs, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> does not increase the risk of ketoacidosis when used as an adjunctive therapy to insulin in individuals with T1D. Moreover, these findings support prior studies that demonstrate that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> improves glucose control and reduces hypoglycemia and suggests a protective effect of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against acidosis in people with T1D. Thus, accumulating data suggest that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has robust potential as an adjunctive therapy for T1D. Full study results were published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diabetes Obesity and Metabolism</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> journal in conjunction with the 82nd American Diabetes Association Scientific Sessions on June 6, 2022. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our drug candidates, their partnership status, and their respective stages of development:</span></div><div style="margin-top:6pt;text-align:center"><img src="vtvt-20220630_g1.jpg" alt="vtvt-20220630_g1.jpg" style="height:381px;margin-bottom:5pt;vertical-align:text-bottom;width:570px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4pt">Chronic obstructive pulmonary disease</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Type 1 Diabetes Program &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TTP399</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is planning two pivotal, placebo-controlled clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with T1D and has engaged with FDA on the optimal clinical trial designs for these studies. The studies will recruit a total of approximately 1000 patients and at least one of the studies will be one year of treatment. The FDA and the company have agreed on the primary endpoint for the studies as the difference between placebo and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-treated group in number of hypoglycemia events. These pivotal studies are expected to start in 4Q 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we announced positive results of a mechanistic study of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with T1D. The study demonstrated that patients with T1D taking </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experienced no increase in ketone levels relative to placebo during a period of acute insulin withdrawal, indicating no increased risk of ketoacidosis. Consistent with previous clinical studies, improved fasting plasma glucose levels and fewer hypoglycemic events were observed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treated group during the week of treatment prior to the insulin withdrawal test. The FDA has declined to approve SGLT2 inhibitors as an adjunctive therapy in T1D, with concerns over the potential risks of diabetic ketoacidosis (&#8220;DKA&#8221;) in focus. DKA can lead to hospitalization and, if untreated, death. To address these concerns, vTv, following the FDA&#8217;s recommendation, conducted this mechanistic study to demonstrate that treatment with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a liver-selective glucokinase activator, will not result in increased production of ketones, a precursor to ketoacidosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we announced that the FDA granted BTD for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an adjunctive therapy to insulin for the treatment of T1D. This designation provides a sponsor with added support and the potential to expedite development and review timelines for a promising new investigational medicine.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company announced entry into agreements that include a $25.0 million investment by G42 Investments. Under the terms of the agreements, the Company agreed to sell G42 Investments 10,386,274 shares of the Company&#8217;s Class A common stock at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30.0 million in additional shares of Class A common stock to G42 Investments (or cash in lieu of such issuance at the option of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments) if the FDA approves the marketing and sale of a pharmaceutical product containing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a liver selective glucokinase activator, as the active ingredient for treatment of T1D in the United States. The agreements set forth the terms under which the Company and Cogna, an affiliate of G42 Investments, plan to collaborate on clinical trials for pharmaceutical products that contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including Cogna funding a portion of the Phase 3 clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the Company granting Cogna an exclusive license to develop and commercialize pharmaceutical products containing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a specified territory, principally consisting of the Middle East, Africa and Central Asia.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holding Company Structure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC, the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results under the VIE accounting model in its consolidated financial statements.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from up-front proceeds, milestones and research fees under collaboration and license agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts, and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories, and clinical research organizations (&#8220;CRO(s)&#8221;) in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits, and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception, including our predecessor companies, through June&#160;30, 2022, we have incurred approximately $605.4 million in research and development expenses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses by project for the three and six months ended June&#160;30, 2022, and 2021 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Azeliragon</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">TTP399</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">HPP737</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other projects</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and further advance the development of our other drug candidates, subject to the availability of additional funding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing, or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the uncertainty of the scope, rate of progress, and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential benefits of our candidates over other therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to market, commercialize, and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">future clinical trial results;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to enroll patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and receipt of any regulatory approvals; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the filing, prosecuting, defending, and enforcing of patent claims and other intellectual property rights, and the expense of doing so.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, benefits, and related costs for employees in executive, finance, corporate development, human resources, and administrative support functions. Other significant general and administrative expenses include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs, and information systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income represents non-cash interest income related to the imputed interest from our promissory note receivable, all of which are recognized in our Condensed Statement of Operations using the effective interest method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interest expense is immaterial. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income/expense primarily consists of unrealized gains or losses attributable to the changes in fair value of the equity investments held by our licensees, as well as the recognition of changes in fair value of the warrants to purchase shares of our Class A common stock held by a related party.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended June&#160;30, 2022, and 2021</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,679</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(643)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,027)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,670)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,943)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,091)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,091)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(707)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,151)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,543)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended June&#160;30, 2022, and 2021 were insignificant. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $2.2 million and $2.4 million for the three months ended June&#160;30, 2022, and 2021, respectively. The decrease in research and development expenses during this period of $0.2 million or 9.5%, was primarily driven by i) a decrease in clinical trial costs of $0.3 million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">azeliragon,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> driven by the discontinuance of its development as a potential treatment of Alzheimer&#8217;s disease in patients with type 2 diabetes, ii) decreased spending of $0.7 million related to the multiple ascending dose study for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to its completion in 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> iii) decreases in indirect costs of $0.6 million offset by iv) higher spending on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $1.3 million, due to trial preparation costs, and v) higher spending on other projects costs of $0.1 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.8 million and $2.2 million for the three months ended June&#160;30, 2022, and 2021, respectively. The decrease in general and administrative expenses during this period of $0.4&#160;million, or 18.3%, was primarily driven by i) decreases in payroll costs of $0.9 million due to the reduction in workforce in connection with the Company&#8217;s restructuring plan that occurred in December 2021, ii) decreases in share-based expense of $0.2 million, offset by iii) increases of $0.4 million in legal expense, and iv) increases of $0.3 million other general and administrative costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended June&#160;30, 2022, and 2021, was insignificant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended June&#160;30, 2022, and 2021, was insignificant.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) / Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense was $0.1 million for the three months ended June&#160;30, 2022, and was driven by an unrealized loss related to our investment in Reneo as well as the gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to a related party (&#8220;Related Party Warrants&#8221;). Other income was $3.8 million for the three months ended June&#160;30, 2021, and was related to the unrealized gain recognized related to our investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants in our own stock held by a related party.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_492"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the six months ended June&#160;30, 2022, and 2021</span></div><div style="margin-top:6pt;text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:58.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June&#160;30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,540</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,179</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,406</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,773</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,946</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,508)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,950)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,558)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,856)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,181</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,037)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,315)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,768)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,547)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,515)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,783)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,732)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,357)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,423)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,158)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,309)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the six months ended June&#160;30, 2022, includes a $2.0 million increase to the transaction price for the license performance obligations under the amended license agreement with Huadong due to the satisfaction of a development milestone. Revenue for the six months ended June&#160;30, 2021, relates to the reallocation of revenue to the license and technology transfer performance obligation made in connection with the First Huadong Amendment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $5.3 million and $5.5 million for the six months ended June&#160;30, 2022, and 2021, respectively. The decrease in research and development expenses during the period of $0.2 million, or 3.6%, was primarily driven by i) a decrease in clinical trial costs of $0.9 million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">azeliragon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was mainly driven by discontinuance of its development as a potential treatment of Alzheimer&#8217;s disease in patients with type 2 diabetes, ii) decreased spending of $1.7 million related to the multiple ascending dose study for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to its completion in 2021, iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases in indirect costs of $1.1 million offset by iv) higher spending on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, due to trial preparation costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $3.5 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $7.2 million and $4.4 million for the six months ended June&#160;30, 2022, and 2021, respectively. The increase of $2.8 million has been primarily driven by i) increases of $2.6 million in legal expense, ii) increases of $0.8 million in severance costs, iii) increases of $0.7 million in other general and administrative costs, offset by iv) decreases of $0.1 million in shared based expense, and v) decreases of $1.2 million in payroll costs due to the reduction in workforce in connection with the Company&#8217;s restructuring plan that occurred in December 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the six months ended June&#160;30, 2022, and 2021, was insignificant.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the six months ended June&#160;30, 2022, and 2021, was insignificant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income / (Expense)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense was $2.9 million for the six months ended June&#160;30, 2022 and is driven by an unrealized loss recognized related to the Company&#8217;s investment in Reneo as well as the gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to a related party. Other income was $2.2 million for the six months ended June&#160;30, 2021, and was driven by an unrealized gain recognized related to the Company&#8217;s investment in Reneo as well as losses related to the change in fair value of the outstanding warrants in our own stock held by a related party.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we have an accumulated deficit of $253.3 million as well as a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of June&#160;30, 2022, our liquidity sources included cash and cash equivalents of $17.9 million. In addition to available cash and cash equivalents discussed above, we are evaluating several financing strategies to fund the on-going and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including direct equity investments and the potential licensing and monetization of other Company programs such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also has a promissory note of $12.5 million under the G42 Purchase Agreement payable to the Company on or before May 31, 2023 (see Note 9) and on July 25, 2022 announced a $10.0 million Class A common stock investment by CinPax, LLC, consisting of $6.0 million in cash and $4.0 million payable on November 22, 2022 (see Note 14).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we may use the remaining availability of $37.3 million under our Sales Agreement with Cantor Fitzgerald pursuant to which we could offer and sell, from time to time, shares of our Class A common stock under the ATM Offering and our ability to sell approximately 9.4 million shares of Class A common stock to Lincoln Park pursuant and subject to the limitations of the LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in our Class A common stock. These factors raise substantial doubt about our ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the Sales Agreement with Cantor Fitzgerald pursuant to which we may offer and sell, from time to time, through or to Cantor Fitzgerald, as sales agent or principal, shares of our Class A common stock having an aggregate offering price of up to $68.5 million. We are not obligated to sell any shares under the Sales Agreement. Under the terms of the Sales Agreement, we will pay Cantor Fitzgerald a commission of up to 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. As of June&#160;30, 2022, we have sold $31.2 million worth of Class A common stock under the ATM Offering for net proceeds of $30.3 million, leaving $37.3 million available to be sold. The shares are offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3. In no event will we sell Class A common stock under this registration statement with a value exceeding more than one-third of the &#8220;public float&#8221; (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Purchase Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the LPC Purchase Agreement, pursuant to which we have the right to sell to Lincoln Park shares of the Company&#8217;s Class A common stock having an aggregate value of up to $47.0 million. As of June&#160;30, 2022, we have issued 5,331,306 of these shares for gross proceeds of approximately $11.1 million, leaving $35.9 million available to be sold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the 36-month term of the LPC Purchase Agreement, we have the right, but not the obligation, from time to time, in our sole discretion, to direct Lincoln Park to purchase up to 250,000 shares per day (the &#8220;Regular Purchase Share Limit&#8221;) of the Class A common stock (each such purchase, a &#8220;Regular Purchase&#8221;). The Regular Purchase Share Limit will increase to 275,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $4.00 per share and will further increase to 300,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $5.00 per share. In any case, Lincoln Park&#8217;s maximum obligation under any single Regular Purchase will not exceed $2,000,000. The purchase price for shares of Class A common stock to be purchased by </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lincoln Park under a Regular Purchase will be equal to the lower of (in each case, subject to the adjustments described in the LPC Purchase Agreement): (i) the lowest sale price for the Class A common stock on the applicable purchase date and (ii) the arithmetic average of the three lowest closing sales prices for the Class A common stock during the 10 consecutive trading days prior to the purchase date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we direct Lincoln Park to purchase the maximum number of shares of Class A common stock that we may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the LPC Purchase Agreement, we may direct Lincoln Park to make an &#8220;accelerated purchase&#8221; and an &#8220;additional accelerated purchase&#8221;, each of an additional number of shares of Class A common stock which may not exceed the lesser of: (i) 300% of the number of shares purchased pursuant to the corresponding Regular Purchase and (ii) 30% of the total number of shares of the common stock traded during a specified period on the applicable purchase date as set forth in the LPC Purchase Agreement. The purchase price for such shares will be the lesser of (i) 97% of the volume weighted average price of the Class A common stock over a certain portion of the date of sale as set forth in the LPC Purchase Agreement and (ii) the closing sale price of the Class A common stock on the date of sale (an &#8220;Accelerated Purchase&#8221;). Under certain circumstances and in accordance with the LPC Purchase Agreement, we may direct Lincoln Park to purchase shares in multiple Accelerated Purchases on the same trading day.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LPC Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of its Class A common stock if those shares, when aggregated with all other shares of Class A common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of Class A common stock as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,297)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,784&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,385&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2022, our net cash used in operating activities decreased by $9.0 million from the six months ended June&#160;30, 2021 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant contributor to the change in cash used during the year was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">driven by working capital changes offset by cash received of $6.8 million in excess of the fair value of the Class A common stock issued to G42 investments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, net cash used in investing activities was insignificant. There were no cash flows from investing activities for the six months ended June&#160;30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2022, net cash provided by financing activities was driven by sales of our Class A common stock to a collaboration partner. For the six months ended June&#160;30, 2021, net cash provided by financing activities was driven by sales of shares of our Class A common stock during the six months ended June&#160;30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our ongoing development activities, particularly as we continue the research, development, and clinical trials of, and seek regulatory approval for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing, and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to finance our operations into the third quarter of 2023 through the use of our cash and cash equivalents and based on current operating plans, we are evaluating several financing strategies to fund the on-going and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including direct equity investments and the potential licensing and monetization of other Company programs such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also has a promissory note of $12.5 million under the G42 Purchase Agreement payable to the Company on or before May 31, 2023. The timing of any such transactions is not certain, and we may not be able to complete such transactions on acceptable terms, or at all. Even if we are able to complete such transactions, it may contain restrictions on our operations or cause substantial dilution to our stockholders. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates. Additionally, we may rely on our ability to sell shares of our Class A common stock pursuant to the ATM Offering and LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock, and we may use our available capital resources sooner than we currently expect.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The progress, costs, results, and timing of our planned trials to evaluate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a potential treatment of T1D;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of the FDA to rely upon our completed and planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the outcome, costs, and timing of seeking and obtaining FDA and any other regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability of our drug candidates to progress through clinical development successfully;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to expand our research and development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with securing, establishing, and maintaining commercialization capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of acquiring, licensing, or investing in businesses, products, drug candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need and ability to hire additional management and scientific and medical personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing, or other arrangements into which we may enter in the future;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of any payments we are required to make to M&amp;F TTP Holdings Two LLC in the future under the Tax Receivable Agreement; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the impact and duration of the COVID-19 outbreak / pandemic.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. We currently have committed external source of funds available through the ATM Offering, LPC Purchase Agreement and a Promissory Note under the G42 Purchase Agreement for $12.5 million payable to the Company on or before May 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may be required </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to obtain additional funding, we could be forced to delay, reduce, or eliminate our research and development programs or commercialization efforts, or pursue one or more alternative strategies, such as restructuring, any of which could adversely affect our business prospects.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we did not have outstanding any off-balance sheet arrangements as defined under SEC rules. </span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Critical Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. There have been no material changes to our critical accounting policies and estimates in 2022.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report includes certain forward-looking statements within the meaning of the federal securities laws regarding, among other things, our management&#8217;s intentions, plans, beliefs, expectations, or predictions of future events, which are considered forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements often include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;outlook&#8221;, &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate&#8221; or similar expressions. These statements are based upon assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you read this quarterly report, you should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties, and assumptions, including those described under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q. Although we believe that these forward-looking statements are based upon reasonable assumptions, you should be aware that many factors, including those described under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q, could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward-looking statements made herein are made only as of the date of this quarterly report. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this quarterly report.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of recent accounting pronouncements in Note 2, &#8220;Summary of Significant Accounting Policies&#8221;, to the Condensed Consolidated Financial Statements in this Form 10-Q.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_109"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any material interest rate exposure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents in a financial institution that management believes to be of high credit quality. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the value of our investment portfolio.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any material foreign currency exposure.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_112"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our Chief Executive Officer and Chief Accounting Officer, management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of June&#160;30, 2022. Based upon that evaluation, our  Chief Executive Officer and Chief Accounting Officer concluded that, as of June&#160;30, 2022, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized, and reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Accounting Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes to Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Website Availability of Reports and other Corporate Governance Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence, and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on the SEC&#8217;s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_118"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_121"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are set forth under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. There have been no material changes to our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_124"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022, the Company issued the following unregistered securities:</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company sold  10,386,274 shares of the Company&#8217;s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_127"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_130"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_133"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_136"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="projectg-collaborationandl.htm">Cogna Technology Solutions LLC, Collaboration and License Agreement</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20220630xexx311.htm">Certification of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20220630xexx311.htm">President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20220630xexx312.htm">Certification of Chief Accounting Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20220630xexx321.htm">Certification of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20220630xexx321.htm">President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20220630xexx322.htm">Certification of Chief Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;&#160;&#160;&#160;&#160;Confidential treatment received with respect to portions of this exhibit.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i7213a6cb68bb48ed8c21afe0782e56bd_139"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7213a6cb68bb48ed8c21afe0782e56bd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;15, 2022</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:58.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTV THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Barry Brown</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barry Brown</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>projectg-collaborationandl.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if3d95cb665db4012bc3df24549a8a91b_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-right:5.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXECUTION VERSION</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.8pt;padding-left:102.67pt;padding-right:102.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Collaboration and License Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of May 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between vTv Therapeutics LLC, a Delaware limited liability company having an address at 3980 Premier Dr. Suite 310, High Point, North Carolina 27265 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Cogna Technology Solutions LLC, an Abu Dhabi limited liability company having an address at Abu Dhabi 624, Plot C18, E48 RG Building, Al Salam, Abu Dhabi, United Arab Emirates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Company and Partner may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:99.97pt;padding-right:99.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Company, a biopharmaceutical company, is developing a proprietary candidate known as TTP399 and owns or controls certain Patents, Know-How and other Intellectual Property relating to such candidate&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Partner possesses substantial resources and expertise in clinical development and commercialization of pharmaceutical products&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Company and Partner desire to collaborate on certain Development of the Product and to grant Partner certain rights to Commercialize the Product within the Partner Territory, in each case, as further described in, and subject to, the terms and conditions of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company and Partner hereby agree as follows&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capitalized terms used in this Agreement shall have the meanings ascribed to such terms in this Agreement, including as specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any use of the term &#8220;Purchaser&#8221; therein shall mean &#8220;Partner&#8221; for the purposes hereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that for purposes of this Agreement (a) Company, its Subsidiaries, MAF and its Subsidiaries will not be deemed an Affiliate of Partner or its Subsidiaries, (b) Partner and its Subsidiaries will not be deemed an Affiliate of Company, its Subsidiaries, MAF or its Subsidiaries and (c) notwithstanding the foregoing other than in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; as to Company, shall be deemed to mean Subsidiary.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-right:6.05pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as applicable, the FCPA, the U.S. Travel Act, 18 U.S.C.</font></div><div style="padding-right:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 1952, the U.K. Bribery Act 2010, any Law enacted to implement the OECD Convention on</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Combating Bribery of Foreign Officials in International Business Transactions, and any other anti- corruption or anti-bribery Laws of similar effect in other countries or jurisdictions in which products, payments or services will be provided under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all applicable national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, and permits of or from any Regulatory Authority or other Governmental Authority having jurisdiction over or related to the subject item. For clarity, the Parties acknowledge and agree that, with respect to Partner&#8217;s and any Partner Member&#8217;s conduct of any Partner-Conducted Clinical Trials, and related activities hereunder, &#8220;compliance with Applicable Laws&#8221; shall be deemed to require compliance with the Laws of the applicable country or jurisdiction in which the Partner-Conducted Clinical Trial takes place or the IND is filed, as well as compliance with the FD&#38;C Act, 21 CFR Parts 11, 50, 54, 56, 58 and 312 that are applicable as a result of Partner&#8217;s assumption of responsibilities as a CRO for a Sponsor with its principal place of business in the United States.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each respective period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31, or the applicable part thereof during the first or last quarter of the Term.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each respective period of twelve (12) consecutive months ending on December 31, or the applicable part thereof during the first or last year of the Term.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">cGCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the current clinical practice requirements set out in (a) ICH Harmonized Guidance on current Good Clinical Practice (CPMP&#47;ICH&#47;135&#47;95), (b) U.S. Code of Federal Regulations, Title 21, Chapters 50, 54, 56, 58 and 312, (c) EU Directive 2001&#47;20&#47;EC and related guidelines, and (d) any foreign equivalents of any of the foregoing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">cGLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58, and such other comparable regulatory standards in jurisdictions outside the U.S.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the current minimum standards for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, distribution or holding of a drug as specified by Applicable Laws of the relevant jurisdictions at the time of manufacturing conducted in accordance with this Agreement, including (a) 21 C.F.R. Part 210 and 211, (b) Directive 2003&#47;94&#47;EC, (c) Volume 4, Rules Governing Medicinal Products in the EU, Part I and II, and (d) any foreign equivalents thereof.</font></div><div><font><br></font></div><div style="padding-left:41pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Hold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that (a) the FDA has issued an order to a Party pursuant to 21 CFR</font></div><div style="padding-left:5pt;padding-right:6.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 312.42 to delay a proposed Clinical Trial or to suspend an ongoing Clinical Trial of the Compound or Product in the United States or (b) a Regulatory Authority other than the FDA has issued an equivalent order to that set forth in (a) in any other country or group of countries.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Investigator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an individual who actually conducts a clinical investigation (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, under whose immediate direction the drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the investigator is the responsible leader of the team. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subinvestigator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; includes any other individual member of that team.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any clinical trial, which is any experiment in which a drug is administered or dispensed to, or used involving, one or more human subjects, including any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial or Phase 4 Clinical Trial.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Collaboration Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Clinical Trial that is set forth in, and conducted under, the Global Development Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means with respect to a pharmaceutical product, any and all activities directed to the marketing, promotion, importation, distribution, pricing and reimbursement approval, offering for sale, and sale of such pharmaceutical product, and interacting with Regulatory Authorities regarding the foregoing, but excluding, Development and Manufacturing. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; have a correlative meaning.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party and its obligations to Develop, Manufacture or Commercialize (as applicable) the Product under this Agreement, those efforts and resources commonly used in the pharmaceutical industry (which shall be no less than those efforts used by the applicable Party) for the development and commercialization of a pharmaceutical product which is at a similar stage of development or commercialization, taking into account product profile, efficacy and safety, proprietary position, including patent and regulatory exclusivity, regulatory status, including anticipated or approved labeling and anticipated or approved post-approval requirements and present and future market and commercial potential, including competitive market conditions (but not taking into account any payment owed to the other Party under this Agreement). Without limiting the foregoing, Commercially Reasonable Efforts requires that a Party&#58; (a) establish a plan to achieve objectives and assign specific responsibilities for the achievement of that plan and (b) make and implement decisions and allocate resources designed to advance progress with respect to such objectives.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Intellectual Property, owned by or licensed to Company or any of its Affiliates that is&#58; (a) (i) owned by or licensed to Company or any of its Affiliates as of the Effective Date or (ii) created or developed by a Company Member during the Term of this Agreement but outside of Company&#8217;s performance of activities contemplated under this Agreement, including improvements thereto, without using or referencing any Partner IP, and</font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) that is provided or otherwise made available to Partner under or in connection with this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company Know-How, Company Patents and Company Developed IP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How to the extent Controlled by Company or any of its Subsidiaries as of the Effective Date or any time during the Term that is incorporated into, or otherwise necessary for the Partner to Develop, Commercialize or Manufacture, the Product for use in the Partner Territory, excluding any Patents filed thereon or with respect thereto. Notwithstanding the foregoing, Company Know-How shall not include any Know-How to the extent related to any components, compounds or agents that are not the Compound, or products that are not the Product.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Company, its Subsidiaries or its or their Sublicensees or subcontractors (including, for clarity, any of its CROs).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, to the extent Controlled by Company or any of its Subsidiaries as of the Effective Date or any time during the Term, any and all Patents (a) to the extent set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; (b) to the extent Covering any Company Know-How&#59; (c) continuations, divisionals, renewals, continuations-in-part, and patents of addition claiming priority to any Patents described in the foregoing (a) or (b) and all foreign equivalents thereof&#59; and (d) restorations, extensions, supplementary protection certificates, reissues and re-examinations of the Patents described in the foregoing (a), (b) or (c), each of the foregoing subsections (c) and (d), to the extent the claims of such Patents are fully supported by any Patent described in the foregoing subsections (a) or (b). Notwithstanding the foregoing, Company Patents shall not include any Patents to the extent related to any components, compounds or agents that are not the Compound, or products that are not the Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means worldwide, other than the Partner Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Completion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as to a particular Clinical Trial, the earlier of (a) the date on which the last subject in such Clinical Trial completes the last visit as described in the protocol for such Clinical Trial and (b) the date such Clinical Trial or this Agreement is terminated.</font></div><div style="margin-top:0.3pt;padding-left:41pt;padding-right:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; means TTP399, an oral, small molecule liver selective glucokinase activator. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:247%">&#8221; means any and all Know-How and other information or data</font></div><div style="margin-top:0.3pt;padding-left:5pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that is generated or collected by or on behalf of a Party Member or which one Party Member provides or otherwise makes available to any other Party Member in connection with this Agreement, whether orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, Data, designs or formulae&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that all confidential Company IP will be deemed Company&#8217;s Confidential Information and all confidential Partner IP will be deemed Partner&#8217;s Confidential Information.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Intellectual Property, the legal authority or right (whether by ownership, license or otherwise, but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant the applicable access to, or license or sublicense under, such Intellectual Property to the other Party pursuant to this Agreement, without breaching the terms of any agreement or other arrangement with a Third Party, or violating any Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Co-Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any applicable Clinical Trial under this Agreement, such Clinical Trial is being &#8220;co-sponsored&#8221; by each of Partner and Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Co-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which for purposes of this Agreement shall mean that (a) Company is the Sponsor (as defined below), and (b) subject to and in accordance with 21 CFR 312.52, and any corresponding Applicable Laws in any other countries or regulatory jurisdictions, Company has transferred to Partner, and following such transfer Partner is responsible for, certain of Company&#8217;s responsibilities (and corresponding liabilities therefor) as the Sponsor of such Clinical Trial (i.e., Partner-Conducted Clinical Trials) in accordance with, and subject to, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.2(e)(ii)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cover(ed)(ing)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Patent and the subject matter at issue, that, but for a license granted under a Valid Claim of such Patent, the Development, Manufacture, use, sale, offer for sale, importation or other Commercialization of the subject matter at issue would infringe such Valid Claim, or, in the case of a Patent that is a patent application, would infringe a Valid Claim in such patent application if it were to issue as a patent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CRF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Case Report Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the collection of documents designed specifically for recording Data pursuant to the protocol for a Clinical Trial. For clarity, a CRF is completed for each subject and will be in electronic form, validated and in compliance with all Applicable Laws.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a contract research organization.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Clinical Trial, a clinical study report, or other equivalent document or series of materials, constituting a summary report of the clinical and medical data resulting from such Clinical Trial and prepared for incorporation into submissions seeking Regulatory Approval for the Product, and includes all statistical analyses of such data per the Statistical Analysis Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all scientific, technical, test, marketing or sales data pertaining to the Product that is generated by or on behalf of any Party Member, including research data, clinical pharmacology data, pre-clinical data and clinical data.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all development activities with respect to a compound or product that are directed to obtaining Regulatory Approval, including all non-clinical, preclinical and clinical testing and studies&#59; toxicology, pharmacokinetic and pharmacological studies&#59; statistical analyses&#59; assay development&#59; protocol design and development&#59; the preparation, filing and submission of any NDA therefor&#59; and all regulatory affairs related to any of the foregoing. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; have correlative meanings.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:84.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; means the European Medicines Agency or any successor thereof. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; means the European Economic Area and Switzerland.</font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Chief Executive Officer of Company (or any other executive officer as appointed by Company) and the Chief Executive Officer of Partner (or any other executive officer as appointed by Partner).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exploit(ation)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to make, have made, import, export, use, sell or offer for sale, including to research, Develop, Manufacture, export, transport, and distribute, promote, market, or have sold or otherwise dispose of and otherwise Commercialize.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Export Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Applicable Laws governing the export or re-export of commodities, software, technologies, or services, including the Export Control Reform Act of 2018, 50 U.S.C. &#167;&#167; 4801-4852&#59; the Export Administration Act of 1979, 24 U.S.C. &#167;&#167; 4601 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167; 1701 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; the Trading with the Enemy Act, 50 U.S.C. &#167;&#167; 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; sections 38 and 39 of the Arms Export Control Act, 22</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">U.S.C. &#167;&#167; 2778 and 2779&#59; and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:217%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">). &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; means the U.S. Federal Food, Drug and Cosmetic Act.</font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Food and Drug Administration or any successor thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on a country-by-country basis, the first sale by a Partner Member to a Third Party for end use in such country after Regulatory Approval has been granted for the Product in such country.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means external acts beyond the reasonable control of the affected Party, including acts of God, fires, floods, storms, wars, earthquakes, acts of terrorism, riots or civil commotions, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, legal or government restrictions or government acts or orders (even if caused by the Sars-Cov-2 pandemic), epidemics or pandemics (excluding the current Sars-Cov-2 pandemic in and of itself).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity, as they exist from time to time, consistently applied.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) any elected or appointed official of any Governmental Authority (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a legislator or a member of a ministry of health), (b) any employee or other Person acting for or on behalf of a Governmental Authority, a Governmental Authority department or agency, an institution or entity owned or controlled by a Governmental Authority (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an HCP employed by a Governmental Authority-owned or -controlled hospital, or a Person serving on a healthcare committee that advises a Governmental Authority), or an enterprise or instrumentality performing a governmental function, (c) any candidate for public office, or officer, employee, or other Person acting for or on behalf of a political party or candidate for public office, (d) an employee or other Person acting for or on behalf of a public international organization (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the United Nations, the Red Cross, or the World Bank), (e) any member of a military or a royal or ruling family or (f) any Person otherwise categorized as an official of a Governmental Authority under Law.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Healthcare Professional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; includes any physician, nurse, pharmacist, or other person who may administer, prescribe, purchase, or recommend pharmaceutical products or other healthcare products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the International Conference on Harmonization (of Technical Requirements for Pharmaceuticals for Human Use).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:6.25pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IDMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the independent data monitoring committee, which shall be established pursuant to the terms hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:6.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means International Financial Reporting Standards of the International Accounting Standards Board or any successor entity, as they exist from time to time, consistently applied.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) an Investigational New Drug Application as defined in the FD&#38;C Act or 21 C.F.R. Part 312, or any successor application or procedure required to initiate a Clinical Trial in the United States, (b) any counterpart in any country other than the United States and (c) all supplements and amendments to any of the foregoing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means those Collaboration Clinical Trials for Development of the Initial Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain pharmaceutical product that is formulated as a tablet for oral administration and contains either four hundred (400) or eight hundred (800) milligrams of the Compound as the sole active pharmaceutical ingredient to the extent administered in a Clinical Trial, or approved, for treatment of Type 1 diabetes.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Patents, Trademarks, Know-How, registered designs, design rights, copyrights (including rights in computer software), domain names, rights in databases and any and all other intellectual property and proprietary rights in any country or regulatory jurisdiction throughout the world, whether registered or not, together with all applications and registrations therefor.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investigator&#8217;s Brochure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the written document containing a brief description of the drug substance and formulation of the Product, a summary of the pharmacological and toxicological effects of the Product in animals and human nonclinical models, a summary of the pharmacokinetics and biological disposition of the Product in animals and humans, a summary of information relating to safety and effectiveness of the Product in humans obtained from prior clinical studies, and a description of possible risks and side effects to be anticipated on the basis of prior experience with the Product under investigation or with related drugs.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IPR Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Third Party Claim alleging Development or Commercialization of the Product by or on behalf of any Partner Member infringes, misappropriates or otherwise violates any Patent or Know-How owned by any Third Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IRB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means institutional review board, or its equivalent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all technical, scientific, regulatory and other information, results, knowledge, techniques and data, in whatever form and whether or not confidential, patented or patentable, including inventions, invention disclosures, discoveries, plans, processes, practices, methods, knowledge, trade secrets, know-how, instructions, skill, experience, ideas, concepts, data (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality control, and preclinical and clinical data), formulae, formulations, compositions, specifications, marketing, pricing, distribution, cost, sales and manufacturing data or descriptions. Know-How does not include Patents claiming any of the foregoing.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the actual knowledge of the executive officers of Company or Partner, as applicable, as listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:6.2pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means liabilities, expenses and losses, including personal injury or death of any person, property damage, including reasonable legal expenses and attorneys&#8217; fees.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all activities related to making, having made, production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of any compound or product, including process development, testing method development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; have correlative meanings.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Safety Issue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Party&#8217;s good faith belief that there is an unacceptable risk for harm in humans based upon (a) preclinical safety data, including data from animal toxicology studies or (b) the observation of serious adverse effects in humans after dosing the Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a New Drug Application, as defined in the FD&#38;C Act or 21 C.F.R. Part 314 or any foreign equivalent thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the gross amounts billed or invoiced by any Partner Member for sale of the Product, less the following deductions, without duplication, to the extent allocable to the Product and invoiced or otherwise directly incurred in accordance with IFRS and Partner&#8217;s usual and customary accounting practices&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt">trade discounts, returns, credits or allowances,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.02pt">credits or allowances additionally granted on account of rejections, returns, recalls (unless caused by its gross negligence or willful misconduct) or billing errors, commissions,</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.7pt">import&#47;export or other custom duties, reasonable prepaid outbound freight expenses, insurance and other transportation costs incurred in transporting the applicable Product,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.02pt">sale taxes, VAT, and other governmental charges (other than taxes on the income or capital of Partner),</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt">government mandated rebates,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.03pt">refunds and rebates for spoiled, damaged, outdated, rejected or returned Product or as otherwise required by Applicable Laws, and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.02pt">amounts that are actually written off as non-collectible for the sale of the Product after Partner Members&#8217; commercially reasonable best efforts to collect such amounts.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the case of any sale of the Product for non-cash consideration, Net Sales shall be calculated as the fair market price of the Product in the applicable country of sale or disposal. Sales of the Product between Partner and other Partner Members for resale shall be excluded from</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the computation of Net Sales, but the subsequent resale of the Product to a Third Party shall be included within the computation of Net Sales.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The supply of the Product as samples, for use in nonclinical, preclinical, or clinical trials, or for use in any test or studies reasonably necessary to comply with any Applicable Laws, or as is otherwise normal and customary in the industry, shall not be included in the computation of Net Sales, so long as Partner Members do not receive consideration of monetary value for the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Novo Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Agreement Concerning Glucokinase Activator Project, by and between Novo Nordisk A&#47;S (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Novo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and vTv Therapeutics, Inc. (f&#47;k&#47;a TransTech Pharma, Inc., &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">vTv Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;), dated as of February 20, 2007, as amended from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Intellectual Property, owned by or licensed to any Partner Member that is&#58; (a) (i) owned by or licensed to Partner or any Partner Member as of the Effective Date or (ii) created or developed by Partner or a Partner Member during the Term of this Agreement but outside of Partner&#8217;s performance of activities contemplated under this Agreement, in both cases including any improvements thereto, without using or referencing any Company IP, and (b) that is provided or otherwise made available to Company under or in connection with this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner-Conducted Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Collaboration Clinical Trial to be conducted by Partner pursuant to this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner-Conducted Initial Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Initial Clinical Trial to be conducted by Partner pursuant to this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Partner Know-How, Partner Patents and Partner Developed IP, including Partner Background IP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How to the extent Controlled by Partner or any of its Affiliates as of the Effective Date or any time during the Term that is necessary or reasonably useful for the Development, Manufacture, or Commercialization of the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Partner, its Affiliates or its or their Sublicensees or subcontractors (including, for clarity, any of its CROs).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Patents to the extent Controlled by Partner or any of its Affiliates as of the Effective Date or any time during the Term that is necessary or reasonably useful for the Development, Manufacture or Commercialization of the Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means those countries set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, in the case of Partner, any Partner Party Member, and in the case of Company, any Company Member.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means patents, patent applications, and all related continuations, continuations- in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 1 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial that is designed in a manner that is generally consistent with 21 CFR &#167; 312.21(a).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 2 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial that is designed in a manner that is generally consistent with 21 CFR &#167; 312.21(b).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial that is designed in a manner that is generally consistent with 21 CFR &#167; 312.21(c).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 4 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any post-marketing approval clinical study, whether initiated by a Party or at the request of any Governmental Authority, to delineate additional information about the Product&#8217;s risks, benefits, and optimal use.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical product containing the Compound as an active ingredient, alone or in combination with other active ingredients, in any formulation or dosage form and for any mode of administration for treatment of any and all indications and uses in humans and animals.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Common Stock Purchase Agreement, dated as of the Effective Date, by and among vTv Inc., G42 Investments AI Holding RSC Ltd and, solely for purposes of Sections 5.3, 5.11 and Section 6 thereof, Group 42 Holding Limited.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all approvals of any applicable Regulatory Authority required to commence commercial sale of the applicable product in the applicable country or regulatory jurisdiction, including approval of an NDA in the United States and pricing and reimbursement approval where required.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given country or regulatory jurisdiction, including the FDA and EMA.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to the Product other than Patents, including rights similar to those conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity) and in the EU under Directive 2001&#47;83&#47;EC.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications and authorizations (or waivers) with respect to the testing, Development, Manufacture or Commercialization of a compound or product made to or received from any Regulatory Authority in a given country or regulatory jurisdiction, including any INDs, NDAs and labels.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Right of Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in 21 C.F.R. &#167; 314.3(b) or equivalents thereto under Applicable Laws in jurisdictions outside the United States.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Title 21 CFR Part 312, Subpart D, and any corresponding Applicable Laws in any other countries or regulatory jurisdictions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any permitted sublicensee of Partner under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsequent Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Collaboration Clinical Trial set forth in the Global Development Plan that is not an Initial Clinical Trial.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a specified Person, any corporation or other Person of which securities or other interests having the power to elect a majority of that corporation&#8217;s or other Person&#8217;s board of directors or similar governing body, or otherwise having the power to direct the business and policies of that corporation or other Person (other than securities or other interests having such power only upon the happening of a contingency that has not occurred) are held by the specified Person or one or more of its Subsidiaries.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person other than (a) in the case of Company, any Subsidiary of Company and (b) in the case of Partner, any Affiliate of a Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any claim, demand, action or other proceeding brought by any Third Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means trade names, brand names, trade dress, logos, slogans, trademarks and service marks and all other indicia of origin (whether registered or unregistered), and registrations, applications for registration, renewals and extensions thereof, together with all translations, adaptations, combinations and derivations thereof and all goodwill associated therewith.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States of America, including its territories and possessions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) a claim of an issued and unexpired Patent that has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal or (b) a claim of a pending patent application that has not been revoked, cancelled, withdrawn, or abandoned or finally disallowed without the possibility of appeal or refiling of such application.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;The following table identifies the location of definitions set forth in various Sections of the Agreement&#58;</font></div><div><font><br></font></div><div style="padding-left:14.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.583%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acquiror</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 15.5(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Acquisition Transaction</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 15.5(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Alliance Manager</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 3.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Annual Limitation</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.6(b)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Arbitral Tribunal</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 15.11(d)</font></div></td></tr></table></div><div style="height:79.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_10"></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="padding-left:14.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.583%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Auditor</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 9.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Clinical Investigator Meeting</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.3(c)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Clinical Trial Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.3(b)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Clinical Trials Database</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.5(c)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Clinical Trials Master File</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.5(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CMO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Collaboration Protocol</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.2(d)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Commercial Supply Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Company Abandoned Patent</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.2(b)(iii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Company Developed IP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.1(b)(i)(3)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Company Indemnifiable IPR Claim</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.1(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Company Indemnitee</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Company-Conducted Clinical Trials</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.2(e)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Compliance Policies</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 11.1(h)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Data Management Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.5(b)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Database Lock</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.10(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delivery</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.2(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Disclosing Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 13.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dispute</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 15.11(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Effective Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Election Notice</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.2(b)(iii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Final Partner-Conducted Clinical Trial CSR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.11(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Financial Disclosure Form</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.3(b)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Finished Product</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">FTO Analysis</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Global Development Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Global Trademarks</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 6.6(c)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">IDMC Charter</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.8(c)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Indemnifying Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnitee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Indemnity Notice</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Informed Consent</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.3(e)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insights</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 2.2(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JDC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 3.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LCIA</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 15.11(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Local Trademark</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 6.6(c)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Manufacturing Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.3(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Material Breach by Company</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Material Breach by Partner</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Monitoring Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.7</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">New York Courts</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 15.11(j)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Non-Conforming Product</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.2(d)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parties</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Partner</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr></table></div><div style="height:71.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_13"></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="padding-left:14.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.583%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Partner Commercialization Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 6.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Partner Developed IP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.1(b)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Partner Indemnitee</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 12.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Partner Site</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.3(b)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Partner Territory Infringement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Pharmacovigilance Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 5.8</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Prosecuting Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Prosecution Activities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Quality Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recipient</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 13.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Regulatory Meeting</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 5.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Rejection Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 7.2(d)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Royalty Rate</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 8.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Royalty Term</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 8.1(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Site</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.3(b)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Statistical Analysis Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.5(f)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Subject Recruitment Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.3(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Sunshine Reporting Laws</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 11.1(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 14.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Third Party Infringement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.3(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Trademark Infringement Claim</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 10.6(a)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Trademark Searches</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 6.6(c)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Transfer of Responsibilities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 4.2(e)(ii)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">UNCITRAL Rules</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Section 15.11(b)</font></div></td></tr></table></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any reference in this Agreement to a &#8220;Section,&#8221; &#8220;Exhibit&#8221; or &#8220;Schedule&#8221; refers to the corresponding Section, Exhibit or Schedule of or to this Agreement, unless the context indicates otherwise. The table of contents and the headings of Sections are provided for convenience only and are not intended to affect the construction or interpretation of this Agreement. All words used in this Agreement are to be construed to be of such gender or number as the circumstances require. The words &#8220;including,&#8221; &#8220;includes&#8221; or &#8220;include&#8221; are to be read as listing nonexclusive examples of the matters referred to, whether or not words such as &#8220;without limitation&#8221; or &#8220;but not limited to&#8221; are used in each instance. Where this Agreement states that a party &#8220;shall,&#8221; &#8220;will&#8221; or &#8220;must&#8221; perform in some manner or otherwise act or omit to act, it means that the party is legally obligated to do so in accordance with this Agreement. Any reference to a statute is deemed also to refer to any amendments or successor legislation as in effect at the relevant time. Any reference to a contract or other document as of a given date means the contract or other document as amended, supplemented and modified from time to time through such date. Any words (including capitalized terms defined herein) in the singular will be held to include the plural and vice versa and words (including capitalized terms defined herein) of one gender will be held to include the other gender as the context requires. The terms &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;herewith&#8221; and words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement. All references to any period of days will be deemed to be to the relevant number of calendar days unless otherwise specified.  All references herein to &#8220;$&#8221; or dollars will refer to United States dollars, unless</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_16"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:6.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise specified. All accounting terms not otherwise defined herein have the meanings given to them in accordance with GAAP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.15pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Licenses Granted to Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, during the Term, Company hereby grants to Partner&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">an exclusive (even as to Company, except to the extent expressly set forth herein), sublicensable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), non-assignable (except to the extent permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) license under the Company IP to use, promote, market, sell, offer for sale, import into, distribute and otherwise Commercialize (but not to Develop or Manufacture) the Product for use for those indications for which Partner is granted Regulatory Approval in the Partner Territory in accordance with the terms hereof, solely within the Partner Territory&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">a non-exclusive, sublicensable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), non-assignable (except to the extent permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) license under the Company IP to Develop (but not to Manufacture or Commercialize) the Product in the Company Territory solely in accordance with, and subject to, the Global Development Plan&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">an exclusive (even as to Company), sublicensable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), non-assignable (except to the extent permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) license under the Company IP to Develop (but not to Manufacture or Commercialize) the Product in the Partner Territory solely in accordance with, and subject to, the Global Development Plan&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">an exclusive (even as to Company, except to the extent expressly set forth herein), sublicensable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), non-assignable (except to the extent permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) license under the Company IP to Manufacture (but not to Develop or Commercialize) the Product in the Partner Territory solely for commercial sale of such Product in the Partner Territory (such commercial sale, for clarity, solely in accordance with, and subject to, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Partner shall have the right to grant sublicenses under the licenses granted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to its Affiliates and Third Parties, in each case, without Company&#8217;s consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Partner shall not have the right to grant sublicenses to any Affiliate or Third Party, in each case, that is a Sanctioned Person or is owned or controlled (for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as such term is used in and construed under Rule 405 under the Securities Act) by a Sanctioned Person.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Partner shall have the right to grant sublicenses under the licenses granted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to its Affiliates and Third Parties, subject to prior written consent of the Company (such consent not to be unreasonably withheld, conditioned, or delayed and if Company fails to grant or deny such consent within seven (7) days of receipt of Partner&#8217;s request for such consent, such consent shall be deemed to be granted)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Partner shall not have the right to grant any sublicense to any Affiliate or Third Party that is a Sanctioned Person or owned or controlled by a Sanctioned Person. Notwithstanding the foregoing, Company hereby consents to Partner granting (i) its Affiliate, Insights Pharmaceutical Research LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a sublicense in the rights granted to Partner under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to serve as a CRO for the purpose of the conduct of the Partner-Conducted Clinical Trials and (ii) to the extent necessary, the Sites and Clinical Investigators, appointed by either Partner or Insights, and in each case, selected in accordance with the terms of this Agreement, for the Partner-Conducted Clinical Trials&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in each case (in respect of the foregoing (i) and (ii)), that the sublicense agreement therefor is in writing.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">As soon as reasonably practicable following the Effective Date, Company shall, or shall cause vTv Inc. to, use commercially reasonable efforts to obtain a waiver from Novo with respect to the obligation set forth in Section 2.1(c) of the Novo Agreement to provide Novo with notice of sublicenses granted under the Novo Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, for clarity, in no event shall the foregoing require Company to agree to or make any payments or other concessions. Notwithstanding anything to the contrary herein, in the event Company is unable to obtain such waiver from Novo despite its use of commercially reasonable efforts in accordance with the foregoing, Partner must provide Company with forty-five (45) days advance written notice of each sublicense granted with respect to any licenses granted to Partner hereunder in order to ensure that Company complies with its obligations with respect thereto under the Novo Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">For clarity, granting a sublicense shall not relieve Partner of any obligations hereunder and Partner shall cause each of its Sublicensees to comply, and shall remain responsible for its Sublicensees&#8217; compliance, with the terms of this Agreement that are applicable to Partner and all Applicable Laws. Sublicenses granted hereunder shall be subject to, and consistent with, the terms of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Reserved Rights of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Company hereby expressly reserves&#58; (i) rights under Company IP to exercise its rights and perform its obligations under this Agreement and (ii) all rights to practice, and to grant licenses under, the Company IP outside of the scope of the licenses granted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, including the right to Manufacture the Compound and Product anywhere in the world (except in the Partner Territory for commercial sale by or on behalf of Partner within the Partner Territory), Develop the Product outside the scope of the Global Development Plan in the Company Territory, and Exploit compounds and products (other than the Product within the scope of Partner&#8217;s exclusive licenses granted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Partner acknowledges and agrees that nothing herein shall preclude Company from conducting research, or Development activities not set forth in the Global Development Plan, with respect to the Product in the Company Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, during</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term, Partner shall be granted rights to Data (if any) generated in connection with any such research or Development activities, solely for Partner to conduct Development in accordance with the Global Development Plan within the scope of the licenses granted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and Commercialize the Product for use in the Partner Territory within the scope of the license granted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Licenses Granted to Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Partner hereby grants to Company in partial consideration for the issue of certain shares in vTv Inc. to Sparkly Holdings SPV Ltd pursuant to the Purchase Agreement&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">an exclusive (even as to Partner), fully paid-up, royalty-free, sublicensable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), non-transferable (except to the extent permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) license under the Partner IP, to the extent necessary to use, promote, market, sell, offer for sale, import, distribute and otherwise Commercialize (but not Develop or Manufacture) the Product for use in the Company Territory&#59;</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">an exclusive (even as to Partner, except to the extent expressly set forth herein), fully paid-up, royalty-free, sublicensable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), non-transferable (except to the extent permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), license under the Partner IP, to the extent necessary to Develop the Product in the Company Territory&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">an exclusive (even as to Partner, except to the extent expressly set forth herein), fully paid-up, royalty-free, sublicensable (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each such sublicense is consistent with the terms of this Agreement and solely to the extent permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), non-transferable (except to the extent permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), worldwide license under the Partner IP, to the extent necessary to Manufacture the Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Company may not Manufacture the Product in the Partner Territory for commercial sale in the Partner Territory.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Reserved Rights of Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner hereby expressly reserves&#58; (a) rights under Partner IP to exercise its rights and perform its obligations under this Agreement and (b) all rights to practice, and to grant licenses under, the Partner IP outside of the scope of the licenses granted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> including the right to develop, commercialize and&#47;or manufacture any product other than the Product, anywhere in the world.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company shall have the right to grant sublicenses under the licenses granted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to its Affiliates and Third Parties, in each case, without Partner&#8217;s consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Company shall not have the right to grant sublicenses to any Affiliate or Third Party, in each case, that is a Sanctioned Person or is owned or controlled (for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as such term is used in and construed under Rule 405 under the Securities Act) by a Sanctioned Person. For clarity, granting a sublicense shall not relieve Company of any obligations hereunder and Company shall cause each of its Sublicensees to comply, and shall remain responsible for its Sublicensees&#8217; compliance, with the terms of this Agreement that are applicable to Company. Sublicenses granted hereunder shall be subject to, and consistent with, the terms of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except to the extent expressly set forth in this Agreement, neither Party is granted any license or other right, title or interest, by implication or otherwise, in, to or under any Intellectual Property of the other Party. Each Party shall ensure that neither it, nor any of its Party Members, practices any Intellectual Property licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Disclosure of Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Term, Partner shall, and shall cause the Partner Members to, without additional compensation, disclose and make available to Company, in electronic form or such other form agreed upon by the Parties in writing, any Partner Know-How not previously provided to Company, promptly after the earlier of developing, making, conceiving or reducing to practice such Partner Know-How.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Promptly following the Effective Date, each Party shall appoint an employee with appropriate qualifications and experience to act as its alliance manager (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Each Alliance Manager shall be responsible for facilitating communications between the Parties and shall act as a liaison between the Parties with respect to activities to be conducted pursuant to this Agreement. Each Alliance Manager shall be permitted to attend meetings of the JDC as a non-voting participant. Each Party may replace its Alliance Manager with another qualified employee at any time with prior notice to the other Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties shall establish a joint development committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), composed of three (3) members for each Party, to coordinate and oversee Development of the Product under the Global Development Plan and Commercialization of the Product for use throughout the Partner Territory. The JDC shall in particular&#58;</font></div><div style="padding-right:5.8pt;text-align:justify;text-indent:89.95pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.75pt">coordinate, monitor and oversee implementation of the Global </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Plan&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.07pt">provide a forum for and facilitate communications between the </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Parties with respect to the activities conducted hereunder&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.75pt">review and approve changes to the Global Development Plan and </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any Collaboration Protocols&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.23pt">monitor and coordinate the Parties&#8217; regulatory activities, </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">responsibilities and obligations hereunder, including with respect to pharmacovigilance and safety matters worldwide, as such activities, responsibilities and obligations are further set forth in the Pharmacovigilance Agreement&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.75pt">review and approve the Partner Commercialization Plan and any </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">changes thereto&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.08pt">oversee the  exchange  of information  as  required  under the</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmacovigilance Agreement and all Applicable Laws&#59;</font></div><div style="margin-bottom:6pt;text-indent:89.95pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:89.95pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:89.95pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:89.95pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.07pt">monitor and oversee Commercialization of the Product by the Partner</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:23pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Members under this Agreement&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.07pt">provide a forum for dispute resolution as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.74pt">perform such other functions to the extent related to or in support of</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this Agreement or otherwise agreed upon by the Parties in writing.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div id="if3d95cb665db4012bc3df24549a8a91b_19"></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">JDC Membership and Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">JDC Members</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each JDC member shall have sufficient expertise and seniority within the applicable Party to fulfill the JDC&#8217;s responsibilities as set forth herein at the applicable time. The initial JDC members of each Party shall be appointed as soon as reasonably practicable following the Effective Date. Each Party may replace its JDC members upon written notice to the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each Party shall strive to maintain continuity in its JDC membership. Company shall appoint one of its JDC members to act as the JDC chairperson, which chairperson may be replaced with another Company JDC member or qualified employee in Company&#8217;s sole discretion upon written notice to Partner.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Prior to the First Commercial Sale of the Product in the Partner Territory, the JDC shall meet at least four (4) times per year (which meetings may be conducted via teleconference&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that at least two (2) meetings per year shall be conducted by videoconference), spaced at regular intervals, unless the Parties agree otherwise. Following the First Commercial Sale of the Product in the Partner Territory, the JDC shall meet at least two (2) times per year, with such meetings spaced at regular intervals, unless the Parties agree otherwise. Either Party may call a special meeting of the JDC upon at least five (5) days&#8217; prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting. Each Party may invite individuals who are not JDC members to participate in JDC meetings in a non-voting capacity&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (i) the other Party is given prior written notice thereof and in the case of any Third Party participants, grants written consent and (ii) such non-member is subject to written confidentiality and non-use obligations consistent with the terms of this Agreement. In accordance with the foregoing, Partner hereby grants Company consent for MAF representatives to participate in JDC meetings. The JDC chairperson shall prepare and circulate agendas to JDC members at least five (5) Business Days prior to each JDC meeting. The chairperson of the JDC shall circulate minutes to the JDC members within thirty (30) days from the date of the relevant meeting. Each Party shall have ten (10) Business Days from receipt to comment on and approve such minutes (such approval to be in writing and not to be unreasonably withheld, conditioned or delayed) and if such Party fails to respond within such time period, the minutes shall be deemed to have been approved by such Party.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">All decisions of the JDC shall be made in good faith by unanimous vote, with each Party&#8217;s JDC members collectively having one (1) vote. If the JDC cannot reach an agreement as to such matter within thirty (30) days after such matter was referred to the JDC</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:6pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for resolution, then either Party at any time may refer such issue to the Executive Officers for resolution.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">If the Executive Officers cannot resolve such matter within ten (10) Business Days of the date on which such matter was first referred to them by either Party&#8217;s JDC members, then&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Company shall have the deciding vote on any matter that Company reasonably believes could detrimentally and materially impact in any way&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;padding-left:203.05pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt">the ability to obtain or maintain any Regulatory </font></div><div style="margin-top:6pt;padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:1.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Approval for the Product&#59; </font></div><div style="margin-top:6pt;padding-left:203.05pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">the Commercialization of the Product in the </font></div><div style="margin-top:6pt;padding-left:41pt;text-align:justify;text-indent:1.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company Territory</font></div><div style="margin-top:6pt;padding-left:203.05pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">the Manufacture of the Compound or the Product </font></div><div style="margin-top:6pt;padding-left:41pt;text-align:justify;text-indent:1.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by or on behalf of any Company Member&#59;</font></div><div style="margin-top:6pt;padding-left:203.05pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">the research or Development (including any </font></div><div style="margin-top:6pt;padding-left:41pt;text-align:justify;text-indent:1.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaboration Clinical Trials) of the Compound or the Product in the Company Territory or Partner Territory, including, for clarity, any revisions to the Global Development Plan and any decisions regarding (including with respect to any changes to) any Collaboration Protocol&#59; and</font></div><div style="margin-top:6pt;padding-left:203.05pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.18pt">the scope, validity or enforceability of any </font></div><div style="margin-top:6pt;padding-left:41pt;text-align:justify;text-indent:1.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company IP&#59;</font></div><div style="margin-top:6pt;padding-left:180pt;text-align:justify;text-indent:-31.42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">Partner shall have the deciding vote on any and all matters </font></div><div style="margin-top:6pt;padding-left:41pt;text-align:justify;text-indent:1.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">solely related to the Development or Commercialization of the Product in the Partner Territory, or Manufacture by Partner of the Product for use in the Partner Territory to the extent permitted hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in each case, that such matter does not fall under Company&#8217;s final decision-making authority pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)(i)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="margin-top:6pt;padding-left:180pt;text-align:justify;text-indent:-34.47pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">the status quo shall be maintained for all other matters.</font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Notwithstanding the foregoing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> neither Party shall </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the deciding vote (as set forth in Sections </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_19" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)(i)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_22" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)(ii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) on, and the JDC shall not have decision-making authority regarding&#58; (i) the imposition of any additional material obligations on the other Party (1) other than those for which it is expressly responsible hereunder, (2) that would violate any Applicable Laws or otherwise impose liability on a Party or any of its Affiliates&#59; or (3) that would cause such Party to forgo any of its rights under this Agreement&#59; (ii) any decision that is expressly stated to require the Parties&#8217; mutual agreement&#59; or (iii) any matters that would excuse the Party with the deciding vote from its obligations under this Agreement. For clarity, notwithstanding anything to the contrary herein, (x) in the event that the JDC fails to amend the Global Development Plan to include any Subsequent Clinical Trial, the Global Development Plan shall not be amended to include such Subsequent Clinical Trial and (y) in no event shall the JDC have decision-making authority with respect to the research, Development, or Commercialization</font></div><div style="padding-left:167.05pt;text-align:justify;text-indent:-9pt"><font><br></font></div><div id="if3d95cb665db4012bc3df24549a8a91b_22"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.801%"><div style="padding-left:41pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.396%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.803%"></div></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_25"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Compound or Product within the Company Territory (other than in respect of the Collaboration Clinical Trials as and to the extent expressly set forth herein) or the Manufacture of the Compound or Product in the Company Territory or Partner Territory (other than Manufacture of the Product by Partner for commercial sale in the Partner Territory).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Limitations on Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The JDC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement. Without limiting the generality of the foregoing, the JDC shall not have the power to amend this Agreement, and no decision of the JDC may be in contravention of any terms and conditions of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, the Parties shall collaborate with respect to the Development of the Product as further described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Development of the Product under this Agreement shall be conducted pursuant to a comprehensive written global development plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Global</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which, when approved in writing by the JDC shall be incorporated by reference into this Agreement and shall set forth the activities to be undertaken by each Party under this Agreement to Develop the Product for use throughout the Partner Territory and Company Territory. Except as expressly stated herein, to the extent any terms or conditions of the Global Development Plan expressly conflict with the terms or conditions of this Agreement, the terms and provisions of this Agreement shall control. For clarity and notwithstanding anything to the contrary herein, in no event shall Partner or any Partner Member conduct any Development activities with respect to the Compound or the Product that are not expressly set forth in, or otherwise in compliance with, the Global Development Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Development Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms hereof, the Global Development Plan shall allocate Development responsibilities under this Agreement for the Product between the Parties, including that Partner shall provide data management and services related to its genomic capabilities for the Partner-Conducted Clinical Trials.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Initial Global Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The initial Global Development Plan shall be developed jointly by the Parties and shall set forth the Parties&#8217; responsibilities for the Initial Clinical Trials. The JDC shall meet and agree upon such Global Development Plan as soon as reasonably practicable following the Effective Date. During the Term, any changes to the Global Development Plan, including any changes required by Applicable Laws and changes made in response to any communications with any Regulatory Authority, shall be developed jointly by the Parties and shall require the JDC&#8217;s written approval.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt;text-decoration:underline">Clinical Trial Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt;text-decoration:underline">Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties acknowledge and agree that the protocols for the Collaboration Clinical Trials shall require approval by the JDC and following such approval, shall be incorporated into the Global Development Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Changes to the Protocols</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any changes to the protocol for any Collaboration Clinical Trial set forth in the then-current Global Development Plan (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Collaboration Protocol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), including any country-specific appendices required by Applicable Laws and changes made in response to any communications with any Regulatory Authorities, shall require the JDC&#8217;s written approval.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Sponsorship and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt;text-decoration:underline">Company-Conducted Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As between the Parties, Company shall be the Sponsor of all Collaboration Clinical Trials that are not Partner- Conducted Clinical Trials (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company-Conducted Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Except to the extent expressly set forth herein, as between the Parties, Company shall have sole discretion and control over the conduct of the Company-Conducted Clinical Trials.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Partner-Conducted Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As between the Parties, Company and Partner shall be Co-Sponsors of the Partner-Conducted Clinical Trials, and in furtherance of the foregoing, in accordance with 21 CFR 312.52, and any corresponding Applicable Laws in any other countries or regulatory jurisdictions, Company hereby transfers the responsibilities (and all corresponding liabilities therefor) of a Sponsor to Partner for the Partner-Conducted Clinical Trials as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (such transfer, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer of Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, if designating Company as the Sponsor in furtherance of the foregoing would violate any Applicable Laws (including, by way of example, local Laws that require the Sponsor to have a presence in the applicable jurisdiction in order to be the Sponsor of a Clinical Trial with subjects in such jurisdiction), Partner shall notify Company and the Parties shall meet to discuss whether any amendments hereto are required (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any such amendments shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) to ensure that no such violation occurs. In the event required by any Regulatory Authority under 21 CFR 312.52, or any other corresponding Applicable Laws in any other countries or regulatory jurisdictions, the Parties shall prepare a separate written document documenting the Transfer of Responsibilities. In connection with the Partner- Conducted Clinical Trials, Partner shall provide Company with any information and assistance requested by Company to fulfill its obligations as a Co-Sponsor hereunder, and Partner agrees that time is of the essence with regard to the foregoing and shall take all steps necessary to comply with any such requests. Partner acknowledges and agrees that, in order to comply with its obligations as a Co-Sponsor hereunder, Company shall have the right to terminate or pause any Partner-Conducted Clinical Trial hereunder. Without limiting the foregoing, Partner shall ensure that any portion of any Partner-Conducted Clinical Trial that is conducted outside the United States complies with all Applicable Laws that are necessary or useful to obtain Regulatory Approval of the Product within the United States and the EU.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Sites and Clinical Investigators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Selection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As between the Parties, each Party shall be responsible for selecting the study sites for the Collaboration Clinical Trials with respect to which it has responsibility under the Global Development Plan (which, for clarity, in the case of Partner, such Clinical Trials are the Partner-Conducted Clinical Trials, and in the case of Company, such Clinical Trials are Company-Conducted Clinical Trials), and will inform the JDC of each such study site&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, within seven (7) days of submission of such sites to the JDC, the JDC will have the right to reject any such sites proposed by Partner that the JDC determines in its reasonable judgment are not appropriate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt;text-decoration:underline">Clinical Trial Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">For any Partner-Conducted Clinical Trials, Partner (or Partner Member, as applicable) shall enter into an agreement with each such study site, which agreement will be substantially in the form(s) provided by Company and consented to by Partner in writing (such consent not to be withheld except to the extent that such form violates any Applicable Laws) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Trial Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If a Partner Site requires any material changes to such form Clinical Trial Agreement, Partner shall provide Company with written notice thereof and such changes shall require the Company&#8217;s prior written approval. Upon execution of a Clinical Trial Agreement with any site for any Collaboration Clinical Trial, such study site shall be deemed a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Site</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and any such Site for a Partner-Conducted Clinical Trial shall be deemed to be a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Site</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; For clarity, each Clinical Trial Agreement shall be on commercially reasonable and customary terms, consistent with industry standards for similar agreements and sufficient to enable Partner to comply with its obligations hereunder with respect to the applicable Collaboration Clinical Trial, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.2(e)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the terms pertaining to ownership of Intellectual Property and publications, and treatment of Confidential Information and to enable Company to exercise its rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">The Clinical Trial Agreements for the Partner-Conducted Clinical Trials shall also require, to the extent required by Applicable Laws, that the Clinical Investigators, any Subinvestigators (including any research fellows, residents and associates) and any others required by Applicable Laws at each Partner Site, complete a financial disclosure document, which will be substantially in the form(s) provided by or on behalf of Company and consented to by Partner in writing (such consent not to be withheld except to the extent that such form violates any Applicable Laws) within seven (7) days following receipt of such form (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Disclosure Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). For clarity, if any of the foregoing individuals that are required by Applicable Laws to complete such Financial Disclosure Form do not complete such Financial Disclosure Form, such individuals may not participate in, or do any work in connection with, the Partner-Conducted Clinical Trials.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Meetings and Communications with Sites</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Partner (or Partner Member, as applicable) shall conduct meetings with the Clinical Investigators of the Partner-Conducted Clinical Trials (each, a</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Investigator Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), of which the JDC will be provided with reasonable advance written notice and to which Company (or, at Company&#8217;s option, any Company Members) shall have the right (but not the obligation) to attend and participate. Minutes of such Clinical Investigator Meetings shall promptly be made available to the JDC upon the JDC&#8217;s request.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">Partner shall promptly provide the JDC with copies of all communications relevant to the Partner-Conducted Clinical Trials provided to Partner Sites and any other material communications between Partner and any individual Partner Sites.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Subject Recruitment Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In recruiting subjects for any Partner- Conducted Clinical Trial, Partner shall comply with the subject recruitment plan for such Clinical Trial, which plan Partner shall prepare, and communicate to the JDC, for the JDC&#8217;s review and approval, within a reasonable period of time (which shall be no more than thirty (30) days) after the Effective Date (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subject Recruitment Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). For clarity, prior to engaging in any recruiting activities, Partner shall ensure that the applicable IRBs and&#47;or other ethics committees approve any related materials and activities as required by the JDC and all Applicable Laws. Notwithstanding anything to the contrary herein, in the event that the JDC fails to approve such Subject Recruitment Plan in writing, the Global Development Plan shall automatically be amended to remove such Partner-Conducted Clinical Trial and for clarity, Company shall be permitted to conduct such Clinical Trial outside of the scope of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Informed Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Company, with support from Partner, shall prepare the informed consent documents for use in any Collaboration Clinical Trial. Partner shall ensure that the informed consent of each subject participating in each Partner-Conducted Clinical Trial is obtained in accordance with all Applicable Laws (including, for clarity, all Applicable Laws required to obtain Regulatory Approval for the Product within the United States), including completion of such informed consent document. Such informed consent document for a Collaboration Clinical Trial shall be substantially in the form to be approved by the JDC within thirty (30) days of the Effective Date (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Informed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If a Partner Site or subject requires any material changes to such form Informed Consent, Partner shall provide Company with written notice thereof and such changes shall require the Company&#8217;s prior written approval. For clarity, the Informed Consent document that each subject executes shall expressly state that such subject understands that such Party is providing support for the Clinical Trial and shall authorize disclosure of Data and results related to such Clinical Trial to Company, Partner and each of their respective Party Members, as applicable, for any purpose, subject to all Applicable Laws&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (1) the Parties agree that neither Party shall provide the other Party any personally identifiable data of the subjects unless required for handling, investigating or reporting adverse events and in such case, such provision shall be subject to the terms of the Pharmacovigilance Agreement and (2) each Party&#8217;s use of any such data and results shall be subject to and in accordance with the terms hereof.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:5.95pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">Partner shall ensure that the Informed Consent has been obtained from each subject participating in a Partner-Conducted Clinical Trial prior to</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">administration of the Product, or any placebo of the Product, to such subject in accordance with the applicable Collaboration Protocol.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.08pt;text-decoration:underline">Inclusion and Exclusion Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall not waive any exclusion or inclusion criteria specified in the Collaboration Protocol for any Partner-Conducted Clinical Trial without Company&#8217;s prior written consent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Investigator&#8217;s Brochure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">As between the Parties, Company shall maintain the Investigator&#8217;s Brochure for the Product. Partner shall, promptly following receipt of written notice from Company of the need for an Investigator&#8217;s Brochure update, provide Company with all information regarding the Partner-Conducted Clinical Trials that is necessary to enable Company to update the Investigator&#8217;s Brochure.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Promptly following the Effective Date, Company shall provide Partner with the most recent version of the Investigator&#8217;s Brochure for the Initial Product. Company shall also promptly provide Partner with any updated versions of such Investigator&#8217;s Brochure. Each Party shall ensure that each Site in such Party&#8217;s respective territory, and all applicable IRBs and other ethics committees, receive a copy of, and promptly receive any updates to, the Investigator&#8217;s Brochure for the applicable Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Data Collection and Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">CRF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner, in consultation with Company, shall be responsible for preparing the form of CRF for the Partner-Conducted Clinical Trials in accordance with the Collaboration Protocols and Company&#8217;s CRF standards.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt;text-decoration:underline">Data Management Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Partner, in consultation with Company, shall be responsible for preparing the data management plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Management Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the Partner- Conducted Clinical Trials, and the Data Management Plan for the Partner-Conducted Initial Clinical Trial shall be submitted to the JDC for its review and approval promptly following the Effective Date. Partner shall use Commercially Reasonable Efforts to comply with the Data Management Plan. For clarity, the applicable Data Management Plan must be agreed upon by the JDC prior to recruitment of subjects for the applicable Partner-Conducted Clinical Trials.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">With respect to any data collected in connection with the Partner-Conducted Clinical Trials, Partner shall ensure that such data is held in one or more appropriate facilities with information security protections in accordance with all Applicable Laws, including (1) unique accounts for all operators&#59; (2) cancellation of an account when an employee or other personnel terminates employment&#59; (3) deactivation of an account when an employee or other personnel ceases working on the applicable Clinical Trials&#59; (4) required password changes at frequent intervals&#59; and (5) regular backups of electronic data.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Clinical Trials Database</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Partner, in consultation with Company, shall establish a Clinical Trials database for the purpose of hosting the data collected from each Partner Site for the Partner-Conducted Clinical Trials (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Trials Database</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such Clinical Trials Database shall be established by Partner for the Partner-Conducted Initial Clinical Trial promptly following the Effective Date (but, for clarity, will not be populated until the Partner-Conducted Initial Clinical Trial is conducted in accordance with the terms hereof) and Company shall be provided with access to such database (including the information therein) beginning on the date of such Clinical Trials Database&#8217;s establishment. Partner, in consultation with Company, shall promptly update the Clinical Trials Database upon any final amendments to the Collaboration Protocol, as necessary, and in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall promptly update the Clinical Trials Database upon receiving data for the Partner-Conducted Clinical Trials from any Partner Site, and Partner shall use reasonable efforts to ensure that the Partner Sites, promptly following collection thereof at such Partner Site, provide data in connection with the Partner-Conducted Clinical Trials to Partner or its Affiliate, as applicable.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:5.85pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">Partner shall provide the JDC with electronic copies of any data related to the Partner-Conducted Clinical Trials requested by the JDC at JDC meetings and in accordance with Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.03pt">Partner shall provide SAS datasets to Company in accordance with specifications as defined by Company (1) when fifty percent (50%) of subjects have been dosed for six (6) months (where the Collaboration Protocol provides for interim analysis)&#59; (2) when the data in the Clinical Trials Database is equivalent to one hundred percent (100%) of total data expected to be recorded in the Clinical Trials Database&#59; (3) if a safety signal is identified&#59; or (4) if a request is received from any applicable Regulatory Authorities, in relation to the Partner-Conducted Clinical Trials.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.95pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.69pt">Partner shall maintain the Clinical Trials Database for the Partner-Conducted Clinical Trials, including ensuring that information included in the Clinical Trials Database is accurate and up-to-date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.02pt">Company shall be responsible for registering, maintaining and updating any registries pertaining to the Initial Clinical Trials to the extent required by any Applicable Laws, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.clinicaltrials.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.clinicalstudyresults.org</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and the PHRMA Website Synopsis.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Clinical Trials Master File</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall establish and maintain a Clinical Trials master file for each Partner-Conducted Clinical Trial in the format as agreed upon by the JDC (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Trials Master File</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Clinical Trials Master File for the Partner-Conducted Initial Clinical Trial shall be established promptly following the Effective Date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Source Data Verification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall be responsible for source verification of data records with respect to the Partner-Conducted Clinical Trials, as set forth in the Monitoring Plan. At Company&#8217;s request, Partner shall provide Company with copies of any</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reports relating to source data verification and other types of Partner-Conducted Clinical Trials audits.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.08pt;text-decoration:underline">Statistical Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties shall collaborate to perform any statistical analysis required in accordance with the statistical analysis plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Statistical Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the Collaboration Clinical Trials. The Statistical Analysis Plan for the Collaboration Clinical Trials shall be developed by Company in consultation with the JDC. The Parties shall cooperate in good faith in carrying out the Statistical Analysis Plans.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Audits&#59; Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">During the term of a Partner-Conducted Clinical Trial, Company (on its own or through a Third Party) shall have the right, at its expense, to conduct quality oversight inspections and audits of the facilities (including Partner Sites) and services utilized, and activities performed, by or on behalf of Partner in connection with any Partner-Conducted Clinical Trial in accordance with its standard operating procedures and shall provide Partner with copies of such audit reports upon request, subject to Company giving to Partner no less than two (2) Business Days&#8217; prior written notice of its intent to audit.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Upon thirty (30) days&#8217; prior written notice and during normal business hours, no more frequently than once per Calendar Year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Company or any of its Affiliates, or a Third Party auditor appointed by Company and reasonably acceptable to Partner, may inspect and audit any and all records created by Partner Members in the conduct of the Partner-Conducted Clinical Trials solely for the purpose of confirming Partner&#8217;s compliance with this Agreement and Applicable Laws in the conduct of such Clinical Trials&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the scope of such audit is reasonable in its intended purpose. Partner agrees to make available employees of Partner and its Affiliates, and cause applicable Partner Members to make their employees available, as reasonably requested by Company, to answer Company&#8217;s reasonable questions in connection with such inspection or audit. Notwithstanding the foregoing, if Company has a reasonable, good faith belief that Partner has failed to materially comply with this Agreement or Applicable Laws in the conduct of the Partner-Conducted Clinical Trials and such reasonable, good faith belief is supported by reasonable evidence, Company shall have the right to conduct an audit and inspection described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> upon thirty (30) days&#8217; prior written notice and without regard to the Annual Limitation. All expenses of any inspection or audit requested by Company pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including the fees and expenses of any Third Party auditor engaged by Company for such purpose) shall be borne by Company. All information obtained by Company as a result of such inspection or audit shall be Confidential Information in accordance with the terms hereof. Any Third Party auditor appointed by Company pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be subject to confidentiality obligations no less restrictive than those set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to such Confidential Information.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Monitoring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (a) Partner shall monitor the Partner-Conducted Clinical Trials, and Company shall monitor the Collaboration Clinical Trials that it is conducting, in each case, in accordance with the monitoring plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Monitoring Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to ensure compliance with this Agreement and all Applicable Laws, and (b) each Party shall share information with the JDC pertaining to such monitoring, in each case (with respect the foregoing (a) and (b)) in accordance</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the Monitoring Plan for the Collaboration Clinical Trials (which shall be prepared by Company, in consultation with Partner, and submitted to the JDC for its review and approval).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">IRBs and Other Ethics Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Partner shall be responsible for obtaining the approval of the IRBs and other ethics committees required prior to commencing, and during, the Partner-Conducted Clinical Trials at every Partner Site. Partner shall ensure that such IRBs and such other relevant ethics committees have current registrations and accreditations as required by Applicable Laws and shall provide all ethics committees, including all IRBs, and Regulatory Authorities, with all necessary documentation prior to, and during the course of, the Partner-Conducted Clinical Trials as required by Applicable Laws.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Partner shall be responsible for responding to all queries from the IRBs and other ethics committees in respect of the Partner-Conducted Clinical Trials&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (i) following Partner&#8217;s reasonable request, Company shall make itself reasonably available to assist with any such queries and (ii) if such query relates solely to the Company&#8217;s responsibilities or activities hereunder, Company shall prepare the applicable response and provide Partner with a copy thereof.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">IDMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Company shall establish an IDMC, and the charter that governs such IDMC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IDMC Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), for the Collaboration Clinical Trials.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">The Parties, via the JDC, shall ensure that the IDMC is provided with all required information and data in a timely manner as specified in the IDMC Charter.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Environmental Health and Safety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">In conducting the Partner-Conducted Clinical Trials, Partner shall comply with all Applicable Laws relating to environmental, health and safety matters and shall be solely responsible for establishing material and specimen handling guidelines and for ensuring use of controls, including appropriate personal protective equipment, that minimize potential worker exposure, obtaining the material safety data sheets and providing the appropriate training for workers who will be potentially exposed to the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Each Party shall promptly notify the JDC, in writing, of any worker claims of suspected occupational illnesses related to working with the Product, regardless of whether such claims are received during the Term or any time thereafter. After termination of this Agreement for whatever reasons, or expiration of this Agreement, each Party shall promptly notify the other Party in writing of any worker claims of suspected occupational illnesses related to working with the Product during the Term, of which it has Knowledge.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Completion of Partner-Conducted Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">With respect to each Partner-Conducted Clinical Trial, Partner shall use Commercially Reasonable Efforts to keep the Partner Sites operational, including continuing to dose subjects with the Product in accordance with the Collaboration Protocol, and conducting any follow-up work required, until the Completion Date for such Partner-Conducted Clinical Trial. On and following the Completion Date for each Partner-Conducted Clinical Trial, Partner shall close out such Clinical Trial in accordance with the Collaboration Protocol for such Clinical Trial, including performing any and all subject follow-up, providing Company with any and all data not provided as of such date and undertaking all activities required to lock the database (which shall occur no later than sixty (60) calendar days after the date on which the last subject in such Clinical Trial completes the last visit as described in the Collaboration Protocol for such Clinical Trial) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Database Lock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). For clarity, copies of documents, including any CRFs and the Clinical Trials Master File, shall be transferred to Company within sixty (60) days of the Completion Date of each Partner-Conducted Clinical Trial or, at Company&#8217;s request, destroyed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such destruction is in compliance with ICH guidelines and Applicable Laws). Notwithstanding the foregoing, neither Party shall provide the other Party (or its Party Members) with any personally identifiable information, unless as required under the Pharmacovigilance Agreement in relation to adverse events and as per Applicable Laws.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Upon the Completion Date of a Partner-Conducted Clinical Trial, unless otherwise agreed upon by the Parties in writing, Partner, at its expense, shall return to the location specified by Company at such time, or, at Company&#8217;s option, destroy, any unused Product and placebo of Product from such Clinical Trial, and shall comply with all Applicable Laws in so returning or destroying such Product or placebo of Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Data Results and CSRs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Within ninety (90) days of Database Lock, or any interim Database Lock, in each case, for a Partner-Conducted Clinical Trial, Partner shall promptly provide to Company (i) the analysis report, including the information, tables and value added data set, set forth in the Statistical Analysis Plan or otherwise agreed upon (including with respect to the format) by the JDC and (ii) all raw data collected for such Clinical Trial.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Partner shall deliver to Company the top-line results from the Partner-Conducted Clinical Trials within ninety (90) days after Database Lock for such Clinical Trial. Such top-line results shall include the primary and secondary endpoints, as well as available safety and exposure data.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">The CSR, and any interim CSRs, for each Partner-Conducted Clinical Trial shall be prepared by Partner, with support from Company, in compliance with all Applicable Laws, including ICH E3 guidelines. The final, signed CSR for each Partner-Conducted Clinical Trial (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Partner-Conducted Clinical Trial CSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be provided to Company promptly (but not more than ninety (90) days) following Database Lock of such Partner-Conducted Clinical Trial and any interim CSRs shall be provided to Company promptly (but no more than ninety (90) days) following the corresponding interim Database Lock for such Clinical Trial. In the event that there are any additional safety or efficacy data pertaining to a Partner-Conducted</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Clinical Trial that come into the possession of a Partner Member after Partner has provided Company with the Final Partner-Conducted Clinical Trial CSR for such Partner-Conducted Clinical Trial, including as a result of any long-term safety monitoring which occurs or continues after the Database Lock, Partner shall promptly prepare and promptly provide Company with a supplement to such CSR.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">At each regularly scheduled JDC meeting, Partner shall provide the JDC with regular reports detailing its Development activities for the Product under the Global Development Plan, and a summary of the Data and results from such activities.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">In addition to the reports and notices described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.12(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following Company&#8217;s reasonable request and subject to reasonable notice, Partner shall make its and its applicable Affiliates&#8217; employees and any applicable Third Parties (to the extent permitted hereunder) available for an in-person, video or telephonic meeting with Company to discuss its progress with respect to its conduct of any Development activities under the Global Development Plan. Partner shall provide Company with access to the Data and results from the Partner- Conducted Clinical Trials upon Company&#8217;s reasonable request.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except to the extent otherwise expressly set forth herein, each Party shall bear its own costs and expenses incurred in performing Development activities under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall use Commercially Reasonable Efforts to conduct those Development activities that it is assigned under the Global Development Plan and, seek Regulatory Approval for the Product in one or more countries or regulatory jurisdictions in the Partner Territory.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall Develop the Product under this Agreement in compliance with the applicable Collaboration Protocol and all Applicable Laws, including good scientific and clinical practices, cGCP, cGLP, and cGMP. For the avoidance of doubt, Partner shall ensure that the Partner-Conducted Clinical Trials are conducted in accordance with (a) 21 CFR 312.120 and 21 CFR 314.106 and shall provide Company with any and all supporting documentation required under such regulations in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.16</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and (b) all Applicable Laws with respect to privacy and data protections.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Development Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall maintain complete, current and accurate records of all Development activities conducted by it under this Agreement, including all Data and other information arising or otherwise resulting from such activities, including all records required under all Applicable Laws. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory (including, in the case of records maintained by Partner, as required to obtain and maintain Regulatory Approval in the Company Territory) and patent purposes and shall be made available to Company upon reasonable request.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Use of Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Each Party may perform its activities under the Global Development Plan through one or more subcontractors&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each Party complies with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (in the case of subcontractors engaged by Partner) or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (in the case of subcontractors engaged by Company) as if such subcontractor was a Sublicensee hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (i) such Party will remain responsible for performance of the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself, (ii) each subcontractor is subject to confidentiality and non-use obligations consistent with the terms of this Agreement and (iii) each subcontractor agrees in writing to assign all Intellectual Property developed in the course of performing any such work to such Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Without limiting any other obligations of Partner hereunder, in the event that Partner is permitted to engage a Third Party in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to conduct any Partner-Conducted Clinical Trial (or portion thereof) or Manufacture or Commercialization of the Product pursuant to the terms hereof, Partner shall conduct due diligence and ongoing oversight with respect to such Third Party to ensure compliance with this Agreement, including that such Third Party can comply with all applicable terms and obligations of this Agreement (including the applicable Collaboration Protocol) and Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Global Development Plan shall set forth the regulatory strategy for seeking Regulatory Approval for the Product following completion of specified Development activities under the Global Development Plan in the Partner Territory and Company Territory. Under the oversight of the JDC and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Party shall be responsible for implementing such regulatory strategy in its respective territory.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">INDs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As between the Parties, Partner shall use Commercially Reasonable Efforts to prepare and submit any INDs and amendments thereto for each Partner- Conducted Clinical Trial as required by Applicable Laws in the countries where Partner Sites have been selected at its sole cost and expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, if fulfilling such obligations with respect to the Partner-Conducted Clinical Trials would violate any Applicable Laws (including, by way of example, local Laws that require the submitting Person to have a presence in the applicable jurisdiction in order to submit an IND for a Clinical Trial with subjects in such jurisdiction or the Sponsor to submit the applicable IND), Partner shall notify Company and the Parties shall meet to discuss and determine whether any amendments hereto are required (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any such amendments shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). Following Partner&#8217;s reasonable request and at Partner&#8217;s expense, Company shall provide Partner with reasonable assistance with respect to preparation of the INDs for each Partner-Conducted Clinical Trial. At least thirty (30) days prior to the contemplated submission date of any such IND with respect to a Partner-Conducted Clinical Trial, Partner shall submit to Company a completed draft thereof, confer with Company thereon, and incorporate all comments provided by Company prior to submission to the applicable Regulatory Authorities. For clarity, except to the extent otherwise agreed upon by the Parties in writing, Partner shall not have the right to submit any INDs to any Regulatory Authorities with</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to the Compound or the Product for any Clinical Trials that are not Partner-Conducted Clinical Trials. Partner shall reimburse Company for costs and expenses incurred by or on behalf of Company and Company Members in connection with fulfilling its obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the Partner-Conducted Clinical Trials. For clarity, Company shall have the sole right and discretion to prepare and submit any INDs and amendments thereto for all Company- Conducted Clinical Trials and following Company&#8217;s reasonable request and at Company&#8217;s expense, Partner shall provide Company with assistance in connection therewith.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Regulatory Approvals and Other Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner will be responsible for obtaining, under its name and at its cost, any import licenses or permits for the entry of the Product into the Partner Territory. Partner shall be responsible for preparing, filing and otherwise seeking Regulatory Approval for the Product in the Partner Territory, subject to the guidance of the JDC. For clarity, Company shall retain all rights to prepare, file and otherwise seek Regulatory Approval for the Product in the Company Territory. In no event shall Company file any applications for Regulatory Approval for use of the Product outside the Company Territory, and in no event shall Partner file any applications for Regulatory Approval for use of the Product outside the Partner Territory. Without limiting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.1(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, upon the written request of either Party, the other Party shall, at the requesting Party&#8217;s cost and expense, reasonably assist and cooperate with the other Party in the exercise of its rights and obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.1(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Review Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Prior to its submission of any applications for Regulatory Approval for which it has responsibility pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.1(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Partner shall provide Company with an opportunity to review and comment on such Regulatory Filings and Company shall provide its comments thereon (if any) within sixty (60) days, or such other period of time agreed upon by the Parties in writing. In the event that a Regulatory Authority establishes a response deadline for any Regulatory Filing or material action shorter than such period, the Parties shall cooperate to ensure Company has a reasonable opportunity for review and comment within such deadlines. Without limiting Partner&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the JDC shall discuss, and Partner shall incorporate, any such comments from Company (including with respect to the Product label), except to the extent in violation of any Applicable Laws. At Company&#8217;s request, Partner shall provide the Company with an English translation of the Regulatory Approval along with the original document.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt">Meetings with Regulatory Authorities.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">No later than thirty (30) days before commencement of each Calendar Quarter (or as soon as reasonably practicable if Partner becomes aware following such time), Partner shall provide Company with a schedule of any meetings or teleconferences with any Regulatory Authority (or related advisory committees) planned for the next Calendar Quarter in the Partner Territory that are related to the Product (each, a &#8220;Regulatory Meeting&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">In the case of any Regulatory Approval granted to Partner, and following the grant of such approval, Partner shall be responsible for any communications with the Regulatory Authorities occurring or required in connection with its regulatory responsibilities set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to the Product for use in the Partner Territory, and without limiting Partner&#8217;s obligations hereunder, Company shall have the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right to provide input in preparation for such Regulatory Meetings and to the extent permitted by Applicable Laws, to have its representatives attend the Regulatory Meetings. Without limiting Partner&#8217;s obligations hereunder, Partner shall implement any such input from Company, except to the extent in violation of any Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">In the case of any IND or meetings with respect to any research or Development activities hereunder, as between the Parties, Company shall be responsible for such communications with the Regulatory Authorities occurring or required with respect to the Product, and without limiting Company&#8217;s obligations hereunder, Partner shall provide Company with any input in preparation for, or that is otherwise required for, such Regulatory Meetings and in the case of any Partner-Conducted Clinical Trials, to the extent permitted by Applicable Laws, to have its representatives attend the Regulatory Meetings.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Partner further acknowledges that Company may be required to communicate with Regulatory Authorities in the Partner Territory as a result of any of its or the Company Members&#8217; Manufacturing in or for such territory. To the extent permitted by Applicable Laws and related to Partner&#8217;s rights under this Agreement, Company shall keep Partner reasonably informed of such discussions and without limiting Company&#8217;s obligations hereunder, Partner shall have the right to provide input in preparation for such discussions or communications and to the extent permitted by Applicable Laws, to have its representatives attend any such discussions with Regulatory Authorities in the Partner Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Regulatory Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall permit, and shall cause the other Partner Members to permit, Regulatory Authorities to conduct inspections of any Partner Member (including Partner Sites) relating to its Development, Manufacture or Commercialization of the Product upon request of any such Regulatory Authority. Partner shall promptly notify Company of any such inspection, shall supply Company with all information and correspondence related thereto and, without limiting Partner&#8217;s obligations hereunder, Company shall have the right to provide input in preparation for, and in response to, such inspection and to the extent permitted by Applicable Laws, to have its representatives attend any such inspections in the Partner Territory. Following Partner&#8217;s reasonable request, Company agrees to provide support to Partner in any such inspection and shall supply all necessary information pertinent thereto.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Notification of Threatened Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall notify the other Party in writing within twenty-four (24) hours of any information it receives regarding any threatened or pending action, inspection or communication by any Person or Regulatory Authority with respect to the Product, including any such threatened or pending actions, inspections or communications which may affect the safety or efficacy claims of the Product or its continued Development or Commercialization under this Agreement. Upon receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at an acceptable procedure for taking appropriate action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, in the event that the Parties fail to agree, Company shall have final decision making authority.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Right of Reference to Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Subject to the terms and conditions of this Agreement, Company hereby grants Partner a non-exclusive, sublicensable (solely in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.8pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) Right of Reference, to any Regulatory Filings to the extent Controlled by Company in connection with Company&#8217;s Development activities under the Global Development Plan, solely to the extent necessary for Partner to Develop, Manufacture or Commercialize the Product for use throughout the Partner Territory, in each case, to the extent permitted hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Subject to the terms and conditions of this Agreement, Partner hereby grants Company a non-exclusive, sublicensable (solely in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), worldwide Right of Reference, to Regulatory Filings to the extent Controlled by Partner in connection with Partner&#8217;s Development activities under the Global Development Plan, solely to the extent necessary for Company to Develop, Manufacture and Commercialize the Product, in each case, to the extent permitted hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Complaints</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Term, each Party shall promptly forward to the other Party any complaints that it receives related to the Product. Company in the Company Territory, and Partner in the Partner Territory, shall respond to any complaints of which such Party becomes aware relating to the Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, following such Party&#8217;s reasonable written request, the other Party shall provide reasonable cooperation in connection therewith. Notwithstanding the foregoing, as between the Parties, if a complaint pertains to the Manufacturing, appearance or general physical characteristics of the Product or other processes at the manufacturing facility, the Party responsible for Manufacturing the applicable batch(es) shall be solely responsible for responding to such complaint.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall notify the other Party in writing promptly following its determination that any event, incident or circumstance has occurred that would reasonably be expected to result in the need for a recall, market suspension or market withdrawal of the Product and shall include in such notice the reasoning behind such determination and any supporting facts. As between the Parties, Partner shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal in the Partner Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that prior to any implementation of such a recall, market suspension or market withdrawal, Partner shall consult with Company and shall reasonably consider Company&#8217;s comments in good faith. If a recall, market suspension or market withdrawal is mandated by a Regulatory Authority in the Partner Territory, as between the Parties, Partner shall initiate such a recall, market suspension or market withdrawal in compliance with Applicable Laws. For clarity, as between the Parties, Company shall have sole discretion with respect to all recalls in the Company Territory. To the extent a recall, market suspension or market withdrawal undertaken pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.7</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> arises due to Manufacture of a Product supplied by or on behalf of one Party to the other Party, the Party responsible for Manufacturing the applicable batch(es) shall be solely responsible for all costs and expenses related thereto. The Party with responsibility for conducting the applicable recall, market suspension or market withdrawal under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.7</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall otherwise be responsible for such costs and expenses.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As soon as reasonably practicable following the Effective Date, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Product, including safety data sharing, adverse events reporting and safety signal and risk management (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which agreement shall be amended by the Parties from time to time to the extent necessary to comply with any changes in Applicable Laws or guidance received</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Regulatory Authorities. Each Party agrees not to enter into any clinical activity implicating pharmacovigilance obligations for the Product with respect to its respective Development activities under the Global Development Plan prior to execution of the Pharmacovigilance Agreement. Each Party agrees to comply, and shall cause its Party Members to comply, with its obligations under the Pharmacovigilance Agreement. In the event of any conflict or inconsistency between this Agreement and the Pharmacovigilance Agreement with respect to (a) safety-related matters, the Pharmacovigilance Agreement shall prevail and (b) any other matter, this Agreement shall prevail. Company shall maintain the global safety database for the Initial Product for so long as the Initial Product is under Development, Manufacture or Commercialization by the Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the oversight of the JDC and the terms and conditions of this Agreement (including this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), Partner shall have the sole and exclusive responsibility, for Commercializing the Product for use throughout the Partner Territory, including</font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities and other payors regarding the price and reimbursement status of the Product, (c) marketing and promotion, (d) booking sales and distribution and performance of related services, (e) handling all aspects of order processing, invoicing and collection, inventory and receivables, (f) providing customer support, including handling medical queries (with the Company&#8217;s technical support as reasonably requested by the Partner, and in compliance with the regulator&#8217;s requirements in the Partner Territory), and performing other related functions and (g) conforming its practices and procedures to Applicable Laws relating to the promotion, sales and marketing, access, and distribution of the Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Reasonably in advance of (but in no event less than sixty (60) days prior to) the anticipated First Commercial Sale of the Product for use in a country or regulatory jurisdiction in the Partner Territory, Partner shall provide the JDC with a Commercialization plan that sets forth its anticipated Commercialization activities for the Product throughout the Partner Territory, for the JDC&#8217;s review and approval (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). On an annual basis (or more frequently if material changes are made to such plan), Partner shall update the Partner Commercialization Plan and will provide each such updated Partner Commercialization Plan to the JDC for its review and approval.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Term, Partner shall use Commercially Reasonable Efforts to Commercialize the Product for all indications for which Regulatory Approval is granted in the Partner Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Commercial Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall update the JDC at each regularly scheduled JDC meeting regarding its Commercialization activities with respect to the Product in the Partner Territory. Each such update shall be in a form to be agreed by the JDC and shall summarize Partner Members&#8217; significant Commercialization activities with respect to the Product in the Partner Territory, and shall contain at least such information at such level of detail reasonably required by Company to determine Partner&#8217;s compliance with its diligence obligations set forth herein. Such updates shall include, on a country-by-county basis, Partner Members&#8217; sales and marketing activities.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Standards of Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall, and shall cause applicable Partner Members to, perform all Commercialization activities with respect to the Product throughout the Partner Territory in a professional and ethical business manner and in compliance in all material respects with Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Coordination of Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties recognize that their collaboration may benefit from the coordination of certain activities in support of the Commercialization of the Product in both the Partner Territory and the Company Territory. As such, the Parties, through the JDC, may coordinate Commercialization strategies for the Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, for branding and messaging, international congresses, advisory boards), and without limiting its obligations hereunder (including as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), Partner shall conduct Commercialization activities for the Product in the Partner Territory in a manner consistent with such global strategy.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company may provide promotional materials for use by the applicable Partner Members in performing Partner&#8217;s obligations hereunder. Partner shall, and shall cause applicable Partner Members to, share their promotional materials for the Product with the JDC on a regular basis (for any materials not yet shared, no less frequently than each meeting of the JDC), and without limiting Partner&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the JDC shall have the right to review and comment on any of the Partner Members&#8217; promotional materials prior to their use in the Partner Territory, which comments shall be considered in good faith by Partner. If any such promotional materials are originally created in a language other than the English language, then at Company&#8217;s request and at Company&#8217;s expense, Partner shall provide an English translation along with the original materials to the JDC. Partner shall, and shall ensure that all applicable Partner Members, comply with Applicable Laws with respect to the use of promotional materials for the Product in the Partner Territory. Insofar as claims are allowed or authorized for the Product in Partner&#8217;s Territory that are not so authorized where Company sells the Product, Partner agrees to work with Company in good faith and to take such reasonable action as is necessary to help ensure the claims made in Partner&#8217;s Territory are not imputed to other jurisdictions.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Branding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt;text-decoration:underline">Global Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. It is the Parties&#8217; intent to maintain consistent global branding for the Product to the extent permitted by Applicable Laws. To the extent such consistent global branding is permitted under Applicable Laws, Company shall own all Trademarks related to the Product and associated domain names in and outside the Partner Territory (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Global Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.6(a)(i)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as between the Parties, Company, shall be responsible for conducting Trademark searches (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trademark Searches</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), selecting, registering, prosecuting, defending and maintaining the Global Trademarks worldwide at its sole cost and expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any costs or expenses incurred in connection with conducting Trademark Searches shall be borne equally between the Parties. As between the Parties, Company or its Subsidiary shall own all right, title, and interest in and to the Global Trademarks, all corresponding Trademark applications and registrations thereof, and all common law rights</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereto. All goodwill of the business associated with or symbolized by the Global Trademarks shall inure to the benefit of Company or its Subsidiary (as applicable). Partner acknowledges Company&#8217;s (or its Subsidiary&#8217;s, as applicable) exclusive ownership of the Global Trademarks in accordance with the foregoing and agrees not to take any action inconsistent with such ownership.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.85pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Local Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Company provides Partner with written notice that it is not obtaining a Global Trademark for the Product in any country or regulatory jurisdiction in the Partner Territory, or otherwise grants Partner prior written consent, Partner shall have the right to select an alternate Trademark (and associated domain names) for use with the Product in the Partner Territory (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Local</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in consultation with, and subject to the prior written approval (not to be unreasonably withheld, conditioned or delayed) of, Company. Partner shall be responsible, at its sole cost and expense, for developing, searching, filing, registering, maintaining, defending and enforcing the Local Trademarks. As between the Parties, Partner shall own all right, title and interest in and to the Local Trademarks, all corresponding Trademark applications and registrations thereof, and all common law rights thereto. All goodwill of the business associated with or symbolized by the Local Trademarks shall inure to the benefit of Partner. Company acknowledges Partner&#8217;s exclusive ownership of the Local Trademarks in accordance with the foregoing and agrees not to take any action inconsistent with such ownership.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Use of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall only promote, market, sell, offer for sale, import, distribute and otherwise Commercialize the Product in the Partner Territory under the applicable Global Trademark or Local Trademark, alone or in combination with Partner&#8217;s G42 logo.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Commercialization in Company Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For clarity, as between the Parties, Company shall have the exclusive right to Commercialize the Product in the Company Territory at its own cost and expense, with or without Third Party(ies).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.08pt;text-decoration:underline">Ex-Territory Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to Applicable Laws, neither Party shall engage in any advertising or promotional activities relating to the Product directed primarily to customers or other buyers or users of the Product located outside of its territory or accept orders for the Product from or sell the Product into such other Party&#8217;s territory for its own account, and, if a Party receives any order for the Product in the other Party&#8217;s territory, it shall refer such orders to the other Party, to the extent it is not prohibited from doing so under Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Export Monitoring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall use commercially reasonable efforts to monitor and prevent exports of the Product from its own territory for Commercialization in the other Party&#8217;s territory using methods permitted under Applicable Laws that are commonly used in the industry for such purpose (if any), and shall promptly inform the other Party in writing of any such exports of the Product from its territory, and any actions taken to prevent such exports. Each Party agrees to use commercially reasonable efforts as permitted by Applicable Laws to take reasonable actions requested in writing by the other Party to prevent exports of the Product from its territory for Commercialization in the other Party&#8217;s territory.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Supply, Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties acknowledge and agree that, as between the Parties, Company shall have the sole right to Manufacture the Product for Development.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Clinical Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Solely for purposes of use in the Development activities hereunder, Company shall, itself or through any of its Subsidiaries or a Third Party (any such Third Party, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), use Commercially Reasonable Efforts to supply Partner the Product for dosing subjects in the Partner-Conducted Clinical Trials as set forth in the Global Development Plan and placebo of such Product, in finished form (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Finished Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the quantities, and subject to the timeline, set forth in the Global Development Plan and in accordance with an applicable quality agreement to be entered into by the Parties prior to supply of the Finished Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). To the extent Company is unable to meet the quantities or timeline set forth in the Global Development Plan, as between the Parties, Company shall endeavor to supply Finished Product on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">pro rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis such that each Party shall receive a percentage of Finished Product equal to the percentage of dosage units of Finished Product administered by such Party or its Party Members, as applicable, during the previous Calendar Quarter as compared to the aggregate dosage units of Finished Product administered by both Parties and their applicable Party Members during such Calendar Quarter&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that in the event Company&#8217;s inability to meet the quantities or timeline set forth in the Global Development Plan occurs during the first Calendar Quarter following the Effective Date, Finished Product shall be allocated between the Parties in a manner which would reasonably cause the least disruption to the Parties&#8217; Development activities hereunder, as determined by Company using its reasonable business judgment, on a good faith basis. Partner shall use, and shall cause all applicable Partner Members to use, all Finished Product supplied by Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> solely to conduct Development in the Partner Territory in accordance with the terms of this Agreement and the Global Development Plan.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Finished Product supplied by Company for Development use in the Partner-Conducted Initial Clinical Trial will be supplied at a total cost of two thousand five hundred dollars ($2,500) per subject (including any VAT, if applicable), regardless of whether such subject is dosed with the Initial Product or placebo. Along with each shipment of Finished Product, Company will invoice Partner, and Partner shall pay each such invoice within thirty (30) days after receipt thereof. Price of supply of the Finished Product for any other Partner-Conducted Clinical Trials or Development activities conducted hereunder shall be agreed upon by the Parties in writing prior to commencement of such Partner-Conducted Clinical Trial.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Product Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.1(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> risk of loss and damage for, and title to, Finished Product supplied under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall pass to Partner on Delivery of the Finished Product. Company (itself or through any of its Subsidiaries or CMO) shall deliver the Finished Product DDP Abu Dhabi, or any other location that the Parties mutually agree upon in writing, (Delivery Duty Paid) INCOTERMS 2020 at the delivery location (as designated by the Partner) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt;text-decoration:underline">Acceptance and Non-Conforming Finished Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">In the event that any Finished Product supplied by Company to Partner under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, at the time of Delivery by Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is damaged, or shipment documentation including certificates of origin as required by applicable Governmental Authorities is missing or incomplete, or such Finished Product does not otherwise conform to the specifications therefor (as set forth in the Quality Agreement) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Conforming Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as soon as reasonably practicable following Partner&#8217;s request, Company shall, at its cost, replace such Non-Conforming Product, and Partner shall, at Company&#8217;s option and expense, return to Company or dispose of such Non-Conforming Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Partner shall have notified Company in writing of the Non-Conforming Product before the earliest of (1) thirty (30) days after Delivery of such Finished Product, (2) five (5) days before the applicable Company Member is obligated to notify the CMO that manufactured such Finished Product of any non-conformity (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Partner has reasonable prior notice of such time periods), or (3) Partner&#8217;s use of such Finished Product for any purpose (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rejection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If Partner does not notify Company in writing within the Rejection Period of such Non-Conforming Product, then Partner shall be deemed to have accepted the applicable Finished Product. Such replacement of Non-Conforming Product shall be Partner&#8217;s sole remedy and Company&#8217;s sole liability for Company&#8217;s supply of Non- Conforming Product.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">If Partner notifies Company of any Non-Conforming Product in writing within the Rejection Period therefor, and Company disagrees that the applicable Finished Product is Non-Conforming Product and the Parties fail to resolve such disagreement within thirty (30) days after Company&#8217;s receipt of Partner&#8217;s written notice (or any applicable shorter period), then Company shall have the right to have a qualified independent third party laboratory test such Product to determine whether or not it so conforms. The determination of such tests shall be binding upon the Parties for all purposes hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that if such tests are unable to determine whether or not such rejected Finished Product is Non-Conforming Product, such Finished Product shall be deemed to not be Non-Conforming Product. The expenses of the analysis or testing will be borne by the Party against which the laboratory rules.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Use of the Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Partner shall (1) only use Finished Product supplied by or on behalf of Company for the sole purpose of conducting the Partner-Conducted Clinical Trials in accordance with the respective Collaboration Protocols and (2) ensure subject dosing compliance per the respective Collaboration Protocols for such Clinical Trials.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.85pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">For each dose administered to a subject in a Partner-Conducted Clinical Trial, Partner shall implement procedures and ensure that records are maintained specifying the date and time that such dose of the Finished Product is administered, the amount of the Finished Product administered to such subject, the lot number of the Finished Product from which such dosage came, and the number of the subject to which such dosage</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt;padding-right:6.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">was administered.&#160;&#160;&#160;&#160;Partner shall provide copies of such records to Company upon Company&#8217;s reasonable request.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Commercial Supply and Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Commercial Supply By Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As soon as reasonably practicable after completion of the Initial Clinical Trials, Partner shall notify Company in writing if it would like Company to supply Partner Members with Initial Product for commercial sale in the Partner Territory and, in the event such notice has been provided, the Parties shall meet to negotiate in good faith the terms of a supply agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercial Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and related quality agreement, pursuant to which a Company Member (which may be its CMO) shall supply Partner with the Initial Product for Commercialization in accordance with the terms hereof. The Parties acknowledge and agree that such Commercial Supply Agreement shall specify that the Initial Product shall be supplied to Partner at a price equal to Company&#8217;s cost of goods as set forth in such Commercial Supply Agreement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Commercial Supply By Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall promptly notify Company in the event that a Partner Member plans to Manufacture the Product in accordance with the rights expressly granted to Partner hereunder and, at Company&#8217;s option, the Parties shall meet to negotiate in good faith the terms of a Commercial Supply Agreement and related quality agreement, pursuant to which a Partner Member (which may be its CMO) shall supply Company with the Product for Commercialization outside of the Partner Territory in accordance with the terms hereof. The Parties acknowledge and agree that such Commercial Supply Agreement shall specify that the Product shall be supplied to Company or any Company Member, as applicable, on terms at least as favorable to Company as those under which Partner supplies the Product to a Third Party that is not an Affiliate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Manufacturing by Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As soon as reasonably practicable following Partner notifying Company in writing of its intention to Manufacture the Products as per </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.3(b)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Parties shall meet to negotiate in good faith the terms of a manufacturing agreement and related quality agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Company shall use Commercially Reasonable Efforts to provide Partner with the Compound and eCTD for the Product in accordance with the terms thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, during the Royalty Term, Partner shall make non-creditable royalty payments to Company on the Net Sales of the Product sold in the Partner Territory at a royalty rate of eight percent (8%) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Royalties shall be paid on a country-by-country basis in the Partner Territory from the First Commercial Sale of the Product in such country by or on behalf of a Partner Member until the latest of (i) expiration of the last-to-expire Valid Claim of the Company Patents Covering the Product in such country, (ii) the expiration of any Regulatory Exclusivity covering the Product in such country or (iii) ten (10) years after the First Commercial Sale of the Product in such country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Royalty Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Applicable Laws in a particular country or regulatory jurisdiction require a royalty reduction after the expiration of the relevant Patents in such country or regulatory jurisdiction, and the Royalty Term for a particular Product in such country or jurisdiction remains in effect pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1(b)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> then the Royalty Rate shall be reduced by twenty percent (20%) for the Product in such country (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a reduction from eight percent (8%) to six percent (6%)) during the remainder of the Royalty Term that extends beyond expiration of the relevant Patents.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Company Payments to Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company shall be solely responsible for all payments, including royalties and milestone payments, due with respect to the Novo Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, notwithstanding anything to the contrary herein, Partner shall cooperate with Company to provide Company (at Company&#8217;s cost and expense) with any information and documentation that Company reasonably requests to fulfill its obligations under the Novo Agreement, subject to the obligations of confidentiality and non-use set forth in the Novo Agreement. For clarity, Partner shall be responsible for all other amounts owed by Partner to Third Parties with respect to its exercise of any rights granted hereunder.</font></div><div><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment&#59; Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Payment&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Royalty payments payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be calculated and reported for each Calendar Quarter. All royalty payments due under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be paid net sixty (60) days after the end of each Calendar Quarter and shall be accompanied by a report setting forth, on a country-by-country basis, Net Sales of the Product in the Partner Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including the number of Products sold, the gross sales and Net Sales of Products (including the deductions from gross sales to arrive at Net Sales), the royalties payable, the exchange rates used and any adjustments to royalties in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Exchange Rate&#59; Methods of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All payments hereunder shall be payable in U.S. Dollars. Wherever it is necessary to convert currencies for Net Sales invoiced in a currency other than the U.S. Dollar, such conversion shall be made into U.S. Dollars at the conversion rate existing in the United States (as reported in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) on the last Business Day of the applicable Calendar Quarter or, if such rate is unavailable, a substitute therefor reasonably selected by the Parties. All payments owed under this Agreement shall be made by wire transfer to a bank and account designated in writing by the Party entitled to receive such payment, unless otherwise specified in writing by such Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Taxes on Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall be solely responsible for the payment of (and all liabilities with respect to) all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Tax Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party and its Affiliates shall be entitled to deduct and withhold from any amounts payable pursuant to this Agreement such amounts that are required to be deducted and withheld under any provision of Applicable Laws. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">similar obligations in respect of any payments made by Partner to Company under this Agreement. To the extent Partner is required by Applicable Laws to deduct and withhold taxes on any payment to Company, Partner shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Company an official tax certificate or other evidence of payment of such taxes that is reasonably satisfactory to Company. Company shall provide Partner any tax forms that may be reasonably necessary in order for Partner to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty or Applicable Laws. Company shall use reasonable efforts to provide any such tax forms to Partner in advance of the due date.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Taxes Resulting from Partner&#8217;s Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner represents and warrants that, as of the Effective Date, Partner is not required by Applicable Laws to deduct or withhold taxes on any amounts payable to Company under this Agreement. If, pursuant to Applicable Laws, Partner is required to withhold taxes on any payment made to Company under this Agreement, then the sum payable by Partner (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Company receives a sum equal to the sum which it would have received if no taxes were required to be deducted and withheld under Applicable Laws. The Parties shall use commercially reasonable efforts to invoke the application of any applicable bilateral income tax treaty or similar agreement that would reduce or eliminate otherwise applicable taxes with respect to payments payable pursuant to this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Records&#59; Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall maintain complete and accurate records in sufficient detail in relation to this Agreement to permit the other Party to confirm the accuracy of the amount of royalty and other payments payable under this Agreement. Each Party shall keep such books and records for at least five (5) years following the Calendar Year to which they pertain or such longer period required by Applicable Laws. Upon reasonable prior notice, such records shall be inspected during regular business hours at such place or places where such records are customarily kept by an independent certified public accountant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of confirming Net Sales and the corresponding payments made, or required to be made, by or to the audited Party pursuant to this Agreement. Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit. Such audits may occur no more often than once each Calendar Year and not more frequently than once with respect to records covering any specific period of time. Each Party shall only be entitled to audit the books and records from the three (3) Calendar Years prior to the Calendar Year in which the audit request is made. The Auditor shall not disclose the audited Party&#8217;s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments to or by the audited Party under this Agreement. In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within thirty (30) days after the Auditor&#8217;s report. The auditing Party shall bear the full cost of such audit unless such audit reveals an overpayment to, or an underpayment by, the audited Party that resulted from a discrepancy in the financial report provided by the audited Party for the audited period, which underpayment or overpayment was more than seven and one half percent (7.5%) of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt;text-decoration:underline">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that any payment due under this Agreement is not paid within fifteen (15) days of when due in accordance with the applicable provisions of this Agreement, without limiting any rights or remedies hereunder, the payment shall accrue interest from the date due at the lesser of six percent (6%) per annum or the maximum rate under Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the rights and licenses expressly granted under this Agreement, as between the Parties, Company shall retain all rights, title and interest in, to and under any and all Company Background IP and Partner shall retain all rights, title and interest in, to and under any and all Partner Background IP.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt;text-decoration:underline">Developed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:176.05pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.69pt">As between the Parties, Company shall own any and all&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:41.95pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.02pt">Patents and Know-How discovered, invented or otherwise created solely by or on behalf of a Company Member in the course of exercising Company&#8217;s rights or performing its obligations hereunder&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:41.95pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.02pt">Patents and Know-How discovered, invented or otherwise created by or on behalf of either Party, its Affiliates, its licensees or its Sublicensees (to the extent applicable) solely or jointly together with the other Party, its Affiliates, its licensees or its Sublicensees (to the extent applicable), to the extent related to the Compound or Product&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:41.7pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.02pt">Patents and Know-How discovered, invented or otherwise created jointly by or on behalf of Partner or any of its Affiliates, its licensees or its Sublicensees, on the one hand, and Company or any of its Affiliates, licensees or Sublicensees, on the other hand, in the course of exercising its rights or performing its obligations hereunder (such Intellectual Property described in the foregoing (1) through (3), explicitly excluding the Partner Background IP, being referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Developed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">As between the Parties, Partner shall own any and all Patents and Know-How discovered, invented or otherwise created solely by or on behalf of a Partner Member (to the extent applicable) in the course of exercising the rights that it is granted hereunder or that it retains as specified herein or otherwise&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such Intellectual Property is not Company Developed IP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Developed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.03pt">For clarity, for purposes of this Agreement, inventorship will be determined in accordance with United States patent Laws (regardless of where the applicable activities occurred).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent that a Party Member is assigned or otherwise obtains ownership of any right, title, or interest in or to any Intellectual Property in contravention of the foregoing (i) or (ii), such Party hereby assigns, and shall cause its Party Member to assign, to the other Party all such right, title and interest.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.2(b)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as between the Parties, Company, in the case of the Company IP, and Partner, in the case of the Partner IP (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prosecuting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), shall have the exclusive right to (i) prosecute and maintain, at its expense, all pending and new Patent applications included within such Intellectual Property and (ii) respond to oppositions, nullity actions, re-examinations, revocation actions and similar proceedings filed by Third Parties against the issuance of such Patents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prosecution Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt;text-decoration:underline">Patents Exclusively Licensed to Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt;text-decoration:underline">Existing Patent Applications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. With respect to any Patents that have been filed, but have not issued, as of the Effective Date and are exclusively licensed to Partner hereunder in any country or regulatory jurisdiction in the Partner Territory, the Company shall remain responsible for all costs of prosecuting such Patent application following the Effective Date, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.2(b)(iii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">New Patent Applications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If, at any time during the Term, Company decides to file any Patent applications that have not been filed as of the Effective Date and, upon filing, would be exclusively licensed by Company to Partner hereunder in any country or regulatory jurisdiction in the Partner Territory, Company shall notify the JDC at the next scheduled JDC meeting and the JDC members shall discuss in good faith the countries and regulatory jurisdictions in the Partner Territory in which such application will be filed.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:41.6pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.02pt">In the event that, for any such Patent application, the JDC members (or the Executive Officers) agree on any countries or regulatory jurisdictions (without either Party exercising its final decision making authority under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)(i)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)(ii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if and to the extent applicable), then Company shall have the sole right to file such Patent applications in such countries and jurisdictions and the Parties shall share equally (on a 50-50 basis) the costs of filing and prosecuting such Patent applications, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.2(b)(iii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:41.75pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.02pt">In the event that, for any such Patent application, the JDC members and Executive Officers do not agree on any such countries or regulatory jurisdictions (without either Party exercising its final decision making authority under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)(i)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4(b)(ii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if and to the extent applicable), then Partner shall have the right to notify the Company in writing that, notwithstanding such failure to agree, Partner would like Company to file such Patent application in one or more of such countries or regulatory jurisdictions. If Partner provides such written notice within ten (10) Business Days of the JDC meeting when such matter is first discussed, then Company shall file such Patent</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt;padding-right:41.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">application, in Company&#8217;s name, in such countries and regulatory jurisdictions identified in Partner&#8217;s notice at Partner&#8217;s sole cost and expense, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.2(b)(iii)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.03pt;text-decoration:underline">Issued Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that Company elects, in any country or regulatory jurisdiction in the Partner Territory, not to continue to maintain an issued Patent exclusively licensed to Partner hereunder with respect to a country or regulatory jurisdiction in the Partner Territory (such Patent, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Abandoned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) without the intent to pursue substantially similar subject matter in a continuation or divisional filing or an equivalent thereof, it shall notify Partner of such election in writing at least forty-five (45) days prior to any filing or payment due date, or any other due date that requires action (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Following receipt of an Election Notice, and if requested by Partner, (1) Company shall and hereby does assign to Partner its right, title and interest in and to such Company Abandoned Patent in such country or regulatory jurisdiction (as applicable), and (2) upon the effective date of such assignment (A) Partner may continue maintenance of such Company Abandoned Patent in such country or regulatory jurisdiction at its sole cost and expense, in which case (B) Partner hereby grants Company a nonexclusive license to such Company Abandoned Patent for all uses other than those within the scope of the exclusive licenses granted to Partner with respect to such Patent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For clarity, any such Company Abandoned Patent shall not constitute a Company Patent hereunder, except with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. With respect to any Patents exclusively licensed to a Party that is not the Prosecuting Party, such Party will provide reasonable assistance to the Prosecuting Party, at the Prosecuting Party&#8217;s expense, in connection with the Prosecution Activities, where such assistance shall include providing reasonable access to relevant Persons and executing all documentation reasonably requested by the Prosecuting Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner will promptly notify Company in writing of (i) any actual or threatened infringement, misappropriation, other violation, or challenge to the validity, scope or enforceability by a Third Party of any Company IP in the Partner Territory of which it becomes aware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Territory Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (ii) any allegation by a Third Party that any of such Third Party&#8217;s Intellectual Property is infringed, misappropriated, or otherwise violated by the Development, Commercialization, or other Exploitation of the Product in the Partner Territory of which it becomes aware.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Company Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company shall have the first right (but not the obligation), at its own expense and by counsel of its own choice, to control enforcement of the Company IP against any actual or threatened infringement, misappropriation or other violation, or challenge to the validity, scope or enforceability by a Third Party, including any Partner Territory Infringement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Prior to commencing any suit, action or proceeding with respect to a Partner Territory Infringement to the extent reasonably practicable, Company shall reasonably consult with Partner and shall consider Partner&#8217;s timely recommendations regarding the proposed suit, action or proceeding, except to the extent delay may reasonably result in the loss of rights by or otherwise adversely impact Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Partner Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall have the right (but not the obligation) to control, at its own expense and by counsel of its own choice, enforcement of the Company IP against any Partner Territory Infringement (i) if Company provides Partner with written notice that it is not exercising its right to control such enforcement, or (ii) if Company fails to initiate, or file the relevant response to, (as applicable) a suit, action or proceeding with respect to such Partner Territory Infringement prior to or upon the earlier of (1) expiration of the ninety (90)-day period following first receipt by Company of written notice from Partner of such Partner Territory Infringement or (2) thirty (30) days prior to the deadline for filing, or filing the applicable response to (as applicable), such suit, action or proceeding (including suits, actions or proceedings based on a Third Party&#8217;s filing of a Paragraph IV Certification under 21 CFR &#167;314.94(a)(12)(i)(A)(4)).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Rights of Non-Controlling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary herein, the Party that is not controlling the suit, action or proceeding pertaining to enforcement of the Company IP against Third Party Infringement as described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall cooperate fully, including if required to bring such action, the provision of a power of attorney, and agrees to be joined as a party plaintiff to such suit, action or proceeding, upon the reasonable request and expense of the Party controlling such action if necessary for standing purposes. The Party that is not controlling such a suit, action or proceeding shall have the right to be represented by counsel (which shall act in an advisory capacity only, except for matters solely directed to such Party) of its own choice and at its own expense (subject to the immediately preceding sentence in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.3(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in any such suit, action or proceeding. To the extent reasonably practicable, the Party that is controlling such suit, action or proceeding shall give the other Party timely written notice of any proposed settlement and shall not settle, stipulate to any facts or make any admission with respect to any such Partner Territory Infringement without such other Party&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed) if such settlement, stipulation or admission would (i) give rise to liability of such other Party or any its Affiliates, (ii) grant to a Third Party a license or covenant not to sue under any Intellectual Property that such Party or any of its Affiliates owns or has rights or (iii) otherwise impair such Party&#8217;s or any of its Affiliates&#8217; rights under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any and all recoveries resulting from a suit, action or proceeding relating to a claim of Third Party Infringement shall first be applied to reimburse each Party&#8217;s costs and expenses in connection with such suit, action or proceeding, with any remaining recoveries allocated to the Party that controls such action, suit or proceeding in accordance with the terms hereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Defense Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Prior to Commercialization of the Product by or on behalf of Partner (including by any Partner Member to the extent permitted hereunder) in each country or regulatory jurisdiction in the Partner Territory, the Parties shall cooperate in good faith to have a patent attorney that is reasonably acceptable to both Parties conduct a freedom to operate analysis (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FTO Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to determine whether Commercialization of the Product in such country or regulatory jurisdiction would be reasonably likely to become the subject of an IPR Claim (the cost and expense of any such FTO Analysis to be shared equally by the Parties) and, if based on such FTO Analysis, an IPR Claim is reasonably likely, the Parties shall promptly meet to consider the appropriate course of action. If the Product becomes the subject of an IPR Claim in a country or regulatory jurisdiction within the Partner Territory, Partner shall promptly (a) notify Company in writing and the Parties shall promptly meet to consider the IPR Claim and the appropriate course</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of action and (b) take reasonable steps to mitigate any resulting Losses. If, in Company&#8217;s reasonable discretion, it is not commercially reasonable to procure sufficient rights to one or more Patents that are the subject of the IPR Claim, or modify the Product, to ensure that such IPR Claim is not pursued by the applicable Third Party, Partner shall, and shall cause the Partner Members, to promptly cease Exploiting the Product in such country or regulatory jurisdiction (as applicable). Notwithstanding the foregoing, following receipt of the FTO Analysis, Partner shall have the right to commence or continue Commercialization of the Product in the applicable countries or regulatory jurisdictions in the Partner Territory its sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Company&#8217;s indemnification obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply if the FTO Analysis identifies one or more Patents in the Partner Territory (nor shall they apply if Partner fails to comply with its obligations under the second sentence in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and in each such case, Partner shall be obligated to indemnify Company in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Patent Term Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.2(b)(iii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Company shall have the sole authority to select the appropriate Company Patents for patent term extensions, including supplementary protection certificates and any other extensions that are now available or become available in the future, for the Product in the Company Territory and Partner Territory, and shall consult with Partner with respect to such decisions for the Partner Territory and shall consider the comments and concerns of Partner in good faith. Partner shall cooperate with Company in obtaining such patent term extensions, including by signing all necessary papers.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall comply with reasonable policies provided by Company from time to time to maintain the goodwill and value of the Global Trademarks. Partner shall not, and shall cause its Affiliates not to, (i) use, seek to register, or otherwise claim rights in the Partner Territory to any Trademark that is confusingly similar to, misleading or deceptive with respect to, or that materially dilutes, any of the Global Trademarks or Local Trademarks or (ii) knowingly do, cause to be done, or knowingly omit to do any act, the doing, causing or omitting of which endangers, undermines, impairs, destroys or similarly affects, in any material respect, the validity or strength of any of the Global Trademarks or Local Trademarks (including any registration or pending registration application relating thereto) or the value of the goodwill pertaining to any of the Global Trademarks or Local Trademarks.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Enforcement of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">Company shall have the first right, but not the obligation, at Company&#8217;s expense and by counsel of its own choice, to (1) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, defend the Global Trademarks, including defending against any alleged, threatened or actual claim by a Third Party that the use of any Global Trademark infringes, dilutes or misappropriates any Trademark of that Third Party or constitutes unfair trade practices, or any other claims that may be brought by a Third Party against a Party in connection with the use of or relating to any Global Trademark (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Infringement Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (2) to enforce the Global Trademarks, including taking such action as Company deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution or misappropriation of, or unfair trade practices or any other like offense relating to, any Global Trademark, it being agreed that the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.3(b)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(e)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall apply&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, for the purpose of this</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.6(a)(i)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> use of &#8220;Company IP&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.3(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to mean &#8220;Global Trademarks&#8221;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">Partner shall have the first right, but not the obligation, at Partner&#8217;s expense and by counsel of its own choice, to enforce and defend the Local Trademarks in the Partner Territory, including (1) defending against any alleged, threatened or actual claim by a Third Party that the use of any Local Trademark in the Partner Territory infringes, dilutes or misappropriates any Trademark of that Third Party or constitutes unfair trade practices, or any other claims that may be brought by a Third Party against a Party in connection with the use of or relating to any Local Trademark in the Territory with respect to the Product and (2) taking such action as Partner deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution or misappropriation of, or unfair trade practices or any other like offense relating to, any Local Trademark in the Partner Territory by a Third Party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.03pt">Each Party shall provide to the other Party all reasonable assistance requested by such Party in connection with any such action, claim or suit under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.6(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, including allowing such Party access to such other Party&#8217;s documents and to such other Party&#8217;s personnel who may have possession of relevant information.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Trademark License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Company hereby grants to Partner an exclusive, royalty-free, limited license under the Global Trademarks solely to promote, market, sell, offer for sale, import, distribute and otherwise Commercialize the Product in the Partner Territory in accordance with the terms of this Agreement. Unless terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such license shall be in effect, on a country-by-country basis, as long as the sale of the Product under a Global Trademark is not discontinued by Partner.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Mutual Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.2pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Each Party represents and warrants to the other as of the Effective Date, and covenants, that&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:6.15pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.95pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual or individuals executing this Agreement on its behalf have been duly authorized to do so by all requisite corporate or partnership action,</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.03pt">this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, nor </font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="padding-left:0.05pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="padding-left:0.05pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="padding-left:0.05pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="padding-left:0.05pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="padding-left:0.05pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="padding-left:0.05pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="padding-left:0.05pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:1.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">violate any material law or regulation of any court or other Governmental Authority having jurisdiction over it, </font></div><div style="padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.13pt">it has the right to grant the licenses granted by it under this Agreement&#59; and </font></div><div style="padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.18pt">it has not, and will not during the term of such license, grant</font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any right to any Third Party that would conflict with the rights granted to the other Party hereunder.</font></div><div id="if3d95cb665db4012bc3df24549a8a91b_28"></div><div style="text-indent:18pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Each Party covenants to the other that in the performance of its obligations under this Agreement, such Party shall comply with, and shall cause its Party Members and its respective Indemnitees to comply, with all Applicable Laws. Neither Party shall, nor shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith after consultation with counsel, may violate, any Applicable Laws.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Each Party hereby represents, warrants and covenants to the other Party that it is not debarred or disqualified under the FD&#38;C Act, or any other comparable Applicable Laws in any country or jurisdiction, and it does not, and will not during the Term, employ or use the services of any Person who is debarred or disqualified, in connection with activities relating to the Product. In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any Person providing services to such Party, including any Party Member, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such Person to perform any such services.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Each Party acknowledges that the other Party may be subject to federal, state, local and international Laws related to the tracking and reporting of payments and transfers of value provided to health care professionals, health care organizations, and other relevant individuals and entities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sunshine Reporting Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and agrees to provide the other Party with all information regarding such payments or transfers of value by such Party as necessary for such other Party to comply in a timely manner with its reporting obligations under the Sunshine Reporting Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Neither Party shall, and each Party shall ensure its respective Indemnitees and Party Members do not, directly or indirectly, including through Third Parties, (i) pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Government Official, Governmental Authority, or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, or (ii) request or accept any such improper payment or (iii) cause a violation of any Anti-Corruption Laws. For example, this includes knowingly providing any inducement for such Government Official or Person (i) to approve, reimburse, prescribe, or purchase a product, to influence the outcome of a Clinical Trial, or otherwise to benefit the Company&#8217;s business activities improperly or (ii) with the intent to influence or reward, or the effect of influencing or rewarding any Person for acting in breach of an expectation of good faith, impartiality or trust, or which it was otherwise improper for the recipient to accept. Each Party</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_31"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">represents and warrants that as of the Effective Date, none of its respective Indemnitees or Party Members have, directly or indirectly, (i) promised, offered or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a Government Official, Governmental Authority or any other Person in connection with the performance of Partner&#8217;s obligations under this Agreement, (ii) requested or accepted any such improper payment or (iii) caused a violation of any Anti-Corruption Laws, and each Party covenants that its respective Indemnitees and Party Members and others acting on its or their behalf or for its or their benefit shall not, directly or indirectly, engage in any of the foregoing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.08pt">Each Party shall take reasonable steps to ensure, so far as they lawfully can, that its execution and performance of this Agreement is conducted in compliance with all Applicable Laws, including Anti-Corruption Laws, Export Control Laws and Sanctions. In connection with this Agreement, neither Party shall, and each Party shall cause its respective Indemnitees and other Party Members not to, (i) violate Anti-Corruption Laws, Export Control Laws, Sanctions, or any other Applicable Laws or otherwise cause any reputational harm to the other Party or (ii) engage, directly or indirectly, in any activities or business, including any activities or business with or involving any Sanctioned Person or any Sanctioned Jurisdiction, to the extent such activities or business would be prohibited by Sanctions, Anti-Corruption or Export Control Laws if conducted by an entity formed in the United States, in a country that is a European Union member state, or in the United Kingdom.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Each Party shall promptly notify the other Party in writing if it has any information or reason to believe that there may be a material actual or potential violation, or any activities or business that may cause any of its respective Indemnitees or other Party Members to be in violation, of (i) Anti-Corruption Laws, Sanctions, Export Control Laws, or any other Applicable Laws, rules or regulations in the performance of this Agreement or the Development, Manufacture or Commercialization of the Product or (ii) any of its policies and procedures relating to the foregoing.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">In connection with the performance of its obligations under this Agreement, each Party shall comply, and shall cause its respective Indemnitees and other Party Members to comply, with its own anti-corruption and anti-bribery policy, economic sanctions policy, export controls policy, and code of ethics (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Parties shall cooperate in good faith to ensure that each Party implements (to the extent necessary) and complies with a compliance program (which program shall include compliance with Compliance Policies and periodic training and shall be updated from time to time as necessary or otherwise appropriate), that is designed to ensure that such Party, its Indemnitees and Party Members comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1(f)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Prior to commencing Commercialization of the Product in the Partner Territory or any other activities in connection with this Agreement that, if conducted improperly, could result in a breach of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1(f)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Partner shall certify in writing that it has fully implemented such a compliance program (including Compliance Policies) and such program (including such Compliance Policies) is operating effectively. Each Party shall comply, and shall cause its respective Indemnitees and other Party Members to comply, with its own Compliance Policies. In connection with the performance of its obligations under this Agreement, each Party shall immediately notify the other Party in writing if it has any information or reason to believe that there may be a failure by any of its Indemnitees or other Party Members to comply with any of its</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compliance Policies. Partner shall maintain adequate policies, controls and systems to ensure compliance with its Compliance Policies and the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.74pt">Each Party agrees to maintain and enforce, at all times during the Term, (i) a system of internal accounting controls designed to ensure the making and keeping of fair and accurate books, records, and accounts with respect to any products, payments, or services provided under this Agreement (and each Party agrees, during the Term, to regularly monitor and audit its and its Party Members&#8217; business activities to ensure compliance with its policies, the Compliance Policies, the terms of this Agreement, and the adequacy of internal controls, and implements remediation in response to identified issues) and (ii) a compliance and ethics program containing adequate systems, policies, and procedures for the detection, investigation, documentation, and remediation of any allegations, reports, or findings related to a potential violation of Applicable Laws, including Anti-Corruption Law, with respect to the products, payments and services under this Agreement (such policies and procedures should set out rules governing interactions with HCPs and Government Officials, the engagement of Third Parties, and where appropriate, conducting due diligence, and the investigation, documentation, and remediation of any allegations, reports, or findings related to a potential violation of Applicable Laws). Each Party will have the right, upon reasonable prior written notice and during regular business hours, to conduct at its own cost and expense, inspections and audits of the other Party&#8217;s books and records in the event of a suspected violation of, or to ensure compliance with the representations, warranties or covenants of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in the absence of good cause for such inspections and audits, each Party shall exercise this right no more than once annually. Each Party acknowledges and agrees that the access rights provided in the foregoing sentence do not create or imply any obligation on the part of a Party to inspect or audit the other Party&#8217;s books, records or accounts or otherwise limit the other Party&#8217;s rights or remedies hereunder. Each Party agrees to permit, during the term of this Agreement and for five (5) years after final payment has been made under this Agreement, the other Party&#8217;s external auditors access to any of its relevant books, documents, papers, and records involving transactions related to the products, payments or services provided under this Agreement, and the audited Party agrees to cooperate fully in any audit or in connection with any investigation regarding any potential violations of Applicable Laws, including all Anti-Corruption Laws, applicable in connection with the products, payments, or services provided under this Agreement.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.74pt">Each Party agrees, at all times during the Term, to&#58; (i) maintain truthful and complete documentation supporting, in reasonable detail, the work and services performed and any expenses incurred in connection with this Agreement and (ii) maintain financial books and records that timely, fairly, accurately, and completely reflect all financial transactions, in accordance with all Applicable Laws, including Anti-Corruption Laws (for example, invoices, reports, statements, books, and other records), and shall maintain such books and records during the Term and for five (5) years after final payment has been made under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">In the event either Party, its Indemnitees or other Party Members engages in, is reported to have engaged in, or there is a reasonable basis to believe may have engaged in conduct that may constitute a violation of any Anti-Corruption Laws, Sanctions, Export Control Laws and its Compliance Policies, such Party shall perform a diligent investigation of the facts of the alleged or possible violation, appropriate disciplinary and remedial action by such Party up to and including termination of employment or relationship with any Person involved in</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the violation or any relationship obtained through improper means, and confirmation to the other Party that it has taken appropriate remedial action.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.74pt">Each Party shall cause its respective Indemnitees and Party Members working under its direction or control in connection with the performance of its obligations under this Agreement to submit to periodic training on compliance with Anti- Corruption, Laws, Sanctions, Export Control Laws and its Compliance Policies.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.74pt">Each Party shall annually certify to the other Party in writing its compliance, in connection with the performance of its obligations under this Agreement, with the representations, warranties, or covenants in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, which certification shall be issued by Party&#8217;s Executive Officer.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Each Party shall have the right to immediately suspend or terminate this Agreement in its entirety, and without any further liability or obligation, in the event it has reason to believe that the other Party or any Indemnitee or Party Member of the other Party or others acting on its or their behalf or for its or their benefit has violated, is violating, or is reasonably likely to violate Anti-Corruption Laws, Sanctions, Export Control Laws, or any portion of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in connection with performance of such Party&#8217;s obligations under this Agreement. In the event a Party terminates this Agreement as set forth in the foregoing sentence, the terminating Party shall not pay for, and the breaching Party shall not be entitled to receive payment on account of, any services that have been completed and not previously paid for that involved any conduct of the breaching Party that the terminating Party reasonably suspects breaches this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or that causes, or is reasonably likely to cause, any of the representations, warranties or covenants in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> not to be true and correct or to otherwise be breached, as applicable. Further, breaching Party shall be liable for damages or remedies as provided by law, and the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall apply as applicable.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Additional Representations and Warranties by Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company hereby represents and warrants to Partner as of the Effective Date&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Company is the sole owner of the Company Patents set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and all such Patents are subsisting, and to its Knowledge, valid and enforceable. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> sets forth a true a complete list of the Company Patents Controlled by the Company which are related to the Compound and to the development of the Product&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">to its Knowledge, no Third Party is infringing, misappropriating or otherwise violating the Company IP within the Partner Territory&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">no claim or litigation is or has been, in the past three (3) years, pending, or to its Knowledge, threatened in writing, by any Person against Company or its Subsidiaries alleging that the Company Patents are invalid or unenforceable or that the Development of the Product in the Partner Territory infringes, misappropriates or otherwise violates any Intellectual Property of any Person&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Company has used reasonable measures to protect the confidentiality of material Confidential Information included in the Company Know-How&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Company and its Subsidiaries have conducted any and all preclinical studies and Clinical Trials for the Initial Product in material compliance with all Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Additional Representations, Warranties and Covenants by the Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner hereby represents, warrants and covenants, as applicable, to Company&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Partner, on behalf of itself and all Partner Members, covenants that it has obtained or will obtain written agreements from each of its and their employees, consultants and contractors who perform Development activities pursuant to this Agreement, which agreements shall obligate such Persons to obligations of confidentiality and non-use that are no less restrictive than, and to assign Intellectual Property in a manner consistent with, the provisions of this Agreement&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">at all times during the Term, Partner will maintain its licenses, consents, authorizations and registrations to do business and continue to make any notifications as may be necessary or required by all Applicable Laws (including local laws, regulations, policies or administrative requirements) in order to provide the products or services encompassed within this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EXCEPT AS EXPRESSLY STATED IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, IN THE COMMERCIAL SUPPLY AGREEMENT, THE MANUFACTURING AGREEMENT OR THE PURCHASE AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF TITLE, VALIDITY, ENFORCEABILITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. EXCEPT TO THE EXTENT EXPRESSLY SET FORTH HEREIN, AND IN RESPECT OF THE DEVELOPMENT OF THE PRODUCT, ANY ITEMS PROVIDED BY COMPANY OR ITS SUBSIDIARIES HEREUNDER ARE MADE AVAILABLE ON AN &#8220;AS IS&#8221; BASIS, WITHOUT WARRANTY WITH RESPECT TO COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR REGULATIONS OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED, AND EACH PARTY HEREBY ACKNOWLEDGES AND AGREES THAT SUCH ITEMS ARE EXPERIMENTAL IN NATURE AND MAY HAVE UNKNOWN CHARACTERISTICS.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Indemnification by Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Company hereby agrees to defend, indemnify and hold harmless Partner, its Affiliates and its and their respective directors, officers, employees, consultants and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Losses incurred in connection with any Third Party Claims to the extent arising from or relating to&#58; (a) the gross negligence, fraud or willful misconduct of any Company Indemnitee or other Company Member in connection with this Agreement (including in connection with the exercise any of Company&#8217;s rights or performance of any of its obligations hereunder), (b) the Material Breach by Company of this Agreement, (c) the Development, Manufacturing, use, handling, storage, Commercialization or other disposition of the Product by any Company Indemnitee or other Company Member or (d)</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">death of or personal injury to any subject of the Initial Clinical Trial (or any other Collaboration Clinical Trial for which the related Collaboration Protocol is being developed by Company, and provided to Partner) arising out of such subject&#8217;s use of the Product under any such Clinical Trial unless such death or personal injury is caused by a failure of any Partner Indemnitee or other Partner Member to comply with (i) the Collaboration Protocol, (ii) the applicable requirements in the Federal Food, Drug, and Cosmetic Act and its implementing regulations (including 21 CFR Parts 50, 54, 56, 58 and 312) and publicly-available FDA guidelines, (iii) cGCP, or (iv) any other Laws in the jurisdictions where such Collaboration Clinical Trial is being conducted, in each case, and to the extent such death or personal injury does not arise from Partner failing to comply with the terms of this Agreement&#59; except to the extent that any of the foregoing (a) through (d) was caused by (x) the gross negligence or willful misconduct of any Partner Indemnitee or other Partner Member or (ii) material breach of this Agreement by Partner. Solely as used in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Breach by Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a material breach by Company of (1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as a result of Company Commercializing the Product Developed under this Agreement and in accordance with the Global Development Plan outside of the Company Territory or (2) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.15</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.3</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.1(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, which in each case has not been cured within sixty (60) days of Partner providing written notice to Company of such material breach (provided that, in the case of any such breach that is cured in accordance with the foregoing, Losses that are indemnifiable hereunder shall include those Losses that arise as a result of such breach (whether such Losses arise prior to or after the date on which such breach is cured)).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Subject to Partner&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Company hereby agrees to defend, indemnify and hold harmless the Partner Indemnitees from and against fifty percent (50%) of all Losses incurred in connection with any IPR Claim or Trademark Infringement Claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (i) such Patents that are the subject of the IPR Claim were not identified by the FTO Analysis or such Trademarks that are the subject of the Trademark Infringement Claim were not identified or flagged by the intellectual property counsel or other intellectual property specialist in connection with the Trademark Search in the Partner Territory, as applicable and in the case of any IPR Claim, Partner complies with the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and (ii) such infringement, misappropriation or other violation is not caused by, nor did it arise out of, Partner&#8217;s or any Partner Member&#8217;s failure to comply with the terms hereof or in the case of misappropriation of trade secrets, any action or omission by any Partner Member (subject to the remainder of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Indemnifiable IPR Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding the foregoing, Company shall not be obligated to indemnify the Partner Indemnitees as described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (i) to the extent the foregoing was caused by (x) the gross negligence or willful misconduct of any Partner Indemnitee or other Partner Member or</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) material breach of this Agreement by Partner or (ii) if Partner fails to comply with its obligations in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For clarity, (i) Partner shall be responsible for the remaining fifty percent (50%) of Losses incurred in connection with any Company Indemnifiable IPR Claim, for which Partner shall reimburse Company on a quarterly basis within sixty (60) days of Company providing Partner with an invoice for Losses incurred during the applicable Calendar Quarter and</font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Company shall be the Indemnifying Party for any IPR Claim in respect of which Company has indemnification obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Indemnification by Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to, and not in lieu of, Partner&#8217;s indemnification obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Partner hereby agrees to defend, indemnify and hold harmless Company, its Affiliates and its and their respective directors, officers, employees,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consultants and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Losses incurred in connection with any Third Party Claims to the extent arising from or relating to&#58; (a) the gross negligence, fraud or willful misconduct of any Partner Indemnitee or other Partner Member in connection with this Agreement (including in connection with the exercise any of Partner&#8217;s rights or performance of any of its obligations hereunder), (b) the Material Breach by Partner of this Agreement, (c) subject to Company&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, death of or personal injury to any subject of any Partner-Conducted Clinical Trials caused by a failure of any Partner Indemnitee or other Partner Member to comply with (i) the Collaboration Protocol,</font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) the applicable requirements in the Federal Food, Drug, and Cosmetic Act and its implementing regulations (including 21 CFR Parts 50, 54, 56, 58 and 312) and publicly-available FDA guidelines, (iii) cGCP, (iv) use, handle, store, distribute or dispose of the Finished Product provided for use in any Clinical Trials hereunder according to the specifications for the Product, cGMP and current good distribution practices or (iv) any other Applicable Laws in the jurisdictions where such Partner-Conducted Clinical Trials are being conducted, (d) any IPR Claim or Trademark Infringement Claim to the extent not a Company Indemnifiable IPR Claim or (e) any Partner Indemnitee&#8217;s or other Partner Member&#8217;s use of any (1) Intellectual Property in material breach of this Agreement or (2) Local Trademark&#59; except to the extent that any of the foregoing</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) through (e) was caused by (x) the gross negligence or willful misconduct of any Company Indemnitee or other Company Member or (y) material breach of this Agreement by Company. Solely as used in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Breach by Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (1) a material breach by any Partner Indemnitee or other Partner Member of (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as a result of Commercializing or Manufacturing the Product outside of the Partner Territory, (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as a result of Developing the Product outside the scope of the Global Development Plan or (iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.8</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.2</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.15</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.16</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.17</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.4</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2(e)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.1(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> which in each case has not been cured within sixty (60) days of Company providing written notice to Partner of such material breach (provided that, in the case of any such breach that is cured in accordance with the foregoing, Losses that are indemnifiable hereunder shall include those Losses that arise as a result of such breach (whether such Losses arise prior to or after the date on which such breach is cured)) or (2) a failure of Partner to pay all amounts due and payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> at the time such amounts have become due and payable.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">If a Company Indemnitee or Partner Indemnitee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, solely for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (i) Company, its Subsidiaries and its and their respective directors, officers, employees, consultants and agents and</font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) Partner Indemnitees) learns of any Third Party Claim that a Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be obligated to indemnify hereunder, such Indemnitee shall notify (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnity Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) such Indemnifying Party in writing, describing such claim in reasonable detail as promptly as practicable (and in any event within fifteen (15) calendar days) after becoming aware of such claim. Failure to give an Indemnity Notice shall not relieve the Indemnifying Party of its indemnification obligations hereunder, except to the extent that such Indemnifying Party is materially prejudiced by such failure.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">An Indemnifying Party has the right to elect to assume direction and control of the defense (including the right to settle claims for monetary compensation), at its own</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost and by its own counsel (which shall be reasonably satisfactory to the Indemnitee), any Third Party Claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the Indemnifying Party shall not be entitled to defend such claim, and shall pay the reasonable fees and expenses of one separate counsel for all Indemnitees, if such claim for indemnification relates to or arises in connection with any criminal action, indictment or allegation. Within thirty (30) calendar days after the Indemnity Notice (or sooner, if the claim requires), the Indemnifying Party shall notify the Indemnitee in writing if it is elects to assume direction and control of the defense and, in such event, the Indemnitee shall entrust its defense to the Indemnifying Party in the context of the Third Party Claim and may employ separate counsel to take advice from (but not control) such claim at its sole cost and following the Indemnifying Party&#8217;s reasonable request and at the Indemnifying Party&#8217;s cost, shall reasonably cooperate with the Indemnifying Party in the prosecution or defense thereof. If the Indemnifying Party fails to provide an election notice in accordance with the foregoing, or the Indemnifying Party is not permitted to defend the claim in accordance with the first sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.3(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Indemnitee may defend such claim at the Indemnifying Party&#8217;s cost and for clarity, it shall not be a defense to such obligation to pay such costs that the Indemnifying Party was not consulted in the defense thereof, that such Indemnifying Party&#8217;s views or opinions as to the conduct of such defense were not accepted or adopted, that such Indemnifying Party does not approve of the quality or manner of the defense thereof or that such Third Party Claim was resolved by reason of a settlement rather than by a judgment or other determination of liability.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Unless the Indemnifying Party fails to assume defense of a Third Party Claim, or the Indemnifying Party is not permitted to defend the claim in accordance with the first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.3(b)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Indemnitees may not settle or compromise any Third Party Claim without the Indemnifying Party&#8217;s prior written consent. No Indemnifying Party shall settle any Third Party Claim without the Indemnitee&#8217;s prior written consent if such settlement will (i) permit any injunction, declaratory judgment, other order or other non-monetary relief to be entered, directly or indirectly, against any Indemnitee or (ii) ascribe any fault on any Indemnitee. Without limiting the foregoing, the Indemnifying Party shall not, without prior written consent of the Indemnitee, settle any Third Party Claim or consent to the entry of any judgment which does not include as an unconditional term thereof the delivery by the claimant or plaintiff to the Indemnitee of a written release from all Losses in respect of such Third Party Claim.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EXCEPT FOR LIABILITY FOR BREACH OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">PROVIDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">HOWEVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, THAT THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12</a><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div><div><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 13.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that each Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) receiving any Confidential Information of the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of Disclosing</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party, and both Parties shall keep confidential and, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall not publish or otherwise disclose the terms of this Agreement. Recipient may use Disclosing Party&#8217;s Confidential Information only to the extent required to exercise its rights or fulfill its obligations under this Agreement, and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or, where Company is Recipient, the Novo Agreement, subject to compliance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Recipient shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors and other representatives do not disclose, or use in violation of the terms hereof, the Confidential Information of the Disclosing Party. Recipient shall promptly notify Disclosing Party in writing upon discovery of any unauthorized use or disclosure of the Confidential Information of Disclosing Party. Each Party shall be responsible for any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by its Party Members and their respective Affiliates and its and their respective employees, directors and officers, and such other Persons to which a Recipient provides Confidential Information of the Disclosing Party as if such Persons were a party to this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The obligations of confidentiality and restriction on use under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to any information that Recipient can prove by competent written evidence (a) is now, or hereafter becomes, through no act or failure to act on the part of Recipient, generally known or available to the public, (b) is known by Recipient at the time of receiving such information, as evidenced by its records, other than by previous disclosure of Disclosing Party, or its Party Members, Affiliates or its or their employees, agents, consultants, or contractors, (c) is hereafter furnished to Recipient without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right or (d) is independently discovered or developed by Recipient without the use of, or access to, Confidential Information of Disclosing Party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Recipient may disclose Confidential Information of Disclosing Party to the extent expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.75pt">submission of Regulatory Filings to Develop, Manufacture and Commercialize the Product and obtain Regulatory Approval for the Product to the extent expressly permitted hereunder&#59;</font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.07pt">prosecuting or defending litigation to the extent permitted by this Agreement&#59;</font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.75pt">complying with applicable orders of courts or other Governmental  Authorities&#59;</font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.07pt">in the case of Company as the Disclosing Party, disclosures under and in accordance with the Novo Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Novo is under written obligations of confidentiality and non-use as set forth in the Novo Agreement&#59;</font></div><div style="padding-right:5.95pt;text-indent:125.95pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.85pt">disclosure to its Party Members, Affiliates and its and their employees, consultants, contractors and agents, in each case on a need-to-know basis in connection with the Development, Manufacture or Commercialization of the Product in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein&#59; and</font></div><div style="padding-left:5pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.08pt">disclosure to potential and actual investors, acquirors, licensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such Party redacts the financial terms and other provisions of this Agreement that are not reasonably required to be disclosed in connection with such potential investment, acquisition or collaboration.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event Recipient is required to make a disclosure of Disclosing Party&#8217;s Confidential Information pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, it shall, except where impracticable, give reasonable advance written notice to Disclosing Party of such disclosure and use efforts to secure confidential treatment of such Confidential Information at least as diligent as Recipient would use to protect its own confidential information, but in no event less than reasonable efforts. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder. Any information disclosed pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div id="if3d95cb665db4012bc3df24549a8a91b_34"></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Publicity&#59; Public Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of any press releases or announcements relating to this Agreement, which shall be agreed in advance by the Parties prior to the issuance thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that a Party may not unreasonably withhold, condition or delay consent to such releases by more than five (5) Business Days and that either Party may issue press releases or disclosures to the SEC or other applicable Governmental Authorities as it determines, based on advice of counsel, is reasonably necessary to comply with Applicable Laws or the rules and regulations of any applicable stock exchange. Each Party shall provide the other Party with advance written notice of legally required disclosures to the extent practicable and the Parties shall consult with each other on the provisions of this Agreement to be redacted in any filings made by a Party with the SEC or as otherwise required by Applicable Laws&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that each Party shall have the right to make such filings as it reasonably determines necessary under Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner may not publish or otherwise disclose any results or other Data related to this Agreement unless it obtains prior written consent from Company as per the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, written consent of Company shall not be required to publish any information that does not constitute Confidential Information. If Partner wishes to publish research papers or research reports related to the Collaboration Clinical Trials, Partner shall give Company at least forty-five (45) calendar days to review the draft contents of any publication, abstract, poster or slide deck related to such Clinical Trial before it is presented at the conferences and the draft contents of any journal article before it is submitted for publication, shall consult with the Company with respect thereto, so that the Company can review each proposed submission to identify patentable subject matter and&#47;or any inadvertent disclosure of Confidential Information (including Confidential Information contained in any unpublished Patent application in relation to the Product) and Partner shall comply with Company&#8217;s request to delete references to its Confidential Information in any such paper or other materials. Absent any response from</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company within such forty-five (45) calendar day period, Partner shall be free to assume that Company has no objection to the proposed publication and shall have the right to proceed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Prior Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As of the Effective Date, the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement, including the Confidentiality Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be in addition to, and not in limitation of, the confidentiality provisions of the Purchase Agreement. Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information for purposes of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages would not be a sufficient remedy for any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In addition to all other remedies, a Party shall be entitled to specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The obligations and prohibitions contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the expiration or termination of this Agreement for a period of seven (7) years&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, with respect to any Confidential Information that qualifies as a trade secret under Applicable Laws, such obligations and prohibitions shall survive for so long as such Confidential Information qualifies as a trade secret under Applicable Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall expire upon expiration of the last Royalty Term in the Partner Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Notwithstanding anything to the contrary herein, on a country-by- country basis, upon the expiration of the Agreement in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.1(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">the licenses granted to Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to be perpetual, fully paid-up and royalty-free (except to the extent expressly set forth herein) solely with respect to the Product Commercialized by the Company in such country as of the expiration date, but shall be on a non-exclusive basis. The Parties understand and agree that such licenses exclude any license in the Local Trademarks&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">the licenses granted to Partner under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to be perpetual, non-exclusive, fully paid up and royalty-free solely with respect to Products Commercialized by Partner in the Partner Territory as of the date of expiration.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall have the right to terminate this Agreement in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement or the Closing Note and has not cured such breach within sixty (60) days (thirty (30) days with respect to any payment breach) after written notice of such breach from the non-breaching Party.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall have the right to terminate this Agreement in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the Laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within sixty (60) days after the commencement thereof.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Material Safety Issue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company shall have the right to terminate this Agreement immediately upon written notice if it reasonably deems it necessary to protect the safety, health or welfare of subjects enrolled in any Collaboration Clinical Trial on the basis of a Material Safety Issue.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Clinical Hold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event a Clinical Hold is imposed on any Collaboration Clinical Trial, the Parties shall meet to discuss the basis for the Clinical Hold, how long the Clinical Hold is expected to last, and how they might address the issue that caused the Clinical Hold. If such Clinical Hold has not been lifted ninety (90) days after such Clinical Hold has been imposed, Company shall have the right (in its sole discretion) to immediately terminate this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Sanctioned Person Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that either Party becomes a Sanctioned Person (whether due to a Change of Control or otherwise), such Party shall immediately notify the other Party in writing and the notified Party shall have the right to terminate this Agreement upon written notice. In the event that a Sublicensee becomes a Sanctioned Person (whether due to Change of Control or otherwise), such Sublicensee shall be immediately terminated by Partner and Partner shall immediately notify Company. Either Party shall have the right to immediately suspend or terminate this Agreement in its entirety in the event a Sublicensee of the other Party becomes a Sanctioned Person and such Sublicensee is not terminated by such Party immediately after written notice received from the other Party.</font></div><div><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of termination of this Agreement&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.75pt;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:176.05pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.69pt;text-decoration:underline">Licenses Granted to Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:41.9pt;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.02pt;text-decoration:underline">Termination&#160;&#160;&#160;&#160;by&#160;&#160;&#160;&#160;Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3(d)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in the event this Agreement is terminated by</font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:41pt;padding-right:41.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company as set forth herein, all licenses granted by Company to Partner hereunder, and sublicenses granted by Partner to any Company IP, shall automatically terminate.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:41.8pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.02pt;text-decoration:underline">Termination by Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3(d)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in the event this Agreement is terminated by Partner as set forth herein, (1) the licenses granted by Company to Partner pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and sublicenses granted by Partner under and in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall automatically terminate and (2) the licenses granted by Company to Partner pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and sublicenses granted by Partner under and in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(d)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed perpetual solely with respect to Products Commercialized by Partner in the Partner Territory as of the effective date of termination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that on a country-by-country and Product-by-Product basis, upon the expiration of the Royalty Term, such licenses shall be deemed to be nonexclusive, fully paid-up and royalty-free.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41pt;padding-right:5.85pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Licenses Granted to Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All licenses granted by Partner to Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and sublicenses granted by Company, to any Partner IP shall automatically terminate upon termination of the Agreement. All licenses granted by Partner to Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and sublicenses granted by Company, to any Partner IP shall automatically terminate upon termination of the Agreement (i) by Partner in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or (ii) by Company on the basis of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Material Safety Issue) or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Clinical Hold)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such Clinical Hold is not imposed as a result of the acts or omissions of Partner. Except as expressly set forth in the preceding sentence, upon termination of this Agreement, all licenses to Partner IP (excluding Partner Background IP) granted by Partner to Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall continue solely with respect to the Products Commercialized by the Company as of the termination date and shall be deemed to be nonexclusive, fully paid-up and royalty-free. The Parties understand and agree that such licenses set forth in the preceding sentence exclude any license to the Local Trademarks. In the event of termination of this Agreement by the Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(e)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Partner shall grant to Company an exclusive and royalty free license to use the Local Trademarks in the Partner Territory, solely to the extent necessary to use, promote, market, sell, offer for sale, import into, distribute and otherwise Commercialize (but not to Develop or Manufacture) the Product for a transitional period of twelve (12) months following the effective date of termination, except to the extent a longer period of time is required for approval from Regulatory Authorities for Commercialization.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event this Agreement is terminated by Company as set forth herein or by the Parties by mutual written agreement, Partner shall, at Company&#8217;s written request, to the extent permitted under Applicable Laws, promptly following the effective date of termination&#58; (i) assign and transfer to Company (or its designee) all of Partner&#8217;s right, title, and interest in and to any and all Regulatory Filings (including Regulatory Approvals), and materials, in each case, to the extent related to Development or Commercialization of the Product and (ii) disclose to Company all documents embodying the foregoing that are in any Partner Member&#8217;s possession or control or that any Partner Member is able to obtain using reasonable</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">efforts. In the event of termination of this Agreement by the Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(e)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Partner shall, at Company&#8217;s request and to the extent permissible under Applicable Laws, transfer to the Company clinical and commercial agreements (to the extent assignable and not cancelled). If any such contracts described in the foregoing sentence are not assignable to Company or its designee, but are reasonably necessary for Company to continue Development or Commercialization of the Product in the Partner Territory, then Partner shall reasonably cooperate with Company to negotiate for the continuation of such services for Company from such entity, for a reasonable period (not to exceed twelve (12) months) after termination at Company&#8217;s cost until Company establishes an alternate, validated source of such services.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Development Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties shall promptly meet to prepare a close-out schedule, and Partner shall cease performing all work not necessary for the orderly close-out of its activities or obligations hereunder or required by Applicable Laws. Partner shall either, as directed by Company&#58; (i) wind-down any ongoing Development activities (including Clinical Trials) of the Product conducted by any Partner Member in an orderly fashion or (ii) promptly transfer such Development activities to Company or its designee, in compliance with all Applicable Laws&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, (1) in the event of termination by Company in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(d)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Partner shall proceed as specified in clause (i) above and (2) in the event of termination by Company in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1(n)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(e)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Partner shall proceed as specified in clause (ii) above. Company shall remain responsible for the costs of the activities for which it was responsible under the Global Development Plan from the effective date of termination until completion of such Clinical Trial (or early termination of such Clinical Trial by Company).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Commercial Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except to the extent this Agreement is terminated by Company in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1(n)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(c)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(e)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or terminated by the Partner in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1(n)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(e)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Partner shall, as directed by Company, (i) continue certain ongoing Manufacturing (if any) and Commercialization activities of Partner Members with respect to the Product in the Partner Territory for a period of up to six (6) months as determined by Company and (ii) handoff such Manufacturing (if any) and Commercialization activities to Company or its designee, on a timetable to be set by Company, not to exceed six (6) months, and in compliance with all Applicable Laws. During such commercial wind-down period, Partner shall continue to book sales and pay royalties to Company. Except as necessary to conduct the foregoing activities as directed by Company, Partner shall immediately discontinue its (and shall ensure that Partner Members immediately discontinue their) promotion, marketing, offering for sale, and servicing of the Product and use of all Global Trademarks and Local Trademarks. In addition, Partner shall immediately deliver to Company (at Company&#8217;s expense) all samples, demonstration equipment, sales and marketing materials, catalogs, and literature related to the Product in Partner&#8217;s possession or control.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Transition Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Partner shall use commercially reasonable efforts to seek an orderly transition of the Development, and in the event of termination of this Agreement by Company, the Manufacture (if any) and Commercialization, of the Product to Company or its designee. Except to the extent this Agreement is terminated by Partner for Company&#8217;s material breach of this Agreement in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or pursuant to</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(e)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> without limiting any other rights of Company hereunder, (i) Company may, in its sole discretion, postpone the effective date of such termination for up to six (6) months and (ii) Partner shall, at no cost to Company, provide reasonable consultation and assistance for a period of no more than ninety (90) days after the effective date of such termination (and in any case not to exceed a total of two hundred (200) hours of working time) to transfer or transition Development, and in the event of termination of this Agreement by Company pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2(a)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(e)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Manufacture (if any) and Commercialization, of the Product to Company hereunder (including the transfer of all Company Developed IP not already in Company&#8217;s possession). Such assistance does not include sharing Partner&#8217;s Background IP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.08pt;text-decoration:underline">Remaining Inventories</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Company shall have the right, at its discretion, to purchase from Partner any or all of the inventory of the Product held by Partner as of the date of termination at a price equal to the transfer price paid by Partner to acquire such inventory from Company. Company shall notify Partner in writing within sixty (60) days after the date of termination whether Company elects to exercise such right.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon Disclosing Party&#8217;s request, Recipient shall promptly return to Disclosing Party or, at Disclosing Party&#8217;s option, destroy, all copies of the Confidential Information in Recipient&#8217;s or its Party Members&#8217; possession and shall certify in writing as to such destruction. Notwithstanding the foregoing, Recipient (a) may retain a single copy of the Confidential Information in its legal files for the sole purpose of ascertaining its ongoing rights and responsibilities respecting such information and (b) shall not be required to destroy any computer files created during automatic system back up that are subsequently stored securely by Recipient. Recipient shall continue to be bound by the terms and conditions of this Agreement with respect to such retained Confidential Information in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1(a)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(d)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (solely in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3(a)(i)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (solely in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.1(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3(a)(ii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.5(b)(ii)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.16</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.7</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.8</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.1(b)</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</a><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 15.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Fees and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as set forth in the Transaction Documents, each Party will pay its own direct and indirect expenses incurred by it in connection with the preparation and negotiation of this Agreement and the consummation of the transactions contemplated by this Agreement, including all fees and expenses of its advisors and representatives.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices, requests, consents and other communications under this Agreement to either Party must be in writing and are deemed duly delivered when (a) delivered if delivered personally or by nationally recognized overnight courier service (costs prepaid), (b) transmitted via e-mail (including via attached .pdf document) to the e-mail address set out below or (c) received or rejected by the addressee, if sent by United States of America certified or registered mail, return receipt requested&#59; in each case to the following addresses or email of the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">individual (by name or title) designated below (or to such other address, email or individual as a Party may designate by notice to the other Party)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Company&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:217.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vTv Therapeutics, LLC </font></div><div style="padding-left:72pt;padding-right:217.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Richard Nelson</font></div><div style="padding-left:113pt;padding-right:217.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3980 Premier Dr., Suite 310 High Point, NC 27265</font></div><div style="padding-left:113pt;padding-right:159.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58;&#160;&#160;&#160;&#160;rnelson&#64;vtvtherapeutics.com Attention&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy (which will not constitute notice) to&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:135.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Skadden, Arps, Slate, Meagher &#38; Flom LLP One Manhattan West</font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, New York 10001</font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58;&#160;&#160;&#160;&#160;peter.serating&#64;skadden.com</font></div><div style="padding-left:113pt;padding-right:159.6pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">michael.zeidel&#64;skadden.com Attention&#58;&#160;&#160;&#160;&#160;Peter D. Serating</font></div><div style="padding-left:176.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael J. Zeidel</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Partner&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G42 Healthcare</font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dr. Fahed Al Marzooqi, COO</font></div><div style="padding-left:113pt;padding-right:135.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MBA UAI Campus, Madasar City, Building 1B Masdar, Abu Dhabi, United Arab Emirates </font></div><div style="padding-left:108pt;padding-right:135.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Email&#58;&#160;&#160;&#160;&#160;fahed.almarzooqi&#64;g42.ai</font></div><div style="padding-left:113pt;padding-right:162.9pt;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G42.Legal&#64;g42.ai </font></div><div style="padding-left:72pt;padding-right:162.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;&#160;&#160;&#160;&#160;Dr. Fahed Al Mazooqi, COO</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Transaction Documents and the Confidentiality Agreement (together with the exhibits and schedules thereto) and the other written agreements entered into between the Parties as of the date hereof, contain the entire understanding of the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the Parties acknowledge have been merged into such documents, exhibits and schedules.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Amendments and Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Parties or, in the case of a waiver, by the Party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement will be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor will any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt;text-decoration:underline">Successors and Permitted Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer without the other Party&#8217;s consent to (i) a wholly owned Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such Party shall remain primarily liable for any acts or omissions of such Subsidiary or (ii) to any Third Party who acquires all or substantially all of the business or assets of the assigning Party by merger, sale of assets or otherwise&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that in no event may either Party assign or transfer this Agreement or any rights or obligations hereunder to a Sanctioned Person. Any permitted assignee shall, in writing to the non-assigning Party, expressly assume performance of such assigning Party&#8217;s rights and obligations. Any permitted assignment is binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is null, void and of no legal effect.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Notwithstanding anything in this Agreement to the contrary, in no event shall the Intellectual Property licensed to Partner by Company or any of its Affiliates include any Intellectual Property to the extent Controlled by any Third Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acquiror</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any of its Affiliates that acquires all or any part of, or otherwise undergoes a Change of Control with, Company or any Affiliate of Company (any such transaction, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acquisition Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which Intellectual Property (i) is Controlled, immediately prior to the effective date of the applicable Acquisition Transaction, by the Acquiror or any of its Affiliates (other than, for clarity, Company or any of its Affiliates immediately prior to the effective date of the acquisition) or (ii) is Controlled by the Acquiror or any of its Affiliates (other than, for clarity, Company or any of its Affiliates immediately prior to the effective date of the acquisition) on or after the effective date of such Acquisition Transaction, but was not created using any Intellectual Property licensed from Partner pursuant to the terms hereof.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is intended for the benefit of the Parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction will not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. In the event that any provision hereof would, under Applicable Laws, be invalid or unenforceable in any respect, each of the Parties intend that such provision will be construed by modifying or limiting it so as to be valid and enforceable to the maximum extent compatible with, and possible under, Applicable Laws.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement are not performed by either Party in accordance with their specific terms or were otherwise breached by such Party. Without prejudice to the dispute resolution provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties accordingly agree that, in addition to any other remedy to which the Parties are entitled at law or in equity, each Party is entitled to injunctive relief to prevent breaches of this Agreement by the other Party and otherwise to enforce specifically the provisions of this Agreement against the other Party. Each Party expressly waives</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any requirement that the other Party obtain any bond or provide any indemnity in connection with any action seeking injunctive relief or specific enforcement of the provisions of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.05pt;text-decoration:underline">Business Days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the last or appointed day for the taking of any action or the expiration of any right required or granted in this Agreement or any other Transaction Document is not a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.05pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties agree that each of them and their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting Party will not be employed in the interpretation of this Agreement or any amendments hereto.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.05pt;text-decoration:underline">Governing Law&#59; Venue and Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">All questions concerning the construction, validity, enforcement and interpretation of this Agreement will be governed by and construed and enforced in accordance with the internal procedural and substantive laws of the laws of England and Wales, without regard to the principles of conflicts of law thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">Except for any matters to be determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any dispute, controversy, or claim arising out of or relating to this Agreement (and any subsequent amendments thereof), or the breach, termination, or validity thereof, and any question of the arbitral tribunal&#8217;s jurisdiction or the existence, scope or validity of this arbitration agreement or the arbitrability of any claim (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), shall be resolved by final and binding arbitration administered by the London Court of International Arbitration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LCIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in accordance with the Arbitration Rules of United Nations Commission on International Trade Law then in effect (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UNCITRAL Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), except as modified herein, with the LCIA being the appointing authority for purposes of the UNCITRAL Rules.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">The seat of arbitration shall be New York, New York, and the arbitration shall be conducted in the English language. The arbitration, and any decisions and awards arising thereunder, will be subject to the Federal Arbitration Act (9 U.S.C. &#167; 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">The arbitral tribunal shall consist of one arbitrator (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tribunal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) mutually agreed by the Parties. If the Parties cannot mutually agree upon the selection of the Arbitral Tribunal within thirty (30) days of the notice of arbitration, the arbitrator shall be appointed by the LCIA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.15pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt">Any arbitration hereunder shall be confidential, and the Parties and their representatives agree not to disclose to any Third Party the existence or status of the arbitration or any information related thereto, except and to the extent that disclosure is required by Applicable Laws or is required to protect or pursue a legal right.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.08pt">In addition to monetary damages, the Arbitral Tribunal shall be empowered to award equitable relief, including an injunction and specific performance of any obligation under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">The award of the Arbitral Tribunal shall be final and binding upon the Parties thereto, and shall be the sole and exclusive remedy between the Parties regarding any Dispute presented to the Arbitral Tribunal. Judgment upon any award may be entered in any court having jurisdiction over any party or any of its assets.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt">The Arbitral Tribunal shall have the power to award attorneys&#8217; fees, costs and related expenses, as well as the costs of the arbitration, to such extent and to such Parties as it sees fit, in accordance with the UNCITRAL Rules.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.74pt">Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.11</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall preclude either Party from seeking interim or provisional relief from a court of competent jurisdiction including a temporary restraining order, preliminary injunction or other interim relief concerning a Dispute either prior to or during any arbitration if necessary to protect the interest of such Party or to preserve the status quo pending the arbitration proceeding.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.74pt">The Parties submit to the non-exclusive jurisdiction of the federal and state courts located in the Borough of Manhattan, New York County in the State of New York (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New York Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), for the enforcement of any arbitral award rendered hereunder and to compel arbitration or for interim or provisional remedies in aid of arbitration. The Parties hereby unconditionally and irrevocably waive any right to stay or dismiss any such proceeding brought before the New York Courts on the basis of inappropriate or improper venue. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service will constitute good and sufficient service of process and notice thereof. Nothing contained herein will be deemed to limit in any way any right to serve process in any other manner permitted by law. Furthermore, nothing herein shall affect the Parties&#8217; right to bring legal action or proceedings to enforce an arbitral award in any other court of competent jurisdiction.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.05pt;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement (other than failure to make payment when due) by reason of any Force Majeure Event. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Written notice of a Party&#8217;s failure or delay in performance due to Force Majeure Event must be given to the other Party within ten</font></div><div style="padding-left:5pt;padding-right:6.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10) days after its occurrence. All delivery dates under this Agreement that have been affected by Force Majeure Event shall be tolled for the duration of such force majeure.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.05pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as expressly set forth herein, in the event of a conflict between this Agreement and the Schedules, this Agreement shall control.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.05pt;text-decoration:underline">Counterparts and Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in two or more counterparts, all of which when taken together will be considered one and the same agreement and will become effective when counterparts have been signed by each Party and delivered to the other Party, it being understood that both Parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by email</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery of a &#8220;.pdf&#8221; format data file, such signature will create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:99.95pt;padding-right:99.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(Signature Page Follows)</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_37"></div><hr style="page-break-after:always"><div style="min-height:79.2pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5.1pt;text-indent:35.95pt"><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties hereto have caused this Collaboration and License Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></div><div><font><br></font></div><div style="margin-top:9.4pt;padding-left:257.6pt"><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">vTv THERAPEUTICS LLC</font></div><div><font><br></font></div><div style="margin-top:9.8pt;padding-left:257.6pt;text-indent:0.1pt"><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">By&#58; vTv Therapeutics Inc., its managing member</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:275.65pt"><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:105%">By&#58;       </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:105%;text-decoration:underline">&#47;s&#47; Richard S. Nelson                </font></div><div style="padding-left:275.65pt"><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:105%">Name&#58; Richard S. Nelson</font></div><div style="margin-top:0.95pt;padding-left:275.65pt"><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Interim Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:100pt;padding-right:100pt;text-align:center"><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#91;Signature Page to Collaboration and License Agreement&#93;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_40"></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5.5pt;padding-right:5.6pt;text-align:justify;text-indent:36pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WI1NESS WHEREOF, the Parties hereto have caused this Collaboration and License Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></div><div><font><br></font></div><div style="margin-top:10.05pt;padding-left:256.6pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">vTv Therapeutics, LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:256.25pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;        &#47;s&#47;                                                </font></div><div style="margin-top:0.75pt;padding-left:277.55pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Name&#58;  Richard Nelson</font></div><div style="margin-top:0.45pt;padding-left:256.05pt;padding-right:6.75pt;text-indent:21.45pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:333%">Title&#58;&#160;&#160;&#160;&#160;Interim Chief Executive Officer Cogna Technology Solutions LLC</font></div><div style="margin-top:0.15pt;padding-left:36.22pt;padding-right:36.22pt;text-align:center"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:92%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;      By&#58; </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:92%;text-decoration:underline">               &#47;s&#47; Peng Xiao                               </font></div><div style="margin-top:0.75pt;padding-left:277.55pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Name&#58;  Peng Xiao</font></div><div style="margin-top:0.7pt;padding-left:277.05pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Authorised Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-align:center"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#91;Signature Page to Collaboration and License Agreement&#93;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">&#91;</font></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_43"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:283.45pt;padding-right:283.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:283.55pt;padding-right:283.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Company Patents</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, the licenses granted to Partner with respect to Company Patents under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if3d95cb665db4012bc3df24549a8a91b_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are limited to the Partner Territory and expressly exclude any Patents with respect to other countries or regulatory jurisdictions unless expressly set forth in the Global Development Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-right:12.7pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;453,330</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;14&#47;2006</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,598,391</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;6&#47;2009</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12&#47;757,217</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;9&#47;2010</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,851,636</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12&#47;14&#47;2010</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12&#47;942,297</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;9&#47;2010</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,263,634</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9&#47;11&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="margin-top:0.1pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">vTv Therapeutics</font></div><div style="margin-top:0.1pt;padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GB</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AT</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">HETEROARYL-UREAS AND</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">THEIR USE AS GLUCOKINASE ACTIVATORS</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.890%"><tr><td style="width:1.0%"></td><td style="width:5.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CH</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CZ</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">HETEROARYL-UREAS AND</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">THEIR USE AS GLUCOKINASE ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DK</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.57pt;padding-right:4.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FI</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">HETEROARYL-UREAS AND</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">THEIR USE AS GLUCOKINASE ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HU</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IT</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NL</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PT</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.55pt;padding-right:4.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">HETEROARYL-UREAS AND</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">THEIR USE AS GLUCOKINASE ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AU</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:24.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2005203930</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2005203930</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;16&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:23.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PI0506662-0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.85pt;padding-right:4.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PI0506662-0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;25&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">HETEROARYL-UREAS AND</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">THEIR USE AS GLUCOKINASE ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:32.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2551324</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2551324</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;27&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CN</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:14.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200580002021.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ZL200580002021.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;4&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IL</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">176257</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">176257</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7&#47;31&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:10.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3624&#47;DELNP&#47;2006</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">252466</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;16&#47;2012</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.890%"><tr><td style="width:1.0%"></td><td style="width:5.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:22.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2006-548114</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4834840</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;7&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-2006-7013454</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.85pt;padding-right:4.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-1196313</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;25&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PA&#47;a&#47;2006&#47;007667</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">297252</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;21&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">HETEROARYL-UREAS AND</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">THEIR USE AS GLUCOKINASE ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RU</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:24.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2006122209</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2386622</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;20&#47;2010</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ZA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:24.8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2006&#47;05467</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2006&#47;05467</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;28&#47;2008</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.55pt;padding-right:4.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HK</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">07107531.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1103074</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8&#47;17&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">HETEROARYL-UREAS AND</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">THEIR USE AS GLUCOKINASE ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NO</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:29.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20063351</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">337003</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12&#47;21&#47;2015</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PL</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">05700554.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1723128</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;7&#47;2012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:22.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2011-103784</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5415477</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;22&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KR</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-2012-7000490</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;6&#47;2005</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.85pt;padding-right:4.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-1126225</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;6&#47;2012</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ACTIVATORS</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.451%"><tr><td style="width:1.0%"></td><td style="width:5.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-right:12.7pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14&#47;071,976</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;5&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,004,782</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;26&#47;2018</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15&#47;983,249</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;18&#47;2018</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,588,943</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;17&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#47;744,956</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;16&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,980,861</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;20&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">GLUCOKINASE ACTIVATOR</font></div><div style="padding-left:18.7pt;padding-right:17.15pt;text-indent:2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">COMPOSITIONS FOR THE TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.87pt;padding-right:4.87pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">602013077007.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">GLUCOKINASE ACTIVATOR</font></div><div style="padding-left:18.7pt;padding-right:17.15pt;text-indent:2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">COMPOSITIONS FOR THE TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GB</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.57pt;padding-right:4.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CH</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ES</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IT</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13726933.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2849776</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;21&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,872,021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">GLUCOKINASE ACTIVATOR</font></div><div style="padding-left:18.7pt;padding-right:17.15pt;text-indent:2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">COMPOSITIONS FOR THE TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CN</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201380024802.X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2015-512779</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6234443</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;2&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX&#47;a&#47;2014&#47;013105</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">360304</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;29&#47;2018</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">GLUCOKINASE ACTIVATOR</font></div><div style="padding-left:18.7pt;padding-right:17.15pt;text-indent:2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">COMPOSITIONS FOR THE TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">vTv</font></div><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.55pt;padding-right:4.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HK</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15103235.2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AU</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2017203835</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2017203835</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;7&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-2021-7006420</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2013</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.75pt;padding-right:17.15pt;text-indent:-3.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE</font></div><div style="padding-left:18.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">TREATMENT OF DIABETES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:12.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17&#47;480,856</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9&#47;21&#47;2021</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.67pt;padding-right:7.67pt;text-align:center;text-indent:0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:114%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="margin-top:0.1pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.451%"><tr><td style="width:1.0%"></td><td style="width:5.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2964197</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.87pt;padding-right:4.87pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">602014062792.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2964197</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GB</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2964197</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CH</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2964197</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.8pt;text-indent:18.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE</font></div><div style="padding-left:6.1pt;text-indent:1.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">ACTIVATOR AND METHODS OF MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.7pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ES</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2964197</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.55pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2964197</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IT</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14710738.7</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.87pt;padding-right:4.87pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">502020000058210</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;25&#47;2020</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-right:19.25pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AU</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2014226292</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:19.35pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2014226292</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;17&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,903,440</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:25.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,903,440</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;13&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2015-561469</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:28.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6441829</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;30&#47;2018</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX&#47;a&#47;2015&#47;011110</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:31.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">372548</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;23&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.55pt;padding-right:4.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HK</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42021034616.9</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.8pt;text-indent:18.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE</font></div><div style="padding-left:6.1pt;text-indent:1.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">ACTIVATOR AND METHODS OF MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.7pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CN</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">202011088593.3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;28&#47;2014</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.7pt;padding-right:7.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">MAKING AND USING THE SAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:8.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.55pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#47;741,224</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;13&#47;2020</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,952,993</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;23&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:16.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17&#47;178,402</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;18&#47;2021</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.890%"><tr><td style="width:1.0%"></td><td style="width:5.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:19.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:8.07pt;padding-right:8.07pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17&#47;178,404</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;18&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19740096.3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AU</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019287437</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,093,025</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CN</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201980028636.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN</font></div><div style="padding-left:5.57pt;padding-right:5.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">COMBINATION WITH INSULIN OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.7pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020-563743</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.55pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-2020-7029851</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX&#47;a&#47;2020&#47;008905</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.890%"><tr><td style="width:1.0%"></td><td style="width:5.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:19.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:8.07pt;padding-right:8.07pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.55pt;padding-right:4.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HK</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62021031811.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;10&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.7pt;padding-right:8.7pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">OR INSULIN ANALOGS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WO</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PCT&#47;US2021&#47;017743</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;12&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.92pt;padding-right:14.92pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SULFOXIDE AND SULFONE GLUCOKINASE ACTIVATORS AND METHODS OF USE</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">THEREOF</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WO</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PCT&#47;US2021&#47;036082</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;7&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:6.25pt;padding-right:6.25pt;text-align:center;text-indent:0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CRYSTALLINE FORMS OF &#123;2-&#91;3- CYCLOHEXYL-3-(TRANS-4- PROPOXY-CYCLOHEXYL)- UREIDO&#93;-THIAZOL-5- YLSULFANYL&#125;-ACETIC ACID AND</font></div><div style="padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">AND USES THEREOF</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WO</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PCT&#47;US2021&#47;036084</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;7&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.25pt;padding-right:6.25pt;text-align:center;text-indent:0.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SALTS OR CO-CRYSTALS OF &#123;2- &#91;3-CYCLOHEXYL-3-(TRANS-4- PROPOXY-CYCLOHEXYL)- UREIDO&#93;-THIAZOL-5- YLSULFANYL&#125;-ACETIC ACID AND</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">USES THEREOF</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:8.15pt;padding-right:8.15pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Published</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13&#47;114,964</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,359,313</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;7&#47;2016</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.3pt;padding-right:9.3pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin In Combination With A Glucokinase Activator And Compositions Comprising Metformin And A Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:8.07pt;padding-right:8.07pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14&#47;988,143</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#47;11&#47;2016</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,855,251</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#47;2&#47;2018</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.3pt;padding-right:9.3pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin In Combination With A Glucokinase Activator And Compositions Comprising Metformin And A Glucokinase</font></div><div style="margin-top:0.05pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:8.07pt;padding-right:8.07pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.5pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.342%"><tr><td style="width:1.0%"></td><td style="width:5.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.148%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:19.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-right:12.7pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15&#47;687,824</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8&#47;28&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,064,846</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:10.17pt;padding-right:10.17pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9&#47;4&#47;2018</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.3pt;padding-right:9.3pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin In Combination With A Glucokinase Activator And Compositions Comprising Metformin And A Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">US</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#47;058,512</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8&#47;8&#47;2018</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,363,244</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:7.4pt;padding-right:7.4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7&#47;30&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9.82pt;padding-right:9.82pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compositions Comprising Metformin and A Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-right:16.05pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Issued</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics</font></div><div style="padding-left:4.92pt;padding-right:4.92pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11787250.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:28.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2576524</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;25&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising</font></div><div style="padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Metformin and a Glucokinase Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11787250.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:28.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2576524</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;25&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.4pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GB</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11787250.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:28.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2576524</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;25&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.7pt;padding-right:5.7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ES</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11787250.7</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:28.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2576524</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;25&#47;2017</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.12pt;padding-right:18.12pt;text-align:center;text-indent:-0.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a</font></div><div style="padding-left:5.57pt;padding-right:5.57pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Glucokinase Activator and Compositions Comprising</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-right:11.85pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%">Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11787250.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2576524</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;25&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IT</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:25.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11787250.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2576524</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10&#47;25&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AU</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:24.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2011258460</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2011258460</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;4&#47;2015</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CA</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:29.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,799,591</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,799,591</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#47;11&#47;2019</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CN</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:14.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201180025744.3</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ZL201180025744.3</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;4&#47;2015</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="margin-top:0.05pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.5pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">JP</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.95pt;padding-right:4.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2013-512164</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5902676</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;18&#47;2016</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KR</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-2012-7033687</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:4.85pt;padding-right:4.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-1860120</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;15&#47;2018</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.35pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MX&#47;a&#47;2012&#47;013617</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">347372</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#47;25&#47;2017</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.6pt;padding-right:4.6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TW</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100118368</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;25&#47;2011</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.85pt;padding-right:4.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I508723</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:4.67pt;padding-right:4.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11&#47;21&#47;2015</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.1pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.55pt;padding-right:4.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HK</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.97pt;padding-right:4.97pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13108290.5</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-right:4.95pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1181044</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.62pt;padding-right:4.62pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#47;4&#47;2015</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="margin-top:0.05pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.451%"><tr><td style="width:1.0%"></td><td style="width:5.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CNTRY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPLICATION NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">DATE</font></div><div style="padding-left:16.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">FILED</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:4.82pt;padding-right:4.82pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PATENT NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:122%">GRANT</font></div><div style="padding-left:19.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:113%">DATE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.65pt;padding-left:5.65pt;padding-right:5.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATUS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 17pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OWNER</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.65pt;padding-right:4.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KR</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-2018-7006115</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5&#47;24&#47;2011</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:4.85pt;padding-right:4.85pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10-1878252</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7&#47;9&#47;2018</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.4pt;padding-right:10.4pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase</font></div><div style="padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Activator</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.25pt;padding-left:12.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:5.02pt;padding-right:5.02pt;text-align:center;text-indent:-0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">vTv Therapeutics LLC</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.197%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 1&#93;</font></div></td></tr></table></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_46"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 2</font></div><div><font><br></font></div><div style="text-align:center;text-indent:5.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Knowledge Individuals</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:44.623%"><div><font><br></font></div><div style="padding-right:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">For Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font></div><div style="padding-right:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Richard Nelson </font></div><div style="padding-right:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carmen Valcarce </font></div><div style="padding-right:30.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jennifer Freeman</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">For Partner&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dr. Fahed Al Marzooqi </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Divyesh Mahajan </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joanne Norman</font></div><div style="margin-top:3.95pt;padding-left:93.22pt;padding-right:93.22pt;text-align:center"><font><br></font></div><div style="padding-left:93.22pt;padding-right:93.22pt;text-align:center"><font><br></font></div></div><div style="display:inline-block;max-width:10.753%;min-width:9.753%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:44.624%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.541%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 2&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:44.623%"><div><font><br></font></div></div><div style="display:inline-block;max-width:10.753%;min-width:9.753%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:44.624%"></div></div><div style="margin-top:3.95pt;padding-left:112.45pt;padding-right:112.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:112.42pt;padding-right:112.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Partner Territory</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cyprus, Lebanon, Syria, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Iran, Iraq, Oman, Yemen, Nigeria, Ethiopia, Egypt, Democratic Republic of the Congo, Tanzania, South Africa, Kenya, Uganda, Algeria, Sudan, Morocco, Angola, Mozambique, Ghana, Madagascar, Cameroon, Cote d&#8217;Ivoire, Niger, Burkina Faso, Mali, Malawi, Zambia, Senegal, Chad, Somalia, Zimbabwe, Guinea, Rwanda, Benin, Burundi, Tunisia, South Sudan, Togo, Sierra Leone, Libya, Congo, Liberia, Central African Republic, Mauritania, Eritrea, Namibia, Gambia, Botswana, Gabon, Lesotho, Guinea-Bissau, Equatorial Guinea, Mauritius, Eswatini, Djibouti, Comoros, Cabo Verde, Sao Tome &#38; Principe, Seychelles, Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Afghanistan, Ukraine, Uzbekistan, India, Pakistan, Turkey, Malaysia and Indonesia</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.541%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 3&#93;</font></div></td></tr></table></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_49"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:112.45pt;padding-right:112.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:112.45pt;padding-right:112.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Transfer of Responsibilities</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:112.45pt;padding-right:112.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Responsibilities for Partner-Conducted Clinical Trial</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.172%"><tr><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td></tr><tr style="height:28pt"><td colspan="3" rowspan="2" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:137.4pt;padding-right:137.4pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TASK</font></div></td><td colspan="3" rowspan="2" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.75pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font></div></td><td colspan="3" rowspan="2" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner</font></div></td></tr><tr style="height:36pt"><td colspan="3" style="background-color:#000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PROTOCOL</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">Preparing drafts and final versions of the Collaboration Protocol (subject to JDC approval)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Distributing copies of the Collaboration Protocol to the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Preparing drafts and final versions of country-specific appendices (subject to JDC approval)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preparing translations of the Collaboration Protocol and distributing copies of such translations to the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preparing drafts and final versions of amendments to the Collaboration Protocols (subject to JDC approval)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Distributing copies of the amendments&#47;country-specific appendices of the Collaboration Protocol</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tracking Partner Site acceptance and approval of the Collaboration Protocol, any amendments thereto and country-specific appendices thereof</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Obtaining ethics committees&#8217;, including IRBs, approval of Collaboration Protocol &#47; amendments</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DATA CAPTURES</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initial CRF Draft Preparation</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 24.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provisions of the CRF to the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 24.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Technical support for eCRFs</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 24.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical Trial Master File creation and maintenance</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 24.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">Clinical Trial Database creation and maintenance, including obtaining and inputting data from Clinical Investigators</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provide SAS datasets to Company to the defined specifications (1) when fifty percent (50%) of subjects have been dosed for six (6) months </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(where the Collaboration Protocol provides for interim analysis)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; (2) when the data in the Clinical Trials Database is equivalent to one hundred percent (100%) of total data expected to</font></div><div style="padding-left:5.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">be recorded in the Clinical Trials Database&#59; (3) if a safety signal is</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.45pt;padding-left:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.541%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 4&#93;</font></div></td></tr></table></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_52"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.172%"><tr><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.6pt;padding-left:137.4pt;padding-right:137.4pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TASK</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:7.95pt;padding-right:7.95pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.12pt;padding-right:8.12pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">identified&#59; or (4) if a request is received from any applicable Regulatory Authorities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SUBJECTS</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preparing (subject to JDC approval), implementing and complying with the Subject Recruitment Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Preparing the form of Informed Consent documents (and any amendments thereto) for use in the Collaboration Clinical Trial</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preparing translation of the form of Informed Consent, including authorization to share private information with Company consistent with all Applicable Laws</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Ensuring that subjects are given proper informed consent and make informed and knowing signatures</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Distribution of the Informed Consent to the Partner Sites&#47;approved CROs</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Obtaining ethics committees&#8217;, including IRBs, approval of the Informed Consent and authorization</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font></td><td colspan="9" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CLINICAL SUPPLY</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Supply and labelling of Finished Product for the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Providing relevant instructions to Company with respect to labelling of Finished Product, in accordance with Applicable Laws</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.1pt;padding-left:5.35pt;padding-right:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Maintain records that document shipment, receipt, disposition, return and destruction of the Finished Product supplied for the Clinical Trial</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assure the return&#47;destruction of all unused Finished Product from Partner Sites and maintain records of such returns&#47;destruction</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PHARMACOVIGILANCE</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compliance with the Pharmacovigilance Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ETHICS ACTIVITIES</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ensure that a copy of, and updates to, the Investigator&#8217;s Brochure are promptly provided to the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:5.35pt;padding-right:4.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tracking proof of submission of safety reports to the Regulatory Authorities, ethics committees, including IRBs, and Clinical Investigators, in accordance with Applicable Laws</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">Ensuring that ethics committees, including IRBs, have all necessary qualifications and remain in good standing throughout the Clinical Trial</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Responding to queries from ethics committees, including IRBs,</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.541%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 4&#93;</font></div></td></tr></table></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_55"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.172%"><tr><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.6pt;padding-left:137.4pt;padding-right:137.4pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TASK</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.75pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.12pt;padding-right:8.12pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Complying with Applicable Laws relating to disclosure and approval from ethics committees, including IRBs</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Paying any fees associated with ethics committees, including IRBs,</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Establishing and maintaining material and specimen handling guidelines</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:0.2pt;padding-right:0.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SELECTION OF INVESTIGATORS</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selection of Clinical Investigators&#47;Partner Sites (subject to JDC approval) and ensuring that such Clinical Investigators and&#47;or Partner Sites are appropriately qualified and eligible to conduct the Clinical Trial under the Collaboration Protocol</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Communication of termination to the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ensuring that the Partner Sites comply with all Applicable Laws (including GCP)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Entering into the Clinical Study Agreement with the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Paying all expenses associated with the Partner-Conducted Clinical Trial and ensuring that such payments are in compliance with Applicable Laws, and Regulatory Authority and ethics committee, including IRBs, requirements</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Obtaining executed Financial Disclosure Forms from the relevant Persons</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Conduct of initiation&#47;opening visit for the Clinical Trial at each Partner Site</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confirming all documentation and approvals are in place for activation of the Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Formally activating a Partner Site</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUDITING AND MONITORING</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Complying with the Monitoring Plan with respect to the Clinical Trial</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Complying with the audit requirement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INVESTIGATOR MEETINGS</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Planning and conducting the Investigator Meetings</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of Investigator Meetings</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DATA MANAGEMENT</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preparing (subject to JDC approval) and complying with the Data Management Plan</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.541%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 4&#93;</font></div></td></tr></table></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_58"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.470%"><tr><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.6pt;padding-left:137.4pt;padding-right:137.4pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TASK</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:7.95pt;padding-right:7.95pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.12pt;padding-right:8.12pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Source verification of data records, as set forth in the Monitoring Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject randomization, per the Collaboration Protocol</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ensuring timely data completion and review</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Updating Clinical Trials Database</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRIAL CLOSEOUT</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decision on appropriate time for closure of each Site subject to and in accordance with the Collaboration Protocol</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Partner Site closure on a timely basis as data is completed and subjects off study</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XII.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SAFETY MONITORING</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Conducting safety monitoring and ensuring all appropriate informed consent documents (and any required updates) are obtained</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XIII.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COMMUNICATION</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Obtaining and managing copies of all correspondence with the Partner Sites and providing such to JDC at the JDC&#8217;s request</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Providing the JDC with pertinent information regarding the Partner- Conducted Clinical Trial as agreed upon by the JDC, including all correspondence with Regulatory Authorities and ethics committees, including IRBs</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XIV.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.3pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STATISTICAL ANALYSIS AND TRIAL REPORT</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Statistical analysis of any data pursuant to the Statistical Analysis Plan and providing such analysis to Company</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.2pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preparation of final report and providing such report to Company</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.2pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XV.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CROs</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selection of CRO (subject to Company&#8217;s approval).</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Enter into the written CRO agreement with the approved CRO</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XVI.</font></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.45pt;padding-left:5.6pt"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">REGULATORY AFFAIRS</font></div></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initial development of Investigator&#8217;s Brochure</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Updates to Investigator&#8217;s Brochure</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compilation of IND and any amendments</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Submission of IND to applicable Regulatory Authorities (to the extent permitted by Applicable Laws) and any amendments</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.541%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 4&#93;</font></div></td></tr></table></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_61"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.172%"><tr><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.6pt;padding-left:137.4pt;padding-right:137.4pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TASK</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:7.95pt;padding-right:7.95pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font></div></td><td colspan="3" style="background-color:#000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.12pt;padding-right:8.12pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Partner</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Submission of Partner Site Information to the Regulatory Authorities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">End of Clinical Trial notice.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CofA, CofC, TSE&#47;BSE Certification, GMP Compliance Statement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.95pt;padding-left:5.35pt;padding-right:4.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Translations of any documents for submission to the Regulatory Authorities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.2pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorization of first CTS shipment to Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.2pt;padding-left:0.17pt;padding-right:0.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.2pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collection of Regulatory Documents from Partner Sites</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.2pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">End of Study Declaration to ethics committees, including IRBs</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.541%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Schedule 4&#93;</font></div></td></tr></table></div></div></div><div id="if3d95cb665db4012bc3df24549a8a91b_64"></div><hr style="page-break-after:always"><div style="min-height:79.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:112.42pt;padding-right:112.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:112.45pt;padding-right:112.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Anti-Corruption Compliance Certification</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to Section 11.1(m) of the Collaboration and License Agreement between vTv Therapeutics LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Cogna Technology Solutions LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) dated May</font></div><div style="padding-left:6pt;padding-right:6.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), I, &#91;Name&#93;, on behalf of &#91;Party&#93;, hereby certify that to my knowledge&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:42pt;padding-right:6.05pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">&#91;Party&#93; has provided a copy of the Compliance Policies and communicated regarding such documents to all persons acting on its behalf in connection with work und this Agreement, including any employees, agents, contractors or subcontractors.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:42pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">With respect to any products, payments or services provided under this Agreement, &#91;Party&#93; has not taken any action directly or indirectly to knowingly (i) offer, promise, provide, or authorize the offer or provision of money or anything of value, in order to improperly or corruptly seek to influence any Government Official or any other Person in order to obtain or retain business or any other improper business advantage&#59; (ii) request or accept any such improper payment&#59; or (iii) cause a violation of any Anti-Corruption Law. For example, this includes knowingly providing any inducement for such Government Official or person to approve, reimburse, prescribe, or purchase a product, to influence the outcome of a clinical trial, or otherwise to benefit Company&#8217;s business activities improperly&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:42pt;padding-right:5.95pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">&#91;Party&#93; has ensured that it and every agent, contractor, or subcontractor performing services in connection with the Agreement has agreed to comply with and be bound by the provisions of the Agreement that address compliance with Anti-Corruption Laws&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt">&#91;Party&#93; has met all relevant disclosure obligations required under the Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:42pt;padding-right:6pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">&#91;Party&#93; has informed &#91;Other Party&#93; in good faith of any significant changes in information provided during pre-contractual due diligence&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:42pt;padding-right:6.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">To the extent required by the Agreement, &#91;Party&#93; has provided training on its policies and Anti-Corruption Laws to its officers, directors, employees, and appropriate third parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:42pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Capitalized terms used but not defined herein shall have the meaning assigned to such term in the Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:204.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">COMPANY NAME&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%"> NAME&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:6pt;padding-right:263.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">TITLE&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%"> DATE&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:112.4pt;padding-right:112.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Exhibit A&#93;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>vtvt-20220630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i39204efd707c4f559677dae1efd0cf03_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Sekhri, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;15, 2022</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>vtvt-20220630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id065cd247d8c48db8024376c74a962f0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Barry Brown, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;15, 2022</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Barry Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Barry Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Accounting Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>vtvt-20220630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i73e769fc1cf64504bf62fadd7bbc0745_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Paul J. Sekhri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;15, 2022</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>vtvt-20220630xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i77b39a13e507455b9aefba47661791a3_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Barry Brown, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;15, 2022</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Barry Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barry Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vtvt-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cc23dfa8-b7f1-4dd2-bc21-5440216f3885,g:7d227720-4a1d-461e-9922-f5c0b011aa4f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtvt="http://vtvtherapeutics.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vtvtherapeutics.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://vtvtherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessBasisofPresentationandGoingConcern" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern">
        <link:definition>2101101 - Disclosure - Description of Business, Basis of Presentation and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessBasisofPresentationandGoingConcernDetail" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail">
        <link:definition>2402401 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements">
        <link:definition>2106103 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsTables">
        <link:definition>2307301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail">
        <link:definition>2408403 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail">
        <link:definition>2409404 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails">
        <link:definition>2410405 - Disclosure - Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation">
        <link:definition>2111104 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>2312302 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail">
        <link:definition>2413406 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail">
        <link:definition>2414407 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail">
        <link:definition>2415408 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://vtvtherapeutics.com/role/Investments">
        <link:definition>2116105 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://vtvtherapeutics.com/role/InvestmentsTables">
        <link:definition>2317303 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail">
        <link:definition>2418409 - Disclosure - Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" roleURI="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail">
        <link:definition>2419410 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2421411 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://vtvtherapeutics.com/role/Leases">
        <link:definition>2122107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://vtvtherapeutics.com/role/LeasesTables">
        <link:definition>2323304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://vtvtherapeutics.com/role/LeasesDetails">
        <link:definition>2424412 - Disclosure - Leases - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail">
        <link:definition>2425413 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1">
        <link:definition>2425413 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterest" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest">
        <link:definition>2126108 - Disclosure - Redeemable Noncontrolling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestTables" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables">
        <link:definition>2327305 - Disclosure - Redeemable Noncontrolling Interest (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail">
        <link:definition>2428414 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail">
        <link:definition>2429415 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://vtvtherapeutics.com/role/StockholdersDeficit">
        <link:definition>2130109 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail">
        <link:definition>2431416 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>2132110 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>2433417 - Disclosure - Related-Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://vtvtherapeutics.com/role/IncomeTaxes">
        <link:definition>2134111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2435418 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://vtvtherapeutics.com/role/NetLossperShare">
        <link:definition>2136112 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://vtvtherapeutics.com/role/NetLossperShareTables">
        <link:definition>2337306 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail">
        <link:definition>2438419 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail">
        <link:definition>2439420 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments">
        <link:definition>2140113 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2341307 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail">
        <link:definition>2442421 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
        <link:definition>2443422 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail">
        <link:definition>2444423 - Disclosure - Fair Value of Financial Instruments - Significant Inputs Utilized in the Valuation of Letter Agreement Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vtvtherapeutics.com/role/SubsequentEvents">
        <link:definition>2145114 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://vtvtherapeutics.com/role/SubsequentEventsDetails">
        <link:definition>2446424 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareLineItems" abstract="true" name="ScheduleOfEarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PercentageOfAmountOfCashSavings" abstract="false" name="PercentageOfAmountOfCashSavings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_PhaseTwoMultiRegionalClinicalTrialMember" abstract="true" name="PhaseTwoMultiRegionalClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" abstract="false" name="CollaborativeArrangementNoteReceivableDiscountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_IssuanceOfClassACommonStockUnderATMOffering" abstract="false" name="IssuanceOfClassACommonStockUnderATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_ChangeInFairValueOfWarrantsRelatedParty" abstract="false" name="ChangeInFairValueOfWarrantsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" abstract="false" name="CollaborativeArrangementRoyaltiesReceivablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_PercentageOfNonVotingEconomicInterestByParent" abstract="false" name="PercentageOfNonVotingEconomicInterestByParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_AggregateOfferingPriceOfShares" abstract="false" name="AggregateOfferingPriceOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_MaximumSponsoringContributionAmount" abstract="false" name="MaximumSponsoringContributionAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_OperatingLeasesImputedInterest" abstract="false" name="OperatingLeasesImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue" abstract="false" name="IssuanceOfClassACommonStockUnderATMOfferingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_G42InvestmentsMember" abstract="true" name="G42InvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_NewsoaraBiopharmaCoLtdMember" abstract="true" name="NewsoaraBiopharmaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" abstract="true" name="FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_TemporaryEquityChangeInRedemptionValue" abstract="false" name="TemporaryEquityChangeInRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" abstract="false" name="RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" abstract="false" name="EquityInvestmentsWithReadilyDeterminableFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CommonStockAndPreferredStockSharesAuthorized" abstract="false" name="CommonStockAndPreferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" abstract="false" name="MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" abstract="false" name="ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" abstract="false" name="PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" abstract="true" name="DevelopmentalAndRegulatoryMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" abstract="false" name="RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vtvt_SalesBasedMilestonesPaymentMember" abstract="true" name="SalesBasedMilestonesPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_RedeemableNoncontrollingInterestsMember" abstract="true" name="RedeemableNoncontrollingInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_SatisfactionOfMilestonePaymentMember" abstract="true" name="SatisfactionOfMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage" abstract="false" name="CollaborativeArrangementRoyaltiesReceivablePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_ProceedsFromSaleOfCommonStock" abstract="false" name="ProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_AnterisBioIncMember" abstract="true" name="AnterisBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" abstract="true" name="LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract" abstract="true" name="CommitmentContingencyAndRelatedPartyTransactionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_TypeTwoDiabetesMember" abstract="true" name="TypeTwoDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" abstract="true" name="HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_IncreaseInCommonStockSharesAuthorized" abstract="false" name="IncreaseInCommonStockSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivablePaymentPeriod" abstract="false" name="SaleOfStockConsiderationReceivablePaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" abstract="false" name="AdjustmentsToTransactionPriceForPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_VTvLLCMember" abstract="true" name="VTvLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_StrategicAdvisorMember" abstract="true" name="StrategicAdvisorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PotentialMilestonePayment" abstract="false" name="PotentialMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LetterAgreementWarrantsMember" abstract="true" name="LetterAgreementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_InvestmentOwnershipPercentage" abstract="false" name="InvestmentOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_WarrantLiabilityRelatedPartyMember" abstract="true" name="WarrantLiabilityRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_LicenseAgreementObligationsAxis" abstract="true" name="LicenseAgreementObligationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_OtherIndicationMember" abstract="true" name="OtherIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CollaborateArrangementContingentConsiderationTransferredCash" abstract="false" name="CollaborateArrangementContingentConsiderationTransferredCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" abstract="false" name="ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtvt_NotesReceivableCurrent" abstract="false" name="NotesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_PublicFloat" abstract="false" name="PublicFloat" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivablesPaymentTerm" abstract="false" name="SaleOfStockConsiderationReceivablesPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_OneCustomerMember" abstract="true" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" abstract="false" name="RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" abstract="false" name="MaximumFundingPercentageOfResearchAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_LPCPurchaseAgreementMember" abstract="true" name="LPCPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_LicenseFeeReceived" abstract="false" name="LicenseFeeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" abstract="true" name="ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" abstract="true" name="G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_OtherIncomeExpensesRelatedParty" abstract="false" name="OtherIncomeExpensesRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_TypeOneDiabetesMember" abstract="true" name="TypeOneDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_PercentageOfNonVotingEconomicInterest" abstract="false" name="PercentageOfNonVotingEconomicInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod" abstract="false" name="CollaborativeArrangementTechnologyTransferServicesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_JDRFInternationalMember" abstract="true" name="JDRFInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_NovoLicenseAgreementMember" abstract="true" name="NovoLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_MacAndrewsAndForbesIncorporatedMember" abstract="true" name="MacAndrewsAndForbesIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CantorFitzgeraldMember" abstract="true" name="CantorFitzgeraldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_OwnershipPercentageOfMajorityOwner" abstract="false" name="OwnershipPercentageOfMajorityOwner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_LesseeOperatingLeaseTerminationPeriod" abstract="false" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" abstract="false" name="CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LicenseAgreementObligationsDomain" abstract="true" name="LicenseAgreementObligationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" abstract="true" name="VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_LicenseAndTechnologyTransferServicesMember" abstract="true" name="LicenseAndTechnologyTransferServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareTable" abstract="true" name="ScheduleOfEarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_G2InvestmentMember" abstract="true" name="G2InvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" abstract="false" name="EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" abstract="false" name="StockIssuedDuringPeriodSharesPurchaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" abstract="false" name="StockIssuedDuringPeriodValuePurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_FundingReceived" abstract="false" name="FundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" abstract="true" name="FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_MFTTPHoldingsLLCMember" abstract="true" name="MFTTPHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CognaMember" abstract="true" name="CognaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_ReneoPharmaceuticalsIncMember" abstract="true" name="ReneoPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vtvt-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cc23dfa8-b7f1-4dd2-bc21-5440216f3885,g:7d227720-4a1d-461e-9922-f5c0b011aa4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b571e54a-5960-4b9b-b626-8eddb104264b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e172a46b-0d58-402c-9c94-acfc4a6f4d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b571e54a-5960-4b9b-b626-8eddb104264b" xlink:to="loc_us-gaap_AssetsCurrent_e172a46b-0d58-402c-9c94-acfc4a6f4d26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_587cb782-115a-4f6d-a900-7d82ee0c4841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b571e54a-5960-4b9b-b626-8eddb104264b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_587cb782-115a-4f6d-a900-7d82ee0c4841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8ceaa69-242e-4ded-90ee-9aa6a127dcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b571e54a-5960-4b9b-b626-8eddb104264b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8ceaa69-242e-4ded-90ee-9aa6a127dcfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d7e834b3-f25e-4396-98d6-6f12420599f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b571e54a-5960-4b9b-b626-8eddb104264b" xlink:to="loc_us-gaap_LongTermInvestments_d7e834b3-f25e-4396-98d6-6f12420599f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2308cde-12ad-4f31-bf4c-64ec6449917e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_de54cbc7-49f7-43b7-ab3a-cb9a4ff1f058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2308cde-12ad-4f31-bf4c-64ec6449917e" xlink:to="loc_us-gaap_Liabilities_de54cbc7-49f7-43b7-ab3a-cb9a4ff1f058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d1da28d8-1661-4363-b13f-06444f7ab501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2308cde-12ad-4f31-bf4c-64ec6449917e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d1da28d8-1661-4363-b13f-06444f7ab501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_21f0b321-b477-43e0-bf6e-d19da05e8b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2308cde-12ad-4f31-bf4c-64ec6449917e" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_21f0b321-b477-43e0-bf6e-d19da05e8b0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_751fa529-e393-4f97-9a1d-507a4fef7bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2308cde-12ad-4f31-bf4c-64ec6449917e" xlink:to="loc_us-gaap_StockholdersEquity_751fa529-e393-4f97-9a1d-507a4fef7bd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9520f0be-0385-4278-aa50-600ecfee8a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c085f7bd-76e9-4779-8bed-720e0ae5d187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9520f0be-0385-4278-aa50-600ecfee8a3b" xlink:to="loc_us-gaap_CommonStockValue_c085f7bd-76e9-4779-8bed-720e0ae5d187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0218e964-2cbf-4f86-9d54-61be6ad5fd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9520f0be-0385-4278-aa50-600ecfee8a3b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0218e964-2cbf-4f86-9d54-61be6ad5fd38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a6f8d34-72ab-44ae-86da-38ea6511d3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9520f0be-0385-4278-aa50-600ecfee8a3b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a6f8d34-72ab-44ae-86da-38ea6511d3f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c871288-ea98-4496-aeac-a582dcbd46e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1768ac80-6ba4-4285-bc6e-5be9100fdb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c871288-ea98-4496-aeac-a582dcbd46e0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1768ac80-6ba4-4285-bc6e-5be9100fdb1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a325ac04-a889-435f-8052-c23a81087b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c871288-ea98-4496-aeac-a582dcbd46e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a325ac04-a889-435f-8052-c23a81087b01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8aafbf85-8015-40f0-b817-072d4acbc9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c871288-ea98-4496-aeac-a582dcbd46e0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8aafbf85-8015-40f0-b817-072d4acbc9a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_5ae736f6-3a30-4ca8-8b52-433c6778902e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c871288-ea98-4496-aeac-a582dcbd46e0" xlink:to="loc_us-gaap_NotesPayableCurrent_5ae736f6-3a30-4ca8-8b52-433c6778902e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4955dc94-1ba6-4a13-96c2-abedba96cf60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_47732ef3-cbe9-4dbd-9157-af3e20fd6891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4955dc94-1ba6-4a13-96c2-abedba96cf60" xlink:to="loc_us-gaap_DepositsAssetsCurrent_47732ef3-cbe9-4dbd-9157-af3e20fd6891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf29c040-6bae-4fbf-b1b8-b0df9b0ff645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4955dc94-1ba6-4a13-96c2-abedba96cf60" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf29c040-6bae-4fbf-b1b8-b0df9b0ff645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0e35a84-bca0-4e20-9836-49fa30658c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4955dc94-1ba6-4a13-96c2-abedba96cf60" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0e35a84-bca0-4e20-9836-49fa30658c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5248571e-cd3c-41fe-9fd2-9e930645516e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4955dc94-1ba6-4a13-96c2-abedba96cf60" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5248571e-cd3c-41fe-9fd2-9e930645516e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent_57939cca-5982-4ab1-b435-6995dae440c2" xlink:href="vtvt-20220630.xsd#vtvt_NotesReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4955dc94-1ba6-4a13-96c2-abedba96cf60" xlink:to="loc_vtvt_NotesReceivableCurrent_57939cca-5982-4ab1-b435-6995dae440c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d727efcf-ba73-4078-acdc-0ede494cf533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_ea14b499-71f5-4fad-a0e6-cee9853e6346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d727efcf-ba73-4078-acdc-0ede494cf533" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_ea14b499-71f5-4fad-a0e6-cee9853e6346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73d9e3a9-5e26-4dce-a05c-d399304d1bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d727efcf-ba73-4078-acdc-0ede494cf533" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73d9e3a9-5e26-4dce-a05c-d399304d1bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f0f10853-3443-4d99-9abb-825fb9480af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d727efcf-ba73-4078-acdc-0ede494cf533" xlink:to="loc_us-gaap_LiabilitiesCurrent_f0f10853-3443-4d99-9abb-825fb9480af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_dd883656-2775-49ff-aaf7-398a9d874c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d727efcf-ba73-4078-acdc-0ede494cf533" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_dd883656-2775-49ff-aaf7-398a9d874c9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fa783e40-5aa7-4bbe-937d-865cbad73f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e7f92fd8-bacf-4b97-812c-54471727d269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_fa783e40-5aa7-4bbe-937d-865cbad73f2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e7f92fd8-bacf-4b97-812c-54471727d269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e712335f-a866-4960-ae06-a437ae63bd99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_fa783e40-5aa7-4bbe-937d-865cbad73f2b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e712335f-a866-4960-ae06-a437ae63bd99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aa350a69-c040-4867-a290-46343a600dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c892e063-d7b4-467b-81fd-1141093ca7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aa350a69-c040-4867-a290-46343a600dfc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c892e063-d7b4-467b-81fd-1141093ca7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a2de4c40-6db6-432d-b091-dc482d8241b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aa350a69-c040-4867-a290-46343a600dfc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a2de4c40-6db6-432d-b091-dc482d8241b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6a253-aec7-4632-8848-7e786cbbb4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e38b1c29-4350-4e1a-9544-4ed85367c737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6a253-aec7-4632-8848-7e786cbbb4f2" xlink:to="loc_us-gaap_OperatingIncomeLoss_e38b1c29-4350-4e1a-9544-4ed85367c737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIncomeExpensesRelatedParty_56eea02f-a332-4dc0-bf9f-ae35344fcf71" xlink:href="vtvt-20220630.xsd#vtvt_OtherIncomeExpensesRelatedParty"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6a253-aec7-4632-8848-7e786cbbb4f2" xlink:to="loc_vtvt_OtherIncomeExpensesRelatedParty_56eea02f-a332-4dc0-bf9f-ae35344fcf71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_81cc365a-b761-498e-b227-62c6b413b08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6a253-aec7-4632-8848-7e786cbbb4f2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_81cc365a-b761-498e-b227-62c6b413b08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_16b0c41e-358b-4566-af56-5bfd69cd6d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6a253-aec7-4632-8848-7e786cbbb4f2" xlink:to="loc_us-gaap_InterestExpense_16b0c41e-358b-4566-af56-5bfd69cd6d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9981464f-04de-4702-b5c9-af736022c24f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6a253-aec7-4632-8848-7e786cbbb4f2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9981464f-04de-4702-b5c9-af736022c24f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae04b35d-e3c7-4f57-95a2-d7e2c0d371fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3b9148f4-1b35-4e04-bdf9-5bbbf4d2f6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ae04b35d-e3c7-4f57-95a2-d7e2c0d371fb" xlink:to="loc_us-gaap_ProfitLoss_3b9148f4-1b35-4e04-bdf9-5bbbf4d2f6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2b06167d-deb4-46f1-946b-719378b29487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ae04b35d-e3c7-4f57-95a2-d7e2c0d371fb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2b06167d-deb4-46f1-946b-719378b29487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_503e15eb-b4ac-40fc-a559-5d1924bf4059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2fe245d-4ae5-4f2a-9805-c638f9b821a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_503e15eb-b4ac-40fc-a559-5d1924bf4059" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2fe245d-4ae5-4f2a-9805-c638f9b821a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_eda36320-ba9e-4c14-aa01-ddba87b60714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_503e15eb-b4ac-40fc-a559-5d1924bf4059" xlink:to="loc_us-gaap_OperatingExpenses_eda36320-ba9e-4c14-aa01-ddba87b60714" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de2dcffa-9298-49a2-8415-193d881249cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2f5f3cd4-3404-4686-96b1-553064a09e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de2dcffa-9298-49a2-8415-193d881249cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2f5f3cd4-3404-4686-96b1-553064a09e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c95235e-64ef-4bec-a2d1-13097ef327c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de2dcffa-9298-49a2-8415-193d881249cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c95235e-64ef-4bec-a2d1-13097ef327c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_459324be-b68f-4e32-af3a-55b9e2b57635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de2dcffa-9298-49a2-8415-193d881249cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_459324be-b68f-4e32-af3a-55b9e2b57635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4078eca3-fde6-4937-98e7-393e658afb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53d05e38-1147-4772-82c1-befc786e9fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4078eca3-fde6-4937-98e7-393e658afb19" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53d05e38-1147-4772-82c1-befc786e9fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_163760bb-8d6c-4898-8b57-b8b9b97b3903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4078eca3-fde6-4937-98e7-393e658afb19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_163760bb-8d6c-4898-8b57-b8b9b97b3903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_83d24680-cf13-4d25-9d74-16f3c7c2ec34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4078eca3-fde6-4937-98e7-393e658afb19" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_83d24680-cf13-4d25-9d74-16f3c7c2ec34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ProceedsFromSaleOfCommonStock_d4951002-8da9-4534-87b9-f42f340809ae" xlink:href="vtvt-20220630.xsd#vtvt_ProceedsFromSaleOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4078eca3-fde6-4937-98e7-393e658afb19" xlink:to="loc_vtvt_ProceedsFromSaleOfCommonStock_d4951002-8da9-4534-87b9-f42f340809ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_7f5cdb7b-b80e-4bca-a50f-045405e320b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_7f5cdb7b-b80e-4bca-a50f-045405e320b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_accd1a42-4733-43c9-95d7-ce2c09acf78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_ShareBasedCompensation_accd1a42-4733-43c9-95d7-ce2c09acf78c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_477f7f5b-9714-49b7-bc56-dcfe5c4b7519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_InterestIncomeOperating_477f7f5b-9714-49b7-bc56-dcfe5c4b7519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c77a8861-732e-498c-a206-31348d7fb172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_ProfitLoss_c77a8861-732e-498c-a206-31348d7fb172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e543b417-c754-4a0b-ae33-02a946ce41b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e543b417-c754-4a0b-ae33-02a946ce41b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_406296ba-3e48-4aeb-a4fc-bba948536b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_Depreciation_406296ba-3e48-4aeb-a4fc-bba948536b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ae6c59a6-6fd6-4a6f-8f90-528310ef44f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ae6c59a6-6fd6-4a6f-8f90-528310ef44f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_90f1c657-8ae8-41a3-bcef-d9aa6646fe15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_90f1c657-8ae8-41a3-bcef-d9aa6646fe15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_95c94d3b-bff2-44f0-8990-bd3bba07cbed" xlink:href="vtvt-20220630.xsd#vtvt_ChangeInFairValueOfWarrantsRelatedParty"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_95c94d3b-bff2-44f0-8990-bd3bba07cbed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_44a90e59-7517-4e0f-99c2-f3a002a58bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2024bbaa-4dc2-445a-91c6-a26a8c8de5c0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_44a90e59-7517-4e0f-99c2-f3a002a58bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09b2cd27-ea11-4c14-aa3a-ce62650fc21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_df9fe5e9-17f6-4705-986f-ea43cbacce0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09b2cd27-ea11-4c14-aa3a-ce62650fc21d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_df9fe5e9-17f6-4705-986f-ea43cbacce0d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0987514-7411-474e-a543-413509b60673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8f67506d-1977-4449-9ec6-6be6bcf6700d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0987514-7411-474e-a543-413509b60673" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8f67506d-1977-4449-9ec6-6be6bcf6700d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a5999d79-f56b-4f53-bd9c-e7b9be7c5c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0987514-7411-474e-a543-413509b60673" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a5999d79-f56b-4f53-bd9c-e7b9be7c5c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4f819c7d-ccc6-4381-bc78-9d16933e6c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0987514-7411-474e-a543-413509b60673" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4f819c7d-ccc6-4381-bc78-9d16933e6c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8153366a-dcd6-4583-82e6-00c10acd0c48" xlink:href="vtvt-20220630.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0987514-7411-474e-a543-413509b60673" xlink:to="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8153366a-dcd6-4583-82e6-00c10acd0c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5fc4348b-8234-45d9-9aca-6d55e037f9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0987514-7411-474e-a543-413509b60673" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5fc4348b-8234-45d9-9aca-6d55e037f9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1021880d-5cb0-4ee1-8da8-552bbbc6cb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0987514-7411-474e-a543-413509b60673" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1021880d-5cb0-4ee1-8da8-552bbbc6cb1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="simple" xlink:href="vtvt-20220630.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98959051-81d2-4c88-be56-5c20657291fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0b2f4786-f8b8-4012-9a8a-5f225efd6c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98959051-81d2-4c88-be56-5c20657291fa" xlink:to="loc_us-gaap_OperatingLeaseLiability_0b2f4786-f8b8-4012-9a8a-5f225efd6c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest_63f37b14-a3e2-4952-924c-37ceb8fe20af" xlink:href="vtvt-20220630.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98959051-81d2-4c88-be56-5c20657291fa" xlink:to="loc_vtvt_OperatingLeasesImputedInterest_63f37b14-a3e2-4952-924c-37ceb8fe20af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_48bbde87-3efc-4a38-b4af-6615ee6da281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6f7c190b-74f4-42ea-8c5c-6a91b1eb392d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_48bbde87-3efc-4a38-b4af-6615ee6da281" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6f7c190b-74f4-42ea-8c5c-6a91b1eb392d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_a2181e66-c730-4682-9b0a-725047e62852" xlink:href="vtvt-20220630.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_48bbde87-3efc-4a38-b4af-6615ee6da281" xlink:to="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_a2181e66-c730-4682-9b0a-725047e62852" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_aca75f8d-9109-418a-9be7-02e35a2de416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4043128a-8c66-4a89-9900-f2d80f6e83b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_aca75f8d-9109-418a-9be7-02e35a2de416" xlink:to="loc_us-gaap_ProfitLoss_4043128a-8c66-4a89-9900-f2d80f6e83b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f087dc21-7146-44d9-95ad-8e1db478a4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_aca75f8d-9109-418a-9be7-02e35a2de416" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f087dc21-7146-44d9-95ad-8e1db478a4c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d4c8bf0a-ba0d-4794-8f49-4bd4461f7f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_59f12c50-a3b3-4efb-af13-4c127b729c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d4c8bf0a-ba0d-4794-8f49-4bd4461f7f7c" xlink:to="loc_us-gaap_ProfitLoss_59f12c50-a3b3-4efb-af13-4c127b729c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16368eda-116e-4919-8a69-9b9f6c45290e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d4c8bf0a-ba0d-4794-8f49-4bd4461f7f7c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16368eda-116e-4919-8a69-9b9f6c45290e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7d128691-5f16-43eb-b9f5-1264d5224791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_efcc880e-a9d6-4f17-9785-24539f2ed966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7d128691-5f16-43eb-b9f5-1264d5224791" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_efcc880e-a9d6-4f17-9785-24539f2ed966" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vtvt-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cc23dfa8-b7f1-4dd2-bc21-5440216f3885,g:7d227720-4a1d-461e-9922-f5c0b011aa4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20220630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended" id="i9673325932f04857ac6fa8634cbeec89_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4e20ab18-4278-4982-bdc1-fac20d512ee3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentType_4e20ab18-4278-4982-bdc1-fac20d512ee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8232ac77-c42b-441b-afc7-646ac8445473" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentQuarterlyReport_8232ac77-c42b-441b-afc7-646ac8445473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bd2f89c3-4fda-4b1e-b0d6-50b9cd2ca3ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentPeriodEndDate_bd2f89c3-4fda-4b1e-b0d6-50b9cd2ca3ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0b78e376-cc55-42c9-a568-74ea79ec72e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentTransitionReport_0b78e376-cc55-42c9-a568-74ea79ec72e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fb578304-21d4-4a4f-be74-8f43b4b49f09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityFileNumber_fb578304-21d4-4a4f-be74-8f43b4b49f09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d08856f5-a3ec-49d1-aa4b-7a17debc9ff7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityRegistrantName_d08856f5-a3ec-49d1-aa4b-7a17debc9ff7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_52b6ec30-d3f2-4498-bac0-c803a4064369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityIncorporationStateCountryCode_52b6ec30-d3f2-4498-bac0-c803a4064369" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_96aed983-8256-42b8-8566-4ee9706b0bf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityTaxIdentificationNumber_96aed983-8256-42b8-8566-4ee9706b0bf7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_76884ef0-bb21-490e-869d-b12c99e9939c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressAddressLine1_76884ef0-bb21-490e-869d-b12c99e9939c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8a1b781d-f357-4a21-8c68-d6ac3ec63aec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressAddressLine2_8a1b781d-f357-4a21-8c68-d6ac3ec63aec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0074c0f7-d888-4abc-9429-a9686a7f37de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressCityOrTown_0074c0f7-d888-4abc-9429-a9686a7f37de" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7c769f5e-78d5-4eab-8687-2140749dd9de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressStateOrProvince_7c769f5e-78d5-4eab-8687-2140749dd9de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d6b81078-c70e-4563-a688-e39869c54424" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressPostalZipCode_d6b81078-c70e-4563-a688-e39869c54424" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d5b85ef1-ad92-425d-80ec-e9a558696fd5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_CityAreaCode_d5b85ef1-ad92-425d-80ec-e9a558696fd5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_81903d33-fdab-439e-b614-40db6a5b053f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_LocalPhoneNumber_81903d33-fdab-439e-b614-40db6a5b053f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cda7b855-cb67-4f7c-a750-317327badce6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_Security12bTitle_cda7b855-cb67-4f7c-a750-317327badce6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_242dfe2e-216a-463a-8f7e-ea515525b081" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_TradingSymbol_242dfe2e-216a-463a-8f7e-ea515525b081" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_98967ec6-da87-4d9e-b52f-c9e6df6b0ed9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_SecurityExchangeName_98967ec6-da87-4d9e-b52f-c9e6df6b0ed9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ca77e674-0f44-4e78-bde7-abaec7ffcb0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityCurrentReportingStatus_ca77e674-0f44-4e78-bde7-abaec7ffcb0b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_42d6809f-1d81-49cf-bd1f-dd1a3da4c7ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityInteractiveDataCurrent_42d6809f-1d81-49cf-bd1f-dd1a3da4c7ad" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bff164a9-181f-4fe5-b11d-bb0551b34962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityFilerCategory_bff164a9-181f-4fe5-b11d-bb0551b34962" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_73ba8a35-c5f8-469f-830d-2d548de1b206" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntitySmallBusiness_73ba8a35-c5f8-469f-830d-2d548de1b206" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_abe90b82-bdbf-41d2-a6a8-11c1cdfca3fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityEmergingGrowthCompany_abe90b82-bdbf-41d2-a6a8-11c1cdfca3fa" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b9a742b1-d359-4f77-9f47-16d3d676e0c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityShellCompany_b9a742b1-d359-4f77-9f47-16d3d676e0c1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6f2f14fe-881c-4444-bea3-8c8edb0381a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6f2f14fe-881c-4444-bea3-8c8edb0381a6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ac3bf5f8-646e-4861-b297-b29c6d73bd79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityCentralIndexKey_ac3bf5f8-646e-4861-b297-b29c6d73bd79" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c7597602-1946-40c6-b29e-9fdf77da68c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_CurrentFiscalYearEndDate_c7597602-1946-40c6-b29e-9fdf77da68c0" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4ffdc1b2-7d11-4d25-9153-c984bad2a44c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentFiscalYearFocus_4ffdc1b2-7d11-4d25-9153-c984bad2a44c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d313d770-dfb2-4f06-b30e-f47a87a87be0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d313d770-dfb2-4f06-b30e-f47a87a87be0" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9d306df2-f2d8-4555-a2ee-69a72286420f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_AmendmentFlag_9d306df2-f2d8-4555-a2ee-69a72286420f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_d70b2040-775d-4acf-9f8b-4a0e6711cf8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentInformationTable_d70b2040-775d-4acf-9f8b-4a0e6711cf8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb5d4813-b9e8-4407-bfdc-31ec2d455a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_d70b2040-775d-4acf-9f8b-4a0e6711cf8e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb5d4813-b9e8-4407-bfdc-31ec2d455a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bb5d4813-b9e8-4407-bfdc-31ec2d455a76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb5d4813-b9e8-4407-bfdc-31ec2d455a76" xlink:to="loc_us-gaap_ClassOfStockDomain_bb5d4813-b9e8-4407-bfdc-31ec2d455a76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb5d4813-b9e8-4407-bfdc-31ec2d455a76" xlink:to="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3414846c-f9b2-45ef-8c49-735fbbd4ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:to="loc_us-gaap_CommonClassAMember_3414846c-f9b2-45ef-8c49-735fbbd4ed86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_515a3840-018b-4e05-9ad2-4c4321a4d3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:to="loc_us-gaap_CommonClassBMember_515a3840-018b-4e05-9ad2-4c4321a4d3c8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i5ee1fd17dea8406eb0bdb3af6e4f0f12_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:to="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14fc2c84-19d3-4a25-8621-c27a3c81d271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14fc2c84-19d3-4a25-8621-c27a3c81d271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_172e6996-6e26-4796-bbdd-2f4e20f63949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_172e6996-6e26-4796-bbdd-2f4e20f63949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent_0ab3636e-ccaf-4bea-8e42-3886e1e60d0d" xlink:href="vtvt-20220630.xsd#vtvt_NotesReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_vtvt_NotesReceivableCurrent_0ab3636e-ccaf-4bea-8e42-3886e1e60d0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af235a7c-62dd-468f-b83b-ff341b3e93c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af235a7c-62dd-468f-b83b-ff341b3e93c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_47feda78-1c48-4ce6-9092-77b98a36bb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_DepositsAssetsCurrent_47feda78-1c48-4ce6-9092-77b98a36bb64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_34cebba3-0819-4c2a-9325-62c876d7ece3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_AssetsCurrent_34cebba3-0819-4c2a-9325-62c876d7ece3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d9fbd1a2-09dd-485d-85f2-e4131414b269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d9fbd1a2-09dd-485d-85f2-e4131414b269" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5c4c00f-5557-4f11-9405-a7bf443862cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5c4c00f-5557-4f11-9405-a7bf443862cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_e1fa79ca-819e-4eea-a328-453bc939c865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_LongTermInvestments_e1fa79ca-819e-4eea-a328-453bc939c865" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f1d5c0b0-5d52-4ce4-8044-0585f6a8b01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_Assets_f1d5c0b0-5d52-4ce4-8044-0585f6a8b01b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d6532965-2d30-4174-828a-58860fd188e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d6532965-2d30-4174-828a-58860fd188e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_90b9eb41-ec5c-4105-a12a-4a59f7354df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_90b9eb41-ec5c-4105-a12a-4a59f7354df6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eabec723-3b2d-41af-ad3c-3aa137ecfdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eabec723-3b2d-41af-ad3c-3aa137ecfdf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_0c40fe75-5635-498b-a7c8-57deb91aeb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_NotesPayableCurrent_0c40fe75-5635-498b-a7c8-57deb91aeb1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_af235486-712a-4359-940f-882a033ca8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_LiabilitiesCurrent_af235486-712a-4359-940f-882a033ca8e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e4774554-7bb4-4cd3-843c-14fcc9e35a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e4774554-7bb4-4cd3-843c-14fcc9e35a24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4732506a-9d9f-4117-9c78-ae7f1e607e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4732506a-9d9f-4117-9c78-ae7f1e607e98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_380e55ac-7983-448e-a7be-41fe3b9d9f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_380e55ac-7983-448e-a7be-41fe3b9d9f28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8491ae90-f826-4128-a2ba-5e5f3726e165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_Liabilities_8491ae90-f826-4128-a2ba-5e5f3726e165" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8dbccc85-1e45-406b-8ee2-d5dc55fbb833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8dbccc85-1e45-406b-8ee2-d5dc55fbb833" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_757b7654-de93-48d9-aa6b-f2a45bdffbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_757b7654-de93-48d9-aa6b-f2a45bdffbfa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6facb381-21e6-414f-a2e1-20196db3c7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:to="loc_us-gaap_CommonStockValue_6facb381-21e6-414f-a2e1-20196db3c7cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2114c815-3993-46f9-835d-8eb576890d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2114c815-3993-46f9-835d-8eb576890d54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9690faa9-3dcc-4bea-ad11-735bb7473f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9690faa9-3dcc-4bea-ad11-735bb7473f8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c543526-fce0-4793-83f5-7876a8e8b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_StockholdersEquity_4c543526-fce0-4793-83f5-7876a8e8b7c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1c2408-9e03-49a5-9dfa-a4e51e3795ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1c2408-9e03-49a5-9dfa-a4e51e3795ba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3559e17f-f682-4eda-8f47-cb42940b81eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:to="loc_us-gaap_StatementTable_3559e17f-f682-4eda-8f47-cb42940b81eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7869bf40-b6a4-4788-a172-5054adff2a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3559e17f-f682-4eda-8f47-cb42940b81eb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7869bf40-b6a4-4788-a172-5054adff2a5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7869bf40-b6a4-4788-a172-5054adff2a5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7869bf40-b6a4-4788-a172-5054adff2a5c" xlink:to="loc_us-gaap_ClassOfStockDomain_7869bf40-b6a4-4788-a172-5054adff2a5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7869bf40-b6a4-4788-a172-5054adff2a5c" xlink:to="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_54d5c9a9-e8eb-44c7-b42e-a903e68a0c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:to="loc_us-gaap_CommonClassAMember_54d5c9a9-e8eb-44c7-b42e-a903e68a0c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_04639c79-10e6-42fa-b8a5-283066899ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:to="loc_us-gaap_CommonClassBMember_04639c79-10e6-42fa-b8a5-283066899ae3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="if63c18d4a8e0418685cfb9e0b68dcf8e_CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_28399485-e028-4e51-bcec-6f0d590721f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_28399485-e028-4e51-bcec-6f0d590721f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4f8cb49c-e970-4418-9e46-6fb38bbe5f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4f8cb49c-e970-4418-9e46-6fb38bbe5f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_565c110b-afdd-4a88-a173-f896d3b7a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_565c110b-afdd-4a88-a173-f896d3b7a362" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_77301ac8-84c5-4d70-ac51-f0e07850c5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:to="loc_us-gaap_StatementTable_77301ac8-84c5-4d70-ac51-f0e07850c5b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77301ac8-84c5-4d70-ac51-f0e07850c5b2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83" xlink:to="loc_us-gaap_ClassOfStockDomain_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83" xlink:to="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_073a0f12-da46-4204-966d-0d8fe05223d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:to="loc_us-gaap_CommonClassAMember_073a0f12-da46-4204-966d-0d8fe05223d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b3536a87-0a3d-47e9-a1e3-30eb06962f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:to="loc_us-gaap_CommonClassBMember_b3536a87-0a3d-47e9-a1e3-30eb06962f23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended" id="ic476fc6e5a8b493688d770c2c623ca33_CondensedConsolidatedStatementsofOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8a407d7-b3fe-4c72-9888-8b0f0dda12c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8a407d7-b3fe-4c72-9888-8b0f0dda12c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b7d25411-0deb-428d-9553-a26a12f879be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b7d25411-0deb-428d-9553-a26a12f879be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f1a4c044-6c35-4919-99bd-96570f6ce140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f1a4c044-6c35-4919-99bd-96570f6ce140" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e0420687-73a1-4234-9a6a-4a0ffdf2318d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:to="loc_us-gaap_OperatingExpenses_e0420687-73a1-4234-9a6a-4a0ffdf2318d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_90805be8-7057-4cd7-bea5-2b8e667ebd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_OperatingIncomeLoss_90805be8-7057-4cd7-bea5-2b8e667ebd9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f9530602-edf5-446a-b70b-cb2e154b4b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f9530602-edf5-446a-b70b-cb2e154b4b1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIncomeExpensesRelatedParty_ac5b6938-58a8-4a10-b569-6b203b42185c" xlink:href="vtvt-20220630.xsd#vtvt_OtherIncomeExpensesRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_vtvt_OtherIncomeExpensesRelatedParty_ac5b6938-58a8-4a10-b569-6b203b42185c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_40fabf91-22b3-489f-9b1f-005590112470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_40fabf91-22b3-489f-9b1f-005590112470" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2c17dd4d-d344-412f-8402-b537c9ece91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_InterestExpense_2c17dd4d-d344-412f-8402-b537c9ece91d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b74b577-eb80-4b0e-8b67-3c68d6bcfc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b74b577-eb80-4b0e-8b67-3c68d6bcfc62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c9f6862-6caa-4844-b24d-fe4031ab75f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c9f6862-6caa-4844-b24d-fe4031ab75f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_187b7aaf-8034-4464-8e9c-8187b1f76600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_ProfitLoss_187b7aaf-8034-4464-8e9c-8187b1f76600" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_645ca932-8b59-4799-b715-5dc2cf9438c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_645ca932-8b59-4799-b715-5dc2cf9438c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_002e589b-4c8c-4576-9e89-f9c39d0ec31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_NetIncomeLoss_002e589b-4c8c-4576-9e89-f9c39d0ec31e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4413300e-2f85-4c40-868f-de2ea477c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4413300e-2f85-4c40-868f-de2ea477c6c1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e96325a-469b-457e-a53e-af3fd0acc1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e96325a-469b-457e-a53e-af3fd0acc1b4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8ce17aeb-6bc0-4f33-9a4e-20ed2bee9d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8ce17aeb-6bc0-4f33-9a4e-20ed2bee9d84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bec3c74d-6cd6-451c-a890-921232846b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bec3c74d-6cd6-451c-a890-921232846b23" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61192ca1-43eb-4056-9ceb-2c844adefaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61192ca1-43eb-4056-9ceb-2c844adefaef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d025a46-3b34-4fb5-8d2d-1a7bd6005c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_StatementTable_2d025a46-3b34-4fb5-8d2d-1a7bd6005c09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2d025a46-3b34-4fb5-8d2d-1a7bd6005c09" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c" xlink:to="loc_us-gaap_ClassOfStockDomain_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f5172277-abf8-416f-a745-6bda0d76fd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c" xlink:to="loc_us-gaap_ClassOfStockDomain_f5172277-abf8-416f-a745-6bda0d76fd7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0a4be754-1057-48f9-b3b0-7d7f50144bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f5172277-abf8-416f-a745-6bda0d76fd7a" xlink:to="loc_us-gaap_CommonClassAMember_0a4be754-1057-48f9-b3b0-7d7f50144bb0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="extended" id="i1a4fca45e8d8424a90c0985de1258193_CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_a1148851-f7d4-4850-82e0-025dad4b83cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_a1148851-f7d4-4850-82e0-025dad4b83cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8fcbd048-3151-4bc2-8a6b-50ab72036e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8fcbd048-3151-4bc2-8a6b-50ab72036e17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TemporaryEquityChangeInRedemptionValue_fb7aa68f-20c3-41a0-b66d-f05b83a78e5a" xlink:href="vtvt-20220630.xsd#vtvt_TemporaryEquityChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:to="loc_vtvt_TemporaryEquityChangeInRedemptionValue_fb7aa68f-20c3-41a0-b66d-f05b83a78e5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_90df6ed6-936e-4c47-93cb-bb753eac8fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_895e9ea6-0910-4fd2-9ad1-1267dab370c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_895e9ea6-0910-4fd2-9ad1-1267dab370c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_034ffd75-1f47-4739-8bf4-f8264fde9949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockholdersEquity_034ffd75-1f47-4739-8bf4-f8264fde9949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_08054bfd-a3d9-4119-99b5-325b48040639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_NetIncomeLoss_08054bfd-a3d9-4119-99b5-325b48040639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f5d9221-cebc-437e-b2d1-77f5de2566f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f5d9221-cebc-437e-b2d1-77f5de2566f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54e12ae4-ff87-4dae-b07d-f18d26a55be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54e12ae4-ff87-4dae-b07d-f18d26a55be3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d22bebf7-10ed-4713-9135-b7de1b6557fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d22bebf7-10ed-4713-9135-b7de1b6557fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_9b0e7335-ede3-493a-9282-bcc9853776d5" xlink:href="vtvt-20220630.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_9b0e7335-ede3-493a-9282-bcc9853776d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue_356d1e5d-45df-4305-8d7f-526465bc6a12" xlink:href="vtvt-20220630.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue_356d1e5d-45df-4305-8d7f-526465bc6a12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_badba30e-eb1b-4319-aba8-005559ffd6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_badba30e-eb1b-4319-aba8-005559ffd6a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_771f9341-b3a8-49b7-ba11-1e19c6941ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_771f9341-b3a8-49b7-ba11-1e19c6941ca1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_889c6ddb-6157-4d40-8f3e-7cdcf46e0b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_889c6ddb-6157-4d40-8f3e-7cdcf46e0b53" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_4b78edd6-d2a9-49ca-83be-ec90ef9f55f1" xlink:href="vtvt-20220630.xsd#vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_4b78edd6-d2a9-49ca-83be-ec90ef9f55f1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_3b6e1d51-9a58-4c7d-b4ed-ebf2ad698fe3" xlink:href="vtvt-20220630.xsd#vtvt_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_3b6e1d51-9a58-4c7d-b4ed-ebf2ad698fe3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_545c9fa0-04f5-465a-864e-2475de115ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_545c9fa0-04f5-465a-864e-2475de115ae6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7dbe7635-9572-41ea-8ac1-89c4d36cc0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7582776b-ba82-47ac-82c8-c7ecace60fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:to="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fbd6cf1f-36e1-419d-b2fb-1440ea40374b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fbd6cf1f-36e1-419d-b2fb-1440ea40374b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fbd6cf1f-36e1-419d-b2fb-1440ea40374b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fbd6cf1f-36e1-419d-b2fb-1440ea40374b" xlink:to="loc_us-gaap_EquityComponentDomain_fbd6cf1f-36e1-419d-b2fb-1440ea40374b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fbd6cf1f-36e1-419d-b2fb-1440ea40374b" xlink:to="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9b98afaa-4ebc-49fa-b1b8-7d16b80dec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9b98afaa-4ebc-49fa-b1b8-7d16b80dec77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e3f16137-49a2-4318-a9ce-7906effc96d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_CommonStockMember_e3f16137-49a2-4318-a9ce-7906effc96d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dda83cbb-eba0-4d99-b6de-6338956e3233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dda83cbb-eba0-4d99-b6de-6338956e3233" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1d3838aa-3fcb-40ca-8769-4b3a16a0ec07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_RetainedEarningsMember_1d3838aa-3fcb-40ca-8769-4b3a16a0ec07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c37e679-73dc-4b40-a2a6-6946c91f0722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c37e679-73dc-4b40-a2a6-6946c91f0722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c37e679-73dc-4b40-a2a6-6946c91f0722_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c37e679-73dc-4b40-a2a6-6946c91f0722" xlink:to="loc_us-gaap_ClassOfStockDomain_7c37e679-73dc-4b40-a2a6-6946c91f0722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c37e679-73dc-4b40-a2a6-6946c91f0722" xlink:to="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_788230fe-b10d-431d-a353-d876e7850be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:to="loc_us-gaap_CommonClassAMember_788230fe-b10d-431d-a353-d876e7850be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b2a91aa2-af22-4857-b42a-8d13aa6b92f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:to="loc_us-gaap_CommonClassBMember_b2a91aa2-af22-4857-b42a-8d13aa6b92f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember_b12c409f-d4b8-4b8b-8ac4-83113b1a7d70" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestsMember_b12c409f-d4b8-4b8b-8ac4-83113b1a7d70" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#DescriptionofBusinessBasisofPresentationandGoingConcernDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="extended" id="i0b22c4411d2343a9b02690e0de6fec73_DescriptionofBusinessBasisofPresentationandGoingConcernDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:href="vtvt-20220630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_dbe4b11c-7fc2-4029-b28f-e5a5d0da9179" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_dbe4b11c-7fc2-4029-b28f-e5a5d0da9179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_2f7d7694-1d5e-4970-865b-4f00d8544608" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_2f7d7694-1d5e-4970-865b-4f00d8544608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43a86624-f06e-44bc-ae92-2d8c61bb1f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43a86624-f06e-44bc-ae92-2d8c61bb1f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_253e1d37-55d2-4ef6-86a8-7214359777db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_253e1d37-55d2-4ef6-86a8-7214359777db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_0f62e844-eb02-47c6-b20d-5355f0f68a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_0f62e844-eb02-47c6-b20d-5355f0f68a87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_01e4239d-84f4-43eb-9c6e-5d0097bf1707" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_01e4239d-84f4-43eb-9c6e-5d0097bf1707" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_bb11bb38-51b5-4bff-bf9d-c773b6bb6ee6" xlink:href="vtvt-20220630.xsd#vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_bb11bb38-51b5-4bff-bf9d-c773b6bb6ee6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18c2a8eb-4df9-4873-a0fb-0f0b471c805a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18c2a8eb-4df9-4873-a0fb-0f0b471c805a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:href="vtvt-20220630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5af79f81-6ccd-4353-989e-f2beaa1c444f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_dei_LegalEntityAxis_5af79f81-6ccd-4353-989e-f2beaa1c444f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5af79f81-6ccd-4353-989e-f2beaa1c444f_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5af79f81-6ccd-4353-989e-f2beaa1c444f" xlink:to="loc_dei_EntityDomain_5af79f81-6ccd-4353-989e-f2beaa1c444f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b5b8144c-6a9e-48f3-bc18-4fb401af46b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5af79f81-6ccd-4353-989e-f2beaa1c444f" xlink:to="loc_dei_EntityDomain_b5b8144c-6a9e-48f3-bc18-4fb401af46b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_6658fd46-1388-4b8f-a045-e382365bcf18" xlink:href="vtvt-20220630.xsd#vtvt_VTvLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b5b8144c-6a9e-48f3-bc18-4fb401af46b8" xlink:to="loc_vtvt_VTvLLCMember_6658fd46-1388-4b8f-a045-e382365bcf18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ce951622-4d8d-4285-bbae-506f2dfc0014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ce951622-4d8d-4285-bbae-506f2dfc0014" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ce951622-4d8d-4285-bbae-506f2dfc0014_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ce951622-4d8d-4285-bbae-506f2dfc0014" xlink:to="loc_us-gaap_ClassOfStockDomain_ce951622-4d8d-4285-bbae-506f2dfc0014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_37403692-2733-4ce8-9256-e729a0470ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ce951622-4d8d-4285-bbae-506f2dfc0014" xlink:to="loc_us-gaap_ClassOfStockDomain_37403692-2733-4ce8-9256-e729a0470ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ddb39c3c-608d-43a4-90af-4d76a8335c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_37403692-2733-4ce8-9256-e729a0470ea5" xlink:to="loc_us-gaap_CommonClassAMember_ddb39c3c-608d-43a4-90af-4d76a8335c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsAxis_1156f624-ded7-4a86-a1ab-4affdfe3a312" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAgreementObligationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_vtvt_LicenseAgreementObligationsAxis_1156f624-ded7-4a86-a1ab-4affdfe3a312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain_1156f624-ded7-4a86-a1ab-4affdfe3a312_default" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis_1156f624-ded7-4a86-a1ab-4affdfe3a312" xlink:to="loc_vtvt_LicenseAgreementObligationsDomain_1156f624-ded7-4a86-a1ab-4affdfe3a312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain_95dab81a-44f7-4f55-95b4-d8398021ca76" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis_1156f624-ded7-4a86-a1ab-4affdfe3a312" xlink:to="loc_vtvt_LicenseAgreementObligationsDomain_95dab81a-44f7-4f55-95b4-d8398021ca76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_7729a650-efe2-41da-b06f-690630301d74" xlink:href="vtvt-20220630.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_LicenseAgreementObligationsDomain_95dab81a-44f7-4f55-95b4-d8398021ca76" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_7729a650-efe2-41da-b06f-690630301d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_834fd422-4be9-4e17-a8c2-f22022def4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_834fd422-4be9-4e17-a8c2-f22022def4a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_834fd422-4be9-4e17-a8c2-f22022def4a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_834fd422-4be9-4e17-a8c2-f22022def4a8" xlink:to="loc_us-gaap_RelatedPartyDomain_834fd422-4be9-4e17-a8c2-f22022def4a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2e06edba-2fb4-42d0-a1b9-13033006ec20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_834fd422-4be9-4e17-a8c2-f22022def4a8" xlink:to="loc_us-gaap_RelatedPartyDomain_2e06edba-2fb4-42d0-a1b9-13033006ec20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_1667779d-9a44-4e1c-9712-e745e7b892dd" xlink:href="vtvt-20220630.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2e06edba-2fb4-42d0-a1b9-13033006ec20" xlink:to="loc_vtvt_CantorFitzgeraldMember_1667779d-9a44-4e1c-9712-e745e7b892dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_srt_CounterpartyNameAxis_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_530d0f4e-b23e-4ac7-92eb-7b59aa3e0360" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_530d0f4e-b23e-4ac7-92eb-7b59aa3e0360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentMember_52df5e31-1cf6-4da7-bcfd-941f51c80288" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:to="loc_vtvt_G2InvestmentMember_52df5e31-1cf6-4da7-bcfd-941f51c80288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6831a943-bebc-45fe-8d24-cc3847eadf52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6831a943-bebc-45fe-8d24-cc3847eadf52" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6831a943-bebc-45fe-8d24-cc3847eadf52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6831a943-bebc-45fe-8d24-cc3847eadf52" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6831a943-bebc-45fe-8d24-cc3847eadf52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dee6bc75-5de3-4aee-b6a8-ecab296929bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6831a943-bebc-45fe-8d24-cc3847eadf52" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dee6bc75-5de3-4aee-b6a8-ecab296929bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dda99b68-ef13-4ea0-9460-3768a0f5e32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dee6bc75-5de3-4aee-b6a8-ecab296929bc" xlink:to="loc_us-gaap_SubsequentEventMember_dda99b68-ef13-4ea0-9460-3768a0f5e32a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i1831f576b5c1430488a2d222a38f06ba_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_9430779d-e2af-4f4c-ad2d-6dfff72025fe" xlink:href="vtvt-20220630.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e3c9c926-26d7-4c88-a62f-3304e2a3cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_9430779d-e2af-4f4c-ad2d-6dfff72025fe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e3c9c926-26d7-4c88-a62f-3304e2a3cc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:href="vtvt-20220630.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_9430779d-e2af-4f4c-ad2d-6dfff72025fe" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dfd2eb60-c947-49ac-879d-e75811f4030b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dfd2eb60-c947-49ac-879d-e75811f4030b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfd2eb60-c947-49ac-879d-e75811f4030b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dfd2eb60-c947-49ac-879d-e75811f4030b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfd2eb60-c947-49ac-879d-e75811f4030b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_355b526a-abbc-4618-a4f6-dc8b17188aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dfd2eb60-c947-49ac-879d-e75811f4030b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_355b526a-abbc-4618-a4f6-dc8b17188aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_e79da493-fc73-4a96-a03b-97e1af542ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_355b526a-abbc-4618-a4f6-dc8b17188aca" xlink:to="loc_us-gaap_SalesRevenueNetMember_e79da493-fc73-4a96-a03b-97e1af542ab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e0c7e342-5359-46c8-9e36-2ffaabd89b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e0c7e342-5359-46c8-9e36-2ffaabd89b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e0c7e342-5359-46c8-9e36-2ffaabd89b06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e0c7e342-5359-46c8-9e36-2ffaabd89b06" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e0c7e342-5359-46c8-9e36-2ffaabd89b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6c79dd5e-ce55-4e7b-bf70-16e38552bf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e0c7e342-5359-46c8-9e36-2ffaabd89b06" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6c79dd5e-ce55-4e7b-bf70-16e38552bf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1ea42c02-a899-4d9c-8b34-79a2faa54b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6c79dd5e-ce55-4e7b-bf70-16e38552bf32" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1ea42c02-a899-4d9c-8b34-79a2faa54b2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0116080c-f2cf-44c6-977e-83fb8b6a417b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:to="loc_srt_MajorCustomersAxis_0116080c-f2cf-44c6-977e-83fb8b6a417b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0116080c-f2cf-44c6-977e-83fb8b6a417b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0116080c-f2cf-44c6-977e-83fb8b6a417b" xlink:to="loc_srt_NameOfMajorCustomerDomain_0116080c-f2cf-44c6-977e-83fb8b6a417b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7fa06729-9b61-44ae-86c4-555df54db409" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0116080c-f2cf-44c6-977e-83fb8b6a417b" xlink:to="loc_srt_NameOfMajorCustomerDomain_7fa06729-9b61-44ae-86c4-555df54db409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember_d098f616-325e-49a4-887a-4d220356b35c" xlink:href="vtvt-20220630.xsd#vtvt_OneCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fa06729-9b61-44ae-86c4-555df54db409" xlink:to="loc_vtvt_OneCustomerMember_d098f616-325e-49a4-887a-4d220356b35c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" id="i390d88a630bb471f8b4ee949ce625563_CollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ba98982f-6577-4d47-8123-a2f6e296396f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ba98982f-6577-4d47-8123-a2f6e296396f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3bb8287-ad14-471d-b8fd-01fd064e12c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3bb8287-ad14-471d-b8fd-01fd064e12c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_29d44b60-2214-494e-864a-cbff0072caac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_29d44b60-2214-494e-864a-cbff0072caac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_b4751b8c-5fcf-4f50-94c7-ce4e9a601001" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_b4751b8c-5fcf-4f50-94c7-ce4e9a601001" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f5348fa6-3841-47af-9445-2ffe041c92be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f5348fa6-3841-47af-9445-2ffe041c92be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_55498078-e190-4463-a873-cb6ed9c103ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_55498078-e190-4463-a873-cb6ed9c103ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod_04a86795-d185-43b2-99b9-89abbcb7dd55" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivablePaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod_04a86795-d185-43b2-99b9-89abbcb7dd55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_6c477d56-dda4-4f4b-ab80-2e283f549ae4" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_6c477d56-dda4-4f4b-ab80-2e283f549ae4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_954e867e-ca26-44fe-8341-497745509730" xlink:href="vtvt-20220630.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_954e867e-ca26-44fe-8341-497745509730" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage_724f748e-9dba-4bc5-89a4-926574aaa83b" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage_724f748e-9dba-4bc5-89a4-926574aaa83b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_80898bc8-0697-48d9-874e-c10a14422894" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_80898bc8-0697-48d9-874e-c10a14422894" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7fb6aebc-25fb-461c-a6b7-6d141ca27176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SharePrice_7fb6aebc-25fb-461c-a6b7-6d141ca27176" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_6ead0813-6e39-40ad-92fe-db09acb68eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_6ead0813-6e39-40ad-92fe-db09acb68eb1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5fa81c25-1ccf-4f73-890d-6306da327314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5fa81c25-1ccf-4f73-890d-6306da327314" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_d2baae0e-d9ed-453f-a0ef-b2f4f4b16adc" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_d2baae0e-d9ed-453f-a0ef-b2f4f4b16adc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f38ead6-5634-4e19-af7a-0656e64dfe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f38ead6-5634-4e19-af7a-0656e64dfe4d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_89992f3f-b59d-4d63-a5b6-c599fa93c5a0" xlink:href="vtvt-20220630.xsd#vtvt_AdjustmentsToTransactionPriceForPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_89992f3f-b59d-4d63-a5b6-c599fa93c5a0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumSponsoringContributionAmount_1a0a5c95-4d24-475e-928f-95a8f7a6de98" xlink:href="vtvt-20220630.xsd#vtvt_MaximumSponsoringContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_MaximumSponsoringContributionAmount_1a0a5c95-4d24-475e-928f-95a8f7a6de98" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_65b29af0-b73f-4ac9-9745-d3518db01ab9" xlink:href="vtvt-20220630.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_65b29af0-b73f-4ac9-9745-d3518db01ab9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod_d8d943b2-6383-4c63-baa6-44f98a0599e1" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod_d8d943b2-6383-4c63-baa6-44f98a0599e1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_94bac0e7-308c-4cc8-912b-f62c0677ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_94bac0e7-308c-4cc8-912b-f62c0677ed84" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_4da5e39e-03f7-4442-a191-9c6d2318125d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_4da5e39e-03f7-4442-a191-9c6d2318125d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_60c61974-f387-4902-ad01-b635b69fb3a6" xlink:href="vtvt-20220630.xsd#vtvt_LicenseFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_LicenseFeeReceived_60c61974-f387-4902-ad01-b635b69fb3a6" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_5b41fb57-cea3-4a05-9333-fc36bc66af58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_5b41fb57-cea3-4a05-9333-fc36bc66af58" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones_a865dde3-8e6e-460b-8023-d2207ede9f5e" xlink:href="vtvt-20220630.xsd#vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones_a865dde3-8e6e-460b-8023-d2207ede9f5e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_6eb0c2ac-e229-4e59-bdf2-8cc28327c1d5" xlink:href="vtvt-20220630.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_6eb0c2ac-e229-4e59-bdf2-8cc28327c1d5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FundingReceived_ac18369f-791e-476f-a6c4-89ebf2a6dbcd" xlink:href="vtvt-20220630.xsd#vtvt_FundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_FundingReceived_ac18369f-791e-476f-a6c4-89ebf2a6dbcd" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25aa4013-878f-4256-8647-64b284a82677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25aa4013-878f-4256-8647-64b284a82677" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a23f335-0417-48f8-a65a-67ea2a17d43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a23f335-0417-48f8-a65a-67ea2a17d43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a23f335-0417-48f8-a65a-67ea2a17d43d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a23f335-0417-48f8-a65a-67ea2a17d43d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a23f335-0417-48f8-a65a-67ea2a17d43d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a23f335-0417-48f8-a65a-67ea2a17d43d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_dc4fd5cf-e07a-4aea-9ddb-fd681b5334fb" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_dc4fd5cf-e07a-4aea-9ddb-fd681b5334fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1f3f4e9e-ae02-4bfa-ba8e-6eae3841dd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1f3f4e9e-ae02-4bfa-ba8e-6eae3841dd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3296dd0-b141-4d31-870e-5703bca59a62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_dei_LegalEntityAxis_f3296dd0-b141-4d31-870e-5703bca59a62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f3296dd0-b141-4d31-870e-5703bca59a62_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f3296dd0-b141-4d31-870e-5703bca59a62" xlink:to="loc_dei_EntityDomain_f3296dd0-b141-4d31-870e-5703bca59a62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f3296dd0-b141-4d31-870e-5703bca59a62" xlink:to="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_81a729c2-7292-418b-8076-a02a2ce3ff90" xlink:href="vtvt-20220630.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_81a729c2-7292-418b-8076-a02a2ce3ff90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_a57ad88b-6bb8-41a0-b887-c126cae321ff" xlink:href="vtvt-20220630.xsd#vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_a57ad88b-6bb8-41a0-b887-c126cae321ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_0a694ed5-6136-41a0-838a-2a0ccab410bb" xlink:href="vtvt-20220630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_0a694ed5-6136-41a0-838a-2a0ccab410bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_0f1ae615-5010-49d9-8d44-23ed87fb9305" xlink:href="vtvt-20220630.xsd#vtvt_AnterisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_AnterisBioIncMember_0f1ae615-5010-49d9-8d44-23ed87fb9305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember_4e60f45e-cde1-479b-9f8b-8c59727ee2ee" xlink:href="vtvt-20220630.xsd#vtvt_JDRFInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_JDRFInternationalMember_4e60f45e-cde1-479b-9f8b-8c59727ee2ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_223c12cc-f9ec-4b83-bc92-0cdafdff6157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_us-gaap_OtherCommitmentsAxis_223c12cc-f9ec-4b83-bc92-0cdafdff6157" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_223c12cc-f9ec-4b83-bc92-0cdafdff6157_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_223c12cc-f9ec-4b83-bc92-0cdafdff6157" xlink:to="loc_us-gaap_OtherCommitmentsDomain_223c12cc-f9ec-4b83-bc92-0cdafdff6157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_13e6677a-4543-4b55-a8df-dfbe1d3e2162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_223c12cc-f9ec-4b83-bc92-0cdafdff6157" xlink:to="loc_us-gaap_OtherCommitmentsDomain_13e6677a-4543-4b55-a8df-dfbe1d3e2162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_7fb3987c-7956-4083-91e6-a9c2dbbe90f7" xlink:href="vtvt-20220630.xsd#vtvt_PhaseTwoMultiRegionalClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_13e6677a-4543-4b55-a8df-dfbe1d3e2162" xlink:to="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_7fb3987c-7956-4083-91e6-a9c2dbbe90f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c400018-2bcf-4873-ac99-77b5fe47ed68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_srt_ProductOrServiceAxis_8c400018-2bcf-4873-ac99-77b5fe47ed68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c400018-2bcf-4873-ac99-77b5fe47ed68_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c400018-2bcf-4873-ac99-77b5fe47ed68" xlink:to="loc_srt_ProductsAndServicesDomain_8c400018-2bcf-4873-ac99-77b5fe47ed68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c400018-2bcf-4873-ac99-77b5fe47ed68" xlink:to="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_a671c1d9-5594-41d1-b50a-d9a5cd8cd0a2" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_a671c1d9-5594-41d1-b50a-d9a5cd8cd0a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesMember_9a23a8a8-4a8e-4be6-af88-c7a2cf5dd32a" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAndTechnologyTransferServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesMember_9a23a8a8-4a8e-4be6-af88-c7a2cf5dd32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_srt_CounterpartyNameAxis_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_afc4f23c-829b-48c7-9387-bf5b057d060a" xlink:href="vtvt-20220630.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:to="loc_vtvt_G42InvestmentsMember_afc4f23c-829b-48c7-9387-bf5b057d060a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_3197a510-efce-4790-b6c1-b1568bec28d5" xlink:href="vtvt-20220630.xsd#vtvt_CognaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:to="loc_vtvt_CognaMember_3197a510-efce-4790-b6c1-b1568bec28d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e902528-2db3-4897-bfa4-03e1339ba8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e902528-2db3-4897-bfa4-03e1339ba8a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e902528-2db3-4897-bfa4-03e1339ba8a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e902528-2db3-4897-bfa4-03e1339ba8a9" xlink:to="loc_us-gaap_ClassOfStockDomain_9e902528-2db3-4897-bfa4-03e1339ba8a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_efa6f15f-1421-48a6-8fc3-11b601521c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e902528-2db3-4897-bfa4-03e1339ba8a9" xlink:to="loc_us-gaap_ClassOfStockDomain_efa6f15f-1421-48a6-8fc3-11b601521c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_630019ba-ae60-44e9-9775-8be6cc4b572d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_efa6f15f-1421-48a6-8fc3-11b601521c48" xlink:to="loc_us-gaap_CommonClassAMember_630019ba-ae60-44e9-9775-8be6cc4b572d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i9e4d0234e9b245aab4ea0dea213596c4_ShareBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_912137aa-ef00-4d97-b16c-e4f97234c3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_912137aa-ef00-4d97-b16c-e4f97234c3f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3789d115-6552-4339-94c9-93e766f44ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3789d115-6552-4339-94c9-93e766f44ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bf82a6bd-11e1-473f-a887-28f278f75b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bf82a6bd-11e1-473f-a887-28f278f75b6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1b05015-acf6-46ba-b04a-ea0525f87172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1b05015-acf6-46ba-b04a-ea0525f87172" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5b7d040-2c3f-40bd-b62d-370ac2ccaa16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5b7d040-2c3f-40bd-b62d-370ac2ccaa16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5366fbc9-26e2-4a6b-8f1a-26b9488c6a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5366fbc9-26e2-4a6b-8f1a-26b9488c6a44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d93a7f63-c405-400a-b6a7-9338ba231fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d93a7f63-c405-400a-b6a7-9338ba231fed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled_3a717fe0-e706-40d4-b52c-2cf81093c7fb" xlink:href="vtvt-20220630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled_3a717fe0-e706-40d4-b52c-2cf81093c7fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c279fb15-553e-442f-8ac0-b5583dbbece9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:to="loc_us-gaap_AwardTypeAxis_c279fb15-553e-442f-8ac0-b5583dbbece9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c279fb15-553e-442f-8ac0-b5583dbbece9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c279fb15-553e-442f-8ac0-b5583dbbece9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c279fb15-553e-442f-8ac0-b5583dbbece9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29637e9d-4ae3-43df-a6ce-b7bb5e901b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c279fb15-553e-442f-8ac0-b5583dbbece9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29637e9d-4ae3-43df-a6ce-b7bb5e901b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3d9e9332-74d0-4a92-9294-7b4706e95cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29637e9d-4ae3-43df-a6ce-b7bb5e901b89" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3d9e9332-74d0-4a92-9294-7b4706e95cbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_542a85d0-2d5b-4092-82a5-0301b1299848" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:to="loc_srt_TitleOfIndividualAxis_542a85d0-2d5b-4092-82a5-0301b1299848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_542a85d0-2d5b-4092-82a5-0301b1299848_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_542a85d0-2d5b-4092-82a5-0301b1299848" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_542a85d0-2d5b-4092-82a5-0301b1299848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81d21a89-6ff2-4dd9-95f3-90a9c311b8bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_542a85d0-2d5b-4092-82a5-0301b1299848" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81d21a89-6ff2-4dd9-95f3-90a9c311b8bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StrategicAdvisorMember_09a4877c-1e0e-4d2a-9ea0-ae5bf1a045cf" xlink:href="vtvt-20220630.xsd#vtvt_StrategicAdvisorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81d21a89-6ff2-4dd9-95f3-90a9c311b8bf" xlink:to="loc_vtvt_StrategicAdvisorMember_09a4877c-1e0e-4d2a-9ea0-ae5bf1a045cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="extended" id="ie1247250dd0a4e1083c18d7ed80f13be_ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6707a24-5d4e-4001-bdf7-140184dbcb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_721f798d-e3a6-4f19-a274-3e81dc66f892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6707a24-5d4e-4001-bdf7-140184dbcb95" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_721f798d-e3a6-4f19-a274-3e81dc66f892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a7316af-61d6-4214-a7d1-c1f3e321ddce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6707a24-5d4e-4001-bdf7-140184dbcb95" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a7316af-61d6-4214-a7d1-c1f3e321ddce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_185df70f-adb0-437c-9115-5003c682dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a7316af-61d6-4214-a7d1-c1f3e321ddce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_185df70f-adb0-437c-9115-5003c682dd60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_185df70f-adb0-437c-9115-5003c682dd60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_185df70f-adb0-437c-9115-5003c682dd60" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_185df70f-adb0-437c-9115-5003c682dd60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_185df70f-adb0-437c-9115-5003c682dd60" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3390695e-9912-4809-ad8c-4315efa02d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3390695e-9912-4809-ad8c-4315efa02d4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea7fbd11-defe-404f-885b-bc1bcb7aca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea7fbd11-defe-404f-885b-bc1bcb7aca30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#InvestmentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="extended" id="i7fc184f67eaa4c2397b2d825d2e0afa4_InvestmentsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_InvestmentOwnershipPercentage_16eb14fc-6198-426c-b178-0947de4b1463" xlink:href="vtvt-20220630.xsd#vtvt_InvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:to="loc_vtvt_InvestmentOwnershipPercentage_16eb14fc-6198-426c-b178-0947de4b1463" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c58af4eb-3da2-439a-818a-9cfc05aed6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c58af4eb-3da2-439a-818a-9cfc05aed6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1a46f7a9-8bbb-4be0-88c9-4db5673bc013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:to="loc_us-gaap_StatementTable_1a46f7a9-8bbb-4be0-88c9-4db5673bc013" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_96e6d301-f932-49af-9ae2-9db7a8dce20e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1a46f7a9-8bbb-4be0-88c9-4db5673bc013" xlink:to="loc_dei_LegalEntityAxis_96e6d301-f932-49af-9ae2-9db7a8dce20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_96e6d301-f932-49af-9ae2-9db7a8dce20e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_96e6d301-f932-49af-9ae2-9db7a8dce20e" xlink:to="loc_dei_EntityDomain_96e6d301-f932-49af-9ae2-9db7a8dce20e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c6124c20-a5e7-49a8-861b-73acb32f969c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_96e6d301-f932-49af-9ae2-9db7a8dce20e" xlink:to="loc_dei_EntityDomain_c6124c20-a5e7-49a8-861b-73acb32f969c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_c6875180-ac37-4770-b361-33c5ad16e25a" xlink:href="vtvt-20220630.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c6124c20-a5e7-49a8-861b-73acb32f969c" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_c6875180-ac37-4770-b361-33c5ad16e25a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="extended" id="i9a28aaaf7b46429bb6fe313ed22b249f_InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3b6655ca-e3a9-410c-ad5d-a3fc0efe4130" xlink:href="vtvt-20220630.xsd#vtvt_EquityInvestmentsWithReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:to="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3b6655ca-e3a9-410c-ad5d-a3fc0efe4130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_05a8923b-b7f8-457c-b6e9-8d7614be8a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_05a8923b-b7f8-457c-b6e9-8d7614be8a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_81bfeeef-bd28-4c7f-874a-e9f0ae156b98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:to="loc_dei_LegalEntityAxis_81bfeeef-bd28-4c7f-874a-e9f0ae156b98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_81bfeeef-bd28-4c7f-874a-e9f0ae156b98_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_81bfeeef-bd28-4c7f-874a-e9f0ae156b98" xlink:to="loc_dei_EntityDomain_81bfeeef-bd28-4c7f-874a-e9f0ae156b98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_81bfeeef-bd28-4c7f-874a-e9f0ae156b98" xlink:to="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_3cffadcc-a46f-48f6-9bdd-42d341066f5a" xlink:href="vtvt-20220630.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_3cffadcc-a46f-48f6-9bdd-42d341066f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_179e9f9f-4f70-4dd6-83bf-d3b6a20c68ad" xlink:href="vtvt-20220630.xsd#vtvt_AnterisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:to="loc_vtvt_AnterisBioIncMember_179e9f9f-4f70-4dd6-83bf-d3b6a20c68ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_087b56d9-c0bb-4860-8936-0afa6aa5484c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_087b56d9-c0bb-4860-8936-0afa6aa5484c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_087b56d9-c0bb-4860-8936-0afa6aa5484c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_087b56d9-c0bb-4860-8936-0afa6aa5484c" xlink:to="loc_us-gaap_EquityComponentDomain_087b56d9-c0bb-4860-8936-0afa6aa5484c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_087b56d9-c0bb-4860-8936-0afa6aa5484c" xlink:to="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6cabb31e-c6c9-483f-8896-ea82f81508cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:to="loc_us-gaap_CommonStockMember_6cabb31e-c6c9-483f-8896-ea82f81508cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_81949502-92ff-46d0-9d57-936053270b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:to="loc_us-gaap_PreferredStockMember_81949502-92ff-46d0-9d57-936053270b1f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i49ab76ac0bc14c69800b6cc79f3d0c77_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_3004dc03-5619-427a-876a-dd3586055cf8" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_ea0d9763-6c27-486d-b7dd-f4a563b2741c" xlink:href="vtvt-20220630.xsd#vtvt_PotentialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_3004dc03-5619-427a-876a-dd3586055cf8" xlink:to="loc_vtvt_PotentialMilestonePayment_ea0d9763-6c27-486d-b7dd-f4a563b2741c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_3004dc03-5619-427a-876a-dd3586055cf8" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_us-gaap_OtherCommitmentsAxis_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28" xlink:to="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_fc536038-f7c6-4aa1-a340-a58dbea939ea" xlink:href="vtvt-20220630.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_fc536038-f7c6-4aa1-a340-a58dbea939ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_f6e70150-4adc-4ed8-9944-52c93edf6bc3" xlink:href="vtvt-20220630.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_f6e70150-4adc-4ed8-9944-52c93edf6bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SatisfactionOfMilestonePaymentMember_3e0243bc-3029-4701-9f75-090951fca716" xlink:href="vtvt-20220630.xsd#vtvt_SatisfactionOfMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:to="loc_vtvt_SatisfactionOfMilestonePaymentMember_3e0243bc-3029-4701-9f75-090951fca716" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4decbe50-e335-46af-8251-a8720e4cdaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4decbe50-e335-46af-8251-a8720e4cdaea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4decbe50-e335-46af-8251-a8720e4cdaea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4decbe50-e335-46af-8251-a8720e4cdaea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4decbe50-e335-46af-8251-a8720e4cdaea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8183bebf-bb3a-441a-9cc3-5b4de5b456fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4decbe50-e335-46af-8251-a8720e4cdaea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8183bebf-bb3a-441a-9cc3-5b4de5b456fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_df2a426c-c476-435e-970f-ffc44ab2188c" xlink:href="vtvt-20220630.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8183bebf-bb3a-441a-9cc3-5b4de5b456fb" xlink:to="loc_vtvt_NovoLicenseAgreementMember_df2a426c-c476-435e-970f-ffc44ab2188c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_20727495-222c-464c-90ee-09a144c01412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_20727495-222c-464c-90ee-09a144c01412" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20727495-222c-464c-90ee-09a144c01412_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_20727495-222c-464c-90ee-09a144c01412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20727495-222c-464c-90ee-09a144c01412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_20727495-222c-464c-90ee-09a144c01412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_f5644d33-5c6d-4ceb-92da-12b5f16d19d4" xlink:href="vtvt-20220630.xsd#vtvt_OtherIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:to="loc_vtvt_OtherIndicationMember_f5644d33-5c6d-4ceb-92da-12b5f16d19d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_f9157c6d-92f3-41e1-8a96-0dd8b4db2588" xlink:href="vtvt-20220630.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:to="loc_vtvt_TypeOneDiabetesMember_f9157c6d-92f3-41e1-8a96-0dd8b4db2588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_7fc0240f-b0c4-45b3-97b6-9e884c77a9c2" xlink:href="vtvt-20220630.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:to="loc_vtvt_TypeTwoDiabetesMember_7fc0240f-b0c4-45b3-97b6-9e884c77a9c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_307a99ce-06d9-49ab-a2eb-2d8d5016c11e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_srt_RangeAxis_307a99ce-06d9-49ab-a2eb-2d8d5016c11e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_307a99ce-06d9-49ab-a2eb-2d8d5016c11e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_307a99ce-06d9-49ab-a2eb-2d8d5016c11e" xlink:to="loc_srt_RangeMember_307a99ce-06d9-49ab-a2eb-2d8d5016c11e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b74f0ab1-63e0-4408-bf21-12f2794e1b6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_307a99ce-06d9-49ab-a2eb-2d8d5016c11e" xlink:to="loc_srt_RangeMember_b74f0ab1-63e0-4408-bf21-12f2794e1b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ee08e29-fe4c-4f1b-beb5-b9eee952b5e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b74f0ab1-63e0-4408-bf21-12f2794e1b6c" xlink:to="loc_srt_MaximumMember_3ee08e29-fe4c-4f1b-beb5-b9eee952b5e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RedeemableNoncontrollingInterestAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="extended" id="iec4f94bdc6e140a6a1bbe43c0a817435_RedeemableNoncontrollingInterestAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_d51a28a2-1272-420a-a38f-3c14f0ae2348" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_d51a28a2-1272-420a-a38f-3c14f0ae2348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_9b75cd76-c011-424c-8b24-948f73d42692" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_9b75cd76-c011-424c-8b24-948f73d42692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_26cd9d52-ca82-4379-a673-daa13bf3b2e0" xlink:href="vtvt-20220630.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_26cd9d52-ca82-4379-a673-daa13bf3b2e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_01197fb2-bbbe-4257-a706-2b49f8a2c71d" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_01197fb2-bbbe-4257-a706-2b49f8a2c71d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:to="loc_dei_LegalEntityAxis_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0" xlink:to="loc_dei_EntityDomain_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_69502b4c-6d40-4319-95f1-0fef9a6bf865" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0" xlink:to="loc_dei_EntityDomain_69502b4c-6d40-4319-95f1-0fef9a6bf865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_274d696c-9dfc-40de-93d9-84018260a7b2" xlink:href="vtvt-20220630.xsd#vtvt_VTvLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_69502b4c-6d40-4319-95f1-0fef9a6bf865" xlink:to="loc_vtvt_VTvLLCMember_274d696c-9dfc-40de-93d9-84018260a7b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72dc97bf-c78b-439d-a482-92a3ebf15f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72dc97bf-c78b-439d-a482-92a3ebf15f11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_72dc97bf-c78b-439d-a482-92a3ebf15f11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72dc97bf-c78b-439d-a482-92a3ebf15f11" xlink:to="loc_us-gaap_ClassOfStockDomain_72dc97bf-c78b-439d-a482-92a3ebf15f11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fc74c26d-39d0-48c9-9abb-1c9076ae2427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72dc97bf-c78b-439d-a482-92a3ebf15f11" xlink:to="loc_us-gaap_ClassOfStockDomain_fc74c26d-39d0-48c9-9abb-1c9076ae2427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c1ba015f-638e-429f-919e-c7306626b3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fc74c26d-39d0-48c9-9abb-1c9076ae2427" xlink:to="loc_us-gaap_CommonClassAMember_c1ba015f-638e-429f-919e-c7306626b3a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fc5f2033-393a-41e1-9962-35bbb1f5a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fc5f2033-393a-41e1-9962-35bbb1f5a45b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_fc5f2033-393a-41e1-9962-35bbb1f5a45b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fc5f2033-393a-41e1-9962-35bbb1f5a45b" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_fc5f2033-393a-41e1-9962-35bbb1f5a45b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_234edac1-081b-4b32-a405-e379e169741e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fc5f2033-393a-41e1-9962-35bbb1f5a45b" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_234edac1-081b-4b32-a405-e379e169741e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_69377408-ce3b-4a92-aaa5-5eb4122efc81" xlink:href="vtvt-20220630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_234edac1-081b-4b32-a405-e379e169741e" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_69377408-ce3b-4a92-aaa5-5eb4122efc81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended" id="ib642439b398b49f5bf3b23e84a2cc958_StockholdersDeficitAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f8453c33-fba8-4bbc-bcab-661674bf564e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f8453c33-fba8-4bbc-bcab-661674bf564e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized_49a00240-b6a8-48cc-bee4-d93b17ad778d" xlink:href="vtvt-20220630.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_IncreaseInCommonStockSharesAuthorized_49a00240-b6a8-48cc-bee4-d93b17ad778d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_0d21c326-48f6-4c9b-9afd-1fe58bd13629" xlink:href="vtvt-20220630.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_0d21c326-48f6-4c9b-9afd-1fe58bd13629" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5a489d7-e942-4e21-932d-03ed612cf324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5a489d7-e942-4e21-932d-03ed612cf324" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_45846185-d1a8-4e52-8282-bb87d929f7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_45846185-d1a8-4e52-8282-bb87d929f7ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e4a3b6e2-99c0-44ac-9d1a-026840a3299a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e4a3b6e2-99c0-44ac-9d1a-026840a3299a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_11a77e66-0b42-460a-a495-48d029369617" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_11a77e66-0b42-460a-a495-48d029369617" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbde5245-061e-4552-a88c-43435d67e572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbde5245-061e-4552-a88c-43435d67e572" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_420333f7-05ee-400a-82c0-7f839af47576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_420333f7-05ee-400a-82c0-7f839af47576" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm_4ae6b9fd-8053-42aa-b454-48559b266150" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivablesPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm_4ae6b9fd-8053-42aa-b454-48559b266150" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27f832c6-bbd1-4565-a1bb-79742372eb38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27f832c6-bbd1-4565-a1bb-79742372eb38" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PublicFloat_8e9af72b-673b-4c47-bc1c-158eafde6b75" xlink:href="vtvt-20220630.xsd#vtvt_PublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_PublicFloat_8e9af72b-673b-4c47-bc1c-158eafde6b75" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AggregateOfferingPriceOfShares_78f2fe3f-88ac-48e1-8469-55943fc8c380" xlink:href="vtvt-20220630.xsd#vtvt_AggregateOfferingPriceOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_AggregateOfferingPriceOfShares_78f2fe3f-88ac-48e1-8469-55943fc8c380" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9eef0de4-d859-4021-8694-214515b748ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9eef0de4-d859-4021-8694-214515b748ee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9d811c23-4f1f-461d-be2a-b49a1097446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9d811c23-4f1f-461d-be2a-b49a1097446f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d811c23-4f1f-461d-be2a-b49a1097446f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d811c23-4f1f-461d-be2a-b49a1097446f" xlink:to="loc_us-gaap_ClassOfStockDomain_9d811c23-4f1f-461d-be2a-b49a1097446f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d811c23-4f1f-461d-be2a-b49a1097446f" xlink:to="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9257189f-c506-454e-82f4-cfe95903697c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:to="loc_us-gaap_CommonClassAMember_9257189f-c506-454e-82f4-cfe95903697c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4795ba80-6584-4538-9123-8578af8cbad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:to="loc_us-gaap_CommonStockMember_4795ba80-6584-4538-9123-8578af8cbad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef489cf6-4cbc-444b-86fd-b9e9b028ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef489cf6-4cbc-444b-86fd-b9e9b028ab58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ef489cf6-4cbc-444b-86fd-b9e9b028ab58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef489cf6-4cbc-444b-86fd-b9e9b028ab58" xlink:to="loc_us-gaap_RelatedPartyDomain_ef489cf6-4cbc-444b-86fd-b9e9b028ab58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef489cf6-4cbc-444b-86fd-b9e9b028ab58" xlink:to="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_b808636e-3367-4177-99fa-d77ac360830e" xlink:href="vtvt-20220630.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:to="loc_vtvt_CantorFitzgeraldMember_b808636e-3367-4177-99fa-d77ac360830e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_cbb12eaf-7ba4-40a8-8f52-adc7131ed3fd" xlink:href="vtvt-20220630.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_cbb12eaf-7ba4-40a8-8f52-adc7131ed3fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_15704c40-4502-4a8e-940e-674d592ee532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_us-gaap_TransactionTypeAxis_15704c40-4502-4a8e-940e-674d592ee532" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_15704c40-4502-4a8e-940e-674d592ee532_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_15704c40-4502-4a8e-940e-674d592ee532" xlink:to="loc_us-gaap_TransactionDomain_15704c40-4502-4a8e-940e-674d592ee532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_2e370fdc-98b9-4893-8259-90301f209932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_15704c40-4502-4a8e-940e-674d592ee532" xlink:to="loc_us-gaap_TransactionDomain_2e370fdc-98b9-4893-8259-90301f209932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AtTheMarketOfferingMember_407f7276-a584-4cb1-bc45-709051fae255" xlink:href="vtvt-20220630.xsd#vtvt_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_2e370fdc-98b9-4893-8259-90301f209932" xlink:to="loc_vtvt_AtTheMarketOfferingMember_407f7276-a584-4cb1-bc45-709051fae255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_203b86ed-fd0e-4c54-ab4e-0f664d10e776" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_srt_RangeAxis_203b86ed-fd0e-4c54-ab4e-0f664d10e776" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_203b86ed-fd0e-4c54-ab4e-0f664d10e776_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_203b86ed-fd0e-4c54-ab4e-0f664d10e776" xlink:to="loc_srt_RangeMember_203b86ed-fd0e-4c54-ab4e-0f664d10e776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e34b559d-9f06-4db0-8df4-a8ea74d84b0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_203b86ed-fd0e-4c54-ab4e-0f664d10e776" xlink:to="loc_srt_RangeMember_e34b559d-9f06-4db0-8df4-a8ea74d84b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f68263fa-65da-405c-a731-a7e9e7e65f8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e34b559d-9f06-4db0-8df4-a8ea74d84b0a" xlink:to="loc_srt_MaximumMember_f68263fa-65da-405c-a731-a7e9e7e65f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f28ba33c-3901-4afb-9a9d-e29ef1249865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_srt_CounterpartyNameAxis_f28ba33c-3901-4afb-9a9d-e29ef1249865" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f28ba33c-3901-4afb-9a9d-e29ef1249865_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f28ba33c-3901-4afb-9a9d-e29ef1249865" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f28ba33c-3901-4afb-9a9d-e29ef1249865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be12187-413b-4316-b6c0-8b24956e85a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f28ba33c-3901-4afb-9a9d-e29ef1249865" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be12187-413b-4316-b6c0-8b24956e85a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_d7b96804-cd99-47c4-b7b3-f5f063e421ec" xlink:href="vtvt-20220630.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be12187-413b-4316-b6c0-8b24956e85a8" xlink:to="loc_vtvt_G42InvestmentsMember_d7b96804-cd99-47c4-b7b3-f5f063e421ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended" id="i7ebc1224107d4c399179fe13b3f77f84_RelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_9154172c-abc4-4737-a5ff-266b5fae4686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_9154172c-abc4-4737-a5ff-266b5fae4686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_cc9a049a-dcf5-46f9-9300-af6d12c390f6" xlink:href="vtvt-20220630.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_cc9a049a-dcf5-46f9-9300-af6d12c390f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_a6d5bd65-3cff-417f-abc1-a0af594ea2d8" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_a6d5bd65-3cff-417f-abc1-a0af594ea2d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_dd1f537e-513a-4364-be2e-37efd891ba8f" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_dd1f537e-513a-4364-be2e-37efd891ba8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef37792b-8578-46a7-a5c7-7284566d3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef37792b-8578-46a7-a5c7-7284566d3e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ef37792b-8578-46a7-a5c7-7284566d3e0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef37792b-8578-46a7-a5c7-7284566d3e0b" xlink:to="loc_us-gaap_RelatedPartyDomain_ef37792b-8578-46a7-a5c7-7284566d3e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_071d69fe-9cde-4f4e-b39f-d79a58a9bc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef37792b-8578-46a7-a5c7-7284566d3e0b" xlink:to="loc_us-gaap_RelatedPartyDomain_071d69fe-9cde-4f4e-b39f-d79a58a9bc24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_f79d6191-095a-4312-b7d8-20215671ef0f" xlink:href="vtvt-20220630.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_071d69fe-9cde-4f4e-b39f-d79a58a9bc24" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_f79d6191-095a-4312-b7d8-20215671ef0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4646042-ccf9-46ad-bd08-6e4a841b4df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4646042-ccf9-46ad-bd08-6e4a841b4df4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4646042-ccf9-46ad-bd08-6e4a841b4df4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4646042-ccf9-46ad-bd08-6e4a841b4df4" xlink:to="loc_us-gaap_ClassOfStockDomain_f4646042-ccf9-46ad-bd08-6e4a841b4df4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4646042-ccf9-46ad-bd08-6e4a841b4df4" xlink:to="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_f83c2065-694f-4fcd-9974-dc66c1b38418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:to="loc_us-gaap_CommonClassBMember_f83c2065-694f-4fcd-9974-dc66c1b38418" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3e945f50-c1e6-4de4-b0f2-2e8e6ff699b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:to="loc_us-gaap_CommonClassAMember_3e945f50-c1e6-4de4-b0f2-2e8e6ff699b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b1965859-ace8-4342-80b4-6f265355e61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b1965859-ace8-4342-80b4-6f265355e61c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_b1965859-ace8-4342-80b4-6f265355e61c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b1965859-ace8-4342-80b4-6f265355e61c" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_b1965859-ace8-4342-80b4-6f265355e61c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_48ffe8a3-3b45-4c4b-9e4b-2f6e3183cdde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b1965859-ace8-4342-80b4-6f265355e61c" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_48ffe8a3-3b45-4c4b-9e4b-2f6e3183cdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_c16cbe27-7eed-4ff1-9022-d28d16f5422a" xlink:href="vtvt-20220630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_48ffe8a3-3b45-4c4b-9e4b-2f6e3183cdde" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_c16cbe27-7eed-4ff1-9022-d28d16f5422a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="i41b3f08069ad4bafb57b9c9944087cb9_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:href="vtvt-20220630.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b2436971-792e-4df1-92f7-0ac05a0cd7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b2436971-792e-4df1-92f7-0ac05a0cd7c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_0a10597f-b546-429e-8cab-b8131dd4aced" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_0a10597f-b546-429e-8cab-b8131dd4aced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_da987760-472b-465e-94d5-b693671a6bfe" xlink:href="vtvt-20220630.xsd#vtvt_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:to="loc_vtvt_IncomeTaxesTable_da987760-472b-465e-94d5-b693671a6bfe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e027803b-48d0-45ea-85cf-d91a2ab0ee97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_IncomeTaxesTable_da987760-472b-465e-94d5-b693671a6bfe" xlink:to="loc_dei_LegalEntityAxis_e027803b-48d0-45ea-85cf-d91a2ab0ee97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e027803b-48d0-45ea-85cf-d91a2ab0ee97_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e027803b-48d0-45ea-85cf-d91a2ab0ee97" xlink:to="loc_dei_EntityDomain_e027803b-48d0-45ea-85cf-d91a2ab0ee97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7416f389-d76d-4ab3-b606-c0c9ba4d054e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e027803b-48d0-45ea-85cf-d91a2ab0ee97" xlink:to="loc_dei_EntityDomain_7416f389-d76d-4ab3-b606-c0c9ba4d054e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_b4fc70de-6b50-4fb2-9dba-df98d1e4f04b" xlink:href="vtvt-20220630.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7416f389-d76d-4ab3-b606-c0c9ba4d054e" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_b4fc70de-6b50-4fb2-9dba-df98d1e4f04b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended" id="ie2d5155b8d474b2b9e51b52f145a5afa_NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:href="vtvt-20220630.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_916767cb-63ef-45b9-b7fc-bc61bdeb053a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_ProfitLoss_916767cb-63ef-45b9-b7fc-bc61bdeb053a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c5881bd3-7425-4334-8c05-b5f26ea4a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c5881bd3-7425-4334-8c05-b5f26ea4a9d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9040e7b-69bb-418e-ba6f-7525febfd88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9040e7b-69bb-418e-ba6f-7525febfd88a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_263caf34-5a35-4390-9036-0e7dac45ee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_263caf34-5a35-4390-9036-0e7dac45ee0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_575cb379-beef-4162-988a-fada2b3c7081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_575cb379-beef-4162-988a-fada2b3c7081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7e22e45-f416-49a8-8635-408b61038807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7e22e45-f416-49a8-8635-408b61038807" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b60bee95-b59c-4312-aa32-db0eeca7a95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_EarningsPerShareBasic_b60bee95-b59c-4312-aa32-db0eeca7a95c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0c2c36f3-920b-4c78-b957-c9fe8a5361cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0c2c36f3-920b-4c78-b957-c9fe8a5361cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_223da861-bfdc-4442-b873-6aaf35495b1b" xlink:href="vtvt-20220630.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_223da861-bfdc-4442-b873-6aaf35495b1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_80ba0dc6-bffb-4230-8a5f-8280e5779879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_223da861-bfdc-4442-b873-6aaf35495b1b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_80ba0dc6-bffb-4230-8a5f-8280e5779879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_80ba0dc6-bffb-4230-8a5f-8280e5779879_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_80ba0dc6-bffb-4230-8a5f-8280e5779879" xlink:to="loc_us-gaap_ClassOfStockDomain_80ba0dc6-bffb-4230-8a5f-8280e5779879_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_948d9771-e69d-4cdf-8e5a-65138d79c661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_80ba0dc6-bffb-4230-8a5f-8280e5779879" xlink:to="loc_us-gaap_ClassOfStockDomain_948d9771-e69d-4cdf-8e5a-65138d79c661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0c93b460-bbc1-4646-85c0-cb570c8ede5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_948d9771-e69d-4cdf-8e5a-65138d79c661" xlink:to="loc_us-gaap_CommonClassAMember_0c93b460-bbc1-4646-85c0-cb570c8ede5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended" id="i73d4fc1b7fbc4709b90949cc0f6d427a_NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5060b9d2-3605-451d-8c6e-f4fce2c9436e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01bbb43e-8680-4eb2-90ee-caccf9077773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5060b9d2-3605-451d-8c6e-f4fce2c9436e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01bbb43e-8680-4eb2-90ee-caccf9077773" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2240733c-aaea-4054-96e8-7d1b488eef4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5060b9d2-3605-451d-8c6e-f4fce2c9436e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2240733c-aaea-4054-96e8-7d1b488eef4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d1215d-ccc7-41a9-bf02-29dc72f269f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2240733c-aaea-4054-96e8-7d1b488eef4f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d1215d-ccc7-41a9-bf02-29dc72f269f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82d1215d-ccc7-41a9-bf02-29dc72f269f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d1215d-ccc7-41a9-bf02-29dc72f269f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82d1215d-ccc7-41a9-bf02-29dc72f269f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d1215d-ccc7-41a9-bf02-29dc72f269f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_fe751408-32d0-4783-a8ac-0693f4f503dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:to="loc_us-gaap_CommonClassBMember_fe751408-32d0-4783-a8ac-0693f4f503dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_077964a6-34e5-4cf2-8f9a-f62d8210a28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:to="loc_us-gaap_EmployeeStockOptionMember_077964a6-34e5-4cf2-8f9a-f62d8210a28c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e59dd019-03a3-48b4-8784-135aaee1fa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:to="loc_us-gaap_WarrantMember_e59dd019-03a3-48b4-8784-135aaee1fa8b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended" id="iaa49180a922c4cbb89d1c4be3212541e_FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0fd0d641-473a-47c1-adeb-020234b00d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0fd0d641-473a-47c1-adeb-020234b00d36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fde7547c-fbb4-4315-8865-2083240edca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_fde7547c-fbb4-4315-8865-2083240edca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_52fba435-f454-47f7-b464-045ef28ec4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_52fba435-f454-47f7-b464-045ef28ec4b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b0d2bb2-0f46-433f-9864-71b195c13e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b0d2bb2-0f46-433f-9864-71b195c13e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b0d2bb2-0f46-433f-9864-71b195c13e43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b0d2bb2-0f46-433f-9864-71b195c13e43" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b0d2bb2-0f46-433f-9864-71b195c13e43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4eba95e5-af75-4781-8f07-562ccb2a48f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b0d2bb2-0f46-433f-9864-71b195c13e43" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4eba95e5-af75-4781-8f07-562ccb2a48f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4c53bb4a-f87d-4db6-9df3-00341ae0bde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4eba95e5-af75-4781-8f07-562ccb2a48f5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4c53bb4a-f87d-4db6-9df3-00341ae0bde2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0b283c28-2ee3-4efb-a759-f84f9f321731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0b283c28-2ee3-4efb-a759-f84f9f321731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_18d9136c-8c00-40b6-9cb4-6bcce3909952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_18d9136c-8c00-40b6-9cb4-6bcce3909952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cd2f0f53-1d2f-4ebc-9d6c-c2eb52c5d9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cd2f0f53-1d2f-4ebc-9d6c-c2eb52c5d9b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b53d399e-64da-4fa8-9ebf-4cf44aeb42be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b53d399e-64da-4fa8-9ebf-4cf44aeb42be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b53d399e-64da-4fa8-9ebf-4cf44aeb42be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b53d399e-64da-4fa8-9ebf-4cf44aeb42be" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b53d399e-64da-4fa8-9ebf-4cf44aeb42be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d968d7f-cd21-49a5-a1b6-118147266c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b53d399e-64da-4fa8-9ebf-4cf44aeb42be" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d968d7f-cd21-49a5-a1b6-118147266c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_30b97e9c-8b97-4833-8f43-307d7236b712" xlink:href="vtvt-20220630.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d968d7f-cd21-49a5-a1b6-118147266c17" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_30b97e9c-8b97-4833-8f43-307d7236b712" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_38b8e900-474b-47e0-ba9b-854ccd50c759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_38b8e900-474b-47e0-ba9b-854ccd50c759" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_38b8e900-474b-47e0-ba9b-854ccd50c759_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_38b8e900-474b-47e0-ba9b-854ccd50c759" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_38b8e900-474b-47e0-ba9b-854ccd50c759_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9a54f4af-fc79-47c7-9245-f1f354e61c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_38b8e900-474b-47e0-ba9b-854ccd50c759" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9a54f4af-fc79-47c7-9245-f1f354e61c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_fe52108a-ff1d-4f61-bfd4-6d48cbc4ba71" xlink:href="vtvt-20220630.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9a54f4af-fc79-47c7-9245-f1f354e61c57" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_fe52108a-ff1d-4f61-bfd4-6d48cbc4ba71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended" id="ieabd612d12254a43b84816408030bfaa_FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_4b6099ef-2bbf-4063-b676-f42577f31055" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_4b6099ef-2bbf-4063-b676-f42577f31055" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f48b4641-c13d-43f7-b383-b0077d1171dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f48b4641-c13d-43f7-b383-b0077d1171dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c396739b-110d-43db-912b-522d911d9157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c396739b-110d-43db-912b-522d911d9157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cff7598d-2251-44ec-b48a-6796a72b0495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cff7598d-2251-44ec-b48a-6796a72b0495" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_71e25db2-7bcb-461b-bc82-531e60a8584f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_71e25db2-7bcb-461b-bc82-531e60a8584f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3cc94d40-76a4-428d-9ecb-f8c6cfd6ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_4b6099ef-2bbf-4063-b676-f42577f31055" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_883350b2-3172-4afa-aeea-0c6bdbeaf08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_883350b2-3172-4afa-aeea-0c6bdbeaf08c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_883350b2-3172-4afa-aeea-0c6bdbeaf08c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_883350b2-3172-4afa-aeea-0c6bdbeaf08c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_883350b2-3172-4afa-aeea-0c6bdbeaf08c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894e4c6e-3899-401b-b662-10f61db98c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_883350b2-3172-4afa-aeea-0c6bdbeaf08c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894e4c6e-3899-401b-b662-10f61db98c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_37730270-cd73-453d-a215-3ac6fdb3e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894e4c6e-3899-401b-b662-10f61db98c1f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_37730270-cd73-453d-a215-3ac6fdb3e56c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_7d383073-0abd-4e27-8792-177e14d6bb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_7d383073-0abd-4e27-8792-177e14d6bb57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7d383073-0abd-4e27-8792-177e14d6bb57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7d383073-0abd-4e27-8792-177e14d6bb57" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7d383073-0abd-4e27-8792-177e14d6bb57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_51300e86-e333-46b0-ad7b-ccd5d145dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7d383073-0abd-4e27-8792-177e14d6bb57" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_51300e86-e333-46b0-ad7b-ccd5d145dd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_962407d4-1b2a-4db4-a639-cd494e7697fb" xlink:href="vtvt-20220630.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_51300e86-e333-46b0-ad7b-ccd5d145dd22" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_962407d4-1b2a-4db4-a639-cd494e7697fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail" xlink:type="extended" id="i3301530994364a15b47a981282714a5b_FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0dfc9758-97c1-484f-ba5e-e2b6417e03a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_022fcef0-b4f2-45da-b35b-635326955e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0dfc9758-97c1-484f-ba5e-e2b6417e03a7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_022fcef0-b4f2-45da-b35b-635326955e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0dfc9758-97c1-484f-ba5e-e2b6417e03a7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa40b469-992b-4fc6-922e-22b9e6aca986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa40b469-992b-4fc6-922e-22b9e6aca986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember_8040e431-bcaf-4b34-b608-9975aca74957" xlink:href="vtvt-20220630.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa40b469-992b-4fc6-922e-22b9e6aca986" xlink:to="loc_vtvt_LetterAgreementWarrantsMember_8040e431-bcaf-4b34-b608-9975aca74957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16480588-5a67-4e4c-9709-d15733710996" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:to="loc_srt_RangeAxis_16480588-5a67-4e4c-9709-d15733710996" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16480588-5a67-4e4c-9709-d15733710996_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16480588-5a67-4e4c-9709-d15733710996" xlink:to="loc_srt_RangeMember_16480588-5a67-4e4c-9709-d15733710996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16480588-5a67-4e4c-9709-d15733710996" xlink:to="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_32cd81fe-ae69-47a9-9119-ae8c638fb92c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:to="loc_srt_MinimumMember_32cd81fe-ae69-47a9-9119-ae8c638fb92c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca899218-f6ee-4c64-849e-1b71dbb20e0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:to="loc_srt_MaximumMember_ca899218-f6ee-4c64-849e-1b71dbb20e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0d50266b-4a87-46de-a1dd-c1549a2d9192" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:to="loc_srt_WeightedAverageMember_0d50266b-4a87-46de-a1dd-c1549a2d9192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_85807bf8-d15f-49c8-a13e-8bfffc2daa95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_85807bf8-d15f-49c8-a13e-8bfffc2daa95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_85807bf8-d15f-49c8-a13e-8bfffc2daa95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_85807bf8-d15f-49c8-a13e-8bfffc2daa95" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_85807bf8-d15f-49c8-a13e-8bfffc2daa95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_85807bf8-d15f-49c8-a13e-8bfffc2daa95" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_90612c7c-f03e-4978-b3b0-3c4b919a4675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_90612c7c-f03e-4978-b3b0-3c4b919a4675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1cc5594-2231-4e85-aedf-4f8c7e8d43ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1cc5594-2231-4e85-aedf-4f8c7e8d43ba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtvt-20220630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="extended" id="ibd0056e1a1244775afb148a5343c7cb4_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd017614-7375-4397-968f-b2997cc62588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd017614-7375-4397-968f-b2997cc62588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_94da4a17-2dca-482f-92e4-059324490a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_94da4a17-2dca-482f-92e4-059324490a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_ed543fa6-6e3a-4d92-bbad-473ab1aa3bf8" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_ed543fa6-6e3a-4d92-bbad-473ab1aa3bf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0baa3e8-5b88-48ca-8d2f-a5db2821b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0baa3e8-5b88-48ca-8d2f-a5db2821b4aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_918770af-bb66-46c1-afb4-b6d732b51ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ReceivablesNetCurrent_918770af-bb66-46c1-afb4-b6d732b51ca6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_93555afd-9b94-42e2-a5ae-6566d93e18c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_93555afd-9b94-42e2-a5ae-6566d93e18c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6cf521f5-ec80-4f7e-96dd-0b6608f1a1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6cf521f5-ec80-4f7e-96dd-0b6608f1a1cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f17e6716-2070-4919-a16b-dde9a080f8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f17e6716-2070-4919-a16b-dde9a080f8a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_cfc13cd0-1eef-4259-b9b7-1f6896e48d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_cfc13cd0-1eef-4259-b9b7-1f6896e48d88" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22f29707-2c41-4289-8033-8177fdb63df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22f29707-2c41-4289-8033-8177fdb63df0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_581fb49b-e02b-42d4-9f1f-c9077c7ca68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_581fb49b-e02b-42d4-9f1f-c9077c7ca68b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c45cacf8-8572-4f68-a28f-52a37a5873ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c45cacf8-8572-4f68-a28f-52a37a5873ed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4e3a7a23-ee47-4043-a205-a61caff19626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4e3a7a23-ee47-4043-a205-a61caff19626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4e3a7a23-ee47-4043-a205-a61caff19626_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4e3a7a23-ee47-4043-a205-a61caff19626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4e3a7a23-ee47-4043-a205-a61caff19626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11dcda68-e19d-42f3-97dd-e329eb296f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4e3a7a23-ee47-4043-a205-a61caff19626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11dcda68-e19d-42f3-97dd-e329eb296f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_898622fc-f978-4836-9728-5d64534d79f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_11dcda68-e19d-42f3-97dd-e329eb296f1d" xlink:to="loc_us-gaap_SubsequentEventMember_898622fc-f978-4836-9728-5d64534d79f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_717df4c8-40ca-48bb-9811-1cad270abf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:to="loc_us-gaap_StatementClassOfStockAxis_717df4c8-40ca-48bb-9811-1cad270abf06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_717df4c8-40ca-48bb-9811-1cad270abf06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_717df4c8-40ca-48bb-9811-1cad270abf06" xlink:to="loc_us-gaap_ClassOfStockDomain_717df4c8-40ca-48bb-9811-1cad270abf06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_78f5876a-7c76-4640-a05f-51a99e04f8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_717df4c8-40ca-48bb-9811-1cad270abf06" xlink:to="loc_us-gaap_ClassOfStockDomain_78f5876a-7c76-4640-a05f-51a99e04f8db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_674da1df-9747-4d32-b44f-e34492beeaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_78f5876a-7c76-4640-a05f-51a99e04f8db" xlink:to="loc_us-gaap_CommonClassAMember_674da1df-9747-4d32-b44f-e34492beeaca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2768886b-14b2-4c81-ac4d-3463e7a19594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:to="loc_us-gaap_VestingAxis_2768886b-14b2-4c81-ac4d-3463e7a19594" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2768886b-14b2-4c81-ac4d-3463e7a19594_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_2768886b-14b2-4c81-ac4d-3463e7a19594" xlink:to="loc_us-gaap_VestingDomain_2768886b-14b2-4c81-ac4d-3463e7a19594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_2768886b-14b2-4c81-ac4d-3463e7a19594" xlink:to="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2905574d-a534-4dd0-84d6-87f0753a20eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2905574d-a534-4dd0-84d6-87f0753a20eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e663fa44-59f9-41d1-b0f8-934c35d661c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e663fa44-59f9-41d1-b0f8-934c35d661c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vtvt-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cc23dfa8-b7f1-4dd2-bc21-5440216f3885,g:7d227720-4a1d-461e-9922-f5c0b011aa4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_468e123d-7e4d-4200-bb59-03f32b7d1b43_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_label_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_documentation_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable non controlling interest exchange agreement stock conversion ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:to="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_VTvLLCMember_ab09417c-4408-498e-ac9b-01824aaf2cd5_terseLabel_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">vTv Therapeutics LLC</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_label_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">V Tv L L C [Member]</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_documentation_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">vTv LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember" xlink:href="vtvt-20220630.xsd#vtvt_VTvLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_VTvLLCMember" xlink:to="lab_vtvt_VTvLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_334d09bf-9067-46e5-96a4-5017ccce3745_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2bc57d96-aee7-4d03-9feb-c754f897e3dc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_79764014-bad7-4285-99ed-2012cd9c8ad3_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_67ba658a-7e5a-410e-ac30-6896984304f2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_61c6c73e-c528-419f-9053-042cd26dd441_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_97b0f4fa-9bf4-4c33-891a-f270eac172c5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAgreementObligationsDomain_c4504ed7-64ea-4c09-93ba-c880980200cd_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsDomain_label_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations [Domain]</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsDomain_documentation_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAgreementObligationsDomain" xlink:to="lab_vtvt_LicenseAgreementObligationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b63c2508-1600-403c-ab8e-7cef773c851e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_91c49353-60f4-43ef-8930-3daaaaf65f36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ChangeInContractWithCustomerLiabilityRollForward_bbbc7f46-836c-4a1d-a889-1105a49cb8dd_terseLabel_en-US" xlink:label="lab_vtvt_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Roll Forward]</link:label>
    <link:label id="lab_vtvt_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_vtvt_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_vtvt_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_vtvt_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="vtvt-20220630.xsd#vtvt_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_vtvt_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_009cc7d0-69e3-4d78-8452-9971a735f0aa_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in redemption value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1bb2a88e-428c-42b9-b4d7-48b236e6bf30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_6b2a7227-c79f-473b-86bd-b97814705e34_terseLabel_en-US" xlink:label="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment with readily determinable fair value:</link:label>
    <link:label id="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_label_en-US" xlink:label="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments With Readily Determinable Fair Value</link:label>
    <link:label id="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_documentation_en-US" xlink:label="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments with readily determinable fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:href="vtvt-20220630.xsd#vtvt_EquityInvestmentsWithReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:to="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_0b1fe33b-5c27-42fe-a3b8-da87f12e2647_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, contingent consideration</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:to="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_47f6bc04-ffea-4f4d-92d3-d8b7a7e3e156_terseLabel_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances</link:label>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_label_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent</link:label>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_documentation_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:href="vtvt-20220630.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:to="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eff1f292-22d5-4791-b3e0-39253e70b475_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled_21e1f563-8004-4a64-9abd-ba83cdc3b4b5_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options cancelled (in shares)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" xlink:href="vtvt-20220630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" xlink:to="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cc448d55-5a77-4d0c-bfb7-d39b3200de41_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cae8ae8f-4ae6-4e70-8461-582ef9a01185_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58c15b96-f8da-44d6-8027-7b12ec209624_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_64d365c0-8965-424e-8559-5bbee23554d3_terseLabel_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MacAndrews &amp; Forbes Incorporated</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_label_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mac Andrews And Forbes Incorporated [Member]</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_documentation_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MacAndrews and Forbes Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:href="vtvt-20220630.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:to="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d5966cca-7feb-459d-a2a4-5f0dcd688524_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a40a7d9f-940d-4cdf-8eaf-4d8c6fd961f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_d76b4d18-9d71-43e1-a99e-dc1b2b941860_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_3d2710e2-e888-49cd-8aec-1fb18043de5d_terseLabel_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 2 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Two Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 2 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember" xlink:href="vtvt-20220630.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeTwoDiabetesMember" xlink:to="lab_vtvt_TypeTwoDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_8ac932ab-37ca-4802-8947-74bdded43a54_terseLabel_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, termination period</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_label_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_documentation_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:href="vtvt-20220630.xsd#vtvt_LesseeOperatingLeaseTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:to="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G2InvestmentMember_fd6efe3d-7003-4cae-867c-b88457a4eb0f_terseLabel_en-US" xlink:label="lab_vtvt_G2InvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investment</link:label>
    <link:label id="lab_vtvt_G2InvestmentMember_label_en-US" xlink:label="lab_vtvt_G2InvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investment [Member]</link:label>
    <link:label id="lab_vtvt_G2InvestmentMember_documentation_en-US" xlink:label="lab_vtvt_G2InvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentMember" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G2InvestmentMember" xlink:to="lab_vtvt_G2InvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_a274c732-3dfd-47b2-b150-ac40a531b489_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:href="vtvt-20220630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8365806a-123d-490a-af40-3243af0f5a6c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_89562e06-f9c5-48bd-9694-0c5a4c51120c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_fc1ab429-2b05-4d3b-8d97-e34558d5a0e7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_419a3e16-5544-4602-a305-3e08d03d5076_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b4001546-bdbc-4365-a047-9805d829f256_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_c62a7ea4-c84a-4735-90e3-26037bee7675_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_123929a9-4919-41f8-a308-fbd5f347464c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3859731a-9f18-4a66-9d4f-a49363a2a602_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f793b60a-b9a9-45f7-87df-924452f93f8a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2b773c6a-3ff2-4e59-b943-61c2a9401df8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ef97a867-99ca-498a-bcc0-b9ba30f09e08_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fcb661b8-4fc5-4927-a950-87d99f9e5941_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7de2c6b0-1602-4684-951e-e07b88f02bad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_20ffd5ea-3209-424f-91c2-aa5d99795e7b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_8925875d-5c31-44b6-bb5b-4d02c193894e_terseLabel_en-US" xlink:label="lab_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interests And Equity Method Investments Disclosure [Abstract]</link:label>
    <link:label id="lab_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_label_en-US" xlink:label="lab_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interests And Equity Method Investments Disclosure [Abstract]</link:label>
    <link:label id="lab_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_documentation_en-US" xlink:label="lab_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interests And Equity Method Investments Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:href="vtvt-20220630.xsd#vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:to="lab_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FundingReceived_be002a25-3175-47fb-a009-47395b6ba992_terseLabel_en-US" xlink:label="lab_vtvt_FundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received</link:label>
    <link:label id="lab_vtvt_FundingReceived_label_en-US" xlink:label="lab_vtvt_FundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received</link:label>
    <link:label id="lab_vtvt_FundingReceived_documentation_en-US" xlink:label="lab_vtvt_FundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FundingReceived" xlink:href="vtvt-20220630.xsd#vtvt_FundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FundingReceived" xlink:to="lab_vtvt_FundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e337b10d-9f55-402d-b79d-45960a4236d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_e8416930-0451-4910-bca1-691a31f447bb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3b52c718-ca63-4bca-9b68-e0f26993f6ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ProceedsFromSaleOfCommonStock_1790229c-b39e-4e7c-89c4-d5f4d1dc82ad_terseLabel_en-US" xlink:label="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of Class A common stock to collaboration partner, net of offering costs</link:label>
    <link:label id="lab_vtvt_ProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_vtvt_ProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ProceedsFromSaleOfCommonStock" xlink:href="vtvt-20220630.xsd#vtvt_ProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ProceedsFromSaleOfCommonStock" xlink:to="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_39f43c62-674e-4218-8cbc-3d0a25f3eab5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_4646ce1f-fc42-42d7-9951-08aee3c53111_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, value</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f9736436-cbae-4fe2-919a-73b6c9beeef0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8dc6eda5-27d5-4f54-a151-69304f8f0350_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CantorFitzgeraldMember_134e7688-ff0a-4e79-b644-8d2e7d3bbce7_terseLabel_en-US" xlink:label="lab_vtvt_CantorFitzgeraldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor Fitzgerald</link:label>
    <link:label id="lab_vtvt_CantorFitzgeraldMember_label_en-US" xlink:label="lab_vtvt_CantorFitzgeraldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
    <link:label id="lab_vtvt_CantorFitzgeraldMember_documentation_en-US" xlink:label="lab_vtvt_CantorFitzgeraldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor fitzgerald member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember" xlink:href="vtvt-20220630.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CantorFitzgeraldMember" xlink:to="lab_vtvt_CantorFitzgeraldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8b181799-1cc1-4b93-9c52-59bccccbe458_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_c1e2183a-cfc3-4d3c-af50-1ee5ea51bbbb_terseLabel_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novo License Agreement</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_label_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novo License Agreement [Member]</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novo license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember" xlink:href="vtvt-20220630.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NovoLicenseAgreementMember" xlink:to="lab_vtvt_NovoLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9fd101c4-c229-4c90-bca5-495e3b9051ee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2313a714-bca4-4a8a-b007-07bcdc8ae38d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1da7ae05-1bf4-4dc3-b4d3-7dcc314cac08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9f08e6-71f6-4e32-a2a6-ce45437cbc79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_c8f7f4a3-6e58-445e-8222-7300c4ec5b72_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_label_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_documentation_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNoncontrollingInterestsMember" xlink:to="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_d9ec11c9-3991-445f-8d31-aa934873e97d_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_4857deba-7850-4e6e-9241-0d965a88a182_terseLabel_en-US" xlink:label="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 MRCT</link:label>
    <link:label id="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_label_en-US" xlink:label="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Two Multi Regional Clinical Trial [Member]</link:label>
    <link:label id="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_documentation_en-US" xlink:label="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase two multi-regional clinical trial.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:href="vtvt-20220630.xsd#vtvt_PhaseTwoMultiRegionalClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:to="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1d8b6c12-e07f-4df1-bf2a-b0ab5b6e78d7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_85cc130b-6ee3-4198-b950-c1277c76b3b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_42b44360-7874-43fc-9d6d-5f2cec1abf86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a113b99c-d69b-4de2-bd2b-ba71d8d4319f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ac287295-6193-4fb7-b4ac-0640ed39132f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a40e1ea5-10fe-4f89-bd98-ae37d4484083_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining operating lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768e619a-a596-4ce8-ab2b-2bbb22305a0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_14197a32-5a63-4ea1-9ea3-d15bd65b5c0e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_268fa6af-9099-49d3-a76b-cafcd2b5f7c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A common stock to collaboration partner</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f5d04133-c3e2-477d-99df-971f53f70566_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5a9967e2-dcb4-4424-8a9b-5deb20247089_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9aeb58a3-96df-4e3e-b681-174b456523c4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd577628-6f22-40a4-b300-76b70a275746_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_09376744-72f6-4151-95a2-086e7c557921_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_241f92e7-b7e4-44a3-849a-097ee4eaffd3_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_592071f2-ff30-4027-893e-c5e8d974e3f9_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5f75a7d2-1a26-4127-8da7-1a5052330c10_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_0949fd1d-b754-4566-8069-61f1358e327b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_9ec1c964-14d0-46a1-a924-8fa6a9e66b2e_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption amount of noncontrolling interest</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_label_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest Temporary Equity Redemption Value</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_documentation_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest temporary equity redemption value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:to="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_2cddcee8-76b3-427f-8f48-3d8cec7ab7a2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_10c0e04a-75e2-4f57-91b2-f119ba2bdd5d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_4fffee11-a853-4af0-aca0-cf1ab1281628_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c96c473e-73ae-4973-b8b2-c978c2bb66b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Change in fair value included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1a04e866-1c83-4b36-9659-fd91078d715a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract_bdac2cf3-6cb5-4551-8cc5-9d9b21c30a2d_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Contingency And Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Contingency And Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract_documentation_en-US" xlink:label="lab_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment, Contingency And Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:to="lab_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2320e223-bcce-425b-be38-4095a85f37c6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_010a4a74-fd2d-40e9-aa2f-94441cebe06d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e83801f8-deff-488b-877f-4dd7b2713589_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8f8cf07f-f167-44d1-aee3-17af1326a1b4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contract Liabilities Related to Company's Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ac416ab1-09ca-48bd-ac77-4be8992ff38c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aaf5ab17-8906-48da-af77-bb2c54b72a6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_0039de40-3299-4d75-b008-45ea9e9fa642_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction, gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1062b76b-bc39-48a3-9878-9c8d22404003_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7e56633f-e700-4ccb-b71c-ed06275e39dc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bde52e39-3b09-4afa-be15-0f0891857fd2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_a20eb3ba-c1dc-4bd9-bc51-ca618843da67_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0d7dbc09-80e0-4277-9da1-030856efa830_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TemporaryEquityChangeInRedemptionValue_9e5921d9-984b-4e1a-97de-56440fb0364e_terseLabel_en-US" xlink:label="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in redemption value of noncontrolling interest</link:label>
    <link:label id="lab_vtvt_TemporaryEquityChangeInRedemptionValue_label_en-US" xlink:label="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Change In Redemption Value</link:label>
    <link:label id="lab_vtvt_TemporaryEquityChangeInRedemptionValue_documentation_en-US" xlink:label="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Change In Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:href="vtvt-20220630.xsd#vtvt_TemporaryEquityChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:to="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfa3a84c-7ee3-4768-97c4-a6537e9dc32c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d1bbb61d-3e72-402d-90ef-61e112b18a87_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_c3be5e1d-e08c-471d-bbb7-b98d47962f12_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_953e27d5-0330-4725-b818-4845ae67f5a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52e385bd-3aea-4537-b393-7d2548e8fe17_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2e900d17-8c40-462d-b24d-7e2b00803d39_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca49ec68-17f0-4117-8054-4a9caf310d77_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a87fc353-655f-4ad8-b5be-74252f6be2d9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_1b491f17-ca7d-4ffa-b6ef-3edfae900969_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3a2c0967-6141-4687-aa95-de0ffd9ba2b5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_6ce155bf-3d4e-4e5a-994a-a521afe4d3ce_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:to="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2ac41256-00b1-4a3f-ba5d-313e2d855105_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_2f5705fa-179d-4b73-a60e-5386bebc405b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8c282a49-0742-4866-9fbd-524ab0cb4b79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c0d9f140-67df-48ce-bf3f-a12f978b7f4f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90a1c2af-46b3-40a7-8774-ed8b7368a99c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period to recognize unrecognized share-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_26b0f760-853f-46f4-8e6a-10c165014c52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AnterisBioIncMember_0d5d6055-d404-427c-b1ea-03a2a8ddbc89_terseLabel_en-US" xlink:label="lab_vtvt_AnterisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anteris Bio Inc</link:label>
    <link:label id="lab_vtvt_AnterisBioIncMember_label_en-US" xlink:label="lab_vtvt_AnterisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anteris Bio Inc [Member]</link:label>
    <link:label id="lab_vtvt_AnterisBioIncMember_documentation_en-US" xlink:label="lab_vtvt_AnterisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anteris Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember" xlink:href="vtvt-20220630.xsd#vtvt_AnterisBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AnterisBioIncMember" xlink:to="lab_vtvt_AnterisBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_087f2c41-290f-43b0-b589-c038427c2758_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_efbe1ea5-89a6-4cd4-aeef-c562918b8845_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of cash savings percentage</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_label_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Amount Of Cash Savings</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_documentation_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of amount of cash savings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:to="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_4317ce31-39df-4c61-9c5d-fe2048f7f54a_terseLabel_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborate arrangement, contingent consideration transferred, cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_label_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_documentation_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:href="vtvt-20220630.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:to="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1b0633db-25a8-4f0a-af7c-d2cecdd88dad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Common Stock to Collaboration Partner (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_9a9765fe-348c-427f-a7cd-53953d1a816a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares purchased (in usd per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_382406f5-fdc5-4e4f-be97-aac978dec6b6_terseLabel_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 1 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type One Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 1 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember" xlink:href="vtvt-20220630.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeOneDiabetesMember" xlink:to="lab_vtvt_TypeOneDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5682e9af-9683-4949-94c5-f2de590346da_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_8026253d-367f-4a05-b52c-d3f4ef745a90_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_80948e6f-30e6-4918-a75f-9ffdcf38affb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AtTheMarketOfferingMember_1351724a-5d07-414c-8259-442cff1e6685_terseLabel_en-US" xlink:label="lab_vtvt_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering</link:label>
    <link:label id="lab_vtvt_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_vtvt_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_vtvt_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_vtvt_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AtTheMarketOfferingMember" xlink:href="vtvt-20220630.xsd#vtvt_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AtTheMarketOfferingMember" xlink:to="lab_vtvt_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G42InvestmentsMember_ca64692f-312b-4721-8900-6c22c059cf78_terseLabel_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G42 Investments</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_label_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G42 Investments [Member]</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_documentation_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G42 Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember" xlink:href="vtvt-20220630.xsd#vtvt_G42InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G42InvestmentsMember" xlink:to="lab_vtvt_G42InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_cd1695f0-8c8a-4f70-b457-554f1ace299f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesTable_da90309c-24d1-4bf5-b22b-29db71a0f3ec_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_label_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable" xlink:href="vtvt-20220630.xsd#vtvt_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesTable" xlink:to="lab_vtvt_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5a196e2e-7083-4900-a150-327dc3b93098_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_0f12a8a0-a73e-44dc-aa44-d493eb7bcaf5_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:href="vtvt-20220630.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d1d2c717-d8b5-4703-9fb2-e6db138c8daa_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_770347f8-e319-47eb-ab1d-ca8cee7e8fdd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_944931fd-5f95-47b0-bb01-b598dc95f46e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c4eb6064-e8f4-46fe-91af-3772fc8ba6f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e5886a3-9f5c-4b68-aa4a-0b244fae7aaa_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b80e7c25-5216-4a2b-b452-e6aea133c36c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9986b1db-9aa4-4480-b820-0bbddbc75dab_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b425359c-a95b-493b-9f8d-f714b5f6a6f7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_648a4a7a-3a3a-4b72-b8ba-9a8b9e00da6b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_fe81661e-b0a0-43e9-8cd2-044642e39eb5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7e1cfb66-7397-44fc-b580-0bf1750aa11b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_a006eea4-ec9e-42ac-9d0e-9d20c049897b_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_75f0d022-b27b-4861-8a67-4526dedbee23_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_832a0518-28e7-4aa7-b81b-0771a2d0d818_terseLabel_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Common Stock under LPC Agreement</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_label_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase Agreement</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_documentation_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:href="vtvt-20220630.xsd#vtvt_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:to="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_690ee69b-d13b-4ba1-a068-bf48892796de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_d50082fd-a0c6-45a2-9348-0b461288ef53_terseLabel_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:href="vtvt-20220630.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a09806bf-6b3f-46e8-8168-2df8c79f96c3_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_d849cb9e-bfb2-4780-a5f5-4132a7dbe67f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_e8a77dce-4df6-4e68-9a20-35caff059c0a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_032dc810-92e8-48b4-be52-457fcb280540_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_999f63fa-dd9d-4bc1-98a1-0467388fd2e2_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d04fabd2-5e17-49a4-8135-16717edaea9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a1a4fa68-047a-4011-84e5-273c153873c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_1a55f6e6-267a-4f27-a146-770a20194533_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_9e9fe5b0-2ef5-4371-8c9a-2d02e5f731a7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b45e8023-98b1-43d5-b016-a131848f9174_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ec740dfb-de29-4eee-a694-b0b84d1ef081_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5da7c5b6-f30e-4eb6-94f8-727944d67a94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9565271c-6b7c-4bfa-ad32-08334de387f1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_966b8e1f-f90f-4f55-8876-a25a45ebcc41_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering_65476e7f-ca8c-40b2-a304-0951360fab27_terseLabel_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Class A Common Stock Under ATM Offering (in shares)</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering_label_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Class A Common Stock Under ATM Offering</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering_documentation_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Class A Common Stock Under ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:href="vtvt-20220630.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:to="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4cd56c58-579f-4f3a-9ec6-553de7a7741d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_ad09037a-17e0-426b-9523-be9ffb9a7029_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod_2526fe2f-1fe1-4c17-ac5c-703a9813dc9e_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration receivable, payment period</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Receivable, Payment Period</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Receivable, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivablePaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_68616249-28a3-4789-99b6-a18859595d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e01aa9b4-9616-4d23-80f4-7a1f982a64a3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f8bf6469-c501-41d1-88f5-a967dee95a46_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fa75927a-9ad0-4213-b9dd-37ab91956492_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d2213f2f-73d5-4acb-a27e-77ff6af594a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_e99d3e70-f8d4-4108-853f-3864662cc529_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:href="vtvt-20220630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_85319ae5-4c31-4dd3-b00c-151a3ee48eb8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_27657fd6-d7dc-4aa4-b00d-b1d7a69f7566_terseLabel_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days used to determine exchange value based on weighted average price of Class A common stock</link:label>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_label_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock</link:label>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_documentation_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period used to determine exchange value based on weighted average price of Class A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:href="vtvt-20220630.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:to="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_7be31e9f-916f-43cc-a296-2cf991ec5f5b_terseLabel_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newsoara Biopharma Co Ltd</link:label>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_label_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newsoara Biopharma Co Ltd [Member]</link:label>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_documentation_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newsoara Biopharma Co Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:href="vtvt-20220630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:to="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c7e6cb7a-0348-4c4f-a75a-ae16ab584a20_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_5be2134e-cd05-440b-aa4c-28fa4484e4f1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_22ea37d8-27ad-4376-9750-c3256323a627_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_65a20344-f31d-4cbd-8c31-4e59db5db742_negatedLabel_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_label_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Imputed Interest</link:label>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_documentation_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases imputed interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest" xlink:href="vtvt-20220630.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OperatingLeasesImputedInterest" xlink:to="lab_vtvt_OperatingLeasesImputedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba3e5770-2357-4bf8-90aa-2ce436cf0db8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7de97728-a669-44b3-8a0a-63097ab87529_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_c60000fb-4011-485a-85a4-e28619c12089_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f255e9cf-86c2-4aec-b016-6533afa834dc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26e58cc7-a933-48e7-83eb-44ebcca5d1ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to non-vested share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_JDRFInternationalMember_6b51b93f-1e03-42a9-95e3-01a4297a4acb_terseLabel_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JDRF</link:label>
    <link:label id="lab_vtvt_JDRFInternationalMember_label_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J D R F International [Member]</link:label>
    <link:label id="lab_vtvt_JDRFInternationalMember_documentation_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JDRF international.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember" xlink:href="vtvt-20220630.xsd#vtvt_JDRFInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_JDRFInternationalMember" xlink:to="lab_vtvt_JDRFInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_af7d3a03-3d4a-41f1-8b23-1775d90bf5b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_585594f9-5be1-4cd1-b1f7-7a0edc8f15ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Compensation Expense Related to Grants of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b746f4f1-3f23-40a5-b0c5-fc64446356b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_670bd740-4302-4495-8256-a345e042101f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_30df1a98-9977-4819-9951-b435f5b3178a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Income Attributable to Vtv Therapeutics Inc</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_e84e847b-01ff-4bc7-891d-0f1e03508322_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net, current</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_f848311e-4f80-41dc-951e-a489c5167196_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6c0c7519-5925-4507-a63e-3ddd2fee32ea_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_eec8c345-4352-41f1-8355-88e650f4820f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2a9f4a9e-5510-4874-8dc4-25ac5901e195_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_359c30e9-5fd2-486d-a9e8-91cd2ec3dd3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_15bdf227-dfc0-4e55-a92c-1acf08114e0c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5fb41773-2265-48ed-9015-4c7c145ebd39_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_598ed732-f233-4e8c-9f93-54ad664d5fb9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cc4e84b6-b240-497c-821b-02bee2698e91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_16935de6-cd3c-4423-97d0-9d30688a7fc7_terseLabel_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M&amp;F TTP Holdings LLC</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_label_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M F T T P Holdings L L C [Member]</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_documentation_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M&amp;F TTP Holdings LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember" xlink:href="vtvt-20220630.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MFTTPHoldingsLLCMember" xlink:to="lab_vtvt_MFTTPHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_03fc975c-3588-4b44-827f-48e1af152588_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ff3f55de-29a6-4479-a98e-0c93dadc2434_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8f95e1b7-2f4b-404c-ad00-1e4f72737084_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_cd32b488-3a3e-4517-9112-18477ff8fb93_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4d1807d-a6b9-4e42-a3b7-af2971dac4eb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8cd39637-8b2b-4a23-afdd-3282e8832db8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3ca037d4-08d9-4d1a-a780-813511caa567_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialMilestonePayment_74334fea-cd15-426c-9286-4ac02b978146_terseLabel_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_label_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_documentation_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment" xlink:href="vtvt-20220630.xsd#vtvt_PotentialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialMilestonePayment" xlink:to="lab_vtvt_PotentialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8b7ded7-5a56-41ef-8527-8366a0ed3244_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_071c284c-062e-489b-aedf-655f115d729b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_InvestmentOwnershipPercentage_1f9d49f1-d75c-48fd-bcf3-aa97a280ef22_terseLabel_en-US" xlink:label="lab_vtvt_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, ownership percentage</link:label>
    <link:label id="lab_vtvt_InvestmentOwnershipPercentage_label_en-US" xlink:label="lab_vtvt_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Ownership Percentage</link:label>
    <link:label id="lab_vtvt_InvestmentOwnershipPercentage_documentation_en-US" xlink:label="lab_vtvt_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment ownership percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_InvestmentOwnershipPercentage" xlink:href="vtvt-20220630.xsd#vtvt_InvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_InvestmentOwnershipPercentage" xlink:to="lab_vtvt_InvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_bf90f5ae-d977-41c3-855d-700a04a9525e_terseLabel_en-US" xlink:label="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed</link:label>
    <link:label id="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_label_en-US" xlink:label="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block]</link:label>
    <link:label id="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_documentation_en-US" xlink:label="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of investment in equity security with and without readily determinable fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:href="vtvt-20220630.xsd#vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:to="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_99ca5baa-ad3b-4b1d-a5f4-8ade88847266_terseLabel_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_label_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_documentation_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets and liabilities measured on recurring basis table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1b9c1766-f157-4573-b765-eedecd380ef5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_65ec296b-4e2c-42be-82d1-4966758063a1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d431f192-b371-49e9-8d59-009ad0a19b9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Award Activity for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_46021d53-3806-4697-9896-7a67540865ff_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3627538b-2bc1-4420-b9e6-17cc933f5254_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7ecc4f51-fd51-482b-a3d9-2522e80570e3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment without readily determinable fair values assessed under the measurement alternative:</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2a443b2f-a512-4cb8-81ba-bb16a9e105e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_e05858b6-7563-48b2-91d4-3b61a71dfc81_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a37ac3f2-e25b-43f2-87b4-d7a8b72868ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c9643278-efc6-446a-aa35-0e24f4fecb92_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_15896c7d-b013-4c01-a543-f2b7edf8ad99_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_1e655548-c2fe-40b1-8c72-74aa3fc711d7_terseLabel_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_label_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestone Payments Receivable</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:href="vtvt-20220630.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:to="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_905cc1dc-5dc7-4ad2-b7eb-c161c0746d37_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_573497af-fb59-493c-82c2-50aed1722351_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_51a46d5e-0286-4019-9a58-65e9d4b70244_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399a8008-6179-4e88-9b01-d0bfe7cb6688_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac4ecef2-f2e6-441a-b3d9-aa0166d25184_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_66d34a02-c90f-4510-ac8d-8e6e1971a8aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d2cd0ba6-f2e4-43d5-9eea-6caf6e24fb9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_89a7df20-865d-43d8-b7e6-107709e3acc9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f8741f8f-76c3-49dc-a927-4ff0d2243825_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SatisfactionOfMilestonePaymentMember_404775e5-05d0-4995-b396-dfc54bfb78f1_terseLabel_en-US" xlink:label="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfaction of Milestone Payment</link:label>
    <link:label id="lab_vtvt_SatisfactionOfMilestonePaymentMember_label_en-US" xlink:label="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfaction Of Milestone Payment [Member]</link:label>
    <link:label id="lab_vtvt_SatisfactionOfMilestonePaymentMember_documentation_en-US" xlink:label="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfaction of milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SatisfactionOfMilestonePaymentMember" xlink:href="vtvt-20220630.xsd#vtvt_SatisfactionOfMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SatisfactionOfMilestonePaymentMember" xlink:to="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_1681308d-7985-4415-a5e7-829e4d2e6cfc_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on note receivable</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:to="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_2d767c27-6b01-4391-836b-c86ae6262d04_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_label_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems" xlink:href="vtvt-20220630.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesLineItems" xlink:to="lab_vtvt_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e20d4acf-5b29-4f26-a5a2-4fc2a137d74c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_3a6b9700-d933-4289-833f-1bec791171b9_terseLabel_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of class A common stock under LPC agreement, shares (in shares)</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_label_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Purchase Agreement</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_documentation_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Common Stock under LPC agreement shares..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:href="vtvt-20220630.xsd#vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:to="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_9a530eac-2bae-4ed5-9364-3738fd217cdf_terseLabel_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_label_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_documentation_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets and liabilities measured on recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41c530ce-a02d-445b-b92f-077b046bfe58_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_d30ee18e-833d-440d-9935-6b7b6fb48b21_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_bd7650c7-0701-412e-93d8-fb4cb8214ca8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c0363268-6dad-48ab-bfc1-e9f3fa973856_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_aad8f62f-a46e-45d0-a4cc-aeadb13fc7f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock value</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_9bdf19e6-60c8-4b19-a42b-f0a3a4117b90_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8bfb911c-e182-4f9a-9c07-929ed1acce43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty_589eae76-d47a-4893-a1fc-792b2678d777_terseLabel_en-US" xlink:label="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrants, related party</link:label>
    <link:label id="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty_label_en-US" xlink:label="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrants Related Party</link:label>
    <link:label id="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty_documentation_en-US" xlink:label="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrants related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:href="vtvt-20220630.xsd#vtvt_ChangeInFairValueOfWarrantsRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:to="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a15d1761-e379-4d73-bc6c-f001dc8518bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarizes the Conclusions Reached Regarding Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8118c935-b99c-4bb0-a17d-939bd2a59474_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_873fa7f2-fbc2-4a0d-87ac-3e098754b902_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f2dad8c7-003a-465d-a099-1e399b229a2f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_05e39f98-eefe-4023-b4b1-8e7956518ae6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_35515e28-03b8-4c29-b0e5-bb9370d70806_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1b233387-3f13-4c3b-abbd-eb38eef4ec73_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inputs utilized in the valuation of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_36caf0c7-0388-4aef-ac38-fcacfcc9226a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2a5cc7dd-3b80-4b7e-8a3e-ec76da32fb2a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c128b05a-2000-4448-a7ec-27ca98c4e3da_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7c976af0-d49e-4014-90dd-41a6f38e1b27_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4a4bf1c6-c69b-4fc0-b0db-5c8b696707f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases / Issuance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_80166cef-8b68-417e-85ce-70cd22ea10dd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_34bf150f-7c4f-4b46-9402-afc3b1857ea6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_74f7f19f-2f8b-41bb-8b31-333eecd0087a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_413958d5-e687-4d8f-b3e5-d6f42a0b650e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_400469a2-42ed-4f0d-972f-c0bfdbe3cfa7_terseLabel_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developmental and Regulatory Milestone Payment</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_label_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developmental And Regulatory Milestone Payment [Member]</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_documentation_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developmental and regulatory milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:href="vtvt-20220630.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:to="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_3cc85e86-b702-426e-a2db-fb9354e5146c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_69f197b1-0888-4092-b3d4-827fa1cc6419_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f8cbd18c-037c-422e-9449-aad4405e75fc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_88ae423f-3cdd-4add-9977-b07690e4728a_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties receivable, period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:to="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock_b93228f4-65c8-419c-8cbf-f823b3fa0a36_terseLabel_en-US" xlink:label="lab_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes</link:label>
    <link:label id="lab_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock_label_en-US" xlink:label="lab_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes [Table Text Block]</link:label>
    <link:label id="lab_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock_documentation_en-US" xlink:label="lab_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" xlink:href="vtvt-20220630.xsd#vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" xlink:to="lab_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5a7a314-edba-4509-9513-d605a433530e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_fab42fb6-488b-47ad-9f0b-8ea8d00f8e34_terseLabel_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="vtvt-20220630.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_08f99777-2a26-4884-9bcb-9a0eebf70c3d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_fe57f226-429b-428b-bae6-ce08366042c6_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d23b0ba-b827-46ec-8d3f-65cc61965e4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f79db356-56fd-4b74-a4b6-0fdbbebfb325_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a592e49-9b3c-4b6c-b201-8c6e49d33d30_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod_c541daae-5b02-4c27-913f-4cf4ec8321fc_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred services per agreement terms</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Technology Transfer Services Period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Technology Transfer Services Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod" xlink:to="lab_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OtherIndicationMember_bdcad21d-dd7c-4fbd-98ca-4d04e89d58b5_terseLabel_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Indication</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_label_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Indication [Member]</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_documentation_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other indication.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember" xlink:href="vtvt-20220630.xsd#vtvt_OtherIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OtherIndicationMember" xlink:to="lab_vtvt_OtherIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_57ace453-9c11-4db6-a67a-bc14fa9559f5_terseLabel_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital stock, shares authorized (in shares)</link:label>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_label_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Preferred Stock Shares Authorized</link:label>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and preferred stock shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:href="vtvt-20220630.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:to="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAssumed1_a18359c3-2e1f-4be0-8c49-915360c805aa_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Assumed</link:label>
    <link:label id="lab_us-gaap_NotesAssumed1_label_en-US" xlink:label="lab_us-gaap_NotesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAssumed1" xlink:to="lab_us-gaap_NotesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d0c4ba86-0bd6-42a3-89e3-18b0d9ecb610_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ffbd9c53-fb19-4f03-97d9-f3bf9b12c17c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_0cade91a-ac44-40fb-8343-39c3af871302_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales / Repurchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_10248be0-e0ef-4003-90ed-2ddf5353a1b8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_88ebed17-4096-47a8-b6e1-6cefadf27afb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_61ec21d8-79f2-48ff-80c0-c7187b144f7d_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_label_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non Voting Economic Interest By Parent</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_documentation_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non voting economic interest by parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:to="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue_a1e12802-be48-472f-8a54-9e89c03f392e_terseLabel_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A common stock under ATM offering</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue_label_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Class A Common Stock Under ATM Offering Value</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue_documentation_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Class A Common Stock Under ATM Offering Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue" xlink:href="vtvt-20220630.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue" xlink:to="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_93f1cc24-0dbc-4bd7-aa10-87745e1d09e7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d4d08464-b768-42fd-b65c-3e448924f932_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options granted under the Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_e8f17af2-4815-4cd5-998f-f871f743f865_terseLabel_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding percentage of research and development milestones</link:label>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_label_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Funding Percentage Of Research And Development Milestones</link:label>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding percentage of research and development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:href="vtvt-20220630.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:to="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_d2b8e061-05b5-4f8f-9aac-eb0a150e431c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_3d53409f-c469-48ff-a61a-c7acbd5dca2d_terseLabel_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement</link:label>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_label_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]</link:label>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:to="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_681a9439-62ca-4d13-88b3-18026a0cc5b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3622d4dc-e0a4-43a5-bda8-a54c85da1e16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_af9d1554-9ad3-4bd9-a342-00d795360358_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_af5b64da-7320-4336-b1d4-904fc1b0fc20_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_84b20cf3-28fd-4ef2-8a85-f3ff6b4e17e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_82a4dbd4-551a-4f41-ad63-9fc1d857cdd3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c231161d-567e-4215-b29f-ca9a7109d155_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_StrategicAdvisorMember_a3af5492-6088-4d7a-8148-9807df61a2db_terseLabel_en-US" xlink:label="lab_vtvt_StrategicAdvisorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Advisor</link:label>
    <link:label id="lab_vtvt_StrategicAdvisorMember_label_en-US" xlink:label="lab_vtvt_StrategicAdvisorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Advisor [Member]</link:label>
    <link:label id="lab_vtvt_StrategicAdvisorMember_documentation_en-US" xlink:label="lab_vtvt_StrategicAdvisorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic advisor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StrategicAdvisorMember" xlink:href="vtvt-20220630.xsd#vtvt_StrategicAdvisorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_StrategicAdvisorMember" xlink:to="lab_vtvt_StrategicAdvisorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_ba1b4b40-754e-4b65-aa2a-139ceac44239_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received in advance and not recognized as revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_b00a2ec0-d87d-4b9a-b8af-69621fdd2486_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d8bdd46-1c79-41b6-a45d-5bf980846c25_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_34044fac-03ee-4a4d-ae03-9b8000be97a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5604c121-3541-410a-bf5a-140c79135e21_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2d11919b-3bd5-44b0-aa05-da5c1ddae1a3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9a97b65d-0b9e-4273-8f4d-ef50a9d739fd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f07f5f8f-50a2-4d30-989a-374ce1769ab8_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_108ec02c-e44f-42f4-b124-afd2abd19045_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a771cc84-2098-48dc-9809-01f4418e8a70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cc3da72a-d04e-4872-8c61-3025beb24ec0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_b9f29455-f167-401b-8273-05ba8bd866bf_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" xlink:href="vtvt-20220630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" xlink:to="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_6fb5ea1a-0119-4f98-8da8-804363615717_terseLabel_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Redeemable Non controlling Interest To Class A Common Stock</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_label_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_documentation_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of redeemable non controlling interest to class A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:href="vtvt-20220630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:to="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2f814bbe-1c05-4b87-b8db-28006dc98c6b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f0deb8f3-ffac-47cf-9992-70aeb7f9f8da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_f63d2398-4865-417b-926d-feac738ad3d2_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm_a57a94ef-9376-422e-997a-9104b3b39073_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, consideration, receivables, payment term</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration, Receivables, Payment Term</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration, Receivables, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivablesPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_094a3f2f-82c6-4e58-a4f4-4f471eb05419_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:href="vtvt-20220630.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_8eceb452-f802-43e0-ab2a-f93c29a5d1a1_totalLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_9099f5ad-f351-47e9-805d-409ace9dd9f3_terseLabel_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestones Payment</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_label_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestones Payment [Member]</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_documentation_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:href="vtvt-20220630.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:to="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_42841c57-dcdb-4c67-9612-2bf6922839c1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5eb0271c-0817-4433-afa1-a10f2b32140c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseFeeReceived_ba9124c9-01e5-494e-b58d-52b748a09238_terseLabel_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_label_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee Received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_documentation_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived" xlink:href="vtvt-20220630.xsd#vtvt_LicenseFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseFeeReceived" xlink:to="lab_vtvt_LicenseFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AggregateOfferingPriceOfShares_342f8598-19d1-47c6-a514-43d4cdf46372_terseLabel_en-US" xlink:label="lab_vtvt_AggregateOfferingPriceOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_vtvt_AggregateOfferingPriceOfShares_label_en-US" xlink:label="lab_vtvt_AggregateOfferingPriceOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Offering Price Of Shares</link:label>
    <link:label id="lab_vtvt_AggregateOfferingPriceOfShares_documentation_en-US" xlink:label="lab_vtvt_AggregateOfferingPriceOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AggregateOfferingPriceOfShares" xlink:href="vtvt-20220630.xsd#vtvt_AggregateOfferingPriceOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AggregateOfferingPriceOfShares" xlink:to="lab_vtvt_AggregateOfferingPriceOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_78558602-54c6-4a3d-a977-df8b8d8181ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ce1bd987-783f-43ca-ade0-bfd284b91b0d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0582fbb7-d567-4301-a963-87b08b1e1d27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_58e3edbf-5d7c-4809-a690-d0ec7e44a1c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_97aac92e-ba8c-4592-af38-5ee1e9b0c7e6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_5be62d77-0350-4eb3-ae2f-debbb27df3c0_terseLabel_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="vtvt-20220630.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4ac0f2b4-e6aa-4a15-80ed-cbda304b52fa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_51a7b5c7-42bd-4f93-961b-5ec1ed19191e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9ebf928-28fb-4c54-b54f-ae7b6e3081d3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3f1d5602-5224-479b-a5ff-e830ccb47b50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_31a49764-0a1a-4d0e-87d3-bd560b7bbf61_terseLabel_en-US" xlink:label="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to transaction price for performance obligations</link:label>
    <link:label id="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_label_en-US" xlink:label="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Transaction Price For Performance Obligations</link:label>
    <link:label id="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_documentation_en-US" xlink:label="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to transaction price for performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:href="vtvt-20220630.xsd#vtvt_AdjustmentsToTransactionPriceForPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:to="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_047fbbd4-fcf0-4de5-91f1-cdb1c6711011_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_b8cc584d-9a6b-4c4c-ba44-8bc0b0b48523_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_6e94f52f-4d8c-4afd-82e9-0c7d3555879b_verboseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest ownership percentage</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_label_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non Voting Economic Interest</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_documentation_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non voting economic interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfNonVotingEconomicInterest" xlink:to="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_85fee2e1-00fc-456e-9d22-20e396539c5f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_47535cdc-b7d4-41e1-93f9-9948c06c8a34_terseLabel_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Information</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Information Policy [Policy Text Block]</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited interim financial information policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="vtvt-20220630.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7564aff5-4de1-4991-b9ce-fa48b6c571fb_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_522829a7-9992-48b0-8bcb-981a7325d4be_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5df8322e-2a83-4915-9eff-b2422a9d2f46_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Class A common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2b61bc47-fd2e-4450-8081-69bcbd3a0181_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f6dc817f-32c8-4dd8-811c-0370dc2255b4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1fe37c6b-27f5-460f-9b95-d235a46b2b7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LPCPurchaseAgreementMember_a65a9f6c-8bb5-4146-a9b1-62ac5ef05987_terseLabel_en-US" xlink:label="lab_vtvt_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LPC Purchase Agreement</link:label>
    <link:label id="lab_vtvt_LPCPurchaseAgreementMember_label_en-US" xlink:label="lab_vtvt_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">L P C Purchase Agreement [Member]</link:label>
    <link:label id="lab_vtvt_LPCPurchaseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LPC purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember" xlink:href="vtvt-20220630.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LPCPurchaseAgreementMember" xlink:to="lab_vtvt_LPCPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e2c5c09d-6902-4fb8-92ea-4e1e95023092_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5e90f41a-3e75-4095-b5d0-20013e143967_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_fdb81656-1981-4205-8962-f57abbbfaa97_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f748efa8-3389-4a00-8c60-3cb688fe1c36_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f63de84-548e-498a-ab29-6f6e21d1bd3d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_248b8bd2-0cee-4d5e-99a5-4dd5b26cd91d_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_fb730db9-fe05-44e2-b950-363cc56635ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_151fa104-6436-42a5-9253-28404839c920_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_dab4e56a-bfe5-466b-852f-22cf7b206119_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_91c3ca57-3da6-4b46-a02f-9c253aa584aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1539ba5e-1162-4f85-b2b0-5c45dc1de708_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f9c34f18-3c3e-47c0-9d01-d2a5f0f2671d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Class B common stock for class A common stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WarrantLiabilityRelatedPartyMember_b1072df9-199f-46e2-b724-d02a9b2e8043_terseLabel_en-US" xlink:label="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, related party</link:label>
    <link:label id="lab_vtvt_WarrantLiabilityRelatedPartyMember_label_en-US" xlink:label="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability Related Party [Member]</link:label>
    <link:label id="lab_vtvt_WarrantLiabilityRelatedPartyMember_documentation_en-US" xlink:label="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember" xlink:href="vtvt-20220630.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WarrantLiabilityRelatedPartyMember" xlink:to="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c7055981-2611-416c-9db7-3cb67978c1a0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_992cb47f-40d4-43cb-9e3c-59780c680bb4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_6a3fd89a-6e54-4c64-887a-45634fdb5221_terseLabel_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Agreement Warrants</link:label>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_label_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Agreement Warrants [Member]</link:label>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter agreement warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember" xlink:href="vtvt-20220630.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LetterAgreementWarrantsMember" xlink:to="lab_vtvt_LetterAgreementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_df38675f-b041-438a-a353-859eb42f5b98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_108470b5-0a63-48bb-91e5-57a92ab9868e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held by related party (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5289677e-da17-489f-807a-4ee559f53f3b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_e440fd77-2d86-4a91-89e2-56aac49425b3_terseLabel_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares authorized (in shares)</link:label>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_label_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Common Stock Shares Authorized</link:label>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_documentation_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in common stock shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:href="vtvt-20220630.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:to="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OtherIncomeExpensesRelatedParty_149bf77b-e989-45f0-bf1c-4adca117126a_terseLabel_en-US" xlink:label="lab_vtvt_OtherIncomeExpensesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense) &#8211; related party</link:label>
    <link:label id="lab_vtvt_OtherIncomeExpensesRelatedParty_label_en-US" xlink:label="lab_vtvt_OtherIncomeExpensesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expenses Related Party</link:label>
    <link:label id="lab_vtvt_OtherIncomeExpensesRelatedParty_documentation_en-US" xlink:label="lab_vtvt_OtherIncomeExpensesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net amount of other related party income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIncomeExpensesRelatedParty" xlink:href="vtvt-20220630.xsd#vtvt_OtherIncomeExpensesRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OtherIncomeExpensesRelatedParty" xlink:to="lab_vtvt_OtherIncomeExpensesRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c77e9f6f-cac8-41d4-8f58-723fc7ae9918_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MaximumSponsoringContributionAmount_0f37d2b7-62e6-4d68-b7de-374ff1e97311_terseLabel_en-US" xlink:label="lab_vtvt_MaximumSponsoringContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount to clinical trial</link:label>
    <link:label id="lab_vtvt_MaximumSponsoringContributionAmount_label_en-US" xlink:label="lab_vtvt_MaximumSponsoringContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Sponsoring Contribution Amount</link:label>
    <link:label id="lab_vtvt_MaximumSponsoringContributionAmount_documentation_en-US" xlink:label="lab_vtvt_MaximumSponsoringContributionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum sponsoring contribution amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumSponsoringContributionAmount" xlink:href="vtvt-20220630.xsd#vtvt_MaximumSponsoringContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MaximumSponsoringContributionAmount" xlink:to="lab_vtvt_MaximumSponsoringContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CognaMember_41cf2170-0f13-4fb5-bc45-ab85812ccc21_terseLabel_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cogna</link:label>
    <link:label id="lab_vtvt_CognaMember_label_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cogna [Member]</link:label>
    <link:label id="lab_vtvt_CognaMember_documentation_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cogna</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember" xlink:href="vtvt-20220630.xsd#vtvt_CognaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CognaMember" xlink:to="lab_vtvt_CognaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_30b5f3e0-bbbf-4bed-9c94-cfa67c96da50_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PublicFloat_369d9501-514e-4a20-b3cd-99234574d31b_terseLabel_en-US" xlink:label="lab_vtvt_PublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public float</link:label>
    <link:label id="lab_vtvt_PublicFloat_label_en-US" xlink:label="lab_vtvt_PublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Float</link:label>
    <link:label id="lab_vtvt_PublicFloat_documentation_en-US" xlink:label="lab_vtvt_PublicFloat" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public float.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PublicFloat" xlink:href="vtvt-20220630.xsd#vtvt_PublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PublicFloat" xlink:to="lab_vtvt_PublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_986d0553-8e1b-4f7f-9f53-1f0697d11b3c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aa37ee71-4d69-4706-bf7d-203b7462d468_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9deb6f04-a8de-4b60-bf93-3b98906256a8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ae97322c-c762-4aba-93d8-41c827b4a54e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f0b3df8f-c2d4-4dca-8142-c2a698147760_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_105cdecf-6bb8-4b3a-8a05-e7d1acae5e55_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_e8f88de7-9ad8-43db-8133-c997d08b3863_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6f823508-c6c7-4ddd-a9df-23c1a3b7267a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_37e57298-2da3-407b-a427-06e39fc1591e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OneCustomerMember_3e8a29e7-9822-4b41-a01b-bb39d19b8f8a_terseLabel_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer</link:label>
    <link:label id="lab_vtvt_OneCustomerMember_label_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer [Member]</link:label>
    <link:label id="lab_vtvt_OneCustomerMember_documentation_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember" xlink:href="vtvt-20220630.xsd#vtvt_OneCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OneCustomerMember" xlink:to="lab_vtvt_OneCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5f99d104-9d65-43b7-b0f2-17664fc50d43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_76077577-7abe-4af5-8971-2382c257a443_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable" xlink:to="lab_vtvt_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_68f1beaf-1273-409b-9113-3cf9d2d5de41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-qualified stock option awards vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage_d50c0df8-3625-4bc5-86ca-c8ebd7b3beca_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties receivable, percent</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Percentage</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage" xlink:to="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_340d0b50-b29f-474a-a3d5-17203e9c9b03_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c3d9ed2a-58ef-4498-9137-5bd0ed8f028a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a6fbe113-9cb0-46d4-a75a-b9ea458bf5f5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6c788ce9-117b-4a7b-8ec8-c088beb021da_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8a836fd2-83c3-4e4e-9d79-176e4163c309_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_77b38784-33fb-4d64-b785-449e238716d9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesMember_e5e71d34-51b4-4585-8ae4-8faf33ee256a_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Technology Transfer Services</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesMember_label_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Technology Transfer Services [Member]</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesMember_documentation_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and technology transfer services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAndTechnologyTransferServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:to="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_c8d819b9-d503-4e46-ab5b-d848e23e6b97_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized amount of transaction price allocated to performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cf06962b-6d31-4468-84c3-74fa3f5fdd7d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-qualified stock option awards expiration term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8e64b868-6a72-4fc7-9212-af8ed51efe93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fbfa3511-7012-4d7c-b19d-8bfb7aec681d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Lease Liabilities for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_198111d8-8966-424a-b245-3e4c522aee98_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_930a46ac-cd04-4598-872a-2b74ee669e72_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7bdc4eb2-41c1-4be7-9eea-cee738ffe63a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7ec4f678-ed58-4f23-b595-90101acacba7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1c9b917f-72cb-4f41-8767-a143f42cb67d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_f74ee58e-5f86-4ff4-b76a-132bf6346dce_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_709f316d-acaa-4e8c-a19e-711cf84b4ffe_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a1308a86-2b7d-418e-b63c-bbd91b0c25ab_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c8902f0e-fbfa-44c9-adc1-beebde20bca0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_bb1bdc98-8c4f-495d-a78e-22eb79e1d8ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2d2d424c-409a-4e90-a5d1-18ef018cadd6_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueDisclosureAbstract_f8d84741-672e-4830-b3d7-a98a95606cb3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="lab_us-gaap_DeferredRevenueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones_131d727f-f6c6-4b3d-ba5b-76314158e679_terseLabel_en-US" xlink:label="lab_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum research funding receivable achievement based on research and development milestones</link:label>
    <link:label id="lab_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones_label_en-US" xlink:label="lab_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Research Funding Receivable Based On Achievement Of Research And Development Milestones</link:label>
    <link:label id="lab_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum research funding receivable based on achievement of research and development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" xlink:href="vtvt-20220630.xsd#vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" xlink:to="lab_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_6d2166e2-6786-4fdc-99cc-a2f0b9ad78ce_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Technology Transfer Services of Chemistry and Manufacturing Know-How</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_label_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member]</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_documentation_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and technology transfer services of chemistry and manufacturing know-how.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:to="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_05f38578-66ef-4dbe-b09f-6b3b98c8acb9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_98b91dca-caf5-44af-82e6-3b7c3a150724_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9d6c6310-9088-40e6-91d2-890a15137f66_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_39d1d12c-843b-462a-9064-11a47740aa72_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_09fab0f7-9555-4bfd-95fd-d4a53199c3e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NotesReceivableCurrent_5eb7c8e1-4dba-49be-b259-0f5a094d4dbd_terseLabel_en-US" xlink:label="lab_vtvt_NotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note receivable</link:label>
    <link:label id="lab_vtvt_NotesReceivableCurrent_label_en-US" xlink:label="lab_vtvt_NotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Current</link:label>
    <link:label id="lab_vtvt_NotesReceivableCurrent_documentation_en-US" xlink:label="lab_vtvt_NotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent" xlink:href="vtvt-20220630.xsd#vtvt_NotesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NotesReceivableCurrent" xlink:to="lab_vtvt_NotesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_384c5ac7-915e-4858-9876-f22aeecf0d75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_d0e691c5-6e79-4c09-a4ba-2972dcf35ef8_terseLabel_en-US" xlink:label="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining available stock value</link:label>
    <link:label id="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Availability Stock Issued During Period Value New Issues</link:label>
    <link:label id="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_documentation_en-US" xlink:label="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under our controlled equity offering sales agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:href="vtvt-20220630.xsd#vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAgreementObligationsAxis_50063f0e-207c-4ad3-aa61-f2378bba8dbe_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsAxis_label_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations [Axis]</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsAxis_documentation_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsAxis" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAgreementObligationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis" xlink:to="lab_vtvt_LicenseAgreementObligationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5874ee3a-023d-4775-a684-9bff5fa1197c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a9289038-1765-4cc6-9a47-72b0fbda78ac_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2445c042-7bf2-40a8-a754-cc5fa9e0a05d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_a6708537-29fc-41ba-b068-ae505775682e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_768a0b0d-3f4f-49b1-8039-922776b17360_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_42f4ed8e-ba59-40f7-b0d4-879c6a6a7264_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae0f2a52-93b5-4751-a765-17c869b86029_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ee534a90-c8d1-489f-9eaa-334c31f0eca7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_0ffbb559-b8ea-405e-8e7f-a3a1c6fbd3fe_terseLabel_en-US" xlink:label="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hangzhou Zhongmei Huadong Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:href="vtvt-20220630.xsd#vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:to="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_af5c06e6-83b3-438d-93f9-480ac079967f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0689616c-ce3d-48f7-a1be-09f527452664_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_919a5aae-ccdc-4cf6-b25f-058ace3709a3_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3e5f4b04-623b-41bb-a3c4-cf08cfbfa3d1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cf6a6df7-dba1-4f1b-82e1-0b511eed4699_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0550559f-905e-4008-bb5b-15ca80d8574f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_708d7f32-8ce8-4b76-bcd4-1de0f86fc7e3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d6823e36-7c06-40c4-b4ba-16cb44f67d70_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestAndDividendsReceived_60661d09-108c-4dfe-b730-0f0aec9cf2b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestAndDividendsReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest and Dividends Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:to="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c3565b2f-6670-41b0-acdd-ec46717f31b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c083596a-c019-4cf0-8171-eab5576c3e87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5061c471-76fb-4ab3-ba09-d58ab597df0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_40a5fb40-ab1d-430f-a20e-a1a7eb2a3f39_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from change in estimated transaction prices</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_afbe4085-05f9-4109-8657-147a0d1735c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_4dbb31b4-a58b-42d8-8263-63514fcac605_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and financing receivable, after allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_654aafd5-63df-4364-8a12-01f6c14bc1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_7d26719f-4525-4929-9338-46d3e8394acf_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_f69751db-3750-4070-9fba-a7b2f139052e_terseLabel_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of majority owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_label_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage Of Majority Owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_documentation_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of majority owner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:href="vtvt-20220630.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:to="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ReneoPharmaceuticalsIncMember_12575cbd-9866-42b3-884d-f1a5d3087333_terseLabel_en-US" xlink:label="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reneo</link:label>
    <link:label id="lab_vtvt_ReneoPharmaceuticalsIncMember_label_en-US" xlink:label="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reneo Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_vtvt_ReneoPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reneo Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember" xlink:href="vtvt-20220630.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ReneoPharmaceuticalsIncMember" xlink:to="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bfe9d2a2-50f6-4f1a-b0fe-532be51a2be3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_bc1fe234-55ce-4cc9-8b39-75ae2b2eabdd_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_dc17e239-6d35-4b90-8213-5bb63236b986_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business, Basis of Presentation and Going Concern</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_3fd8adee-ed50-4cf2-a9ff-80ffa2d5c62e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vtvt-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cc23dfa8-b7f1-4dd2-bc21-5440216f3885,g:7d227720-4a1d-461e-9922-f5c0b011aa4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a5ffd0ee-867a-4cc9-9410-855fb46a5239" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_d70b2040-775d-4acf-9f8b-4a0e6711cf8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ffd0ee-867a-4cc9-9410-855fb46a5239" xlink:to="loc_dei_DocumentInformationTable_d70b2040-775d-4acf-9f8b-4a0e6711cf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb5d4813-b9e8-4407-bfdc-31ec2d455a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_d70b2040-775d-4acf-9f8b-4a0e6711cf8e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb5d4813-b9e8-4407-bfdc-31ec2d455a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb5d4813-b9e8-4407-bfdc-31ec2d455a76" xlink:to="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3414846c-f9b2-45ef-8c49-735fbbd4ed86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:to="loc_us-gaap_CommonClassAMember_3414846c-f9b2-45ef-8c49-735fbbd4ed86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_515a3840-018b-4e05-9ad2-4c4321a4d3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_41ce70a3-1a14-44c7-adc3-4292da995d26" xlink:to="loc_us-gaap_CommonClassBMember_515a3840-018b-4e05-9ad2-4c4321a4d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_d70b2040-775d-4acf-9f8b-4a0e6711cf8e" xlink:to="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4e20ab18-4278-4982-bdc1-fac20d512ee3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentType_4e20ab18-4278-4982-bdc1-fac20d512ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8232ac77-c42b-441b-afc7-646ac8445473" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentQuarterlyReport_8232ac77-c42b-441b-afc7-646ac8445473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bd2f89c3-4fda-4b1e-b0d6-50b9cd2ca3ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentPeriodEndDate_bd2f89c3-4fda-4b1e-b0d6-50b9cd2ca3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0b78e376-cc55-42c9-a568-74ea79ec72e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentTransitionReport_0b78e376-cc55-42c9-a568-74ea79ec72e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fb578304-21d4-4a4f-be74-8f43b4b49f09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityFileNumber_fb578304-21d4-4a4f-be74-8f43b4b49f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d08856f5-a3ec-49d1-aa4b-7a17debc9ff7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityRegistrantName_d08856f5-a3ec-49d1-aa4b-7a17debc9ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_52b6ec30-d3f2-4498-bac0-c803a4064369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityIncorporationStateCountryCode_52b6ec30-d3f2-4498-bac0-c803a4064369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_96aed983-8256-42b8-8566-4ee9706b0bf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityTaxIdentificationNumber_96aed983-8256-42b8-8566-4ee9706b0bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_76884ef0-bb21-490e-869d-b12c99e9939c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressAddressLine1_76884ef0-bb21-490e-869d-b12c99e9939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8a1b781d-f357-4a21-8c68-d6ac3ec63aec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressAddressLine2_8a1b781d-f357-4a21-8c68-d6ac3ec63aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0074c0f7-d888-4abc-9429-a9686a7f37de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressCityOrTown_0074c0f7-d888-4abc-9429-a9686a7f37de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7c769f5e-78d5-4eab-8687-2140749dd9de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressStateOrProvince_7c769f5e-78d5-4eab-8687-2140749dd9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d6b81078-c70e-4563-a688-e39869c54424" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityAddressPostalZipCode_d6b81078-c70e-4563-a688-e39869c54424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d5b85ef1-ad92-425d-80ec-e9a558696fd5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_CityAreaCode_d5b85ef1-ad92-425d-80ec-e9a558696fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_81903d33-fdab-439e-b614-40db6a5b053f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_LocalPhoneNumber_81903d33-fdab-439e-b614-40db6a5b053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cda7b855-cb67-4f7c-a750-317327badce6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_Security12bTitle_cda7b855-cb67-4f7c-a750-317327badce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_242dfe2e-216a-463a-8f7e-ea515525b081" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_TradingSymbol_242dfe2e-216a-463a-8f7e-ea515525b081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_98967ec6-da87-4d9e-b52f-c9e6df6b0ed9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_SecurityExchangeName_98967ec6-da87-4d9e-b52f-c9e6df6b0ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ca77e674-0f44-4e78-bde7-abaec7ffcb0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityCurrentReportingStatus_ca77e674-0f44-4e78-bde7-abaec7ffcb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_42d6809f-1d81-49cf-bd1f-dd1a3da4c7ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityInteractiveDataCurrent_42d6809f-1d81-49cf-bd1f-dd1a3da4c7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bff164a9-181f-4fe5-b11d-bb0551b34962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityFilerCategory_bff164a9-181f-4fe5-b11d-bb0551b34962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_73ba8a35-c5f8-469f-830d-2d548de1b206" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntitySmallBusiness_73ba8a35-c5f8-469f-830d-2d548de1b206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_abe90b82-bdbf-41d2-a6a8-11c1cdfca3fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityEmergingGrowthCompany_abe90b82-bdbf-41d2-a6a8-11c1cdfca3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b9a742b1-d359-4f77-9f47-16d3d676e0c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityShellCompany_b9a742b1-d359-4f77-9f47-16d3d676e0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6f2f14fe-881c-4444-bea3-8c8edb0381a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6f2f14fe-881c-4444-bea3-8c8edb0381a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ac3bf5f8-646e-4861-b297-b29c6d73bd79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_EntityCentralIndexKey_ac3bf5f8-646e-4861-b297-b29c6d73bd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c7597602-1946-40c6-b29e-9fdf77da68c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_CurrentFiscalYearEndDate_c7597602-1946-40c6-b29e-9fdf77da68c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4ffdc1b2-7d11-4d25-9153-c984bad2a44c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentFiscalYearFocus_4ffdc1b2-7d11-4d25-9153-c984bad2a44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d313d770-dfb2-4f06-b30e-f47a87a87be0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d313d770-dfb2-4f06-b30e-f47a87a87be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9d306df2-f2d8-4555-a2ee-69a72286420f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8484d455-867a-47f8-ac0e-92246ef19e35" xlink:to="loc_dei_AmendmentFlag_9d306df2-f2d8-4555-a2ee-69a72286420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2cb2ed45-d750-49f8-96fc-7cd0c1a586e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3559e17f-f682-4eda-8f47-cb42940b81eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2cb2ed45-d750-49f8-96fc-7cd0c1a586e8" xlink:to="loc_us-gaap_StatementTable_3559e17f-f682-4eda-8f47-cb42940b81eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7869bf40-b6a4-4788-a172-5054adff2a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3559e17f-f682-4eda-8f47-cb42940b81eb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7869bf40-b6a4-4788-a172-5054adff2a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7869bf40-b6a4-4788-a172-5054adff2a5c" xlink:to="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_54d5c9a9-e8eb-44c7-b42e-a903e68a0c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:to="loc_us-gaap_CommonClassAMember_54d5c9a9-e8eb-44c7-b42e-a903e68a0c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_04639c79-10e6-42fa-b8a5-283066899ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dd07da80-9a63-47d7-8c5c-01a4ac911e31" xlink:to="loc_us-gaap_CommonClassBMember_04639c79-10e6-42fa-b8a5-283066899ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3559e17f-f682-4eda-8f47-cb42940b81eb" xlink:to="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:to="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14fc2c84-19d3-4a25-8621-c27a3c81d271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14fc2c84-19d3-4a25-8621-c27a3c81d271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_172e6996-6e26-4796-bbdd-2f4e20f63949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_172e6996-6e26-4796-bbdd-2f4e20f63949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent_0ab3636e-ccaf-4bea-8e42-3886e1e60d0d" xlink:href="vtvt-20220630.xsd#vtvt_NotesReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_vtvt_NotesReceivableCurrent_0ab3636e-ccaf-4bea-8e42-3886e1e60d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af235a7c-62dd-468f-b83b-ff341b3e93c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af235a7c-62dd-468f-b83b-ff341b3e93c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_47feda78-1c48-4ce6-9092-77b98a36bb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_DepositsAssetsCurrent_47feda78-1c48-4ce6-9092-77b98a36bb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_34cebba3-0819-4c2a-9325-62c876d7ece3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1252ea6f-5352-437c-982e-6b34cf8ac967" xlink:to="loc_us-gaap_AssetsCurrent_34cebba3-0819-4c2a-9325-62c876d7ece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d9fbd1a2-09dd-485d-85f2-e4131414b269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d9fbd1a2-09dd-485d-85f2-e4131414b269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5c4c00f-5557-4f11-9405-a7bf443862cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5c4c00f-5557-4f11-9405-a7bf443862cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_e1fa79ca-819e-4eea-a328-453bc939c865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_LongTermInvestments_e1fa79ca-819e-4eea-a328-453bc939c865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f1d5c0b0-5d52-4ce4-8044-0585f6a8b01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_74fe96ed-9f9c-4818-8c7a-eb7c044ad4cb" xlink:to="loc_us-gaap_Assets_f1d5c0b0-5d52-4ce4-8044-0585f6a8b01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df6e6dbb-6d7c-46c1-98af-f34d3adf6986" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d6532965-2d30-4174-828a-58860fd188e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d6532965-2d30-4174-828a-58860fd188e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_90b9eb41-ec5c-4105-a12a-4a59f7354df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_90b9eb41-ec5c-4105-a12a-4a59f7354df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eabec723-3b2d-41af-ad3c-3aa137ecfdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eabec723-3b2d-41af-ad3c-3aa137ecfdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_0c40fe75-5635-498b-a7c8-57deb91aeb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_NotesPayableCurrent_0c40fe75-5635-498b-a7c8-57deb91aeb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_af235486-712a-4359-940f-882a033ca8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a790b28-b3e1-4854-97e7-6e854981e0cd" xlink:to="loc_us-gaap_LiabilitiesCurrent_af235486-712a-4359-940f-882a033ca8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e4774554-7bb4-4cd3-843c-14fcc9e35a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e4774554-7bb4-4cd3-843c-14fcc9e35a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4732506a-9d9f-4117-9c78-ae7f1e607e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4732506a-9d9f-4117-9c78-ae7f1e607e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_380e55ac-7983-448e-a7be-41fe3b9d9f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_380e55ac-7983-448e-a7be-41fe3b9d9f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8491ae90-f826-4128-a2ba-5e5f3726e165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_Liabilities_8491ae90-f826-4128-a2ba-5e5f3726e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8dbccc85-1e45-406b-8ee2-d5dc55fbb833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8dbccc85-1e45-406b-8ee2-d5dc55fbb833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_757b7654-de93-48d9-aa6b-f2a45bdffbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_757b7654-de93-48d9-aa6b-f2a45bdffbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6facb381-21e6-414f-a2e1-20196db3c7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:to="loc_us-gaap_CommonStockValue_6facb381-21e6-414f-a2e1-20196db3c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2114c815-3993-46f9-835d-8eb576890d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2114c815-3993-46f9-835d-8eb576890d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9690faa9-3dcc-4bea-ad11-735bb7473f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cf59fc5f-8f26-46b2-9275-9f5550a24199" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9690faa9-3dcc-4bea-ad11-735bb7473f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c543526-fce0-4793-83f5-7876a8e8b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_StockholdersEquity_4c543526-fce0-4793-83f5-7876a8e8b7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1c2408-9e03-49a5-9dfa-a4e51e3795ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52209a0f-7b49-40a5-87ed-18a9ec2524a2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1c2408-9e03-49a5-9dfa-a4e51e3795ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8526239f-fae3-4805-8474-2c87c4714d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_77301ac8-84c5-4d70-ac51-f0e07850c5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8526239f-fae3-4805-8474-2c87c4714d51" xlink:to="loc_us-gaap_StatementTable_77301ac8-84c5-4d70-ac51-f0e07850c5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77301ac8-84c5-4d70-ac51-f0e07850c5b2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30df2bfe-f54e-43cc-bd93-ec0cfa2e9a83" xlink:to="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_073a0f12-da46-4204-966d-0d8fe05223d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:to="loc_us-gaap_CommonClassAMember_073a0f12-da46-4204-966d-0d8fe05223d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b3536a87-0a3d-47e9-a1e3-30eb06962f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_063a17cd-1c71-4e38-8086-da43c551f5e9" xlink:to="loc_us-gaap_CommonClassBMember_b3536a87-0a3d-47e9-a1e3-30eb06962f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77301ac8-84c5-4d70-ac51-f0e07850c5b2" xlink:to="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_28399485-e028-4e51-bcec-6f0d590721f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_28399485-e028-4e51-bcec-6f0d590721f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4f8cb49c-e970-4418-9e46-6fb38bbe5f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4f8cb49c-e970-4418-9e46-6fb38bbe5f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_565c110b-afdd-4a88-a173-f896d3b7a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b8bfc31c-44a7-4a66-a2e2-987b605222dd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_565c110b-afdd-4a88-a173-f896d3b7a362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b6382e33-a2ad-4055-9dba-3fd27ca0ea06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2d025a46-3b34-4fb5-8d2d-1a7bd6005c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b6382e33-a2ad-4055-9dba-3fd27ca0ea06" xlink:to="loc_us-gaap_StatementTable_2d025a46-3b34-4fb5-8d2d-1a7bd6005c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d025a46-3b34-4fb5-8d2d-1a7bd6005c09" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f5172277-abf8-416f-a745-6bda0d76fd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a9d1fa73-ac65-456b-a0e9-85b12d36fe1c" xlink:to="loc_us-gaap_ClassOfStockDomain_f5172277-abf8-416f-a745-6bda0d76fd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0a4be754-1057-48f9-b3b0-7d7f50144bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f5172277-abf8-416f-a745-6bda0d76fd7a" xlink:to="loc_us-gaap_CommonClassAMember_0a4be754-1057-48f9-b3b0-7d7f50144bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2d025a46-3b34-4fb5-8d2d-1a7bd6005c09" xlink:to="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8a407d7-b3fe-4c72-9888-8b0f0dda12c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8a407d7-b3fe-4c72-9888-8b0f0dda12c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b7d25411-0deb-428d-9553-a26a12f879be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b7d25411-0deb-428d-9553-a26a12f879be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f1a4c044-6c35-4919-99bd-96570f6ce140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f1a4c044-6c35-4919-99bd-96570f6ce140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e0420687-73a1-4234-9a6a-4a0ffdf2318d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_198ca204-6e68-4763-9aa2-f11d98bdfc82" xlink:to="loc_us-gaap_OperatingExpenses_e0420687-73a1-4234-9a6a-4a0ffdf2318d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_90805be8-7057-4cd7-bea5-2b8e667ebd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_OperatingIncomeLoss_90805be8-7057-4cd7-bea5-2b8e667ebd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f9530602-edf5-446a-b70b-cb2e154b4b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f9530602-edf5-446a-b70b-cb2e154b4b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIncomeExpensesRelatedParty_ac5b6938-58a8-4a10-b569-6b203b42185c" xlink:href="vtvt-20220630.xsd#vtvt_OtherIncomeExpensesRelatedParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_vtvt_OtherIncomeExpensesRelatedParty_ac5b6938-58a8-4a10-b569-6b203b42185c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_40fabf91-22b3-489f-9b1f-005590112470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_40fabf91-22b3-489f-9b1f-005590112470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2c17dd4d-d344-412f-8402-b537c9ece91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_InterestExpense_2c17dd4d-d344-412f-8402-b537c9ece91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b74b577-eb80-4b0e-8b67-3c68d6bcfc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b74b577-eb80-4b0e-8b67-3c68d6bcfc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c9f6862-6caa-4844-b24d-fe4031ab75f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c9f6862-6caa-4844-b24d-fe4031ab75f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_187b7aaf-8034-4464-8e9c-8187b1f76600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_ProfitLoss_187b7aaf-8034-4464-8e9c-8187b1f76600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_645ca932-8b59-4799-b715-5dc2cf9438c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_645ca932-8b59-4799-b715-5dc2cf9438c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_002e589b-4c8c-4576-9e89-f9c39d0ec31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_NetIncomeLoss_002e589b-4c8c-4576-9e89-f9c39d0ec31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4413300e-2f85-4c40-868f-de2ea477c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4413300e-2f85-4c40-868f-de2ea477c6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e96325a-469b-457e-a53e-af3fd0acc1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e96325a-469b-457e-a53e-af3fd0acc1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8ce17aeb-6bc0-4f33-9a4e-20ed2bee9d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8ce17aeb-6bc0-4f33-9a4e-20ed2bee9d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bec3c74d-6cd6-451c-a890-921232846b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bec3c74d-6cd6-451c-a890-921232846b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61192ca1-43eb-4056-9ceb-2c844adefaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49a19cae-5c27-4db4-b5c0-ce9efd91263f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61192ca1-43eb-4056-9ceb-2c844adefaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_736cda59-de06-4891-ae8e-d51f420a2d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_736cda59-de06-4891-ae8e-d51f420a2d1b" xlink:to="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fbd6cf1f-36e1-419d-b2fb-1440ea40374b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fbd6cf1f-36e1-419d-b2fb-1440ea40374b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fbd6cf1f-36e1-419d-b2fb-1440ea40374b" xlink:to="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9b98afaa-4ebc-49fa-b1b8-7d16b80dec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9b98afaa-4ebc-49fa-b1b8-7d16b80dec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e3f16137-49a2-4318-a9ce-7906effc96d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_CommonStockMember_e3f16137-49a2-4318-a9ce-7906effc96d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dda83cbb-eba0-4d99-b6de-6338956e3233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dda83cbb-eba0-4d99-b6de-6338956e3233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1d3838aa-3fcb-40ca-8769-4b3a16a0ec07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c000890-4445-43d5-9bba-ad62912270c7" xlink:to="loc_us-gaap_RetainedEarningsMember_1d3838aa-3fcb-40ca-8769-4b3a16a0ec07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c37e679-73dc-4b40-a2a6-6946c91f0722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c37e679-73dc-4b40-a2a6-6946c91f0722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c37e679-73dc-4b40-a2a6-6946c91f0722" xlink:to="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_788230fe-b10d-431d-a353-d876e7850be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:to="loc_us-gaap_CommonClassAMember_788230fe-b10d-431d-a353-d876e7850be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b2a91aa2-af22-4857-b42a-8d13aa6b92f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:to="loc_us-gaap_CommonClassBMember_b2a91aa2-af22-4857-b42a-8d13aa6b92f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember_b12c409f-d4b8-4b8b-8ac4-83113b1a7d70" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_919fec2c-d2e0-4253-a9b2-42e879a8d96d" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestsMember_b12c409f-d4b8-4b8b-8ac4-83113b1a7d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bf4f7a14-e1c3-42e7-9e5b-2e5f31fbcade" xlink:to="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_a1148851-f7d4-4850-82e0-025dad4b83cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_a1148851-f7d4-4850-82e0-025dad4b83cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8fcbd048-3151-4bc2-8a6b-50ab72036e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_8fcbd048-3151-4bc2-8a6b-50ab72036e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TemporaryEquityChangeInRedemptionValue_fb7aa68f-20c3-41a0-b66d-f05b83a78e5a" xlink:href="vtvt-20220630.xsd#vtvt_TemporaryEquityChangeInRedemptionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:to="loc_vtvt_TemporaryEquityChangeInRedemptionValue_fb7aa68f-20c3-41a0-b66d-f05b83a78e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_90df6ed6-936e-4c47-93cb-bb753eac8fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b4596299-4618-42ef-af83-1b74ad7c528d" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_90df6ed6-936e-4c47-93cb-bb753eac8fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_847b61dc-b272-45b0-9f77-6ca4e6631da2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_895e9ea6-0910-4fd2-9ad1-1267dab370c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_895e9ea6-0910-4fd2-9ad1-1267dab370c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_034ffd75-1f47-4739-8bf4-f8264fde9949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockholdersEquity_034ffd75-1f47-4739-8bf4-f8264fde9949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_08054bfd-a3d9-4119-99b5-325b48040639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_NetIncomeLoss_08054bfd-a3d9-4119-99b5-325b48040639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f5d9221-cebc-437e-b2d1-77f5de2566f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f5d9221-cebc-437e-b2d1-77f5de2566f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54e12ae4-ff87-4dae-b07d-f18d26a55be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54e12ae4-ff87-4dae-b07d-f18d26a55be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d22bebf7-10ed-4713-9135-b7de1b6557fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d22bebf7-10ed-4713-9135-b7de1b6557fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_9b0e7335-ede3-493a-9282-bcc9853776d5" xlink:href="vtvt-20220630.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_9b0e7335-ede3-493a-9282-bcc9853776d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue_356d1e5d-45df-4305-8d7f-526465bc6a12" xlink:href="vtvt-20220630.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue_356d1e5d-45df-4305-8d7f-526465bc6a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_badba30e-eb1b-4319-aba8-005559ffd6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_badba30e-eb1b-4319-aba8-005559ffd6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_771f9341-b3a8-49b7-ba11-1e19c6941ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_771f9341-b3a8-49b7-ba11-1e19c6941ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_889c6ddb-6157-4d40-8f3e-7cdcf46e0b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_889c6ddb-6157-4d40-8f3e-7cdcf46e0b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_4b78edd6-d2a9-49ca-83be-ec90ef9f55f1" xlink:href="vtvt-20220630.xsd#vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_4b78edd6-d2a9-49ca-83be-ec90ef9f55f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_3b6e1d51-9a58-4c7d-b4ed-ebf2ad698fe3" xlink:href="vtvt-20220630.xsd#vtvt_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_3b6e1d51-9a58-4c7d-b4ed-ebf2ad698fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_545c9fa0-04f5-465a-864e-2475de115ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_545c9fa0-04f5-465a-864e-2475de115ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7dbe7635-9572-41ea-8ac1-89c4d36cc0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7dbe7635-9572-41ea-8ac1-89c4d36cc0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7582776b-ba82-47ac-82c8-c7ecace60fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4d25a761-1f37-4458-8a92-0abe4abe63dc" xlink:to="loc_us-gaap_StockholdersEquity_7582776b-ba82-47ac-82c8-c7ecace60fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aef5586a-330f-45e9-ad08-311ca83e03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aef5586a-330f-45e9-ad08-311ca83e03e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fa01137b-386c-49ae-bd38-f3dd2e6e9f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aef5586a-330f-45e9-ad08-311ca83e03e8" xlink:to="loc_us-gaap_ProfitLoss_fa01137b-386c-49ae-bd38-f3dd2e6e9f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3841cc0-af0f-471a-998c-06cace54985a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aef5586a-330f-45e9-ad08-311ca83e03e8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3841cc0-af0f-471a-998c-06cace54985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_de8d6577-b5f8-4c34-956c-446a6b4b2f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3841cc0-af0f-471a-998c-06cace54985a" xlink:to="loc_us-gaap_Depreciation_de8d6577-b5f8-4c34-956c-446a6b4b2f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_5c65083c-61a6-4e26-b3ae-fc51be2ba266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3841cc0-af0f-471a-998c-06cace54985a" xlink:to="loc_us-gaap_InterestIncomeOperating_5c65083c-61a6-4e26-b3ae-fc51be2ba266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0f5a4203-0e09-49a9-8441-4f4321e6ec8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3841cc0-af0f-471a-998c-06cace54985a" xlink:to="loc_us-gaap_ShareBasedCompensation_0f5a4203-0e09-49a9-8441-4f4321e6ec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b223595c-474b-4649-b288-a09e9f12ff94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3841cc0-af0f-471a-998c-06cace54985a" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b223595c-474b-4649-b288-a09e9f12ff94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_930a0268-e750-4cec-8aeb-3b8c5e37625f" xlink:href="vtvt-20220630.xsd#vtvt_ChangeInFairValueOfWarrantsRelatedParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b3841cc0-af0f-471a-998c-06cace54985a" xlink:to="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_930a0268-e750-4cec-8aeb-3b8c5e37625f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f63c9be-366f-4b25-812b-fc6a151e0bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aef5586a-330f-45e9-ad08-311ca83e03e8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f63c9be-366f-4b25-812b-fc6a151e0bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f3640f28-c8ff-4dbf-b196-b60afb860409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f63c9be-366f-4b25-812b-fc6a151e0bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f3640f28-c8ff-4dbf-b196-b60afb860409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c87fc4bb-01de-400f-bce6-6133c44cf2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f63c9be-366f-4b25-812b-fc6a151e0bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c87fc4bb-01de-400f-bce6-6133c44cf2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3d5aeae8-e7fb-4f6d-97cc-90946b89aa62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f63c9be-366f-4b25-812b-fc6a151e0bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3d5aeae8-e7fb-4f6d-97cc-90946b89aa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_223a979c-cd67-4578-bb90-0bbe0041e2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f63c9be-366f-4b25-812b-fc6a151e0bfc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_223a979c-cd67-4578-bb90-0bbe0041e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bdd5a7d-5f77-4a68-9525-ea1f9897548d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aef5586a-330f-45e9-ad08-311ca83e03e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bdd5a7d-5f77-4a68-9525-ea1f9897548d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65b81c1f-4a75-40e0-9060-2699b4b9dbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65b81c1f-4a75-40e0-9060-2699b4b9dbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f71d092-391a-4ea5-9d04-5c84ca77448a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65b81c1f-4a75-40e0-9060-2699b4b9dbc0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f71d092-391a-4ea5-9d04-5c84ca77448a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40c702ce-6258-470e-b420-4f31fe86d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65b81c1f-4a75-40e0-9060-2699b4b9dbc0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40c702ce-6258-470e-b420-4f31fe86d89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0772bb66-8f82-49f3-ba2c-2ee2ff7f0c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0772bb66-8f82-49f3-ba2c-2ee2ff7f0c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ProceedsFromSaleOfCommonStock_98ca6f8b-fcd5-45f1-b784-55d6c98a50bf" xlink:href="vtvt-20220630.xsd#vtvt_ProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0772bb66-8f82-49f3-ba2c-2ee2ff7f0c49" xlink:to="loc_vtvt_ProceedsFromSaleOfCommonStock_98ca6f8b-fcd5-45f1-b784-55d6c98a50bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_14f061c0-2a35-4143-853f-5ddbdec3d330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0772bb66-8f82-49f3-ba2c-2ee2ff7f0c49" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_14f061c0-2a35-4143-853f-5ddbdec3d330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_46a02c4f-09b1-4688-b5b1-50660534b45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0772bb66-8f82-49f3-ba2c-2ee2ff7f0c49" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_46a02c4f-09b1-4688-b5b1-50660534b45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_fc807e52-f1b9-4e55-bb13-7e73dda7534d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0772bb66-8f82-49f3-ba2c-2ee2ff7f0c49" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_fc807e52-f1b9-4e55-bb13-7e73dda7534d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f94b42c-24a0-479c-9bf9-46bdf1b7af75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0772bb66-8f82-49f3-ba2c-2ee2ff7f0c49" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f94b42c-24a0-479c-9bf9-46bdf1b7af75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0d22f6eb-f18a-4d51-8af5-1ffc4277e5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0d22f6eb-f18a-4d51-8af5-1ffc4277e5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ea7e3c2-260d-4a8b-af5c-98069e2ccc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ea7e3c2-260d-4a8b-af5c-98069e2ccc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e6cb2c-c0a4-465a-81c0-f1335a0a7ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e6cb2c-c0a4-465a-81c0-f1335a0a7ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fc562a72-d5e6-4f6a-8531-05b3903321c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8908283b-1038-47a6-8002-45cc3a9de2a6" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fc562a72-d5e6-4f6a-8531-05b3903321c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_2966caf5-0523-44da-8a27-929a62b26cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fc562a72-d5e6-4f6a-8531-05b3903321c4" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_2966caf5-0523-44da-8a27-929a62b26cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAssumed1_9976ed8a-1711-4c53-af29-b934105d6516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fc562a72-d5e6-4f6a-8531-05b3903321c4" xlink:to="loc_us-gaap_NotesAssumed1_9976ed8a-1711-4c53-af29-b934105d6516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern" xlink:type="simple" xlink:href="vtvt-20220630.xsd#DescriptionofBusinessBasisofPresentationandGoingConcern"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8c9bcacd-669e-4034-853d-73006c4fbdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f45d1961-2d30-4df8-9879-dbaa7a2077bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c9bcacd-669e-4034-853d-73006c4fbdee" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f45d1961-2d30-4df8-9879-dbaa7a2077bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#DescriptionofBusinessBasisofPresentationandGoingConcernDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_7e76e62b-8648-4b70-9dc2-8a68f10c50a0" xlink:href="vtvt-20220630.xsd#vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:href="vtvt-20220630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract_7e76e62b-8648-4b70-9dc2-8a68f10c50a0" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5af79f81-6ccd-4353-989e-f2beaa1c444f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_dei_LegalEntityAxis_5af79f81-6ccd-4353-989e-f2beaa1c444f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b5b8144c-6a9e-48f3-bc18-4fb401af46b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5af79f81-6ccd-4353-989e-f2beaa1c444f" xlink:to="loc_dei_EntityDomain_b5b8144c-6a9e-48f3-bc18-4fb401af46b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_6658fd46-1388-4b8f-a045-e382365bcf18" xlink:href="vtvt-20220630.xsd#vtvt_VTvLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b5b8144c-6a9e-48f3-bc18-4fb401af46b8" xlink:to="loc_vtvt_VTvLLCMember_6658fd46-1388-4b8f-a045-e382365bcf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ce951622-4d8d-4285-bbae-506f2dfc0014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ce951622-4d8d-4285-bbae-506f2dfc0014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_37403692-2733-4ce8-9256-e729a0470ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ce951622-4d8d-4285-bbae-506f2dfc0014" xlink:to="loc_us-gaap_ClassOfStockDomain_37403692-2733-4ce8-9256-e729a0470ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ddb39c3c-608d-43a4-90af-4d76a8335c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_37403692-2733-4ce8-9256-e729a0470ea5" xlink:to="loc_us-gaap_CommonClassAMember_ddb39c3c-608d-43a4-90af-4d76a8335c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsAxis_1156f624-ded7-4a86-a1ab-4affdfe3a312" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAgreementObligationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_vtvt_LicenseAgreementObligationsAxis_1156f624-ded7-4a86-a1ab-4affdfe3a312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain_95dab81a-44f7-4f55-95b4-d8398021ca76" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis_1156f624-ded7-4a86-a1ab-4affdfe3a312" xlink:to="loc_vtvt_LicenseAgreementObligationsDomain_95dab81a-44f7-4f55-95b4-d8398021ca76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_7729a650-efe2-41da-b06f-690630301d74" xlink:href="vtvt-20220630.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_LicenseAgreementObligationsDomain_95dab81a-44f7-4f55-95b4-d8398021ca76" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_7729a650-efe2-41da-b06f-690630301d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_834fd422-4be9-4e17-a8c2-f22022def4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_834fd422-4be9-4e17-a8c2-f22022def4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2e06edba-2fb4-42d0-a1b9-13033006ec20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_834fd422-4be9-4e17-a8c2-f22022def4a8" xlink:to="loc_us-gaap_RelatedPartyDomain_2e06edba-2fb4-42d0-a1b9-13033006ec20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_1667779d-9a44-4e1c-9712-e745e7b892dd" xlink:href="vtvt-20220630.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2e06edba-2fb4-42d0-a1b9-13033006ec20" xlink:to="loc_vtvt_CantorFitzgeraldMember_1667779d-9a44-4e1c-9712-e745e7b892dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_srt_CounterpartyNameAxis_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fc68ec9f-6423-4ff6-91fc-94fd1c5cb80a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_530d0f4e-b23e-4ac7-92eb-7b59aa3e0360" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_530d0f4e-b23e-4ac7-92eb-7b59aa3e0360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentMember_52df5e31-1cf6-4da7-bcfd-941f51c80288" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a364341f-c467-4149-9a83-963812761208" xlink:to="loc_vtvt_G2InvestmentMember_52df5e31-1cf6-4da7-bcfd-941f51c80288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6831a943-bebc-45fe-8d24-cc3847eadf52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6831a943-bebc-45fe-8d24-cc3847eadf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dee6bc75-5de3-4aee-b6a8-ecab296929bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6831a943-bebc-45fe-8d24-cc3847eadf52" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dee6bc75-5de3-4aee-b6a8-ecab296929bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dda99b68-ef13-4ea0-9460-3768a0f5e32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_dee6bc75-5de3-4aee-b6a8-ecab296929bc" xlink:to="loc_us-gaap_SubsequentEventMember_dda99b68-ef13-4ea0-9460-3768a0f5e32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:href="vtvt-20220630.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_7f8345ac-54b3-4319-994d-eea083c1d2c2" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_dbe4b11c-7fc2-4029-b28f-e5a5d0da9179" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_dbe4b11c-7fc2-4029-b28f-e5a5d0da9179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_2f7d7694-1d5e-4970-865b-4f00d8544608" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_2f7d7694-1d5e-4970-865b-4f00d8544608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43a86624-f06e-44bc-ae92-2d8c61bb1f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43a86624-f06e-44bc-ae92-2d8c61bb1f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_253e1d37-55d2-4ef6-86a8-7214359777db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_253e1d37-55d2-4ef6-86a8-7214359777db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_0f62e844-eb02-47c6-b20d-5355f0f68a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_0f62e844-eb02-47c6-b20d-5355f0f68a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_01e4239d-84f4-43eb-9c6e-5d0097bf1707" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_01e4239d-84f4-43eb-9c6e-5d0097bf1707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_bb11bb38-51b5-4bff-bf9d-c773b6bb6ee6" xlink:href="vtvt-20220630.xsd#vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_bb11bb38-51b5-4bff-bf9d-c773b6bb6ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18c2a8eb-4df9-4873-a0fb-0f0b471c805a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_75d43385-266e-474f-9bbf-1425a477f62e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18c2a8eb-4df9-4873-a0fb-0f0b471c805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtvt-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a0124ae-fb4a-464d-8b02-3eb25a9fcb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e768342d-4ae8-4d19-a293-2d48b6bb80da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a0124ae-fb4a-464d-8b02-3eb25a9fcb15" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e768342d-4ae8-4d19-a293-2d48b6bb80da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtvt-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_93e2f652-dfb7-4933-9fed-6ceafe6fabe2" xlink:href="vtvt-20220630.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_93e2f652-dfb7-4933-9fed-6ceafe6fabe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_94c6a855-475b-45e9-99b3-80e5ef88592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_us-gaap_UseOfEstimates_94c6a855-475b-45e9-99b3-80e5ef88592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_95f36516-1fd1-4e5f-ba78-340f5ea22fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_95f36516-1fd1-4e5f-ba78-340f5ea22fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_df9ef44b-d0da-463f-83ac-e62bb93dc7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_df9ef44b-d0da-463f-83ac-e62bb93dc7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_847e9646-cc3a-4c8e-ad02-c506c83b2074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_847e9646-cc3a-4c8e-ad02-c506c83b2074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d17980ef-004d-4334-9add-18110153c61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d17980ef-004d-4334-9add-18110153c61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b217f04b-4ce8-4035-85d2-48f8fa036afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b217f04b-4ce8-4035-85d2-48f8fa036afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4354ba09-374b-4571-a294-abe66a39d8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b55edcc5-0d2c-4232-b4de-71a07edee6cc" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4354ba09-374b-4571-a294-abe66a39d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a12ec63e-7656-4965-b7fe-264d2fddd125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:href="vtvt-20220630.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a12ec63e-7656-4965-b7fe-264d2fddd125" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dfd2eb60-c947-49ac-879d-e75811f4030b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dfd2eb60-c947-49ac-879d-e75811f4030b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_355b526a-abbc-4618-a4f6-dc8b17188aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dfd2eb60-c947-49ac-879d-e75811f4030b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_355b526a-abbc-4618-a4f6-dc8b17188aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_e79da493-fc73-4a96-a03b-97e1af542ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_355b526a-abbc-4618-a4f6-dc8b17188aca" xlink:to="loc_us-gaap_SalesRevenueNetMember_e79da493-fc73-4a96-a03b-97e1af542ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e0c7e342-5359-46c8-9e36-2ffaabd89b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e0c7e342-5359-46c8-9e36-2ffaabd89b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6c79dd5e-ce55-4e7b-bf70-16e38552bf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e0c7e342-5359-46c8-9e36-2ffaabd89b06" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6c79dd5e-ce55-4e7b-bf70-16e38552bf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1ea42c02-a899-4d9c-8b34-79a2faa54b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6c79dd5e-ce55-4e7b-bf70-16e38552bf32" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1ea42c02-a899-4d9c-8b34-79a2faa54b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0116080c-f2cf-44c6-977e-83fb8b6a417b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:to="loc_srt_MajorCustomersAxis_0116080c-f2cf-44c6-977e-83fb8b6a417b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7fa06729-9b61-44ae-86c4-555df54db409" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0116080c-f2cf-44c6-977e-83fb8b6a417b" xlink:to="loc_srt_NameOfMajorCustomerDomain_7fa06729-9b61-44ae-86c4-555df54db409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember_d098f616-325e-49a4-887a-4d220356b35c" xlink:href="vtvt-20220630.xsd#vtvt_OneCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fa06729-9b61-44ae-86c4-555df54db409" xlink:to="loc_vtvt_OneCustomerMember_d098f616-325e-49a4-887a-4d220356b35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_9430779d-e2af-4f4c-ad2d-6dfff72025fe" xlink:href="vtvt-20220630.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_69612490-f469-403d-8ca1-445656dbab1d" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_9430779d-e2af-4f4c-ad2d-6dfff72025fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e3c9c926-26d7-4c88-a62f-3304e2a3cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_9430779d-e2af-4f4c-ad2d-6dfff72025fe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e3c9c926-26d7-4c88-a62f-3304e2a3cc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e984557a-e481-4757-8959-9553b554ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_cec36bfd-2023-411d-89fc-80dd29364c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e984557a-e481-4757-8959-9553b554ab31" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_cec36bfd-2023-411d-89fc-80dd29364c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ccadabdf-130a-444f-9890-0a8590c056c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cdb83893-072d-41f8-84f2-b1afa6fa25d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ccadabdf-130a-444f-9890-0a8590c056c9" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cdb83893-072d-41f8-84f2-b1afa6fa25d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock_e6817d27-323f-4f13-b197-88594f6e4306" xlink:href="vtvt-20220630.xsd#vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ccadabdf-130a-444f-9890-0a8590c056c9" xlink:to="loc_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock_e6817d27-323f-4f13-b197-88594f6e4306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14340d87-fcb3-4170-9be0-91520ac99e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14340d87-fcb3-4170-9be0-91520ac99e4e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a23f335-0417-48f8-a65a-67ea2a17d43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a23f335-0417-48f8-a65a-67ea2a17d43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a23f335-0417-48f8-a65a-67ea2a17d43d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_dc4fd5cf-e07a-4aea-9ddb-fd681b5334fb" xlink:href="vtvt-20220630.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_dc4fd5cf-e07a-4aea-9ddb-fd681b5334fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1f3f4e9e-ae02-4bfa-ba8e-6eae3841dd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e95453e4-1e97-444b-a062-5fa55637be81" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1f3f4e9e-ae02-4bfa-ba8e-6eae3841dd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3296dd0-b141-4d31-870e-5703bca59a62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_dei_LegalEntityAxis_f3296dd0-b141-4d31-870e-5703bca59a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f3296dd0-b141-4d31-870e-5703bca59a62" xlink:to="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_81a729c2-7292-418b-8076-a02a2ce3ff90" xlink:href="vtvt-20220630.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_81a729c2-7292-418b-8076-a02a2ce3ff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_a57ad88b-6bb8-41a0-b887-c126cae321ff" xlink:href="vtvt-20220630.xsd#vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_a57ad88b-6bb8-41a0-b887-c126cae321ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_0a694ed5-6136-41a0-838a-2a0ccab410bb" xlink:href="vtvt-20220630.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_0a694ed5-6136-41a0-838a-2a0ccab410bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_0f1ae615-5010-49d9-8d44-23ed87fb9305" xlink:href="vtvt-20220630.xsd#vtvt_AnterisBioIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_AnterisBioIncMember_0f1ae615-5010-49d9-8d44-23ed87fb9305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember_4e60f45e-cde1-479b-9f8b-8c59727ee2ee" xlink:href="vtvt-20220630.xsd#vtvt_JDRFInternationalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_49b3c167-1f27-4508-a588-3dbc93279e38" xlink:to="loc_vtvt_JDRFInternationalMember_4e60f45e-cde1-479b-9f8b-8c59727ee2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_223c12cc-f9ec-4b83-bc92-0cdafdff6157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_us-gaap_OtherCommitmentsAxis_223c12cc-f9ec-4b83-bc92-0cdafdff6157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_13e6677a-4543-4b55-a8df-dfbe1d3e2162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_223c12cc-f9ec-4b83-bc92-0cdafdff6157" xlink:to="loc_us-gaap_OtherCommitmentsDomain_13e6677a-4543-4b55-a8df-dfbe1d3e2162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_7fb3987c-7956-4083-91e6-a9c2dbbe90f7" xlink:href="vtvt-20220630.xsd#vtvt_PhaseTwoMultiRegionalClinicalTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_13e6677a-4543-4b55-a8df-dfbe1d3e2162" xlink:to="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_7fb3987c-7956-4083-91e6-a9c2dbbe90f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c400018-2bcf-4873-ac99-77b5fe47ed68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_srt_ProductOrServiceAxis_8c400018-2bcf-4873-ac99-77b5fe47ed68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c400018-2bcf-4873-ac99-77b5fe47ed68" xlink:to="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_a671c1d9-5594-41d1-b50a-d9a5cd8cd0a2" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_a671c1d9-5594-41d1-b50a-d9a5cd8cd0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesMember_9a23a8a8-4a8e-4be6-af88-c7a2cf5dd32a" xlink:href="vtvt-20220630.xsd#vtvt_LicenseAndTechnologyTransferServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_16ec02e1-a0b6-43cd-a2c4-0e3d3fc242a6" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesMember_9a23a8a8-4a8e-4be6-af88-c7a2cf5dd32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_srt_CounterpartyNameAxis_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ccc9bd07-49d5-4738-a661-ad3e6b7ee23a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_afc4f23c-829b-48c7-9387-bf5b057d060a" xlink:href="vtvt-20220630.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:to="loc_vtvt_G42InvestmentsMember_afc4f23c-829b-48c7-9387-bf5b057d060a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_3197a510-efce-4790-b6c1-b1568bec28d5" xlink:href="vtvt-20220630.xsd#vtvt_CognaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2d85712d-f064-48ea-a814-b80a9a907363" xlink:to="loc_vtvt_CognaMember_3197a510-efce-4790-b6c1-b1568bec28d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e902528-2db3-4897-bfa4-03e1339ba8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e902528-2db3-4897-bfa4-03e1339ba8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_efa6f15f-1421-48a6-8fc3-11b601521c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e902528-2db3-4897-bfa4-03e1339ba8a9" xlink:to="loc_us-gaap_ClassOfStockDomain_efa6f15f-1421-48a6-8fc3-11b601521c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_630019ba-ae60-44e9-9775-8be6cc4b572d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_efa6f15f-1421-48a6-8fc3-11b601521c48" xlink:to="loc_us-gaap_CommonClassAMember_630019ba-ae60-44e9-9775-8be6cc4b572d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1290fa29-26a0-4816-a55d-4aeb0cbbc45a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ba98982f-6577-4d47-8123-a2f6e296396f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ba98982f-6577-4d47-8123-a2f6e296396f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3bb8287-ad14-471d-b8fd-01fd064e12c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f3bb8287-ad14-471d-b8fd-01fd064e12c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_29d44b60-2214-494e-864a-cbff0072caac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_29d44b60-2214-494e-864a-cbff0072caac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_b4751b8c-5fcf-4f50-94c7-ce4e9a601001" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_b4751b8c-5fcf-4f50-94c7-ce4e9a601001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f5348fa6-3841-47af-9445-2ffe041c92be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f5348fa6-3841-47af-9445-2ffe041c92be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_55498078-e190-4463-a873-cb6ed9c103ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_55498078-e190-4463-a873-cb6ed9c103ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod_04a86795-d185-43b2-99b9-89abbcb7dd55" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivablePaymentPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod_04a86795-d185-43b2-99b9-89abbcb7dd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_6c477d56-dda4-4f4b-ab80-2e283f549ae4" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_6c477d56-dda4-4f4b-ab80-2e283f549ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_954e867e-ca26-44fe-8341-497745509730" xlink:href="vtvt-20220630.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_954e867e-ca26-44fe-8341-497745509730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage_724f748e-9dba-4bc5-89a4-926574aaa83b" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage_724f748e-9dba-4bc5-89a4-926574aaa83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_80898bc8-0697-48d9-874e-c10a14422894" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_80898bc8-0697-48d9-874e-c10a14422894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7fb6aebc-25fb-461c-a6b7-6d141ca27176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_SharePrice_7fb6aebc-25fb-461c-a6b7-6d141ca27176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_6ead0813-6e39-40ad-92fe-db09acb68eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_6ead0813-6e39-40ad-92fe-db09acb68eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5fa81c25-1ccf-4f73-890d-6306da327314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5fa81c25-1ccf-4f73-890d-6306da327314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_d2baae0e-d9ed-453f-a0ef-b2f4f4b16adc" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_d2baae0e-d9ed-453f-a0ef-b2f4f4b16adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f38ead6-5634-4e19-af7a-0656e64dfe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f38ead6-5634-4e19-af7a-0656e64dfe4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_89992f3f-b59d-4d63-a5b6-c599fa93c5a0" xlink:href="vtvt-20220630.xsd#vtvt_AdjustmentsToTransactionPriceForPerformanceObligations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_89992f3f-b59d-4d63-a5b6-c599fa93c5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumSponsoringContributionAmount_1a0a5c95-4d24-475e-928f-95a8f7a6de98" xlink:href="vtvt-20220630.xsd#vtvt_MaximumSponsoringContributionAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_MaximumSponsoringContributionAmount_1a0a5c95-4d24-475e-928f-95a8f7a6de98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_65b29af0-b73f-4ac9-9745-d3518db01ab9" xlink:href="vtvt-20220630.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_65b29af0-b73f-4ac9-9745-d3518db01ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod_d8d943b2-6383-4c63-baa6-44f98a0599e1" xlink:href="vtvt-20220630.xsd#vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod_d8d943b2-6383-4c63-baa6-44f98a0599e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_94bac0e7-308c-4cc8-912b-f62c0677ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_94bac0e7-308c-4cc8-912b-f62c0677ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_4da5e39e-03f7-4442-a191-9c6d2318125d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_4da5e39e-03f7-4442-a191-9c6d2318125d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_60c61974-f387-4902-ad01-b635b69fb3a6" xlink:href="vtvt-20220630.xsd#vtvt_LicenseFeeReceived"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_LicenseFeeReceived_60c61974-f387-4902-ad01-b635b69fb3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_5b41fb57-cea3-4a05-9333-fc36bc66af58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_5b41fb57-cea3-4a05-9333-fc36bc66af58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones_a865dde3-8e6e-460b-8023-d2207ede9f5e" xlink:href="vtvt-20220630.xsd#vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones_a865dde3-8e6e-460b-8023-d2207ede9f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_6eb0c2ac-e229-4e59-bdf2-8cc28327c1d5" xlink:href="vtvt-20220630.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_6eb0c2ac-e229-4e59-bdf2-8cc28327c1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FundingReceived_ac18369f-791e-476f-a6c4-89ebf2a6dbcd" xlink:href="vtvt-20220630.xsd#vtvt_FundingReceived"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_vtvt_FundingReceived_ac18369f-791e-476f-a6c4-89ebf2a6dbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25aa4013-878f-4256-8647-64b284a82677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2baafd68-524a-470b-b6b5-1f1aa74cbe7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25aa4013-878f-4256-8647-64b284a82677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_08b79775-04aa-4985-975a-a664ee69ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e91ca986-1320-460e-8447-971ef8b3adc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_08b79775-04aa-4985-975a-a664ee69ca52" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e91ca986-1320-460e-8447-971ef8b3adc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_68adeef0-18f8-4251-b461-97dbf2365fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_08b79775-04aa-4985-975a-a664ee69ca52" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_68adeef0-18f8-4251-b461-97dbf2365fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4dfb6752-c100-4dfa-a3b3-52f6c9b52f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_08b79775-04aa-4985-975a-a664ee69ca52" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4dfb6752-c100-4dfa-a3b3-52f6c9b52f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6329cf1-a9b8-4bdd-b9f3-72962eaf27fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward_805174bd-1bf8-407e-b8f8-51d3b738226d" xlink:href="vtvt-20220630.xsd#vtvt_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6329cf1-a9b8-4bdd-b9f3-72962eaf27fd" xlink:to="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward_805174bd-1bf8-407e-b8f8-51d3b738226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_063dd3dd-b6dd-42cd-bb5d-8c78a94ed236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward_805174bd-1bf8-407e-b8f8-51d3b738226d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_063dd3dd-b6dd-42cd-bb5d-8c78a94ed236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b634b198-a649-4b5e-93e0-dfe99f7a17f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward_805174bd-1bf8-407e-b8f8-51d3b738226d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b634b198-a649-4b5e-93e0-dfe99f7a17f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_bd789566-f64d-45cd-94e6-15a4707bc305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward_805174bd-1bf8-407e-b8f8-51d3b738226d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_bd789566-f64d-45cd-94e6-15a4707bc305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9413b9fc-d5c3-4616-a8a0-94786cc26978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ChangeInContractWithCustomerLiabilityRollForward_805174bd-1bf8-407e-b8f8-51d3b738226d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9413b9fc-d5c3-4616-a8a0-94786cc26978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="vtvt-20220630.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1380a963-1086-4ddb-b433-fcf245ca337c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b087ca10-2096-42d6-ae42-43f4ed41e4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1380a963-1086-4ddb-b433-fcf245ca337c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b087ca10-2096-42d6-ae42-43f4ed41e4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="vtvt-20220630.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8c4bfd6-81a3-4820-a265-cd5bbda9f1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8dd8074a-f2dd-41cd-921e-0f46a03437d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8c4bfd6-81a3-4820-a265-cd5bbda9f1d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8dd8074a-f2dd-41cd-921e-0f46a03437d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5969ce09-d6f3-41b3-8faf-767801c78f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8c4bfd6-81a3-4820-a265-cd5bbda9f1d0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5969ce09-d6f3-41b3-8faf-767801c78f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_7779c215-296b-45b7-a756-606cc090db9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7779c215-296b-45b7-a756-606cc090db9b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c279fb15-553e-442f-8ac0-b5583dbbece9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:to="loc_us-gaap_AwardTypeAxis_c279fb15-553e-442f-8ac0-b5583dbbece9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29637e9d-4ae3-43df-a6ce-b7bb5e901b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c279fb15-553e-442f-8ac0-b5583dbbece9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29637e9d-4ae3-43df-a6ce-b7bb5e901b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3d9e9332-74d0-4a92-9294-7b4706e95cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29637e9d-4ae3-43df-a6ce-b7bb5e901b89" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3d9e9332-74d0-4a92-9294-7b4706e95cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_542a85d0-2d5b-4092-82a5-0301b1299848" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:to="loc_srt_TitleOfIndividualAxis_542a85d0-2d5b-4092-82a5-0301b1299848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81d21a89-6ff2-4dd9-95f3-90a9c311b8bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_542a85d0-2d5b-4092-82a5-0301b1299848" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81d21a89-6ff2-4dd9-95f3-90a9c311b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StrategicAdvisorMember_09a4877c-1e0e-4d2a-9ea0-ae5bf1a045cf" xlink:href="vtvt-20220630.xsd#vtvt_StrategicAdvisorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_81d21a89-6ff2-4dd9-95f3-90a9c311b8bf" xlink:to="loc_vtvt_StrategicAdvisorMember_09a4877c-1e0e-4d2a-9ea0-ae5bf1a045cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5aff849f-7016-444f-bed5-2799cfe111f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_912137aa-ef00-4d97-b16c-e4f97234c3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_912137aa-ef00-4d97-b16c-e4f97234c3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3789d115-6552-4339-94c9-93e766f44ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3789d115-6552-4339-94c9-93e766f44ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bf82a6bd-11e1-473f-a887-28f278f75b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bf82a6bd-11e1-473f-a887-28f278f75b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1b05015-acf6-46ba-b04a-ea0525f87172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f1b05015-acf6-46ba-b04a-ea0525f87172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5b7d040-2c3f-40bd-b62d-370ac2ccaa16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5b7d040-2c3f-40bd-b62d-370ac2ccaa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5366fbc9-26e2-4a6b-8f1a-26b9488c6a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5366fbc9-26e2-4a6b-8f1a-26b9488c6a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d93a7f63-c405-400a-b6a7-9338ba231fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d93a7f63-c405-400a-b6a7-9338ba231fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled_3a717fe0-e706-40d4-b52c-2cf81093c7fb" xlink:href="vtvt-20220630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9bae2e8-7f83-473f-a7c8-8f5839bcfd2d" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled_3a717fe0-e706-40d4-b52c-2cf81093c7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e889b617-34c0-47ee-8376-503955b05ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e889b617-34c0-47ee-8376-503955b05ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3af68f46-05a8-468e-94e5-3bdaefa2f4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e889b617-34c0-47ee-8376-503955b05ee3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3af68f46-05a8-468e-94e5-3bdaefa2f4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_143cd13e-f909-41a8-a7bd-79059255be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e889b617-34c0-47ee-8376-503955b05ee3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_143cd13e-f909-41a8-a7bd-79059255be5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4bd93668-fb0c-4761-8adc-a0056ca0a5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e889b617-34c0-47ee-8376-503955b05ee3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4bd93668-fb0c-4761-8adc-a0056ca0a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9dd502c7-52cd-4ca7-9107-a1e27f9bb69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e889b617-34c0-47ee-8376-503955b05ee3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9dd502c7-52cd-4ca7-9107-a1e27f9bb69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0d20f64-c8ca-4ba8-8071-c1fbdd1c28a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0d20f64-c8ca-4ba8-8071-c1fbdd1c28a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b12ff744-02b2-4b1b-931c-f35444b08f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b12ff744-02b2-4b1b-931c-f35444b08f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3666e819-9d64-4dc2-9687-3ef2f792b43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_3666e819-9d64-4dc2-9687-3ef2f792b43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dca35bb8-05e8-41f7-a11f-34ff4fe9a05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dca35bb8-05e8-41f7-a11f-34ff4fe9a05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_de454769-3302-491e-93a4-0f7289b50693" xlink:href="vtvt-20220630.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_de454769-3302-491e-93a4-0f7289b50693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec33269e-5787-49af-b1a1-aec22594f31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_de454769-3302-491e-93a4-0f7289b50693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec33269e-5787-49af-b1a1-aec22594f31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dd6ab60d-fad1-4b33-8956-bae3d21c43b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_de454769-3302-491e-93a4-0f7289b50693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dd6ab60d-fad1-4b33-8956-bae3d21c43b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4ad2ef27-1767-4225-833f-80983f6472d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_de454769-3302-491e-93a4-0f7289b50693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4ad2ef27-1767-4225-833f-80983f6472d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec5c8bdc-727f-4f1e-bb92-679e5a191783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward_de454769-3302-491e-93a4-0f7289b50693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec5c8bdc-727f-4f1e-bb92-679e5a191783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a242dfe4-5cea-454d-aa3e-07956df72d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a242dfe4-5cea-454d-aa3e-07956df72d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f5069d1f-6241-4f58-9a63-ded31735aee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f59cd1c5-75f0-4cae-a709-0483c4e307a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f5069d1f-6241-4f58-9a63-ded31735aee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f80aa2a-7857-473b-a8a7-735cd3fe804a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a7316af-61d6-4214-a7d1-c1f3e321ddce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f80aa2a-7857-473b-a8a7-735cd3fe804a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a7316af-61d6-4214-a7d1-c1f3e321ddce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_185df70f-adb0-437c-9115-5003c682dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a7316af-61d6-4214-a7d1-c1f3e321ddce" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_185df70f-adb0-437c-9115-5003c682dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_185df70f-adb0-437c-9115-5003c682dd60" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3390695e-9912-4809-ad8c-4315efa02d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3390695e-9912-4809-ad8c-4315efa02d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea7fbd11-defe-404f-885b-bc1bcb7aca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51eecb77-d7ef-4735-9114-6c59a42de5b3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea7fbd11-defe-404f-885b-bc1bcb7aca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6707a24-5d4e-4001-bdf7-140184dbcb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a7316af-61d6-4214-a7d1-c1f3e321ddce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6707a24-5d4e-4001-bdf7-140184dbcb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_721f798d-e3a6-4f19-a274-3e81dc66f892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6707a24-5d4e-4001-bdf7-140184dbcb95" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_721f798d-e3a6-4f19-a274-3e81dc66f892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Investments" xlink:type="simple" xlink:href="vtvt-20220630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc487c11-bef4-4ff8-8deb-368105ea371a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4f7e42e7-ab64-42cb-a421-9886e088bf45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc487c11-bef4-4ff8-8deb-368105ea371a" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4f7e42e7-ab64-42cb-a421-9886e088bf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsTables" xlink:type="simple" xlink:href="vtvt-20220630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_56fc4f2c-a997-4db4-8197-0da50df45d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_24a0012c-ed21-4cda-964e-f2b38f32d476" xlink:href="vtvt-20220630.xsd#vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_56fc4f2c-a997-4db4-8197-0da50df45d60" xlink:to="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_24a0012c-ed21-4cda-964e-f2b38f32d476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#InvestmentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0c9e8276-2f4a-4799-82b2-b3905c5532fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1a46f7a9-8bbb-4be0-88c9-4db5673bc013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0c9e8276-2f4a-4799-82b2-b3905c5532fb" xlink:to="loc_us-gaap_StatementTable_1a46f7a9-8bbb-4be0-88c9-4db5673bc013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_96e6d301-f932-49af-9ae2-9db7a8dce20e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1a46f7a9-8bbb-4be0-88c9-4db5673bc013" xlink:to="loc_dei_LegalEntityAxis_96e6d301-f932-49af-9ae2-9db7a8dce20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c6124c20-a5e7-49a8-861b-73acb32f969c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_96e6d301-f932-49af-9ae2-9db7a8dce20e" xlink:to="loc_dei_EntityDomain_c6124c20-a5e7-49a8-861b-73acb32f969c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_c6875180-ac37-4770-b361-33c5ad16e25a" xlink:href="vtvt-20220630.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c6124c20-a5e7-49a8-861b-73acb32f969c" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_c6875180-ac37-4770-b361-33c5ad16e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1a46f7a9-8bbb-4be0-88c9-4db5673bc013" xlink:to="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_InvestmentOwnershipPercentage_16eb14fc-6198-426c-b178-0947de4b1463" xlink:href="vtvt-20220630.xsd#vtvt_InvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:to="loc_vtvt_InvestmentOwnershipPercentage_16eb14fc-6198-426c-b178-0947de4b1463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c58af4eb-3da2-439a-818a-9cfc05aed6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_246597e0-6cc7-41a5-b93f-a60a563d9efe" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c58af4eb-3da2-439a-818a-9cfc05aed6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_04776d40-4a91-4ea0-af08-1a0804434586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_04776d40-4a91-4ea0-af08-1a0804434586" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_81bfeeef-bd28-4c7f-874a-e9f0ae156b98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:to="loc_dei_LegalEntityAxis_81bfeeef-bd28-4c7f-874a-e9f0ae156b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_81bfeeef-bd28-4c7f-874a-e9f0ae156b98" xlink:to="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_3cffadcc-a46f-48f6-9bdd-42d341066f5a" xlink:href="vtvt-20220630.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_3cffadcc-a46f-48f6-9bdd-42d341066f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_179e9f9f-4f70-4dd6-83bf-d3b6a20c68ad" xlink:href="vtvt-20220630.xsd#vtvt_AnterisBioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10be41a5-d483-4a65-a633-a8908bc5ec95" xlink:to="loc_vtvt_AnterisBioIncMember_179e9f9f-4f70-4dd6-83bf-d3b6a20c68ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_087b56d9-c0bb-4860-8936-0afa6aa5484c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_087b56d9-c0bb-4860-8936-0afa6aa5484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_087b56d9-c0bb-4860-8936-0afa6aa5484c" xlink:to="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6cabb31e-c6c9-483f-8896-ea82f81508cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:to="loc_us-gaap_CommonStockMember_6cabb31e-c6c9-483f-8896-ea82f81508cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_81949502-92ff-46d0-9d57-936053270b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ba3b49f-07f3-41e8-bbe3-e74d2aaef162" xlink:to="loc_us-gaap_PreferredStockMember_81949502-92ff-46d0-9d57-936053270b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_abd240de-acbc-404f-8a39-7aff41133f5c" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3b6655ca-e3a9-410c-ad5d-a3fc0efe4130" xlink:href="vtvt-20220630.xsd#vtvt_EquityInvestmentsWithReadilyDeterminableFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:to="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3b6655ca-e3a9-410c-ad5d-a3fc0efe4130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_05a8923b-b7f8-457c-b6e9-8d7614be8a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_2b15c7e8-f02b-483f-95ed-2fdc0b115495" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_05a8923b-b7f8-457c-b6e9-8d7614be8a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_32337004-9391-4533-87cc-ae39ed780ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2ab7dc69-2926-42de-bcc8-21efa2044ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_32337004-9391-4533-87cc-ae39ed780ba9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2ab7dc69-2926-42de-bcc8-21efa2044ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8f71a745-b730-46cf-9f3c-1eeb7f162d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8f71a745-b730-46cf-9f3c-1eeb7f162d56" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_us-gaap_OtherCommitmentsAxis_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_9a31026f-f1a0-4e7f-ab39-1b53f66a7b28" xlink:to="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_fc536038-f7c6-4aa1-a340-a58dbea939ea" xlink:href="vtvt-20220630.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_fc536038-f7c6-4aa1-a340-a58dbea939ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_f6e70150-4adc-4ed8-9944-52c93edf6bc3" xlink:href="vtvt-20220630.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_f6e70150-4adc-4ed8-9944-52c93edf6bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SatisfactionOfMilestonePaymentMember_3e0243bc-3029-4701-9f75-090951fca716" xlink:href="vtvt-20220630.xsd#vtvt_SatisfactionOfMilestonePaymentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_0f298387-1472-4f55-ae57-62f0ee890bad" xlink:to="loc_vtvt_SatisfactionOfMilestonePaymentMember_3e0243bc-3029-4701-9f75-090951fca716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4decbe50-e335-46af-8251-a8720e4cdaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4decbe50-e335-46af-8251-a8720e4cdaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8183bebf-bb3a-441a-9cc3-5b4de5b456fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4decbe50-e335-46af-8251-a8720e4cdaea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8183bebf-bb3a-441a-9cc3-5b4de5b456fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_df2a426c-c476-435e-970f-ffc44ab2188c" xlink:href="vtvt-20220630.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8183bebf-bb3a-441a-9cc3-5b4de5b456fb" xlink:to="loc_vtvt_NovoLicenseAgreementMember_df2a426c-c476-435e-970f-ffc44ab2188c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_20727495-222c-464c-90ee-09a144c01412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_20727495-222c-464c-90ee-09a144c01412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_20727495-222c-464c-90ee-09a144c01412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_f5644d33-5c6d-4ceb-92da-12b5f16d19d4" xlink:href="vtvt-20220630.xsd#vtvt_OtherIndicationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:to="loc_vtvt_OtherIndicationMember_f5644d33-5c6d-4ceb-92da-12b5f16d19d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_f9157c6d-92f3-41e1-8a96-0dd8b4db2588" xlink:href="vtvt-20220630.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:to="loc_vtvt_TypeOneDiabetesMember_f9157c6d-92f3-41e1-8a96-0dd8b4db2588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_7fc0240f-b0c4-45b3-97b6-9e884c77a9c2" xlink:href="vtvt-20220630.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1162c02d-145a-4cde-a571-e2db9bab0889" xlink:to="loc_vtvt_TypeTwoDiabetesMember_7fc0240f-b0c4-45b3-97b6-9e884c77a9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_307a99ce-06d9-49ab-a2eb-2d8d5016c11e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_srt_RangeAxis_307a99ce-06d9-49ab-a2eb-2d8d5016c11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b74f0ab1-63e0-4408-bf21-12f2794e1b6c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_307a99ce-06d9-49ab-a2eb-2d8d5016c11e" xlink:to="loc_srt_RangeMember_b74f0ab1-63e0-4408-bf21-12f2794e1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ee08e29-fe4c-4f1b-beb5-b9eee952b5e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b74f0ab1-63e0-4408-bf21-12f2794e1b6c" xlink:to="loc_srt_MaximumMember_3ee08e29-fe4c-4f1b-beb5-b9eee952b5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_3004dc03-5619-427a-876a-dd3586055cf8" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_cc7750da-e494-4694-a60f-5e310a7b4e91" xlink:to="loc_vtvt_CommitmentsAndContingenciesLineItems_3004dc03-5619-427a-876a-dd3586055cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_ea0d9763-6c27-486d-b7dd-f4a563b2741c" xlink:href="vtvt-20220630.xsd#vtvt_PotentialMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_3004dc03-5619-427a-876a-dd3586055cf8" xlink:to="loc_vtvt_PotentialMilestonePayment_ea0d9763-6c27-486d-b7dd-f4a563b2741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Leases" xlink:type="simple" xlink:href="vtvt-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0258d415-db5c-4d5f-9465-e159a0b2123f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0a952764-1e8c-4661-a115-e5a4d22bdf84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0258d415-db5c-4d5f-9465-e159a0b2123f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0a952764-1e8c-4661-a115-e5a4d22bdf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="vtvt-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ea810116-38ea-477f-9eef-8ae6f4695f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ebb5137b-dd4e-473a-a80c-9cdcea6d8afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea810116-38ea-477f-9eef-8ae6f4695f37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ebb5137b-dd4e-473a-a80c-9cdcea6d8afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesDetails" xlink:type="simple" xlink:href="vtvt-20220630.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_16e68ed9-87c2-47d2-b9ca-258ed97f71fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseTerminationPeriod_a6989e45-5b72-4ce0-acba-68c6b0ec7947" xlink:href="vtvt-20220630.xsd#vtvt_LesseeOperatingLeaseTerminationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16e68ed9-87c2-47d2-b9ca-258ed97f71fb" xlink:to="loc_vtvt_LesseeOperatingLeaseTerminationPeriod_a6989e45-5b72-4ce0-acba-68c6b0ec7947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_beafa5f9-a9bf-431b-9a14-f46023068b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16e68ed9-87c2-47d2-b9ca-258ed97f71fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_beafa5f9-a9bf-431b-9a14-f46023068b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_487b3e85-8d8a-4e1f-849f-598b88844ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16e68ed9-87c2-47d2-b9ca-258ed97f71fb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_487b3e85-8d8a-4e1f-849f-598b88844ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0ac87264-53c2-4d67-bf5a-ba6d0d6395df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16e68ed9-87c2-47d2-b9ca-258ed97f71fb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0ac87264-53c2-4d67-bf5a-ba6d0d6395df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_846e9237-1743-45b6-b60b-2bb383f50739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_846e9237-1743-45b6-b60b-2bb383f50739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a9fd20f7-35dc-409c-b646-7af4428fa4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a9fd20f7-35dc-409c-b646-7af4428fa4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7377e7b-1fe5-43f0-a8c6-6c96acf2fc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7377e7b-1fe5-43f0-a8c6-6c96acf2fc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7cd066d3-78d7-46f8-823b-57d2fe691086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7cd066d3-78d7-46f8-823b-57d2fe691086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0c3f67a4-de5d-4263-a5a6-17e075a5fb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0c3f67a4-de5d-4263-a5a6-17e075a5fb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_3809941e-47dd-4cff-8585-c23ca5da03ba" xlink:href="vtvt-20220630.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_3809941e-47dd-4cff-8585-c23ca5da03ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a37d202b-2492-4b53-89ec-1d0c44f3ebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a37d202b-2492-4b53-89ec-1d0c44f3ebf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest_780d81a7-d187-4187-8383-23735bb63a29" xlink:href="vtvt-20220630.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_vtvt_OperatingLeasesImputedInterest_780d81a7-d187-4187-8383-23735bb63a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fd33de84-92fd-4e8e-b1ca-5c0c45ab2808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e34ed037-5d6b-46f8-a0b3-87d8da649b81" xlink:to="loc_us-gaap_OperatingLeaseLiability_fd33de84-92fd-4e8e-b1ca-5c0c45ab2808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="simple" xlink:href="vtvt-20220630.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RedeemableNoncontrollingInterest"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_82e3be9c-440c-4a41-a238-4b15b99dfb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_4081a2c7-2be0-497a-9fcc-3f92eeb8e807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_82e3be9c-440c-4a41-a238-4b15b99dfb96" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_4081a2c7-2be0-497a-9fcc-3f92eeb8e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RedeemableNoncontrollingInterestTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_742ca109-a5d7-4d6e-9a2f-2cb7ccdbc1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_e7a6fff4-48e8-4929-9161-3b238e73d4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_742ca109-a5d7-4d6e-9a2f-2cb7ccdbc1c6" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_e7a6fff4-48e8-4929-9161-3b238e73d4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RedeemableNoncontrollingInterestAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_e888e504-d43c-4695-bfab-ff3708fad95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_e888e504-d43c-4695-bfab-ff3708fad95c" xlink:to="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:to="loc_dei_LegalEntityAxis_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_69502b4c-6d40-4319-95f1-0fef9a6bf865" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f60568f5-98ea-4ad6-9f7f-6ee88ba147e0" xlink:to="loc_dei_EntityDomain_69502b4c-6d40-4319-95f1-0fef9a6bf865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_274d696c-9dfc-40de-93d9-84018260a7b2" xlink:href="vtvt-20220630.xsd#vtvt_VTvLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_69502b4c-6d40-4319-95f1-0fef9a6bf865" xlink:to="loc_vtvt_VTvLLCMember_274d696c-9dfc-40de-93d9-84018260a7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72dc97bf-c78b-439d-a482-92a3ebf15f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72dc97bf-c78b-439d-a482-92a3ebf15f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fc74c26d-39d0-48c9-9abb-1c9076ae2427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72dc97bf-c78b-439d-a482-92a3ebf15f11" xlink:to="loc_us-gaap_ClassOfStockDomain_fc74c26d-39d0-48c9-9abb-1c9076ae2427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c1ba015f-638e-429f-919e-c7306626b3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fc74c26d-39d0-48c9-9abb-1c9076ae2427" xlink:to="loc_us-gaap_CommonClassAMember_c1ba015f-638e-429f-919e-c7306626b3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fc5f2033-393a-41e1-9962-35bbb1f5a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fc5f2033-393a-41e1-9962-35bbb1f5a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_234edac1-081b-4b32-a405-e379e169741e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_fc5f2033-393a-41e1-9962-35bbb1f5a45b" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_234edac1-081b-4b32-a405-e379e169741e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_69377408-ce3b-4a92-aaa5-5eb4122efc81" xlink:href="vtvt-20220630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_234edac1-081b-4b32-a405-e379e169741e" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_69377408-ce3b-4a92-aaa5-5eb4122efc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_215a4af3-e4a0-41a7-858d-59b9a96c8385" xlink:to="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_d51a28a2-1272-420a-a38f-3c14f0ae2348" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_d51a28a2-1272-420a-a38f-3c14f0ae2348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_9b75cd76-c011-424c-8b24-948f73d42692" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_9b75cd76-c011-424c-8b24-948f73d42692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_26cd9d52-ca82-4379-a673-daa13bf3b2e0" xlink:href="vtvt-20220630.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_26cd9d52-ca82-4379-a673-daa13bf3b2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_01197fb2-bbbe-4257-a706-2b49f8a2c71d" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_01d7b1db-f663-42d1-8c85-f04a6b4395c5" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_01197fb2-bbbe-4257-a706-2b49f8a2c71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_36f64a6e-397e-408a-9773-2bb97f8f8a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_19b8594d-4c75-4b69-a076-7fa19a8cb7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_36f64a6e-397e-408a-9773-2bb97f8f8a9e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_19b8594d-4c75-4b69-a076-7fa19a8cb7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_b6e115a4-6f3e-4c27-a458-28d34666d1db" xlink:href="vtvt-20220630.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_36f64a6e-397e-408a-9773-2bb97f8f8a9e" xlink:to="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_b6e115a4-6f3e-4c27-a458-28d34666d1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_1c536494-38df-4bd0-a1ca-28b2dddc1a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_36f64a6e-397e-408a-9773-2bb97f8f8a9e" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_1c536494-38df-4bd0-a1ca-28b2dddc1a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="vtvt-20220630.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b9069e55-1fe6-46de-af1b-c74290172c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_74ab2ff4-2136-4647-a27f-bcb077bea9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b9069e55-1fe6-46de-af1b-c74290172c79" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_74ab2ff4-2136-4647-a27f-bcb077bea9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8dada229-767c-41e9-97f6-2dc06c31c2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8dada229-767c-41e9-97f6-2dc06c31c2a0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9d811c23-4f1f-461d-be2a-b49a1097446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9d811c23-4f1f-461d-be2a-b49a1097446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d811c23-4f1f-461d-be2a-b49a1097446f" xlink:to="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9257189f-c506-454e-82f4-cfe95903697c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:to="loc_us-gaap_CommonClassAMember_9257189f-c506-454e-82f4-cfe95903697c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4795ba80-6584-4538-9123-8578af8cbad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b07d6ff4-9d26-41a7-ae97-475f5e101a68" xlink:to="loc_us-gaap_CommonStockMember_4795ba80-6584-4538-9123-8578af8cbad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef489cf6-4cbc-444b-86fd-b9e9b028ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef489cf6-4cbc-444b-86fd-b9e9b028ab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef489cf6-4cbc-444b-86fd-b9e9b028ab58" xlink:to="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_b808636e-3367-4177-99fa-d77ac360830e" xlink:href="vtvt-20220630.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:to="loc_vtvt_CantorFitzgeraldMember_b808636e-3367-4177-99fa-d77ac360830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_cbb12eaf-7ba4-40a8-8f52-adc7131ed3fd" xlink:href="vtvt-20220630.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5b2dd163-c922-4d47-94d5-5b7c53af0338" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_cbb12eaf-7ba4-40a8-8f52-adc7131ed3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_15704c40-4502-4a8e-940e-674d592ee532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_us-gaap_TransactionTypeAxis_15704c40-4502-4a8e-940e-674d592ee532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_2e370fdc-98b9-4893-8259-90301f209932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_15704c40-4502-4a8e-940e-674d592ee532" xlink:to="loc_us-gaap_TransactionDomain_2e370fdc-98b9-4893-8259-90301f209932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AtTheMarketOfferingMember_407f7276-a584-4cb1-bc45-709051fae255" xlink:href="vtvt-20220630.xsd#vtvt_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_2e370fdc-98b9-4893-8259-90301f209932" xlink:to="loc_vtvt_AtTheMarketOfferingMember_407f7276-a584-4cb1-bc45-709051fae255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_203b86ed-fd0e-4c54-ab4e-0f664d10e776" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_srt_RangeAxis_203b86ed-fd0e-4c54-ab4e-0f664d10e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e34b559d-9f06-4db0-8df4-a8ea74d84b0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_203b86ed-fd0e-4c54-ab4e-0f664d10e776" xlink:to="loc_srt_RangeMember_e34b559d-9f06-4db0-8df4-a8ea74d84b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f68263fa-65da-405c-a731-a7e9e7e65f8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e34b559d-9f06-4db0-8df4-a8ea74d84b0a" xlink:to="loc_srt_MaximumMember_f68263fa-65da-405c-a731-a7e9e7e65f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f28ba33c-3901-4afb-9a9d-e29ef1249865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_srt_CounterpartyNameAxis_f28ba33c-3901-4afb-9a9d-e29ef1249865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be12187-413b-4316-b6c0-8b24956e85a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f28ba33c-3901-4afb-9a9d-e29ef1249865" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be12187-413b-4316-b6c0-8b24956e85a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_d7b96804-cd99-47c4-b7b3-f5f063e421ec" xlink:href="vtvt-20220630.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8be12187-413b-4316-b6c0-8b24956e85a8" xlink:to="loc_vtvt_G42InvestmentsMember_d7b96804-cd99-47c4-b7b3-f5f063e421ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_02aa81c7-b751-4a1d-b3e1-5f6d94c01018" xlink:to="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f8453c33-fba8-4bbc-bcab-661674bf564e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f8453c33-fba8-4bbc-bcab-661674bf564e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized_49a00240-b6a8-48cc-bee4-d93b17ad778d" xlink:href="vtvt-20220630.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_IncreaseInCommonStockSharesAuthorized_49a00240-b6a8-48cc-bee4-d93b17ad778d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_0d21c326-48f6-4c9b-9afd-1fe58bd13629" xlink:href="vtvt-20220630.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_0d21c326-48f6-4c9b-9afd-1fe58bd13629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5a489d7-e942-4e21-932d-03ed612cf324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5a489d7-e942-4e21-932d-03ed612cf324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_45846185-d1a8-4e52-8282-bb87d929f7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_45846185-d1a8-4e52-8282-bb87d929f7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e4a3b6e2-99c0-44ac-9d1a-026840a3299a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e4a3b6e2-99c0-44ac-9d1a-026840a3299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_11a77e66-0b42-460a-a495-48d029369617" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_11a77e66-0b42-460a-a495-48d029369617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbde5245-061e-4552-a88c-43435d67e572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbde5245-061e-4552-a88c-43435d67e572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_420333f7-05ee-400a-82c0-7f839af47576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_420333f7-05ee-400a-82c0-7f839af47576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm_4ae6b9fd-8053-42aa-b454-48559b266150" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivablesPaymentTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm_4ae6b9fd-8053-42aa-b454-48559b266150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27f832c6-bbd1-4565-a1bb-79742372eb38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27f832c6-bbd1-4565-a1bb-79742372eb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PublicFloat_8e9af72b-673b-4c47-bc1c-158eafde6b75" xlink:href="vtvt-20220630.xsd#vtvt_PublicFloat"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_PublicFloat_8e9af72b-673b-4c47-bc1c-158eafde6b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AggregateOfferingPriceOfShares_78f2fe3f-88ac-48e1-8469-55943fc8c380" xlink:href="vtvt-20220630.xsd#vtvt_AggregateOfferingPriceOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_vtvt_AggregateOfferingPriceOfShares_78f2fe3f-88ac-48e1-8469-55943fc8c380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9eef0de4-d859-4021-8694-214515b748ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e391ad05-d931-4931-b76f-83726d7599f8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9eef0de4-d859-4021-8694-214515b748ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1663be85-2fc3-47cf-b864-f4588046bcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e443d22b-9d25-4eab-ba72-83983bf4b1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1663be85-2fc3-47cf-b864-f4588046bcab" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e443d22b-9d25-4eab-ba72-83983bf4b1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract_e3238ffc-640f-454e-861a-0bf988fbbddf" xlink:href="vtvt-20220630.xsd#vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract_e3238ffc-640f-454e-861a-0bf988fbbddf" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef37792b-8578-46a7-a5c7-7284566d3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef37792b-8578-46a7-a5c7-7284566d3e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_071d69fe-9cde-4f4e-b39f-d79a58a9bc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ef37792b-8578-46a7-a5c7-7284566d3e0b" xlink:to="loc_us-gaap_RelatedPartyDomain_071d69fe-9cde-4f4e-b39f-d79a58a9bc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_f79d6191-095a-4312-b7d8-20215671ef0f" xlink:href="vtvt-20220630.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_071d69fe-9cde-4f4e-b39f-d79a58a9bc24" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_f79d6191-095a-4312-b7d8-20215671ef0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4646042-ccf9-46ad-bd08-6e4a841b4df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4646042-ccf9-46ad-bd08-6e4a841b4df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4646042-ccf9-46ad-bd08-6e4a841b4df4" xlink:to="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_f83c2065-694f-4fcd-9974-dc66c1b38418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:to="loc_us-gaap_CommonClassBMember_f83c2065-694f-4fcd-9974-dc66c1b38418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3e945f50-c1e6-4de4-b0f2-2e8e6ff699b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3ae130f6-af32-4c37-8ce0-56543901e34b" xlink:to="loc_us-gaap_CommonClassAMember_3e945f50-c1e6-4de4-b0f2-2e8e6ff699b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b1965859-ace8-4342-80b4-6f265355e61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b1965859-ace8-4342-80b4-6f265355e61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_48ffe8a3-3b45-4c4b-9e4b-2f6e3183cdde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_b1965859-ace8-4342-80b4-6f265355e61c" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_48ffe8a3-3b45-4c4b-9e4b-2f6e3183cdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_c16cbe27-7eed-4ff1-9022-d28d16f5422a" xlink:href="vtvt-20220630.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_48ffe8a3-3b45-4c4b-9e4b-2f6e3183cdde" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_c16cbe27-7eed-4ff1-9022-d28d16f5422a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a62a9538-c341-4048-a507-22b98209f010" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_9154172c-abc4-4737-a5ff-266b5fae4686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_9154172c-abc4-4737-a5ff-266b5fae4686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_cc9a049a-dcf5-46f9-9300-af6d12c390f6" xlink:href="vtvt-20220630.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_cc9a049a-dcf5-46f9-9300-af6d12c390f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_a6d5bd65-3cff-417f-abc1-a0af594ea2d8" xlink:href="vtvt-20220630.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_a6d5bd65-3cff-417f-abc1-a0af594ea2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_dd1f537e-513a-4364-be2e-37efd891ba8f" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1ac0824-6490-44e8-91be-ca28ad9813a7" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_dd1f537e-513a-4364-be2e-37efd891ba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vtvt-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f2895377-23ac-4378-9255-70cd0d8f5d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d4fb8db3-cc57-4e98-ba1b-76c2c875ad07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2895377-23ac-4378-9255-70cd0d8f5d99" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d4fb8db3-cc57-4e98-ba1b-76c2c875ad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_728ea365-e4d3-4b40-ba10-104767fb8562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_da987760-472b-465e-94d5-b693671a6bfe" xlink:href="vtvt-20220630.xsd#vtvt_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_728ea365-e4d3-4b40-ba10-104767fb8562" xlink:to="loc_vtvt_IncomeTaxesTable_da987760-472b-465e-94d5-b693671a6bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e027803b-48d0-45ea-85cf-d91a2ab0ee97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_da987760-472b-465e-94d5-b693671a6bfe" xlink:to="loc_dei_LegalEntityAxis_e027803b-48d0-45ea-85cf-d91a2ab0ee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7416f389-d76d-4ab3-b606-c0c9ba4d054e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e027803b-48d0-45ea-85cf-d91a2ab0ee97" xlink:to="loc_dei_EntityDomain_7416f389-d76d-4ab3-b606-c0c9ba4d054e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_b4fc70de-6b50-4fb2-9dba-df98d1e4f04b" xlink:href="vtvt-20220630.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7416f389-d76d-4ab3-b606-c0c9ba4d054e" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_b4fc70de-6b50-4fb2-9dba-df98d1e4f04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:href="vtvt-20220630.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_da987760-472b-465e-94d5-b693671a6bfe" xlink:to="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b2436971-792e-4df1-92f7-0ac05a0cd7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b2436971-792e-4df1-92f7-0ac05a0cd7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_0a10597f-b546-429e-8cab-b8131dd4aced" xlink:href="vtvt-20220630.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesLineItems_919a0d2a-a5a0-4c17-80bb-8c2e6565a084" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_0a10597f-b546-429e-8cab-b8131dd4aced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShare" xlink:type="simple" xlink:href="vtvt-20220630.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ef20e9b1-b73a-4fbc-bd9f-527e85ee6159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8e751df4-2f5b-4de8-8f67-77b1e0118920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ef20e9b1-b73a-4fbc-bd9f-527e85ee6159" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8e751df4-2f5b-4de8-8f67-77b1e0118920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="vtvt-20220630.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2180f9cb-6426-481f-92ce-5d4873e7798f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ac0c30c6-a44b-4d90-9a7c-ef91257dab14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2180f9cb-6426-481f-92ce-5d4873e7798f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ac0c30c6-a44b-4d90-9a7c-ef91257dab14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_695f4d42-1958-4896-8494-d766e358094b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2180f9cb-6426-481f-92ce-5d4873e7798f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_695f4d42-1958-4896-8494-d766e358094b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_597db14a-4794-42d2-970f-20202799fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_223da861-bfdc-4442-b873-6aaf35495b1b" xlink:href="vtvt-20220630.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_597db14a-4794-42d2-970f-20202799fcd4" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_223da861-bfdc-4442-b873-6aaf35495b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_80ba0dc6-bffb-4230-8a5f-8280e5779879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_223da861-bfdc-4442-b873-6aaf35495b1b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_80ba0dc6-bffb-4230-8a5f-8280e5779879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_948d9771-e69d-4cdf-8e5a-65138d79c661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_80ba0dc6-bffb-4230-8a5f-8280e5779879" xlink:to="loc_us-gaap_ClassOfStockDomain_948d9771-e69d-4cdf-8e5a-65138d79c661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0c93b460-bbc1-4646-85c0-cb570c8ede5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_948d9771-e69d-4cdf-8e5a-65138d79c661" xlink:to="loc_us-gaap_CommonClassAMember_0c93b460-bbc1-4646-85c0-cb570c8ede5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:href="vtvt-20220630.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_223da861-bfdc-4442-b873-6aaf35495b1b" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_916767cb-63ef-45b9-b7fc-bc61bdeb053a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_ProfitLoss_916767cb-63ef-45b9-b7fc-bc61bdeb053a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c5881bd3-7425-4334-8c05-b5f26ea4a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c5881bd3-7425-4334-8c05-b5f26ea4a9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9040e7b-69bb-418e-ba6f-7525febfd88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9040e7b-69bb-418e-ba6f-7525febfd88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_263caf34-5a35-4390-9036-0e7dac45ee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b6744a1b-bfd5-4bea-8bf1-16fdf689fb4e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_263caf34-5a35-4390-9036-0e7dac45ee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_575cb379-beef-4162-988a-fada2b3c7081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_575cb379-beef-4162-988a-fada2b3c7081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7e22e45-f416-49a8-8635-408b61038807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7792a75c-bb6c-401d-b34b-c349facace81" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7e22e45-f416-49a8-8635-408b61038807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b60bee95-b59c-4312-aa32-db0eeca7a95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_EarningsPerShareBasic_b60bee95-b59c-4312-aa32-db0eeca7a95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0c2c36f3-920b-4c78-b957-c9fe8a5361cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_cc03e160-b403-4a04-9f27-63a4b25ac3b4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0c2c36f3-920b-4c78-b957-c9fe8a5361cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_055b6a44-ae4e-4074-923d-9bcd8a02d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2240733c-aaea-4054-96e8-7d1b488eef4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_055b6a44-ae4e-4074-923d-9bcd8a02d2a8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2240733c-aaea-4054-96e8-7d1b488eef4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d1215d-ccc7-41a9-bf02-29dc72f269f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2240733c-aaea-4054-96e8-7d1b488eef4f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d1215d-ccc7-41a9-bf02-29dc72f269f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d1215d-ccc7-41a9-bf02-29dc72f269f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_fe751408-32d0-4783-a8ac-0693f4f503dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:to="loc_us-gaap_CommonClassBMember_fe751408-32d0-4783-a8ac-0693f4f503dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_077964a6-34e5-4cf2-8f9a-f62d8210a28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:to="loc_us-gaap_EmployeeStockOptionMember_077964a6-34e5-4cf2-8f9a-f62d8210a28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e59dd019-03a3-48b4-8784-135aaee1fa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a8adc90-6304-4b1e-b520-8751aa6cc205" xlink:to="loc_us-gaap_WarrantMember_e59dd019-03a3-48b4-8784-135aaee1fa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5060b9d2-3605-451d-8c6e-f4fce2c9436e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2240733c-aaea-4054-96e8-7d1b488eef4f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5060b9d2-3605-451d-8c6e-f4fce2c9436e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01bbb43e-8680-4eb2-90ee-caccf9077773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5060b9d2-3605-451d-8c6e-f4fce2c9436e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01bbb43e-8680-4eb2-90ee-caccf9077773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4b61e8f2-759d-4991-95f2-90ad173cf793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f6e2f2b0-4f42-42d5-b96d-e8cc0bee91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4b61e8f2-759d-4991-95f2-90ad173cf793" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f6e2f2b0-4f42-42d5-b96d-e8cc0bee91ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0d3cbe68-0f2e-4da0-8c77-45fca75acab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4daa9b82-98e2-42b1-b7bc-6fdc9d4c64f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0d3cbe68-0f2e-4da0-8c77-45fca75acab6" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4daa9b82-98e2-42b1-b7bc-6fdc9d4c64f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0525e4fc-08a5-4979-8ae3-05e2132e7927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0d3cbe68-0f2e-4da0-8c77-45fca75acab6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0525e4fc-08a5-4979-8ae3-05e2132e7927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bfeae675-ccda-4991-8058-e10c3fd72a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0d3cbe68-0f2e-4da0-8c77-45fca75acab6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bfeae675-ccda-4991-8058-e10c3fd72a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1dd750c4-4e2e-4f52-b637-aeed8c5f5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1dd750c4-4e2e-4f52-b637-aeed8c5f5ecf" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b0d2bb2-0f46-433f-9864-71b195c13e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b0d2bb2-0f46-433f-9864-71b195c13e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4eba95e5-af75-4781-8f07-562ccb2a48f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b0d2bb2-0f46-433f-9864-71b195c13e43" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4eba95e5-af75-4781-8f07-562ccb2a48f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4c53bb4a-f87d-4db6-9df3-00341ae0bde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4eba95e5-af75-4781-8f07-562ccb2a48f5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4c53bb4a-f87d-4db6-9df3-00341ae0bde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa3f0c34-3fcc-4e2b-866c-1f451b6088ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0b283c28-2ee3-4efb-a759-f84f9f321731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0b283c28-2ee3-4efb-a759-f84f9f321731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_18d9136c-8c00-40b6-9cb4-6bcce3909952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_18d9136c-8c00-40b6-9cb4-6bcce3909952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cd2f0f53-1d2f-4ebc-9d6c-c2eb52c5d9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_080c9714-421b-4ba6-9877-b06b91413321" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cd2f0f53-1d2f-4ebc-9d6c-c2eb52c5d9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b53d399e-64da-4fa8-9ebf-4cf44aeb42be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b53d399e-64da-4fa8-9ebf-4cf44aeb42be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d968d7f-cd21-49a5-a1b6-118147266c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b53d399e-64da-4fa8-9ebf-4cf44aeb42be" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d968d7f-cd21-49a5-a1b6-118147266c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_30b97e9c-8b97-4833-8f43-307d7236b712" xlink:href="vtvt-20220630.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d968d7f-cd21-49a5-a1b6-118147266c17" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_30b97e9c-8b97-4833-8f43-307d7236b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_38b8e900-474b-47e0-ba9b-854ccd50c759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_38b8e900-474b-47e0-ba9b-854ccd50c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9a54f4af-fc79-47c7-9245-f1f354e61c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_38b8e900-474b-47e0-ba9b-854ccd50c759" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9a54f4af-fc79-47c7-9245-f1f354e61c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_fe52108a-ff1d-4f61-bfd4-6d48cbc4ba71" xlink:href="vtvt-20220630.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9a54f4af-fc79-47c7-9245-f1f354e61c57" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_fe52108a-ff1d-4f61-bfd4-6d48cbc4ba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_209a8bf0-3564-48d9-b2a1-1b81ed7b5be2" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0fd0d641-473a-47c1-adeb-020234b00d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0fd0d641-473a-47c1-adeb-020234b00d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fde7547c-fbb4-4315-8865-2083240edca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_fde7547c-fbb4-4315-8865-2083240edca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_52fba435-f454-47f7-b464-045ef28ec4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_367f217d-c6fa-49af-8bcc-43cc764e92fe" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_52fba435-f454-47f7-b464-045ef28ec4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6069804d-c02f-456a-8d01-0513a78f048a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6069804d-c02f-456a-8d01-0513a78f048a" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_883350b2-3172-4afa-aeea-0c6bdbeaf08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_883350b2-3172-4afa-aeea-0c6bdbeaf08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894e4c6e-3899-401b-b662-10f61db98c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_883350b2-3172-4afa-aeea-0c6bdbeaf08c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894e4c6e-3899-401b-b662-10f61db98c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_37730270-cd73-453d-a215-3ac6fdb3e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_894e4c6e-3899-401b-b662-10f61db98c1f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_37730270-cd73-453d-a215-3ac6fdb3e56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_7d383073-0abd-4e27-8792-177e14d6bb57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_7d383073-0abd-4e27-8792-177e14d6bb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_51300e86-e333-46b0-ad7b-ccd5d145dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_7d383073-0abd-4e27-8792-177e14d6bb57" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_51300e86-e333-46b0-ad7b-ccd5d145dd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_962407d4-1b2a-4db4-a639-cd494e7697fb" xlink:href="vtvt-20220630.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_51300e86-e333-46b0-ad7b-ccd5d145dd22" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_962407d4-1b2a-4db4-a639-cd494e7697fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_4b6099ef-2bbf-4063-b676-f42577f31055" xlink:href="vtvt-20220630.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_6beecf74-4096-4fc7-af06-a3b295128118" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_4b6099ef-2bbf-4063-b676-f42577f31055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_4b6099ef-2bbf-4063-b676-f42577f31055" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f48b4641-c13d-43f7-b383-b0077d1171dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f48b4641-c13d-43f7-b383-b0077d1171dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c396739b-110d-43db-912b-522d911d9157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c396739b-110d-43db-912b-522d911d9157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cff7598d-2251-44ec-b48a-6796a72b0495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cff7598d-2251-44ec-b48a-6796a72b0495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_71e25db2-7bcb-461b-bc82-531e60a8584f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_71e25db2-7bcb-461b-bc82-531e60a8584f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3cc94d40-76a4-428d-9ecb-f8c6cfd6ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8aae0a53-2dd3-41a0-b15f-fe030917f62f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3cc94d40-76a4-428d-9ecb-f8c6cfd6ada9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail" xlink:type="simple" xlink:href="vtvt-20220630.xsd#FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e712b977-55c1-45f8-a6fd-a16baed48a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e712b977-55c1-45f8-a6fd-a16baed48a08" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa40b469-992b-4fc6-922e-22b9e6aca986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f7a2d1e-1bfe-48a1-b60c-4d1560e69c00" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa40b469-992b-4fc6-922e-22b9e6aca986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember_8040e431-bcaf-4b34-b608-9975aca74957" xlink:href="vtvt-20220630.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa40b469-992b-4fc6-922e-22b9e6aca986" xlink:to="loc_vtvt_LetterAgreementWarrantsMember_8040e431-bcaf-4b34-b608-9975aca74957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16480588-5a67-4e4c-9709-d15733710996" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:to="loc_srt_RangeAxis_16480588-5a67-4e4c-9709-d15733710996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_16480588-5a67-4e4c-9709-d15733710996" xlink:to="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_32cd81fe-ae69-47a9-9119-ae8c638fb92c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:to="loc_srt_MinimumMember_32cd81fe-ae69-47a9-9119-ae8c638fb92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca899218-f6ee-4c64-849e-1b71dbb20e0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:to="loc_srt_MaximumMember_ca899218-f6ee-4c64-849e-1b71dbb20e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0d50266b-4a87-46de-a1dd-c1549a2d9192" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_42eaeda4-e482-4163-9303-0ae3792027b3" xlink:to="loc_srt_WeightedAverageMember_0d50266b-4a87-46de-a1dd-c1549a2d9192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_85807bf8-d15f-49c8-a13e-8bfffc2daa95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_85807bf8-d15f-49c8-a13e-8bfffc2daa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_85807bf8-d15f-49c8-a13e-8bfffc2daa95" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_90612c7c-f03e-4978-b3b0-3c4b919a4675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_90612c7c-f03e-4978-b3b0-3c4b919a4675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1cc5594-2231-4e85-aedf-4f8c7e8d43ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3672f41c-67e1-439a-9d5e-094956991510" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1cc5594-2231-4e85-aedf-4f8c7e8d43ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0dfc9758-97c1-484f-ba5e-e2b6417e03a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8e9fa377-5498-48c6-a012-d7ac0b1180a9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0dfc9758-97c1-484f-ba5e-e2b6417e03a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_022fcef0-b4f2-45da-b35b-635326955e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0dfc9758-97c1-484f-ba5e-e2b6417e03a7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_022fcef0-b4f2-45da-b35b-635326955e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtvt-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_75e57fda-1538-4213-a3d5-26f0967cf27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3a938ee0-e6a0-49ef-8d1f-93fab068803d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_75e57fda-1538-4213-a3d5-26f0967cf27b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3a938ee0-e6a0-49ef-8d1f-93fab068803d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtvt-20220630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6ab8c64d-73bd-4a6c-87e2-23dccef60f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6ab8c64d-73bd-4a6c-87e2-23dccef60f94" xlink:to="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4e3a7a23-ee47-4043-a205-a61caff19626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4e3a7a23-ee47-4043-a205-a61caff19626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11dcda68-e19d-42f3-97dd-e329eb296f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4e3a7a23-ee47-4043-a205-a61caff19626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11dcda68-e19d-42f3-97dd-e329eb296f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_898622fc-f978-4836-9728-5d64534d79f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_11dcda68-e19d-42f3-97dd-e329eb296f1d" xlink:to="loc_us-gaap_SubsequentEventMember_898622fc-f978-4836-9728-5d64534d79f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_717df4c8-40ca-48bb-9811-1cad270abf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:to="loc_us-gaap_StatementClassOfStockAxis_717df4c8-40ca-48bb-9811-1cad270abf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_78f5876a-7c76-4640-a05f-51a99e04f8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_717df4c8-40ca-48bb-9811-1cad270abf06" xlink:to="loc_us-gaap_ClassOfStockDomain_78f5876a-7c76-4640-a05f-51a99e04f8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_674da1df-9747-4d32-b44f-e34492beeaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_78f5876a-7c76-4640-a05f-51a99e04f8db" xlink:to="loc_us-gaap_CommonClassAMember_674da1df-9747-4d32-b44f-e34492beeaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2768886b-14b2-4c81-ac4d-3463e7a19594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:to="loc_us-gaap_VestingAxis_2768886b-14b2-4c81-ac4d-3463e7a19594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_2768886b-14b2-4c81-ac4d-3463e7a19594" xlink:to="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2905574d-a534-4dd0-84d6-87f0753a20eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2905574d-a534-4dd0-84d6-87f0753a20eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e663fa44-59f9-41d1-b0f8-934c35d661c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f1f7ff94-4189-443e-81ee-ab60f4bc61b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e663fa44-59f9-41d1-b0f8-934c35d661c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_682c06f4-6c6c-42fb-b527-8433c87c4f82" xlink:to="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd017614-7375-4397-968f-b2997cc62588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bd017614-7375-4397-968f-b2997cc62588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_94da4a17-2dca-482f-92e4-059324490a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_94da4a17-2dca-482f-92e4-059324490a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_ed543fa6-6e3a-4d92-bbad-473ab1aa3bf8" xlink:href="vtvt-20220630.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_ed543fa6-6e3a-4d92-bbad-473ab1aa3bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0baa3e8-5b88-48ca-8d2f-a5db2821b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f0baa3e8-5b88-48ca-8d2f-a5db2821b4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_918770af-bb66-46c1-afb4-b6d732b51ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ReceivablesNetCurrent_918770af-bb66-46c1-afb4-b6d732b51ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_93555afd-9b94-42e2-a5ae-6566d93e18c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_93555afd-9b94-42e2-a5ae-6566d93e18c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6cf521f5-ec80-4f7e-96dd-0b6608f1a1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6cf521f5-ec80-4f7e-96dd-0b6608f1a1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f17e6716-2070-4919-a16b-dde9a080f8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f17e6716-2070-4919-a16b-dde9a080f8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_cfc13cd0-1eef-4259-b9b7-1f6896e48d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_cfc13cd0-1eef-4259-b9b7-1f6896e48d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22f29707-2c41-4289-8033-8177fdb63df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22f29707-2c41-4289-8033-8177fdb63df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_581fb49b-e02b-42d4-9f1f-c9077c7ca68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_581fb49b-e02b-42d4-9f1f-c9077c7ca68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c45cacf8-8572-4f68-a28f-52a37a5873ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_38323ac7-ea0e-4261-a472-6197f31c2b06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c45cacf8-8572-4f68-a28f-52a37a5873ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vtvt-20220630_g1.jpg
<TEXT>
begin 644 vtvt-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#B17AI9@  34T *@    @ ! $[  (
M   (   (2H=I  0    !   (4IR=  $    0   0RNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA=GEA($<
M  60 P "    %   $*"0!  "    %   $+22D0 "     S<W  "2D@ "
M S<W  #J'  '   (#   ")0     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT,#?]^?_ *]'E^(/^A@;_OS_ /7J_11[68790\OQ!_T,#?\ ?G_Z]'E^(/\
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M_P#UZT#&P7<5X]:-ISC'-'M*@79G^7X@_P"A@;_OS_\ 7H\OQ!_T,#?]^?\
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MH\OQ!_T,#?\ ?G_Z]7\'TI=K8SCCZ4>UJ!=F?Y?B#_H8&_[\_P#UZ/+\0?\
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M]:['Q9=30_$3PG#%.R1RRRB6->!(-A(JY)\/_#TFNG5_(FCO#()28[AE4D#
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M5/\ H%P_]_*/:X;N'/3+G]LS<_\ $GO^>O[OK2?VQ*.FC7X_X!53_A9VJ?\
M0+A_[^4?\+.U3_H%P_\ ?RCVN&[ASTRV=7E/71K_ /[XH_MB7_H#7_M\E5/^
M%G:I_P! N'_OY1_PL[5/^@7#_P!_*/:X;^8.>F7/[8F_Z ]__P!^Z3^UY?\
MH#7^?7953_A9VJ?] N'_ +^4?\+.U3_H%P_]_*7M,+W#GIEO^V)?^@/?_P#?
M%']L2_\ 0'O_ /OBJG_"SM4_Z!</_?RC_A9VJ?\ 0+A_[^4_:X;N'/3+?]L2
M_P#0'O\ _OBE_MB7_H#W_P#WQ5/_ (6=JG_0+A_[^4?\+.U3_H%P_P#?RCVN
M&[ASTRCXAU25[G26.DWR[;O/*=?E:MIM8EW'&CW_ /WQ6)J?CG4M2FLY&TZ%
M?LTWFX\WKP1_6K__  LW5!TTN'_O[3]KAN[#GIEO^V)?^@/?_P#?%']L2_\
M0'O_ /OBJG_"SM4_Z!</_?RC_A9VJ?\ 0+A_[^4O:X;N'/3+G]L2_P#0&O\
M_OBD_MB7J=&OR?7953_A9VJ?] N'_OY1_P +.U3_ *!</_?RCVN&[ASTRW_;
M$O\ T![_ /[XH_M>7_H#7_O\G6JG_"SM4_Z!</\ W\H_X6=JG_0+A_[^4>UP
MW\P<],MG6)3_ ,P>_P#^^*/[7E_Z ^H9]=E5/^%G:I_T"X?^_E'_  L[5/\
MH%P_]_*/:X;N'/3+G]L3?] >_P#^_=)_;$N<_P!CW^?7953_ (6=JG_0+A_[
M^4?\+.U3_H%P_P#?RCVN&[ASTRY_;$O_ $!K_P#[XH_MB7OHVH?]\53_ .%G
M:I_T"X?^_E'_  L[5/\ H%P_]_*/:X;N'/3+G]KR_P#0'O\ /ILH_M>8'/\
M8VH=<?ZNJ:_$_4A@OI<6T'YMLG-=UHFN6NNZ>EU:,,X^=#U0]P:UI^RJ.T67
M'DEHF><Z=JLH\4:NW]D7QR(^-G^]6Q_:\W_0&U#_ +XK>T;_ )'+6N_RQ?\
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MA[?N^E']KS?] :__ ._=>@XHQ1["(<AY]_:\W_0&O_\ OW1_:\W'_$GO^/\
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MMX+672KA=0DN!";;C*9!.XG/3 H [*BFQDF-2W!QS3J "BBB@ HHHH ****
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M@?X5C07]M<.J1>')F+Y*G[6>0/PJ'^V]/& = D)S@_Z:>OY4O]C[#_<G0?\
M"LF_Z#1_[X'^%)_PK%O^@U_XX/\ "LA+N.3&WPQ./EW9-X<$>W%13ZI9VTOE
MS^'98WQG:UX<_P J=L)_*/\ <HW?^%9./^8T?^^!_A2?\*Q;_H,_^.+_ (5S
MXUS3CC_B0R'/3_33Q^E2PZG:7+,L'AV5V1267[8<@#OTI)8/L+]RS;_X5DW_
M $&3_P!\#_"C_A63?]!D_P#? _PKG_[;T_G&@2'_ +?3_A2_VUI__0 D_P#
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M$'T7_GG-_P!_31_P@^B_\\YO^_IH Z#S$_O+^='F)_>7\ZY__A!]%_YYS?\
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M** "@T4'I0!S6C?\CIK?^[%_[-72US6C?\CIK?\ NQ?^S5TM !1110 4444
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M_G1ONO\ GBOYT 6:*K;[K_GBOYT;[K_GBOYT 6:*K;[K_GBOYT;[K_GBOYT
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MH/0G&#7I=_HMEJ,,Z7$";ID*/(JX?!'][K69HG@O3]%BG3_C[\[:&\Y0>!G
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M!1_;VE?]!"W_ ._@H T**S_[>TK_ *"%O_W\%']O:5_T$+?_ +^"@#0HK/\
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MSGG%.WN)W*ADL[^_+0J_#SX?1>&;1;R_19=2E&6)&1$/05WU9PUW2^VH6_\
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M!0!H52U@_P#$EO/^N+?R-,_M[2O^@A;_ /?P53U;7-+?1[M5O[?)A;'SCTH
MD\*?\BIIW_7!?Y5L5S/A?6],C\,6"O?VX80KQO'I6K_;VE?]!"W_ ._@H T*
M\O\ CH1_PB=K_P!?'^%>@?V]I7_00M_^_@KBOB=9)XJT&&VTF_LO.27<?,E
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M ,S_ (1W1_\ H'6__?-'_".Z/_T#K?\ [YK3HH S/^$=T?\ Z!UO_P!\T?\
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M_?%:E%,#+_X1W2/^@=!_WQ1_PCND?] Z#_OBM2B@#+_X1W2/^@=!_P!\4?\
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MEMYD"[@F/0>U;T*,J\^2)SXBM&A#GD>T!+KM*O\ WS1LNO\ GJG_ 'S7S/\
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M*/['K]T']L4/,^E]EU_SU3_OFC9=?\]4_P"^:^:/^$W\4?\ 09N/_'?\*/\
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M.:XN+QK>S>*I]"BT^)IUMS.C+*&"X(!5\'Y3SQTZ&KW@OQ/<^)8[\W-FEO\
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M2XKF]MQ;RR+N,:MD#/O0!?HHHH **** "BBB@ KBI]&TW4/&NH2:O:1W 2)
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M=F/V^%[K\#H_^$5\*?\ 0)@_[XH_X17PI_T"8/\ OBN<_P"%V^'_ /GVN_\
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M_P! F#_OBN<_X7;X?_Y]KO\ [XH_X7;X?_Y]KO\ [XH]CC.S#ZQA>Z_ Z/\
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ME]:7DMHCW-HV^.8_>SZGUZ5M8HP!0!CS>&=,FU)KZ2(F=F5BV[N 0/YFHO\
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MDG?8G7IS7/\ B/\ Y#6A?]?1_I70BN>\1_\ (:T+_KZ/]*YST#=/4T4'J:*
M.?\ #7_(;US_ *^1_*NDKF_#7_(;US_KY'\JZ2@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *\L\6^!3XT\<W6+W[+]F@0<+G.0#7J=<S;8;QIJB[_+
M/E1\^ORBM*=2=.7-#<SJ4XU(\LEH<#_PHISC.MGW_=]:!\"Y./\ B=_AY8KU
M?RO^GIO^^J41?]/;?]]5UO,,7?XCD67X;K$\G_X42_\ T&R>.<QC_"C_ (45
M)GC7#_W[%>L>5_T]M_WU1Y?_ $^-_P!]4?VAB?Y@^HX;^4\G_P"%%/\ ]!O_
M ,ABC_A13_\ 0;_\ABO6/*_Z>V_[Z%'E?]/;?]]"G_:.*_F#ZAA_Y4>3_P#"
MBG_Z#?\ Y#%'_"BG_P"@W_Y#%>L>5_T]M_WT*/*_Z>V_[ZH_M#%_S#_L_#_R
MGD__  HI_P#H-_\ D,4?\**?_H-_^0Q7K'E?]/;?]]4GE#_G[;_OJC^T<5_,
M']GX?^4\H_X44_\ T&__ "&*/^%%/_T&_P#R&*]8\K_IZ;_OJCRO^GMO^^J/
M[1Q7\P?V?A_Y3R?_ (44_P#T&_\ R&*/^%%/_P!!O_R&*]8\G_IZ;_OH4>3_
M -/3?]]"C^T<5_,']GX?^4\ANO@B]K9S3G62WEH6QY0["H=)^#+ZGI-O>_VQ
ML\Y-VWRQQ7K6I1[=*NO](W?NF^4GKQ5/PO'O\+V+"<Q[H@=H;I1_:.*_F#^S
M\/\ RGGO_"BG_P"@W_Y#%'_"BG_Z#?\ Y#%>L>3_ -/;?]]"CR?^GIO^^A1_
M:.*_F#^S\/\ RGD__"BG_P"@W_Y#%'_"BG_Z#?\ Y#%>L>3_ -/3?]]"CR?^
MGIO^^A1_:.*_F#^S\/\ RGD__"BG_P"@W_Y#%'_"BG_Z#?\ Y#%>L>3_ -/3
M?]]"CR?^GIO^^A1_:.*_F#^S\/\ RGD__"BG_P"@W_Y#%'_"BG_Z#?\ Y#%>
ML>3_ -/3?]]"CR?^GIO^^A1_:.*_F#^S\/\ RGD__"BG_P"@W_Y#%'_"BG_Z
M#?\ Y#%>L>3_ -/3?]]"CR?^GIO^^A1_:.*_F#^S\/\ RGD__"BG_P"@W_Y#
M%'_"BG_Z#?\ Y#%>L>3_ -/3?]]"CR?^GIO^^A1_:.*_F#^S\/\ RGD__"BG
M_P"@W_Y#%'_"BG_Z#?\ Y#%>L>3_ -/3?]]"CR?^GIO^^A1_:.*_F#^S\/\
MRGBVJ_!]M-ELX_[7W?:IO+!\L<'!/]*T?^%%/_T&O_(8KN?$B[+S2/WOF!KS
M')Z?(W-;_E?]/3<?[0H_M'%_S!_9^'_E/)_^%%/_ -!O_P ABC_A13_]!O\
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M_P#@0W^-4J*/9T_Y4'MJO=_>7?[:U;_H*WO_ ($-_C1_;6K?]!6]_P# AO\
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MO_9JZ6N:T;_D=-;_ -V+_P!FKI: "BBB@ HHHH **** "BBB@ HHHH ****
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M4?\ "1:I_P!"[=?]]?\ UJ .CHKG/^$BU3_H7;K_ +Z_^M1_PD6J?]"[=?\
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M\)%JG_0NW7_?7_UJ/^$BU3_H7;K_ +Z_^M2&='17.?\ "1:I_P!"[=?]]?\
MUJ/^$BU3_H7;K_OK_P"M0!T=(:YW_A(M4_Z%VZ_[Z_\ K4?\)'JG/_%.7?\
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MI_T+MU_WU_\ 6H Z.BN<_P"$BU3_ *%VZ_[Z_P#K4?\ "1:I_P!"[=?]]?\
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M-6Q_R"K?_OZ?\*/^%X:M_P! JW_[^G_"L!?AY?'/F7<"N6*1*>LF!GBK6G^
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MC2M"S1@_*XQP?S%7]7P'8GZSCSI/^%XZM_T"K?\ [^G_  H_X7CJW_0*M_\
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M** "BBB@ HHHH **** "BBB@ JCK/_($O/\ KBW\JO52UC_D"W?_ %Q;^1H
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MG1A!#&(RMP%[#T-=N"K1H5O:2V.+&T)8BC[..YXU<^(+VZTRSL'8""RSL .
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M*O\ !/\ SU'_ (%?_7I_VO1[,G^QJO='@^1[49'M7O'_  J_P3_SU'_@5_\
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M%5O[1L_^?R#_ +^"C^T;/_G\@_[^"@"S15;^T;/_ )_(/^_@H_M&S_Y_(/\
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M10!A_P#"&Z%_SX+_ -_&_P :XN\3PAH'C*_AUE8X!)%&4!=N>![UZA7S]\9
M!XY ;KY"X/X"NO"4(UZJA)G)B\1*A2<XH[8:]\-\?ZV+Z[V_QI?[>^&W_/>'
M_OXW^->21^$M6GTI=0BMU:)T,B@,-S*.IQ6:;&[9T M)<N,J-AYKVEE5!NRF
M>-_:U=)>X>V_V]\-O^>\/_?QO\:/[>^&W_/:'_OMO\:\1%E=&1T%M)OC&7&P
MY44HL+LLJBUFW.,J-AY%5_9%'^9_@']L5_Y?S/;3KWPV SYT/_?QO\:/[?\
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M0O\ GP7_ +^-_C6Y10!A_P#"&Z%_SX+_ -_&_P :/^$-T+_GP7_OXW^-;E%
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M .N+?R-7:I:QSHMY_P!<6_E0!4\*?\BIIW_7!?Y5L'I61X5_Y%73_P#K@O\
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M_P"?NPS_ -<S_A728HQ0!S?V?Q;G_C\L?^^#_A2^1XN_Y_+#_OV?\*Z/%&*
M.<\CQ=_S^6'_ '[/^%'D>+O^?RP_[]G_  KH\48H YSR/%W_ #^6'_?L_P"%
M'D>+O^?RP_[]G_"NCQ1B@#G/(\6_\_EA_P!\'_"L*RA\3?\ "8:GMN;,2>5'
MGY#CH/:N_P 5X7\5]2OM.\<,+"[EMM\"EO+;&>!73AJ#Q%3D3.?$5HT8<\E<
M]0$'BS'%Y8_]\'_"E^S^+/\ G[L?^^#_ (5\]'Q/KP&3JUT!_O4G_"4:[T_M
M>YSW&_I7I+):J22:/,_MJE:_*SZ&^S^+/^?NQ_[X/^%'V?Q9_P _=C_WP?\
M"OGG_A*-=/35KK_ONG-XD\0( 7U2[4,,J2W7Z4?V/6[H/[9I?RL^A/(\6?\
M/Y8_]\'_  H\CQ9_S^6/_?!_PKY[7Q+X@=U1-4O"[=%W<GZ4A\3Z\&(.K70(
MZY>C^QJK^T@_MFDOLL^A?(\6?\_=C_WP?\*/L_BS_G[L?^^#_A7SR/%&N_\
M06NA_P #H_X2C7O^@M=?@]/^Q:W\R%_;5'LSZ&^S^+/^?NQ_[X/^%'D>+?\
MG\L?^^#_ (5\]?\ "4:]VU:Z/T>C_A)]>_Z"UU_WU1_8M;^9!_;5'LSZ%\CQ
M9_S^6/\ WP?\*/(\6?\ /Y8_]\'_  KYZ_X2?7O^@K=?]]T?\)/KW_06NO\
MONC^Q:W=!_;5'LSZ%\CQ9_S^6/\ WP?\*/(\6?\ /Y8_]\'_  KYY_X2?7O^
M@M=?]]T?\)/KW_06NO\ ONG_ &-6[H/[9H]F>^:C!XJ&E77F7=B5\IONH?3Z
M55\,P^*3X9L#%=62IY0P"AR/TKPQ_$NN2(5?5;I@P((+=<TD7B+6H(EBAU.Z
M2-1A5#]*/[&J]T']M4>S/HCR/%G_ #^6/_?!_P */(\6?\_EC_WP?\*^>?\
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M%='BC% '.>1XN_Y_+#_OV?\ "D,'BW/_ !]V/_?L_P"%=)BD(H \^TJ#Q/\
M\)9K&RZL1)B//RG_ &O:M[R/%I/%W8C_ (!_]:DT;_D=-;_W8O\ V:ND ]Z
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M89^-&/>G_9Y_^>,O_?-'V>;_ )X2_P#?-;\T>_XG-[.?;\!F/>C'O3_L\_\
MSPE_[YH^SS?\\)?^^:.:/?\ $/9S[?@,Q[T8]Z>89@N3%(%_W:002L,K#*1V
M.VCFCW_$/9S[?@-Q[T8]Z?\ 9Y_^>$O_ 'S1]GG_ .>$O_?-'-'O^(>SGV_
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M,T,>&(.=RD>@P/SID.N^-;G4=1B:'R@K;44Q\QC> &!Z'C)->H$9ZC(_G0%
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MNB_\]Y/^_+?X4?\ ":Z+_P ]Y/\ ORW^%;?V:#_GC'_WP*/LT'_/&/\ [X%
M&)_PFNB_\]Y/^_+?X4?\)KHO_/>3_ORW^%;?V:#_ )XQ_P#? H^S0?\ /&/_
M +X% &)_PFNB_P#/>3_ORW^%'_":Z+_SWD_[\M_A6W]F@_YXQ_\ ? H^S0?\
M\8_^^!0!B?\ ":Z+_P ]Y/\ ORW^%'_"9Z-N_P!?(<G_ )Y-_A6W]F@_YXQ_
M]\"C[-!_SQC_ .^10!PNE>+-(C\7:R[3/AA%_P LF_VO:M__ (331?\ GO)_
MWY;_  JOH\,3>,M:!B0@+%CY1_M5T?V:#_GC'_WP* ,3_A-=%_Y[R?\ ?EO\
M*/\ A-=%_P">\G_?EO\ "MO[-!_SQC_[X%'V:#_GC'_WP* ,3_A-=%_Y[R?]
M^6_PH_X371?^>\G_ 'Y;_"MO[-!_SQC_ .^!1]F@_P">,?\ WP* ,3_A-=%_
MY[R?]^6_PH_X371?^>\G_?EO\*V_LT'_ #QC_P"^!1]F@_YXQ_\ ? H Q/\
MA-=%_P">\G_?EO\ "C_A-=%_Y[R?]^6_PK;^S0?\\8_^^!1]F@_YXQ_]\"@#
M$_X371?^>\G_ 'Y;_"C_ (371?\ GO)_WY;_  K;^S0?\\8_^^!1]F@_YXQ_
M]\"@#$_X371?^>\G_?EO\*/^$UT7_GO)_P!^6_PK;^S0?\\8_P#O@4?9H/\
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M 4444 %%%% !1110 4444 %%%% '->*_^/\ T7_K\'_H#5THKFO%?_']HO\
MU^#_ - :NE% !1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 <UHW_(Z
M:W_NQ?\ LU=+7-:-_P CIK?^[%_[-72T %%%% !1110 4444 %%%% !1110
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M_P (U>_]#!??]]'_ !H Z.BN<_X1J]_Z&"^_[Z/^-'_"-7O_ $,%]_WT?\:
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MPY7W.&*J#@32'_MLW3UZU*EK+(KE1<$1C+GS6X'J>:Z]+;2'"*+9$$IE+!R
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MK1O^1TUO_=B_]FKI:YK1O^1TUO\ W8O_ &:NEH **** "BBB@ HHHH ****
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M:*Y?_A,9?^@%J'_?%'_"8R_] +4/^^* .HHKE_\ A,9?^@%J'_?%'_"8R_\
M0"U#_OB@#J**Y?\ X3&7_H!:A_WQ1_PF,O\ T M0_P"^* .HHKE_^$QE_P"@
M%J'_ 'Q1_P )C+_T M0_[XH ZBBN7_X3&7_H!:A_WQ1_PF,O_0"U#_OB@#J*
M*Y?_ (3&7_H!:A_WQ1_PF,O_ $ M0_[XH ZBBN7_ .$QE_Z 6H?]\4?\)C+_
M - +4/\ OB@!WBP_Z=HO_7X/_0&KIA7G^MZ]>:A=:<\&A7_^C7'FO\O;:1Z>
M]; \8R_] *__ .^: .HHKE_^$QE_Z 6H?]\4?\)C+_T M0_[XH ZBBN7_P"$
MQE_Z 6H?]\4?\)C+_P! +4/^^* .HHKE_P#A,9?^@%J'_?%'_"8R_P#0"U#_
M +XH ZBBN7_X3&7_ * 6H?\ ?%'_  F,O_0"U#_OB@#J**Y?_A,9?^@%J'_?
M%'_"8R_] +4/^^* .HHKE_\ A,9?^@%J'_?%'_"8R_\ 0"U#_OB@#J*0FN8_
MX3&7_H!:A_WQ2?\ "8RG&="U#/7[E $FC?\ (Z:W_NQ?^S5TH-<!I^NW=MX@
MU&\DT*_\NY5 OR^F?\:UAXRF/_,"O^G'RT =317+_P#"8R_] +4/^^*/^$QE
M_P"@%J'_ 'Q0!U%%<O\ \)C+_P! +4/^^*/^$QE_Z 6H?]\4 =117+_\)C+_
M - +4/\ OBC_ (3&7_H!:A_WQ0!U%%<O_P )C+_T M0_[XH_X3&7_H!:A_WQ
M0!U%%<O_ ,)C+_T M0_[XH_X3&7_ * 6H?\ ?% '445R_P#PF,O_ $ M0_[X
MH_X3&7_H!:A_WQ0!U%4M8_Y MY_UQ;^58G_"8R_] +4/^^*K:AXKGN=/N(8]
M"U#=)&RCY?44 ;/A/_D5-._ZX+_*MBN(T/Q)<:?HEI:RZ%J'F0Q*C?+[5?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.K:M<7S((C,V[8#G%4L>]>R?\*7T/_H-R?\ ?2_XT?\ "F-#_P"@W)_WTO\
MC71_:F%225]#GEE.)E*[9XWM^E/@MY;JY2WMXVEFD.%5:]A_X4QH>1_Q.Y.O
M]X?XUT'A3P!H7A6[>\CNENKD\+)*PR@]JBKFU"WN+4TIY/7Y_?>A#\//A[%X
M:M5OM142ZE(N2W_/(>@]ZZ"W_P"1VN?^O=?YFMG[7;?\_$7_ 'V*Q+5TE\:W
M)C=77[.H)!SW-?-5*LJLW.>[/I:=.-*"A'8Z$4M(*6LS4**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R6\
M,Z4SE_LV"6+'#$9/YTG_  C&E?\ /M_X^W^-%% !_P (QI7_ #[?^/M_C1_P
MC&E?\^W_ (^W^-%% !_PC&E?\^W_ (^W^-'_  C&D_\ /M_X^W^-%% !_P (
MQI/_ #[?^/M_C1_PC&D_\^W_ (^W^-%% !_PC&D_\^W_ (^W^-'_  C&E?\
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887941088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">vTv Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3916571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3980 Premier Dr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">High Point<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">841-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VTVT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001641489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885229968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,863<span></span>
</td>
<td class="nump">$ 13,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableCurrent', window );">Promissory note receivable</a></td>
<td class="nump">11,941<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Current deposits</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">30,609<span></span>
</td>
<td class="nump">15,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">5,772<span></span>
</td>
<td class="nump">9,173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,989<span></span>
</td>
<td class="nump">25,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,825<span></span>
</td>
<td class="nump">8,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">18,669<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Warrant liability, related party</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,599<span></span>
</td>
<td class="nump">10,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">15,916<span></span>
</td>
<td class="nump">24,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">243,772<span></span>
</td>
<td class="nump">238,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(253,303)<span></span>
</td>
<td class="num">(248,834)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(8,526)<span></span>
</td>
<td class="num">(9,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; deficit</a></td>
<td class="nump">36,989<span></span>
</td>
<td class="nump">25,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887871072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">77,329,051<span></span>
</td>
<td class="nump">66,942,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">23,093,860<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887715216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,205<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">5,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,831<span></span>
</td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">7,179<span></span>
</td>
<td class="nump">4,406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,036<span></span>
</td>
<td class="nump">4,679<span></span>
</td>
<td class="nump">12,517<span></span>
</td>
<td class="nump">9,946<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(4,027)<span></span>
</td>
<td class="num">(4,670)<span></span>
</td>
<td class="num">(10,508)<span></span>
</td>
<td class="num">(8,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(167)<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
<td class="num">(3,401)<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OtherIncomeExpensesRelatedParty', window );">Other income (expense) &#8211; related party</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="num">(717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes and noncontrolling interest</a></td>
<td class="num">(4,091)<span></span>
</td>
<td class="num">(841)<span></span>
</td>
<td class="num">(13,315)<span></span>
</td>
<td class="num">(6,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss before noncontrolling interest</a></td>
<td class="num">(4,091)<span></span>
</td>
<td class="num">(841)<span></span>
</td>
<td class="num">(13,515)<span></span>
</td>
<td class="num">(6,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interest</a></td>
<td class="num">(940)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(3,357)<span></span>
</td>
<td class="num">(1,934)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(3,151)<span></span>
</td>
<td class="num">(608)<span></span>
</td>
<td class="num">(10,158)<span></span>
</td>
<td class="num">(4,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to vTv Therapeutics Inc. common shareholders</a></td>
<td class="num">$ (3,151)<span></span>
</td>
<td class="num">$ (608)<span></span>
</td>
<td class="num">$ (10,158)<span></span>
</td>
<td class="num">$ (4,849)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)</a></td>
<td class="nump">70,366,823<span></span>
</td>
<td class="nump">58,615,137<span></span>
</td>
<td class="nump">68,664,259<span></span>
</td>
<td class="nump">57,549,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)</a></td>
<td class="nump">70,366,823<span></span>
</td>
<td class="nump">58,615,137<span></span>
</td>
<td class="nump">68,664,259<span></span>
</td>
<td class="nump">57,549,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OtherIncomeExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other related party income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OtherIncomeExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891880667808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Class A Common Stock</div></th>
<th class="th"><div>Class B Common Stock</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Redeemable Noncontrolling Interest</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class B Common Stock</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Class A Common Stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 83,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">(1,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="num">(21,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">60,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,050,710<span></span>
</td>
<td class="nump">23,094,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(80,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 209,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (290,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Common Stock to Collaboration Partner (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,180,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A common stock to collaboration partner</a></td>
<td class="nump">5,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange of Class B common stock for class A common stock, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement', window );">Issuance of class A common stock under LPC agreement, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,941,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement', window );">Issuance of Class A Common Stock under LPC Agreement</a></td>
<td class="nump">9,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="nump">21,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,771<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,193,967<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="num">(47,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">224,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(273,114)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">60,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,571,904<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="num">(56,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">217,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(274,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IssuanceOfClassACommonStockUnderATMOffering', window );">Issuance Of Class A Common Stock Under ATM Offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,180,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue', window );">Issuance of Class A common stock under ATM offering</a></td>
<td class="nump">5,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement', window );">Issuance of class A common stock under LPC agreement, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement', window );">Issuance of Class A Common Stock under LPC Agreement</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,193,967<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="num">(47,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">224,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(273,114)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">24,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">(3,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="num">(5,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">15,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,942,777<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,942,777<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">(9,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">238,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Common Stock to Collaboration Partner (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A common stock to collaboration partner</a></td>
<td class="nump">5,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="nump">5,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,689<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,329,051<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,329,051<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="num">(8,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">243,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253,303)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">15,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,942,777<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="num">(8,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">238,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(247,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Common Stock to Collaboration Partner (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A common stock to collaboration partner</a></td>
<td class="nump">5,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="num">(2,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,489)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,329,051<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,329,051<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="num">$ (8,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 243,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (253,303)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IssuanceOfClassACommonStockUnderATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Class A Common Stock Under ATM Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IssuanceOfClassACommonStockUnderATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Class A Common Stock Under ATM Offering Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Class A Common Stock under LPC agreement shares..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_StockIssuedDuringPeriodValuePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_TemporaryEquityChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Change In Redemption Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_TemporaryEquityChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885098832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss before noncontrolling interest</a></td>
<td class="num">$ (13,515)<span></span>
</td>
<td class="num">$ (6,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Non-cash interest income</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="nump">3,401<span></span>
</td>
<td class="num">(2,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ChangeInFairValueOfWarrantsRelatedParty', window );">Change in fair value of warrants, related party</a></td>
<td class="num">(545)<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,536<span></span>
</td>
<td class="num">(1,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">6,769<span></span>
</td>
<td class="num">(996)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(315)<span></span>
</td>
<td class="num">(9,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of Class A common stock to collaboration partner, net of offering costs</a></td>
<td class="nump">5,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Class A common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(256)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,784<span></span>
</td>
<td class="nump">14,385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash and cash equivalents</a></td>
<td class="nump">4,448<span></span>
</td>
<td class="nump">5,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period</a></td>
<td class="nump">13,415<span></span>
</td>
<td class="nump">5,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash and cash equivalents, end of period</a></td>
<td class="nump">17,863<span></span>
</td>
<td class="nump">10,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="nump">5,689<span></span>
</td>
<td class="nump">21,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAssumed1', window );">Notes Assumed</a></td>
<td class="nump">$ 11,891<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ChangeInFairValueOfWarrantsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrants related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ChangeInFairValueOfWarrantsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887037472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Going Concern<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business, Basis of Presentation and Going Concern</a></td>
<td class="text">Description of Business, Basis of Presentation and Going Concern<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary, which is a clinical stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Condensed Consolidated Financial Statements. As of June&#160;30, 2022, various holders own non-voting interests in vTv LLC, representing a 23.0% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#8217;s interest to 77.0% of vTv LLC&#8217;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (&#8220;vTv Units&#8221;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of Class B common stock) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#8220;Lenders&#8221;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#8220;M&amp;F Group&#8221;), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates &#8220;MacAndrews&#8221;). in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (the &#8220;Letter Agreements&#8221;).  In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor Fitzgerald&#8221;) (the &#8220;ATM Offering&#8221;), the purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) (the &#8220;LPC Purchase Agreement&#8221;), and the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#8220;G42 Investments&#8221;) (the &#8220;G42 Purchase Agreement&#8221;). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern and Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June&#160;30, 2022, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June&#160;30, 2022, the Company had an accumulated deficit of $253.3 million and has generated net losses in each year of its existence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company&#8217;s liquidity sources included cash and cash equivalents of $17.9 million. To meet our future funding requirements into the third quarter of 2023, including funding the on-going and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also has a promissory note of $12.5 million under </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the G42 Purchase Agreement payable to the Company on or before May 31, 2023 (see Note 9) and on July 25, 2022, announced a $10.0 million investment by CinPax, LLC (see Note 14).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also use its remaining availability of $37.3 million under our Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company&#8217;s Class A common stock (the &#8220;ATM Offering&#8221;) and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 9 for further details. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact on our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891975190192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2022, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and six months ended June&#160;30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2021, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of June&#160;30, 2022, the results of operations for the three and six months ended June&#160;30, 2022, and 2021 and cash flows for the six months ended June&#160;30, 2022, and 2021. The December&#160;31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note receivable, and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One customer represented 100% of the revenue earned during the three and six months ended June&#160;30, 2022, and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891891085120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;), pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company&#8217;s Class A common stock, par value $0.01 per share (the &#8220;G42 Common Stock) at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company&#8217;s board of directors approved appointing the new director to the Company&#8217;s board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;FDA Approval&#8221;) of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#8220;Cogna Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#8220;Cogna&#8221;) (&#8220;Collaboration Partner&#8221;), which requires Cogna to work with the Company in performing Phase 3 clinical trials for the Company&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compound (the &#8220;Licensed Product&#8221;) as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Cogna Agreement, Cogna will obtain rights to the Company&#8217;s license of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for purposes of performing Phase 3 clinical trials in the Partner Territory, but will not have access to the various intellectual property (&#8220;IP&#8221;) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. Separately, the Company will conduct its Phase 3 clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. at its own cost that similarly </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not be reimbursed. The results of each party&#8217;s Phase 3 clinical trials will be combined by the Company to seek FDA approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Cogna Agreement, Cogna has the right to develop and commercialize the Licensed Product in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of FDA approval of the Licensed Product, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, are conditioned upon receipt of the FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA Approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territories, the Company will receive royalties of 8% from Cogna on the sale of the Licensed Product for ten years after the first commercial sale of the Licensed Product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#8220;Recently Issued Accounting Guidance&#8221; in this 10-Q for details of the ASU.  Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of the Licensed Product, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete R&amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#8220;JDC&#8221;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would have to complete its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the Phase 3 clinical trials. As of June 30, 2022, the Phase 3 clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The material right is predicated upon FDA approval. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after the Licensed Product is approved by the FDA.  As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and six months ended June 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company has recognized the cash and a non-interest bearing promissory note receivable of with a principal balance of $12.5 million. The promissory note receivable was classified and accounted for under ASC 310 and was measured at its fair value of and will be subsequently remeasured at its amortized cost thru its maturity date. The </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company also recorded the $18.7 million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and six months ended June 30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reneo License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Reneo Pharmaceuticals, Inc. (&#8220;Reneo&#8221;) (the &#8220;Reneo License Agreement&#8221;), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company&#8217;s peroxisome proliferation activated receptor delta (PPAR-&#948;) agonist program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic, prophylactic or diagnostic application in humans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has fully allocated the transaction price to the license and the technology transfer services, which represents a single combined performance obligation because they were not capable of being distinct on their own. The revenue related to this performance obligation was recognized on a straight-line basis over the technology transfer service period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue related to this performance obligation has been fully recognized and no revenue related to this performance obligation was recognized for the three and six months ended June&#160;30, 2022, and 2021. There have been no adjustments to the transaction price for the performance obligations under the Reneo License Agreement during the three and six months ended June&#160;30, 2022, and 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#8220;Huadong&#8221;) (the &#8220;Huadong License Agreement&#8221;), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s glucagon-like peptide-1 receptor agonist (&#8220;GLP-1r&#8221;) program, including the compound</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic uses in humans or animals, in China and certain other pacific rim countries, including Australia and South Korea (collectively, the &#8220;Huadong License Territory&#8221;). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company&#8217;s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021, the Company entered into the First Huadong Amendment which eliminated the Company&#8217;s obligation to sponsor a multi-region clinical trial (the &#8220;Phase 2 MRCT&#8221;), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC Topic 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $1.0 million of revenue on a cumulative catch-up basis during the six months ended June&#160;30, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant performance obligations under this license agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company&#8217;s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company&#8217;s obligation to participate on a joint development committee (the &#8220;JDC&#8221;), and (iv) other obligations considered to be de minimis in nature. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. This combined performance obligation was considered complete as of June&#160;30, 2021. The Company recognized $1.0 million of revenue related to this combined performance obligation during the six months ended June&#160;30, 2021. During the six months ended June 30, 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the six months ended June&#160;30, 2022, as the related performance obligation was fully satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of June&#160;30, 2022, and revenue will be recognized using the proportional performance model over the period of the Company&#8217;s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of June&#160;30, 2022, was de minimis. An immaterial amount of revenue for this performance obligation has been recognized during six months ended June&#160;30, 2022, and 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement-</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#8220;Newsoara&#8221;) (the &#8220;Newsoara License Agreement&#8221;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s phosphodiesterase type 4 inhibitors (&#8220;PDE4&#8221;) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#8220;Newsoara License Territory&#8221;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#8217;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of June&#160;30, 2022. No revenue related to this performance obligation was recognized and there have been no changes to the transaction price during the three and six months ended June&#160;30, 2022, and 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anteris License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (&#8220;Anteris&#8221;) (the &#8220;Anteris License Agreement&#8221;), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company&#8217;s Nrf2 activator, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of $2.0 million. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $151.0 million. Anteris is also obligated to pay the Company royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30-day period after the effective date. In accordance with ASC Topic 606, the Company identified all the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the $2.0 million initial license payment, as well as the fair value of the equity interest received in Anteris of $4.2 million. The revenue related to this performance obligation was fully recognized during the year ended December&#160;31, 2020, as the technology transfer services were considered complete as of that date. No revenue related to this performance obligation was recognized and there have been no changes to the transaction price during the three and six months ended June&#160;30, 2022, and 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JDRF Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a research and collaboration agreement with JDRF International (the &#8220;JDRF Agreement&#8221;) to support the funding of the Simplici-T1 Study, a Phase 2 study to explore the effects of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with type 1 diabetes. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JDRF Agreement was amended in June 2021 to provide additional funding for the Company&#8217;s mechanistic study exploring the effects of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the terms of the JDRF Agreement, JDRF will provide research funding of up to $3.4 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a treatment for type 1 diabetes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments that the Company receives from JDRF under this agreement will be recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of June&#160;30, 2022, the Company had received funding under this agreement of $3.4 million. Research and development costs have been offset by a total of  $3.4 million over the course of this agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company&#8217;s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in short-term and long-term contract liabilities for the six months ended June&#160;30, 2022, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration received in advance and not recognized as revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891891120640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of June&#160;30, 2022, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $1.7 million, which is expected to be recognized over a weighted average period of 2.3 years. The weighted average grant date fair value of options granted during the six months ended June&#160;30, 2022, and 2021 was $0.65 and $2.21 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at June&#160;30, 2022, was de minimis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the &#8220;Board&#8221;) of the Company of her decision to resign from her positions as Chief Executive Officer, President, and Board member, effective as of March&#160;29, 2022, and served in these roles through March&#160;29, 2022 (the &#8220;Effective Date&#8221;). Ms. Prasad agreed to serve as a Strategic Advisor to the Company for six months after the Effective Date. Ms. Prasad will retain 624,659 of the outstanding options previously granted to her, which will vest at the end of the 15-month period following the Effective Date. As a result of the separation agreement, these options were modified to accelerate vesting at the Effective Date. These options will remain exercisable for the original ten-year period and the remaining 1,873,976 of her options were cancelled. The additional stock compensation expense for the modification during the six months ended June&#160;30, 2022, was de minimis.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,056,035&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,871,508)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496,888&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858,805&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886356112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Reneo and Anteris License Agreements, the Company has received equity ownership interests of less than 20% of the voting equity of the investee. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company&#8217;s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo&#8217;s initial public offering, the Company&#8217;s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:71.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No adjustments have been made to the value of the Company&#8217;s investment in Anteris since its initial measurement either due to impairment or based on observable price changes. The Company recognized an unrealized loss on its investment in Reneo of $0.2&#160;million and $3.4 million for the three and six months ended June&#160;30, 2022, respectively. During the three and six months ended June 30, 2021, the Company recognized an unrealized gain on its investment in Reneo of $2.9 million. These adjustments were recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886245872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo License Agreement&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This agreement was amended in May 2019 to create </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under this agreement.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886334288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. The Company has notified the lessor that it intends to exercise the early termination option and is negotiating an amendment to the lease. Further, this lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of June&#160;30, 2022, and December&#160;31, 2021, the weighted average incremental borrowing rate for the operating leases held by the Company was 13.1%. At June&#160;30, 2022, and December&#160;31, 2021, the weighted average remaining lease terms for the operating leases held by the Company were 2.6 years and 3.1 years, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating leases as of June&#160;30, 2022, were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the six months ended June&#160;30, 2022, and 2021 were immaterial amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887066912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text">Redeemable Noncontrolling Interest<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 23.0% noncontrolling interest in vTv LLC outstanding as of June&#160;30, 2022 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At June&#160;30, 2022, and December&#160;31, 2021, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $15.9 million and $25.0 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,512)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,087)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,374)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886260992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">Stockholders&#8217; Deficit<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Certificate of Incorporation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into the Sales Agreement with Cantor Fitzgerald as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act (the &#8220;ATM Offering&#8221;). The shares are offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3. In no event will we sell Class A common stock under this registration statement with a value exceeding more than one-third of the &#8220;public float&#8221; (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021, and June&#160;25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company&#8217;s Class A common stock, by an aggregate offering price of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $50.0 million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, the Company sold 2,180,337 shares of its Class A common stock under the ATM Offering for net proceeds of $5.3 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, the Company did not sell any shares under the ATM Offering. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Lincoln Park. pursuant to the LPC Purchase Agreement. During the three and six months ended June&#160;30, 2021, the Company sold 441,726 and 3,941,726 shares under the LPC Purchase Agreement for total proceeds of $1.0 million and $9.1 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months June&#160;30, 2022, the Company did not sell any shares under the LPC Purchase Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886222848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, subsidiaries and affiliates of MacAndrews &amp; Forbes Incorporated (collectively &#8220;MacAndrews&#8221;) indirectly controlled 23,084,267 shares of the Company&#8217;s Class B common stock and 36,519,212 shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately 59.4% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews has the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#8220;Letter Agreement Warrants&#8221;) to purchase additional shares of the Company&#8217;s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#8217;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to an exchange agreement (the &#8220;Exchange Agreement&#8221;) pursuant to which the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the &#8220;Board of Directors&#8221;). As of June&#160;30, 2022, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B commons stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain </span></div>governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886269664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three months ended June&#160;30, 2022. The Company&#8217;s income tax provision for the six months ended June&#160;30, 2022, was $0.2 million related to foreign withholding taxes. The Company did not record an income tax provision for the three months ended June 30, 2021. The Company&#8217;s income tax provision for the six months ended June&#160;30, 2021, was a de minimis amount related to foreign withholding taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of  21% on June&#160;30, 2022, is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885622272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,151)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,158)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,366,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,615,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,664,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,549,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,492,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,582,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886304368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable, and other accrued liabilities, approximate fair value due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the promissory note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of June&#160;30, 2022, and December&#160;31, 2021 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:31.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, Reneo completed its initial public offering.  As a result, the fair value of the Company&#8217;s investment in Reneo&#8217;s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.  As such, the Company&#8217;s investment in Reneo is adjusted each reporting period to its fair value based on its most recent closing price, which is considered a Level 1 fair value measurement under the fair value hierarchy.    </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and six months ended June&#160;30, 2022. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#8217;s current capitalization. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June&#160;30, 2022, and December&#160;31, 2021, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:30.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.47% - 138.02%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.68% - 142.86%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.13%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% - 3.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% - 1.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div>Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants. Increases (decreases) in the estimates of the Company&#8217;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885622272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CinPax Partnership</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2022, the Company and CinPax, LLC (&#8220;CinPax&#8221;), a subsidiary of CinRx Pharma, LLC (&#8220;CinRx&#8221;) entered into a Common Stock and Warrant Purchase Agreement (the &#8220;CinRx Purchase Agreement&#8221;). Under the terms of the CinRx Purchase Agreement, CinPax acquired 4,154,549 shares of Class A common stock at an issue price of approximately $2.41 per share, for an aggregate purchase price of $10.0 million, consisting of  (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a promissory note of CinPax payable on November 22, 2022. The CinRx Purchase Agreement also provides CinRx a warrant to purchase up to 1,200,000 shares of Class A common stock at an initial exercise price of approximately $0.72 per share, that become exercisable upon agreed vesting triggers (including FDA Approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In addition to the investment, the CinRx Purchase Agreement sets forth the terms under which the Company will leverage the CinRx team&#8217;s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leadership</span></div>On July 25, 2022, the Company entered into an employment agreement with Paul Sekhri, who was appointed President and Chief Executive Officer and a member of the Board (the &#8220;Sekhri Employment Agreement&#8221;). In addition to outlining the terms of Mr. Sekhri&#8217;s compensation, it also provides for the grant of stock options (the &#8220;Options&#8221;) to purchase 2,200,000 shares of Class A common stock at an exercise price of $0.79 per share pursuant to an inducement award agreement (the &#8220;Inducement Award Agreement&#8221;). Subject to potential acceleration upon the achievement of certain performance metrics as set forth in the Inducement Award Agreement, 25% of the Options will vest on the first anniversary of the grant date and the remaining 75% of the Options will vest quarterly over three years thereafter. Upon certain terminations of employment, a portion of the Options will vest on a pro rata basis based on the number of days employed during the four-year term.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887717968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2022, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and six months ended June&#160;30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2021, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of June&#160;30, 2022, the results of operations for the three and six months ended June&#160;30, 2022, and 2021 and cash flows for the six months ended June&#160;30, 2022, and 2021. The December&#160;31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note receivable, and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical </span></div>experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.</span></div>One customer represented 100% of the revenue earned during the three and six months ended June&#160;30, 2022, and 2021, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. </span></div>The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886239456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Liabilities Related to Company's Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company&#8217;s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock', window );">Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in short-term and long-term contract liabilities for the six months ended June&#160;30, 2022, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration received in advance and not recognized as revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance on June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887663216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Award Activity for the Period</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,056,035&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,871,508)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496,888&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at June 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858,805&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Compensation Expense Related to Grants of Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:39.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886337712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock', window );">Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:71.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in equity security with and without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886233712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities for Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating leases as of June&#160;30, 2022, were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886331856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock', window );">Summary of Net Income Attributable to Vtv Therapeutics Inc</a></td>
<td class="text">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,151)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,512)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,087)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,374)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591554-111686<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891886318240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,151)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,158)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,366,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,615,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,664,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,549,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,492,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,582,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891889910448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summarizes the Conclusions Reached Regarding Fair Value Measurements</a></td>
<td class="text">The following table summarizes the conclusions reached regarding fair value measurements as of June&#160;30, 2022, and December&#160;31, 2021 (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:31.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June&#160;30, 2022, and December&#160;31, 2021, were:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:30.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.47% - 138.02%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.64%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.68% - 142.86%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.13%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% - 3.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% - 1.26%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885243824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Going Concern (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (253,303)<span></span>
</td>
<td class="num">$ (248,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,863<span></span>
</td>
<td class="nump">$ 13,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G2InvestmentMember', window );">G2 Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Cantor Fitzgerald</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues', window );">Remaining available stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | LPC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,437,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterest', window );">Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterestByParent', window );">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest by parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining availability under our controlled equity offering sales agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G2InvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G2InvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseAgreementObligationsAxis=vtvt_LPCPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseAgreementObligationsAxis=vtvt_LPCPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_VTvLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_VTvLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891888035248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vtvt_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vtvt_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891879814624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,205,000<span></span>
</td>
<td class="nump">$ 2,437,000<span></span>
</td>
<td class="nump">$ 5,338,000<span></span>
</td>
<td class="nump">$ 5,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares)</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod', window );">Consideration receivable, payment period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue', window );">Collaborative arrangement, contingent consideration</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash', window );">Collaborate arrangement, contingent consideration transferred, cash</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid', window );">Discount on note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, value</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage', window );">Royalties receivable, percent</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod', window );">Royalties receivable, period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Reneo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations', window );">Adjustments to transaction price for performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_MaximumSponsoringContributionAmount', window );">Maximum contribution amount to clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unrecognized amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations', window );">Adjustments to transaction price for performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Newsoara Biopharma Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue recognized from change in estimated transaction prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Newsoara Biopharma Co Ltd | License And Technology Transfer Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Anteris Bio Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceived', window );">License fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Anteris Bio Inc | License and Technology Transfer Services of Chemistry and Manufacturing Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations', window );">Adjustments to transaction price for performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod', window );">Transferred services per agreement terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceived', window );">License fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestAndDividendsReceived', window );">Equity interest received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | JDRF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones', window );">Maximum research funding receivable achievement based on research and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones', window );">Maximum funding percentage of research and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FundingReceived', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestAndDividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for dividends and interest on the entity's equity and debt investments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestAndDividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to transaction price for performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_AdjustmentsToTransactionPriceForPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborate Arrangement, Contingent Consideration Transferred, Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborateArrangementContingentConsiderationTransferredCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Note Receivable, Discount Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementNoteReceivableDiscountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Receivable, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Receivable, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Technology Transfer Services Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_FundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_FundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum funding percentage of research and development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum research funding receivable based on achievement of research and development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_MaximumSponsoringContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum sponsoring contribution amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_MaximumSponsoringContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivablePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Receivable, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivablePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_CognaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_CognaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_PhaseTwoMultiRegionalClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_PhaseTwoMultiRegionalClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_AnterisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_AnterisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_JDRFInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_JDRFInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891889846272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">18,669<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">$ 18,695<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891884728608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Revenue from Contract with Customer [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Consideration received in advance and not recognized as revenue</a></td>
<td class="nump">18,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 18,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891880596032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,384,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,056,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtvt_StrategicAdvisorMember', window );">Strategic Advisor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Non-qualified stock option awards vesting period</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Non-qualified stock option awards expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options (in shares)</a></td>
<td class="nump">624,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled', window );">Stock options cancelled (in shares)</a></td>
<td class="nump">1,873,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Non-qualified stock option awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Non-qualified stock option awards expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to non-vested share-based compensation arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize unrecognized share-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtvt_StrategicAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtvt_StrategicAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885559648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Beginning balance (in shares) | shares</a></td>
<td class="nump">7,056,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(2,871,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Ending balance (in shares) | shares</a></td>
<td class="nump">5,384,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">2,496,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and expected to vest (in shares) | shares</a></td>
<td class="nump">4,858,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, weighted average remaining contractual term</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">2.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">3.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">5.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887679536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885638128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,401)<span></span>
</td>
<td class="nump">$ 2,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember', window );">Reneo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_InvestmentOwnershipPercentage', window );">Equity method investments, ownership percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="num">$ (3,400)<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891879800544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investment without readily determinable fair values assessed under the measurement alternative:</a></td>
<td class="nump">$ 5,772<span></span>
</td>
<td class="nump">$ 9,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember', window );">Reneo | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue', window );">Equity investment with readily determinable fair value:</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_AnterisBioIncMember', window );">Anteris Bio Inc | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investment without readily determinable fair values assessed under the measurement alternative:</a></td>
<td class="nump">$ 4,245<span></span>
</td>
<td class="nump">$ 4,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity investments with readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EquityInvestmentsWithReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_AnterisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_AnterisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891879772464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2007</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Other Indication | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Type 1 Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Type 2 Diabetes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember', window );">Sales-based Milestones Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_SatisfactionOfMilestonePaymentMember', window );">Satisfaction of Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_SatisfactionOfMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_SatisfactionOfMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891889832256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LesseeOperatingLeaseTerminationPeriod', window );">Lessee, operating lease, termination period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">13.10%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining operating lease term</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887958176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining six months)</a></td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OperatingLeasesImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OperatingLeasesImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OperatingLeasesImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887686160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue', window );">Redemption amount of noncontrolling interest</a></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock', window );">Number of days used to determine exchange value based on weighted average price of Class A common stock</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterest', window );">Noncontrolling interest ownership percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period used to determine exchange value based on weighted average price of Class A common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest exchange agreement stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest temporary equity redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_VTvLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_VTvLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885350688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to vTv Therapeutics Inc. common shareholders</a></td>
<td class="num">$ (3,151)<span></span>
</td>
<td class="num">$ (608)<span></span>
</td>
<td class="num">$ (10,158)<span></span>
</td>
<td class="num">$ (4,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent', window );">(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="num">(2,525)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet', window );">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</a></td>
<td class="num">$ (4,512)<span></span>
</td>
<td class="num">$ (723)<span></span>
</td>
<td class="num">$ (9,087)<span></span>
</td>
<td class="num">$ (7,374)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591554-111686<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891879814992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 25, 2021</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
<th class="th"><div>Nov. 24, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockAndPreferredStockSharesAuthorized', window );">Capital stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,040<span></span>
</td>
<td class="nump">$ 5,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares)</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm', window );">Sale of Stock, consideration, receivables, payment term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncreaseInCommonStockSharesAuthorized', window );">Increase in shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Cantor Fitzgerald | ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,180,337<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,180,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PublicFloat', window );">Public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_AggregateOfferingPriceOfShares', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | LPC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">441,726<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,941,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | LPC Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_AggregateOfferingPriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_AggregateOfferingPriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockAndPreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock and preferred stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockAndPreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IncreaseInCommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IncreaseInCommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public float.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivablesPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration, Receivables, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivablesPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=vtvt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=vtvt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_LPCPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_LPCPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891879802480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_MacAndrewsAndForbesIncorporatedMember', window );">MacAndrews &amp; Forbes Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OwnershipPercentageOfMajorityOwner', window );">Ownership percentage of majority owner</a></td>
<td class="nump">59.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_MacAndrewsAndForbesIncorporatedMember', window );">MacAndrews &amp; Forbes Incorporated | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Shares held by related party (in shares)</a></td>
<td class="nump">23,084,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_MacAndrewsAndForbesIncorporatedMember', window );">MacAndrews &amp; Forbes Incorporated | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Shares held by related party (in shares)</a></td>
<td class="nump">36,519,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of affiliates held for management investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611322-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OwnershipPercentageOfMajorityOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage of majority owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OwnershipPercentageOfMajorityOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest exchange agreement stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_MacAndrewsAndForbesIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_MacAndrewsAndForbesIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891880561584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember', window );">M&amp;F TTP Holdings LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891880617792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,091)<span></span>
</td>
<td class="num">$ (841)<span></span>
</td>
<td class="num">$ (13,515)<span></span>
</td>
<td class="num">$ (6,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net loss attributable to noncontrolling interests</a></td>
<td class="num">(940)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(3,357)<span></span>
</td>
<td class="num">(1,934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted</a></td>
<td class="num">(3,151)<span></span>
</td>
<td class="num">(608)<span></span>
</td>
<td class="num">(10,158)<span></span>
</td>
<td class="num">(4,849)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic</a></td>
<td class="num">$ (3,151)<span></span>
</td>
<td class="num">$ (608)<span></span>
</td>
<td class="num">$ (10,158)<span></span>
</td>
<td class="num">$ (4,849)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)</a></td>
<td class="nump">70,366,823<span></span>
</td>
<td class="nump">58,615,137<span></span>
</td>
<td class="nump">68,664,259<span></span>
</td>
<td class="nump">57,549,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)</a></td>
<td class="nump">70,366,823<span></span>
</td>
<td class="nump">58,615,137<span></span>
</td>
<td class="nump">68,664,259<span></span>
</td>
<td class="nump">57,549,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891887949648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">30,492,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,582,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">5,384,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,474,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">2,014,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,014,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891879664160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Assets:</a></td>
<td class="nump">$ 1,527<span></span>
</td>
<td class="nump">$ 4,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets:</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Assets:</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets:</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Assets:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Warrant liability, related party | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Assets:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">$ 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Warrant liability, related party | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of assets and liabilities measured on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=vtvt_WarrantLiabilityRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=vtvt_WarrantLiabilityRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vtvt_WarrantLiabilityRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vtvt_WarrantLiabilityRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891880627888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Significant Unobservable Inputs (Level 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 1,262<span></span>
</td>
<td class="nump">$ 2,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net Change in fair value included in earnings</a></td>
<td class="num">(545)<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Purchases / Issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Sales / Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">3,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">2,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net Change in fair value included in earnings</a></td>
<td class="num">(545)<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Purchases / Issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Sales / Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">$ 3,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vtvt_WarrantLiabilityRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vtvt_WarrantLiabilityRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891879615856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Significant Inputs Utilized in the Valuation of Letter Agreement Warrants (Detail) - Letter Agreement Warrants<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember', window );">Minimum | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.8347<span></span>
</td>
<td class="nump">0.8268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember', window );">Minimum | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0295<span></span>
</td>
<td class="nump">0.0095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember', window );">Maximum | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">1.3802<span></span>
</td>
<td class="nump">1.4286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember', window );">Maximum | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0300<span></span>
</td>
<td class="nump">0.0126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember', window );">Weighted Average | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">1.1764<span></span>
</td>
<td class="nump">1.2813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember', window );">Weighted Average | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0300<span></span>
</td>
<td class="nump">0.0115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=vtvt_LetterAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139891885149616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - Class A Common Stock<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Jul. 25, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Rate </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="nump">4,154,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares) | $ / shares</a></td>
<td class="nump">$ 2.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net, current | $</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares) | shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares) | shares</a></td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Price of shares purchased (in usd per shares) | $ / shares</a></td>
<td class="nump">$ 0.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Non-qualified stock option awards expiration term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage | Rate</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage | Rate</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>vtvt-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtvt="http://vtvtherapeutics.com/20220630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtvt-20220630.xsd" xlink:type="simple"/>
    <context id="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb646bb66f5041ab8b597cc264142087_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i69b2ce3d438f47a6bb0e8a99436f206d_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i778989260b33429389e1a9ca9b4b1a6d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id3f1ff84e5e8468880c40caf7f418a85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56c05dd51a814c37836f3f0e37c99f3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2632fc86076247a6b51786bef024e90d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1bfde1dac36844ceae1f4d006ceddf50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e8f41c561ac468dbc33b32b7235be53_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i21d658467661472da49eea25c17f94b0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3e22736f72b44c9afae821088c0ab77_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i009bfc074c5a4c0e9142f9616b19f90c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibb85c14dc2c74e2996fe107888561e93_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id905d604d9a943f6b7cb9f24d0dd0b48_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i29266001f249497b93b47c8e3466fd61_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6ef5bed40ce94a93a2cd11d663f62d4f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iae4134a6e3344ae8ad4af1f2240f9dd5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib755a24e8a104d1d8d2b3d1f74c11d40_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18ef80539aee48d48e6f1bb3a8119477_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i49b8aa8d7eba49128b8f62637d391235_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18238700dcf14e91a75ec3b06d1825b1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id22caf6e5b694a3bbc1d3ce68d75a410_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05d9dc5b78d04d55a239f0af2896ed29_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifb8450413dbc4dd08d8c7650588aa198_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i126a3208a6f742618c2561e7779f1845_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id982b9b09f424a87922b57be194129cb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iff9c4e329b59464eb907f13b780450d1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8a489bb6b0fe43528a20c591702e09b0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2c6da094d9ac4affabf82ba8cee1e10f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb0cff36c95e4303a0941bafd6699028_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2b13159810f0458a9344038beefe7235_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i85c3c142ca894d3192a385912e6b2355_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76098cfb60b247ba8a2e8ee82578378e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2452a27b59f747529be02258b1569777_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9521269fab34466aa92f8122d2b5d869_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4c32876481864865b9c009d36cd4047c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic4d35c53128c418ebe084dae0ea68bc8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1f41641fa7594bc5b38df0be185b457b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09ea0ea093f946ddbe1ea6abb5d7c0ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i50c8002790784ec0b6ad74669f5918cf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i62d8796c4850440b83f57f0567a7ca07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c5abc9ec8fa4a5eb2faeea6cc161c75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b6abbeb4fa947868b13efda9bde3af0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia20f8626d64245639e72db76234f04ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc5c6b914922483ab2156d1e3c1fd332_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6587de2ee5f8460daad2b87becd8ceea_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd2ad5a54d8145b688887e50ede3f142_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9a34cc4ae17f472882c70dc69f0341b7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ac25b8b6e8545729210187897d7d519_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4d8922a188e43c18738058811905e2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb96586842464c818639a9b0f427cca5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6a93b41b9e8482d8c8a5e90eb6fc5f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i548922a8ebe2493e96679d156ae2662c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c78efac0aa24b009a92ea9b1b7ce7c6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i882913d768b944228f47edf27a64d407_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e056239209f42eb89288f0b10c1d786_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70938c26b4624098aef25d030f5a7a61_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id13a79cf23134033b57b9a418c172263_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G2InvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="i510f76f9961e4195a66c407fea3e33b3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic87a37201a68429d87e70c2c68af37bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vtvt:LicenseAgreementObligationsAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iec7d98d909f742f7b497b0166dc0cd42_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i59fc879b99594e4fa12d9fd8e5ab7977_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic3050c6fe4714d81b1d708a35d3bfc8d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia89b7ff0156f46f6af23549fe63c886b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i3c93b4c2e340487692d87888bde8fd1d_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ia52cbec3f3c34ef984af52054ced737b_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i391171de436948d1ab5c2af5c2a6b7c3_D20220531-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i660eadb2cefb42f6af2828654b2ecaad_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i48b185c6a31e4b0f875dbc148b1a9690_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7645c4e435b9406cb66205c7447a3bb4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia159a094d3c149ae894a344e958ae6b8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib691d10b9e9048d2ad20c45cc4d7b82a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06ef634eb2724783ab3b95d2e1eb87b0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie3a4c00943074f559aa9f5295140d5d3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida207b1c94f040c49e5bac98b31bd511_I20210114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-14</instant>
        </period>
    </context>
    <context id="i9402a4a07ef14ae1bd27ed58ddf7c7a7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i28ca3ec68a2f405c9d88aea860a19d43_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iedcd02d9e7ed46a9be450435bae20a14_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a1d4d900a634784a41180096d9af11c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie807e06b03a449358e53f1fe6a28f0c2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e7dabf56fb04aae8e954ea2799cbebb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8ee005b698f440db91b1b86a6598a170_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9644a2a90dd449c3a42d337db0986546_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i61786a784a654e5eae26bb310979ad74_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i42c61470a62b4ea8ad0f4884c7064bd7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5c150d5a782c4fc0b12b5a8bf5b8dac1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i717440fba9ae463ba4b738d6cc36588b_D20201211-20201211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="i4678547c424543bbb17a9eec17b01812_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="if487c4d0351a4b53ad7e192011f347f0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4e359c73dd344730844f51f46e651559_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2afc370e61141bdbcb9d5cde256c0e5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i194bd737c73c45978ed3a128fb4083aa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i10084af716e84ec69a70340b4c5bd31b_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ic0bc234ab6f74714aa833022af967b77_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if1e0f604437b48cdbcd972041892c65b_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i82d10b9f39fd4c93bfa1d918b158b70d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieb1b9c3a3531408ab3529984f8566bc3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5fc8150340948bc898873b35fb8418e_D20220329-20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="iba62023a07f44291bd3078c3cb8c0331_I20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtvt:StrategicAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-29</instant>
        </period>
    </context>
    <context id="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtvt:StrategicAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="i3f49c4740cff40429fb52e44fa210e13_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7317531dde4b48dab33ee85599082a64_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id29697fdb6af49c7bc034a9837816d6d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4dda6d8be2724280ae62e19e4a293904_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i152676a2e89f49c1b9dc28a02261abd0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d1cd4fe75eb46dcab4af04b0635b52a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i762b94f808004bfcb8c828bf3cf727d2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5da4992df5e044318a2a0905c425112f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf108c845b044d5b9647b9f0d2f6517e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i783e762f741545f3a0fe0c1d38e6b115_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ida0147ce52f24edbb65de2e822c1593e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i264317da98da4654b1fb27e432d93843_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie3367eb43e184818b02b49d5ae5d81a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77b143ad9f4d4ba1ace4e171385ea567_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd78af64b3f948b895cdd7ac3bc5ef42_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iffa40b257a304d62948a32a686a7716a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic27aa30a7f394af79e2bdf369843816f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4ebac4e45e34b82929898cde894745e_I20070228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="i65905beb758b4791a02bb8d0cb2515a0_I20070228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="i6ead0675511b48ebb66183281497ebc5_I20070228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="i34ddaf589ad6495baf1c05cf44f3896e_I20070228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="i56c0384308fd425590c78419693d5fc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SatisfactionOfMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i910db6d0fa4e476cbe83b47a7fea5ee1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i92612f3dee2a4b16a5b8ceea2175dc30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6511cf535eb14b879d2b9abaf9fd770f_I20210504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="iedc1e3243a7443dfb3c90db73fedab5c_D20210504-20210504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="i0f18b37002444e71902e4b504204e08e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d7c397af1aa46eea7d046dd11d5461b_I20210504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="iff3de8bb3d5c4970bc7c8e651b6af215_I20210504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="ic54bdcd3ea0d44d0987f04e7b4c3ad6d_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ida448d3c156e41c6907f442bbdbdcfd3_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i94c6864ca64f40938eda9aad11bf61c1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b5db27bb04d4dd79864de1cb1a6f970_D20210114-20210114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-14</startDate>
            <endDate>2021-01-14</endDate>
        </period>
    </context>
    <context id="iebf065935ede4806964843da64a9618e_D20210625-20210625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-25</startDate>
            <endDate>2021-06-25</endDate>
        </period>
    </context>
    <context id="ia312c12a8760465dbb649e1f030f2bd7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5c543d697817434690f23877af7b8d92_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7de9e3cb791344979fa4282d8da7fd57_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i320fb888e6cd44998dc594856dc9724d_D20201124-20201124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-24</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="icb1be42149da4a86877d9aa6d3153d8f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06b77eabd9884287918e1f07afb3fdc4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie17c637109e34b5bac99defc70fe5b69_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfa89db2b5b5402c94ff86a30340034c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id69778fbafa14054a1949c92a76c3381_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib893ea7404d94823b4489736f31d8e0a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ee68f1d1f0245e088ff9dcad3a1d1ce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifbeae5448a4743c4972130e10f6a61e0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia12e25238c51408a9b5aabb915d68f4f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3883a4eeb01a4804bfe931960df3630c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7aaf9605ec3d4df997dcb31cc1d69aae_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0e056d11279c4dd88b534da383cad3ab_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icdd0c418f4a147dd908cb4bed116af1c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i323cbf05f2cd4b229244d58c16833346_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96d01a641a694957af47ad5592770a6c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if89aaa594ea04677ac3c150ebeb2e739_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6b89c4b600ca440bb9a9a90ea5e62a11_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1043be2df62a449880a9ce6cbfb89d1f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9cadb9b02403417192c10ca22f8e9080_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i91174829dd374e538fa07971c396f3f0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i118c349b7b7547779cf5d02c7d07c16b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie51365f9948548649ad42309ddd6a7b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e6746b22b7f41f39b2aa3e66ad235be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c7f59ded7334cc8a27ff3af075f6369_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d33804ed69446a581a68a89a6ced16b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0291753a44b74ba594c6c841017b8991_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i39fd9325e67d49ba929177308a09de11_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6e4ad6c963f84d1983f4152763b6d5e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i82047fa01dff4061ac50b8ba5c19afee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8eefc32c333242c2ba2cc3475c9a1886_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1cffc7e1fd3a45358f79cce28478fcf9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i549b94495164498ea6721b08e7ae6b51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaf1b6a13e34941f6b03007d4d7d9ce76_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4459419f08db4ba1875ab5f3a7f77bd9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2c0bac167c154e428feb6ddfa2051544_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie909d9404b144715bd0bec2b55db2950_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia333a79c07f744389589fbe58f3bf987_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i281f26cf97534b859fc01285494a83f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i534e6c90542a42f48822824cfd33db65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc889929911946cc9f3bc54d6854ca47_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i12ec27b58aee4985a776ed1774c95950_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i106c03246dd94c1291ebcee81f596ece_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie552923b1f3f42379e848afe08b6c2e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0f477876785490a8f842fc97272c335_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e8bcca13e6e4588aa129bdeb6bb7ec4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic36d6026ee894b0496ae13eeb6079046_I20220725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="i0826cd3429194c58828df365b21d13d7_D20220725-20220725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="i301fa4d644bd48b0a42d7d3c43ad4466_D20220725-20220725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV8yLTEtMS0xLTI5_18b5bc33-84a0-48f8-92c7-090f493f70d3">0001641489</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV8zLTEtMS0xLTI5_1dad7a44-2371-4a91-a86f-23d3af22b1fc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV80LTEtMS0xLTI5_be02b0fd-5779-4161-8ab0-e487d03d2ecb">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV81LTEtMS0xLTI5_724674a4-5e24-4a39-bb79-2c857769421e">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80L2ZyYWc6YzM3ODFiZGYxYzg0NGU2YjlhNjY4NjRjOWI2Yjg5YzEvdGFibGU6NzA0YTRjNjEyZmM3NDhkZGI1YmM3NDY0ZDc3ZDczYTUvdGFibGVyYW5nZTo3MDRhNGM2MTJmYzc0OGRkYjViYzc0NjRkNzdkNzNhNV82LTEtMS0xLTI5_4a38fd44-ac1c-4e99-8b15-e94a6908272d">false</dei:AmendmentFlag>
    <vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones
      contextRef="if1e0f604437b48cdbcd972041892c65b_D20170801-20170831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNy9mcmFnOjQzYWE3NDYzYWNiZTQ2OTZhMzUzMTkwZjFhOWFhNGQyL3RhYmxlOjU2NWFkMmRmZWM1YTQxN2FhYzUwMzhhOGRiNjdlMTk0L3RhYmxlcmFuZ2U6NTY1YWQyZGZlYzVhNDE3YWFjNTAzOGE4ZGI2N2UxOTRfMS0xLTEtMS0yOQ_4b42c586-0592-41a6-ba1d-8343aed2e91a"
      unitRef="number">0.5</vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones>
    <dei:DocumentType
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA2_d147a47d-d9a0-4a61-bc76-63bd424248b3">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6ZDI3MWZkZTNmNjA2NDUzYzhmNGUzMGRjMjRkZmJhNzUvdGFibGVyYW5nZTpkMjcxZmRlM2Y2MDY0NTNjOGY0ZTMwZGMyNGRmYmE3NV8wLTAtMS0xLTI5_289d6f7a-db91-4b0d-8b79-d592e5799ee5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA3_e0cd2f2c-99cb-4f7d-a571-17b348c4d8ac">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzM4MTYwZGU0ZDU4NGRkZjhiM2MwMDEwZTAyYjdlNTgvdGFibGVyYW5nZTpjMzgxNjBkZTRkNTg0ZGRmOGIzYzAwMTBlMDJiN2U1OF8wLTAtMS0xLTI5_baf2ddbc-2b95-4aa2-85dd-ca18dc49f7ca">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA4_109bbaa3-ad50-4000-9f0d-5fa0f0e6a1b6">001-37524</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTAx_60027565-b2f1-4b34-beae-c68c46a8b8a1">vTv Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8wLTAtMS0xLTI5_ec4b6ade-4e01-4865-b627-5abe7804ddba">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8wLTEtMS0xLTI5_de113c85-5e87-4399-bf50-889df3d0399e">47-3916571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfNA_0856a6a7-480d-4f04-8d64-74150917a06c">3980 Premier Dr</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfOA_75f46729-81d1-4b7e-b0b0-04232c87e976">Suite 310</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfMTE_1b7f4212-e954-4c94-8f8b-fa972f936174">High Point</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTAtMS0xLTI5L3RleHRyZWdpb246NzFmNDUzYzA4N2U1NGEwNGI3NzYwMzg2NDFlMjlmNGJfMTU_6550016f-0e42-4601-9248-b16e632e3974">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6MmJlY2UyMmI2ZjQxNDAyM2EwNzE5NTUxMDM5YjliZDUvdGFibGVyYW5nZToyYmVjZTIyYjZmNDE0MDIzYTA3MTk1NTEwMzliOWJkNV8zLTEtMS0xLTI5_9f5d7c25-458b-4540-961e-c2494dbcda74">27265</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTAy_2b724775-5883-4861-82ac-56ecacd1cde9">336</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTAz_a34d3961-005c-416a-afb9-9e7f982aeb0d">841-0300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzBlY2RlNGU3NzY0NGI1N2E2NGZkMTRhZmU3ZWIzYWEvdGFibGVyYW5nZTpjMGVjZGU0ZTc3NjQ0YjU3YTY0ZmQxNGFmZTdlYjNhYV8xLTAtMS0xLTI5_2bab2a1e-b803-4b5c-ae2f-330f04bf7dbc">Class A common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzBlY2RlNGU3NzY0NGI1N2E2NGZkMTRhZmU3ZWIzYWEvdGFibGVyYW5nZTpjMGVjZGU0ZTc3NjQ0YjU3YTY0ZmQxNGFmZTdlYjNhYV8xLTEtMS0xLTI5_69cb015f-2e72-4c89-a5e8-ef129b9d40b2">VTVT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YzBlY2RlNGU3NzY0NGI1N2E2NGZkMTRhZmU3ZWIzYWEvdGFibGVyYW5nZTpjMGVjZGU0ZTc3NjQ0YjU3YTY0ZmQxNGFmZTdlYjNhYV8xLTItMS0xLTI5L3RleHRyZWdpb246MzUyZDg0NDQ4MWZkNDU2OGJhMjA5MThmYzdhYTRkZmJfNA_f07917d8-9be8-4db3-9918-0a2bec3d10f9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA5_2e534f99-f89a-4ba4-a2c1-18e42e4b1567">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA0_ca822708-d9b4-4c4a-b086-dea7f82cabd5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6NTI5ODBjYmMwMjM3NDY3NmI2NDJmZTE0ZjUyMmM3ZmQvdGFibGVyYW5nZTo1Mjk4MGNiYzAyMzc0Njc2YjY0MmZlMTRmNTIyYzdmZF8xLTAtMS0xLTI5_a83ff6e2-ffe9-4cc1-ad8c-a535eeec0cef">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6NTI5ODBjYmMwMjM3NDY3NmI2NDJmZTE0ZjUyMmM3ZmQvdGFibGVyYW5nZTo1Mjk4MGNiYzAyMzc0Njc2YjY0MmZlMTRmNTIyYzdmZF8xLTQtMS0xLTI5_0124973d-e843-45e4-b8f9-172282e134e7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6NTI5ODBjYmMwMjM3NDY3NmI2NDJmZTE0ZjUyMmM3ZmQvdGFibGVyYW5nZTo1Mjk4MGNiYzAyMzc0Njc2YjY0MmZlMTRmNTIyYzdmZF8yLTEtMS0xLTI5_60c0d469-48cf-4f7f-9f41-d9682f270484">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGV4dHJlZ2lvbjo2ZWFmZTNhOGZkMWE0MGJhYTU3OTQwMTI4YWQ3YmYyYl8yMTA1_7d2824f9-2e04-4b2c-a57b-95b5a524af86">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ibb646bb66f5041ab8b597cc264142087_I20220815"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YWQ2MjU2YWM3NmJlNDg0MGIyMDk5YWM3ZDNkOTM0Y2IvdGFibGVyYW5nZTphZDYyNTZhYzc2YmU0ODQwYjIwOTlhYzdkM2Q5MzRjYl8xLTItMS0xLTI5_ea319233-83c3-4a67-b047-2f6bae259037"
      unitRef="shares">81483600</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i69b2ce3d438f47a6bb0e8a99436f206d_I20220815"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xL2ZyYWc6NmVhZmUzYThmZDFhNDBiYWE1Nzk0MDEyOGFkN2JmMmIvdGFibGU6YWQ2MjU2YWM3NmJlNDg0MGIyMDk5YWM3ZDNkOTM0Y2IvdGFibGVyYW5nZTphZDYyNTZhYzc2YmU0ODQwYjIwOTlhYzdkM2Q5MzRjYl8yLTItMS0xLTI5_5747e7da-d477-44ff-86b5-392d18a8f614"
      unitRef="shares">23093860</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNC0xLTEtMS0yOQ_61e2fea8-cf43-4d75-b995-d960911aa073"
      unitRef="usd">17863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNC0zLTEtMS0yOQ_d946309e-1fd2-46ad-9cfa-ea4ce3dfd182"
      unitRef="usd">13415000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNS0xLTEtMS0yOQ_7101e365-70a5-4fb5-a885-38c9b0997090"
      unitRef="usd">77000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNS0zLTEtMS0yOQ_cb43490c-4020-4c7f-a9a3-be7d3b202f87"
      unitRef="usd">57000</us-gaap:AccountsReceivableNetCurrent>
    <vtvt:NotesReceivableCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0xLTEtMS04NTI3_5a5327f2-ae2b-4a86-aadd-d8f24f8fd6ce"
      unitRef="usd">11941000</vtvt:NotesReceivableCurrent>
    <vtvt:NotesReceivableCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0zLTEtMS04NTI3_a23c190b-02f0-408a-9470-b746305306ce"
      unitRef="usd">0</vtvt:NotesReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0xLTEtMS0yOQ_2f07e035-b72c-41d3-8840-48cc974d71fd"
      unitRef="usd">643000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNi0zLTEtMS0yOQ_32d18b12-019d-4102-8f0a-967fc5c3bb13"
      unitRef="usd">2049000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNy0xLTEtMS0yOQ_4d7b2b23-add4-4767-9fc1-fd02cc0b7010"
      unitRef="usd">85000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfNy0zLTEtMS0yOQ_18d0e955-058e-425a-b90a-ed00efd88783"
      unitRef="usd">100000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOC0xLTEtMS0yOQ_f25f20d3-9af2-4bdd-a9d6-9f862ab62501"
      unitRef="usd">30609000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOC0zLTEtMS0yOQ_d48b7c1a-fa4d-4697-9417-a8e51a7a94f9"
      unitRef="usd">15621000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOS0xLTEtMS0yOQ_c778a958-8d3b-4446-9801-fc514b4f961b"
      unitRef="usd">254000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfOS0zLTEtMS0yOQ_9d89f1fd-a4e0-4707-b9aa-cc0121b130ab"
      unitRef="usd">278000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTAtMS0xLTEtMjk_955a416a-baee-4ff1-94c4-a846d6c8d192"
      unitRef="usd">354000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTAtMy0xLTEtMjk_538d22d1-1f79-4347-8204-e0fea1e7ab64"
      unitRef="usd">402000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTEtMS0xLTEtMjk_79f90e6b-3ccd-475b-ad91-a68345c3d10a"
      unitRef="usd">5772000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTEtMy0xLTEtMjk_72af8ff3-0827-4aa1-a141-a28e0af5aa78"
      unitRef="usd">9173000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTItMS0xLTEtMjk_c1d418fb-fb4d-4165-91ec-d715dce61aa9"
      unitRef="usd">36989000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTItMy0xLTEtMjk_c0861220-8158-40b0-9015-33fdaa08b360"
      unitRef="usd">25474000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTUtMS0xLTEtMjk_3598ce41-5a7a-48d3-b21e-44f8034d376e"
      unitRef="usd">9600000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTUtMy0xLTEtMjk_4d299e20-c4ce-4b32-aafb-78ac5fe27cbe"
      unitRef="usd">8023000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTYtMS0xLTEtMjk_aaa4e5f2-422e-42ef-a593-53f15a7b94a8"
      unitRef="usd">199000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTYtMy0xLTEtMjk_0a4a3eca-598e-4658-8a47-97d75f25184a"
      unitRef="usd">184000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTctMS0xLTEtMjk_e4bbeb0a-8e94-44ab-b364-68724dbfa68d"
      unitRef="usd">26000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTctMy0xLTEtMjk_8a6b476f-d380-4112-b264-b0306d7c44a7"
      unitRef="usd">35000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTgtMS0xLTEtMjk_eb2163d9-ff5d-4656-a61f-e1bb412f0ad5"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTgtMy0xLTEtMjk_51567ae4-a74b-477b-9542-5202608df0ed"
      unitRef="usd">256000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTktMS0xLTEtMjk_634f90aa-f4b0-49af-a510-c3ab8f3c7918"
      unitRef="usd">9825000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMTktMy0xLTEtMjk_79aab99d-9bad-47ba-b88d-21946bbf0c46"
      unitRef="usd">8498000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMS0xLTEtOTE0NA_de6b02d1-f396-493d-867d-4d8a51e05939"
      unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMy0xLTEtOTE0NA_e0f44d20-6b34-419f-9be0-b02c68a31402"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjAtMS0xLTEtMjk_899c17d6-a17b-4be0-8854-0f1da0c9caac"
      unitRef="usd">388000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjAtMy0xLTEtMjk_9ecbf6d8-eef9-450f-a382-02eee4bdfcd5"
      unitRef="usd">492000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMS0xLTEtMjk_9f28f5d4-fbbc-4e68-8af5-06953c60cf71"
      unitRef="usd">717000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjEtMy0xLTEtMjk_3624d149-04ce-4e04-a7af-e78885055d74"
      unitRef="usd">1262000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjItMS0xLTEtMjk_97987d1c-9a9f-48c2-829a-a5a10761d64c"
      unitRef="usd">29599000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjItMy0xLTEtMjk_2ed899ee-3910-41ae-9c05-7602660671fc"
      unitRef="usd">10252000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjMtMS0xLTEtMjk_26e88a6e-aa3e-4891-adc1-975f55f0d191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjMtMy0xLTEtMjk_65bee427-a682-405a-a434-719ef84f7af3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjQtMS0xLTEtMjk_aa8b22cd-d1dd-4510-ae99-69e496507dd9"
      unitRef="usd">15916000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjQtMy0xLTEtMjk_e9eeaf8a-762b-4c76-855a-781aaef49bca"
      unitRef="usd">24962000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM18yNg_8fc138ba-7942-4972-b35f-a68113b2c5ca"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2632fc86076247a6b51786bef024e90d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM18yNg_fb8554a4-2c30-4912-bd5c-21898f1b5511"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2632fc86076247a6b51786bef024e90d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM180MA_ad72df9f-d24f-48c7-8089-593a8c0ef9a7"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM180MA_d459afb6-bbc3-41c6-95fe-5da52b359792"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2632fc86076247a6b51786bef024e90d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM182Mg_2d906bbe-3d00-4e10-8359-473bccfae852"
      unitRef="shares">77329051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMC0xLTEtMjkvdGV4dHJlZ2lvbjo4MDJhOWVmMzcyNzk0NTAyYjQ5OGIxM2ViMjA3MmMyM18yNzQ4Nzc5MDY5NTQ0_6c24785a-4eff-4fb1-94ca-a676daff6b46"
      unitRef="shares">66942777</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i2632fc86076247a6b51786bef024e90d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMS0xLTEtMjk_9fdb402c-bb99-4796-afd4-62c216a96eb5"
      unitRef="usd">773000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i56c05dd51a814c37836f3f0e37c99f3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjYtMy0xLTEtMjk_2f990362-4cab-4b4e-a7df-76b9e1edded7"
      unitRef="usd">669000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV8yNg_26acd74d-87d3-4049-8b9f-38f399ccca48"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV8yNg_f2f326ff-2a47-4df3-aa80-dd4948ccc345"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV80MA_25865c3d-4b7e-4591-9195-3943086d23f0"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV80MA_99f3a5f0-04de-48cf-a1f8-e2a32901bf3d"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV82Ng_a71c7014-e503-4e17-88b8-112d09f3edee"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMC0xLTEtMjkvdGV4dHJlZ2lvbjozODIwNGFmYjA0MzA0OGI0OGEwNTRmMzczNzE5ZmZlMV82Ng_e78d1adf-71fa-45f1-ab12-402f6ad38e27"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i3e8f41c561ac468dbc33b32b7235be53_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMS0xLTEtMjk_0687c60f-dc53-4a56-876f-8262f7f8c234"
      unitRef="usd">232000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1bfde1dac36844ceae1f4d006ceddf50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjctMy0xLTEtMjk_360705b9-da21-444c-9143-7afe701b4db7"
      unitRef="usd">232000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjgtMS0xLTEtMjk_36bb4c64-b19b-4b21-b4f8-94fbb1b5ff6b"
      unitRef="usd">243772000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjgtMy0xLTEtMjk_1291f1b5-698f-4c04-be89-a8ae21f16da6"
      unitRef="usd">238193000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjktMS0xLTEtMjk_654187a8-3f92-4311-99bf-ed82cbe5f961"
      unitRef="usd">-253303000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMjktMy0xLTEtMjk_bde5a6ba-8e05-4f39-8eae-4cb421d86d94"
      unitRef="usd">-248834000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzAtMS0xLTEtMjk_2633192a-78d2-41ed-b6de-5330508c4635"
      unitRef="usd">-8526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzAtMy0xLTEtMjk_cc93dbc6-c72f-4c07-aab8-0429db83e808"
      unitRef="usd">-9740000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzEtMS0xLTEtMjk_074ab28d-f6b7-4fa9-aeb6-4a42d8c6c40e"
      unitRef="usd">36989000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xMy9mcmFnOjQyZDg3NjkyM2M1YzQ2MTE4NDUzYWEyMWM3NjQwZDVmL3RhYmxlOjNmNGI3YWNmYzg1NDQxMmJhNGJkNzkyZDM2ZjY0NWQ0L3RhYmxlcmFuZ2U6M2Y0YjdhY2ZjODU0NDEyYmE0YmQ3OTJkMzZmNjQ1ZDRfMzEtMy0xLTEtMjk_3089dd21-f5ae-4d4a-8f60-14b32ef358d9"
      unitRef="usd">25474000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi0xLTEtMS0yOQ_92bf9ad0-fe91-4fe4-a006-7b72adeb5e78"
      unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi0zLTEtMS0yOQ_5f56dba4-3e87-4b7d-8570-81fccb0c3280"
      unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi01LTEtMS04MzI_d3e00652-025c-457a-a71a-407d455e0986"
      unitRef="usd">2009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMi03LTEtMS0yMTg_d295cf1f-a086-4a29-9df8-d4c215755d47"
      unitRef="usd">996000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC0xLTEtMS0yOQ_4e48a6d2-f4ae-4608-89f1-d24f718938f0"
      unitRef="usd">2205000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC0zLTEtMS0yOQ_db240b16-9b7f-4d35-b6db-2d7775860cc1"
      unitRef="usd">2437000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC01LTEtMS04MzI_b60ce223-79b9-4ac0-a678-eddf007a0cee"
      unitRef="usd">5338000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNC03LTEtMS0yMTg_4bdff61f-0595-4a63-840b-09031883ebed"
      unitRef="usd">5540000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS0xLTEtMS0yOQ_c0f208f4-6c80-42c7-88e2-1fe0a99d91b4"
      unitRef="usd">1831000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS0zLTEtMS0yOQ_b8c28462-4870-4910-a037-0f4f6267de3c"
      unitRef="usd">2242000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS01LTEtMS04MzI_120dfcf3-cc3c-4e23-a1bd-9e7b7042b48f"
      unitRef="usd">7179000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNS03LTEtMS0yMTg_fe0cea21-8a58-4426-86cc-bccde2e90b39"
      unitRef="usd">4406000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi0xLTEtMS0yOQ_d469d60b-35a2-4061-bfb3-2a76cd435aee"
      unitRef="usd">4036000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi0zLTEtMS0yOQ_3e77c42d-aba0-4334-bacf-01c957f04f2c"
      unitRef="usd">4679000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi01LTEtMS0yMTg_d5227a2d-c789-4220-bf7c-13080ab197b8"
      unitRef="usd">12517000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNi03LTEtMS0yMTg_26eba022-6686-4f98-bec2-c509a8bacae4"
      unitRef="usd">9946000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy0xLTEtMS0yOQ_57599c27-660b-4c6a-973f-6876ec272ad9"
      unitRef="usd">-4027000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy0zLTEtMS0yOQ_2b2b4464-e2ca-4d35-a97e-eb8a01bb8deb"
      unitRef="usd">-4670000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy01LTEtMS0yMTg_6676ba0c-d399-40ca-8cb0-1ad63ee22608"
      unitRef="usd">-10508000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfNy03LTEtMS0yMTg_9e3053ea-03b5-4284-9db0-b055cc9e6648"
      unitRef="usd">-8950000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC0xLTEtMS0yOQ_b5c71716-da7f-48ea-8db2-892c7f6b472e"
      unitRef="usd">-167000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC0zLTEtMS0yOQ_556c9c1a-b96c-4af5-9183-8e311fa24fa4"
      unitRef="usd">2898000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC01LTEtMS04Mzg_6ba24b5e-947d-4a29-87a2-ac33c98c3072"
      unitRef="usd">-3401000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOC03LTEtMS0yMTg_fa234744-d1ab-4306-bf5b-f3e15b889dc7"
      unitRef="usd">2898000</us-gaap:OtherNonoperatingIncomeExpense>
    <vtvt:OtherIncomeExpensesRelatedParty
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS0xLTEtMS0yOQ_1a04797c-7ba1-4597-bd08-2c2f9d3557f2"
      unitRef="usd">53000</vtvt:OtherIncomeExpensesRelatedParty>
    <vtvt:OtherIncomeExpensesRelatedParty
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS0zLTEtMS0yOQ_8c930120-d0bc-42b5-b75f-8f935100be65"
      unitRef="usd">931000</vtvt:OtherIncomeExpensesRelatedParty>
    <vtvt:OtherIncomeExpensesRelatedParty
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS01LTEtMS04Mzg_5a647283-c854-4901-9df5-10ea6c4b751b"
      unitRef="usd">545000</vtvt:OtherIncomeExpensesRelatedParty>
    <vtvt:OtherIncomeExpensesRelatedParty
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfOS03LTEtMS0yMTg_98297223-8391-42c1-a2f1-89da46e30783"
      unitRef="usd">-717000</vtvt:OtherIncomeExpensesRelatedParty>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtMS0xLTEtMjk_3acf08b2-4172-4429-addf-00aabefd899b"
      unitRef="usd">50000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtMy0xLTEtMjk_193b3252-af10-4ecf-b34d-617e34ae7fdc"
      unitRef="usd">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtNS0xLTEtODM4_4d947658-03de-4900-bbd4-87d1eaa99838"
      unitRef="usd">50000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTAtNy0xLTEtMjE4_b6423373-2b09-4ec9-9f63-91e5c23b92f9"
      unitRef="usd">1000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtMS0xLTEtMjk_bd30b0ea-9d34-4aa8-98b6-86f33ea8e93a"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtMy0xLTEtMjk_4245c21f-6573-4f58-8379-bc3ae20abd8f"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtNS0xLTEtODM4_36e9db6d-aea6-4a51-bb53-1344d0af7cd4"
      unitRef="usd">1000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTEtNy0xLTEtMjE4_fa31649d-bf4a-4f11-a3e8-f5bd7e1e0454"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItMS0xLTEtMjk_0bc16a84-6cf4-4e0c-a82d-a7390e46e59d"
      unitRef="usd">-4091000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItMy0xLTEtMjk_0900f228-0f99-42ee-b8c6-3ff3a4f1e82d"
      unitRef="usd">-841000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItNS0xLTEtMjE4_23f47f7b-3805-4cbd-8412-5111af8b6a14"
      unitRef="usd">-13315000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTItNy0xLTEtMjE4_15778a2b-4180-4939-829e-44c52b982f54"
      unitRef="usd">-6768000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtMS0xLTEtMjk_f0849f16-6ec9-4e81-913b-63b1a6dcd4e1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtMy0xLTEtMjk_d1cd16e0-253a-4ede-ac82-cf76af224158"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtNS0xLTEtODQ1_b3c527e0-ff4a-4b21-81da-9da888b4768b"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTMtNy0xLTEtMjE4_da63571f-7b57-48b1-8044-6bf56643584b"
      unitRef="usd">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtMS0xLTEtMjk_17dc62d7-3bf4-497a-8300-c76eb8a1264b"
      unitRef="usd">-4091000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtMy0xLTEtMjk_f31c59d6-3622-443f-8884-a29135b97064"
      unitRef="usd">-841000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtNS0xLTEtMjE4_1f8fddde-81af-46aa-beb4-9a2138d76874"
      unitRef="usd">-13515000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTQtNy0xLTEtMjE4_05839e48-c0f2-4405-a96d-c500d8fa83ec"
      unitRef="usd">-6783000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtMS0xLTEtMjk_3e0cdee1-e1b3-4e34-8c49-ef77ea808667"
      unitRef="usd">-940000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtMy0xLTEtMjk_6af9eddd-bae6-4563-b5e9-9b85181f9f75"
      unitRef="usd">-233000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtNS0xLTEtODUx_7d248093-517a-4488-88e6-d0568ac2f016"
      unitRef="usd">-3357000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTUtNy0xLTEtMjE4_7f13bf1a-2a2e-49c7-b06e-ca7f371f9d23"
      unitRef="usd">-1934000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtMS0xLTEtMjk_0e2fb8d8-04e7-41b2-a3c9-68fefee75e57"
      unitRef="usd">-3151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtMy0xLTEtMjk_9d67cb37-3dc3-4800-bebc-6185ba5c4a09"
      unitRef="usd">-608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtNS0xLTEtMjE4_8c3db74f-43a7-4271-8f5f-899d0ba66c4d"
      unitRef="usd">-10158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTYtNy0xLTEtMjE4_48bf5ffd-3d8c-4870-82fc-356738c5c7ed"
      unitRef="usd">-4849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctMS0xLTEtMjk_48a67a14-26c7-410e-a337-a51d20783829"
      unitRef="usd">-3151000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctMy0xLTEtMjk_444c0cae-6d12-4329-b298-f057133d1947"
      unitRef="usd">-608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctNS0xLTEtMjE4_a860a057-acc5-42c5-9596-27b93bb83479"
      unitRef="usd">-10158000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTctNy0xLTEtMjE4_6bc5c83e-a3fc-4000-ac3c-4eb5ef6be6b3"
      unitRef="usd">-4849000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMS0xLTEtMjk_b6d50319-8b88-48af-8663-6ff52c8a9841"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMS0xLTEtMjk_f6721566-cbec-41d3-b653-4da486fe842f"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMy0xLTEtMjk_5c327321-cd7f-4195-ad46-8c41a324e040"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtMy0xLTEtMjk_fa2cf0fe-9ed2-4a1c-8a7b-6a8eca3d17ad"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNS0xLTEtODU3_9898b392-ebe3-4e7d-bb93-bcbcaa095b3a"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNS0xLTEtODU3_a605d9d5-9e1d-462e-a4da-1b6c56d0a8d2"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNy0xLTEtMjE4_47d2c0f1-ef6c-46bd-a300-441f19c81d91"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTgtNy0xLTEtMjE4_6669e51e-bb84-4342-80d5-292ce1cdde37"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMS0xLTEtMjk_ab19c233-cd3b-409c-a35d-de98aec65362"
      unitRef="shares">70366823</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMS0xLTEtMjk_e34fa6ea-7a20-48a9-ac72-5e7be50560c4"
      unitRef="shares">70366823</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMy0xLTEtMjk_5be5ba91-092b-4b98-90ed-5b564d316d0f"
      unitRef="shares">58615137</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktMy0xLTEtMjk_8477af44-2f82-4f21-b652-0a8b4c4d2ed6"
      unitRef="shares">58615137</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNS0xLTEtODU3_207f1f0c-e738-47d0-b9b5-67916e7cd863"
      unitRef="shares">68664259</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNS0xLTEtODU3_4c91b6aa-afeb-43bd-9d43-9867efa8b3fb"
      unitRef="shares">68664259</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNy0xLTEtMjE4_5990c9b8-df86-4e78-b037-8f71cc5a1129"
      unitRef="shares">57549755</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xNi9mcmFnOmU0ODE4Zjg1YjY3MjQwZDI5ZjE2ODJlMzA4NzZjNzMwL3RhYmxlOmQ2M2NlZDFiYjFhNzRhNmRiNTNkZjQ2ODE3NmUyNmJhL3RhYmxlcmFuZ2U6ZDYzY2VkMWJiMWE3NGE2ZGI1M2RmNDY4MTc2ZTI2YmFfMTktNy0xLTEtMjE4_c07e6a21-bf27-4215-873f-aabb55a68d2f"
      unitRef="shares">57549755</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="id3e22736f72b44c9afae821088c0ab77_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xLTEtMS05Mg_da6aeb74-f8e6-4bff-948c-1000607aacdd"
      unitRef="usd">14367000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i009bfc074c5a4c0e9142f9616b19f90c_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy00LTEtMS05Mg_5385914f-1496-4d4a-8ed7-7c59dc99043b"
      unitRef="shares">66942777</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i009bfc074c5a4c0e9142f9616b19f90c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy02LTEtMS05Mg_e1b52ece-43df-4d51-83b0-08f42a958ff0"
      unitRef="usd">669000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibb85c14dc2c74e2996fe107888561e93_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy04LTEtMS05Mg_59d89db7-9a62-4989-885d-37482c453344"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibb85c14dc2c74e2996fe107888561e93_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xMC0xLTEtOTI_88ef409b-7bf3-4e71-b297-3f24b3f29816"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id905d604d9a943f6b7cb9f24d0dd0b48_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xMi0xLTEtOTI_2f52cee6-b977-41a5-b10e-125097ee67a7"
      unitRef="usd">238669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29266001f249497b93b47c8e3466fd61_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xNC0xLTEtOTI_f7cc50b7-d45d-4787-a735-772aba7d25e2"
      unitRef="usd">-247663000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ef5bed40ce94a93a2cd11d663f62d4f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfMy0xNi0xLTEtOTI_04a24069-a7f4-4cc4-9b79-74ef3b22b91d"
      unitRef="usd">-8093000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="iae4134a6e3344ae8ad4af1f2240f9dd5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNC0xLTEtMS05Mg_e93f4e09-2b3f-4293-9cd5-c44d8f153092"
      unitRef="usd">-940000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib755a24e8a104d1d8d2b3d1f74c11d40_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNC0xNC0xLTEtOTI_036b7346-9a16-4c4d-a0b6-69d06a3c19bf"
      unitRef="usd">-3151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNC0xNi0xLTEtOTI_500ad076-e554-481d-8712-0e09dce8b6e6"
      unitRef="usd">-3151000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i18ef80539aee48d48e6f1bb3a8119477_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNS0xMi0xLTEtOTI_911349c4-db27-4bf0-81ae-8b1b046406c7"
      unitRef="usd">167000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNS0xNi0xLTEtOTI_2f5d6ed5-3304-410b-9f74-d24be9be3cf6"
      unitRef="usd">167000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i49b8aa8d7eba49128b8f62637d391235_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi00LTEtMS00MDgy_a2d89fa5-d62b-4604-aa7e-92f19e653cb0"
      unitRef="shares">10386274</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i49b8aa8d7eba49128b8f62637d391235_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi02LTEtMS00MDgy_87b6050b-64e5-480c-ac10-055ab547d5bc"
      unitRef="usd">104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i18238700dcf14e91a75ec3b06d1825b1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xMi0xLTEtNDA4Mg_a4af8a1f-d13b-4d0e-bdff-a687795770e4"
      unitRef="usd">4936000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xNi0xLTEtNDA4Mg_e2167b2c-1bec-4ade-9437-4d8ea2858919"
      unitRef="usd">5040000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vtvt:TemporaryEquityChangeInRedemptionValue
      contextRef="iae4134a6e3344ae8ad4af1f2240f9dd5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xLTEtMS05Mg_23e167ea-29a1-4a97-bb76-8545bb529d3d"
      unitRef="usd">2489000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ib755a24e8a104d1d8d2b3d1f74c11d40_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xNC0xLTEtOTI_036e75a6-0bfb-49a2-a945-27d9a4e754fb"
      unitRef="usd">-2489000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNi0xNi0xLTEtOTI_4b8797fa-e6c7-469f-a20f-43ad6422ea56"
      unitRef="usd">-2489000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="id22caf6e5b694a3bbc1d3ce68d75a410_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xLTEtMS05Mg_9bcbe05c-2b85-43d9-931f-eb2b7f9672c7"
      unitRef="usd">15916000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy00LTEtMS05Mg_0c408d46-6005-43c4-be9b-7296eab789f7"
      unitRef="shares">77329051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy02LTEtMS05Mg_24cdcd44-f704-4487-8cb9-b3ce93b74c6d"
      unitRef="usd">773000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy04LTEtMS05Mg_1648a1d2-4852-4776-a1d1-cc0efef9d2be"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xMC0xLTEtOTI_925c09da-f0b4-49a6-8729-dbca42fdc363"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb8450413dbc4dd08d8c7650588aa198_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xMi0xLTEtOTI_5951dbd6-4037-42e5-a956-497ade5a369a"
      unitRef="usd">243772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i126a3208a6f742618c2561e7779f1845_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xNC0xLTEtOTI_714d09fd-34f8-4ffe-bcf4-963647ae2d30"
      unitRef="usd">-253303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjBmN2M5ZGM1ODZmNDQzZjM4M2VmYzE2ZDlkMTJhMjJiL3RhYmxlcmFuZ2U6MGY3YzlkYzU4NmY0NDNmMzgzZWZjMTZkOWQxMmEyMmJfNy0xNi0xLTEtOTI_5ef63b4c-47ca-4320-b574-a1d3551f634c"
      unitRef="usd">-8526000</us-gaap:StockholdersEquity>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="id982b9b09f424a87922b57be194129cb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xLTEtMS0xOTMz_97417c00-8b9f-45f3-855a-d1c5a990e992"
      unitRef="usd">62647000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iff9c4e329b59464eb907f13b780450d1_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy00LTEtMS0xOTMz_71c8b064-6997-4313-9ce6-59ebf23b80be"
      unitRef="shares">57571904</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iff9c4e329b59464eb907f13b780450d1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy02LTEtMS0xOTMz_fb43921d-410f-4788-9628-1bdf5f59507d"
      unitRef="usd">576000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8a489bb6b0fe43528a20c591702e09b0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy04LTEtMS0xOTMz_745a00d2-10b3-40c0-8862-ba63e59fb3a9"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8a489bb6b0fe43528a20c591702e09b0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xMC0xLTEtMTkzMw_45032156-aff7-4f31-94dd-806f72518e47"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c6da094d9ac4affabf82ba8cee1e10f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xMi0xLTEtMTkzMw_2863bf81-af96-4656-b436-496f25a83bca"
      unitRef="usd">217647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb0cff36c95e4303a0941bafd6699028_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xNC0xLTEtMTkzMw_dbe46e24-9293-4956-9435-72b1c8434458"
      unitRef="usd">-274730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b13159810f0458a9344038beefe7235_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfMy0xNi0xLTEtMTkzMw_c21bbb39-170c-436e-9528-79b5c6c369e4"
      unitRef="usd">-56275000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i85c3c142ca894d3192a385912e6b2355_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNC0xLTEtMS0xOTMz_30234f8c-506c-46d3-9af3-3b3d23718343"
      unitRef="usd">-233000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i76098cfb60b247ba8a2e8ee82578378e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNC0xNC0xLTEtMTkzMw_c72c5634-4bae-4648-8dbb-b53c30157b9f"
      unitRef="usd">-608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNC0xNi0xLTEtMTkzMw_074cd4c1-0df8-47a4-bc09-fceb374e27fb"
      unitRef="usd">-608000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNS0xMi0xLTEtMTkzMw_68eadd29-0324-4e5f-821c-a36becad32f2"
      unitRef="usd">452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNS0xNi0xLTEtMTkzMw_cd9cc7d3-4db6-433d-9b34-3ec8224d8d1b"
      unitRef="usd">452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering
      contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi00LTEtMS0xOTMz_6df68544-30b0-42f2-8c77-f21369580976"
      unitRef="shares">2180337</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue
      contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi02LTEtMS0xOTMz_276d183d-3f92-4079-b708-9d90fe184394"
      unitRef="usd">22000</vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue>
    <vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue
      contextRef="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi0xMi0xLTEtMTkzMw_4a6e6cca-6db4-48a3-a118-6d7fecccaa94"
      unitRef="usd">5313000</vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue>
    <vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNi0xNi0xLTEtMTkzMw_dbe6e504-6643-4ff5-a400-39b721936f2c"
      unitRef="usd">5335000</vtvt:IssuanceOfClassACommonStockUnderATMOfferingValue>
    <vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement
      contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy00LTEtMS0xOTMz_8e2ae32e-3ed8-4c51-bbdb-774cf361e5bc"
      unitRef="shares">441726</vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="i2452a27b59f747529be02258b1569777_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy02LTEtMS0xOTMz_2479c7db-1312-4b7f-9be1-9865f5d54b47"
      unitRef="usd">4000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="i1e11b9287b0b4f6b8e41f0e406ae3e1b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy0xMi0xLTEtMTkzMw_359689fb-4335-40dd-bf90-8e5c9efc9966"
      unitRef="usd">1045000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfNy0xNi0xLTEtMTkzMw_c4ee7718-80ba-45e2-a2d7-bbed61f24ae8"
      unitRef="usd">1049000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:TemporaryEquityChangeInRedemptionValue
      contextRef="i85c3c142ca894d3192a385912e6b2355_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOC0xLTEtMS0xOTMz_9223a671-be86-4d9f-a844-930154432bee"
      unitRef="usd">-2224000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i76098cfb60b247ba8a2e8ee82578378e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOC0xNC0xLTEtMTkzMw_20ac1cb6-f78d-48b7-b385-f85307da914c"
      unitRef="usd">2224000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOC0xNi0xLTEtMTkzMw_12067e5d-1bc4-4e82-9fdc-b972993bd557"
      unitRef="usd">2224000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i9521269fab34466aa92f8122d2b5d869_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xLTEtMS0xOTMz_5a77badc-fc71-4105-aa93-26912f59e5d0"
      unitRef="usd">60190000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4c32876481864865b9c009d36cd4047c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS00LTEtMS0xOTMz_6edc541b-dad0-4beb-a4c1-f6479771a9cc"
      unitRef="shares">60193967</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c32876481864865b9c009d36cd4047c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS02LTEtMS0xOTMz_9458507f-15e3-4de4-a6aa-6199aa546f66"
      unitRef="usd">602000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS04LTEtMS0xOTMz_ab47ddbf-a4e0-4080-841c-32f9a1175690"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xMC0xLTEtMTkzMw_037b55d9-df19-49be-af1a-0e158b79838d"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f41641fa7594bc5b38df0be185b457b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xMi0xLTEtMTkzMw_bbe9d984-ef21-4eb8-9edb-f4ffbfcc1660"
      unitRef="usd">224457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09ea0ea093f946ddbe1ea6abb5d7c0ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xNC0xLTEtMTkzMw_bc4f1176-46d0-4ef0-adef-e2043be9d191"
      unitRef="usd">-273114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmEwNTZjNDBhOTUzYTQxODQ5YzgzYzljYTNmODA2ZGM4L3RhYmxlcmFuZ2U6YTA1NmM0MGE5NTNhNDE4NDljODNjOWNhM2Y4MDZkYzhfOS0xNi0xLTEtMTkzMw_a44597e2-c666-43f2-a317-95b8f2fa3e66"
      unitRef="usd">-47823000</us-gaap:StockholdersEquity>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xLTEtMS0yOQ_3d93f45e-8cda-4e94-8bf6-740fc2be0d80"
      unitRef="usd">24962000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i62d8796c4850440b83f57f0567a7ca07_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy00LTEtMS0yOQ_bef20b97-b383-4f60-997a-22b96e859f6e"
      unitRef="shares">66942777</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i62d8796c4850440b83f57f0567a7ca07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy02LTEtMS0yOQ_19a37ad1-a0d8-45ef-82c8-d7f9e4b7b9af"
      unitRef="usd">669000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1c5abc9ec8fa4a5eb2faeea6cc161c75_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy04LTEtMS0yOQ_d47f7a6f-29f9-41e8-88db-c9135816d2d4"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1c5abc9ec8fa4a5eb2faeea6cc161c75_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xMC0xLTEtMjk_9d0a5237-3712-4089-9e80-6b08125c0a0c"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b6abbeb4fa947868b13efda9bde3af0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xMi0xLTEtMjk_6227a0e9-d789-4034-be50-1b4d5c091ec4"
      unitRef="usd">238193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia20f8626d64245639e72db76234f04ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xNC0xLTEtMjk_b7db9d48-5938-4008-95f3-262bf1a0fef7"
      unitRef="usd">-248834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfMy0xNi0xLTEtMjk_8e0a2dfb-bfb2-48bb-8f2e-43fb1ab5e40f"
      unitRef="usd">-9740000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNC0xLTEtMS0yOQ_430c480a-eb77-48b8-8c59-31a0e9d00497"
      unitRef="usd">-3357000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icc5c6b914922483ab2156d1e3c1fd332_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNC0xNC0xLTEtMjk_73cec52d-efd1-4dce-b001-5058b19a3dfb"
      unitRef="usd">-10158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNC0xNi0xLTEtMjk_c735e2f7-f30e-438d-8127-340d92ba1d32"
      unitRef="usd">-10158000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6587de2ee5f8460daad2b87becd8ceea_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNS0xMi0xLTEtMjk_cf6140e0-9251-418f-861d-fd9929bdb6dd"
      unitRef="usd">643000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNS0xNi0xLTEtMjk_cfa18188-c099-473c-8b79-cda673111283"
      unitRef="usd">643000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icd2ad5a54d8145b688887e50ede3f142_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi00LTEtMS00MDkx_c5fab4dd-3475-49be-9878-b1ae4262d70e"
      unitRef="shares">10386274</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icd2ad5a54d8145b688887e50ede3f142_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi02LTEtMS00MDkx_4401801b-bb82-4c6c-b7a5-20502216ad06"
      unitRef="usd">104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9a34cc4ae17f472882c70dc69f0341b7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xMi0xLTEtNDA5MQ_7c18dfa7-f53b-44b9-b6d8-e312d199a561"
      unitRef="usd">4936000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xNi0xLTEtNDA5MQ_73921fd1-fdd2-4b15-ac16-787eeff862da"
      unitRef="usd">5040000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vtvt:TemporaryEquityChangeInRedemptionValue
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xLTEtMS0yOQ_3c000d24-e826-4cb0-8b2a-434244cab697"
      unitRef="usd">-5689000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="icc5c6b914922483ab2156d1e3c1fd332_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xNC0xLTEtMjk_59073cf3-d3c1-4403-b66f-e2c01bad2494"
      unitRef="usd">5689000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNi0xNi0xLTEtMjk_72240d3b-4d32-476c-a2a5-e00b8178d570"
      unitRef="usd">5689000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xLTEtMS0yOQ_d0053964-cd68-4cb7-aa73-1c1a906e9a80"
      unitRef="usd">15916000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy00LTEtMS0yOQ_0d848ee2-f879-4660-a3e8-bcbd435536c5"
      unitRef="shares">77329051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i05d9dc5b78d04d55a239f0af2896ed29_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy02LTEtMS0yOQ_61d23574-2e84-42db-bd76-2bba2f262495"
      unitRef="usd">773000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy04LTEtMS0yOQ_e83d1f61-934a-46be-ace0-0ba4dfe4d97f"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibbe8e7d3320f49998c34d8dc93a2050e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xMC0xLTEtMjk_f98214c3-030b-40eb-8f09-d282268e91bb"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb8450413dbc4dd08d8c7650588aa198_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xMi0xLTEtMjk_3b9eec52-cd98-445e-92c5-5f3c5eff3255"
      unitRef="usd">243772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i126a3208a6f742618c2561e7779f1845_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xNC0xLTEtMjk_4d7fe64b-8afd-479b-ae33-11c67c5dcc62"
      unitRef="usd">-253303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOmRlYzViNDQwZjdkZDQ1NGRhODg3NDU3MTcxMGE4NjVkL3RhYmxlcmFuZ2U6ZGVjNWI0NDBmN2RkNDU0ZGE4ODc0NTcxNzEwYTg2NWRfNy0xNi0xLTEtMjk_2c7f58e4-8224-4685-a948-66460685a3df"
      unitRef="usd">-8526000</us-gaap:StockholdersEquity>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xLTEtMS0yOQ_b469fbc6-1db1-4544-bd3b-59d8c2439af5"
      unitRef="usd">83895000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id4d8922a188e43c18738058811905e2c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy00LTEtMS0yOQ_7ff74c91-8425-4f90-96ea-bff59122f752"
      unitRef="shares">54050710</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id4d8922a188e43c18738058811905e2c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy02LTEtMS0yOQ_55187918-e1ab-480f-82c3-81f15761652e"
      unitRef="usd">541000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icb96586842464c818639a9b0f427cca5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy04LTEtMS0yOQ_23d6fcb9-e03f-44b6-a0db-0cc52ec9be70"
      unitRef="shares">23094221</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icb96586842464c818639a9b0f427cca5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xMC0xLTEtMjk_9848c94e-ab31-4bbd-9b68-12a30624bd47"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6a93b41b9e8482d8c8a5e90eb6fc5f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xMi0xLTEtMjk_a89e81d9-7c26-4436-b561-2f9c9563b43b"
      unitRef="usd">209161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i548922a8ebe2493e96679d156ae2662c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xNC0xLTEtMjk_16f52b53-01f6-4178-96b2-46114d41ee6d"
      unitRef="usd">-290036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMy0xNi0xLTEtMjk_4682f6bc-70ba-42b0-8589-53c051af575c"
      unitRef="usd">-80102000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNC0xLTEtMS0yOQ_2090fba1-b29c-4331-83b8-15e94f87a8cd"
      unitRef="usd">-1934000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i2c78efac0aa24b009a92ea9b1b7ce7c6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNC0xNC0xLTEtMjk_431e63fc-21a6-4bbd-8951-e2e3cae25d37"
      unitRef="usd">-4849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNC0xNi0xLTEtMjk_88aadff9-dc6d-4941-96f8-5b47b8dead5f"
      unitRef="usd">-4849000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNS0xMi0xLTEtMjk_364d5a1b-1f77-4b35-b060-6551152aee0e"
      unitRef="usd">888000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNS0xNi0xLTEtMjk_bfa3b834-4f98-4720-aebf-ad0fd2954c0c"
      unitRef="usd">888000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi00LTEtMS02MTMx_c866febf-dae3-4afe-b602-ce7a10029598"
      unitRef="shares">2180337</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi02LTEtMS02MTMx_0f12fce1-dc75-45d1-98ba-68b6daa9be9f"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2e056239209f42eb89288f0b10c1d786_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi0xMi0xLTEtNjEzMQ_f5e63ac8-e88d-4526-95d7-436bfc3f26ad"
      unitRef="usd">5313000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi0xNi0xLTEtNjEzMQ_86c579d4-025b-42c4-87df-10c3ba7ef30f"
      unitRef="usd">5335000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi00LTEtMS0yOQ_437b83a7-9a89-4311-ab27-4a1eeac89419"
      unitRef="shares">361</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i70938c26b4624098aef25d030f5a7a61_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNi04LTEtMS0yOQ_92a37a13-6f44-4a9a-9d2f-e37147303620"
      unitRef="shares">-361</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNy00LTEtMS0yOQ_f0065d0d-15a1-49c8-8be6-bd3b62830f59"
      unitRef="shares">20833</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNy0xMi0xLTEtMjk_9eaf4223-2427-4d64-a667-63531daf1070"
      unitRef="usd">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfNy0xNi0xLTEtMjk_5881b382-b678-4de3-b7fb-b93c276422ef"
      unitRef="usd">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement
      contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC00LTEtMS0yOQ_f7cf99fb-4aa8-42a2-ad38-e9f18b02fd15"
      unitRef="shares">3941726</vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="i882913d768b944228f47edf27a64d407_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC02LTEtMS0yOQ_2802b055-f74a-4dab-990b-4bd5043a1ee0"
      unitRef="usd">39000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="i5dcab619fd5440738e3edacf2abb5358_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC0xMi0xLTEtMjk_20c67b63-cb43-424c-bcfc-d33f997527cf"
      unitRef="usd">9048000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOC0xNi0xLTEtMjk_b336d761-0db6-4f08-b445-c4672c40815b"
      unitRef="usd">9087000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:TemporaryEquityChangeInRedemptionValue
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOS0xLTEtMS0yOQ_a6e3d6b7-f629-4afe-a73b-1e315480e4a4"
      unitRef="usd">-21771000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i2c78efac0aa24b009a92ea9b1b7ce7c6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOS0xNC0xLTEtMjk_0cbec8e0-2797-455b-ab0b-da3685bab538"
      unitRef="usd">21771000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfOS0xNi0xLTEtMjk_b270afd6-a949-4ef7-9fa0-3e2aebbbdb53"
      unitRef="usd">21771000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMS0xLTEtMjk_b4d70168-6bb2-4909-9069-59dae042bf77"
      unitRef="usd">60190000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4c32876481864865b9c009d36cd4047c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtNC0xLTEtMjk_8590ffc6-c94f-4152-a892-25027ad13276"
      unitRef="shares">60193967</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c32876481864865b9c009d36cd4047c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtNi0xLTEtMjk_206281f6-cf46-4d0c-9ee3-ff79cac0c52c"
      unitRef="usd">602000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtOC0xLTEtMjk_d9822d25-2e68-47c1-ad1d-ca797d554cb4"
      unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic4d35c53128c418ebe084dae0ea68bc8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTAtMS0xLTI5_584395f4-dfa6-4dbe-aae1-54e0a3daa4e9"
      unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f41641fa7594bc5b38df0be185b457b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTItMS0xLTI5_c9e1d1b1-c3a0-4fb2-9800-1a4346a2da58"
      unitRef="usd">224457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09ea0ea093f946ddbe1ea6abb5d7c0ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTQtMS0xLTI5_c886af3c-6188-471e-93fb-71b8a6b01044"
      unitRef="usd">-273114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8xOS9mcmFnOjFiODBkZmMxMDk3NDRiZjdiNTIxNTE1YTQyZGRhZWRiL3RhYmxlOjhjYzQ3YzEwNjdkMTQ1ZTk5ZmRkYjM1MTdkMzhiMWFjL3RhYmxlcmFuZ2U6OGNjNDdjMTA2N2QxNDVlOTlmZGRiMzUxN2QzOGIxYWNfMTAtMTYtMS0xLTI5_0e651b9c-f7d5-4ee4-9691-9e41a23f5874"
      unitRef="usd">-47823000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMy0xLTEtMS0yOQ_dbdcb811-b181-4095-a049-ed581e80c13a"
      unitRef="usd">-13515000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMy0zLTEtMS0yOQ_c92e3c45-197e-4a99-aebd-554ee2e460aa"
      unitRef="usd">-6783000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNS0xLTEtMS0yOQ_1486266f-3776-4219-bb15-eec67ceb520d"
      unitRef="usd">45000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNS0zLTEtMS0yOQ_7cc1054e-556c-47c7-812d-81920be4cf5a"
      unitRef="usd">45000</us-gaap:Depreciation>
    <us-gaap:InterestIncomeOperating
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0xLTEtMS0xMjEzNA_4c79a055-9c68-435e-b67d-5b3b72293a2c"
      unitRef="usd">50000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0zLTEtMS0xMjEzNA_a7f54658-8601-40e6-857a-edbde4521f5d"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:ShareBasedCompensation
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0xLTEtMS0yOQ_26334554-2efa-4ab0-b658-0effac2deb55"
      unitRef="usd">643000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNi0zLTEtMS0yOQ_18234489-d632-4a0e-80fc-2bb57dd3ff88"
      unitRef="usd">888000</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNy0xLTEtMS0yOQ_4443f8fc-c8ce-48c8-8c9b-bf65330dda5e"
      unitRef="usd">-3401000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfNy0zLTEtMS0yOQ_c491b75f-e087-4b1a-b7d3-4e117a61f8b7"
      unitRef="usd">2897000</us-gaap:UnrealizedGainLossOnInvestments>
    <vtvt:ChangeInFairValueOfWarrantsRelatedParty
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfOC0xLTEtMS0yOQ_be72e241-a64e-4b84-a659-dca0fcb8552a"
      unitRef="usd">-545000</vtvt:ChangeInFairValueOfWarrantsRelatedParty>
    <vtvt:ChangeInFairValueOfWarrantsRelatedParty
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfOC0zLTEtMS0yOQ_6d3696e3-7878-49ec-9505-4ae856f6643a"
      unitRef="usd">717000</vtvt:ChangeInFairValueOfWarrantsRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTAtMS0xLTEtMjk_d00f3655-d331-4666-a90a-047fb1ad500c"
      unitRef="usd">20000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTAtMy0xLTEtMjk_530c15a0-049f-498b-9e7c-f541b2533954"
      unitRef="usd">-158000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTEtMS0xLTEtMjk_b09c897d-813e-4dc6-ab2e-6e4171e33b00"
      unitRef="usd">-1421000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTEtMy0xLTEtMjk_f0554c81-6db4-4b9b-b404-ba6417fd9108"
      unitRef="usd">-873000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTItMS0xLTEtMjk_239618aa-0f54-4d3d-9d4a-ef3a97881976"
      unitRef="usd">1536000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTItMy0xLTEtMjk_5c95ba63-9ed2-4d26-9806-af6e0c9cb682"
      unitRef="usd">-1302000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTMtMS0xLTEtMjk_61d3576d-93fe-46db-960c-2d0fe6df8bf3"
      unitRef="usd">6769000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTMtMy0xLTEtMjk_c9b983ba-20a5-4104-9de8-bf64ce4dfa94"
      unitRef="usd">-996000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTQtMS0xLTEtMjk_eb1e1b51-2e42-42b9-9ee5-2fc8075ca164"
      unitRef="usd">-315000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTQtMy0xLTEtMjk_f05cbd6b-a1d0-4d74-959e-501e77de8052"
      unitRef="usd">-9297000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMS0xLTEtMzg3MQ_9ad04297-16f6-4733-8063-e9e35c3a8b16"
      unitRef="usd">21000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMy0xLTEtMzg3MQ_5e35c764-9838-4427-bd5e-474cdf0acf4e"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMS0xLTEtMzg3MQ_bd8742da-a515-449b-8051-4bf21dbb2a8f"
      unitRef="usd">-21000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMy0xLTEtMzg3MQ_886c7052-cfc1-41df-9560-bb0c6c25b89d"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <vtvt:ProceedsFromSaleOfCommonStock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMS0xLTEtMzg4Mw_8b8be86a-2160-4a33-a5f3-74f635bb93d0"
      unitRef="usd">5040000</vtvt:ProceedsFromSaleOfCommonStock>
    <vtvt:ProceedsFromSaleOfCommonStock
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMy0xLTEtMzg4Mw_7b2b8619-8e0f-4437-80cf-34fb1e906ffc"
      unitRef="usd">0</vtvt:ProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMS0xLTEtMjk_ba51868e-f641-40da-9255-063a3e2a6cae"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTYtMy0xLTEtMjk_49a052d9-c059-4e9f-aa35-06eaac7a671a"
      unitRef="usd">14422000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMS0xLTEtMjk_7c37405d-30f0-4c27-a333-b588b15661af"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTctMy0xLTEtMjk_978a903b-2f95-432f-894d-2cd2bd08634b"
      unitRef="usd">47000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTgtMS0xLTEtMjk_02dc8f08-cb2a-4774-b088-8eadab2e717c"
      unitRef="usd">256000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTgtMy0xLTEtMjk_d114c3c6-895d-4248-904d-786a8e65c001"
      unitRef="usd">84000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMS0xLTEtMjk_68565bbd-2046-4b94-8678-d3b43e5dbab9"
      unitRef="usd">4784000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMTktMy0xLTEtMjk_061c139a-8538-4110-9e32-317b9a3d1ae6"
      unitRef="usd">14385000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjAtMS0xLTEtMjk_f7d71d7d-add1-4b07-9bcf-1df9945404b2"
      unitRef="usd">4448000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjAtMy0xLTEtMjk_f5399a87-cd1f-4b43-a23c-0d0717f26eb3"
      unitRef="usd">5088000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjEtMS0xLTEtMjk_28305098-2f64-41a8-b6f7-db448be05e12"
      unitRef="usd">13415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjEtMy0xLTEtMjk_9216c740-0508-4bac-9f07-c201b2714088"
      unitRef="usd">5747000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjItMS0xLTEtMjk_99334077-f54f-4cd2-a918-7b48498f0dea"
      unitRef="usd">17863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50c8002790784ec0b6ad74669f5918cf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjItMy0xLTEtMjk_896f53fb-71b4-4a38-b59a-5cbe6205dc4b"
      unitRef="usd">10835000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjUtMS0xLTEtMjk_7098f637-3070-4759-8a2b-4ee8448eba4a"
      unitRef="usd">5689000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMjUtMy0xLTEtMjk_08cecb9f-af49-4a34-8a7f-1873e0c50210"
      unitRef="usd">21771000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:NotesAssumed1
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMzEtMS0xLTEtODk3MQ_9636e173-14e2-4af0-82d4-06b418f1571f"
      unitRef="usd">11891000</us-gaap:NotesAssumed1>
    <us-gaap:NotesAssumed1
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yMi9mcmFnOmIyNDI3OGFkNzQ5MzQ5NGY5ZTc1OGRiNTk2NDcxNGM3L3RhYmxlOmM3Nzk3Y2EzNTkxODQ3MzRhOTBhZmNhMDc3YWQ0NGZjL3RhYmxlcmFuZ2U6Yzc3OTdjYTM1OTE4NDczNGE5MGFmY2EwNzdhZDQ0ZmNfMzEtMy0xLTEtODk3MQ_79a1dfc8-d1f1-47d4-ae51-2c4dd57a9bb9"
      unitRef="usd">0</us-gaap:NotesAssumed1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNjIyOQ_16775de5-cc99-4f2c-98f4-5aea97e21df6">Description of Business, Basis of Presentation and Going Concern&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. (the &#x201c;Company,&#x201d; the &#x201c;Registrant,&#x201d; &#x201c;we&#x201d; or &#x201c;us&#x201d;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#x201c;vTv LLC&#x201d;), the Company&#x2019;s principal operating subsidiary, which is a clinical stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that vTv LLC is a variable-interest entity (&#x201c;VIE&#x201d;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#x2019;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#x2019;s results pursuant to Accounting Standards Codification Topic 810, &#x201c;Consolidation&#x201d; in its Condensed Consolidated Financial Statements. As of June&#160;30, 2022, various holders own non-voting interests in vTv LLC, representing a 23.0% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#x2019;s interest to 77.0% of vTv LLC&#x2019;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (&#x201c;vTv Units&#x201d;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of Class B common stock) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#x201c;Lenders&#x201d;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#x201c;M&amp;amp;F Group&#x201d;), a related party and an affiliate of MacAndrews &amp;amp; Forbes Incorporated (together with its affiliates &#x201c;MacAndrews&#x201d;). in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (the &#x201c;Letter Agreements&#x201d;).  In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor Fitzgerald&#x201d;) (the &#x201c;ATM Offering&#x201d;), the purchase agreement with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) (the &#x201c;LPC Purchase Agreement&#x201d;), and the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#x201c;G42 Investments&#x201d;) (the &#x201c;G42 Purchase Agreement&#x201d;). v&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through June&#160;30, 2022, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of June&#160;30, 2022, the Company had an accumulated deficit of $253.3 million and has generated net losses in each year of its existence. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company&#x2019;s liquidity sources included cash and cash equivalents of $17.9 million. To meet our future funding requirements into the third quarter of 2023, including funding the on-going and future clinical trials of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs such as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company also has a promissory note of $12.5 million under &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the G42 Purchase Agreement payable to the Company on or before May 31, 2023 (see Note 9) and on July 25, 2022, announced a $10.0 million investment by CinPax, LLC (see Note 14).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may also use its remaining availability of $37.3 million under our Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company&#x2019;s Class A common stock (the &#x201c;ATM Offering&#x201d;) and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#x2019;s Class A common stock.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 9 for further details. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;impact on our financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <vtvt:PercentageOfNonVotingEconomicInterest
      contextRef="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfMTU1OA_f82adf74-80b8-409b-9f09-38a10c907d14"
      unitRef="number">0.230</vtvt:PercentageOfNonVotingEconomicInterest>
    <vtvt:PercentageOfNonVotingEconomicInterestByParent
      contextRef="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfMTY1MQ_f1e1f955-3f68-473e-875e-67dc66d7e507"
      unitRef="number">0.770</vtvt:PercentageOfNonVotingEconomicInterestByParent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNDEyNw_43c6b77d-af5f-49fd-a217-56e217335073"
      unitRef="usd">-253300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNDI3MQ_8c753637-f2ad-4a79-ac26-425cbef5fec4"
      unitRef="usd">17900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="id13a79cf23134033b57b9a418c172263_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfMjc0ODc3OTA3OTQ4Mg_18a90141-21cf-496e-88dc-eef7b84828ed"
      unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNTQ5NzU1ODIzOTA4_e01793d3-5286-4d6f-b375-3d1963bd5d32"
      unitRef="usd">10000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues
      contextRef="i510f76f9961e4195a66c407fea3e33b3_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNDc4NA_066d9807-e4ad-4352-8e9a-62deab961c6d"
      unitRef="usd">37300000</vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic87a37201a68429d87e70c2c68af37bb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8yOC9mcmFnOmM1Y2Q0NjJiYjc1NjQ4ZjI4MTBmOGY1NTA4M2EyMGRmL3RleHRyZWdpb246YzVjZDQ2MmJiNzU2NDhmMjgxMGY4ZjU1MDgzYTIwZGZfNTA4OQ_a05362c3-b724-4cb7-a42d-b0c12d2f750a"
      unitRef="shares">9437376</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA4MQ_17f6d26c-e1dd-4c07-908b-8838c48a2f95">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2022, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#x2019; Deficit for the three and six months ended June&#160;30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2021, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of June&#160;30, 2022, the results of operations for the three and six months ended June&#160;30, 2022, and 2021 and cash flows for the six months ended June&#160;30, 2022, and 2021. The December&#160;31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note receivable, and the fair value of the Company&#x2019;s debt, among others. The Company bases its estimates on historical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One customer represented 100% of the revenue earned during the three and six months ended June&#160;30, 2022, and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the revenue recognition guidance established by ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#x2019;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#x2019;s transaction price is allocated to each performance obligation using the Company&#x2019;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development activities on the Company&#x2019;s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3OA_12b435dd-0c12-446b-ba6c-adc53c4557ba">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of June&#160;30, 2022, Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022, and 2021, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#x2019; Deficit for the three and six months ended June&#160;30, 2022, and 2021 and Condensed Consolidated Statements of Cash Flows for the six months ended June&#160;30, 2022, and 2021 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2021, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of June&#160;30, 2022, the results of operations for the three and six months ended June&#160;30, 2022, and 2021 and cash flows for the six months ended June&#160;30, 2022, and 2021. The December&#160;31, 2021 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June&#160;30, 2022, and 2021 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3Nw_2fcfac56-60b5-4d11-a058-4f3a2af2bea5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of the Class B common stock, the useful lives of property and equipment, the fair value of derivative liabilities, the fair value of the promissory note receivable, and the fair value of the Company&#x2019;s debt, among others. The Company bases its estimates on historical &lt;/span&gt;&lt;/div&gt;experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3OQ_a49b93fc-cd67-418a-9cf7-c937743cf2d7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balances of these cash accounts frequently exceed insured limits.&lt;/span&gt;&lt;/div&gt;One customer represented 100% of the revenue earned during the three and six months ended June&#160;30, 2022, and 2021, respectively.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec7d98d909f742f7b497b0166dc0cd42_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_0a0ae344-f568-40f1-8c9a-390556e6bee4"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i59fc879b99594e4fa12d9fd8e5ab7977_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_87bce2d4-44c7-4f30-97ab-73e14ddeaaed"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic3050c6fe4714d81b1d708a35d3bfc8d_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_f7a11484-b8bd-452b-a6d8-648628caf300"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia89b7ff0156f46f6af23549fe63c886b_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfMzY2NA_f8f7af41-5815-4a1b-9a81-4b7fa7e7610c"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA4MA_0a853ac2-deff-4134-91ce-47b62b08fcfa">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3Mw_e97707ee-b767-4110-960c-d0cd2b2ad43f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3NA_f36a02a8-0eeb-435e-afa9-17c77ad52602">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the revenue recognition guidance established by ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#x2019;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#x2019;s transaction price is allocated to each performance obligation using the Company&#x2019;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost-plus margin approach.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3NQ_b62f26dd-c0e2-4ed7-996f-1e6f8c552289">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash and share-based compensation, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, regulatory and compliance costs, fees paid to consultants and other entities that conduct certain research and development activities on the Company&#x2019;s behalf, facilities costs, and overhead costs. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zMS9mcmFnOjIwOWU0MWIwZDBhYzQ4YTBhYzAzMWNkZjllOGM1MGJjL3RleHRyZWdpb246MjA5ZTQxYjBkMGFjNDhhMGFjMDMxY2RmOWU4YzUwYmNfOTA3Ng_2bb88f23-9410-4ac3-897f-a6e824fbce54">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA5OTM_38782788-fd44-401c-b00a-1f2fe12ac432">Collaboration Agreements&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Purchase Agreement and Cogna Collaborative and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#x201c;G42 Investments&#x201d;), entered into a Common Stock Purchase Agreement (the &#x201c;G42 Purchase Agreement&#x201d;), pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company&#x2019;s Class A common stock, par value $0.01 per share (the &#x201c;G42 Common Stock) at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company&#x2019;s board of directors approved appointing the new director to the Company&#x2019;s board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval in the U.S. for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;FDA Approval&#x201d;) of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#x201c;Cogna Agreement&#x201d;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#x201c;Cogna&#x201d;) (&#x201c;Collaboration Partner&#x201d;), which requires Cogna to work with the Company in performing Phase 3 clinical trials for the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; compound (the &#x201c;Licensed Product&#x201d;) as well as jointly creating a global development plan to develop, market, and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in certain countries in the Middle East, Africa, and Central Asia (the &#x201c;Partner Territory&#x201d;). Under the terms of the Cogna Agreement, Cogna will obtain rights to the Company&#x2019;s license of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for purposes of performing Phase 3 clinical trials in the Partner Territory, but will not have access to the various intellectual property (&#x201c;IP&#x201d;) related to the license and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;needed to conduct the trials. Separately, the Company will conduct its Phase 3 clinical trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. at its own cost that similarly &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will not be reimbursed. The results of each party&#x2019;s Phase 3 clinical trials will be combined by the Company to seek FDA approval in the U.S. for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the Cogna Agreement, Cogna has the right to develop and commercialize the Licensed Product in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; for commercial sale under terms to be agreed upon by the parties at a later date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The G42 Purchase Agreement also provides for, following the receipt of FDA approval of the Licensed Product, at the option of G42 Investments, either (a) the issuance of the Company&#x2019;s Class A common stock (the &#x201c;Milestone Shares&#x201d;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#x201c;Milestone Cash Payment&#x201d;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, are conditioned upon receipt of the FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA Approval will be granted or as to the timing thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once commercialization takes place in the Partner Territories, the Company will receive royalties of 8% from Cogna on the sale of the Licensed Product for ten years after the first commercial sale of the Licensed Product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#x201c;Recently Issued Accounting Guidance&#x201d; in this 10-Q for details of the ASU.  Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of the Licensed Product, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#x2019;s behalf to complete R&amp;amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#x201c;JDC&#x201d;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would have to complete its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the Phase 3 clinical trials. As of June 30, 2022, the Phase 3 clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and six months ended June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#x2019;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The material right is predicated upon FDA approval. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after the Licensed Product is approved by the FDA.  As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and six months ended June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the Company has recognized the cash and a non-interest bearing promissory note receivable of with a principal balance of $12.5 million. The promissory note receivable was classified and accounted for under ASC 310 and was measured at its fair value of and will be subsequently remeasured at its amortized cost thru its maturity date. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company also recorded the $18.7 million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and six months ended June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reneo License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license agreement with Reneo Pharmaceuticals, Inc. (&#x201c;Reneo&#x201d;) (the &#x201c;Reneo License Agreement&#x201d;), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company&#x2019;s peroxisome proliferation activated receptor delta (PPAR-&#x3b4;) agonist program, including the compound &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for therapeutic, prophylactic or diagnostic application in humans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has fully allocated the transaction price to the license and the technology transfer services, which represents a single combined performance obligation because they were not capable of being distinct on their own. The revenue related to this performance obligation was recognized on a straight-line basis over the technology transfer service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue related to this performance obligation has been fully recognized and no revenue related to this performance obligation was recognized for the three and six months ended June&#160;30, 2022, and 2021. There have been no adjustments to the transaction price for the performance obligations under the Reneo License Agreement during the three and six months ended June&#160;30, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Huadong License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#x201c;Huadong&#x201d;) (the &#x201c;Huadong License Agreement&#x201d;), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company&#x2019;s glucagon-like peptide-1 receptor agonist (&#x201c;GLP-1r&#x201d;) program, including the compound&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; TTP273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for therapeutic uses in humans or animals, in China and certain other pacific rim countries, including Australia and South Korea (collectively, the &#x201c;Huadong License Territory&#x201d;). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company&#x2019;s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;14, 2021, the Company entered into the First Huadong Amendment which eliminated the Company&#x2019;s obligation to sponsor a multi-region clinical trial (the &#x201c;Phase 2 MRCT&#x201d;), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC Topic 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $1.0 million of revenue on a cumulative catch-up basis during the six months ended June&#160;30, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant performance obligations under this license agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company&#x2019;s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company&#x2019;s obligation to participate on a joint development committee (the &#x201c;JDC&#x201d;), and (iv) other obligations considered to be de minimis in nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. This combined performance obligation was considered complete as of June&#160;30, 2021. The Company recognized $1.0 million of revenue related to this combined performance obligation during the six months ended June&#160;30, 2021. During the six months ended June 30, 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the six months ended June&#160;30, 2022, as the related performance obligation was fully satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of June&#160;30, 2022, and revenue will be recognized using the proportional performance model over the period of the Company&#x2019;s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of June&#160;30, 2022, was de minimis. An immaterial amount of revenue for this performance obligation has been recognized during six months ended June&#160;30, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Newsoara License Agreement-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#x201c;Newsoara&#x201d;) (the &#x201c;Newsoara License Agreement&#x201d;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#x2019;s phosphodiesterase type 4 inhibitors (&#x201c;PDE4&#x201d;) program, including the compound &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#x201c;Newsoara License Territory&#x201d;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#x2019;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The revenue for this performance obligation has been fully recognized as of June&#160;30, 2022. No revenue related to this performance obligation was recognized and there have been no changes to the transaction price during the three and six months ended June&#160;30, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Anteris License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (&#x201c;Anteris&#x201d;) (the &#x201c;Anteris License Agreement&#x201d;), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company&#x2019;s Nrf2 activator, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of $2.0 million. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $151.0 million. Anteris is also obligated to pay the Company royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30-day period after the effective date. In accordance with ASC Topic 606, the Company identified all the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the $2.0 million initial license payment, as well as the fair value of the equity interest received in Anteris of $4.2 million. The revenue related to this performance obligation was fully recognized during the year ended December&#160;31, 2020, as the technology transfer services were considered complete as of that date. No revenue related to this performance obligation was recognized and there have been no changes to the transaction price during the three and six months ended June&#160;30, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;JDRF Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, the Company entered into a research and collaboration agreement with JDRF International (the &#x201c;JDRF Agreement&#x201d;) to support the funding of the Simplici-T1 Study, a Phase 2 study to explore the effects of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with type 1 diabetes. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The JDRF Agreement was amended in June 2021 to provide additional funding for the Company&#x2019;s mechanistic study exploring the effects of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;According to the terms of the JDRF Agreement, JDRF will provide research funding of up to $3.4 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as a treatment for type 1 diabetes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments that the Company receives from JDRF under this agreement will be recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of June&#160;30, 2022, the Company had received funding under this agreement of $3.4 million. Research and development costs have been offset by a total of  $3.4 million over the course of this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities related to the Company&#x2019;s collaboration agreements consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in short-term and long-term contract liabilities for the six months ended June&#160;30, 2022, were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance on January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration received in advance and not recognized as revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance on June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTUxNw_49eff64d-86da-487b-8daa-e14111ae5ebf"
      unitRef="shares">10386274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTUyNQ_1116bf01-1913-46e3-aab3-98c840982fc9"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTUzMw_b20464af-71da-479a-bb6c-f878358ecf5f"
      unitRef="usdPerShare">2.41</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTU0OQ_aa63db3e-bddf-4ac8-88f0-9115953e9ca2"
      unitRef="usd">25000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTU5MQ_000e5d3e-36d9-4172-8e9b-52f9aef343e3"
      unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTU2NQ_4c418cdc-5c56-4883-8fff-65230cc953bb"
      unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <vtvt:SaleOfStockConsiderationReceivablePaymentPeriod
      contextRef="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTE1NDQ4NzIxOTc2MjM_1b8ce159-46a0-4a47-bef0-d61eeecb596a">P1Y</vtvt:SaleOfStockConsiderationReceivablePaymentPeriod>
    <vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue
      contextRef="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE2NTMyMQ_80b69025-f3c3-4dff-9bb5-5c6d6f52a905"
      unitRef="usd">30000000</vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue>
    <vtvt:CollaborateArrangementContingentConsiderationTransferredCash
      contextRef="iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE2NTQ1Ng_26fd75ab-cc72-4cf1-a61a-4ab845db02d1"
      unitRef="usd">30000000</vtvt:CollaborateArrangementContingentConsiderationTransferredCash>
    <vtvt:CollaborativeArrangementRoyaltiesReceivablePercentage
      contextRef="ia52cbec3f3c34ef984af52054ced737b_I20220531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTE1NDQ4NzIxOTc2MjU_80a7dd85-60b2-41de-a53a-0d58d452881c"
      unitRef="rate">0.08</vtvt:CollaborativeArrangementRoyaltiesReceivablePercentage>
    <vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod
      contextRef="i391171de436948d1ab5c2af5c2a6b7c3_D20220531-20220531"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTE1NDQ4NzIxOTc2Mjg_10012510-1373-441c-b246-84f1a12fc04f">P10Y</vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i660eadb2cefb42f6af2828654b2ecaad_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjA0NzMxNDA2MjMxMw_d911f193-af39-4cb8-93d7-3a3c63dca3ce"
      unitRef="usd">5700000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:SharePrice
      contextRef="i660eadb2cefb42f6af2828654b2ecaad_I20220531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE1MTc4MA_330e50ab-8b18-4dfc-aeea-4f4978436b4b"
      unitRef="usdPerShare">0.55</us-gaap:SharePrice>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i48b185c6a31e4b0f875dbc148b1a9690_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE2MzYyOQ_a292d204-2a25-41d2-83f2-4f0866befb6f"
      unitRef="usd">18700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vtvt:CollaborativeArrangementNoteReceivableDiscountPaid
      contextRef="i7645c4e435b9406cb66205c7447a3bb4_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjA0NzMxNDA2NDM2OA_d1d0539c-c26a-4b50-be0a-f7396c8e0261"
      unitRef="usd">600000</vtvt:CollaborativeArrangementNoteReceivableDiscountPaid>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i6648a9f6a98d4bcf8673f2a87ee9a2cc_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE3MDYyNw_4c418cdc-5c56-4883-8fff-65230cc953bb"
      unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i48b185c6a31e4b0f875dbc148b1a9690_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE3MDY2Mg_245ceb7d-35a6-478a-9d5f-a2e990e45f93"
      unitRef="usd">18700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia159a094d3c149ae894a344e958ae6b8_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_1e98489b-f046-4c1f-8d2b-82eedf069169"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib691d10b9e9048d2ad20c45cc4d7b82a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_b8d975b4-39cc-47e3-afc1-c91870bebef0"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i06ef634eb2724783ab3b95d2e1eb87b0_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_c6f7fb3b-48cc-4e37-aa34-d8ccc717dd3f"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie3a4c00943074f559aa9f5295140d5d3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTE4_fea1962b-ce3b-4de3-92a6-4485d038f014"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="ia159a094d3c149ae894a344e958ae6b8_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_576c7914-b45f-4c4a-84f9-6913f360efa2"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="ib691d10b9e9048d2ad20c45cc4d7b82a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_8177b582-22f4-46a0-b099-62bf5a300577"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="i06ef634eb2724783ab3b95d2e1eb87b0_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_c57e6958-2f9b-4b6d-b6d5-b6acd9be8c2b"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="ie3a4c00943074f559aa9f5295140d5d3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTAzNA_ec7328bc-0adc-4bb6-b006-056169b8dbb7"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:MaximumSponsoringContributionAmount
      contextRef="ida207b1c94f040c49e5bac98b31bd511_I20210114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjI2OA_8fa06fd0-cac9-4ab2-9e07-f8aa81cae8e0"
      unitRef="usd">3000000</vtvt:MaximumSponsoringContributionAmount>
    <vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable
      contextRef="ida207b1c94f040c49e5bac98b31bd511_I20210114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjM5Mw_eca982da-c79a-4f5d-8aaf-261226ef75a1"
      unitRef="usd">3000000</vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9402a4a07ef14ae1bd27ed58ddf7c7a7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjg0OQ_ba9f00ef-bfe2-48dd-beeb-62d04157ada9"
      unitRef="usd">1000000</us-gaap:RevenueRemainingPerformanceObligation>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="i28ca3ec68a2f405c9d88aea860a19d43_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNDQ4Nw_ed0e1e63-84b6-4516-a181-a98a23e0b4f1"
      unitRef="usd">1000000</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="iedcd02d9e7ed46a9be450435bae20a14_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNDY3Ng_8737c1b8-d0a2-4fd3-8fa8-2ce0fc475020"
      unitRef="usd">2000000</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7a1d4d900a634784a41180096d9af11c_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_0303b78a-3589-44a1-949c-befe84b32428"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie807e06b03a449358e53f1fe6a28f0c2_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_3a97e4c9-751e-4e51-b3bb-5be6dbea4b81"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7e7dabf56fb04aae8e954ea2799cbebb_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_4ca37572-f673-4f79-87f0-be056509d468"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8ee005b698f440db91b1b86a6598a170_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNjk2Mw_f184302a-4c6f-4f66-bec8-52e9dbd0ab90"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i9644a2a90dd449c3a42d337db0986546_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_07267358-2a15-41f5-8c72-b18622be2307"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i61786a784a654e5eae26bb310979ad74_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_52297c3f-472a-48c3-809f-25071a93eb22"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i42c61470a62b4ea8ad0f4884c7064bd7_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_8759bc02-0143-4113-b32c-aedfec3fe10f"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i5c150d5a782c4fc0b12b5a8bf5b8dac1_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzA0OA_875e0fd9-102e-4a48-b835-bb382c866674"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <vtvt:LicenseFeeReceived
      contextRef="i717440fba9ae463ba4b738d6cc36588b_D20201211-20201211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzUyMw_62131d60-4df0-4643-b90c-62280247bbcd"
      unitRef="usd">2000000</vtvt:LicenseFeeReceived>
    <vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable
      contextRef="i4678547c424543bbb17a9eec17b01812_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfNzY1OA_a224014c-4a89-4939-8a1e-db55e016c192"
      unitRef="usd">151000000</vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <vtvt:CollaborativeArrangementTechnologyTransferServicesPeriod
      contextRef="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMjc0ODc3OTE3NTc4NA_6eed24db-9c02-4f5c-9b58-6b6956284edb">P30D</vtvt:CollaborativeArrangementTechnologyTransferServicesPeriod>
    <vtvt:LicenseFeeReceived
      contextRef="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfODk1Nw_1e4260a4-dd89-48da-8cd2-8ef2d6d96805"
      unitRef="usd">2000000</vtvt:LicenseFeeReceived>
    <us-gaap:ProceedsFromInterestAndDividendsReceived
      contextRef="i9124d2eeddc94ed8a9f8079a908f23d4_D20201211-20201211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTA1Nw_aa556f45-d540-4b8c-9876-2b0e07309a52"
      unitRef="usd">4200000</us-gaap:ProceedsFromInterestAndDividendsReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if487c4d0351a4b53ad7e192011f347f0_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_08704459-800f-43f2-8eab-3dd61479160f"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i4e359c73dd344730844f51f46e651559_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_38697c69-dd0e-4a7f-9ecd-ea37aa73245f"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id2afc370e61141bdbcb9d5cde256c0e5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_a7271ff8-4d54-4f8d-946f-a23e3ab7232d"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i194bd737c73c45978ed3a128fb4083aa_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTIzNw_ed875ea9-89d9-488c-8b0f-848ae33944c0"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="id2afc370e61141bdbcb9d5cde256c0e5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_17bd4f5a-9e1d-49cb-b47a-e145cc9e5b1c"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="i4e359c73dd344730844f51f46e651559_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_cdcaad95-7081-418d-8b21-cc2a1fed7bd4"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="if487c4d0351a4b53ad7e192011f347f0_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_e55c0b92-7e4a-4bc9-9248-28820ee76f5c"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations
      contextRef="i194bd737c73c45978ed3a128fb4083aa_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTMyMg_fa154518-12a9-4d97-a8f2-f054738122c6"
      unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones
      contextRef="i10084af716e84ec69a70340b4c5bd31b_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfOTk5MA_c087146b-fb9b-4973-ae75-70ce06255232"
      unitRef="usd">3400000</vtvt:MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones>
    <vtvt:FundingReceived
      contextRef="ic0bc234ab6f74714aa833022af967b77_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA3NTI_efeac1f7-3196-4317-b1c5-f3f26cb19c28"
      unitRef="usd">3400000</vtvt:FundingReceived>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic0bc234ab6f74714aa833022af967b77_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA4MTk_00d6eea7-f39c-4dae-a270-eeed8046ed37"
      unitRef="usd">3400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTA5OTQ_86dbab48-55d4-4e8c-835f-278511ff09b6">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities related to the Company&#x2019;s collaboration agreements consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMS0xLTEtMS0yOQ_3ae20da8-4a5b-4763-acdb-6c99b3deb516"
      unitRef="usd">26000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMS0zLTEtMS0yOQ_51b57d8b-1e86-4222-a7ca-515c5bd839d3"
      unitRef="usd">35000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0xLTEtMS05MTEw_d12af10b-0b81-4468-8739-bbe1541ff892"
      unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0zLTEtMS05MTEw_1e70ada4-413d-4d54-8233-07f6f8ed6f6c"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0xLTEtMS0yOQ_638c020e-e3ca-4001-86ce-2b4c9b7200c0"
      unitRef="usd">18695000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjFlNWZlMjAwYTNmYzQzN2JiYjY1ZjUzNWVmMTI4ZTFkL3RhYmxlcmFuZ2U6MWU1ZmUyMDBhM2ZjNDM3YmJiNjVmNTM1ZWYxMjhlMWRfMi0zLTEtMS0yOQ_8d7a440a-4312-46db-a244-15e92bee1993"
      unitRef="usd">35000</us-gaap:ContractWithCustomerLiability>
    <vtvt:ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RleHRyZWdpb246OGVmZTI5NmRlNDE0NDkzY2E3MjRlZDYzNjE3MjA5YzVfMTY0OTI2NzUzNTgzOA_92faeb85-e9db-471e-9aa1-170b58f1a6c3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in short-term and long-term contract liabilities for the six months ended June&#160;30, 2022, were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance on January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration received in advance and not recognized as revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance on June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</vtvt:ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfMS0xLTEtMS0xMDExNw_8df8d997-902f-4491-8ea3-fc89103577e1"
      unitRef="usd">35000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfMi0xLTEtMS0xMDExNw_a82a5178-a76d-420a-8566-1ad3a0e629d4"
      unitRef="usd">9000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfMy0xLTEtMS0xMDExNw_6b9b0146-88d9-48ed-88b2-14a1845ee155"
      unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF8zNC9mcmFnOjhlZmUyOTZkZTQxNDQ5M2NhNzI0ZWQ2MzYxNzIwOWM1L3RhYmxlOjZhM2E5MjQwZDJkZDRmNGU5MzBiYzA0ZjVjOWZjYzRlL3RhYmxlcmFuZ2U6NmEzYTkyNDBkMmRkNGY0ZTkzMGJjMDRmNWM5ZmNjNGVfNC0xLTEtMS0xMDExNw_5decdb9f-59a9-4aa3-a3d3-cb889c6ae24a"
      unitRef="usd">18695000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2MA_ea2ee993-ce28-4681-a859-21eb0f718e07">Share-Based Compensation&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of June&#160;30, 2022, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $1.7 million, which is expected to be recognized over a weighted average period of 2.3 years. The weighted average grant date fair value of options granted during the six months ended June&#160;30, 2022, and 2021 was $0.65 and $2.21 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at June&#160;30, 2022, was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the &#x201c;Board&#x201d;) of the Company of her decision to resign from her positions as Chief Executive Officer, President, and Board member, effective as of March&#160;29, 2022, and served in these roles through March&#160;29, 2022 (the &#x201c;Effective Date&#x201d;). Ms. Prasad agreed to serve as a Strategic Advisor to the Company for six months after the Effective Date. Ms. Prasad will retain 624,659 of the outstanding options previously granted to her, which will vest at the end of the 15-month period following the Effective Date. As a result of the separation agreement, these options were modified to accelerate vesting at the Effective Date. These options will remain exercisable for the original ten-year period and the remaining 1,873,976 of her options were cancelled. The additional stock compensation expense for the modification during the six months ended June&#160;30, 2022, was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,056,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,871,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,384,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,496,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,858,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2MQ_fc25cf67-a564-4192-bb7b-6d4438da5c07">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjcx_7fcda7fe-7327-4650-ad88-c8db65b8993f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i82d10b9f39fd4c93bfa1d918b158b70d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfNDMz_0d768c9c-7847-4586-a8c2-cc12b692d2b1"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfNTA2_ed2fd8be-ce5f-49d6-b03b-bbb749cc101c">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id22a6c39c9f349e9938a2aa8a3ad3fa7_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfNjA3_6267ead4-81ee-4c4c-b8d5-5554c6c8356a"
      unitRef="usdPerShare">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieb1b9c3a3531408ab3529984f8566bc3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjc0ODc3OTA3MTYyOA_3ab5e296-976e-4a8f-bdfb-4636a164ed24"
      unitRef="usdPerShare">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="id5fc8150340948bc898873b35fb8418e_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTE1NDQ4NzIwOTQ0MzI_bdd3f930-e627-42f8-94df-3a3f25f38222">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iba62023a07f44291bd3078c3cb8c0331_I20220329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTMwMQ_4c46aae2-4518-4b02-89eb-5573a4c88d77"
      unitRef="shares">624659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTM5Mg_abb96256-8a28-4b4c-af55-d0af77c9041c">P15M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTE1NDQ4NzIwOTQ0OTI_024be064-e0d2-4bb4-96e9-583a80d04830">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled
      contextRef="i5fa2ecc4f97640909602978844dfb020_D20220329-20220329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMTY0MQ_130bb42c-2809-4342-a854-9b33d77071b0"
      unitRef="shares">1873976</vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2Mg_9e4a5166-88a6-4ad3-900c-32b8ab550a98">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,056,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,871,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,384,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,496,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,858,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMS0xLTEtMS0yOQ_d30053fd-0b23-4410-a78e-f6d9baaec7ff"
      unitRef="shares">7056035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMS0zLTEtMS0yOQ_ee3eaacb-659d-4986-88ca-8f91aa748460"
      unitRef="usdPerShare">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMi0xLTEtMS0yOQ_681fba0e-9ebe-4a9e-b200-74cef6757c02"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMi0zLTEtMS0yOQ_1f241a13-1902-492e-9864-cf374c53ecda"
      unitRef="usdPerShare">0.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMy0xLTEtMS0yOQ_7f29b56c-7147-40fa-8f6d-eb8985e1d539"
      unitRef="shares">2871508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfMy0zLTEtMS0yOQ_2d770e5b-0e27-4761-89cb-91b7d2381831"
      unitRef="usdPerShare">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNC0xLTEtMS0yOQ_1161ef3d-26de-468b-8e42-69bd9cbc4286"
      unitRef="shares">5384527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNC0zLTEtMS0yOQ_dca40cc5-0945-4dda-a3d9-9bfe4e888738"
      unitRef="usdPerShare">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNS0xLTEtMS0yOQ_a40392f4-62ac-4351-b54e-afd03b3e7ab8"
      unitRef="shares">2496888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNS0zLTEtMS0yOQ_c9c97889-b50a-4b79-bfd3-ebec578462f0"
      unitRef="usdPerShare">5.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNi0xLTEtMS0yOQ_4ebe738d-d83b-4741-9ec3-7c0cf6073121">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNy0xLTEtMS0yOQ_2d2dbc2a-54ca-494d-8e9e-70b270c5ff8f"
      unitRef="shares">4858805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfNy0zLTEtMS0yOQ_f3f4590a-bdad-4607-b5f2-d32941889e9f"
      unitRef="usdPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOjlmMmUyOTQyNTBiYzQ2OWQ5MGExYTY3OGE3ODY4ODY2L3RhYmxlcmFuZ2U6OWYyZTI5NDI1MGJjNDY5ZDkwYTFhNjc4YTc4Njg4NjZfOC0xLTEtMS0yOQ_f00acf77-54e7-4212-bff7-b62dafa5a0ca">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RleHRyZWdpb246NTgxOGU0Mjg1NmQ0NDQ0N2FkMWM1MjI5NmMxZGEyMDNfMjA2Mw_f7e5a7a4-8fe6-44c8-9d3d-e2434016fdad">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f49c4740cff40429fb52e44fa210e13_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi0xLTEtMS0yOQ_ca456217-3d5a-43a1-99ef-a28dfb00cbbc"
      unitRef="usd">88000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7317531dde4b48dab33ee85599082a64_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi0zLTEtMS0yOQ_114961bc-ea7f-4bb3-a5cd-86830c177fc8"
      unitRef="usd">180000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id29697fdb6af49c7bc034a9837816d6d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi02LTEtMS0xNDk0_1a45cd54-8e54-406a-b5cb-a2a3498b11d9"
      unitRef="usd">180000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4dda6d8be2724280ae62e19e4a293904_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMi04LTEtMS0xNDk0_180bfeb1-2c27-4ae5-a458-cf704adf403c"
      unitRef="usd">356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i152676a2e89f49c1b9dc28a02261abd0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy0xLTEtMS0yOQ_76ca7448-c06a-40f5-b962-136e7de7bf0d"
      unitRef="usd">79000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3d1cd4fe75eb46dcab4af04b0635b52a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy0zLTEtMS0yOQ_101a85ba-6e41-4400-bbdb-46f993b7918f"
      unitRef="usd">272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i762b94f808004bfcb8c828bf3cf727d2_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy02LTEtMS0xNDk0_1be9dcde-ae53-4634-b228-e778cbc82a2e"
      unitRef="usd">463000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5da4992df5e044318a2a0905c425112f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfMy04LTEtMS0xNDk0_50aef29d-a323-4d2a-93b1-9c5d02661d58"
      unitRef="usd">532000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC0xLTEtMS0yOQ_2defc650-91a1-412c-8dc8-2c0cd7f356aa"
      unitRef="usd">167000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC0zLTEtMS0yOQ_a935a825-972b-4066-ae46-77e6570aeb39"
      unitRef="usd">452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC02LTEtMS0xNDk0_6d572657-1cde-45c0-b358-37cb758a923a"
      unitRef="usd">643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80MC9mcmFnOjU4MThlNDI4NTZkNDQ0NDdhZDFjNTIyOTZjMWRhMjAzL3RhYmxlOmIwYzQwMDVkYjFkNTRjZTE5MzVkNDBhOWFmNzUxNGYzL3RhYmxlcmFuZ2U6YjBjNDAwNWRiMWQ1NGNlMTkzNWQ0MGE5YWY3NTE0ZjNfNC04LTEtMS0xNDk0_5a4e5474-85e2-4b32-a17e-7c3ac98c7827"
      unitRef="usd">888000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTYwNA_6c237700-8fdb-41b6-a47e-13a76b1931e6">Investments&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Reneo and Anteris License Agreements, the Company has received equity ownership interests of less than 20% of the voting equity of the investee. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company&#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company&#x2019;s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo&#x2019;s initial public offering, the Company&#x2019;s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment with readily determinable fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reneo common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment without readily determinable fair values assessed under the measurement alternative:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anteris preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No adjustments have been made to the value of the Company&#x2019;s investment in Anteris since its initial measurement either due to impairment or based on observable price changes. The Company recognized an unrealized loss on its investment in Reneo of $0.2&#160;million and $3.4 million for the three and six months ended June&#160;30, 2022, respectively. During the three and six months ended June 30, 2021, the Company recognized an unrealized gain on its investment in Reneo of $2.9 million. These adjustments were recognized as a component of other income/(expense) in the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <vtvt:InvestmentOwnershipPercentage
      contextRef="idf108c845b044d5b9647b9f0d2f6517e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTUx_82820aba-e8dc-4103-ba40-55b3a657f5bf"
      unitRef="number">0.20</vtvt:InvestmentOwnershipPercentage>
    <vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTYwNQ_4775b673-f795-455c-9ad3-4d0dcaf945c0">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment with readily determinable fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reneo common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment without readily determinable fair values assessed under the measurement alternative:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anteris preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock>
    <vtvt:EquityInvestmentsWithReadilyDeterminableFairValue
      contextRef="i783e762f741545f3a0fe0c1d38e6b115_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfMi0xLTEtMS0yOQ_df3eab40-067e-4f16-a6a8-f0954025a655"
      unitRef="usd">1527000</vtvt:EquityInvestmentsWithReadilyDeterminableFairValue>
    <vtvt:EquityInvestmentsWithReadilyDeterminableFairValue
      contextRef="ida0147ce52f24edbb65de2e822c1593e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfMi0zLTEtMS0yOQ_633e3a1d-e4c7-442a-9adf-1ceaae6bee27"
      unitRef="usd">4928000</vtvt:EquityInvestmentsWithReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i264317da98da4654b1fb27e432d93843_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNS0xLTEtMS0yOQ_a9c74ced-ccd1-441c-b6f7-9f2999227ebe"
      unitRef="usd">4245000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ie3367eb43e184818b02b49d5ae5d81a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNS0zLTEtMS0yOQ_1c567d31-9ad9-4235-b46a-dfe08f52d774"
      unitRef="usd">4245000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNi0xLTEtMS0yOQ_ed120d67-6bde-4a49-af1f-f2c5279276b8"
      unitRef="usd">5772000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RhYmxlOjJkMzVmNjI4MjE2ZjRhNzc4Njk3NWNhMjk2YWMwMmZmL3RhYmxlcmFuZ2U6MmQzNWY2MjgyMTZmNGE3Nzg2OTc1Y2EyOTZhYzAyZmZfNi0zLTEtMS0yOQ_6dbc01ee-76bb-45a6-9228-8e8388058397"
      unitRef="usd">9173000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i77b143ad9f4d4ba1ace4e171385ea567_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMjc0ODc3OTA3MTE3NA_1b74c219-0509-4a1e-80b5-aff82a94db99"
      unitRef="usd">-200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="icd78af64b3f948b895cdd7ac3bc5ef42_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfMTQ0Mw_26333ae8-9ebb-4770-8699-f9d7eddaf85e"
      unitRef="usd">-3400000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="iffa40b257a304d62948a32a686a7716a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfNTQ5NzU1ODE0MDk3Nw_61b90f4e-b2d4-4d73-86e3-d1d00c6728db"
      unitRef="usd">2900000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ic27aa30a7f394af79e2bdf369843816f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80My9mcmFnOmZmMDBjOThkNGVlNjQ1ZjY4NjBmZjMzODM3Yjc4ODFhL3RleHRyZWdpb246ZmYwMGM5OGQ0ZWU2NDVmNjg2MGZmMzM4MzdiNzg4MWFfNTQ5NzU1ODE0MDk3Nw_750543cb-e901-4322-ad3d-9d8479e9e731"
      unitRef="usd">2900000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTkxMw_a23fb571-4e89-456b-bbd1-b09fcffd70dc">Commitments and Contingencies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novo Nordisk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#x201c;Novo License Agreement&#x201d;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#x2019;s GKA program, including rights to preclinical and clinical compounds such as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This agreement was amended in May 2019 to create &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under this agreement.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vtvt:PotentialMilestonePayment
      contextRef="if4ebac4e45e34b82929898cde894745e_I20070228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTMzMQ_65499c88-4f2b-4278-abb6-38244c58f9b4"
      unitRef="usd">9000000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment
      contextRef="i65905beb758b4791a02bb8d0cb2515a0_I20070228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTM5OA_c4d77bd6-d8a9-49b8-b482-e15f0b3579cb"
      unitRef="usd">50500000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment
      contextRef="i6ead0675511b48ebb66183281497ebc5_I20070228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTQ2OA_493daaaa-674f-4ebc-9c69-c36d69826001"
      unitRef="usd">115000000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment
      contextRef="i34ddaf589ad6495baf1c05cf44f3896e_I20070228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTU3Nw_11dcd99c-543a-47ab-8226-a4ee1907e706"
      unitRef="usd">75000000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment
      contextRef="i56c0384308fd425590c78419693d5fc6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80Ni9mcmFnOmYwNGRkMzJlMmI0NjQ3N2M4NGI1NmM2MjMyYWFkNjE3L3RleHRyZWdpb246ZjA0ZGQzMmUyYjQ2NDc3Yzg0YjU2YzYyMzJhYWQ2MTdfMTgwMw_83dd0c57-9e85-414e-97bb-43c7fd04e6c2"
      unitRef="usd">2000000</vtvt:PotentialMilestonePayment>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMTA3MA_c95a0151-116e-4e44-baa9-9fe86e83e329">Leases&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. The Company has notified the lessor that it intends to exercise the early termination option and is negotiating an amendment to the lease. Further, this lease does not include any material residual value guarantee or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each of June&#160;30, 2022, and December&#160;31, 2021, the weighted average incremental borrowing rate for the operating leases held by the Company was 13.1%. At June&#160;30, 2022, and December&#160;31, 2021, the weighted average remaining lease terms for the operating leases held by the Company were 2.6 years and 3.1 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for the Company&#x2019;s operating leases as of June&#160;30, 2022, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost and the related operating cash flows for the six months ended June&#160;30, 2022, and 2021 were immaterial amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMTU5NDI5MTg2MDQ1NjQ_2d30893c-1c5f-44c0-b912-62b0e042e944">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vtvt:LesseeOperatingLeaseTerminationPeriod
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMjc0ODc3OTA3MTE4Nw_20df43c3-f853-44a1-8a91-f2e1f7a78cf7">P3Y</vtvt:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfNzA5_937a4f9d-5ccf-4851-bd9b-99c36e18add6"
      unitRef="number">0.131</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfNzA5_c866f834-d87c-49fa-8b82-3cd403b9605d"
      unitRef="number">0.131</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfODIw_011ec20b-ae78-4c27-bbd6-cff00e6b7432">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfODI3_8bfbb476-a201-4db6-9987-06ab4493bdc6">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RleHRyZWdpb246Y2E0NWQzMWQyZDQwNGNkY2E3MWQ0ZTliZDUwMmNkOWNfMTA3MQ_e8642fd1-b60b-4bb5-ac88-aff584d5b710">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for the Company&#x2019;s operating leases as of June&#160;30, 2022, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMC0xLTEtMS0yOQ_780c3078-980b-47d0-bc6f-5f55bbb9693f"
      unitRef="usd">131000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMS0xLTEtMS0yOQ_0dae4cb8-ca95-4ec3-9268-b1466fda7530"
      unitRef="usd">268000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMi0xLTEtMS0yOQ_efad810b-75c8-4043-8137-f1cf1eb14414"
      unitRef="usd">275000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfMy0xLTEtMS0yOQ_9af844e6-d580-4f96-92d0-df0428e0797e"
      unitRef="usd">23000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNC0xLTEtMS0yOQ_f0586fa1-1b51-4964-9b47-2723e40b7e23"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNS0xLTEtMS0yOQ_a5337043-98e0-447c-9316-8379339a8cdd"
      unitRef="usd">0</vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNi0xLTEtMS0yOQ_f286574f-e898-4dd7-a22f-ba82b4e93451"
      unitRef="usd">697000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <vtvt:OperatingLeasesImputedInterest
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfNy0xLTEtMS0yOQ_0bc1c703-77ae-4bd0-a54c-15bb3dec5dab"
      unitRef="usd">110000</vtvt:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF80OS9mcmFnOmNhNDVkMzFkMmQ0MDRjZGNhNzFkNGU5YmQ1MDJjZDljL3RhYmxlOjEyOTUyZGIwOTQ3MDRiMmJiNzRmY2ZjY2QyN2ViNDNlL3RhYmxlcmFuZ2U6MTI5NTJkYjA5NDcwNGIyYmI3NGZjZmNjZDI3ZWI0M2VfOC0xLTEtMS0yOQ_dfde90cf-74c1-4f9c-9d09-30192fb75577"
      unitRef="usd">587000</us-gaap:OperatingLeaseLiability>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTY4Mg_08418acf-5ed0-4966-938a-49a7f30d9128">Redeemable Noncontrolling Interest&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 23.0% noncontrolling interest in vTv LLC outstanding as of June&#160;30, 2022 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#x2019;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At June&#160;30, 2022, and December&#160;31, 2021, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $15.9 million and $25.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company&#x2019;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to vTv Therapeutics Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <vtvt:PercentageOfNonVotingEconomicInterest
      contextRef="ia1710c628ed7445389ceee8a31cae7fa_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTQ1_df1d4013-30ae-492d-a036-2e17e14f7c3f"
      unitRef="number">0.230</vtvt:PercentageOfNonVotingEconomicInterest>
    <vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio
      contextRef="i910db6d0fa4e476cbe83b47a7fea5ee1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMzY1_643851ec-6d96-42b8-b28b-7a54609ab0b6"
      unitRef="number">1</vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio>
    <vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfNzE3_2919ad1c-ae40-40af-875b-50ed83bcfe3b">P20D</vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock>
    <vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
      contextRef="i778989260b33429389e1a9ca9b4b1a6d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTI4Ng_43140235-3545-4227-8f1b-37765bf707d3"
      unitRef="usd">15900000</vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue>
    <vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue
      contextRef="id3f1ff84e5e8468880c40caf7f418a85_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTI5Mw_ccae9e8d-dcf3-408c-8d91-2c71e0f12a4a"
      unitRef="usd">25000000</vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RleHRyZWdpb246MDk0NmE5MjM1NzYzNGUwOTlhM2FlNjM3ZjA5Njg2NmZfMTY4Mw_bec364ac-07f9-4aff-ae3d-6405fe68190a">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to vTv Therapeutics Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi0xLTEtMS0yOQ_0c8c4356-c233-4b58-9978-1990a8cc0498"
      unitRef="usd">-3151000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi0zLTEtMS0yOQ_0cfd515c-56da-401c-9e80-512d12d5e6e8"
      unitRef="usd">-608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi01LTEtMS0xNTI5_6c849923-6877-4537-b372-460021f21671"
      unitRef="usd">-10158000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMi03LTEtMS0xNTI5_5012e5d2-f653-4874-bf2b-8b6881149502"
      unitRef="usd">-4849000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy0xLTEtMS0yOQ_604fd259-6561-426a-9500-0feef4949842"
      unitRef="usd">-1361000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy0zLTEtMS0yOQ_35b4ddc2-a656-4049-87a5-3b9c6a3e829b"
      unitRef="usd">-115000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy01LTEtMS0xNTI5_f3225006-6e08-4b5a-9e1c-5e2e007f73aa"
      unitRef="usd">1071000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfMy03LTEtMS0xNTI5_fbc10911-2f21-40f4-9c33-253cf30765e1"
      unitRef="usd">-2525000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC0xLTEtMS0yOQ_deb3336c-3651-4c3f-b7b0-d7209c2fe0be"
      unitRef="usd">-4512000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC0zLTEtMS0yOQ_447012aa-0bdd-49ef-b2e8-ea0ee8b5ee1c"
      unitRef="usd">-723000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC01LTEtMS0xNTI5_d1ba36f4-1e4b-429b-b311-55c6d1bd9104"
      unitRef="usd">-9087000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81Mi9mcmFnOjA5NDZhOTIzNTc2MzRlMDk5YTNhZTYzN2YwOTY4NjZmL3RhYmxlOmMyM2RiNTA5NWI4MzRjZDY4Mjk3NTYwNjM1YzJlODE0L3RhYmxlcmFuZ2U6YzIzZGI1MDk1YjgzNGNkNjgyOTc1NjA2MzVjMmU4MTRfNC03LTEtMS0xNTI5_85747235-8697-4cff-a370-5e46741d162a"
      unitRef="usd">-7374000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjgzMw_5fbb7bb1-175b-410a-922c-34c00bf8928c">Stockholders&#x2019; Deficit&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment to Certificate of Incorporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#x201c;Charter Amendment&#x201d;) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Investments Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company entered into the Sales Agreement with Cantor Fitzgerald as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) under the Securities Act (the &#x201c;ATM Offering&#x201d;). The shares are offered and sold pursuant to the Company&#x2019;s shelf registration statement on Form S-3. In no event will we sell Class A common stock under this registration statement with a value exceeding more than one-third of the &#x201c;public float&#x201d; (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;14, 2021, and June&#160;25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company&#x2019;s Class A common stock, by an aggregate offering price of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.5 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $50.0 million, respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021, the Company sold 2,180,337 shares of its Class A common stock under the ATM Offering for net proceeds of $5.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022, the Company did not sell any shares under the ATM Offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lincoln Park Capital Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#x2019;s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to Lincoln Park. pursuant to the LPC Purchase Agreement. During the three and six months ended June&#160;30, 2021, the Company sold 441,726 and 3,941,726 shares under the LPC Purchase Agreement for total proceeds of $1.0 million and $9.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months June&#160;30, 2022, the Company did not sell any shares under the LPC Purchase Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i92612f3dee2a4b16a5b8ceea2175dc30_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjk5_546718a0-d36b-4f01-9f03-47d1436df478"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6511cf535eb14b879d2b9abaf9fd770f_I20210504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMzM2_afb022b2-1b87-45db-980f-379dcd8f4cab"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <vtvt:IncreaseInCommonStockSharesAuthorized
      contextRef="iedc1e3243a7443dfb3c90db73fedab5c_D20210504-20210504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMzk5_a3aa9c5c-966b-4bdb-9634-3f5fb0807f47"
      unitRef="shares">100000000</vtvt:IncreaseInCommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0f18b37002444e71902e4b504204e08e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNTgw_4a256817-3845-41b6-8d09-dd828bf227e1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3d7c397af1aa46eea7d046dd11d5461b_I20210504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNTg3_a35e2880-afc2-408a-bd90-e1541d144e01"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <vtvt:CommonStockAndPreferredStockSharesAuthorized
      contextRef="i5ac25b8b6e8545729210187897d7d519_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNzEz_bef62f11-86ae-4a61-9837-1cc5eb47e2e6"
      unitRef="shares">250000000</vtvt:CommonStockAndPreferredStockSharesAuthorized>
    <vtvt:CommonStockAndPreferredStockSharesAuthorized
      contextRef="iff3de8bb3d5c4970bc7c8e651b6af215_I20210504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNzI2_bd5ae52b-5e8a-4dac-9ae6-6206cdf501da"
      unitRef="shares">350000000</vtvt:CommonStockAndPreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzc3Mg_01b35e09-1b48-4efb-9b89-bfc7eecc80f0"
      unitRef="shares">10386274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzc4MA_3e778422-fb09-487c-86d1-bfb1b45d3815"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzc4OQ_a88d881e-78a2-47e9-86de-b93ea8decab3"
      unitRef="usdPerShare">2.41</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzgwNQ_b42893b7-032a-4813-a776-7e3b529b73f2"
      unitRef="usd">25000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzgyNA_e8244b92-8bf5-42e7-8682-0b9e29d3a2fa"
      unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i3c93b4c2e340487692d87888bde8fd1d_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3Mzg0Mw_b1acaa8a-a40f-41a3-a96a-3814d17d1059"
      unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <vtvt:SaleOfStockConsiderationReceivablesPaymentTerm
      contextRef="ife76f6506a0d4ddbb378e5df1200e26c_D20220531-20220531"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTE1NDQ4NzIwOTcxMTE_21ebf9b2-aae1-4ac4-8a0a-cdfaee605977">P1Y</vtvt:SaleOfStockConsiderationReceivablesPaymentTerm>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic54bdcd3ea0d44d0987f04e7b4c3ad6d_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfOTY1_cd769398-0093-444f-87a5-d4088ec7bfeb"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ida448d3c156e41c6907f442bbdbdcfd3_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTAyMw_d773193c-e4f9-4a42-934f-f08ae5197331"
      unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vtvt:PublicFloat
      contextRef="i94c6864ca64f40938eda9aad11bf61c1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTYxOQ_c24a9937-1c8c-412d-8ccc-82f5d9200101"
      unitRef="usd">75000000</vtvt:PublicFloat>
    <vtvt:AggregateOfferingPriceOfShares
      contextRef="i7b5db27bb04d4dd79864de1cb1a6f970_D20210114-20210114"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTk2Nw_8da99cca-9af4-4d6c-8415-b16e7a4ba707"
      unitRef="usd">5500000</vtvt:AggregateOfferingPriceOfShares>
    <vtvt:AggregateOfferingPriceOfShares
      contextRef="iebf065935ede4806964843da64a9618e_D20210625-20210625"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMTk3NA_7a1fe813-0106-4477-bcfa-eea73ed8b3cd"
      unitRef="usd">50000000</vtvt:AggregateOfferingPriceOfShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia312c12a8760465dbb649e1f030f2bd7_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYwNA_3696f786-1903-4a92-964b-a960d1e132ba"
      unitRef="shares">2180337</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5c543d697817434690f23877af7b8d92_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYwNA_ab208109-ac81-4d66-8060-faf01ccf5434"
      unitRef="shares">2180337</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5c543d697817434690f23877af7b8d92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYxOQ_ad5900f7-d893-419a-a182-6e0c5c12f1bb"
      unitRef="usd">5300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia312c12a8760465dbb649e1f030f2bd7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MjYxOQ_b28b98fa-ef16-4179-81dd-09b3d9f06d27"
      unitRef="usd">5300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7de9e3cb791344979fa4282d8da7fd57_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzcxNA_02e2deb1-b39a-40e7-92e5-de519b00f7a9"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i94c6864ca64f40938eda9aad11bf61c1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc0ODc3OTA3MzcxNA_0af78e4d-15cd-4ce0-aedc-7058abebc12d"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i320fb888e6cd44998dc594856dc9724d_D20201124-20201124"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjQwNQ_d2b2e356-5d12-4c30-a240-2658761add54"
      unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icb1be42149da4a86877d9aa6d3153d8f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNDk0NzgwMjMyNzg5OA_a4009195-70ee-41b3-9f69-3590bc85683b"
      unitRef="shares">441726</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i06b77eabd9884287918e1f07afb3fdc4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjY3MQ_64b49abd-a127-4378-a116-44aa3bd8d504"
      unitRef="shares">3941726</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icb1be42149da4a86877d9aa6d3153d8f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNDk0NzgwMjMyNzkwNg_43579ce6-d31c-4bf3-be3f-09bfbea70630"
      unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i06b77eabd9884287918e1f07afb3fdc4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfNDk0NzgwMjMyNzkxOQ_8ad075d1-2ce3-4e96-8c8b-dc30bbb20e9b"
      unitRef="usd">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie17c637109e34b5bac99defc70fe5b69_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc4Mg_436eddc0-b2da-4cc1-b33f-4df031f24b41"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibfa89db2b5b5402c94ff86a30340034c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81NS9mcmFnOmIyZjY5Y2NlMjY1YjQ5ZmY4YzE5YTZmZjMxZWQ4MmMzL3RleHRyZWdpb246YjJmNjljY2UyNjViNDlmZjhjMTlhNmZmMzFlZDgyYzNfMjc4Mg_6ee3526f-df84-494f-8039-c38909adedb5"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfNDI1NA_ef1039c9-24c5-4333-b7a8-8f25204d08f5">Related-Party Transactions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MacAndrews &amp;amp; Forbes Incorporated&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, subsidiaries and affiliates of MacAndrews &amp;amp; Forbes Incorporated (collectively &#x201c;MacAndrews&#x201d;) indirectly controlled 23,084,267 shares of the Company&#x2019;s Class B common stock and 36,519,212 shares of the Company&#x2019;s Class A common stock. As a result, MacAndrews&#x2019; holdings represent approximately 59.4% of the combined voting power of the Company&#x2019;s outstanding common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letter Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews has the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#x201c;Letter Agreement Warrants&#x201d;) to purchase additional shares of the Company&#x2019;s Class A common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#x2019;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exchange Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and MacAndrews are party to an exchange agreement (the &#x201c;Exchange Agreement&#x201d;) pursuant to which the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#x2019;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#x2019;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the &#x201c;Board of Directors&#x201d;). As of June&#160;30, 2022, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivable Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and MacAndrews are party to a tax receivable agreement (the &#x201c;Tax Receivable Agreement&#x201d;), which provides for the payment by the Company to M&amp;amp;F TTP Holdings Two LLC (&#x201c;M&amp;amp;F&#x201d;), as successor in interest to vTv Therapeutics Holdings, LLC (&#x201c;vTv Therapeutics Holdings&#x201d;), and M&amp;amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B commons stock, together with the corresponding number of vTv Units, for shares of the Company&#x2019;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investor Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to an investor rights agreement with M&amp;amp;F, as successor in interest to vTv Therapeutics Holdings (the &#x201c;Investor Rights Agreement&#x201d;). The Investor Rights Agreement provides M&amp;amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;amp;F with certain &lt;/span&gt;&lt;/div&gt;governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares
      contextRef="id69778fbafa14054a1949c92a76c3381_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMTk4_c08f53e7-d7ab-4f2e-b483-87f8b8a62922"
      unitRef="shares">23084267</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares
      contextRef="ib893ea7404d94823b4489736f31d8e0a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMjUw_9dce3554-c88e-41e3-8c92-2afe23975a07"
      unitRef="shares">36519212</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
    <vtvt:OwnershipPercentageOfMajorityOwner
      contextRef="i0ee68f1d1f0245e088ff9dcad3a1d1ce_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMzU3_f89bdb89-2431-4b16-952c-4fc4527df6d0"
      unitRef="number">0.594</vtvt:OwnershipPercentageOfMajorityOwner>
    <vtvt:PercentageOfAmountOfCashSavings
      contextRef="i0ee68f1d1f0245e088ff9dcad3a1d1ce_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF81OC9mcmFnOmQxNmYxMjA3YzQ0NjQxMTlhMjdkN2ZkZTc0MzQ1ZGVjL3RleHRyZWdpb246ZDE2ZjEyMDdjNDQ2NDExOWEyN2Q3ZmRlNzQzNDVkZWNfMjc5Mw_4e09bb76-7161-48bc-ba11-c658a922b55a"
      unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMTQzNA_bbda0de9-5f32-495b-9339-09b8c6f992e4">Income Taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three months ended June&#160;30, 2022. The Company&#x2019;s income tax provision for the six months ended June&#160;30, 2022, was $0.2 million related to foreign withholding taxes. The Company did not record an income tax provision for the three months ended June 30, 2021. The Company&#x2019;s income tax provision for the six months ended June&#160;30, 2021, was a de minimis amount related to foreign withholding taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#x2019;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of  21% on June&#160;30, 2022, is due to the valuation allowance against the Company&#x2019;s expected net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMjc0ODc3OTA3MTMwMw_6691ea61-e678-4aac-ad97-21380f748ea2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMTcw_95162708-9ab0-4c28-8310-b2e67db74f27"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMjc0ODc3OTA3MTMxMQ_73180f04-f74d-48d0-b09b-aff9948fc021"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMjc0ODc3OTA3MTMxMQ_e3773d8b-d84f-4b0f-ad56-42b533186bac"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <vtvt:PercentageOfAmountOfCashSavings
      contextRef="ifbeae5448a4743c4972130e10f6a61e0_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82MS9mcmFnOmYzMmE5ZWQ5M2Y2NjRlNTE4YzViNjM5NTNmYjYxOTk2L3RleHRyZWdpb246ZjMyYTllZDkzZjY2NGU1MThjNWI2Mzk1M2ZiNjE5OTZfMTAzMQ_f4bdaa1f-bb3b-4966-a290-063f0b0f2dad"
      unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RleHRyZWdpb246N2UyYmNmMzE3ZDdkNDUxZmEyY2UxYjg5MjNiM2M3MzZfODEx_dd1b8eab-4163-44b8-8b9a-8ee8c95075e1">Net Loss per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,366,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,615,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,664,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,549,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,384,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,492,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,582,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RleHRyZWdpb246N2UyYmNmMzE3ZDdkNDUxZmEyY2UxYjg5MjNiM2M3MzZfODEy_844f0bb7-cf5f-499b-9865-2c247f163b2a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,366,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,615,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,664,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,549,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy0xLTEtMS0yOQ_4c7cb393-4020-4286-b869-6696c6ab551a"
      unitRef="usd">-4091000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy0zLTEtMS0yOQ_a8674dda-797c-4a6d-8b37-15e8e7c1f5d8"
      unitRef="usd">-841000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy01LTEtMS0xNTcx_61541c3e-6156-41e4-8837-96dee2046065"
      unitRef="usd">-13515000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfMy03LTEtMS0xNTcx_16b72604-007c-4242-be24-01b79c910f9d"
      unitRef="usd">-6783000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC0xLTEtMS0yOQ_c54b9a0d-fa79-4775-aa66-e5731b0e8f7a"
      unitRef="usd">-940000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC0zLTEtMS0yOQ_bf551694-1dd5-48bf-9290-9d5dc598eaca"
      unitRef="usd">-233000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC01LTEtMS0xNTcx_d80d6c5e-e879-4077-a913-d1eacc4fdd64"
      unitRef="usd">-3357000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNC03LTEtMS0xNTcx_c0b8e79a-7e34-407f-ab9b-86b266224c3b"
      unitRef="usd">-1934000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0xLTEtMS0yOQ_145eb8c7-5ee2-4ffd-94d8-f00d12ed8436"
      unitRef="usd">-3151000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0xLTEtMS0yOQ_e17a3abf-d661-49c5-a27a-766f4fcdcbad"
      unitRef="usd">-3151000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0zLTEtMS0yOQ_9aee8ea7-4ed8-47df-8714-37578dcd02b7"
      unitRef="usd">-608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i21d658467661472da49eea25c17f94b0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS0zLTEtMS0yOQ_d89cf0ef-16c2-4dec-9286-7799d5009ce7"
      unitRef="usd">-608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS01LTEtMS0xNTcx_b6773204-aa0b-46e8-b1f3-8260ac8d596a"
      unitRef="usd">-10158000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS01LTEtMS0xNTcx_bbd2e53b-b6eb-4c97-8a67-805baa1aed17"
      unitRef="usd">-10158000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS03LTEtMS0xNTcx_40abe82b-6ba2-4367-ba4c-492eb0b27c3c"
      unitRef="usd">-4849000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNS03LTEtMS0xNTcx_e7c14d3b-60a1-4fff-9319-bba0c34868a8"
      unitRef="usd">-4849000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0xLTEtMS0yOQ_30234d18-cfb2-48a6-955b-467f28791c15"
      unitRef="shares">70366823</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0xLTEtMS0yOQ_8c8e42a8-4b3c-488b-9afe-f4193ddcbc89"
      unitRef="shares">70366823</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0zLTEtMS0yOQ_0615ed1c-3fba-46b0-a3f5-f74cfee63cb5"
      unitRef="shares">58615137</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy0zLTEtMS0yOQ_9f91b997-9509-4b90-a0dc-e575868501b7"
      unitRef="shares">58615137</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy01LTEtMS0xNTcx_49f5b28b-609d-4761-95fa-43285e37858b"
      unitRef="shares">68664259</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy01LTEtMS0xNTcx_717f52a0-361b-475e-b2bd-a81745ddafd7"
      unitRef="shares">68664259</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy03LTEtMS0xNTcx_89490be6-6911-4606-804c-3e5629a9b36d"
      unitRef="shares">57549755</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfNy03LTEtMS0xNTcx_c4688029-bb91-4fe8-a741-208950535f76"
      unitRef="shares">57549755</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0xLTEtMS0yOQ_1bac57eb-f92f-4ec9-a4d8-8efb5c1832b4"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0560613598ef4ba4babfd6aaf5e18bf6_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0xLTEtMS0yOQ_82ddba05-26f8-4efe-aa3b-33f391400816"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0zLTEtMS0yOQ_6b5ce98e-c5ff-44d7-a51e-f9e7b005a1d9"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic3fa0dd7b530448f80d752a38d31f437_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC0zLTEtMS0yOQ_c483145c-c96a-4a98-ae85-accde792cf8b"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC01LTEtMS0xNTcx_087aa3c2-cf35-482f-9a9a-154a4e2583e9"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i03053d8125794a48b38fb920a13e9e23_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC01LTEtMS0xNTcx_445452ce-158a-4c28-bdf4-a6c5e4154a45"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC03LTEtMS0xNTcx_8cacfa7b-1578-4ba5-b677-5d4e5048278d"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibadfc77157fa4014b3b53c6e7725b4c7_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjkyMGU1YzZmYzMxYzQwZGQ5ODZjMGQwYjI3MWNiNzhhL3RhYmxlcmFuZ2U6OTIwZTVjNmZjMzFjNDBkZDk4NmMwZDBiMjcxY2I3OGFfOC03LTEtMS0xNTcx_a7f14686-a853-4a89-bf47-464e11114a41"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RleHRyZWdpb246N2UyYmNmMzE3ZDdkNDUxZmEyY2UxYjg5MjNiM2M3MzZfODEz_3b267752-2e07-4d7c-afd6-9e3b9b6810f8">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,384,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,492,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,582,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia12e25238c51408a9b5aabb915d68f4f_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMS0xLTEtMS0yOQ_590abd08-8971-4f01-a9b5-3cbb6bbea118"
      unitRef="shares">23093860</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3883a4eeb01a4804bfe931960df3630c_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMS0zLTEtMS0yOQ_26751bab-bd72-404b-919d-06287b094ce3"
      unitRef="shares">23093860</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7aaf9605ec3d4df997dcb31cc1d69aae_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMi0xLTEtMS0yOQ_0638b3c0-67a9-4381-a68c-783d20acfffa"
      unitRef="shares">5384527</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0e056d11279c4dd88b534da383cad3ab_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMi0zLTEtMS0yOQ_24e89566-969d-421e-a5e0-eaff1d998204"
      unitRef="shares">4474403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icdd0c418f4a147dd908cb4bed116af1c_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMy0xLTEtMS0yOQ_8fd6681a-b184-43e3-8ef8-d566e216ae21"
      unitRef="shares">2014503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i323cbf05f2cd4b229244d58c16833346_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfMy0zLTEtMS0yOQ_7b5150fb-b631-4778-ac81-d7e845ff55c1"
      unitRef="shares">2014503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfNC0xLTEtMS0yOQ_24cfe10e-b622-4dcd-9c79-6c56c2d4db50"
      unitRef="shares">30492890</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5b1f8be2edb645ec93f45b9adafa26ca_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82NC9mcmFnOjdlMmJjZjMxN2Q3ZDQ1MWZhMmNlMWI4OTIzYjNjNzM2L3RhYmxlOjE0NDRjYzhiZmRiZTRhZGY5YTk4ZmQyZGE2Zjk4ZTQ4L3RhYmxlcmFuZ2U6MTQ0NGNjOGJmZGJlNGFkZjlhOThmZDJkYTZmOThlNDhfNC0zLTEtMS0yOQ_40219987-cca2-4f2e-8dce-63211de48654"
      unitRef="shares">29582766</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMjQyNg_1d0f15e9-3923-47c6-bff0-0ed8985c13d3">Fair Value of Financial Instruments&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable, and other accrued liabilities, approximate fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The Company determined that the promissory note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of June&#160;30, 2022, and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:93.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Changes in Level 3 instruments for the six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in&lt;br/&gt;fair value included in &lt;br/&gt;earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases /&lt;br/&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales /&lt;br/&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2021, Reneo completed its initial public offering.  As a result, the fair value of the Company&#x2019;s investment in Reneo&#x2019;s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.  As such, the Company&#x2019;s investment in Reneo is adjusted each reporting period to its fair value based on its most recent closing price, which is considered a Level 1 fair value measurement under the fair value hierarchy.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and six months ended June&#160;30, 2022. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#x2019;s current capitalization. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June&#160;30, 2022, and December&#160;31, 2021, were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.47% - 138.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.68% - 142.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% - 3.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% - 1.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.&lt;/span&gt;&lt;/div&gt;Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants. Increases (decreases) in the estimates of the Company&#x2019;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMjQyNw_352714f5-dae1-4eba-b4ea-df996d79c68a">The following table summarizes the conclusions reached regarding fair value measurements as of June&#160;30, 2022, and December&#160;31, 2021 (in thousands):&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:93.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i96d01a641a694957af47ad5592770a6c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi0xLTEtMS0yOQ_2c74d6fc-1b3b-4f8c-bb1f-efe0b2a31a04"
      unitRef="usd">1527000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if89aaa594ea04677ac3c150ebeb2e739_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi0zLTEtMS0yOQ_09b9888b-700a-45ba-8072-cd99eb35a6ee"
      unitRef="usd">1527000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi01LTEtMS0yOQ_434b563f-47fb-4e45-bf22-167349e36fd5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMi03LTEtMS0yOQ_b2195e45-1a08-4d45-97f4-1980954238c2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i96d01a641a694957af47ad5592770a6c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy0xLTEtMS0yOQ_de9bec50-848c-4317-9a8c-b8cf10e16f74"
      unitRef="usd">1527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if89aaa594ea04677ac3c150ebeb2e739_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy0zLTEtMS0yOQ_771d4a86-6eaa-4758-b34f-1f08271ec18a"
      unitRef="usd">1527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy01LTEtMS0yOQ_414d0a51-7c37-4914-aa04-376b627c36d5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfMy03LTEtMS0yOQ_49e36711-71c8-440a-b146-0e775e38a76f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6b89c4b600ca440bb9a9a90ea5e62a11_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi0xLTEtMS0yOQ_ef75206a-36ea-4fdc-a669-0b4d4b060162"
      unitRef="usd">717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1043be2df62a449880a9ce6cbfb89d1f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi0zLTEtMS05NjMw_0af432b6-b4ef-43b7-8d57-225164f276a6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9cadb9b02403417192c10ca22f8e9080_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi01LTEtMS05NjMw_b7d544c8-bcab-4236-b821-b73b0501908d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i91174829dd374e538fa07971c396f3f0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNi03LTEtMS0yOQ_e635f98f-8c73-4e7b-b7c3-e23c4a8e8c95"
      unitRef="usd">717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i96d01a641a694957af47ad5592770a6c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy0xLTEtMS0yOQ_c962ca4f-3bfa-4558-a69b-0aa21b0b7be8"
      unitRef="usd">717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if89aaa594ea04677ac3c150ebeb2e739_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy0zLTEtMS0yOQ_17b2cb88-3820-4f81-8e48-1c1936a80063"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1e75b1d6a416458d9e884a15e4c4bdda_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy01LTEtMS0yOQ_2209a872-25a7-455e-a444-07f4792c0168"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i94a3cf6daa1e4f78b4a65017d8ec258e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjBhNDdiYmQ2ZGEwMjQwYjJiNDczY2NhY2NiOTkxNzZmL3RhYmxlcmFuZ2U6MGE0N2JiZDZkYTAyNDBiMmI0NzNjY2FjY2I5OTE3NmZfNy03LTEtMS0yOQ_88132afa-9d96-4c00-af42-d539796f3650"
      unitRef="usd">717000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi0xLTEtMS0yOQ_eb9632fd-6c5a-4111-8f42-fc84417c13b0"
      unitRef="usd">4928000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi0zLTEtMS0yOQ_5d607819-ac9a-493a-aeb3-bf7b0e199420"
      unitRef="usd">4928000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i118c349b7b7547779cf5d02c7d07c16b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi01LTEtMS0yOQ_39ea4b1a-d34c-488e-a92d-ee4d1f2e0090"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie51365f9948548649ad42309ddd6a7b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMi03LTEtMS0yOQ_e23b64c9-3862-4da9-a0f6-7daaa9d0a48a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy0xLTEtMS0yOQ_866caa01-2b14-49a5-b6fb-d2c189ec3d03"
      unitRef="usd">4928000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy0zLTEtMS0yOQ_d71468c0-9819-432f-a2bd-dbc02d4ce0c5"
      unitRef="usd">4928000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i118c349b7b7547779cf5d02c7d07c16b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy01LTEtMS0yOQ_0e6a0330-48d2-4890-9f0c-2f5b47b3285d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie51365f9948548649ad42309ddd6a7b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfMy03LTEtMS0yOQ_73c85129-5749-4666-9caf-6857e6bff99e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi0xLTEtMS0yOQ_57e5f775-2374-405f-9529-e68e5566daa6"
      unitRef="usd">1262000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9e6746b22b7f41f39b2aa3e66ad235be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi0zLTEtMS0yOQ_c2d8f07d-5490-4eff-9196-28e29106897e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9c7f59ded7334cc8a27ff3af075f6369_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi01LTEtMS0yOQ_1fe0b6e9-a753-4908-aa45-f991c9ab7b01"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0d33804ed69446a581a68a89a6ced16b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNi03LTEtMS0yOQ_412fc931-171e-411d-80ad-871a4674f90f"
      unitRef="usd">1262000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i106ecb26f5be4bfcb80d6615c85bc7ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy0xLTEtMS0yOQ_d67bd445-94e5-41e8-89c9-5eb4656ce970"
      unitRef="usd">1262000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idd0bbdfd0fe2465aa756a6e2d67afa17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy0zLTEtMS0yOQ_426a3671-8bf4-42f1-b7fc-bee436ba7d31"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i118c349b7b7547779cf5d02c7d07c16b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy01LTEtMS0yOQ_437a0110-ff12-4666-a4c4-d579b01b6a39"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie51365f9948548649ad42309ddd6a7b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjMxYjU0OTExNWMyNDQ4ZGJhMzM5NGY4MjZlZWNiNTVjL3RhYmxlcmFuZ2U6MzFiNTQ5MTE1YzI0NDhkYmEzMzk0ZjgyNmVlY2I1NWNfNy03LTEtMS0yOQ_8c081918-bc9a-4c34-9b95-cc4ad9fe5d1e"
      unitRef="usd">1262000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMTY0OTI2NzQ0NzM5MA_2dce6462-1e68-4f39-9dd5-ce6561455976">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Changes in Level 3 instruments for the six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in&lt;br/&gt;fair value included in &lt;br/&gt;earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases /&lt;br/&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales /&lt;br/&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0291753a44b74ba594c6c841017b8991_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy0xLTEtMS0yOQ_b269bbfd-267e-416c-bea0-44a75501f4c5"
      unitRef="usd">1262000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy0zLTEtMS0yOQ_86dde42b-650e-4488-8bf1-a10f442354ec"
      unitRef="usd">-545000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy01LTEtMS0yOQ_a30d093f-e137-456c-a059-9ae79e780383"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i45e8ffad05714f66ba6337f6d589f874_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy03LTEtMS0yOQ_b2e462ff-da74-43be-9a76-f1a6ca77f075"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i39fd9325e67d49ba929177308a09de11_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfMy05LTEtMS0yOQ_75abb153-2ae9-46c1-83a0-c3b38f74b639"
      unitRef="usd">717000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6e4ad6c963f84d1983f4152763b6d5e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC0xLTEtMS0yOQ_7ef890ba-e286-47cd-b216-4eb9be532761"
      unitRef="usd">1262000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC0zLTEtMS0yOQ_6d9c5448-0eef-45d5-bca1-5c0e6468a262"
      unitRef="usd">-545000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC01LTEtMS0yOQ_a92a6b8a-37d3-457d-b9c1-ac320da63e26"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i7404ee74cae24cf29b7fb2c361bf22a1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC03LTEtMS0yOQ_4d985d69-4d8b-4ed1-98a2-ac099276623e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i82047fa01dff4061ac50b8ba5c19afee_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNC05LTEtMS0yOQ_222ee44b-5a22-4057-852d-2ec296ddf1d0"
      unitRef="usd">717000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8eefc32c333242c2ba2cc3475c9a1886_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy0xLTEtMS0yOQ_cca6f221-065e-40d8-a4cc-07ed7a12c964"
      unitRef="usd">2871000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy0zLTEtMS0yOQ_b851aa1b-4bb6-4dc3-8e0b-e9fb8aab2e6d"
      unitRef="usd">717000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy01LTEtMS0yOQ_ad7df988-5999-49b5-bb5b-cf15e5cbf097"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i9f098e29aecc4b8b87b9df6d6f7b7c9e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy03LTEtMS0yOQ_ff6b02fb-fb70-4170-acde-3b24501c5cf7"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1cffc7e1fd3a45358f79cce28478fcf9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfNy05LTEtMS0yOQ_67c10141-5b0f-4b83-b889-5945c4bf94f9"
      unitRef="usd">3588000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i549b94495164498ea6721b08e7ae6b51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC0xLTEtMS0yOQ_48cdd956-bd9f-4756-be82-717d832b4c7a"
      unitRef="usd">2871000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC0zLTEtMS0yOQ_500ca8de-66bc-4584-aa11-acf590a05a40"
      unitRef="usd">717000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC01LTEtMS0yOQ_f7eb53d7-ac92-44f2-8928-97b3b5929eee"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i704fe5d088a74bfeb7e206d976a2154f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC03LTEtMS0yOQ_e046a6a1-1fa9-4e67-877c-bb7b1c94f3c4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iaf1b6a13e34941f6b03007d4d7d9ce76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjU1MmUyYWVjMTVhMDQ4Y2Q4MDI4MGM5YTRmOGQxY2FiL3RhYmxlcmFuZ2U6NTUyZTJhZWMxNWEwNDhjZDgwMjgwYzlhNGY4ZDFjYWJfOC05LTEtMS0yOQ_f2ad4264-6b34-46ea-84e4-2627301ffc8d"
      unitRef="usd">3588000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RleHRyZWdpb246NWM1ZDljMGM0OTgwNDE2ZmFjYmJjYTU4ODYzNTU1MDBfMjQyNQ_df2ad41b-1a3f-4de6-a6d6-3b998c56f98b">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of June&#160;30, 2022, and December&#160;31, 2021, were:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.47% - 138.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.64%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.68% - 142.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% - 3.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% - 1.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i4459419f08db4ba1875ab5f3a7f77bd9_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi0xLTEtMS0yOS90ZXh0cmVnaW9uOmY2ZTM3MjFjZTBmODQzYjNiNjM3MGU2NjMxMjZkMDY2XzQ_af952735-7083-4625-a584-9d6967439a56"
      unitRef="number">0.8347</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i2c0bac167c154e428feb6ddfa2051544_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi0xLTEtMS0yOS90ZXh0cmVnaW9uOmY2ZTM3MjFjZTBmODQzYjNiNjM3MGU2NjMxMjZkMDY2Xzk_58bc928e-c1a1-4862-8f48-b554b645bf9e"
      unitRef="number">1.3802</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ie909d9404b144715bd0bec2b55db2950_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi0yLTEtMS0yOQ_a5582348-0757-4dac-910a-8df040ed6528"
      unitRef="number">1.1764</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia333a79c07f744389589fbe58f3bf987_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi00LTEtMS0yOS90ZXh0cmVnaW9uOmQyZWUwMTNiYmYwZTQ1YTc5NDc2ZDA5NjA1MDJjY2FlXzQ_ac471d3a-dcb9-4f3d-bcd5-458adf69678f"
      unitRef="number">0.8268</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i281f26cf97534b859fc01285494a83f3_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi00LTEtMS0yOS90ZXh0cmVnaW9uOmQyZWUwMTNiYmYwZTQ1YTc5NDc2ZDA5NjA1MDJjY2FlXzk_69e663c2-4b94-4e12-bbbb-864b67f300ad"
      unitRef="number">1.4286</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i534e6c90542a42f48822824cfd33db65_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMi01LTEtMS0yOQ_51d8e7e9-9502-4350-801c-5f816b7e9641"
      unitRef="number">1.2813</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="idc889929911946cc9f3bc54d6854ca47_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy0xLTEtMS0yOS90ZXh0cmVnaW9uOmEwNTliMDg2MGUyODRlOGVhODkyNDYwYWNjNDk5YzIwXzQ_998aef53-7e6d-4226-bf84-f93fd9e0f494"
      unitRef="number">0.0295</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i12ec27b58aee4985a776ed1774c95950_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy0xLTEtMS0yOS90ZXh0cmVnaW9uOmEwNTliMDg2MGUyODRlOGVhODkyNDYwYWNjNDk5YzIwXzk_ab91c126-f8ec-4962-9826-40d49d8e7f5b"
      unitRef="number">0.0300</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i106c03246dd94c1291ebcee81f596ece_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy0yLTEtMS0yOQ_9abf302a-c64a-40bc-9fdb-6009c1ca62b9"
      unitRef="number">0.0300</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ie552923b1f3f42379e848afe08b6c2e0_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy00LTEtMS0yOS90ZXh0cmVnaW9uOmJjNTc1ODQzMTVkNjQxN2E4YTJjMzMwY2M1YzQxY2NlXzQ_61976820-dc67-4596-a1f3-5295b3610310"
      unitRef="number">0.0095</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic0f477876785490a8f842fc97272c335_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy00LTEtMS0yOS90ZXh0cmVnaW9uOmJjNTc1ODQzMTVkNjQxN2E4YTJjMzMwY2M1YzQxY2NlXzk_52579d50-65ae-4aa3-89df-38fef0da2876"
      unitRef="number">0.0126</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i9e8bcca13e6e4588aa129bdeb6bb7ec4_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF82Ny9mcmFnOjVjNWQ5YzBjNDk4MDQxNmZhY2JiY2E1ODg2MzU1NTAwL3RhYmxlOjEyOTU1YmZhNjc0NjRmMTk4Y2ZmOWJkZmIyOGM3ODViL3RhYmxlcmFuZ2U6MTI5NTViZmE2NzQ2NGYxOThjZmY5YmRmYjI4Yzc4NWJfMy01LTEtMS0yOQ_c09c9205-e837-400a-ba18-e68ca232d2cc"
      unitRef="number">0.0115</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjY4_18c0d870-0447-457c-a494-355d5bda8274">Subsequent Events&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CinPax Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 25, 2022, the Company and CinPax, LLC (&#x201c;CinPax&#x201d;), a subsidiary of CinRx Pharma, LLC (&#x201c;CinRx&#x201d;) entered into a Common Stock and Warrant Purchase Agreement (the &#x201c;CinRx Purchase Agreement&#x201d;). Under the terms of the CinRx Purchase Agreement, CinPax acquired 4,154,549 shares of Class A common stock at an issue price of approximately $2.41 per share, for an aggregate purchase price of $10.0 million, consisting of  (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a promissory note of CinPax payable on November 22, 2022. The CinRx Purchase Agreement also provides CinRx a warrant to purchase up to 1,200,000 shares of Class A common stock at an initial exercise price of approximately $0.72 per share, that become exercisable upon agreed vesting triggers (including FDA Approval of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In addition to the investment, the CinRx Purchase Agreement sets forth the terms under which the Company will leverage the CinRx team&#x2019;s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leadership&lt;/span&gt;&lt;/div&gt;On July 25, 2022, the Company entered into an employment agreement with Paul Sekhri, who was appointed President and Chief Executive Officer and a member of the Board (the &#x201c;Sekhri Employment Agreement&#x201d;). In addition to outlining the terms of Mr. Sekhri&#x2019;s compensation, it also provides for the grant of stock options (the &#x201c;Options&#x201d;) to purchase 2,200,000 shares of Class A common stock at an exercise price of $0.79 per share pursuant to an inducement award agreement (the &#x201c;Inducement Award Agreement&#x201d;). Subject to potential acceleration upon the achievement of certain performance metrics as set forth in the Inducement Award Agreement, 25% of the Options will vest on the first anniversary of the grant date and the remaining 75% of the Options will vest quarterly over three years thereafter. Upon certain terminations of employment, a portion of the Options will vest on a pro rata basis based on the number of days employed during the four-year term.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjM5Mg_ba4a369f-7910-45e8-8a7f-5fa62880087f"
      unitRef="shares">4154549</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQxOQ_6bba18f4-85b7-4625-9053-43389c6d73d0"
      unitRef="usdPerShare">2.41</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQwOA_e01793d3-5286-4d6f-b375-3d1963bd5d32"
      unitRef="usd">10000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQzNQ_e63640c6-3ab0-4ea0-b679-a72b8a34e245"
      unitRef="usd">6000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ1Mw_fb5d6e48-f7ba-4e6c-a00b-278afcf28588"
      unitRef="usd">4000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ2Nw_b15918e2-3676-4266-87c8-52541caba7a3"
      unitRef="shares">1200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ3NQ_2e5502bf-bd64-43a6-9420-8db25ee5e7bc"
      unitRef="usdPerShare">0.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ4Ng_a5d89fca-9c99-436b-818a-f0d0f1c364a5"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="ic36d6026ee894b0496ae13eeb6079046_I20220725"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjQ5NA_513fcff2-6679-4e97-930d-14e084a5b1cc"
      unitRef="usdPerShare">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i0826cd3429194c58828df365b21d13d7_D20220725-20220725"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjUwMA_203908fd-1695-43e4-b17e-de06bd958bac"
      unitRef="rate">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i301fa4d644bd48b0a42d7d3c43ad4466_D20220725-20220725"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMjc0ODc3OTA4NjUwNg_c70ad24f-a251-4cc1-a670-c47e8b42fed7"
      unitRef="rate">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i85da403e027840539531cb19a0fdf5b8_D20220725-20220725"
      id="id3VybDovL2RvY3MudjEvZG9jOjcyMTNhNmNiNjhiYjQ4ZWQ4YzIxYWZlMDc4MmU1NmJkL3NlYzo3MjEzYTZjYjY4YmI0OGVkOGMyMWFmZTA3ODJlNTZiZF83MC9mcmFnOjE2ZGM5ZTFmOTk4OTQ3NDQ5MThiNDczNzc3ZjhkZmZhL3RleHRyZWdpb246MTZkYzllMWY5OTg5NDc0NDkxOGI0NzM3NzdmOGRmZmFfMTE1NDQ4NzIxMTE4Mzg_e11b060d-f849-4077-a678-9511df0b9cee">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:TI\RO4#ZOZ2,;D_T2\H=BI-_@502P,$%     @ ^I$/5:Y#9!PD!@  ^QP
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M]T:7_^J9D7U3Y8H;CL.)=L%U1Q@J;B@MA=(8E)9!:1Q*$U":/"DD5;PO7-K
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MHK9Z\M8(+W"7T:/X"%,-W)7"49CT+#-)2_SD9>*'I:5DP!^F%!LS+BIC#'G
MRL/N,Q@R,<M0R5.SZK#OS;.NH-= S_(XBI*N@:[4-.A;^I&V0R##"^FO0M/\
M_UIU@5;L@9>E"::A6$ASD7E-==?9.(R<=L@C-HU[$Z;M \AP'W F6YE9!PQ:
MZ?8$.$YFW:6\3RQ(PKXIV[8/9#Y(QLW>R$O<.]B%O)E[SZ3M=*^V[4#"U^X(
M2):QPE;K=E_@#3N7H;OBG\Z2[C+#(T5P'&-_[,*VA0B'6XC/MHS? *46W3WU
M&AYVMDPQ3N;=)L\CUJ7]R=$!1,'D@SV74<BN(:M-^^9I<_9S8T\\.L]O\>6R
M.L%IU50'2I^HA+*@4,[6H#)X'X._9'5&4]UHL;7''"NAM2CLY8;1C$DC ._7
M OQ1WY@/-"=EBW\!4$L#!!0    ( /J1#U5,N^SW-0P  -\?   8    >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&ULM5G;<ALW$OT5E))-V54T)9&69<>VJB39
M3IR2$I7E>!^V]@&< 4G$,\ $P)"6OWY/-RX<RJ22?<B++<X Z-OI[M.85VOK
M/ONE4D%\:1OC7Q\L0^A^/#STU5*UTH]MIPS>S*UK9<!/MSCTG5.RYDUM<S@Y
M.GIVV$IM#LY>\;,;=_;*]J'11MTXX?NVE>[N0C5V_?K@^" _^* 7RT /#L]>
M=7*A;E7XO;MQ^'583JEUJXS7U@BGYJ\/SH]_O'A*ZWG!)ZW6?O"W($MFUGZF
M'^_KUP='I)!J5!7H!(G_5NI2-0T=!#7^3&<>%)&T<?AW/OT=VPY;9M*K2]O\
M6]=A^?K@^8&HU5SV3?A@US^K9,\)G5?9QO._8AW7/CLY$%7O@VW39FC0:A/_
MEU^2'P8;GA_MV3!)&R:L=Q3$6KZ109Z]<G8M'*W&:?0'F\J[H9PV%)3;X/!6
M8U\X>Z-\Y73''K)S<=%[+/!^)"ZDUYX>W3CEE0DR.M'4XB>KS4)<6E,I9UX=
M!FA!9QU62>)%E#C9(_&9N+8F++UX:VI5;^\_A/;%A$DVX6+RX(&_]&8LID<C
M,3F:3!XX;UI<,N7SIGO..Z\JVYM 1M[81E=:>?&?\YD/#A#Z[RZ#XWE/=Y]'
M:?6C[V2E7A]TY$NW4@=G/WQW_.SHY0/:/BW:/GWH]'\D@/^L1+'G +'ZN!(?
ME\K)3O5!5UZ\-]58/ I+)7[X[OED<O3RTK:=-'<C_GG\4@Q>?5 +32$RH;Q-
M;]8J/[ N/^M]>O98K*47VE36==;)H&K\X',]]%>DWQO5R+5TBEZ<=TXW -KQ
MR9A4%4DA ;NEJ. I7<F&MBZ4Z)829:-B6_"P2DOG%FD-,3 ^H(PRSEH5Y(RP
M)FKM%8J,%\%2NNM6?U6DCG:BL6;Q)"C7\E%8S/[%RJ6S_6(IE*F?H#I+(SIG
M0ZQZ8\0"QNFN41P9A,!#3AU#L]OA;,O2-C5IEK0><1AU\#B;SX-!TGLTC6@Y
M,MK9IJ$=ZL]>!WC$0%7E WGM&SE75Y?B40H%O<3O'(\1.S_YE1X>G[X<2D4[
M<M%IOI]Y76NTDI%8+W6UW!F%F;9[ J', @M*O.'YRJZ4NV-3:[5"P^K0?@+Y
M#=!H&KRI*2:>+*N%;_%,M!8-IF^PW_5P%_:2=V, YQH+O%X8/8=DG-0;1!K1
MKED1HU3MMW&T!!AK14%&2M302P:1'!2M6TFGY:Q13XI_H2'Y.[OST_NW!=KH
MV6A[I9IU/3!.V"(#R]$[ 4 .@<^I3XN9,@KZDZ/)%5F=F:HD@$SY&?%'Z&BE
MD8N(Z':FW#<HH(U1NA)SE-.H!J>;,AKJ\@$JNWT_0!MO']X&28^A$GN4K;%K
MZ$.RHSV!(U1KAT01%$CLHW5,$W30,5_2205@IFKZFA(2?HRZMQ;6#6(,E&C$
MLBIQ*QA6R!+;(L>!8&93J(;C/28FK<%0+ I/5;(6F+A_+-P+!N(INKXGD,&L
M00N[#;!9NMH#8S7KR*G_T7;0Y/DQVF:IK8/2D"LFPD:>PKL:1 S2+X>JO-,&
M1FA ^9:*);D?>#YGSZ$KJ]*51XQ;VWNN*\IAQ=H(8\V3E64M,T[\ "@CF-;%
M3D)+I)A,QT?_VKAQ![9&0LWGBHD>XD OG:YX]TXW%Q^6H^"[TU.2LHG]M_%+
M'A]1!?J#X(-=0(:CPIVKR;P/O5-8LK1]4^^),D)6+6F3K&M-;J>BL'$*"E6+
M4/6&0C LE[_3DY+E0Y@B%9)$4J(X.Z[@;2@OE28(6Z&^0+I!C?0]L)W$!+M0
MA#SPT+#$86A\L7,TJ/?B(BL%8EI]CA7F_IKSK37B$994TB\?;R&4U'N;Y9\O
MG(K)^XCKWYR+'SSY*_J8>/'XH2Q!KUO!GAK%-H.1DMRR#;[OT-598*FB*3Y(
M0%)9Q\R)8=CR$]M/2PU*-J145*USE;C?G] 5 HGN^AEU<0L4.@IACMK[F]]*
MO* !$8@1RW9,6[B?I%I4]F+=M81FM/K%I@%+<A:]AU$SQ<WWR<PZQ_6M1YXZ
MUO 3W D$BBLK(P>[19MRU"D&WA[P)UY77FW8$7GA9^OT5RH:JEH:V]C%74I]
M<D3D39GIW6K8C[\_H:2J.U!"\WF#J=&0L%TITG7 P[C"$AM3)CH$66F3MY[M
M@\#66CJ]42%0H<^6I$!>R^K<U XS':N)B6X&S/Z$SM5ML9'K'V3;O7P7WVPX
MB42@&JYYG70A4@3RZQPM7B>>.!#!AV0A[X?D\EY^<4#S(3Z[9G-2UF!,?GBC
MJMA5X9#3$2HL:AS^?#[:>H.?0]C<JBZ4=PE&P^4OME$0O5=P,%#@O2EE:K0G
M&-R5OXG(92*'>/8V<L/?,L1OK\6M)&JZ&Y/WWFV#\A*5!*7EG0Y?%U $)2]Z
M_=*.2S2_65..&(HY_WA=5-JFH9L"7?1CV5<T,#1&W$CW&8IT.B#WWR'Y1EM@
M&B[;*?GJYE+<9!G?V#DJ5&FKH.Y3ZJ>G$X1AA386<7_^'HD;6?R'VTMQ%>JB
MV+VE.W6C-?MU0SZ*G1A8$^<U-E!M<C0+$!: A%2G!V4:@=FNTM1,4ID>0_4U
M*+C;!S46D\8.SJ)9GB(WU7] Y?Y/CKJIM@-BF6CQ3JHY%K^2MGC?\"B<R?$#
MRB_E"KT%4QXRW^D\3_FD.[AEI%Z[F1$/DL63X'4@=N D9.I@8JB8"42ZLG,.
M8VW0=2SHZ]=(LAKKP>&V!W9RQI5&+&O*WH^@S=!Y:U#C5DQ17X!<QTI'3Q'T
MND=/<W".Z14?E%?*:JGQN*9%H.,TU.3A#APSCD448&UZTN7^0-:[;R8N=FO"
MW)!2)4>9Q5B\<[9-;JU4O('(T+A'6.\;-Z?6&C&QT3+-2!J%.!]#_;B=06*^
MWL"2%76(KL$(&C,33U-&DT/ <5%[*$WBZ$R\URLNX:@>C9R5_EJJ\DCTW=S!
M.7Q JP&Z8*%^)^^B!$HE-&+B[%O;:C6+>]*47ESCA[6F0Q--VI.]("]\]]$O
M>F1)O/S82?*W?18[9%7U;1];9\UC)(?O^\G)=#PES9O,',C)&_00Z2(H*L:]
M EC$'7R255)?B#7Q /57FA2.UA0$>Z"GXI-YG*N9G[(2_ ?Y9H76DT+U_?'I
M^$56=4SP;^FVG! 863YC@S":L!=#4/I?6&I7BS][$ ?%!D#%Z2@)IVUY.RT&
M^U]P[I$VZ?ARHQ&H3K!.'S_>3%^@FZ\17JQ04+=/MR)4AX:@%W0K%D SE1\*
M36RSW-9L^D8&0@?R;9C51B1EK8!;P.-K 7@L6#GNR.:%DZV/0P5B^O/-S>GT
M5&S?<S!3H(A+VM!J[ZV[H[*@HL<GXY,"C@VGW=V2"/5</0K?B#)(.X=*S"/T
MM;P3TV.&QU0\\DKEV2+V"Y/8U$D&D#0&$W1%=0SJ'(V/BCH;5XG9G;C4YD9^
M26V_''O\]/&VO:U,-E-3B+R?OIBP2U=2(\E! 0/?KWP_/1UD1C2>L':?*.TA
M0<,A*U+J<$\/'C#8;*^:9B3F5!.#;J,#Z?_-1+<KCW9/>7_!IPJJLJ601>*Y
M1FQ*]8O1T^GI:'KZ[*^FR@TH=G,H_E03+UF7:N!MTW//Q[&#R2O*&G".>XKV
M?-F#HEPJ!U7P1/LT3:P=#3/4F6#-0 9=<5FWE7?Q9DU1T)F#@!KR?(D4HQW9
M32O;]"T_0?;6:1S\N]$8@_5G@',KF/>.D[16 7)C<_7<7J/G@4>IR;Q^YH.,
M25_;GGK%S/9AI^"!?U*;5H(3.M:O*G('S WS7*5ZD],T2AO$/3M3QO*S7BK#
MUZ.JYCN-ON,/>-2RXQ'*M7S_ GC/81%5R363'695<NO2U:B%I!NA?"]'=8%J
M=Z%/Q0U;.5L,W2STY98KRIDI19?M"C,A%0KO^S:'."=<X:E[_)-O%FF)0N,E
M(H/J@U N"A.D]CQ*.);-H/(FQLBIC(>>X)9>8:#D^.C80/D>@^X<21E4"$96
MILS9[+]]QP=L,(7+UZ&R_J//W8.BJ^8-7XMQ$_%>4\A2+XOW<WZ3F'SGGK'$
M+9@ O;FHY$S% %U'#S-#CHD/)_6I10^MC;>R]#&61A"#4==[NKH>W(OEX,R&
MF'P(Q+N^TQT./KJVRBWXT[(7?/$:O[^6I^7K]7G\:+M9'C]]8U['0 *&HN;8
M>C0^/3D0+GY.CC^"[?@3[LR&8%O^<ZDD*B MP/NY1:ZG'R2@?-,_^Q]02P,$
M%     @ ^I$/55)I:)!X#P  -RT  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6RM6MN2U#@2_15%;^PL1!35%QB&X!;1-##+[C)#T##SL+$/*EM5%K@L
M(]G=U'S]GLR49)>KBF9@7L!=UB65EY,G4WY\[?S'4!G3J<_KN@E/CJJN:Q\>
M'X>B,FL=YJXU#=XLG5_K#G_ZU7%HO=$E3UK7QV<G)_>/U]HV1T\?\V]O_-/'
MKN]JVY@W7H5^O=9^\\S4[OK)T>E1^N&M754=_7#\]'&K5^;2=._;-QY_'>=5
M2KLV3;"N4=XLGQR=GSY\=H_&\X#?K+D.HV=%)UDX]Y'^>%4^.3HA@4QMBHY6
MT/CORER8NJ:%(,:GN.91WI(FCI_3ZB_Y[#C+0@=SX>K?;=E53XX>'*G2+'5?
M=V_=]3]-/,^/M%[AZL#_JFL9>^_ND2KZT+EUG P)UK:1__7GJ(?1A <G!R:<
MQ0EG++=LQ%(^UYU^^MB[:^5I-%:C!SXJSX9PMB&C7'8>;RWF=4\OQ1C*+=6E
M735V:0O==.J\*%S?=+99J3>NMH4UX?%QA_UHUG$1UWXF:Y\=6/N^>NV:K@KJ
M15.:<GO^,>3,PIXE89^=?7'!?_7-7-T]F:FSD[.S+ZQW-Q_^+J]W]\!Z>TZI
M_GN^")V'L_QOWX%EO7O[UZ, >AA:79@G1XB08/R5.7KZP]].[Y\\^H*T][*T
M][ZT^G>:ZJ]:6[UO=%_:SI3J5=,9;]?JI6UT4UA=XQ>!"8JW=Y5!S!5NW>IF
M0RLL\[#0Z<X@LKN@*GUEU,*81D%CK?98UC8\SY<8;1 .7<5_1SE:;[%(6T.2
ME6F,UW6]H?>F[61NAWW?-RS@)>T3Z%#G:TA::'7KA[\].#L[>?3S^?D;?CQ]
M='N^*^J%@\<V 4O@*>#DI:;UGNF:9;IDN-2\,GS29)^<'9IY.9P8<WYM(3<I
M*2CHBR7N*F\@1%.J8#^KM<2-H;B9[D!C\'1Z\UZTU46EFQ5T ,6\-:4!HB]J
MHWYQ38$MO*MK.BX;TH2.U[[L7/&Q<G5I?" 5G?[T2#TW< C;?8>T_/!5RKG0
MH5(OD2P&Y7S])MZH/ODGVS6,?O@>#R0Q?$]>1YMYL^KK:$&(O.MREZ;HO>UL
M'/_B<\%VP+G7:QLXHR57O'QQD3R1#VQC5 W"VB&JYAR2OH35ZLV,-MZHTJG&
M=1A5U'T)J]1UDFDTD<58.M=A*(3RYE-OZ:B+C:)8X)TI &K3F;UZ2MK<J\-0
MN;[&8M 1B 'I#^[UH6\D\V8%?M$.)& W#421-OG!QF@?/>"Y*<QZ8;RZ>SJ+
MX4 >#18RH,"%K!.=.*CSINFQYUO3.H_@:!3E=75Z<N?? @&#H^S:X,L.XV3#
MH->&.((-! Y\&-GRT(%G2537VH94!<.M=0,V1$-FQ'J(OK!-=?D!=$"FWL)9
ML0L#(J8T9.4:H^%TGGX;C;VM&J@J!$+WSLG^:JFM!VSN4](@:NN"%=?9!W0<
M$": _/!;]U= &C\4%/_+;XI_,>..:WP=G,?X*54%+(19KG%L8" X(QS6N_7-
M'KSH.P0C_'4:CJ4-1>U"[RD9>?5=(3AZ@U-H/KN#:'XKVN...180N+(K7*"K
M#D2Q-S7K)8[Y%OMMXV\B",E/Z#7I)GFDA0_:ID1B)FI.;I1&DBYT@]TZJ(CC
M7@X?O750,P<C_4*:<TU*(J(1^LV;BDJ(*T)#_$U.2P"*0Q L03L6,PXXR$!L
MAA0UD[BE]0VD-+-!ED!H@'$X%=,_9& ]Z)?$VBO0GY=AKMX'5M<+0,":$PXI
M1^!('  O]]I8H)D<Q7:;OYA<18\.8UPA9UKKCT:9+"IYBPZH EO!BZ[24-1R
M24 GJ$+XC!WTFN3B+3#>Q!Q16[VP]9!;A^ 2#?-)6/<'YN2430I.SU],2?LD
M\N;*-'V4P7QNR70 C)[Q=YC$6H5Z7$FIN^L9IL7'"\Z9I<7)?4(8A.R@J;GZ
ME?(VLLO*T3J<669;VC57NNY9J^1">>8LPH_(0HM.8GOEB=Z7*1<H6H9U02:$
M8^AK[<NXU_8 O*"YC"1M[\%KL'JHM!=?8$^NH7IU3MX.U(!"02CW+<4'X;'/
M]HSM@UGV-4QW)2NWGG(,R48*AYBMY,C==1FU!5)&AC\D =8E2N:0'PDB"1\,
MIH,FS[(#[)%[DC9+LX L\ _*R 0.81NPJ',P,1*QA@I)W%'PU.Q#WAI*2(SI
M#3:$W_0A@ME.R("/+TQMS97 NI"OX!H1?9*?KRM;5 2KDL>$I!#*(CC)2S[T
MY2HZ_<+U$H@%3,TL+)]\?TC-";$*3!ZPYP*)#?*]M>'C",%L@]*ZEVWX""T4
MCGAEF,'YR5$GV%&,5^:3%+*TIZ4C#4JXQ>O0$*(0E 4-<QB!.22'+4X-,W2]
M<.IWK!$F PD<@I%5(CA"5X1ND(0E+0S#(8$.:0)8RL%J8L<&UD+T2PK @-.3
MD[\GOXFPH9#1B*F.\.);*D!LT1KN:]6;N51.7&?1PPN$" S'RAY[(NN,BCM.
MFY5=53A2;3&:C@1GBAQ3<@.LZ>T*:JOA*1W5-!LY"@D;A807(6,D)RR2%/Q@
M!BF(#PS+CY^M9'J&9V)>[*MC1P#((#A5K%EIPS#J4H#XP#]A/,">9&*):\LM
MC042&56O>!;5"67@2H4(2 FZA6S(83,.="(K!:$3MB'H#PD;=Y1TPTKB7^-9
MM/0:L<KN@S 8[4HXP<&OU:?>D??@$!\-NSB0 1 !@F4[*5$9XN1]4&N$.E*W
M%49)&FAZIL$P%TU!X6)J83T4X,D-<L@BQIJ@I6(K7* JXS]PUEJ=WIZKGU%8
MQ;AW@9",CI"9%(1)%)09S:V8#V_/0/6Z5!U]54-DSGZ[1\LD\TTF2YS;78.[
MA,JV0(E5E< FULG ^RL<?,N_V(PW>5?*!F';F'%9]JH;!)SD!/)J;D]+7HX>
M(4GBFY40R*'(?M0M1O*PV,MZ295V23$_4VW=<]3*B"*VB"1;<*>.R(A;4 .3
M5Q??*X96$IF="\C!9X9J#<I%,%-*8TVN;:W]Z"1JC@I<0/ M' B*SNW"I)@^
M1!*9T-*/!JX 5%RV83U(9T,E'G]^>:'>H8XNU/V3^[.\QTLZRP69%G(&]3M9
M^B*B=,A-&)J,:4-+\'>0=$(_O0+0L=A+9)> 2,+)I2@MP$>&6@/"-*60IM #
MOF#;0:(')P^H75?72*Y>F,DYT:A5#(&Q&!B;Q)A-G)2Z &T;"_>13F;)=\3,
M,?-H>37AR%E],&,\=2*%"$*N(.FM@V97,>E&WI]5$<B1A%8>FD+P( DDI\3!
M[%'R/\1N&KG%K>P?G ==DHFA/ .,)K:<M<?70;)4:KQLH8D;H0FYU5I_<$/B
MVN5N@Y?%XI-<AJ*PAML#QB2;;>T_T@4RA$-VZ6)%*94% :=K4]DGSA^50X6[
M[ZG6<F5?=!-,&/@&5<""27!<Y$1#92)C!GP &(9U1*XUZ(=X*,F]@#LJE($#
MY8T8F.BNO&(+2:12>H/3Z TO0J"R^Y;I8)*E8G.L85,IF/H%.7\QZ F0)N1P
M$TNR4::!62']@G!E3@TX,*&B&M9>&]-%1D04#&8#*=;;@9 %"S>X;6SHQ$)_
M? 848P?FD8 Z%@4<)",C4)P0XE'!IBFH("I^7CE7,M8!+PDH8S@-CC\V<$>&
MS!$P.)\ R[8R=$)!J=V^%&P!SX%L);N-D[F@]P!<>7D;<A*A4$S,@\9LU3K;
M!J3<GE+6(I5+0@),:G/G%F#4%O,<J1T&/<'SGP]Q,DM-=2K$F 5K:D,@>R!T
MP-U']CS0WCT<H7XX0Y:;BBM.;ENGBW=!7.;3\?>/.JR#72EW+9%">6&(+ WA
M("R%YN1#"^8OB"UV$BU%SF0,-I'T'0R"[<C-JMH5BKR^KEV1F@3LB <BI ^I
M9IF:8$&72*G 3>XCF;&FXP0C%TZR)[4;:)N#@;03M.]&O!XJJ3"\#U'@M.O!
M[:Q$4[8=D:0[3(6PWHHBG7 5 E&F"BC0"JEC1DZJ7E,JF?0:_7CP&/F%12=2
MFNLB;I;<D7"CE9!B8JJ6"=SK, 4D9Q(5NKYD+,^_=/#).EU$"33D=S!6OX2N
MN*X<K<@IIQR'6WY%6AM6#'U+1438B4=N35OV!9XZ4TM#WJMM&0MURIXZ]<V$
M%>6RCGT;8RCEJ<)XNJDYK#DN;62BVQ_L"U/I>@D9=)$:>U$JWOS*^(INHOBW
MB3UW340 $4L6YAHP64^8M8W<PD8"I6C?D[HR8HY:.M'E(\)E9)@ILT0H$;.G
M?4KZA?N@J:%X3?C>^]!3R=&Y:9RCE#.>>D$9O+/NG%]II))$>%Z)ON*5$,B$
MEU;Q@J(65?IV*IUL@SSIRTP1J,,G")!;45M>N1G;*5UDQ5[EA 'E1L^$]@P-
M&>$=N?DR@6]PC ]&,G!C5@XKY4M-AFC^B_G/.%D/B;2A.GH3&1[)VC>4=S/K
MX?NFN7HC?X8]V9)R)5F.[$T!YE ])*(OUY85M>)RIS^Z..TRZB3'^YU8<G.#
M>'2'/-'NJ'RBR+$C2NM8'?'29%]\1"?%%B"Q&\8^:L1WL;$BOARO#W/W.MY$
M[.V%1U*CI8>]X^#2E9WX.%B6*&F6]AB"9]20GD)=;BZD(F',3*8'G6:;TI#G
MI,N60=<,_5=L'9^L0LTSZ>Y$[XT_%!-+[,>!QC7>+.$IG+QU><78V"870H:G
MBP]A\LN^Z_E0-P.>#G*18X=K!3CFY)>IBG3(&L[LZ,]]B**WKVVB7;<)*.7G
M"8.[ 5GE;H=EM>L%85$98TM+_J5DR#?60SD<QR]C9X0*'OQ)H!%->5"+404D
M52&MVE<A]%AC_!V3=PV>BZB$E]0X^8W9[NNAA@X/"4>Y[3K<=@]][-%REZGL
M5\\<_E.W7IY?/KN->)ON.PQ\W_*]RZWSR_>WU2]NSEO<.;FK8A/@@$CJ5NPE
MG)W<?GA ;KX3E-;1Z N4RP$\4R.$8O@2!)OL!SHA'9QY[#O$+STT5BQEZP(8
M9)>;:,Z,B?$V*RTP? 91RVU!D_I80839I/[LB(U3LDGQR9U-FBAJRV$[661Z
M ;N[*&) .B+<S=KJQ&+PT ()!%D12"E,VQXLM\BY<J O',,V$"+09?36!5OZ
M6$2N^<)0;CK^7&8\:6' ,QOV]R4F#9\JG/[(S?V[<_5"4V--EZ[-Y3)5:%TW
MI2/<":!>+,44?"F[$2/QL(J1S),//;IR@$:!$NI3#QM(HYC6B#50DJ $[ PW
M[9DM<F.QZ":P_(\_=X^][ZO(X]''K" ]*_YDEV]+FTZ^:\V_YJ^"S^5CV&&X
M?%+\FGE]4+598NK)_*<?CZ0;DO[H7,N?QBY<AU*='XDV&D\#\)X^F$I_T ;Y
M6^FG_P=02P,$%     @ ^I$/5<)!\V@6&0  L5<  !@   !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6S57.MSV[:6_U<P;K:3S,B*)#NO)LV,X[0WZ6UNO7&Z
M.[,[^P$B(0D-2? 2I!7UK[_G 8#@2[;3]L[LAZ8V30 'YWU^!^"KO:D^VYU2
MM?B29X7]_F17U^5WCQ_;9*=R:>>F5 7\96.J7-;P:[5];,M*R90&Y=GCU6+Q
M]'$N=7'R^A4]NZI>OS)-G>E"757"-GDNJ\,;E9G]]R?+$__@H][N:GSP^/6K
M4F[5M:I_+:\J^.UQF"75N2JL-H6HU.;[DXOE=V_.\7UZX;^TVMOH9X$[61OS
M&7]YGWY_LD""5*:2&F>0\+\;=:FR#"<",O[IYCP)2^+ ^&<_^X^T=]C+6EIU
M:;+_UFF]^_[D^8E(U48V6?W1[-\IMY\G.%]B,DO_BKU[=W$BDL;6)G>#@8)<
M%_Q_^<7QX2X#5F[ BNCFA8C*M[*6KU]59B\J?!MFPQ]HJS0:B-,%"N6ZKN"O
M&L;5KV$WF5R;2A*/+K:54L#RVKYZ7,/L^,[CQ,WTAF=:3<ST5'PP1;VSXH<B
M56EW_&.@*I"V\J2]61V=\*>FF(NSQ4RL%JO5D?G.PE;/:+ZSB?E^J;:RT+_3
M3F?BTA369#KEC<LB%5>5LK!U?F VXD==R"+1,A/7\)#9(O[W8FWK"G3I_\8X
MQ 2<CQ. ]O6=+66BOC\I<:WJ1IV\_O:;Y=/%RR/;.P_;.S\V^[TD>72F<3JG
MIA=_.U^)JZ9*=F ;[7/BZ*79%E)$(V\4/?]9)V#6\=N?=@K>RTM9'.@-G/1]
M<:-LS8M<O!?O3);J8BL^7E^*G^MT)J0H*WT#DA&9SG6M4I&X&1Y^^\WSU6KQ
MLC<+/5V^?#03\)NJ8( N:B.0PCR'35W7)OD\MI>'-9 7S3E\I9VZ;"K;2!@$
M,^]W.MF).MH;J%R*?^GO;[F8G3U_.EL].Q=V)X'IJ(#10)Q_^>RE%9>9M, .
MW"J2;)%D6%16XD9FC1(/%O/%4I2JXGD&I,=;?21DS5Q,5#0$5I9E69DO&IR>
MR@[BP6I^OIP)B  @&R&WL.DMLKWT;. 98-R#U9/Y MQ4EI&-\?[WT@*!.A4/
M]2/Q8+F:/_%O /]%(NT.Z4 ZD\Q8%#%JP$,]]C:^A9&(B(1U3:ZM-=5!%*8F
M"OJ,!5ZO%2_O%C&%.CTHB7LI0"$K"['(<UM]44GC[1\?C$M[+BYP2U5]_+79
M@)JRJ9'\O:R ')'J"F(3<M4BQPUHHV(#&9/\VN H6- /LRRF&]!C-QIYAT,+
M"(9A<N# Y'3S 84[I 4W0&J:J*J6R/9*%G8#&@*:68.PD4461%0D64-&V7F.
M>KDSP!TK,]1D4"PPT Q83O-(?NT1[;0_<--40"VP)/EGHZUVSS?.*F:H TJ"
M4B7(:=NL?X--(J6V5(G>:"!;?4E42>/FXD=P/6;OV:*^E+H*[EV*#,V]*5'U
MM0&'L@%UHA?Y@?@@#^)LR?%'-,#>3+Q5B<K70)][?BX>PO;T!HBJ,JVJ&8U/
M)2LC2$#IDK3DU_DUD@.SXJ[?5LU67*00SS5&$R+).ZT?WUYX;^($#!'(J3[-
M@G;XZ=/5V8L7'>N&<>+"O1\F@)7=JX]F'4>$<MZ"-&HUZH^\X"&QR#9$<JFW
MV\-: L? ^ENJ*\QZ+"0M]0YE63IQU#N#\@FN;,QM"3#=9GSYV(D>LZ]6 ?$M
MN=:9K@^DN*9(FP2C$ @N5=6^TG6M4.Z@Q?2^07(A&00E G5RE-*[8?.)KI(F
MMS5D 0J4"6/4V-Z9".6R-?0FB8&DN7*)!CB44^3;#/6/PEZE=+Z&';I-('<U
M+)P7H, )3XUBU):5&#(5R#Y*"*"%,HT%ATS</L87!=ND=!=-*E;CKA+TPF#2
M"?%(5N8"M1P-A1S>!S&0R>,_?E+)KC"9V1[$M<D:-N>??[Z<4239;$!@<MQQ
M/XP7"5.W3V-2K\ 5%ZIJ@S 'GDJ!#T&Q,BT8D*%":+GGV0"B!G%A6$'-N")F
MGD$P NM,P/; /\G,DMF-.5)G7YA[F 8#5\0AE^A@;FE0'UO#!I-!Y8/__X:>
M&X2:0$U%'ER*;6;6L'"J;J!H*HGO908,@QVX9S.H :K/RFD/6I6J,%75ORM/
M$"JP5V0@#':AK/<C'W2:9DK\("W,<+$!!RQYIDM8JX*E+ZR6G9TX%H- *S E
MB+A^*W/Q*QD-O@O:E$>92T<[9N[!'H*Y,&NBRQG01(3RRM?Z,,Y!P#F4X%UH
MH3O(S6UYL(&96$,T)G(@>0"'B,EI I8>"+J1$ 8:G '2("PC&Y@5+!,6K=LD
M\_U5D&JE,ND<*HX/U@.,=3N8BVL.5$!@=NA:(Y'"*9A?&18#3PDE7FQ3T2K.
MS7D'V-\Z+DRSDCL!%T7!#;0,-2HU%JIN?@FT*U%K$[&Z@ R@LP8+F.:%32C(
M?B@Y'-F"'Z!!M,>,J=73$-HDCS)[U%F+:\(3ESQDAU98Z\B)IMXS6RC$22DH
M0<#TK-6E*3IH1I@-+&@-55 JUH?.AC"S4.JSP.!Z6S".+6%"^3'JXI])\2-S
M'K%B?*WO/B9U>< X R%KD%OAT(8-"G]\?\5*OU80&#.]J0?;G[NZK+,7H!GM
MG+C%?M;E7LG0SPP))8GRC#G$)0KTJN/I^JQHHY'38MM3.>?-H^@?* 0"86^\
M7 (.=*T*M=&US_2T12;4N\HT6YZD-'NH".+,J*<-+N6FQQ-N&O(\3F*[MH';
MM4U99B0ME-(,4^.6%[DLF@TDQTVE9EZG4+U:9E!"[9(4]K5<WKB$O2F!44Z"
MJ/XH"*KPT%]4E)6R1*=*]LR:ELFP-/K;.(&.\MF.03B%ZJOK+)1<I4^Z>U$>
M,A5-Z?Y#^8C>Q)00TZW[E+^=./5!0\E10XTGKBFE"[X95)U+RZB Y9(9L@1T
M"$8\.%NTU2O*YN'ZD6/F@1C4<PY8\':&^')VG*!+_-,53]5&ST\CN^YO0KC4
MP],Q>"V>>N;*28@^<IV!*F% 09],Q917DTB4.%5</)"M1:65SR((99'L3=A(
MW9P6?"35M6")SO"GZF;8+5)#I@B>'$BU345;)\<P(,7[9V^07"P[LZQU[C2S
M4F8S%[_@/$/74<O/P$(*<5-^26-I.0ADQ".P]<H<9$;6!-QZ_A_L/=ANG5<E
MNYRP DX<P0TAZ "<V]0N1FQT9>N!=4_,,O?(C2^=Q!9\6859!-)I*HS6P,&-
MU!X*<OSTQ:A7LCD88/"0WK*C8=[R[E6Q=;D'FF'!AV!I$<,Z 2:BA_&\CHUM
MV=+Z*C]GJE,*_3E(DZPX_:WAQ;TZ1'M EA,WQT*@VPIV!)!OI'T41;:-YM]0
M\)23RQ1<%Q5(XN+Z5ZJ@3A=GF/]P!' V_M&__Y[Y<Y%0),0]_\W-Z0R>%5 C
MX'?ZGT0F2$+J+&3-L,R<QE=8UO;SJRCTDKV0M_'<#LC&@R?S9\$GV9UILI0S
M)J\F]J[R=BK4E<M,0!T'UN5U9W3D0.8/%O,G3\8GA W#>RK73=Z"A4Y8HY.#
M'^Z7B[C"\GF[[QEDL#7#/ 0-LBVC0P1-LB0>1]53/P3U3=M "?P8LYL"+>?
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M,#&/N CYI<I:4VR[QZ,(8V!(U(D'EK!=-44L[MP?F[D3ZZ?5>'3?>PH;/KB
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M"2;>8$=3@CC&/KCY./J,*OC5+7TLUG)MR%]4#4^%_Q[M!7^&M7V=/V;[05;
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M6;L)&"^4LGW'.=@^HJ__!5!+ P04    " #ZD0]5=4U%<P,%  #K#   &0
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M-KS,"9G5H'.D\+30T4RI88:1W+ 'XKJ!V->&]S=4;+GV()'/YP$)C[+P"E;
M9N _GY ^YXEO\K+/*)W?P. 0;YTEF9>BAF&V2(6W1<G6,12510+_DQ)0QIA:
MP]:B2 SN9VU]F[O[/=M4\F[5/"_(ZG^/\5,6MP'P8=,+%E9C5$ 43P7N ^KN
M S3PG*HYTF4RCCOC32??<C_R^X2CI_<U6:$7XH[-;\2!&/</LR,\I_V3[/@1
M:(PU3Z$C=-Z#,=#S9'*?=K'"U8'49=:3.=-^-CUL?[_8@!0_$(?]HZ,,SY/^
M^&@B?K%M'!*),<9S(H/IH"#.PMAL8V!;8I^7-5YQ]]KN4MO&D^+N+(HFJKA/
M"F'3=%0(^VT.;/)C)Q5V\MV *_"JXXKSG&&2#=_6+-PY& TRC$-:Q\D.>7LP
M&4R[#4Y+=CB4N,+B9Z]N195F%>)993>S^K#%UQ0'1'TW$&^;V(W_ \1X][YZ
MU+6EY!+9[UHV.-EX$@G#S;8=Z#4ZU?Y>86.($$9;T?![NJWY/O]AS^55\(%B
M]QJ[#G@DC8#\%>U+\N3@!P\--<.M ;0BMXQC-A=V8T*:1;O=;I*_2 /L_?'T
M-^"3=$ME< '3 J*CP=%A3[@T6J=%L'4<9^<V8#B.KR4JDAP?P/>%M6&S8 7=
M_YO9OU!+ P04    " #ZD0]5QS)J_W<%  ![#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6RE5]MRVS80_94=Q9-I9Q1=:#N.X\N,[#1IVKCCR:5]
MZ/0!(E<B:A!@ %"*^O4]"U*T-'4\;?-BD<#B[.[9LTOX?.W\72B9(WVIC T7
M@S+&^N5X'/*2*Q5&KF:+G87SE8IX]<MQJ#VK(AVJS#B;3)Z/*Z7MX/(\K=WZ
MRW/71*,MWWH*354IO[EBX]87@^E@N_!>+\LH"^/+\UHM^0/'3_6MQ]NX1RET
MQ39H9\GSXF(PF[Z\.A+[9/"KYG78>2;)9.[<G;R\+2X&$PF(#>=1$!1^5GS-
MQ@@0POC<80YZEW)P]WF+_CKECESF*O"U,[_I(I87@Q<#*GBA&A/?N_6/W.5S
M+'BY,R']I75K>YP-*&]"=%5W&!%4VK:_ZDO'P\Z!%Y.O',BZ UF*NW64HGRE
MHKH\]VY-7JR!)@\IU70:P6DK1?D0/78USL7+:U=5.H+E&$C9@JZ=C=HNV>::
MP_DXPH48CO,.[JJ%R[X"]YQN % &^L$67.R?'R.T/KYL&]]5]BC@3XT=T>%D
M2-DDRQ[!.^SS/4QXA_\G7WJE0VY<:#S3[[-YB!ZB^>,A%EHG1P\[D49Z&6J5
M\\4 G1+8KWAP^?3)]/GD[)$4COH4CAY#_^\E^P8X>L=+9>A&Q<@^T&OO*HIH
M2HHN_0XIEHPC5:WLAG0@;5?.K+C  ZV4UZX)9!)&[5W.7  :?KP.>! C.6^E
MOPSEKO&!R2UHWF";0QC1VP4I"C7G>J%S6'2Q13):S;71,7DM&.&A.^ 7@<U9
MG,W5W'#**%=6UC"S@K-8W1 '!*\B%_OQJSSW#;<T%*T4\"86JG*-C2/ZN)^M
M=1%-ZCT" JJB6GD$A!!D7QQXC;S^D?^(?G$KAS\>7N[HK:77//<-AB)D/CG9
M#PK8[!.A"9=F2\\LY9)*Y>RM$/G&-+F[TQ;SB68RZ%1TGFZ]^Q/3#R,EEOLN
M9^,/])UX>?KD199-SM+F.YUCVO*]A[0Y/?N>UB5"F&_VXG+SJ!+CB(F_Y 8E
M6T$/&,*FP S#8VCF)D&F2I@.O<%D\(3 Y?A^5$@1XQD1-RU?-0N=7@9K$%:E
M)F[%?HB"K_ ]J8<@V38+="E:=DBE6O'N"LK;A$X#4#G['.70?R5Y%$T.4'S5
M4E)HTQ42QG<"Y$,HJ1^&26_>&;C142]5^H[@1*T,Y->^+:ALX%*6E=4B8T0)
MI4$X6 ) H<40-9^%I \Y$DN(9TO(TBOQ]2"W6YIZ5G?8V*5.*C4].0OTYN>9
M9 ?,:@@^4191W,XI9)IC!.@<D29BMB]@J(;(BX"ZY26I0!\_WAZ>GI*H'N&J
M7G=K["D\%6V;WRB1[?14T'/A#C70!BWF+(A5FVZTU#423DH0NRZOOK,E%.OL
ML_L%:=>6*_:JYB9B$=4<T:<D(*%+FGYKTT?TL)3W^2T!7;LH%9>"M6(2LXX4
MS\O&2 MM'DHE.M@)JTTMN1R<CB9B9D0/(BBDZMT*4$Z&5Z>U7FJ]O%+@FYII
M"LFH.498&-+!\61T_$UHV0X:C ZFT^-_%1^JD:0G?..E0+%$N/LSKT*ME0EI
MQCIT]U*&:)*5; "A:.4.\(.37;] OR<\*'#Z3"Y3Q3V_"!=566, R*]W&V70
M_%O2L1EA6SR3[P8T5.BECKV55RG=%A'>HDXC,_F1+/>ZO]AV7M'/@1&]:KQ4
M5"A=X#.$>?D9\Q@"D^.X>TSW!50IM*+:1B<V!]E.MI[-EA@Y%<!DD)G430Q9
MN]>5M -@#4K6SJ)2IGB&TB+>=D1UG=ATRM_MQM%#-XKQSH40B2_3M3?(!];&
M]F[8K_8WZUE[H;PW;Z_E-\HOM96/^ )')Z.3XT$[3;8OT=7I>CEW$9?5]%CB
MOP/V8H#]A4/=NQ=QT/^_<?DW4$L#!!0    ( /J1#U4ATRT2A 0  #D*   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*56;6_;-A#^*P>W*UH@LRTY
M<=*\&$C2%=O0;D&[EP_#/M#2V2(JD2I)V?%^_9XC+259TV## ,.BJ+N'SSUW
M1_)\:]TG7S$'NFUJXR]&50CMZ63BBXH;Y<>V98,O*^L:%?#JUA/?.E9E=&KJ
M23Z=SB>-TF:T.(]S-VYQ;KM0:\,WCGS7-,KMKKBVVXM1-NHG/NAU%61BLCAO
MU9H_<OBUO7%XFPPHI6[8>&T-.5Y=C"ZSTZM#L8\&OVG>^GMCDDB6UGZ2EQ_*
MB]%4"''-11 $A<>&K[FN!0@T/N\Q1\.2XGA_W*._C;$CEJ7R?&WKWW49JHO1
MR8A*7JFN#A_L]GO>QW,D>(6M??RG;;+-8%QT/MAF[PP&C3;IJ6[W.MQS.)E^
MQ2'?.^21=UHHLGRC@EJ<.[LE)]9 DT$,-7J#G#:2E(_!X:N&7UB\8X3DSR<!
M6#(S*?9^5\DO_XK?G-Y;$RI/WYF2RX?^$W 8B.0]D:O\2< ?.S.FV?2 \FF>
M/X$W&P*;1;S9DX'1'Y=+'QQR_^=C,2:(P\<AI!].?:L*OABAX#V[#8\6+YYE
M\^G9$P0/!X*'3Z$_H?R_\:-?*J9KV[3*[*A.4W:UT@53I$SH5]+!4X5._=PI
M%]AYJFVA8C-TR)HC90C=[3!EU@ED#%SMTY@*VZ#]"BY)&_K);KA9PBF?9J])
MK8!'H8I&;<T1U*ZH8!>P$U!@HTP@W;1._-B 2:-*IN4N>M7LO77C&$5:3)NB
M[DI$$4E%O&#1]@:-+;$H6J%]O]VQPKKL&E*>MFAF>3YPD8_:J, #2<=,XN</
MR+#&\DZH;BM=5%2I#4@QRPY3V+71?R%<0+903*Q$0L<UX$IRTN$RV8&O\I[Q
M#<P2_UJKI:YUT!*"ER"UHV'SV6+*V "UL)U!>D&#FS5J6>]ZU<8/DEHE%[W2
M,+[3#$,%8?$S$+GT$C+?LBLT2(@9 @5DKT+,2])&&202F+P&:LHYA%-(3BD)
MBMKUZ1C3V\Z)4@>8&PJBM)S"V">+A"=V1G9:U0@(H748;%3=,:U1=*@!: _2
M^!:<CCLP--C$ZO!CN@R@BRQ 4_0_#_U_$,F^X2*5W"R+T]E!)+B-.ZVD:8/:
M7<?2<;'&L/;2.O2AQ.:D!%8V5>D_RES:HB[[8NP5ER1ELW'V323V/PB!#=(Y
MK!:3X?\C%]0(Y>-Y*MRX.ICU90PY6XYJUKLQO5>A<ZGR(.27Y=@OO,=^\>PD
MSX[/_)=$E'\D$Y&)$I0:)[BGE]+>E>T\./E7I]&*7MZ%[/4M-?%L>$7/H6<F
M%C/*YR<R.*3\^$@&^)O)<TZ13WXFQ8^>B#T[3%G):8JH5;NTC\Q?'],[],*I
M;"]=B-L3G%!A]#++IJ_H1C9K%'2JPT<E>4Y')\?T\T,!4)G $*E%K;[K[U0J
ME*]H%47H);T+EE@.PL>J1@HEJ:B;H5E48SMI@<<.DLF]X[QAMXZ7%@]V\$@G
M^S [W(LNTW7@SCQ=JMXKM]9&^G<%U^GX^&B4MK'^)=@V7@Z6-N"J$8=R8K 3
M WQ?61OZ%UE@N"TN_@902P,$%     @ ^I$/56$Y=[Y%!0  @@T  !D   !X
M;"]W;W)K<VAE971S+W-H965T,30N>&ULO5=;;]LV%/XKA-L5-N#:DFSGUB1
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M@_!:XD\261; _LQ@.EE]\ &;OUV7?P%02P,$%     @ ^I$/5;GU0EDX!P
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M.E6BPKFL.^8*ZEDD=S>G#M6S<JGV,BF4J"O!/@.N")AX?D373OU5HZRWH/?
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MWYX@8IAI#]:GD243NU*CW6W;,W/1>K$T*(9(7;VUR2#B)(6-MI29XL>=3[L
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M'L6CTVA]0FUB"EGFJ%PG'.TE[TBYR%&04"3#U)]9=SXMK1![LW@^@G?[8["
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MS-AKJ;E.)5?LC7;>5O"^=\<##T%$/D@;IN<UTV0'TP/VSFB?._9*9R+[\OP
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M5Z!V&VA]IY0]#%R _D]E]1U02P,$%     @ ^I$/5?YR%\_< P  - D  !D
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M;[#[E[%-#0W5AF4X=JA(%,H=.I-OOPD2__L;S/L=\_XM],FB*1T0*UAHD;W
M=,]D#E,C;:[?@(H4=($P1\E%?HG];?QGLEV)DBJ5UVO01@%MN?)_4%EH=O E
ML62:3E +NZXL'[%I:LW04AT=Q5^A:C2!1A- &<4NHT/X95LM4=JH3&H4?+;%
M1!NG#1!U$Z59G1M63,-[S-!:1(&%"&#@^G'B^E$,[R#J!0_PD=)I  *7VI/K
M^S[XO4$"5,DKY.;%7>BF@\"-_?0>PE[X<,75&5.(W2CMNW$X:-R$\*N-E\)Z
M19EQ90_L"ZO0[3\D;IJF9!4;<EUX;(>26A^=I>F?QF5&QV2DMV4E:)05)+T
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MK]B];-R+O]P_W?WK_@"$RH"3JNP<C75JZF7VY2K[1\#]!L3.[W*#^.(. =\
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MWL5%'WO?"P<+Z8ZX/:[#M2"KFHCGMV^R,)B_TT /]Z'-6JMG+6JB,-59C6'
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M\1N_%P1N,'+6N[PT]>L.AT&WZE<+N5>%W&L->4+5,M_UD;F KQE;T\0LH:;
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ME03"*.CUC'.UGQ@#W;LK^@U02P,$%     @ ^I$/51 5J-S]#P  @M8  !D
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M_3_)YUGRA[7X>>\,<VSF(F$!$A8B81$21C>PT5:>63(;&9$C80($,T3@/XO
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M'>_6D6-Y30V-)TJNB;*G$<T.G%1GC>28L)=R9Q3N,K0S,:KA-)&*NAC-"@6
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MC>2$S<IKT/)%T$UQSW=/A:!I\;@&' -3%>3W):7BY44%J"^CY_\"4$L#!!0
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M%+-UF7U#U!7PC"FPP(SZ_#=N0-Y(*,2_?;E2:^/U:Z.*[(6H: PS ZNH0)7
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M^@JQS5Q?VB#, CV_Y%R]=LP]TOX-2/\"4$L#!!0    ( /J1#U5!65;HJ@,
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M_Q]'D7R_2%Z!RU]Y'/P/4$L#!!0    ( /J1#U7(QYK SP,  )P.   9
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MZK>)V&Y+;D\43[*=O2>N%(^SPQ60.0@3H.\O.%>O)V:SL-@<GOX 4$L#!!0
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MEXW6G['L'W-A9;5[VV+WILC'?P%02P,$%     @ ^I$/58HQ=E_/ 0  ,Q\
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W9RVK"0!B&X5N17(#C
M?X@]H%UUTVWQ!H(=#WA(R$RIWGU%%_8+7713YEN%2<B?%P(/83)[C_LF;]MC
MVFR[-#H=]L<TKS8Y=\\AI.4F'IHT;KMXO%Q9M?VAR9=EOPY=L]PUZQAT,IF&
M_N>,ZF7V<^9H<>[B7R:VJ]5V&5_;Y><A'O,O@\-7V^_2)L9<C19-OXYY7H73
M_GXZA>M!QI?)U>CM8U[U;Q]2A=)!"D%:/L@@R,H'.01Y^: :@NKR05,(FI8/
M>H"@A_)!CQ#T6#[H"8*>R@?)!&6<$"0-L";06I!K(?!:$&PA$%N0;"$P6Q!M
M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O)=!;!Q_;!'HKZJT$>BOJ
MK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MM@
MLX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'
MO9U ;T>]G4!O'VQV$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H7:/>-8'>
M->I=$^A=H][U?^J=\GD?T[WGML;G_R?5^7)OO#_^NKR='+R7*\X!_I&_? -0
M2P,$%     @ ^I$/53+A@>'' 0  $A\  !,   !;0V]N=&5N=%]4>7!E<UTN
M>&ULS=G);L(P% 707T'95L1X@ X"-FVW+8O^@)L\("*)+=M0^/LZ89!:T:B(
M2KV;1(GM=U]LZ6PR?MM9\KUM5=9^DBQ#L ^,^6Q)E?:IL53'D;EQE0[QT2V8
MU=E*+XB)P6#$,E,'JD,_-#62Z?B)YGI=AM[S-K[VA:DGB:/2)[W'_<0F:Y)H
M:\LBTR&.LTV=?TOI'Q+2N+*=XY>%]3=Q0L+.)C0C/P<<UKUNR+DBI]Y,N_"B
MJSB+;4OFPZXDGW:7.-.CF<^+C'*3K:NX)/76D<[]DBA49;HO>M.='.(.T_[*
MK\YORW0%QIDS9ZR/)^;H\KCCD32K^S86(A>*[D\\)<;25W\?-:>=4_[+[+B]
M'\:MVO/PK+U=O\=?S_A4_\(^!$@?$J0/!=+'$*2/$4@?MR!]W('T<0_2!Q^@
M-((B*D<AE:.8RE%0Y2BJ<A16.8JK' 56CB*K0)%5H,@J4&05*+(*%%D%BJP"
M15:!(JM D56@R"I19)4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR*A19%8JL
M"D56A2*K0I%5H<BJ4&15*+(J%%D5BJQ#%%F'*+(._U/6=V-6?_V7MKFGE2[J
M8SYK?X5//P%02P$"% ,4    " #ZD0]5!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /J1#U4>EH9O
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( /J1#U697)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ^I$/5:2.AD)G!@  M20
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M965T-2YX;6Q02P$"% ,4    " #ZD0]5BY)"H50&   U&P  &
M    @($^+@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M^I$/54R[[/<U#   WQ\  !@              ("!R#0  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /J1#U52:6B0> \  #<M   8
M          " @3-!  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " #ZD0]5PD'S:!89  "Q5P  &               @('A4   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ^I$/56\C"I]9!@  4 \
M !D              ("!+6H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " #ZD0]5=4U%<P,%  #K#   &0              @(&]<
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /J1#U7',FK_
M=P4  'L,   9              " @?=U  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ ^I$/52'3+1*$!   .0H  !D
M ("!I7L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #Z
MD0]583EWOD4%  ""#0  &0              @(%@@   >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /J1#U6Y]4)9. <  "(4   9
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M970Q.2YX;6Q02P$"% ,4    " #ZD0]5"U *A" $   T"0  &0
M    @('/I@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M /J1#U4+MI2^O X  )<L   9              " @2:K  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ ^I$/56L:(!:9 P  M0@  !D
M             ("!&;H  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " #ZD0]5_G(7S]P#   T"0  &0              @('IO0  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /J1#U4*[  -V@(
M %@&   9              " @?S!  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ ^I$/55C9<H6V @  _ 4  !D              ("!
M#<4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #ZD0]5
M7'#(I"$#  !,!P  &0              @('ZQP  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( /J1#U4YQ^/^R00  .<+   9
M      " @5++  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ ^I$/54YA#*H5!0  $ X  !D              ("!4M   'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #ZD0]5G1BN/5 %  "1'0
M&0              @(&>U0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( /J1#U4KMIG<N (  (,)   9              " @27;  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ^I$/51 5J-S]
M#P  @M8  !D              ("!%-X  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " #ZD0]5]+""2YH"  #'!@  &0
M@(%([@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /J1
M#U7(IHT$^ (   H'   9              " @1GQ  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ ^I$/5=L&(J\7!0  F!X  !D
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M=#,X+GAM;%!+ 0(4 Q0    ( /J1#U6J91]7B0,  $H2   9
M  " @04( 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M^I$/53'9$>*) @  O0<  !D              ("!Q0L! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " #ZD0]5#4LE?N "   2"   &0
M            @(&%#@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( /J1#U5!65;HJ@,  -<.   9              " @9P1 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ^I$/58;^WC1^ P
MZ@H  !D              ("!?14! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " #ZD0]5PC]Y #4+  "XE   &0              @($R
M&0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /J1#U5X
M#U<@=0,  &L,   9              " @9XD 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ ^I$/5>X?]7P( P  40P  !D
M     ("!2B@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /J1#U6VP<!G\0,  "@6   9              "
M@0<^ 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ^I$/
M58":OR,'!   1 X  !D              ("!+T(! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " #ZD0]5_WB!34@#  "L%   #0
M        @ %M1@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /J1#U67BKL<
MP    !,"   +              "  >!) 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( /J1#U7[PF$9500  *TB   /              "  <E* 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #ZD0]5BC%V7\\!   S'P  &@
M    @ %+3P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #ZD0]5,N&!X<<!   2'P  $P              @ %240$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     /  \ %L0  !*4P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>210</ContextCount>
  <ElementCount>243</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business, Basis of Presentation and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern</Role>
      <ShortName>Description of Business, Basis of Presentation and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Redeemable Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest</Role>
      <ShortName>Redeemable Noncontrolling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136112 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140113 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2145114 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/CollaborationAgreements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/Investments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Redeemable Noncontrolling Interest (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables</Role>
      <ShortName>Redeemable Noncontrolling Interest (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/NetLossperShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail</Role>
      <ShortName>Description of Business, Basis of Presentation and Going Concern (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail</Role>
      <ShortName>Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails</Role>
      <ShortName>Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail</Role>
      <ShortName>Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Leases - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesDetails</Role>
      <ShortName>Leases - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail</Role>
      <ShortName>Redeemable Noncontrolling Interest - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail</Role>
      <ShortName>Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Related-Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related-Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail</Role>
      <ShortName>Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Fair Value of Financial Instruments - Significant Inputs Utilized in the Valuation of Letter Agreement Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Significant Inputs Utilized in the Valuation of Letter Agreement Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vtvt-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/SubsequentEvents</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones -  vtvt-20220630.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="vtvt-20220630.htm">vtvt-20220630.htm</File>
    <File>projectg-collaborationandl.htm</File>
    <File>vtvt-20220630.xsd</File>
    <File>vtvt-20220630_cal.xml</File>
    <File>vtvt-20220630_def.xml</File>
    <File>vtvt-20220630_lab.xml</File>
    <File>vtvt-20220630_pre.xml</File>
    <File>vtvt-20220630xexx311.htm</File>
    <File>vtvt-20220630xexx312.htm</File>
    <File>vtvt-20220630xexx321.htm</File>
    <File>vtvt-20220630xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtvt-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="574">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vtvt-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "contextCount": 210,
   "dts": {
    "calculationLink": {
     "local": [
      "vtvt-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtvt-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vtvt-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vtvt-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtvt-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vtvt-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 435,
   "entityCount": 1,
   "hidden": {
    "http://vtvtherapeutics.com/20220630": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 48,
   "keyStandard": 195,
   "memberCustom": 31,
   "memberStandard": 26,
   "nsprefix": "vtvt",
   "nsuri": "http://vtvtherapeutics.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://vtvtherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Share-Based Compensation",
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Investments",
     "role": "http://vtvtherapeutics.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Leases",
     "role": "http://vtvtherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Redeemable Noncontrolling Interest",
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest",
     "shortName": "Redeemable Noncontrolling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Stockholders' Deficit",
     "role": "http://vtvtherapeutics.com/role/StockholdersDeficit",
     "shortName": "Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - Related-Party Transactions",
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134111 - Disclosure - Income Taxes",
     "role": "http://vtvtherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136112 - Disclosure - Net Loss per Share",
     "role": "http://vtvtherapeutics.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140113 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145114 - Disclosure - Subsequent Events",
     "role": "http://vtvtherapeutics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Investments (Tables)",
     "role": "http://vtvtherapeutics.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Leases (Tables)",
     "role": "http://vtvtherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Redeemable Noncontrolling Interest (Tables)",
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables",
     "shortName": "Redeemable Noncontrolling Interest (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://vtvtherapeutics.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)",
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
     "shortName": "Description of Business, Basis of Presentation and Going Concern (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "id13a79cf23134033b57b9a418c172263_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i2632fc86076247a6b51786bef024e90d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i3e8f41c561ac468dbc33b32b7235be53_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "iec7d98d909f742f7b497b0166dc0cd42_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "iec7d98d909f742f7b497b0166dc0cd42_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "iacbe171406cd44ffb4bf36ef9ed553e1_D20220531-20220531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "vtvt:SaleOfStockConsiderationReceivedOnTransactionGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail)",
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail",
     "shortName": "Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "id3f1ff84e5e8468880c40caf7f418a85_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)",
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails",
     "shortName": "Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtvt:ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "id5fc8150340948bc898873b35fb8418e_D20220329-20220329",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "id5fc8150340948bc898873b35fb8418e_D20220329-20220329",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "id3f1ff84e5e8468880c40caf7f418a85_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)",
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail",
     "shortName": "Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)",
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail",
     "shortName": "Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Investments - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
     "shortName": "Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i77b143ad9f4d4ba1ace4e171385ea567_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)",
     "role": "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
     "shortName": "Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6ead0675511b48ebb66183281497ebc5_I20070228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtvt:PotentialMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6ead0675511b48ebb66183281497ebc5_I20070228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtvt:PotentialMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations - Unaudited",
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations - Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtvt:LesseeOperatingLeaseTerminationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Leases - (Details)",
     "role": "http://vtvtherapeutics.com/role/LeasesDetails",
     "shortName": "Leases - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtvt:LesseeOperatingLeaseTerminationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)",
     "role": "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
     "shortName": "Redeemable Noncontrolling Interest - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i778989260b33429389e1a9ca9b4b1a6d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)",
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail",
     "shortName": "Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "iff3de8bb3d5c4970bc7c8e651b6af215_I20210504",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stockholders' Deficit - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
     "shortName": "Stockholders' Deficit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "iff3de8bb3d5c4970bc7c8e651b6af215_I20210504",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i910db6d0fa4e476cbe83b47a7fea5ee1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Related-Party Transactions - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related-Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i0ee68f1d1f0245e088ff9dcad3a1d1ce_D20220101-20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "vtvt:OwnershipPercentageOfMajorityOwner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ifbeae5448a4743c4972130e10f6a61e0_D20220401-20220630",
      "decimals": "2",
      "lang": "en-US",
      "name": "vtvt:PercentageOfAmountOfCashSavings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)",
     "role": "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
     "shortName": "Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "role": "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
     "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "ia3eab7cb38c64395aadf3af7b03b295f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i96d01a641a694957af47ad5592770a6c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)",
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail",
     "shortName": "Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i96d01a641a694957af47ad5592770a6c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i5ac25b8b6e8545729210187897d7d519_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited",
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
     "shortName": "Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i5ac25b8b6e8545729210187897d7d519_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6e4ad6c963f84d1983f4152763b6d5e8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
     "shortName": "Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6e4ad6c963f84d1983f4152763b6d5e8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i4459419f08db4ba1875ab5f3a7f77bd9_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Fair Value of Financial Instruments - Significant Inputs Utilized in the Valuation of Letter Agreement Warrants (Detail)",
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail",
     "shortName": "Fair Value of Financial Instruments - Significant Inputs Utilized in the Valuation of Letter Agreement Warrants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i4459419f08db4ba1875ab5f3a7f77bd9_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i85da403e027840539531cb19a0fdf5b8_D20220725-20220725",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Subsequent Events (Details)",
     "role": "http://vtvtherapeutics.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i85da403e027840539531cb19a0fdf5b8_D20220725-20220725",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited",
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows - Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business, Basis of Presentation and Going Concern",
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern",
     "shortName": "Description of Business, Basis of Presentation and Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Collaboration Agreements",
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtvt-20220630.htm",
      "contextRef": "i6121b9e53b8d43888e7ef133e0f1b9d8_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r30",
      "r32",
      "r73",
      "r74",
      "r194",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r144",
      "r250",
      "r254",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r193",
      "r211",
      "r266",
      "r267",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r479",
      "r482",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r193",
      "r211",
      "r266",
      "r267",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r479",
      "r482",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r144",
      "r250",
      "r254",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r142",
      "r176",
      "r177",
      "r250",
      "r253",
      "r440",
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r142",
      "r176",
      "r177",
      "r250",
      "r253",
      "r440",
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r193",
      "r211",
      "r256",
      "r266",
      "r267",
      "r297",
      "r298",
      "r299",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r479",
      "r482",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r193",
      "r211",
      "r256",
      "r266",
      "r267",
      "r297",
      "r298",
      "r299",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r479",
      "r482",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r31",
      "r32",
      "r73",
      "r74",
      "r194",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r145",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r413",
      "r415",
      "r418",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r146",
      "r147",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts and financing receivable, after allowance for credit loss"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r309",
      "r310",
      "r311",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r269",
      "r313",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r9",
      "r69",
      "r131",
      "r134",
      "r140",
      "r156",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r339",
      "r346",
      "r372",
      "r401",
      "r403",
      "r455",
      "r467"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r20",
      "r69",
      "r156",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r339",
      "r346",
      "r372",
      "r401",
      "r403"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r75",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business, Basis of Presentation and Going Concern"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r7",
      "r59"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r53",
      "r59",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Total cash, cash equivalents and restricted cash and cash equivalents, end of period",
        "periodStartLabel": "Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r373"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r67",
      "r69",
      "r92",
      "r93",
      "r98",
      "r101",
      "r103",
      "r111",
      "r112",
      "r113",
      "r156",
      "r180",
      "r185",
      "r186",
      "r187",
      "r191",
      "r192",
      "r209",
      "r210",
      "r214",
      "r218",
      "r225",
      "r372",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called by warrants or rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r332",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r457",
      "r472"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r179",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Common Stock"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares (in shares)",
        "periodStartLabel": "Beginning balance, shares (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r403"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, value"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r144",
      "r370",
      "r371",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r144",
      "r370",
      "r371",
      "r488",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r144",
      "r370",
      "r371",
      "r488",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r116",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r120",
      "r121",
      "r144",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r144",
      "r370",
      "r371",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet": {
     "auth_ref": [
      "r233",
      "r344",
      "r350"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net",
        "totalLabel": "Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": {
     "auth_ref": [
      "r344",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]",
        "terseLabel": "Summary of Net Income Attributable to Vtv Therapeutics Inc"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Contract Liabilities Related to Company's Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r235",
      "r236",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails",
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenue recognized from change in estimated transaction prices"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r235",
      "r236",
      "r251"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.",
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "terseLabel": "Consideration received in advance and not recognized as revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r235",
      "r236",
      "r251"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied",
        "terseLabel": "Contract with customer, liability, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]",
        "terseLabel": "Stock Conversion Description"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]",
        "terseLabel": "Conversion of Stock, Name"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r119",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRevenueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Disclosure [Abstract]",
        "terseLabel": "Deferred Revenue Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredRevenueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Current deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r57",
      "r167"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r271",
      "r272",
      "r303",
      "r304",
      "r306",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r24",
      "r72",
      "r183",
      "r185",
      "r186",
      "r190",
      "r191",
      "r192",
      "r395"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "terseLabel": "Warrant liability, related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r41",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r89",
      "r92",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r355",
      "r356",
      "r460",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r41",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r92",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r355",
      "r356",
      "r460",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize unrecognized share-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option",
        "verboseLabel": "Common stock options granted under the Plan"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r35",
      "r36",
      "r37",
      "r76",
      "r77",
      "r78",
      "r80",
      "r86",
      "r88",
      "r110",
      "r157",
      "r225",
      "r232",
      "r309",
      "r310",
      "r311",
      "r323",
      "r324",
      "r354",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r391",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r4",
      "r10",
      "r369"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investment without readily determinable fair values assessed under the measurement alternative:"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity Securities without Readily Determinable Fair Value [Line Items]",
        "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Line Items]"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value [Table]",
        "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Table]"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r195",
      "r198",
      "r199",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r358",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r360",
      "r361",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r195",
      "r257",
      "r258",
      "r263",
      "r265",
      "r358",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r195",
      "r198",
      "r199",
      "r257",
      "r258",
      "r263",
      "r265",
      "r358",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r195",
      "r198",
      "r199",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r358",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r362",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Purchases / Issuance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales",
        "terseLabel": "Sales / Repurchases"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r195",
      "r198",
      "r199",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r365",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "auth_ref": [
      "r363",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "terseLabel": "Net Change in fair value included in earnings"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r197",
      "r223",
      "r352",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r39",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r453",
      "r458",
      "r462",
      "r476"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes and noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r169",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r320",
      "r321",
      "r322",
      "r325",
      "r327",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r71",
      "r87",
      "r88",
      "r130",
      "r319",
      "r326",
      "r328",
      "r477"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r56",
      "r438"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r38",
      "r129",
      "r381",
      "r382",
      "r461"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "negatedTerseLabel": "Non-cash interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r46",
      "r128"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of affiliates held for management investment companies.",
        "label": "Investments in and Advances to Affiliates, Balance, Shares",
        "terseLabel": "Shares held by related party (in shares)"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r454",
      "r463",
      "r491",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r22",
      "r69",
      "r135",
      "r156",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r340",
      "r346",
      "r347",
      "r372",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r69",
      "r156",
      "r372",
      "r403",
      "r456",
      "r469"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable noncontrolling interest and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r23",
      "r69",
      "r156",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r340",
      "r346",
      "r347",
      "r372",
      "r401",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "terseLabel": "Change in redemption value of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestChangeInRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r29",
      "r44",
      "r337",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Minority Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r33",
      "r34",
      "r37",
      "r40",
      "r58",
      "r69",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r87",
      "r88",
      "r99",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r156",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r356",
      "r372",
      "r459",
      "r473"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to vTv Therapeutics Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r33",
      "r34",
      "r37",
      "r87",
      "r88",
      "r342",
      "r348"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: net loss attributable to noncontrolling interest",
        "verboseLabel": "Less: Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r89",
      "r90",
      "r100",
      "r103",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to vTv Therapeutics Inc. common shareholders",
        "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r91",
      "r94",
      "r95",
      "r96",
      "r97",
      "r100",
      "r103"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r203",
      "r342",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r232",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesAssumed1": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes assumed in noncash investing or financing activities.",
        "label": "Notes Assumed",
        "terseLabel": "Notes Assumed"
       }
      }
     },
     "localname": "NotesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r131",
      "r133",
      "r136",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r386",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining operating lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestAndDividendsReceived": {
     "auth_ref": [
      "r51",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for dividends and interest on the entity's equity and debt investments during the current period.",
        "label": "Proceeds from Interest and Dividends Received",
        "terseLabel": "Equity interest received"
       }
      }
     },
     "localname": "ProceedsFromInterestAndDividendsReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Class A common stock, net of offering costs",
        "verboseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r308"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r33",
      "r34",
      "r37",
      "r52",
      "r69",
      "r79",
      "r87",
      "r88",
      "r131",
      "r133",
      "r136",
      "r139",
      "r141",
      "r156",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r338",
      "r341",
      "r343",
      "r348",
      "r349",
      "r356",
      "r372",
      "r462"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss before noncontrolling interest",
        "totalLabel": "Net loss before noncontrolling interest",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r168",
      "r403",
      "r464",
      "r471"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r403",
      "r470",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables, net, current"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r264",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r264",
      "r394",
      "r398",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r392",
      "r393",
      "r395",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayment of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r316",
      "r439",
      "r496"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r232",
      "r403",
      "r468",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r76",
      "r77",
      "r78",
      "r80",
      "r86",
      "r88",
      "r157",
      "r309",
      "r310",
      "r311",
      "r323",
      "r324",
      "r354",
      "r483",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r126",
      "r127",
      "r132",
      "r137",
      "r138",
      "r142",
      "r143",
      "r144",
      "r249",
      "r250",
      "r440"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Unrecognized amount of transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per shares)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r120",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r301",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Compensation Expense Related to Grants of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summarizes the Conclusions Reached Regarding Fair Value Measurements"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r268",
      "r270",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r275",
      "r290",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Award Activity for the Period"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r67",
      "r111",
      "r112",
      "r200",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r218",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Non-qualified stock option awards vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Awards outstanding, Ending balance (in shares)",
        "periodStartLabel": "Awards outstanding, Beginning balance (in shares)",
        "terseLabel": "Outstanding stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Awards outstanding, Ending balance (in usd per share)",
        "periodStartLabel": "Awards outstanding, Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Price of shares purchased (in usd per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Non-qualified stock option awards expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r65",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r67",
      "r69",
      "r92",
      "r93",
      "r98",
      "r101",
      "r103",
      "r111",
      "r112",
      "r113",
      "r156",
      "r180",
      "r185",
      "r186",
      "r187",
      "r191",
      "r192",
      "r209",
      "r210",
      "r214",
      "r218",
      "r225",
      "r372",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r28",
      "r35",
      "r36",
      "r37",
      "r76",
      "r77",
      "r78",
      "r80",
      "r86",
      "r88",
      "r110",
      "r157",
      "r225",
      "r232",
      "r309",
      "r310",
      "r311",
      "r323",
      "r324",
      "r354",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r391",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r110",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r27",
      "r196",
      "r225",
      "r226",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exchange of Class B common stock for class A common stock, shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Class A Common Stock to Collaboration Partner (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options, shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Class A common stock to collaboration partner",
        "verboseLabel": "Stock issued during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r69",
      "r148",
      "r156",
      "r372",
      "r403"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 deficit attributable to vTv Therapeutics Inc."
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r210",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r232",
      "r234",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r380",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r380",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r380",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r380",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r404",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r197",
      "r223",
      "r352",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Change in fair value of investments",
        "terseLabel": "Change in fair value of investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r118",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Inputs utilized in the valuation of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r91",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r89",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtvt_AdjustmentsToTransactionPriceForPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to transaction price for performance obligations.",
        "label": "Adjustments To Transaction Price For Performance Obligations",
        "terseLabel": "Adjustments to transaction price for performance obligations"
       }
      }
     },
     "localname": "AdjustmentsToTransactionPriceForPerformanceObligations",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_AggregateOfferingPriceOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering price of shares.",
        "label": "Aggregate Offering Price Of Shares",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "AggregateOfferingPriceOfShares",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_AnterisBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anteris Bio, Inc.",
        "label": "Anteris Bio Inc [Member]",
        "terseLabel": "Anteris Bio Inc"
       }
      }
     },
     "localname": "AnterisBioIncMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "ATM Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_CantorFitzgeraldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cantor fitzgerald member.",
        "label": "Cantor Fitzgerald [Member]",
        "terseLabel": "Cantor Fitzgerald"
       }
      }
     },
     "localname": "CantorFitzgeraldMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract with Customer, Liability",
        "label": "Change in Contract with Customer, Liability [Roll Forward]",
        "terseLabel": "Revenue from Contract with Customer [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsContractwithCustomerContractAssetContractLiabilityandReceivableChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_ChangeInFairValueOfWarrantsRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of warrants related party.",
        "label": "Change In Fair Value Of Warrants Related Party",
        "terseLabel": "Change in fair value of warrants, related party"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantsRelatedParty",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_CognaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cogna",
        "label": "Cogna [Member]",
        "terseLabel": "Cogna"
       }
      }
     },
     "localname": "CognaMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_CollaborateArrangementContingentConsiderationTransferredCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborate Arrangement, Contingent Consideration Transferred, Cash",
        "label": "Collaborate Arrangement, Contingent Consideration Transferred, Cash",
        "terseLabel": "Collaborate arrangement, contingent consideration transferred, cash"
       }
      }
     },
     "localname": "CollaborateArrangementContingentConsiderationTransferredCash",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value",
        "label": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value",
        "terseLabel": "Collaborative arrangement, contingent consideration"
       }
      }
     },
     "localname": "CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_CollaborativeArrangementNoteReceivableDiscountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Note Receivable, Discount Paid",
        "label": "Collaborative Arrangement, Note Receivable, Discount Paid",
        "terseLabel": "Discount on note receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementNoteReceivableDiscountPaid",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_CollaborativeArrangementRoyaltiesReceivablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Receivable, Percentage",
        "label": "Collaborative Arrangement, Royalties Receivable, Percentage",
        "terseLabel": "Royalties receivable, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesReceivablePercentage",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Receivable, Period",
        "label": "Collaborative Arrangement, Royalties Receivable, Period",
        "terseLabel": "Royalties receivable, period"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesReceivablePeriod",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vtvt_CollaborativeArrangementTechnologyTransferServicesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Technology Transfer Services Period",
        "label": "Collaborative Arrangement, Technology Transfer Services Period",
        "terseLabel": "Transferred services per agreement terms"
       }
      }
     },
     "localname": "CollaborativeArrangementTechnologyTransferServicesPeriod",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vtvt_CommitmentContingencyAndRelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment, Contingency And Related Party Transactions [Abstract]",
        "label": "Commitment Contingency And Related Party Transactions [Abstract]",
        "terseLabel": "Commitment Contingency And Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "CommitmentContingencyAndRelatedPartyTransactionsAbstract",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "xbrltype": "stringItemType"
    },
    "vtvt_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_CommonStockAndPreferredStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and preferred stock shares authorized.",
        "label": "Common Stock And Preferred Stock Shares Authorized",
        "terseLabel": "Capital stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockAndPreferredStockSharesAuthorized",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.",
        "label": "Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent",
        "terseLabel": "(Increase)/Decrease in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances"
       }
      }
     },
     "localname": "ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes [Table Text Block]",
        "terseLabel": "Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes"
       }
      }
     },
     "localname": "ContractWithCustomerContractAssetContractLiabilityAndReceivableChangesTableTextBlock",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developmental and regulatory milestone payment.",
        "label": "Developmental And Regulatory Milestone Payment [Member]",
        "terseLabel": "Developmental and Regulatory Milestone Payment"
       }
      }
     },
     "localname": "DevelopmentalAndRegulatoryMilestonePaymentMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_EquityInvestmentsWithReadilyDeterminableFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investments with readily determinable fair value.",
        "label": "Equity Investments With Readily Determinable Fair Value",
        "terseLabel": "Equity investment with readily determinable fair value:"
       }
      }
     },
     "localname": "EquityInvestmentsWithReadilyDeterminableFairValue",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in equity security with and without readily determinable fair value.",
        "label": "Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block]",
        "terseLabel": "Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed"
       }
      }
     },
     "localname": "EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange of redeemable non controlling interest to class A common stock.",
        "label": "Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]",
        "terseLabel": "Exchange of Redeemable Non controlling Interest To Class A Common Stock"
       }
      }
     },
     "localname": "ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of assets and liabilities measured on recurring basis.",
        "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of assets and liabilities measured on recurring basis table.",
        "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]",
        "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_FundingReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received.",
        "label": "Funding Received",
        "terseLabel": "Funding received"
       }
      }
     },
     "localname": "FundingReceived",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_G2InvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "G2 Investment",
        "label": "G2 Investment [Member]",
        "terseLabel": "G2 Investment"
       }
      }
     },
     "localname": "G2InvestmentMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement",
        "label": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]",
        "terseLabel": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement"
       }
      }
     },
     "localname": "G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_G42InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "G42 Investments",
        "label": "G42 Investments [Member]",
        "terseLabel": "G42 Investments"
       }
      }
     },
     "localname": "G42InvestmentsMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited.",
        "label": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member]",
        "terseLabel": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_IncreaseInCommonStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in common stock shares authorized.",
        "label": "Increase In Common Stock Shares Authorized",
        "terseLabel": "Increase in shares authorized (in shares)"
       }
      }
     },
     "localname": "IncreaseInCommonStockSharesAuthorized",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtvt_InvestmentOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment ownership percentage.",
        "label": "Investment Ownership Percentage",
        "terseLabel": "Equity method investments, ownership percentage"
       }
      }
     },
     "localname": "InvestmentOwnershipPercentage",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vtvt_IssuanceOfClassACommonStockUnderATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Class A Common Stock Under ATM Offering",
        "label": "Issuance Of Class A Common Stock Under ATM Offering",
        "terseLabel": "Issuance Of Class A Common Stock Under ATM Offering (in shares)"
       }
      }
     },
     "localname": "IssuanceOfClassACommonStockUnderATMOffering",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtvt_IssuanceOfClassACommonStockUnderATMOfferingValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Class A Common Stock Under ATM Offering Value",
        "label": "Issuance Of Class A Common Stock Under ATM Offering Value",
        "terseLabel": "Issuance of Class A common stock under ATM offering"
       }
      }
     },
     "localname": "IssuanceOfClassACommonStockUnderATMOfferingValue",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_JDRFInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JDRF international.",
        "label": "J D R F International [Member]",
        "terseLabel": "JDRF"
       }
      }
     },
     "localname": "JDRFInternationalMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_LPCPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LPC purchase agreement.",
        "label": "L P C Purchase Agreement [Member]",
        "terseLabel": "LPC Purchase Agreement"
       }
      }
     },
     "localname": "LPCPurchaseAgreementMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period",
        "label": "Lessee, Operating Lease, Termination Period",
        "terseLabel": "Lessee, operating lease, termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtvt_LetterAgreementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter agreement warrants.",
        "label": "Letter Agreement Warrants [Member]",
        "terseLabel": "Letter Agreement Warrants"
       }
      }
     },
     "localname": "LetterAgreementWarrantsMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSignificantInputsUtilizedintheValuationofLetterAgreementWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_LicenseAgreementObligationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement obligations.",
        "label": "License Agreement Obligations [Axis]",
        "terseLabel": "License Agreement Obligations"
       }
      }
     },
     "localname": "LicenseAgreementObligationsAxis",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_LicenseAgreementObligationsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement obligations.",
        "label": "License Agreement Obligations [Domain]",
        "terseLabel": "License Agreement Obligations"
       }
      }
     },
     "localname": "LicenseAgreementObligationsDomain",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_LicenseAndTechnologyTransferServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and technology transfer services.",
        "label": "License And Technology Transfer Services [Member]",
        "terseLabel": "License And Technology Transfer Services"
       }
      }
     },
     "localname": "LicenseAndTechnologyTransferServicesMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and technology transfer services of chemistry and manufacturing know-how.",
        "label": "License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member]",
        "terseLabel": "License and Technology Transfer Services of Chemistry and Manufacturing Know-How"
       }
      }
     },
     "localname": "LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_LicenseFeeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fee received.",
        "label": "License Fee Received",
        "terseLabel": "License fee received"
       }
      }
     },
     "localname": "LicenseFeeReceived",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_MFTTPHoldingsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "M&amp;F TTP Holdings LLC.",
        "label": "M F T T P Holdings L L C [Member]",
        "terseLabel": "M&amp;F TTP Holdings LLC"
       }
      }
     },
     "localname": "MFTTPHoldingsLLCMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_MacAndrewsAndForbesIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MacAndrews and Forbes Incorporated.",
        "label": "Mac Andrews And Forbes Incorporated [Member]",
        "terseLabel": "MacAndrews &amp; Forbes Incorporated"
       }
      }
     },
     "localname": "MacAndrewsAndForbesIncorporatedMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum funding percentage of research and development milestones.",
        "label": "Maximum Funding Percentage Of Research And Development Milestones",
        "terseLabel": "Maximum funding percentage of research and development milestones"
       }
      }
     },
     "localname": "MaximumFundingPercentageOfResearchAndDevelopmentMilestones",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum research funding receivable based on achievement of research and development milestones.",
        "label": "Maximum Research Funding Receivable Based On Achievement Of Research And Development Milestones",
        "terseLabel": "Maximum research funding receivable achievement based on research and development milestones"
       }
      }
     },
     "localname": "MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_MaximumSponsoringContributionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum sponsoring contribution amount.",
        "label": "Maximum Sponsoring Contribution Amount",
        "terseLabel": "Maximum contribution amount to clinical trial"
       }
      }
     },
     "localname": "MaximumSponsoringContributionAmount",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_NewsoaraBiopharmaCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Newsoara Biopharma Co Ltd.",
        "label": "Newsoara Biopharma Co Ltd [Member]",
        "terseLabel": "Newsoara Biopharma Co Ltd"
       }
      }
     },
     "localname": "NewsoaraBiopharmaCoLtdMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_NotesReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Receivable, Current",
        "label": "Notes Receivable, Current",
        "terseLabel": "Promissory note receivable"
       }
      }
     },
     "localname": "NotesReceivableCurrent",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_NovoLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novo license agreement.",
        "label": "Novo License Agreement [Member]",
        "terseLabel": "Novo License Agreement"
       }
      }
     },
     "localname": "NovoLicenseAgreementMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_OneCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Customer",
        "label": "One Customer [Member]",
        "terseLabel": "One Customer"
       }
      }
     },
     "localname": "OneCustomerMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_OperatingLeasesImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases imputed interest.",
        "label": "Operating Leases Imputed Interest",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "OperatingLeasesImputedInterest",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_OtherIncomeExpensesRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other related party income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.",
        "label": "Other Income Expenses Related Party",
        "terseLabel": "Other income (expense) \u2013 related party"
       }
      }
     },
     "localname": "OtherIncomeExpensesRelatedParty",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_OtherIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other indication.",
        "label": "Other Indication [Member]",
        "terseLabel": "Other Indication"
       }
      }
     },
     "localname": "OtherIndicationMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_OwnershipPercentageOfMajorityOwner": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership percentage of majority owner.",
        "label": "Ownership Percentage Of Majority Owner",
        "terseLabel": "Ownership percentage of majority owner"
       }
      }
     },
     "localname": "OwnershipPercentageOfMajorityOwner",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vtvt_PercentageOfAmountOfCashSavings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of amount of cash savings.",
        "label": "Percentage Of Amount Of Cash Savings",
        "terseLabel": "Amount of cash savings percentage"
       }
      }
     },
     "localname": "PercentageOfAmountOfCashSavings",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vtvt_PercentageOfNonVotingEconomicInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of non voting economic interest.",
        "label": "Percentage Of Non Voting Economic Interest",
        "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC",
        "verboseLabel": "Noncontrolling interest ownership percentage"
       }
      }
     },
     "localname": "PercentageOfNonVotingEconomicInterest",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vtvt_PercentageOfNonVotingEconomicInterestByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of non voting economic interest by parent.",
        "label": "Percentage Of Non Voting Economic Interest By Parent",
        "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC"
       }
      }
     },
     "localname": "PercentageOfNonVotingEconomicInterestByParent",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period used to determine exchange value based on weighted average price of Class A common stock.",
        "label": "Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock",
        "terseLabel": "Number of days used to determine exchange value based on weighted average price of Class A common stock"
       }
      }
     },
     "localname": "PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vtvt_PhaseTwoMultiRegionalClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase two multi-regional clinical trial.",
        "label": "Phase Two Multi Regional Clinical Trial [Member]",
        "terseLabel": "Phase 2 MRCT"
       }
      }
     },
     "localname": "PhaseTwoMultiRegionalClinicalTrialMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestone payments receivable.",
        "label": "Potential Development And Regulatory Milestone Payments Receivable",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_PotentialMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payment.",
        "label": "Potential Milestone Payment",
        "terseLabel": "Potential milestone payment"
       }
      }
     },
     "localname": "PotentialMilestonePayment",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_ProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Common Stock",
        "label": "Proceeds From Sale Of Common Stock",
        "terseLabel": "Proceeds from sale of Class A common stock to collaboration partner, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfCommonStock",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_PublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public float.",
        "label": "Public Float",
        "terseLabel": "Public float"
       }
      }
     },
     "localname": "PublicFloat",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable non controlling interest exchange agreement stock conversion ratio.",
        "label": "Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "RedeemableNonControllingInterestExchangeAgreementStockConversionRatio",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable noncontrolling interest temporary equity redemption value.",
        "label": "Redeemable Noncontrolling Interest Temporary Equity Redemption Value",
        "terseLabel": "Redemption amount of noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_RedeemableNoncontrollingInterestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable noncontrolling interests.",
        "label": "Redeemable Noncontrolling Interests [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestsMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining availability under our controlled equity offering sales agreement",
        "label": "Remaining Availability Stock Issued During Period Value New Issues",
        "terseLabel": "Remaining available stock value"
       }
      }
     },
     "localname": "RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_ReneoPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reneo Pharmaceuticals Inc.",
        "label": "Reneo Pharmaceuticals Inc [Member]",
        "terseLabel": "Reneo"
       }
      }
     },
     "localname": "ReneoPharmaceuticalsIncMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_SaleOfStockConsiderationReceivablePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Consideration Receivable, Payment Period",
        "label": "Sale Of Stock, Consideration Receivable, Payment Period",
        "terseLabel": "Consideration receivable, payment period"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivablePaymentPeriod",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vtvt_SaleOfStockConsiderationReceivablesPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Consideration, Receivables, Payment Term",
        "label": "Sale Of Stock, Consideration, Receivables, Payment Term",
        "terseLabel": "Sale of Stock, consideration, receivables, payment term"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivablesPaymentTerm",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vtvt_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Received on Transaction, Gross",
        "label": "Sale of Stock, Consideration Received on Transaction, Gross",
        "terseLabel": "Sale of stock, consideration received on transaction, gross"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_SalesBasedMilestonesPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestones payment.",
        "label": "Sales Based Milestones Payment [Member]",
        "terseLabel": "Sales-based Milestones Payment"
       }
      }
     },
     "localname": "SalesBasedMilestonesPaymentMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_SatisfactionOfMilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Satisfaction of milestone payment.",
        "label": "Satisfaction Of Milestone Payment [Member]",
        "terseLabel": "Satisfaction of Milestone Payment"
       }
      }
     },
     "localname": "SatisfactionOfMilestonePaymentMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_ScheduleOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Earnings Per Share [Line Items]",
        "label": "Schedule Of Earnings Per Share [Line Items]",
        "terseLabel": "Schedule Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareLineItems",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_ScheduleOfEarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Earnings Per Share [Table]",
        "label": "Schedule Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareTable",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled",
        "terseLabel": "Stock options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelled",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Class A Common Stock under LPC agreement shares..",
        "label": "Stock Issued During Period, Shares, Purchase Agreement",
        "terseLabel": "Issuance of class A common stock under LPC agreement, shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseAgreement",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtvt_StockIssuedDuringPeriodValuePurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Purchase Agreement",
        "label": "Stock Issued During Period, Value, Purchase Agreement",
        "terseLabel": "Issuance of Class A Common Stock under LPC Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseAgreement",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_StrategicAdvisorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic advisor.",
        "label": "Strategic Advisor [Member]",
        "terseLabel": "Strategic Advisor"
       }
      }
     },
     "localname": "StrategicAdvisorMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vtvt_TemporaryEquityChangeInRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Change In Redemption Value",
        "label": "Temporary Equity, Change In Redemption Value",
        "terseLabel": "Change in redemption value of noncontrolling interest"
       }
      }
     },
     "localname": "TemporaryEquityChangeInRedemptionValue",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtvt_TypeOneDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type 1 diabetes.",
        "label": "Type One Diabetes [Member]",
        "terseLabel": "Type 1 Diabetes"
       }
      }
     },
     "localname": "TypeOneDiabetesMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_TypeTwoDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type 2 diabetes.",
        "label": "Type Two Diabetes [Member]",
        "terseLabel": "Type 2 Diabetes"
       }
      }
     },
     "localname": "TypeTwoDiabetesMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial information policy.",
        "label": "Unaudited Interim Financial Information Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Information"
       }
      }
     },
     "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtvt_VTvLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "vTv LLC.",
        "label": "V Tv L L C [Member]",
        "terseLabel": "vTv Therapeutics LLC"
       }
      }
     },
     "localname": "VTvLLCMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtvt_VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interests And Equity Method Investments Disclosure [Abstract]",
        "label": "Variable Interests And Equity Method Investments Disclosure [Abstract]",
        "terseLabel": "Variable Interests And Equity Method Investments Disclosure [Abstract]"
       }
      }
     },
     "localname": "VariableInterestsAndEquityMethodInvestmentsDisclosureAbstract",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "xbrltype": "stringItemType"
    },
    "vtvt_WarrantLiabilityRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability, related party.",
        "label": "Warrant Liability Related Party [Member]",
        "terseLabel": "Warrant liability, related party"
       }
      }
     },
     "localname": "WarrantLiabilityRelatedPartyMember",
     "nsuri": "http://vtvtherapeutics.com/20220630",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "16(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r497": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r498": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r499": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r500": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r501": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r502": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r503": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r504": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r505": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r506": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r507": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r508": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r509": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585"
  },
  "r510": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001641489-22-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641489-22-000008-xbrl.zip
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M8N<\JS@3LZ@@EAXJ=EOFQ)$;3-;+)V">HK.!>?]4B@3>%!B&9N):S>)1%@9
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MN.@O/#CG,E!?]'U]5JWS,X-%X?@+/#<$CJ!]>5&6%WA]+.#??_/::7[R!:3
M"^?L=&?@*<[ _Y%B,PX " _X8JL_N.,(/ EUSV%5UDC:"PZRCKKO1=W![V<7
M[A U!3O*+*-"9*TU@<(/)!Y(K;&QA9I+H,&2+%V,(GTX^\/[0V1 XY32\+O2
MW"D'5 WX.Z;H&5WL0H^Z=7;QZ>+''_:/WL(8]&]_[X#^/3G8YE 1^>?.P"8@
MTUYB4E^LU796\[]@L3/H8KYW-A$@1;)\B1[F4P#HW5_>N;88O,'N;I^>-]BE
M?]Z=U=1?-$(D+IQ2B[?";=*B1\K%@(MRC3R*+0OR'33R&SMQLTD'\J-#!U*?
M'4IO58G5:*B:,TDQ3)&%J.ZGTS(>$\V"<  QDV8YQ^?9:CDERT;G$\&YI6.%
M]DOO?>^R1^8'G!2="PWB3;NPIB"*2"1EE:E</1A&JCNV@"U@YJUQK7=9CYMU
M #XY= !LB80NHFDYM4@/+=^I+"9I2''#H<DE\4TF^4@$VF"V"WNLJV$0]L3
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MO%&\D7OS4*47V'XR"8P?4-5??;CP;P61?>"!7M/A11:J74.F"%47R!%(V53
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MT&D^]WV&NN^%@3,.>_W.^?>XTS"+TZC8HA_<B5FC9HVE.SZK/(BHJ*/!B#K
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M6*>,NHN1 N6TJ/_$TT?0L!!=;%MHAF']5R#L7I57\-X[9^GUSL";@=R3TXA
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M%<%7O6C@ M,^GG/<, NN_A:OKHI[$VC[\C=WJ-K*/Q4(7GL=P5.&Z);G)O7
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MN1XL!SE.J3*VO4.U5LCTNZ 3_=/I>U3?$-R4,HZOY5VD6Z6KVYH@\R@89T9
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M!)B7B3H5)D7V;O]"DQ_KW#7-D(T'.$(<\ZDPYBU60F,F;,#,5N8JRUG?B-A
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M!ZC0I%DPTK=9_KL]?LWU9N[B^*K;AVVM&H1>_AJ:/ F.I8?$+'B:6&"ZU$3
MZ+DD&T W@!EF"H+#)QD0Y84Y:* OP"4987@DH<A"-BSS"%Y49)6(4I6>Y6@4
M!9&"%Y'\'*.!W^X!-^[H5B0+*PY]^U&O,N+=I*I56\EL0(#2+5R]WH!2Z._7
MU,FI5UA_4Z>.)I^8)@_7OJ4K-#;JMO5^$S_  ,IZM]4&KYHAZ!<(08:;2F]
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M<B,^UI-[1]--@^-IDF=:9A4!?TY7R081MQ2K'-8#8:_74$8;>L$RF:<T5Q4
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MOVHU9G"M$)7=#(P ;T':74)+@N'OS1;E'4KB8+SO1KK\CJ*FKI=9$VAT$L<
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M6(>-LBQ0IE?J-1'O?)9@P9(M(@N2F.OV\Z28UTMF) :&%<+G(VI+_HKDABR
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M$./ ,%1*Z>I65=1.V4 ,C#CLT>AS1I!C]DO!L^FTW#;YO7][Z.N+O:WR";O
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M3S[R^=[1))JB08]V]S'"OD/)342EH0G@?,8VBYE06P7I?T?%_!(:^ 9MS<R
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MEPW8EH:.12E:"+/6,KAP&8)0DLTY!8N?>"-FT-/(!?JT&J$Q%=1S#W%)P3#
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MSR]?__6>G7'OA'VQOQU@^K!'"[ _F-=[(%?^ 4R$8AN%%_?W++]^]D=^C0E
M2,H)E,J&B%7$&B"'97[ 6, ?&=[?2O;M*2YS)G&>8WX->N*)+LF2!#3I4AUO
MRD "DMZJ8&)C(74$BO7E<;7YJ^W@T:VVEF4F$E-:#ST4/?V;73"!RPG^\ 4+
MM_RWB5LJ,6F2J5K;P(Z;)U2PRB\$WDZG5?+[NGOHU7"4O)XJ02G1MES3^A+*
M0L[L?3I6[5MABX[P7G?"X:/;"6I%MNP(Y6VS3#%+J]YJ78:J89>J+JAE+<?I
M"2"W7-FY:OL5<</0-=>="'#EVYT"P03+,:V9*.C&G1?)S#1L0S'^(H<+RE,9
MZKYY?7$)E5^HH<(N3&!ZQ0^;<*0UC@GEU!,"92$*Q@I$)-<\:"B(>IE#<?0?
M0@ZGQ7I)-W>KQ,SK'H." 44%1WN'1^NB C=WX$4%P3TZF[Z ??>QOL[J6-D;
M:O+  DR#P),J$O0YY4=0E=HTYQ-YJ_,4(R_N&E[<8(WIY@I8F[T*)H,VL6I-
M[JJ)O3L;NU7S3*\F=D V]G#O^2%,A<-A#' 3AC6VEFW)<N985I'A">&58@$:
MS?)N<5M9V&6U6:%MICZ4B?2-HB(F[I$%HV6]*K+=.S]'<IYX5%NZ$Q3,@3L=
M3P\%,[;:W6VE[+@$*J+^:<3<AF/"P#"V3N4(P8^"P?HN8#XC+RM7I6.'8YU+
M4B'Q?.B2%..TX6L=KD7&?/M@.RU^2RLX3*8LYC<-+9(E=/"@.0 '6X86D^<\
M@F8MB%*=)\.H$+ZL$SMV3PC\D."*UN,X%;:GAF<8#H/?9CP#A36PK$I [2L)
MA0_07"0 -]LO+\]#TT..0(?;F^\__<W"$ PSFAD)9.]EX&#K1HFU7Z7DW@";
M,;GFJ-3<$BJC #E<"_?2^ET5RD/. 3J<@'5RV+D'=1BI]H4A)!Y"]I&P=YXI
MMU%8F;-N8/S XUKQX,D%4DVZ88 9MU*I%X6D9264D!)0L5]SCM'N?R^9B=PT
M[JS)-L%E4!2:&P.Q;6FEHDBYHK(Z)3FB.?^A$,_$CP@;X=4?KG+NO.<OD7O(
M3?7RX>9"P)C+8)&D5-9TQ86B"W!V"2&=E-!22(PH[(!2$G7@N2_+&3K6J8(A
M+,(1>#9HX)E:WDIS'3+^[ZF,&%M<08_5HVY-GVY37^\U?3J8!;;_!F%KZ_G6
MF=R;3XICZZ3H-S_R3Z\+FK0F:3M@M@3/S1DX.7APA,&LYC]"A01."OAC%Q41
ME>$*Z]256RMM;BVKSI50_6X+V>LN>9'0<;44I!B.]%85/NJMA+9ARW^QCCV'
MU\:EI_!YE\HQH'K* 177=!ZO-,>.%MJ&<U00EF'=4OIHXHGAG!) Z,;=HT!_
M81-V@#:U06;+9TIBXO^ X\(Z3MSHR!PM<(J8XV7M01(&-?#V /0KNPB9&FS6
M<;;( ,=2JKV?8\8]8H ^B"DM_OOMB>HVS>2K#LKYI8AK>#[X9"E$I<)']>TE
MINP5W1#@4^H22: N\CP.%I$"?])XE61RQY#+M<I;%N6=?;*I BZ^AX?EOFQ'
M>!YM85=&9+V#\&PT?%,17S.@-K=BV%B!$VY]/D4Z(-A_GX"&3'XT95KMW-XZ
MB2C7;!YY.=7<;:.F?=0E$:R \4!V[R4S#VGBW5%T\2%<JOTW W*I#O=>H$?5
MNS\%JWM<>??LS!\,<.4-8.DE"W(2UG1L  >'ZX?H3#?RTNDD-_IC':= J;F+
M7/_"->7*7W%Y8DD(!:EKI?\U0:W0E\^?O7Q.\J!3B[](>G;DO"G:]$WA=CF&
MU&-(W?\^?%A]LXY^I['UKQ=W&"Q5TQ4.8E) <!QBSX".7O&CL(JC5SQZQ:-7
MO(->L=L7IKUB[1!;^3KE0%L"IW1<R.^ I2ZKB! ?:.(749*BE$-.]M^TH%%*
M,DV^"SOYN,[S1LAPACSA3&U\BV,$$K/ZWMQ8Q72M\!A DDR<YIH]%BG\GD\=
M05R=<;5SD\CMAU=:1E5%,.E%4I25RDU"U:\E^/"?=>S.N(/NC$-W.AYW=T:[
M^]M!9=:3L^MXC$G6X!+)HJ4(.V+J[IP]<FXKH65?EH@W<E0U/L$P']F;X?(:
MJ#8&SF/@O-,(WSW;T>BK#K43O?H#*G!3(^E:VE:$#"F0T= (DI4W@T(A97@G
M96)(%) "CW2M:O0;M0@02+W8$W(+H)0O8!']RBB9R80&,7BDN7I+QS-YY$GW
M.>XU'AGF'+G^=Q\3HV5W5+*+=#,JI54%RC40+,P@O*I(9$XAUI7WHJ*/#)<W
M;J!(:?1)NXZ9L2A59072H  %G2O02\$[%B)? /^0B]+0C$4<;^%^YPVB0D C
M4947U<TS$JIZH0C0M3P++$1S?YM=/490H*(NPD2?^K-2P4"QGY)!^P/'UY^J
M.?J(ON@0EM9>\$X#,E$8<<4BQ8$W6&JW219*)X<00KK]!@B9W$ 6OLX=MW$N
M5(^PHQRKZ*(ZV&E5D@+75\-B*7OO!@EK;?<D*MTT!S:.'$P)%H4'F<9,X1K3
M:BZZ&3N8'$_U X"PDCZ4EJ9S5/_N+@;-_3,=08HKD3+Y;>J<<S-F+BZ-FK+<
MOYGIX.$#<O,L*ZQOC506N!-1[$7:I=)D1Z!F.L]7N@.K<2/#RV.M _\<MC,]
M.Y"B+Q]! +9_-*"XY6!O'YM];Q=Z#>H1^F^N'-?DG0X<R4/Z[I?--I)^C:_U
MEJ\U[OVU@@=F<4;I.GCG46RT"*7O44K/"7MN]??Y6Y;4#^L+^L?LH _51[#0
M!Y4+?"W/U%G_:_T^VWA;6:EV@-=DIVBI3G+HN<<_#[?OLBL%J(BKB :4*"HQ
MF>?S+CBT4=C7P<5A6_,:@D)(O,RUNG'+=:*..^CBDQW)27N>L?G39.7M/?FA
MK89M#83.!J9.X$%3:&^&/0<561+L3<45*!]_%D6I\*DD8HS9&^BCR><UA+U*
M;UA+.SM9@-8G?&KD5X>#V<6;R:\,<P6PK"V@%TWT3C7WT)17PS\9!L=XM;;O
MLO><YIZ542*3O5P!(3QGK%LP2OD"J6LP,4:<,MB[A=351,!J]D88+),R6LFK
MKHJ$D0N4"+M*\E3]07KR8(*%_)$Z%:[D HO1M^?<6!$($ 6?BVB6("T-D!(&
M]IYDGD1#=M1==D*J5T@ )M &.L]A/J-KZ"@8=BZ\^21#,42ZZJ)IA7!]R)=*
M\@7-UZ65857>U_I0'_2=1-EJD<7>"H,_.'R:M,[,D<L4U;0XY5I9 OA9+K;_
M-8N1%NCICU6:)WR(*W(L$B#YB87UL&#^795E' Y_C[3=F_A[E*$YD1<N\K1?
M(][1C$7@20*?3H!#17GO1EADJMG&0,2 /6O<QC-"()0B50HH\(WY98Z5+<86
MR"=7EIE4[GW*.<WQ]9,'AMF1=WYDA.ST*_'G]>9UX&?#$-U34S#]K.K6<S"Y
MV5Q->5DG /R8JS=M..-:D"8;WH^O(Z7CKE4!-\#Z95-?5'\+$H-URBD_=2N+
M[A@8?&+NFK&1D,!-@<$=/5K,O8W$+*\(*V!!YQ!1=S^PSCFZSQ&+-+K!JJD3
M2>)0^1Q*<Z*O9T$/E@W11V 47\E8%<:8R$>?:[C12&)_%S#I%T\))KVK-,@[
ME2Y4MF<0CL7:?I8NE\)R#G[2N]C>I=AT:,M0)%GH'^M^%0='X?6M6(I(\'!M
M8FVV^T-0+C/@4!'IVS>&]AU,(":9M' *HH6-*SB?*JW(7''@U80^]D8>@;<X
M+W4V=LWL:#B9_%^#YXGD0B24&B"4Y$M+"B<,RN0ZD5[&Y,WSZ;-8'DPR*DN
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MG[M729XJ\GS-;2/# (O8G/U_^ ;H353&K?\=Y*8RY&9+@V/MV4L/"HY&-X
MYP[.R9V$>FVW3"?)U7!<F)=[^X?L?5]RNEG3X+.P( 1\E,LNZ4^447:1!-K[
MH>X8&^WY&%_A@-[@Z[W]U]8;U(QBR-R$I8"Z4%()R,>G]"7YI8;T4@>?XD>B
M*[4T$1_G0_)($,EUE?6"-FNW!7:C \26Q&42__]_V@+I\?I/78TQ:KV^OI.P
MK96\< ?D*F?#V3&O^"2U4J(ZG^FN#N+$HW(U)Q<P5E.0U1;*?+=^;^%:&@R$
M[<1_]&5652'.\ZI4,$E(PIX1HWG% N5T027T*"]U;/1'WD?7Y9Z<PL1:ZBSI
M8F0"9L+636?6NTJK\<)-X;2FY\-<20L0U(E_*8ADEX$PJ#JNG(DT$5>"F/(L
M*3MTQ10%:F0NS2#A$ -2OB3A)OWGW"YYLG]OFW [<&2_FW ^I$W8J$LPR,64
M)T)3FW"*#FTFG+:JUF6*Q4S^E'6:DQ+4ZD!-([:RV._>_N7/AZ__>@(:ECY0
M&F W!:XM;YDI@D=+O,AV8$/>L3ISTWT6 W5X& BY>W.\C!)6DI-[11AB<J8_
M(X0-\6N0'^UXKK 5"$J;EQ1N#3K;PA'L27-"JI97R-<+D^B8"Z65%UT#.S)7
MA' 0*M]D1C'7.7\+7+WAN\XS$C 6\8!J$A2XCX6I7-Y+VU92(4K>H9 S@,4,
MS.KRO_#Q273<S D )&#^HTHI8FTPWLER*6( Z,LKLGZ?OPP]';^F_4=E+'KK
M1$8J!X&P<?D+.A4PI%)\FT;SG*;(RG(;V7B>K %R)O=M\.(A&;R&UQ'-@;,V
M%?&%*$U7B;V<. UK41TNA+1?40H"\W@4IM@^0-HH\@C-<%_)OZ"QHF6O75Y8
M:-_5TI1F-B\4]^TJNK$ M=+DE@MP/^0GQ BK^05 <E9$*9S,8!#DWQ<$I(U2
M::[MC[B:J& *&AQHPVU-U0452+.*-N9$OJ"4W!UP;0;-_/5%^B>7\K\ F,'S
M"5,_!(HKFG0L%)2,[*2^ V^1:=?1PC]#5B<J8HO0G1=(7K2M#[<G(;*;<A R
MZN&S+?TI%%H%6FV0-HTRS7E/7J]>HJWB5!US/T3L=M^&4 S)$)+GUQJ7H!WP
M&V98UW)-(*3$%4SD%.?D?K4[! ZIVR7VP%GYA 3B$Z!;EZL^1$ T )HAGXD@
M:-A*\ &XC*KL2R$B;1+L#<-,:0Y:W/)K%S!>^$O;M2X0NMVXF/PS&V?Y0Q 9
MOC#;#?P8*ZT:?$*%43@5VG.MAB%>^1&HJF$86HQ\@^-]S( H'2#6\/6\, X*
MS:/S%=7/1C<(-7,[-RY1EQV0QAO')5E"1QT /]3$X6_DCR@>CCCBLSS%8WE&
M/#O)BZ)>X9\IQ'V7@YI') T*-(^"&T>O5ZX,PPIOO$O2K)#^+\6KVD*US"@,
MB:<,%@1,/+0!(MA>),L9""O#$A'EO$AF]![EO,XO(QS_RE)GE=95OKN,>0;S
MND)A$7BNX$1NF83: /$M.GS^2'.?B452V<HBNL5%OP#+LU432\L>7X/.AH&;
MD%7N@/"E2P\_#A41/"&5"=!#W]*+XYK/!<MQ7U +)?Q5VG,HKLR9V!Z;?N>5
M?H<FY"=.?;G9I-&D^G-52,/II@NN 8:F9T*O%\4Q)!=ALDKX<6AU[07&P1JK
M8W9U['5W=6S[/.?A_I^&4%+[">'J-ZV'=$_G<2<$$W6(.J&7&6J!+M:=A'GA
M'80 5.H^!O&4HT,IYB8?2BYHCY^R'6APE9W&DD%5X\$BEG+YTQ]G9 &_)_/O
M,QEHR V>@JY*)8^R!=KVR[Q<(:49[7<ZD)(4P3($71'2>(,=U ;OE@>=F\9A
MZ]31NNXE='VV@LW)7?MX4VWD8()XTK8YXN)MS[B&9V0EPRCS=0O?2,=BI;+:
MC&TCLYH4"N1&\$W_(WHUEH!-U^(2V86T#"IEQFM:RW4_M)N^"PG:Q7#<]#=[
M5&!MM*]C;<!J4I>+?U4:^?D0H(^+J.#NI1N "0#@5R[9* O-:F6<)?(RQ/YF
M;"+JH$]2>E+4XX>Q8V)@<RUU#]O#;]]0IS\@:)3^5%85.2=,8"A?Y'5QVV-R
M='VM0YKDK:,84^-9LU'M(%EM5UL 2@$QMGZDT#R/E^3V,]NNB!0YX"@NM*HK
ME56ZC(IE6_9=>9FTX]=%7795*:'S2GFP?GJW_5OT&O"Z5WEZI;ZLGE(N$#;[
M_+#6!__M9.KY,5">KC*$"6UWQ,+R#--=E\DLX7RQ-;'^ZY"_;EM>R<):QP /
MSBCIA5F2):UM&-.W#._QI:("6F*U"VJ=KB@XK>%HD=>07Y?W7.)R47E!JM19
M%_N[G*DX7S:M[IUTX&R'V.C7N%X,Q[BV)(,U-\AR56U57TC #T3,!\6S)G>'
M85K$Y0*NN.K\<B%45CDR4"[FOP&_+X?M '_3?HFV&QW;0_,)&:.QT4=MLW.D
MYR:?T+[S LU>N[FS-F"KY5MG[F3\7J<T%@-@TW12ZX\CCC[?RFE-\Q6= Q^B
MK%[ -&+JV^E^U\Z=W<"K+*8U6UJ&$ _$(I^+6%ZM6;N[K0=U1PT#.UH"NAS>
MKF]U*WX28=)T,Q@0T@8NN:7CX<-+%$T;M)L^FYO=2+*Z\F\8 8*&*ZQD" #D
M8\K8<AZ4:J>:CVC#SFG#FK]3H3_&&<!HL PF@RX G1A?]#-OX"$4?_:"K\RQ
M 1;%E^]UP3?:=V< @%E2R9)5E>5;</TE7>"9\BN#61#LG46VARXMV441+8,)
M9?74/[FD3GG:AD??,JLJ3DARZ<)!$4I5R&.#9*I7,18\FZ*M3DW*<74MXKUI
MJ-VK6( \,7>@69/CH!'DM*R/M&W!V6$NWT=$1#(H(;/]O7V,YF_'9CVH9]CK
MFTE%.DM)7O QM.0:Q$;/JI->R'$'[6K)1D0C*1LXT9LIL0"&!^)#>;B"?#L&
M:Z8$,N[Z<=?OU#/TSV'O:;:+ B-A*_)56$_%)6#Y*8(Q=^T>B,DOM?@74X/8
M:_D!_KWU5])2D%L%7Q.J8I/>V)7(A_/-6X;8D<>\JX#C=JC(.\A:2*<U!7\,
M$V@Z>MXNP6 [9.;'HSC-'=27WPRS^_)^Q&GZ2VBT;G#79"YE: 00GB"*Q7]J
MB/=4:BDT 3?:H)NR @IM$^/X<1CLK*Y8C! 8V#K"V,#%2"O\]&B%D4:M7Y?A
MP4O)PT][#H@FY<W>JQ<^\EV#DHVM0@0XLJ.@>@26FG%,C:89J A$;+P(HH;(
M]Q3I5.H,_0QMYUH3.>!-:"3\=R%6#*]$,G],9\[G-6;*9GD.&L %K/V881A\
MF[(A8< 03P@1Y5<59AH+$;JC10-KVMRK8.*5CFFBPN8<R+M1W0) ?LL\@Q"7
MJ;/BA"KLJGG0<8(8W](*&UQ_#)@S1,$0O4,A7,?6:ZB7Z%":WSAO3KTN;J R
M:4<X6V+67$@RG.P\(U1D AN-NKJ2LJR5!T]E%?L1<$XIEZP\>[B?2B"J0Y)/
MP]!Z4J\2HW"'L:@$5Y&3[$K(W:]D3Q0UN<5X9C\!(WQ0A4)U1A#*G5;)@OB"
MG,Z-J*TF!U>Z'>(A;!7<:*Y6<@S4:FU?I!0D=92KRDM,AY2B0DHV*K-=(%R+
M *+RE4=<#< A_7'RF2[2 O3B146X @97^TAM1-!AB&"E<D.5JX%[QK4 -8_D
M M"N-@G84-[=U D6L5U0R^VPT Y22%FPFQ7FQIC6"0,OI99#IH*M@]GH\K44
M94A!4$8J*Y51WLE+HE%CD1YDE5HI339M5S0RL8UL'TTE3QM:2Y6*H^9"1#J7
M-5Y5SHX]'00[[K0^Y&AZO*?7AO<4M7 4'&YT0D<GM*?*VW!U@4.Y^Z_E-BSZ
M)4:W^12B62DX\82E2,J$Z5Z,=O/3DGX2/Z :@,W3<M<30T@F_<J<*G;2O) +
MD-7 R.?86:?_TNZ54ZV8K$7"!"+:<^,GT#B, .P2/@QU'05S;']&#!:FFS#3
MI#-K@+:E=J&"K:)NBN.GIFZ@.&DTA+JV5KNEC#TFI]0I;J(&1.=5^,$P\P8'
MG;"X,MV9,DV$(+90A6VL,BVDG L\%^5!-GDY#6Y$!(AC9'J0AZ4\$A4H&M*!
MR*6Y!!FM]KQCUS- /9J<?YBP'#'-2D'&@2)QURG/G-:0 <\'9&)"[^12X$+L
M=E3^BM=0V^(];>WJ6PXQ#%S$C:DVY7I.<C-X$A=&.Q,'Y50MK\;JX\3@I.F-
ME!M<2<36MB/2S8^Z(/:_$@O]'%*Q@7S:HC-D!["+_]Z!<'Y3V%[ER!..X;L.
M^ZNBKB[E^C8H$AE;N:ZX/!!6W-\;4@RHG> 86A53,@[7>?'=#5ZXOL&$UK#^
MV;O%_L :>30V%W]U3*G'#,8KP^[ ILM+9P?V,X>83L!Z#V<34@UPHN=$9HH%
MM+KCO)GKVD8G;".*_0G$>S!9V&V28.%((U(',0@=YFW*9M)NV\<'G-K5*STC
M>&0W)\-; G=[)#QXF_?PK<3WX5@)"^MH0D"[5Z()G^JHVE'L#ULVA%HKK5:F
MHH 8F3Z/\7/*ST"O. #D+4.!RCIV85%KP9F?Z[C8 )JUPNKV?5KK0<DZ*=>:
M/VO0Q6BN%Y6^J+SC735525NA8W/6."4T=UDF\/P6I-I*DJ!,4"+'D:%\JDEX
MI$IMU25VJ%?D5<5V^SRK;_%HB-I&P:2IX)EGR'*N/13=EP<^%D[]6(#]]0+L
MR^=C ?8AK"QL,<L6%-PE92UT8E, $\74$KH+%+312^4#9(M$81_6$)HA+6OT
M79Z$]L;U]NF#4S_M@,N<#N<P;'&9;P'_<8]#<',3+<<"/V4R#EJ,7$C9LNEY
M&\@/<;#-EM2.W01@Y\U^3#P9 W,TAK]\-C[T C_:@06^',X"/^Q:X"KOIF%\
M+9;.1H=5I;686DD-?QJXMDTI(71K"9CH&VL)8RWAP3&P)L6\Q$JJ_ \HPV]\
MV3TMQ=,?V!<='/=;7Z .(S(UBF+4Z*\"1D"+H9H$\BD1$<B#%XO.]RR2NJ-P
MHFPX9TUG[[1;,<=RB@5-QLISAE&Q%HQN\$P0#0JDR M1W2CRWNH2@ S@YB_J
M @\N>3[-$LUCHX^>T*UXL_?>C6KV.13@%L;[\[E\6FKO.F?R*TPN,$;FE8@Q
MQ<+1#<E'4<Z%$RDW\LF_LU#X>BJ*+7NS,:^K\ACC23N>M'V<M+Z+Z;F7)@&V
M-3F4QZNM*[S*\)2-(D/I'O/M]66#L,.,F_S$MG]0>5Y%R"5BBHO4B=;VU9D@
M\I&4<JDRAA1P"&JBJDR5E#6?I6'E!OME%!!5.8/J+#B,0DCS4)= NQ@E,0/G
ML/C/.3^B%:-\*]LU?ZC:2C8?V#)(C"@J^>=J:D=#,AJ2!_8^U1K'I$ZY]NS$
MKX0V+=K6^+8Q)AT7>#\G)?&0P;E1%;7@)'91,%Y)?F)@1S-ES<&CA%X_7:K>
M"]Z1#QUV'$TS@=YU2EBP.%IB\<^&*$46<&2&_'+FN+/$G\?FZR?6?'W0^P[A
MG.<*,7_.JN\MI<#Y@U?[?:8/I/DZ&$S^X+E%5M>^DH[EUYGP\-P]EM'._-.<
MS-+\,!]WK^UO:A!-"26/7CC7G:)=),,(T1JKB8T$6#2D!!@)**B7GI!N9YG+
M,S._SDRB2'WA,V@Q57:$N?GTZ>ML!)>AE@^RWZLA1[R@-.4<^M/T@:I-6<_*
MI*3<&/H<.>;4_JYPY"$H-"2QW<U(7L\XW>O.35&5O#(C=BX-%C1-RJIK17-.
M,54"7N8;5 J 5^9AMN$+H&JO7A_U\VDF1X]-")LZ'M0<'H%&X="MX0#5/)L[
M,<L=C5A4!5D (!5W[S(I#:"&Q2U, *-3X,ZB.ON,"<(NAJG;+):GM%H&*#LI
MU\8\C9(EO/4TT7#*!"--A3W6Y9Q55$(FLA BF!PR:CD,H)RDBB3-U6=I(!J
M0ZA(:Q@"&5U$2596>H%QB>8+G#)Q$A48[@*<4],>M5E!L'))1@</R2B8DT=G
MI3S&VJU9TWC/0$++V3*B;-LQHN0B5B50P@U8A3\C]JVZ<=4>']ZR[D:GQP E
M"W5T(?<%BE98P.JE_$]L^R:!N0I[RR\%P1MC:C9*Z-UKMND3ZS.Y5 P%%+.!
MZ@X[=6/85L_^R*^UN/R(%[X#O/"^.QV/'B_L'YW#MP4#5.U36U)A-9VC"DN"
MAB-3?8^([<5<J9R551TKX@A7^LQ0;)QE"9H'ZWS2]F,+^8\!-@?UGH([',QB
M^I447&CGWW %Z=(8AX#LP_2;D5..U-:BYEZ=!(DZM-;?P^?D=D$M:8 Y.7[M
M(638%/0* <HB76A;J-8&0_K#II@7NEJZC025-^7OZ ^:\R52Z)&2^,X5Y;#B
M?B*4%S5D">;^ XIB:^V1]C@TS8.^O.HVL\,$BQYJ51=E'67,'>2!JRG=8D9$
MI1#&R0A;PQQ=11M DR\:WB+A2+)G=<E@.0AQ9,R6(AV#**LBH90U,#SH3%Q4
M M571_"!O,RL, P3D93(8T^2ILW2H?N FQW/>XKN=T%79X#)H/6-Z&K_X:;2
M/<RP;:3QQ?YPVBMDKI4LKU4!*F1 +M<@_T6NO#BW"-5X9R49*?4N02\-7"$D
MQV58,E:QF='6T25@0DV2AVKZ-38E,4F_IR1F8S1L#'\9@BQCZ9SS8*]<OLXI
M[(F\B%G2V%('5[P-#EF#R,#ODGM,Q"8+UF=#]C8].KT[72\&LS<V.UUODQ*3
M8GW[3J?_]^3T\]?@^(O\K\_GIU^^O/]7\.7K\=?3M\'9Q^#K'V=?AEI..3WY
M>O;IXR- =@P,_=0WLB.DA7<:G'SZ\.'T_.3L^'WPY=OGSW)A'O]^?GKZX?3C
MUQ"_\.'XX[=WQR=?OYV???S=?!A\.L>//W\[/_GC^,NI_;./IV?RH_/@\_'Y
MUW_)"_S]]$MP_/%?P?DI+'[YE6-85%_@$J?_]^OIQ[?T\3^/S\^//WX]D]_^
M] [_\O>SCV_#@*_&6P=^=?;A\_NS4_D1;*)O7S^=_PO^^@F^]L^S+Z?P<"?O
MO[V% ;L7_7KV];W\^!_'[\_>GGW]E[SVQW>?SD].CW\[>X__AKGX0WY?_T%>
M]]W9UX]P8_G-X!@?ZNSDV_OC<WCVSY^^G.K]_?433@D^TU=[JY]^A1]__2.0
M SP]^QC*A\.=+S__+'<8CDS^\.WI/T[??_I,TTM_^GS^Z>VWDZ\A3L?9U],/
M7^!/_SA[*TW';_^"M_<9/H$Y^?I%OL'?OL@'.SZ'QX5[??OX5L[<\3F\QK?R
M'?WC^.S]\6_O3P.YIX\_!JQ#)>W2V1?660I^._YR]D7&I'+2/WW[JN;O7_@'
M/6#YI'#K]Z?R2>4SAO2OL^./)Z?JB[_+*<(W(]_1Q[?'YV_QS?'?U>O?-+7P
M'7P^7 &P'&!BS)C^..U<&C#%I\<G?_ JA-F0$W9\\O>/G_[Y_O3M[[@FW]*R
M_2+G^OBKG#[Y=9IDF#)YU=/S,W@;<G/(M_51KC7Y9_C5AV-YQ>-_G ;?/L+U
M/@9RT9S+32*__T4^PI=[A4>]V._M_%=(O_V#O6"@1Q:W&RF_]+&R>._O'WJ(
MN&>'1[8RXH.[A@=[/6(N/-?PY4;7T%LF0P&^#3#BZ#L:'V!2S$,G&H;#6"Q$
M!CV'O+HH\7.9IS$J36.V1V?4(#X_7BR2-.$R<^QENBP*#:+$R"&WEE-3+U"'
M=F?"H@O2.(04FHSX@T$K3JKTA>D4'8+@).4@:3()U&"7?][GY2;:/?BZC=<Y
M@5"T]&2ZHR(I(?>!-],$4ZB-R^2"T12_?U'(.P:9N-"LWXLBJG4N%1@'ES+<
M-1UH<'N-\W%Z<*G?5GW&O;B;>0.M3$T'C86FKN4^()WN;]"S>AV)%J^IG4C5
MW*W3,)C,:!X^J*+9;R1)9PQW&T?_9#[U@2*VM#$B6+!SZ5*^V!3_6<IMAIKO
M+<)\:N[BI%3U<1]WPGB86\P\*"<;D,2( /@%!,"!.QU/#0'06>7JZ>R.151A
M!8=V?(GESR3[=UW<*#;CLI[]6YB6654E=ZOHP<21NCS)TS2:\4'B?Q7J[52\
MH2Y$PLJZ/Y%[M<KG0"H%N#@45"#[0&EJWI]:+8,ZLTROP51;;:!14 W5_"3:
MV$&IQ[,-U%E-CPWJ>^[(ZPS] _R(9ZXY;7+$V&M)^70M':>0:(V3U"6A-$4Z
M7SL..&P)H=0V42$1QB(9H\G?.UI9C'!Z)^0CRN&^RW/I![TM:L:5G^3E4E3)
M/#B>5]K5T;(H1M^!#+]UU!SL!R?OSG'T9?#R>1B\?"'_[TC^WVN\SN'^ <FD
MK&IY<LS3FV?1E9P4'."[M\?!12W?'BS-$A]"/L7\]Y//(>G57TVM987E"'X,
M.==)&2=*U0,I.%DQ<<W:T\M)0T80<8GGU#PJA2[L60[ ^M<=YW(W0I\BK#A!
M7H)ZD?#NR5-PWN0:S1JJ^HD?<[&JO&%04=*T[YI>?7) B/=/GE/!=60OP<F/
M=O=DO5]RBW6*[PG)BOG<-U*TGG\RT]?="[[DJ:">-1SHV&/\,%GV@?5/]M]C
M' X[\NIVI@<0@1&Y*((<W*WONOR3_>FXK^]Y7^\?#6A?'^R]P*10S[W1$3%R
MHT:ZB76=J%&A-)3_]U9[F:V\I,1#W:#&ARO\GN8SN0%L(-/G%+1@ZJH$D(/7
M3N9HQ$\.!KY!-I[+.[!#!E5??K'7/W6 <AG'5WO'K[9_6HAP?*EW_E)?CB_U
M\;W45^-+?60O==RFC^V-OF)?:5?''_:](L<%>=<+\G!<D.."',[ ]Y_O[2/E
MQ7CR/:[W.@ .SL?P4H=5]-CO/_>#Q=7QO=[M>SWL_ZT2K,(N:&-;+W&O VUZ
M79A6NC+Y4=T$DZ/GTR".;K 8K2J[!*F Y+CJ_(5.PKFP.L0UJL*O_4P,'N,R
MJC2A$0Z&B\NDW4I?I_;CDH?6D5S7M>Y0P?ITBZX"<A*!K\:C<3<PT[O(K^?R
M]NYO$0;GE@CL@4VN+P66N_&/_%/ZU:I(F'ZX8"59I'1# ?:,7X)]*?5XT^G/
M*4P_BM;Y ?;L?F%HDP$.K9%;&'2!9C3F=XY,Z/F07C>Z7AF[X)SY)7B]3?IF
M"T\VT-R+9"$/J)4HY@AN?OG\OZ9X@FP/[C[[?$Z@;K#47XM(WBPJO@,!&!+,
M8946/R?<U3U/*E[Q_R25M-'S+:99GZ-]OFL\*P%ZZ/#2ZM,768 ]@*B>\VN!
M%!KR>$>>C45B.%/???T4'&=1>E,2_R%>7;^@]3=8]QY;[PE*5&ET<6%NG]A\
M'2O%UP'2,Z5(#="M_6O0\@'@@;+J0MF;$7X143&_[*0Z]!AX%+[ ]Y?TE!HB
M"2*DDN]9W[04 .'3PCVC&,%32Q8\!^:'OB$W<@4B&!0W=&+M3Y_^UF[6,-K6
M"04K&KT*E+K0S %H9':^"=$=-CVVP@&N$CA5?ZI@V)U07#C*" ?O;<#FL!>@
M1!SCCBL$\K5 VY'60\[E+TKN6&R.*)B4QNLD #SPP<2*0WW$P#XY3W,?8Z.^
M<P<[T8CH-6UQU*_/QP%@8J=[P<>\ N-25A&R-?L9#/4,CBZ>HBTC?G_M/7?Y
MRM)MB$4Y+Y+9B)T?[4:?)SZV)7F-*G9SRH,WHVS7H/]\NV:](?7J36YNUV.C
M&W.2A=.15/I.D-_4.UC-[\=C2L;(H4'!]@XT)U/IXX,*-E@5M6:U2!^P+0"-
MIE+J,]XS]N>W9XNVS!1M<"Q"JVO5'5<ADN6L+DH#[0>1A> _M?R6G.";8!9!
MCJ.[YJ)^9FHNABP2!X<*ME!\@2'XCV,Q35IYA),H%5D<%<'_T##6\HC^K(9!
M7V803!I,Q:HN5CE,QICI>'*NSP!JK:X;/Q/<'<^>N]$877!BPN1%I1U@XAA8
MNF14;,$+7=)DYJ,.Z>]QS3^M-3\$=_^AZ:]>#YYO]V"G=$9;2-4&H5UP)GTF
MUE^0T4G(;.Q88$D34;<F?#>;R=%"CE', WL%G@C'[2KCFM;F#HGG1M:J.V"M
M.G2GX^FQ5K6?PSV=N3M-I=BDG1M"T>(Q4"G>(DM\'U2*OGMR3U2*.KG;3J5H
M%9=];L?1/QHCR+Y960:-:KP=&:)E<IZ=: %"7URP#RK 7\"1#^F8?W2$ALAF
M:+AL!3'9RO\7@UI2,JLK7 %$7:L9@]Z!F-*E7$.*HTCC0B&S"!R6T#0!)0QO
MZ9E>"&JI8"9"Q H"A-$(0ZEB"M\AE./]\)E4I># EZ_^0LZM&2:LMA7(N*%*
M4Y.GT5>0VD39N'D; 12T0=P(7(>W0OEZ[@BR-FZJ_.#CB6G'CK719VT[U^<:
MA:L '5JG8-SF B_S1;W/:7KX:7^&./(N*^6#"A <0DQQ-X28MZ2+WK96SS\=
M^3!'%VT(72>0BQUT^-P=$0T@C&8^3##PK9R8M\4R+=#3&^:+>$3,@ /CSNP_
M2OO3WQY'?_C@7FS<_XMMDJ(Z9*CRO3OB&PX[JL=EVM+.A#';:+">VKKN'Y@P
M&JQ[>;']DPKY!HL)EKM,$V8WYC*>5D:JDY>YX-S,:*V>UJ*^-9G@H,8_<K<]
MN@7Y>ER03WQ!#@I']6*D6QT7Y)!>Z(LAH/W'=WK'[[1WGNY1_V+4OQA?ZO8O
M]>7H%8Q>P7 &+E?D4=_O=#0S=_]21T66Q_92QX-C/#@&]$*/^L?8C";FSM_I
MB]'(C$9F. ,_ZC^_,1J9.W^G8\#QV-[IJ[V#B9B.9\=X=@QGX+::UZX^P[@H
M']NB'*7('F&_R?X02JN/ KDYK/=Z:WW200V__\/C5W74FIR>31TUB\AAU%&[
MK8Z:ZH)UFNK5C,H+KJ(;9"Z)EGD-K>)Q3>(J\N_X?"/_Q9/S8%[W[\ $$;&C
M5_*BM+#5^KR,KJ#!?9[+#[RUNB7EXO-M.1>M7[W8:_1V[^\?JDYNYE=\=GAD
M7[P'@L7#'O>I.SDO;TVP^+G(YR*6!JI\1+2==\8/,"B!RFA( I6O<"+.%DV"
M"NX8;NDCG@RZ<WM8A&>CX%_'(,C9+(F-8J19?\(.TW[O_E(X;"Z*05DT#M2
M@0)9(QPNV2_UK)1QJ(RZ?I%--NC@WOPE?8D.]>H^:<=:-+>F02JB(BM5\-U@
MN^1XF/^T$X>QI5,P@"4,E$DW:\30=%(BI.#)<GVTEAI\;R>F7BZ1CY@+&L3$
MV_-IBU<D&6:N,&/$@G/P(7Y];L0L(N!*A+Q*+*HH22$=))V9_\?>NS<GCB3]
MPE]%,1-GPH[ 6B00EW&<C:!M=S<[;MO'IG=F]I\W! A;TR"Q$MCC_?1O95:5
M+B ,V(!*(O>)IZ<;D%2JO%3^\CJ9SGA'*]$K#G]Q(F;<@@@YSU".+=QH,+\'
M?&LGAG6J#>0 &_"HG0KG$.)C>+S]8G./3[P.7?L<3_A\!$W&].#B5B=&[@7.
MV&6/7S6T0_1G?:O%?((;5[==6[FO8>3O&X.;T/EK/F0+Q/YD>(UP:QUZWD);
M?9C65PFF59NP$1TOB\;@,<8157 Y,(<S%IUY[3"<3^19"WR%K1;9LP-_+/L6
M8+_XT$GVI4S=+'1F,R9. ]YG&0SUB>\QZ0M>L54HNQ;Y]+0"3B?L-?SB42_X
M'?2"KQ][+_B&4N;:P ]Y=U>F.06;1X/<3T0((1X@)PXJIF09@X;0Y<CGS7T3
MYP [A4XKV28>>0W>\!JL.DM3<VZA\R[36\-X)$;B$.=]>_GO(8+#!_Q%QL7(
M$>C%^1OT&W=),*7'=.'4#B!J) F/,[?831+F>P7&8";LEA%.^DX?[ZBWG%!&
MI"!&%:YJ=L],(2:_]E@,_L;!'NY@)ENTLJ<[W%+0M=^Y@</^0&!0JR[8-XG8
MUY+%<L+N%?KL)0-\ 8P XOI%)^20L>JZ?9>#A!/V<FS7P5U=C!SB\11N>S[9
M?*@)WUHTZ"J+#^,+8=\$3%.@D,J+TX*W8'CBN[*',DTC'[J,N6!E@!HX1%WF
M!'B"_8,M<_B,(Q1A\L!)?\Z;_XI7.DWRA3@MP0&F1;IEY(_'_HL\@Y>7&S?]
MC[D5".2(ZU<*1W0A/*H2C92,U-3 A]; \$)1#'?U9C%-$#H#WIX9^DC+3>:C
M[76M.UHYHTZ.A17*!(QG9 >XE0A9KP\I^\'*!?+8.7N5"83!D](?<_2J![@!
MV\40SGPQ0($:XQY=0HNIUQ1H,K>DV4#S+)UB&TJ[4"R)H;=,#:?.2CNI)_'^
M,?Z420[\L>QV(AUCA0"^B.P5X;Z3#::=1251>1.V1NM_=IT7WO-\ZGJ(ANUH
MUDNB;S;>1C[A!=J]8\OU :!E!Z>YV$-_BKW<WT3+0]_AR[>GH*"BWF[_G3,;
M"= Z S^V%TU%67HKKIGD Y8/$=@==I3ZXV>.P+D"1D>?P%EXK#.^?,)SVO;X
M0 <&VA_E@<\[^ Z=&>@X3[@+1MK8M?LN+'(9R1]J0&+>@'V@$F#G<=7O'LY;
M6W<:2CM(<!/RPQ+W'.[<HR/O2(^\HKY#_HF<Z?,ZQ ,;)%)XS^#T]2?@JI:#
MO#(.!R:0_GSMD<YS&66:)YRS3')U!N-60S.QB(T?FYPWDOFX".(F#BV8:($!
M0:Z$\&DPT\@3L)51;@R0"?P@\CRKB-.,Z20^SH+_T_.]L\C)B [T$2@TCNK9
M03NL",@XQB,9 #'_5R4U52Z=QX+A-ALC"WPK1C8FD7H+O^4P&G9DS(#W3&*Q
M!/Q8!X,KT9YF;YX_6MCLRML40N;AETK//X.3KS(^&!D'W D5V3 RE1929CV-
MT8'92^@#M1E:932*C!9NR(S=9X?=M/\:GQ@VMSBF[.\>.^U'R_XK?E3)%V2D
M<B!KF,_X2\[S2\XAS[:-#C[P.=NYJ-;$Y[HR!LWZB<_7("V1.7HMS=%\1XQ<
M_7%Q==?3/M_>:]?=SJ?N=;?W)_[KT_U5Y^*K=OM956/GZJ+7O;TA8X<*5I2R
M<VZNNKVO5_?:7>>>2=+#U\[UM?;I2KNZZ75[UU>76N]6N[^ZN/TW^\GG^]MO
M&ONQ=INXHG/#KKJ[NNAVKBM:]^:B>\DNA;]?W-X\7/V_[W"CSK7&)/3N^TVW
MU_WWE7;9^=;Y<O6 /[_^?MF]^:)=WS[TM+O[V\_=W@/[&"Z^$0+S.UL?>VKW
M0>M\N;^Z^L9N"'>#YUYW+Z[80[0O]YV;'ELK6]75]YO+JWL5HRWL[?[--N=2
MZ3K( ^_)U]O?KQAGY;LEO:^='F<P.CF.Z>0P1>N?/+4OU[<WMSW0N: Q>_??
MN=*][G[K]K2D<A8(#O3CY=6WF^[G[D4'&>/VTW7W"_[U04/U1]Q\A-Q<:#M(
M3TKB^_W<=2,W<">=F49-UQ05O0O?&[F @UT[=R!W8.? BD1QE9P#-:@R+8QS
M(,E+,"_9#R;XFYR] UGIM,[?T\ )0T@HGL^>_(#=<<B]8HO3D=%9^8(.7?AX
MF$QV$6XT<'"YD!.4^ ?_-8\38K6YR..'GRB=4'[O#-RIRUY>B4SRP!DX[C-F
M:>/4Y&P&D\[6>.YI$7;ZT@T'8S]4JV:"^[=_.,X4W-'Q;L>I=!B"A%'UX5-:
M/H;\?9R%W\*L<LR@@PX6O/I/$ I#WW:8$,;4,'HYM#H6QW4\$.\HY2;O(#?9
M.O;<Y*9*J<FH(WA.*V.JI^B@>4-BH;*I_Y<H$U!3"99H,J%2X(F9CKDWIB[1
M3)Q:72W:*M />%-K %O4.,$DC))MHP-=UR)K$W,IP%18M(JB'(75![\W?ETP
M[T4Z.V9(.7_#1&IV9TC$1LV.N8:C^7@$R0Q8Y9$HQ..]G-+K%)4$!=&E91 W
MQ52I$GT-*]H+Y')$'5P8AT;BP['GC?_L)[DVP;&0F#1VTSF!D502.[^/*TZ&
M.2:C@F\C5I]<&X,"M6?06B#DN5ZA#;W!9C94!PV!U .H=6:8RT5@)JLT9L E
M[+_3P.7Y6#P;*=:W;AIHR=(X4?NBB?Q7.U6]#8\Z10WLA5A*_22J81(-('C#
MAU0CB HOI,%B.EZ@Q=%BX !*9#]'P!5J0Q\/'WG.8.(LO#^#C<^N/TXY!CBG
MQTGISEI7PN(QM+S744FZJ(E:O"+I*)I/V9UAI3ZF7XF<KKF7<#[!TJ',AM]%
M]"!<M]+E55[%OJ9$H6+(GA^Z6/4FD+CH@4CU+T=YH.5]G,GR6LZHWYQ)WPE6
MM)#IC)B9YF(AY9NM9A)*)>HZP[5'U'C&EH4UPD_(/@2+CVDHGE1I)V1<>*+>
M,CNS%04J5Y'_*)^ Q2JV-L7OT5)-6<$;QCUV%_@H0-S#+%#<@T<8 #WD:PWT
MGIP4E('C/AW>0Q%@0C,+W(' 3GCP4 /;(SP$%.A@&_L0[.F4HWA>41"K6;0:
M8[T\8#8FK]KKB]8D"/AE<KH#2AM SHE]RNNE7M P!-,OT?:'!^NX<XJ9K_8
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M$481_@'IA'+$/73-8&P699O"+?KLJY&+)=8#)JPN'Z U<GD+31C+[(^?'6\
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M!Z<4!;!!KXF[RR&YX./A7E)(KF)B]&CS(''4E1>^B'RN_==%3:XO+(V/_:J
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M"(8!J96/\IYI*<1[==UB6D4%UBN#^:(8:?-W?!-1=T_4!A&U9$2U%  :LZ?
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M=E6D))8=JI%Y)@_.Z+Q"G2 O1 /.'SMB<B?3(B%/C<0<ZZRVOSRN*4M\9::
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M=.]CZ13-I>P=T2Q3 F@'VF@":.K1A ":0J0@@$81MV.-N)DEB+@1;E,!MU'
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MJ$ I7Z+X!(DV7X$ #N7/ERC[H="T4/>@H/QYRER@_/G--MW4#]KSF9+E*<5
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M;*O']C1T?I5_.1^ZX71LO_[J>KAQ>-&Y>%FQ$&" 12@"S^-?1VO2C783EB4
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MA!#D(\AW",BGO8&8*,98 H5"D$\)R$>(KRS25:P@WY=/1Z7Z*,A72"(1XE.
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MLBI3-H12N!2KT.[4G]7<0^ T4U0*=P!I24X% AB!G/0FN2)4DE^))1]C,%0
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MGL&LQK%A4+;?3AA$&$0$L;G"($RG"G>R\=E\NF=)EY\%#I*C._\HAT$YC'4
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M4/>EC +M $SM9,WL<^W0B+M(F:_VZ+>GB*P[<9"'E<,GPU-TCQ9UX;'IYT'
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M(PYS#$8-%TGC"P#X[#MDK.9[_MSD;/YT9YB9)E@0+Q2_\+<G,P+F@%&\CR/
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MY?6+LICXWY[OC.%_@W#H_N]_ 5!+ P04    " #ZD0]5")PV#TO& 0"H Q,
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M\XO'&W]S-[DD/BZ$TCLT /:+\6X%TQMTP^OQG15?3DXQ^6[R/IWC=OW0EKA
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M-D91"E@S40MI%Z(7]G/&Q.RY).* HD",46F9<N />BTAAL=*$R=XD?E.7%(
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M7DG,8F/!&X29=(&32%CPU@KN _C-A#C,-1UI)S#Q_$U-EUB8]+_$9#H%+T2
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M""ZD?J 5BHM#\%/#YF:N958)Q054=/8#62V#>7B:V=V2LYZ&L\3*ZPO>J?R
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MN#.]L3XL.7\"NP@F>.&4#MG)+0XO-XG8Q+21,3 SGRCK5,_5,>+T!';BD>B
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MJE]^DB^73G(N8\DS6A .,AC<U20'=U59DC KJ2FBS%K5#PJY\T.Y;*R45;4
MPW2KP7*;=LD/D4&X_=Q?1Y:]"M3JY=DW304B&H)(*<^X(39C./5("U+$:4J
M7B(QL0"5="^S!GU&\+X:)E]XGGMWXY:R@7"H&<XAC'5!5)06A)G"$B$2/-1&
M")6++*?BR5/*ABQ>[]1[\)G AVF@F$]FILK*&2@^A#*9(CWZT,C=F"!.1!UY
M$KP(M-&]"7+;&4"05KE*<A:EFB21C0A3<4Y$DB1$IIQ+FF89%?8^^E-];.0A
MF2!;SG-_;K\L9P?GMLBY**)$DM@6*6%); DOF":QTK'4$<\2)I\\95^-%=Z'
M0+[T[+TV4U^6AT;%>#(W#9C1#Q;7N-.BYH8*U9$]1"($]))>^.PD?$Z7C(8H
MUHK;B!,E8T%8GC,B(\X)-Z N9&QRFB..=/HU7<%]N.(>']-;-Q;Z8WI;Q[1C
M(VA*F4I4!I8!&/@L9IP4$=@(.<\$-UFJHH@^><K9_3BE/U0I\C24N@WDY<:J
MG;X<^1Y$)+:4);ZLZ=7W[W[CX@V$$^)IEDH)CDW$,@27981G.2<ZD2PQJ99"
M%N#G#/,-8NP^EB7V9<H/-Z+1RX,[+@%!UR.CBB:%(#S%1BM*(U*8)"8)S8&T
MB:;"9"Z[DO!UE(_[*!!N-2H2;;!_W'^78PW&]2^DF-ZOXXP&41GPO+ U"XVC
MH3>1L ?\(YR3<1BX-C/5?%8J'-KJOL?/5B_\P2(K=VD<H23$_[UH=_]U0R'\
M8G^LES_H7'D,[SO1ZT!N:K1 &KSXI-S,O==B;EY8:]2\%ZBW)E#?+\\$L[G.
MJ<XU ?;'KJ\H)X54EE!MBX*E+&(R1@.+L?LT6Z@/Z=QW8ZF7#P]8/G0!E-*D
M* 3/B=+4@GQ@"1%QHDBDHYSF-LZ,3%SI/+]/\N%6JUD>G%5U,IF+T=?:4L.!
M-*?E>(R!*<3G<4>RKX?9)D!U8JFUG)G4<):!@14I%BEA<\LH%SQ]]PKE)HT3
M^@WE9B\&;T\,+@\NBWD2I5'!26PS!GZGX$1F-B=:@F$D390:BO#[R9!M0)?L
MRV0>S3%/A>N&EIGA*4OSN$"CB.<XTR[7*2W<,8_Z8_Z0CGFWK":FF<I91."P
M<[!VA"*%!9=( 4UEG%,&9@Y:._GCK:SY4:T=@^-:M]DYWQ ]]]XE*?_/-WKY
M1Z,#<A#WO(BS2"8)BXN$%X:*0HE",DE%IIT.^-8AM%X'W)X.6)ZM5A1 UBC/
M<;@V>+Q*QT04E)-<,LX*;B-ML($C'_+LJT=:/B0T\5X&]C*PM8,CQ:,HSHLH
M!Y]713(3.F=95M@4SHJRWMWM9>!#DH$=.Y@7F4T3*TE.<::O2,#=30M!4B5-
M%D>I5EA>3J,A3[[:W?V>X.GU*FJV3YV$NP/\[\[;)O!*>K+ *;=+KWO7$.6[
M+O%Q(6YMR5=/QL3[$#W UF-K"7WF<DI8A3 SVIR[;J4!:)J%\1T<8U2 L\EH
MA!'Q$G0A^I5?X^X_-E-HTRO>;X/G3EM3#LKQ9%;.+U\%5O+\]VK\NN&^?R'S
M]4;.[1DY;Y=[7R/PYK(D)TF41X3E:4&XB"5AQG#&N)&""0SV97Q]5.6=C+>[
M)2.@EU&/54;=>A5'+Z/N0D9UZUVY,DHBAHAE!3IB#&14;@GE.6@>E2(5$9Y[
MF.>W -%][Y(1]]]J=-UJ8#$J4W[$CC7\)SI.>B#F RO*63 A'<Z(VH3*^C7U
M,8]-/&]ZQ?LMGN^T00EY;[^J%N=&TUX&WYH,_MS6?AP]_^ F-F5)9FB>$,I,
M#&+81H3'FI$HDXQR2].<VB=/*1WR8ET,/_@RV5XB/5*)=/LM4MLE4@_8].7"
MZ'))&.6%H-HJ3C2U%/Q6D$/"X-1CQ;1.<U%([(F\?["1SC+\VQRM)/A;EQ^?
M_@_\43_Z7,Q.R[&/_\?+XD,9=#^^W7%R=_REG,/3U-4'+'8%)V=F()2:G,-J
M+C$8Z-%=Q P^'KO(X.E,C)QYAY'#.5R^&(N%+ET%R@3+:"K_+Y?D$/AQ: *'
MGU5S^,!!(>PU1%K=J["<E,$;3"=5B83]969&8%=^-'^_*/7\K!8&G5]Y:OP2
MM3\1$E:PF&__28<HV?>ER944X,L[T_T3%^^$2A[31&1*9EQ*QHWF*J;"FBCG
ML4DSJ=_%Z9/Z1V=-8F@J3@V1,R,^@,<%+_B+&%V(R^K)WY:W!?:D2X/=M^_]
MHIJ7]G+[_EG[S?;/KT.CG^(<D5_@N)L97@7+$?=F+8.S&2JI_[J>DCF<2>=[
M(;XTZC?7"BB>;N*2S=1A=\+<:U-=''-_//DX !$S$U.S &%:#5Z-U791<$]?
MPKO%\PG2(\B[9UUY][*1=V\:>3=P*HO^??"VEI8/[:U_TNC@SP;B'%3HW*N$
M<@P:8+* V^IJ"(I@9*IJ, &E,+M Q%'4'?KG]1>]H0SC3VZ@2H/R)FB&_Q+G
M&R71<HTG7G2'G#.@OPP&P8X]!%MR5JI;<*673=5?%Q4\NZJ>FTK-2A?+W!_K
M7T555D?V>&8JV @GDD[@J;^.'&;RG5JK1\]J:_6 _AF#9?G^G_ ,10_Q.>]?
ML8.37\^/?ON3'I[LLX/XQ>7!;Z_/P?(<F7^\OOSKWWHJ8P:6Y[_>@V49'YS_
MLSS\_!:LVK/S@_>GGPY^^Q/N\98>/#^%];RZ^.NWO^SA^U>71W^\HUF>I]JD
M1*FB(,S&BA3<,I(*(XK<Q&"*9MZM*,<+H_?1W"],01F7F8ZM H>Y*!CXQYH7
MX%\D2MOXR0 V'>3;__]D/EN UNG0 &5X39KAP)$#/^H2Q!7P_C9!RPMDBC*S
M<6WD!EY9$?SP75B>_[FCXO5+7'XEJRE54J4FT1GCL>7@.Z5%E@@=F2A"G/9;
M4OS?S)C=?-RV;/U-)._F-UL2)-]%CFRV$3>JT<%/:(VCGHFCOS_S%OS0_2>H
MG<Y7K\UI6<UG8CQOO@W?7)CZ@\FL_FQ1A<]^'ER("@$-)K,I&C1^WBS>UUGU
MN,'/P4J_"'IA?SHK1P,04^D>+G40%C0 EA<#!:^$KA3^]-0,IF<"?&GEW@7+
MW<.E=J+<6%N@WARL5C?5]MR CP6:5@TT:!A1>44,-FMY#ON'RREG@]$$% )H
MRG-W*[C8G0VX\@S<O],S+(<GD]DIT&TZ XGL?,<;62&KSMM]8_CC&="GG((:
M#N9B,$K@_1XKTSM^.IN,M!^MXKG>2=$2C)2IWQ!@*E%5B,?AN*]3ZX)M$O/+
MIN0%.7?M.;___FSP4S@.^"7\=WTFANX !-YV)E[^]^Y3<52Y9]QJ(:M2EV(&
MJ[LX*]79QI,@R\F6PV#&IW!!<^: ^]7DHYE=NE?5YJ,93:8U(BL<S]$(OM%X
M+BI\,SVHSN&SP?ED9-0"O D]6\!VP6^=S>H.D2WA IQ97%IX,MQI,8;3!B=.
MNX6,$?#X1J?D?K-15QB=@433!B4%7*9A8\5\$"CLR?-1S$KTODC#(+!Z9)B:
M'_[UZD4C'RU(38R=+,:.XM,%"$H44$BAYM8;.1@I"DP#>W@YD&9L@ #(*4C+
M>CG2* '2$(6\%V+(WK 9XM2+Q7-I9FMLC#_T3S<#*]3<+\/);#,N8;GN!J;F
MF^TG;%1-KOX9/.EG6)+;4?<VDPM8#S[;O\_<L9@N9R!M!\B)(7C4UAIV[M2<
M$ >*@%(=]M&O_7P";]=A4F#S$FBI&KHUAQ#<[O'D'!0%'$$7JP5K:F_+*X95
M@T\^ >VU%+Q:O2UL[V*$DF4QP]$C<WRM_9;HX/&-M9CI"GA,NS4ZZ^-D,H65
M<!H-6P7=$<ZUVL4![O-J%[]R;[#O=NZ?B['QT<\$GH%^P= Q+SAG3CJ:&5QV
M,<92/_)Q,N^6^54=;AG"^TV].>I &P=; ^[C!7+<2LQ=T)Q&*HO!G<L92Q->
M*&,,%PE5PN167),%7)E!9V;H\ *C(6[J^%]NU2\"5>NBC2;>3N(?S(4Y.'E+
MC_;?61X+;7-&>"0Y85$AL:NS( D70(HBRC5E3Y[&R=[Z],?_VYZ1#8)C.# .
M?J0$U7+9]!DB5VP\0\T!:6X%!^.^<\^OE\=@KHY_:"[ZDQ[\\<Y20VV1IB2Q
M&7!1GAC"\]20+-<JRW1NTBA_\C3/-W)1*[C7A6\0ET.T?]ZC[ >NZ(*B.<VT
MF"]F!BXYFRQ&>HN(!GFKSO!'&._!!Z-)T@JS,'(/&:Q:,M;>XB>-BN[J&-!C
MX8FXB$9(^BO<SQQSH?Z9#$R Y8'W ,44'C.?G!I4&X.+<GX&-P->JMHY@+\N
MS0'TYL'J-2O#C7^"2[ $_^<E]8++JV&!!ONG,^,U[T_.>+'.<H&==+&EXN>K
M5%R#S-MF9%!#NX =O-@4_#KWP,8$"O0![8E++KW:\V18VB?W_G@ISCJ<UN.'
M@HI?M8[!)IWCHZ<+B7Y<,Q>QIMJKXZ.&7K "="&'[MDSY[@Z:S88$LUOX;H#
M 2O#JXO6_!>X6?@]O)0TSO0G<C*;.>/$1>/="O\%VPD<./A](GP Y@T8R5@:
MV-WMC@?MKFN^:OUCW(5_3&;E9]3X1IV-P:0]O0QZ&S?">\YUF.=-">\/__X7
MV$/F<O"K&']H>6K8==E_-[C6CB?NS"/TQUU$V#& .UCX_MDV%EBZ%N\^,O,Y
M6FGUFP1"'@BU/]8S<^%-UY>3F02>_0W,SNF2+W3PW^)\^O>7_IO6(Q(#EZV#
M!V&6T#LHN*\6'(PR1 HZCW WJ1_RJAM>6#E?CJ#U3:IZ:]H[U2O8PWUX;I0W
MB6%#\B&81Z##X)]\N/0-_&>7;=Z8Z;SY+K!1]_)BF0O\[C5\T%D O$<CIX9;
MJ.%LZC62/ N^*7SVPKNF1X'':\_K5GVFS-4@7IO(6L_#HI]'$O?KU;PX2 >?
M;WMS\$W6?$,_;X!SBZLM)WCEN^4C_ SD+@CBE^7\\RE0#12$Y]%GD[V&]]>N
M:6[1?<S^R4%#O^600:O.FO6Y9_^. ;;1> !VR0=8R!1#/X.7(*J&2T>O>]G&
M)_]^_&QP7#]C[3V'C5>XI'ZV+>HW%@//?@2#R4N)_5<@YGS$Y?6;9X/?Y[I9
MV,JE&]>&UVQ?&TBO36RSM:[WN\4--AWB"XR9C"=SU"XSC"7A88:C'#1M1]$"
MLRSK630'@J+=&]SE0?D':,./J' VRRGWBB%DYF2P#&'TCNW0\>)W#$^TNKH3
M4P@1D8U1ACUX;90X9V;DLBAU7.2*Q9^)CYB+A/O!X\LZ%A@2E1A6\%[W9G_8
M!:(;*H)+#SX]6+3XJIU@D7)VI#=V-\80W6JP?/IT7'[VKO5H4MTLGG;?H\Y+
MZ2I'S]]+. J@_BX?0;AP,L#HRU*@UQG3>.I/S=AX6P4_A4.O%V"5SH!!QPOC
M=J*^4JBS$C[6>)$MY[ZBPP>')^/*ITA"4@XW<S6@NYBM16P=:P>9TW6*FI$;
M>X.7;D"Y8VAE?!JL/IZ;XD6K;VC10O:'LUUJB%/"1C?W0K/Z7,)CZT0;7/(1
M#;WI2*A@6,*G0=7@KDQG!I0BRDH??\>P4V6<);;<1M":IL/!8FIGL$/N!D!H
M.*F3L1G4LW6</ 5^Q;C9TL^TD?XW(=3?[$_558)3L(7#ZO%]P0=Q2:S%*7!C
MR&)M#[0M;YRW=I5:G"^\&:Q=/-<1\O]\>RB>](F+C\*_U@<1S05ZBR_$#)$O
MJ_UVC<_]$F]69Y_]8#&2P^<O+@\OWK%$93)'-&F;6L(*"_\"CY:DF8&_DB2-
M\@0G@R5[Z] YR+"CVN_#L]5*#G294148IW<,"(K!)1R%FA/-)_1Y7>SZX0O3
M&QVA)E PJK7(H (!J-P&N83 %5AGW^^0K6.]@!^Z N*R/W\F9C.LH]VAE?#'
M.UZOL/*;JSQ-L&/9QD(3)O*""!5GA,4(S )'SBB&T%1[ZPW+]>D"-0I6GH$#
MA0K3AQ6=%D.5&E2E5Q:-OST_*V=Z\)^%F*$O#\P#Y$Z&@='P9_7/\>+)F)PZ
M6P<Y+]R^2>#.T;1T_/>-C?E=*[I/CI.B&-ZI*WYA7+F@P7;!D Y'([YKK0RP
M)&5N3L&P[FY_"/0U:?K6":V5]W2"-;%HG'OM7],'; U0Z9\;H\1;^[6:!C/L
M=";.*Q_/!8%\OXCVC^/C/,GODF;+53LN6(5Z2^#.G9=5-9E=NOK.706NI@D<
M;67CA"8L2A*9XG ;1KFB>1QGR4T%;LBY5KXK9ZPQ)EN];EI5<9[18N9S.[W0
MW9#W>:^BH^?8J@/K./F#'9R^HSAUF3)*8JK0OLD,X5PK8HS-)6<<\W(@@..]
M=52LQKSQ,?65VO25&L6^VZ-SS(KMW1Y]X\8/T[BQL8KWP53E7LG@J*(W!WSK
MD>&#)O7A=0VJZ]E ^EJ< W$Y2*CS$I+!3Y4Q=9[31Q_'(;.3UGZ$&(]!+2B,
MR.RDEGBJ!:@C$\4Y9U&:%&D"FT\+$5EM4UD7W>=Q2NI_;-9/KO@ TPM']@T&
MU;&"I]0A>N+UD]%'XY,9[*E?UF\S\/YZ+;71-3CY(X5KZ-'S5Y]!4[%W)J)Y
MD>B$I#$'UT!GEL@D3TFB*9P,J5.=X*B":$.=0J.C6B,2)]0^*\?'XE/(KC3\
M1=G/CZS4\5P$*PZ#Y3Z;?BY*-P%%?!3E2,ARA";VCN9<2B.;9[8H,FH8+5*1
M98I%N34B,6#<)=?A/BR?F]?UFO8[2W+'Z%55+8Q^OL!,FI^@Y#QJV"CW37]^
MMKC6BAWNOXNR3!<\RHEAZ%HG:4RX*03)8FV$!-*I#"R[)+\J<.4M._2K5_.J
M6W*FW0H67Z\P7V%'5[WAY'AE1J.AAY&9PP%P&@'_;LME-L6'-I?07)-^=<^[
MEPE&5PX;3B%L .Z)BR2WH?VMY]+OT\K15#P720YG3V2<Q87FN<DC%:N,"YOD
M4F[VM%X=OER+;;G]]=K,9Z3?N.>]-O"FH,U>3F8O73 $CR)6NMSL,$8_VF&$
M^QS]\4Z =9'%*B$RCQEA2N9$L%@3&2D:Z]CF:23 +QBR)!\F>;9^(J^I(6O+
MFC;7  RP0,,WU9R9CA;P)9EXVTZ=E7_6WJ#)$:\PZ<+590,?-"%:3/2$LH42
MZ].FQJE!?)[H/ .KT2>SI5"/+X(W*/E=SEC,/KAJLE(Y&[J.]WP$/^_<?3*?
M"1V*OVXJ'O;NMB*E,5]=MLHN9BXFI3$O,ZJ^98#_SH7;B6,2!(@H?1IQ)K!#
M&+MBYL*'[Q"$>0[,-5G,-]*SPW9U^^+ 1:1\3%;Y_//>X)6MXXV+<>U?^*=U
M1&G-H\('$B_.S-AUN!CM"D,7TXG+X9FI3]5BBX@K8@4U9H%8&/F]<#E_5UP@
MEOIFQN;4A2_NM*HC=$6@,X6Q\*:"H2'!X[)O&R[9!#;BB22-P88_,Q4HV00"
M^=1BI[9*FEJ7+<Q5-Z8X/7L^Q=0I<(4 \7+:5)-@9G489"OL6AN #E4GSMZ!
M#RL;M#A\-2H]<Y<^">@J:5&#XF+ C'+2KBZ[<8'9>VG [(2'H">N+J)N\1$:
M><M_A>?5V)&K%G<!_JHJ\1"&C(MO2ZA:#>8:X6KIX)*"*/G;YANGTFK@PE#Z
MXS5DC66P0@+?:81OAG5=8W#:JPK;L3KEXC7'R*Z4N4HLW20F>C-<A(0^3ER$
M^-OC(KQII73;LW6,[<1 ]GN"A?#YX$VP2]^_NCCZ]]OHX-]@/S[_]>S/S_",
M$_Q[__/!OP\__/5^-()[T(/?_OE^U2X]>+^?_G7RQZ<_W__ZX>"WE^_!+CW#
MOP^>'WSZ,WY]#O>%];Z]^//\T&)@Y>"/=S2WF8XS10S5X"0J')8=<4DX3[AB
M7,2V2%>! V)FI.%6)['@S&:9Y$D1<\N, .Z30JYB(;Q9G)^'OL8.*;K]<S4Q
MO@#UX/K%K"P^EG&6)<S8)&(V85Q2)JTR$<>T1\(:M+G;YD87ZFAP8%PO4GG>
M",E78^\\P7NYS;CT?_[ W)D<[;^CL61)"HR)7A)A+)-$@I0D0JLT42Q-<RE6
MN>V>A,=WK*9L&&,0.*.C/SN\\3BLMR6HN9N:;J4SS4&?NZX:%W[JMEVW& B^
MR,JUPCM3OFV?Q[8E^"]GCSCUO^^.N&CKV/?WC]N*]+6E;K%T?A4CMZ8W9UB$
M(K96.VWY><<\@A\>M367-M@K\S-PXKT%67[""H?Y&;8 H6&SZ3%X(6);7O]
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M<H_F_.S:<U,G<JME-@VW=>?EF@6NI'/QO!JLJ/4I]<#K/K_[Q9O@(,21,W&
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MD%Z*3I9&O6R*F-4U!!L>WXWE7J4SNI-K0!N$#EY?9>I:)\38%U9=S#"MBJ(
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M=]*XZ=1P#(#YZS%CX&9-+L9UCWH=L^]DO,JM<?65,# >Q@&"]N'&$=Q$S-C
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MK9@\J\%60+8"LJND[T3N'57BWP1K%_Q=[#AV)LK(B3)*E.W."9TY3%X!V7<
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M.?V2E*3^A$D0#F%)!LL0V97\8\/.1'PN(R(J*?G<Q'J/Z/IRQD8K,74/!WT
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MYFC!6&"&>!2XDXCS5#ME?$3$!6- [820SN3YNJ8//I5__.JIT;-&LBPR!/T
M@_99W^,U$,LL=K.ZP\%MGE:_9OK]T$\U:;<>&=S/*_N>E?<_N&WYR_"P1H<
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MOQ_'_1T-N!7B+($XR:YIGG=70+,,T,P0H$;C%0&K1@JG$,><(4681)&X2 +
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M[\7KS4^SY%+8*<>9*)"CC"%NA4):2X6(UM@HYS#7:FV3K1,QSYRY-#?NTR:
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M.X8S*S*>946>:-)Q99*-RTK^R0_:&@_P;N;2CVZ_\?W!]$0<"+!JB#(8>58
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MDK86#1-MF&C#1-?.1'_3/]@PT3M%SSG_L)8ZE8D"]$PPR%Q&/E9E\"/#;!0
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M*4P@&5:(W3P<6F<SSE5R8Q[43GNS])C%XE=/*-SF9I-_-+"[+J/8DR[1?4\
M/)OZPN-82QD0GRK"0!V5D:_B5/F&:L*%U:$)PC6IHS<Z&QN>*MV@VQ-"MW79
MV1ITNP]TJQO;3$)8S'7@"[2XL9"FOJ3*^$;I@!JF;:"C!MT:='O*Z+8NT]U3
MK=)];\!6M]\%-I9!& 8^XP;T9BX XM) ^Q0D<):HD/)H[95L&FAKH&T#9OT
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M3="5LW_X[_?V&8R;OF5'AW^=[?_:/S^B^^3H%Z95M9VY*R8BB3D-?*/CQ&<
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MB7%:2CN#_GE1_Z\H >!*=E5F Q2$7"6QVI=;I>0R6\;-#;?;SS&5\Z2'X<0
MZX A&5".GFS5Q&  2D&OC[ZB6BWXG4MF50X4-(:^*X70 R75Q2B:A<=6GN#Q
MQ P"NU[?Z6[?6!<NG14<8OJH9;4";P]E?*L"NMY-YO[[18XVQJCX"=V0XT<
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MAR>R5P;)3&-LWGPZ>)[_40^S@1?T[%QA[(6-*LPJ^6AF Z3&\J85D,_NY5S
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M\O*.N_3GR"Q>8V2'1>+2R\$.N?3:58\E9(>S^%:/O?I:**(G/MAP)^&77][
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MK##'2=_[:<\VUU/*GF"O$6Q.YH90Z^0QBVM%<YULTK,BFS0!+7B6Z[A1M(Q
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M.V&^<Q%A)FOF%W)*RLR]FQ_6!3Y3"1C\CMH)/#(B'3^%Z_'@3D ; 'MVC3Q
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MPU_$=G\<2TF U</$F_%P/SGY4H[]9:1CQ'N$/X#9[-((6QJ%)K$]>0HF?X#
M(Q,?YP'B\YPD'@>$A;RL-EH15<'\$E^M7G(+A\WZI-%AZ(0/T1C5.:BUVYU7
M;V%JUKK=\K\^]ZFM3JVYM]QBE_28WL9W6W&;T9+^R#]O_FEAAVCO\OCGS>GA
MM75Z?E@K\HDK(I83<>=*"],"1VPNGM#8K(#"EGG@WV=?GQ!^V(0=?8F^6)=.
MXEG_C54NO\:AN_H+O+@+<!,HNVY4W2C:+5.964G+-3_%[926WYTPG%G?P^"^
ML+NZ$I7/8)1U(NDF$:ZLC/4)$?T/C\6W7Q[ _-(/AC/XQSB>>'_[_U!+ P04
M    " #ZD0]5CF$F+Q84  "TS0  $0   '9T=G0M,C R,C V,S N>'-D[3UM
M<]NXT=_O5Z#^TNM,%(N2G,292SJR$^?<VI''5I+V^7(#D9"$AB)T "E;^?7=
M!5]EBB IR3&?2IV;QI*PBP5VL=@W +_]_6'FD@63B@OOW9'ULGU$F&<+AWN3
M=T=?AA>M-T=_?__++[_]I=7ZU]GM%?D@[&#&/)^<2T9]YI![[D_)-X>I[V0L
MQ8Q\$_([7]!6Z[T&.A?SI>23J4\Z[4[G\:_RK6UWNLZ8OFF-7H^M5L]Q.JV1
MW;%:)[U>NV.]&G??O#EY,7G[VNET7K_NM%L]:CFMWBN+M4Y/.YW6^,1NC]J6
M16EOK)$^J+?*GK(9)3 P3[U]4.^.IKX_?WM\?']___*^^U+(R7&GW;:._W5]
M=:>;'D5M7>Y]7VG],))NW+Y[C#^/J&)Q\X6_\)/F^&'*))VSP.>V>FF+V3&.
MN/VJVXX!$!TW=, ]Y5//3CIP?-GREW.FUL/ S\?X,_;3;K6M5L?*]N2DQ&6[
M.3D.?SPBU/<E'P4^NQ!R]H&-:> "2.#]&5"7CSES0!1<ALQ>:9#YV:=RPOS/
M=,;4G-JLVF2\_X409!.?S87TB9>#'E,UTM0JZ6NP(Q*R]$K8U-=RBBU5/+!<
M^V/F^@H_M?#3RP?E'!U7[S50K0FE\UH]9V'"WJ-OZE"0D4_K]/3T^ $%;CT%
M:\5'MV_AGRVKT^I:-;HMDL/J?<.G5@RW"QK2Q5:/AAAN2QK6KJTB62B#U)]5
M13+6K]6*DQ #X.A/ZG2HF/UR(A;'#N-5!/]Q<_QCC:A3SQ.^AL=OHN_F<^Z-
M1?@%?(4,>QMS[9:-8PV64\9KEH;^YRV5MA1NR3HZGDLQ9]+G3&45N48PE6S\
M[@B55BO64G^X=/02*(F;Y#I8%3W\^1A F'N5CB2&1>Z_.U+  )>%<]/D@<\E
MJSMP %&P2VA&_[\?OTW=NN,'$#MP_S>&[[!QW>$#"/?X!J-'Z"'\3KCS[NA<
M@!5Z1/"[+[>71E-"]QJVCQ'&*%-:WK?!QH/_2"NU65M$0_UV_+CM(RR!8L[
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M>L,D%\Z.V%ZO-[,@]'KMUS4$(1MGP<Z)[IW$W1/HGP !)*3@(" YEF6__/B
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M0'P*97"&6,9CV6=L&#Z<B>O:6UE&',Z4G.0-V7?9RDU%^=4FTS.@IPG/%[
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M]Y=HQ4)--PM/\QFF\V\?+CQ.;Y**V?FY.+1H8XR2RR$QSPEU9<6Q)<5994Y
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M\]=7LWES"=-[& %_+QHNB @<?5Z&.ZY/(A+A/1,&8DZY]E%2%UPGHR+521C
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MB+V-0)Z].O07[P;2>U]7K*-Z,[ZXFD,:V0C,> @$O17T8+(H=S(2=9-"X@'
M)3LT[4LH)T?\/B+>0'WOH\R_0^E9"NG5%W1XS^#7JR*5]_E>-M%"40-N8=&@
M)Z-CTJBH+!)O'26.,RZX+;79:@=#[03PV:O)<'1L4)[>1Z%;T"YU^WY&FF;,
M\5@N9$6)SJ *[:.(7_%H2X].R!YJ!Q'N"/%4%:@*)1M4J/=9ZUKV$T\4]T&I
MB0C%S<Y!$9MX(LR;D-#%1C'4+Y_\1+($^]#>0XQ//TO0NU3:*POBHT:;6.E
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M!\[)X9NUGK9&])3Z -FZ:R&;EBH9<B)>)+0^V*(N@"*"JR ME6AKU5:!(T?
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M92G>J15JM"X)T=*4Z&&F/.C*6U9':*>I2D/R,T3"^H-7S"8%,%HHXE0)>F"
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MV",JT$/< ]P&;4''!&AMRH&ND@+1*46\39FD'( E 9P]>#SVU)7@D;N=0^G
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MW(X$[S"G@>*OAIC/<2*X>JC)KH;DH3A^+OK+G18&7!L8B?N,2&TC'B#!A*#
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M.B8;PB1E5J80@U-#^5%UIM#[K'<Q$J3-0%9M8@UGV3B;" B/AF]FCGAN)!&
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M5^WTW'KOLPE22^Y"T!D$$Y X#URZ/!H:7,_@GA;(;Q"OIBA[F/W]<0"W#-W
M5#1@2::\M!5 &]<I2(3G%&E@3,GZD3P]\/9:A^\QM@@SW#[L2 2ME8J^!("@
MZ<=H)#ZI1+Q APQ= ,G6CV&WK,T[#WV$^)Q#J=&=-7Y83@8X-ME#3*\N2WN)
M$7KPUG$12##9$JE,)$$#.AC):(8.AO6N=L/XO<&^ /4[+*%#I+GM#GSAVOJ0
MN*0)T'(*<7FEX84CQN<L&1,BJX?<AP,IXF&#O)Z1]NU.XE,\5K(L9 #(!.>!
M+T\TB-^4HH N4P],Z> >2JA[-L=*AR'X@0.H700]Y*%%%QPG> "UD_BWG5[L
M([LAN60T0'LHGF2I$>.U(EX+07 _I#9$!?%!K^$I<+C# 505"G<1V6$/H$3,
MV:>(9K34I;]VUL2%E(CD2:!YK75^Y@=0.XF^^P'4+G*KW9'O56E7-Y[].&YN
M\##C4",=0LFF=!I(FE@1,DGH,7E.H[8^=>)QP\.?(WM]933D#>O"*BCQU\VD
M#4TIZPRU)BB='$&KL=B1FA+KA"8ED$5[KZ25M>WR!P&]").I/C5#5'R_BVGY
M9G0!-5!8^D9 1V["UY^XC;Y9#:D/YOVO@^/!BU *;5"3<;%DZ)2& (* *5G-
M'C+3U6OU'TX5NG;D.Y F["+LP1KSM;G"J_9QT8<@&)"H2Z1".8BPUFD"WO)L
MF:)VO2A I;Y\MT <Z^2P%SD;._/M*]D!#IT_(%DPG2[;D"PQ6>:D4[141LIH
MT.A$B4NJ%!K65 EN:&"UV=Z$XQ0([RW?@T5^%]4<+VY*_"2];B:EUQA,(II)
ME2/!]QRISG5PC6FNW?)*YX/1'E?_R&34SE(:2G2?RR+1:,QHSS%[]56_'O'5
MVH@WI\N"4IDB%41IADL/-YY8G =)22C<Q)2*Z]T#MS9<?WRT7D[IAP8%/A_[
MBU_&%S";X\NYK 0V*ETPG=&"Z,A-V7L3"09=Y2Q+-&7@1K+8:0Y;ASC<*C0,
M<W<\USJ"K'WF\,"<%^X7ODQ&T>0)2"=QP<0_O*:9*!",>A,D.-974P]R*W0
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M=>:$O#@*7I& _B>5BB1E ZE]9E_('*++@TK'445]5';I@U^Z\/)K5-$AY-8
M2,L),*=H]](1ZYP@7B@+UC)?[@446,82,.9M4BY@7%5[5]KE(_7$4447 ]0^
M2JV=M3L0,M]DA0P1) F.@@DN@_!<%!&A3X2>$=*EA=V]R#N0L/OA:Q[X@*)>
MZILWD7W%H&>Y6$W>NMF'M/Y&J!*&2&- .J6A7&6C/TPLX">B.=>46-OIO,&G
MWCEK\%??SIGO7OC+#9L/54/%2]M;(K;C;CN0T<=?ZH**^D?$<1=G@/!WU3=
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MYI W>.AF<%$& (Z_P#VL)$C!BB'Q!=YO\\+0EX=S7 $!  @-_37_556<"#_
M]'=5\??X>_P]_AY_C[_'_]N#FY.;6XA30(A3\"(7IQ /EQ"7P!_> ^L/P !X
M"+B!KQ<!L H!L&-$U.9.3O9"'!RVCNP&QG:&)NQ&=C8<K@;V'%SLG!R "-35
MWL#(RL3IHJ&)F86M*.-*!8+QHH6Q**,&GP*G@KVDB;G%+?<')JKN=^X:N5L9
M"1HS0L5.$XJX"KG:V-N8.!E<=+6QMG44<A6]?(A=")P?W.:X+";RP-A42.6F
M](\=X#O1RS]X<7%Q87?A8;=[8,;!)2@HR,')S<'-S0;N8'-TLW4R<&6S=:3_
M@>"FB:/1 PM[)PL[VXL'[PT,[9R=1"\[.UL8"YD:F/(9&AOSL1D:\!BS<7$9
M&[ 9&/-PL1GS\!@+\'%=YS;E,KS\@[RQT6_4[9T?6!_2-C;B,+$VL3&Q=7($
MM<'%<9GCOY8FJ*+?B/ZA^D$9P3U"D@],#)Q,;H*7V(%9V3@%V#@%[_XT*[N
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MU6]'MJC<R^N) N4#/!!GT5$"=OZ(2:TNQ,+CWN"#[4I_EFJR-OU]PAZ)'G(
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MA]6T]D!G*8C1J.3Y,:0_'_M4V])KQ.QI6!\R/&'P'!9H/U1FYH$DBOO':[$
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M]O06R/4DHK*L]KM&_FQ)F[V#'9@DW-N:GK0T'<#V'A)$1'OP*M46$RQR!11
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M)M^<3Y'DEK6<L3CMY=#Y],H)6\8G-0!]B*[:-SO&>6KLM#0.<JH*GP2I(+2
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M:'QV%?5YB9W*([Q;A)NR*'^U( L3Q).BN:,D0TWC]L9#?%#-XF5M5[$YK_K
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M^(X9#A(,D@4;57-@Q#J>+L)!_$'>R:Y7PK*AO3U9T\)9V/-ENLTRU-_OO[A
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M\JZ,/*=;O"[:7<U3?=(P@6^!]\Y_A<8EB=G%,*Y.EG6Z&>6UCSUN'Y^TTQ.
MAMBH%>S2)^8-NWB]*"/QD*$028]0^<! *V-^V<=&^2GA1GI4O.7U8JZL?SGA
MS:9E2JF/U1G!3YCL_/FOS%T;?*\=#"SS@CV>*YC6!<>+R)$OG&0A]&G+(^51
MZMXLLC0O[::"&.30E?GJY+<XLP%3WG?C/E;V,_6ST26UK"M3SDTU#U<_?%39
M/N#)P-*=HO<5FI(EE-\F+#;JQ*%ZM67285/H!O\NFP$FGB-J8[' 3>1IZ;71
M#KDF S=]1NY"A>8O&_.ZQTS#S"R?G*Q?2*\ZW?.-B=YZCO1YRF>'-Z9VUS,6
MT78IS^!&T1]R#&N;TX4,T^AHO[>8!/7W]0U^HQE2V+QSY$2$1*W(<S&T,6$7
M,'JNQ=Y\[QR8V]?L?[CB3BG,QYNBUGJ*'YKQ$GBG^5V5GLGMD<9@?W_OY_9;
MSN\965\HC!$]G6E*:3*HF.S@O##AIXEB"+9:.WV<16PY,' SENPI_C"Z&/6Q
M'U;]V[[(>7GP$28.6QM!R"UB^29R35RO1[0VCC^XRL;L=#MH0ZC\P<N]GBS3
M=AK#-@Z-&3WK<\O$.;6\!+<=A,1K*4_A("Z%*'PY(T./ON_ L#F6K^!X8A/D
M"6CP%^*,8$]T]Q;Q7QB1L.':6='=0PV/:X:3/S@&15\NID*CN##H_6^9#)["
M.E-AL?RHKDER D\0F84'#B(*X@9H]S\GP@_J&DX$JM@7RU<DN8^<-@Y OOXI
ME;'E\Y4TQ#Y9HUVJ D<#I1Y063C0;\Y1K&_7W";VNVU1+CZ"/5*\\H%1)_5-
M^ _O[[(>S +Q!33;5<Y AO=\&:(F;,]IM!"][8FGH#M(>I1#P^6:[?&,SD\V
MW"PD_-Q^2101SRQZ6T[)O!AGO4EOUJ>N<FSAL\-P7V>;SN@BHG^8%#%="MM>
MQ1\:6'X[O-X'Q?-<>D==^P(=45[D^ 6K[$E)ENP2]E0.PP$\!DFU+4GH%. &
M/%/#ZC9NM6<YWR04M?F) 0?91Y'T<7A<AR&4BJM>H\[5/&%A5*',1 NE_R#W
M]=2]ZC,_3F;VU ?IVCGJ^W5">P4LIZBV\H$)D>=FPZ1(F2?[@N(%+-$WP66Z
M=5\I8V:?!V6<*#[U?8W0?^/;?72OT[OLR&ZSP;N:7"&C2;>E?K]:?-F/YSA\
M92<(MB<#G?0%L'3&(V@!I6R.1W?HB6_L2,UL'+>W>FE.9\'%DXI/[)P1&^H(
MIWIGSZG/7R+HF' 0 AP$9$^A<6OY+Y;PVI?>PD&J+'<6R?":SSJ[1]K<K6]V
M25E [X%OTE#LMPV*>U<3.CO@(Q+-:<Q&T,9M73PP8GWH-[#NSO(!\,EO&^2/
M'14QOO=VX"-<B\7##3LQ@RZ9SH).%]I.Q''S&G MTZ9 -3+BS&!DEUHR&$I#
M*<+U"6JV1K"VX[?U7[7Y$/Y(Q/CC@:']MHBP=9'N/6 TZZ<9M&(0*]U8IZI]
M$S2KS!9A 4?#07)2 !XTX9Y%X1K6J!@'L43S@2)9^6F&L$(L#;B,.0#+XX"O
M@RIQ;#QART_R_B,C$%'3O_9?,-7=5T!_!AH1OH3HQY^(^&5<AT2A0_%J!D\2
MH*^$-4(1;PU:3J*1MMAA%!CIBXS^,H##Y*VDDXE)@43MT82MP[[!"N8!KBFG
MK,,BC3]$7K?'8\>3UT6(H#T=B' L :90<P?@&00*L;30'<O]WAD9M/(K;Q&F
M%KQ?Q[_ZRI]0UW3?Z6ZF%5N L?:M(-Y;EG*D)@ZZG_.S8M>F"$.;T?0*/K X
MO=#G9WU-CM6K-@\57%G,RQ\AX%<M-9]-UCQXD[_,AK"B#W3M800',H%'?J<4
MO9K7PI6W76>64W1B)V#AF;MVSRV*]35O]TFCEI1KB4QZP!^> #9*VH*8KMC7
M@(6B$@_9(=_2^J=?,7OA!:GZT[?P_HELX)/;=1SD$$;HRML9W?41!%X;A2RQ
M)+!#;DWZD$?+J&<A_$^.#%]Y:\R(U:+*!+I +[A(G AY[JCFP:ONK)M>T\66
M?^>.\R*V&R\@_"!9^$%2^P[5NFOY'_:H?\KQ-C5PB/,_G/F'_VE?GI**DI#P
MEREYFG/A3"$ZSU(APV;S<#E]PJ@5Y)L-&?S7%'M2KA)A;V[L=B4=HB#ES^]5
M_PUGIUM*>L@.5J+/YR"WA(TB(-]%S[1X:A+58FPL5]-=E+B.SHQ@\I^H0BNO
MZ 'LW8SC6>_XPVC>]%D$7GL[Q*TJHXQNE#8=3VP_(GETUZ,[C*_#\-%Z\+P/
MQDHGGZ0D_)JR7='8& _S!8$VM9P!;51NQ?4@CHTD>/NV3Q'&3%"7!N4,'7!X
M3C_,N]B]GJG:?^]K45NFY:=+5XHJ=!;G@! 9HP21I8^<HV'VRT=DJ%8?1UED
MHD:>YVC$(T-AY$,^,V$U$:*N *DT"ERXQU5C5Y/>"NQ)>UZT=O^BRE>O;J*Z
M;=]D;.%C_C5Y1W $3,"RV\8Z+)E>TP95Z*T3>M3<7539O,_8FG9"_X;)H%",
MA_X8E$"[X$K>S:8HU]5(:'-QI,BIRN(WKD]]KC>7I[!!YW6NF"36ODP5\=(:
M$X?9R6*V:F652XI7L,EJ\F4V08SKBP*T)3YJO&M]+["T@BE3(9?1=YP0Z,N[
M?RD$?QA+"*]SB@.=!X_ J.'G'WW1OMI0]YP)LB*=G/E-S5LU:E8A,&:2)B"-
MWN%C?$7?7]#IO@JWVWD19XQ?]&H>CQH(#/B^ZQBQX&&-/5S-W_#S;(V";K,7
MV4-)R(M=N0E5JAC&DJ],DB3]/?ZW6<U@M":%&BZ3[0E;E<TPP3OA)W/N/_]&
M/Z#"YG3+EGQ5+HK6^<= 38D?,9M??D#YD4[S141NWGR"5Q? D1C^PUX.\1+6
M1[P2>SJ\].EGP%!=1Y.]\.J.A&;5N?.,/D9+;4UC/?HEN?F4_$%:6IDXR+4G
M3#5%C.PW:B6T.D3/=.<EFEQVL(RXQ:2BJD\_ X\B="\\2J;AQ75BWJZ[3V2B
MA6.T4/4TPIA5KR&7(#K)CH#^ \&0*56QS9ETP:@<J4+8)9E(VO7^8SD+4RM9
M;RE7GS'E%P0=[Y-IO3)0H6QT,4;0)AUY$>6DU9V8+W?K$R5JI^J&4OIQ44]A
MPUA0[.=FJE@8R&[*&!I^F BZ0$VPVT*L\F3,A5$Q/S>B;_=<H?OUU^-<"R)S
MNJB[O,%6(E\[S-']MH.L+]U9B#->3@Z[HV6X35K3[5HJC-,^O$?6*P?/-HO1
MAX3']BBDZ9I2KMZIF;5FXOSV*N_NZ=H-9($Q82?TNR.WNK3]U?AG!6M&!C&/
M"<J>F^CJ9GM,[DE^?YYP/]7 KC+(V@=:^?5KZ2G ^D6A_?-^J2OGPO*/AKSY
M</(F5AUM$NS H_:V(]U*DJ_"N#1%N+)<_4$OLWM,'D&?<?F5=K[YM*^\_1ZA
M]_C7IAY8NVM2U#M(2"!:;>D4%G-NJ\YV*0I+$T4:']6_:+VLK?V[I 7^+:^.
M\XOCX&*X7])%1V1\F-A4AV/U^W"OW,F=,RS C7=(PKXRDO*$:]U3,;7'1$-D
M\UX^*6HDHY%X.MK$6O\#:&.4\GOY;B=>"? 45LUU:*CJ6KD3^N+N'9.K)[2R
M!P0N;J<RCPR_]Q1:A"V#J^\8?CN(;\QRN0\8KL)2+-YZ/%S6[.#:0)-G1:6Z
M:A@,)#81I2/-[5:E=$:8FZZV;BM,*HF-F_/9W@H?"+F9'" [^]V"3(25"_50
MYRH6DX1_^2R-OI9U'G!MQV*A*XE(=RSP722&9^?4S:'KK4IM6YIO8<^^2I_.
MJ7W3?+J-V*)C<K7 I]">BJ=D@'U(OLY 8HUB, AV0P4V*N<0N;<%WU[9+]ST
MN50.LZ>PAP(J/=EI[:?1LHHU5RPD.(3%S$W&/VXJY/UPLF!RSN4\R6;P7.15
M6O'IQ-%!*HVBDB"L2:BZ<!U6G/R%##$%[!!A\5ARY'L$P@1T]F0HE>*/0L[
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M?B@*LO+JRA%SS"J.5[:HFSN<[>+M1YN)=8<$2LM=)V_9S^F;['=\I3UNS3G
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ME.>"<)Q GJG$OEY@FFX4W4,I/IU.O^!A1O1<V*K&EI4.XCI2L92VT[9#%SJ
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M<R+.L2,$FPNXP&>YH=[F]HUVJZ\LVW>>XT4%5JFN2U4:LDK=FD__ )*ULU@
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M1C9P>[(-,H!S-0YL9P"GZP$4ZP$DFP$L6V?<#R='<,'V-)AI.W91'(*]8![
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M"%FK1OKQV*UX%O.5J#,HS2O'Y._3Y</;5;E</(KBRV(V92]WXMORC5+SSTF
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M@F6$9L0H\WEG+V-;GAI!JX"'1E(SKNO&LGM]<8:0YY6C!1R'?@DC%+JL:M7
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M4K@S2+A*^':JFV&3N9U1]BA1V[GG>Q>>7#R*7Y0Y6/D%/NE!6F>AIEPDD6(
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M$HD$#@*N+X$SI L71VH_&2$.,Q'I"Y-!S&.[I%DGNQJ;S;DKZ;_]:QZ%V7\
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M)0=:=(>I4?LCYHB:+#H>E*3L 3FDJQXM]".N7TN=>;E<3A]5B^4DB"/.\C"
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M"ST#X[;W!&I7H/I#E>%%9V<0_*-.1STO-4DI6S>*!(DSGL,H(US7*DDASI(
MLCA*TCB*26J6.Z=/YV,CE5I04"YFW#XO3B_TS:C%%Z:>V::Z7[38W"_:NJ4;
MG&OI09VE?RV_PPBF'JBYBFVRZ7K8J*<>H!S%0_5IHT^DU%Z>A?+CX]-JJ9NO
MV7*2)FJS$R,$91PJYF*4P[PZ A8)YC3A-$/19"[N=:58 Q]2=V]&TPK7TVJW
M3W^S2^>B^ E,:S'5)*KEM(F#Z8;7P(WD +*! HWV<[,HZFE@^^@<-IO0(&?P
M#17VLX%Q5L-X^/6Y\BF9(=,=J=/=Q(!1.$:Z[$?8F+WBJEC(IKNWY&FZ)+--
M'49*8I%D60"C.,ET!NL<XH 0&#&!XI3)@-N%UIAW/3;+\&UU?%(5(2)5$9>J
M&L5L6X[@ITLK@IP<!#,3T0^TGFGY1.6/+<TTHGNIFFF/F+<*'R<[?N6J'N<
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M- DICB4,1: 6JHA@B!,1PR D*,(9T<F+C&]RG.AD;.N*%M/BS/@4= 9G[ X
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M\HK+>>/#ZF7?/2WG<KQ*A4O0&8513L($2\1#J8 0R@'.. 511G&14\1C9J2
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M29J$W-!MKSGU%#WV=3[?IFK"VLJ.Y@!OB39VQ>O*0=L+[P'=$1SP==Y=1W9
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M:_%3U^C:4M[^K*$]V!'O"V,C>]D/UJ/9R$V;JQI?E6#PLL6\^=G1-^Y*;=L
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MGJZ9TRO-UZF)A^4]7XGEZOG+<E6G<U0/<L:V[$K$("Q@04!,6 (0(B' .$P
MPPF%C&$.<6QBHCBA:FJ&RX]^V:E^5;"]0HC;77>]#%K>:K=KP]U-H/@STR=N
M1*RGAT87G&?]Y4YF#DOU> ';D>YT0].H.M<IC(>ZVNW@'BY0?S17<S^V]W6S
M A<921,&0E*H\*TL!KF0ATXNDA 7+(L+H57_QV[ZJ6GM_5,0W9Z"YKN;LO9V
MLW?GZ?"B\U@^(LQ$HBK*27%$ +$X!$5>8!!GB'*8I04F^6S!'U6X[KM)J&@D
MU"?#IY:FRE5<BI(V-]-+4==B)ORQ7"R4JXV><!HH;=V*[D9=4JLW)%6;>=V
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M6$C;BF* &0\!$2S*$2D@"<U:4YR:96HJH2G T<4>7Z$03F.JIPVN1LJS*FA
M6AJ!9!YB,02"J\"'DW.,&XXPQ.91D,#@PU<6"&]2?&X7[-NN;4=;+)C=J7#N
MS4I9)/*![\O%JOOG!UR5E7J_-D$?.'U:E%)#5;MO/DSR2! BS8E$E;Z,0RBM
MBS0&>4;"G$ .6:15S6DL@J>FDA2_3?OB-O4MD!P%/9Z#CNG@;A%LV:Z?ZC,>
MU)P'6]:#'>]7Z#GOGX^>RIS21^%9^_:^AW[I]:^+E\VZB<"T%[%]47;/N+NN
MZ.Z+W/<I!^\9_+.UY'W/:[>CW;W4*4B+QV_JUG/76CK)><P9$2!A&05(=;C
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M2;W)JCKDP=\"JQFI@N7>52M_+!<+%1Y%\+R.-'GO2Q;=#R06:<QXCD B/Q2
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MB,[ ]Y&D>#UQ[Y?!Z S8P?1&=[-8^K+:S(*C$W ;;YYE),ZS'($X%D35IT:
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M5-NIETEK-5= CJ:^@L9K;[\:SF9>L[=\3X6FJ[:>^KKV$YP<78 NZU ?O+8
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M??M2+UW(6+ZKUS)71#4)14@=2#!&Y#HQRA6*]F2$0KX?CQ*]3/>U&CC$J.Q
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M^J'>5E/CQ5^WERZ8RD)$C,4"9YC)>^$2/)<:HLW(H]':EM;#"W<B;-@>P2-
MWQ%Z&CH/74D.\X3ORJ;"ZU(@]I<Y"?#9Q]_>%2*KQF$^,K22&,&,$I27 ;QP
M F)*WFEIK<G7COP[DM%[+#IL8^''P%:O:GA"\-HX#E*;S%'3MM&YD./ ZN1
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M"M.?/RV^_DP?O3FSZ8N+H_J6!0?$UV,K>M%&Z@,#9D/UR\5)F,XGL58B*Y7
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M8A9C4-^8<'M&OLA%H^3 $^UIE8.%F IY""18S1/%T6ZW2]:;GSW,1=H &#I
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MKK.TW9$B.VVYR%"8(7OK,%#@PQ5$QX(/GEEI=GK]^P#:=B9HN)/Q>)TO^E;
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MUHE?W78%VE-%^8P@6X_CQS^&6;+26K01>$%-86!A$%PR8)(W(151$FO=9?]
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M![P(:\SOPW+][<H*2!:]14\N!OTO'7XIP14E03*;K9 F6K[?%=G3:TT+K.E
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M9B#(*+SFPG'NQHR >G^G<@A0VKU3.40J'3BA>];=.2>E9E& Y%: "F3= F(
MEDS,$6F'S7M--JRF[2H .@(FQU73'B*SGI"X5WV+\PI5[>0EG?=U9E&$:(P
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MSK3>"Y-GN?ON*E=_O'-P?M']M9R'.X,1/PP7%S\/RS_",L]<",B"EB!REG5
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M$]\563 (PA70(D@;M+,2F[^W:47\?JA^9E=<DTAV_ ?)5W]1?ZFD_^__]?\
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MLNXC6C-M';;3[2GJLC$JJBZ>@IJ4VV5-0:3F@0O"L[UWH&+B.5/R#E1UW?!
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MB<@U.E,B#P[1D:*7RB(I6_/ A->J/37:D4B%# Y<\S?4$BLA&4NKX%G(,EK
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MA*R0>Z6Z;?*%RYC=;WTO9&ZHCOX%4$L! A0#%     @ ^I$/53RO2C:*> $
M/R 4 !X              ( !     '!R;VIE8W1G+6-O;&QA8F]R871I;VYA
M;F1L+FAT;5!+ 0(4 Q0    ( /J1#U4(G#8/2\8! *@#$P 1
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M+3(P,C(P-C,P7W!R92YX;6Q02P$"% ,4    " #ZD0]5ASO<*/H'  !J)P
M&               @ %?UP4 =G1V="TR,#(R,#8S,'AE>'@S,3$N:'1M4$L!
M A0#%     @ ^I$/5:H)EPK/!P  0"@  !@              ( !C]\% '9T
M=G0M,C R,C V,S!X97AX,S$R+FAT;5!+ 0(4 Q0    ( /J1#U63[@RAX00
M !T3   8              "  93G!0!V='9T+3(P,C(P-C,P>&5X>#,R,2YH
M=&U02P$"% ,4    " #ZD0]5;#\EN\0$  #\$@  &               @ &K
M[ 4 =G1V="TR,#(R,#8S,'AE>'@S,C(N:'1M4$L%!@     ,  P , ,  *7Q
$!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
